# Patent

## Title
AX132 PCSK9 antagonists

## Abstract

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/US2010/054714, filed Oct. 29, 2010, which claims benefit of U.S. provisional application, U.S. Ser. No. 61/256,732, filed Oct. 30, 2009, and claims benefit of U.S. provisional application, U.S. Ser. No. 61/323,148, filed Apr. 12, 2010.


STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not Applicable.
REFERENCE TO MICROFICHE APPENDIX
Not Applicable.
BACKGROUND OF THE INVENTION
Proprotein convertase subtilisin-kexin type 9 (hereinafter called “PCSK9”), also known as neural apoptosis-regulated convertase 1 (“NARC-1”), is a proteinase K-like subtilase identified as the 9th member of the secretory subtilase family; see Seidah et al., 2003 PNAS 100:928-933. The gene for PCSK9 localizes to human chromosome 1p33-p34.3; Seidah et al., supra. PCSK9 is expressed in cells capable of proliferation and differentiation including, for example, hepatocytes, kidney mesenchymal cells, intestinal ileum, and colon epithelia as well as embryonic brain telencephalon neurons; Seidah et al., supra.
Original synthesis of PCSK9 is in the form of an inactive enzyme precursor, or zymogen, of  ̃72-kDa which undergoes autocatalytic, intramolecular processing in the endoplasmic reticulum (“ER”) to activate its functionality. This internal processing event has been reported to occur at the SSVFAQ↓SIPWNL158 motif (SEQ ID NOs: 19 and 20, respectively); Benjannet et al., 2004 J. Biol. Chem. 279:48865-48875. Such internal processing has been reported as a requirement of exit from the ER; Benjannet et al., supra; Seidah et al., supra. The cleaved and, thereby, activated protein is secreted in association with the cleaved peptide; supra.
The sequence for human PCSK9 ( ̃22-kb long with 12 exons encoding a 692 amino acid protein) can be found in one instance at Deposit No. NP—777596.2. Human, mouse and rat PCSK9 nucleic acid sequences have been deposited; see, e.g., GenBank Accession Nos.: AX21327530 (also AX207686), NP—705793 (also Q80W65), and P59996, respectively. PCSK9 possesses several domains found in other proprotein convertases, including an N-terminal signal sequence, a pro domain, a catalytic domain and a cysteine-rich C terminal domain. The PCSK9 catalytic domain shares high sequence similarity with the proteinase K family of subtilases and, notably, a catalytic triad of D186, H226 and S386.
PCSK9 is disclosed and/or claimed in several patent publications including, but not limited to the following: PCT Publication Nos. WO 01/31007, WO 01/57081, WO 02/14358, WO 01/98468, WO 02/102993, WO 02/102994, WO 02/46383, WO 02/90526, WO 01/77137, and WO 01/34768; US Publication Nos. US 2004/0009553 and US 2003/0119038, and European Publication Nos. EP 1 440 981, EP 1 067 182, and EP 1 471 152.
PCSK9 has been ascribed a role in the differentiation of hepatic and neuronal cells (Seidah et al., supra.), is highly expressed in embryonic liver, and has been strongly implicated in cholesterol homeostasis. Studies have suggested a specific role for PCSK9 in cholesterol biosynthesis or uptake. In a study of cholesterol-fed rats, Maxwell et al. found that PCSK9 was downregulated in a similar manner to three other genes involved in cholesterol biosynthesis, Maxwell et al., 2003 J. Lipid Res. 44:2109-2119. The expression of PCSK9 has, in fact, been shown to be regulated by sterol regulatory element-binding proteins (“SREBP”), as seen with other genes involved in cholesterol metabolism; supra. Later support for these findings came about through a study of PCSK9 transcriptional regulation which demonstrated that such regulation was quite typical of other genes implicated in lipoprotein metabolism; Dubuc et al., 2004 Arterioscler. Thromb. Vasc. Biol. 24:1454-1459. Statins have been shown to upregulate PCSK9 expression in a manner attributed to the cholesterol-lowering effects of the drugs; supra. Moreover, it has been shown that PCSK9 promoters possess two conserved sites involved in cholesterol regulation, a sterol regulatory element and an Sp1 site; supra.
Several lines of evidence demonstrate that PCSK9, in particular, lowers the amount of hepatic LDLR protein and thus compromises the liver's ability to remove LDL cholesterol from the circulation. Adenovirus-mediated overexpression of PCSK9 in the livers of mice results in the accumulation of circulating LDL-C due to a dramatic loss of hepatic LDLR protein, with no effect on LDLR mRNA levels; Benjannet et al., 2004 J. Biol. Chem. 279:48865-48875; Maxwell & Breslow, 2004 PNAS 101:7100-7105; Park et al., 2004 J. Biol. Chem. 279:50630-50638; and Lalanne et al., 2005 J. Lipid Res. 46:1312-1319. The effect of PCSK9 over-expression on raising circulating LDL-C levels in mice is completely dependent on the expression of LDLR, again, indicating that the regulation of LDL-C by PCSK9 is mediated through downregulation of LDLR protein. In agreement with these findings, mice lacking PCSK9 or in which PCSK9 mRNA has been lowered by antisense oligonucleotide inhibitors have higher levels of hepatic LDLR protein and a greater ability to clear circulating LDL-C; Rashid et al., 2005 PNAS 102:5374-5379; and Graham et al., 2007 J. Lipid Res. 48(4):763-767. In addition, lowering PCSK9 levels in cultured human hepatocytes by siRNA also results in higher LDLR protein levels and an increased ability to take up LDL-C; Benjannet et al., 2004 J. Biol. Chem. 279:48865-48875; and Lalanne et al., 2005 J. Lipid Res. 46:1312-1319. Together, these data indicate that PCSK9 action leads to increased LDL-C by lowering LDLR protein levels.
A number of mutations in the gene PCSK9 have also been conclusively associated with autosomal dominant hypercholesterolemia (“ADH”), an inherited metabolism disorder characterized by marked elevations of low density lipoprotein (“LDL”) particles in the plasma which can lead to premature cardiovascular failure; see Abifadel et al., 2003 Nature Genetics 34:154-156; Timms et al., 2004 Hum. Genet. 114:349-353; Leren, 2004 Clin. Genet. 65:419-422. A later-published study on the S127R mutation of Abifadel et al., supra, reported that patients carrying such a mutation exhibited higher total cholesterol and apoB 100 in the plasma attributed to (1) an overproduction of apoB 100-containing lipoproteins, such as low density lipoprotein (“LDL”), very low density lipoprotein (“VLDL”) and intermediate density lipoprotein (“IDL”), and (2) an associated reduction in clearance or conversion of said lipoproteins; Ouguerram et al., 2004 Arterioscler. Thromb. Vasc. Biol. 24:1448-1453.
Accordingly, there can be no doubt that PCSK9 plays a role in the regulation of LDL. The expression or upregulation of PCSK9 is associated with increased plasma levels of LDL cholesterol, and the corresponding inhibition or lack of expression of PCSK9 is associated with reduced LDL cholesterol plasma levels. Decreased levels of LDL cholesterol associated with sequence variations in PCSK9 have been found to confer protection against coronary heart disease; Cohen, 2006 N. Engl. J. Med. 354:1264-1272.
The identification of compounds and/or agents effective in the treatment of cardiovascular affliction is highly desirable. In clinical trials, reductions in LDL cholesterol levels have been directly related to the rate of coronary events; Law et al., 2003 BMJ 326:1423-1427. More recently, the moderate lifelong reduction in plasma LDL cholesterol levels was found to correlate with a substantial reduction in the incidence of coronary events; Cohen et al., supra. This was the case even in populations with a high prevalence of non-lipid-related cardiovascular risk factors; supra. Accordingly, there is great benefit to be reaped from the managed control of LDL cholesterol levels.
The present invention advances these interests by providing antagonists of PCSK9 of use for inhibiting the activities of PCSK9 and the corresponding role PCSK9 plays in various therapeutic conditions.
SUMMARY OF THE INVENTION
The present invention relates to protein-specific antagonists of PCSK9 and, in particular embodiments, those antagonists that inhibit human PCSK9. Broadly, protein-specific antagonists of PCSK9 (or “PCSK9-specific antagonists” as referred to herein) are PCSK9 protein binding molecules or molecules effective in the selective binding of PCSK9 and inhibition of PCSK9 function. In particular embodiments, the present invention relates to monoclonal antibody variants having high affinity and desired properties from a therapeutic perspective. These molecules are of import in the treatment of conditions associated with or impacted by PCSK9 function, including, but not limited to hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome and related conditions. PCSK9-specific antagonists are characterized by selective recognition and binding to PCSK9. PCSK9-specific antagonists do not show significant binding to proteins other than PCSK9, other than in those specific instances where the antagonist is supplemented or designed to confer an additional, distinct specificity to the PCSK9-specific binding component.
PCSK9-specific antagonists forming particular embodiments hereof comprise (a) a heavy chain variable region comprising a CDR3 domain comprising (in select embodiments, consisting of) a sequence selected from the group consisting of: SEQ ID NOs: 1-5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NOs: 13-63, residues 4-12 of the foregoing sequences that are 15 amino acids in length, and equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not reduce specificity for PCSK9 by more than 50% (in specific embodiments, by more than 60%, 70%, 80%, and 90%); and/or (b) a light chain variable region comprising a CDR3 domain comprising (in select embodiments, consisting of) a sequence selected from the group consisting of: SEQ ID NOs: 295-301, SEQ ID NO: 303, SEQ ID NOs: 305-334, residues 4-13 of the foregoing sequences that are 16 amino acids in length, and equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not reduce specificity for PCSK9 by more than 50% (in specific embodiments, by more than 60%, 70%, 80%, and 90%).
PCSK9-specific antagonists forming additional embodiments hereof comprise (a) a heavy chain variable region comprising a CDR2 domain comprising (in select embodiments, consisting of) a sequence selected from the group consisting of: SEQ ID NOs: 64-68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NOs: 76-182, residues 4-20 of the foregoing sequences that are 23 amino acids in length, and equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not reduce specificity for PCSK9 by more than 50% (in specific embodiments, by more than 60%, 70%, 80%, and 90%); and/or (b) a light chain variable region comprising a CDR2 domain comprising (in select embodiments, consisting of) a sequence selected from the group consisting of: SEQ ID NOs: 335-339, SEQ ID NO: 341, SEQ ID NOs: 343-346, residues 4-10 of the foregoing sequences that are 13 amino acids in length, and equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not reduce specificity for PCSK9 by more than 50% (in specific embodiments, by more than 60%, 70%, 80%, and 90%).
In specific embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1.2×10−6 M or less. In more specific embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1×10−7 M or less. In additional embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1×10−8 M or less. In further embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 5×10−9 M or less, or of 1×10−9 M or less. In select embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1×10−10 M or less, a KD of 1×10−11 M or less, or a KD of 1×10−12 M or less. In specific embodiments, PCSK9-specific antagonists do not bind proteins other than PCSK9 at the above levels indicated for binding to PCSK9.
Particular embodiments of the present invention include PCSK9-specific antagonists which exhibit binding to PCSK9 at one of the above prescribed levels and compete for binding to PCSK9 with AX132 and its variants as described herein. AX132 and its disclosed variants, described as any antibody molecules fitting within the descriptions, sequence and/or functional limitations provided throughout the present disclosure, form important PCSK9-specific antagonists hereof.
AX132 antibody molecules are characterized as comprising a (i) heavy chain variable region (“VH”) comprising SEQ ID NO: 360 or SEQ ID NO: 361; and (ii) a light chain variable region (“VL”) comprising SEQ ID NO: 511. Said VH and VL regions comprise the full complement of disclosed CDRs 1, 2 and 3 for the VH [SEQ ID NOs: 189 (or SEQ ID NO: 191) as CDR1; SEQ ID NO: 68 (or SEQ ID NO: 70) as CDR2; and SEQ ID NO: 5 (or SEQ ID NO: 7) as CDR3] and VL regions [SEQ ID NOs: 349 (or SEQ ID NO: 351) as CDR1; SEQ ID NO: 339 (or SEQ ID NO: 341) as CDR2; and SEQ ID NO: 301 (or SEQ ID NO: 303) as CDR3], respectively. Examples of AX132 antibody molecules include without limitation: (i) a Fab which comprises a light chain comprising SEQ ID NO: 554 and an Fd chain comprising amino acids comprising amino acids 1-221 of SEQ ID NO: 552 (or SEQ ID NO: 552); (ii) a full length antibody molecule which comprises a light chain comprising SEQ ID NO: 558 and a heavy chain comprising SEQ ID NO: 556; and (iii) an antibody produced by the expression of SEQ ID NO: 560.
AX213 antibody molecules, an example of specific variants described herein, are characterized as comprising a (i) heavy chain variable region (“VH”) comprising SEQ ID NO: 362 or SEQ ID NO: 363; and (ii) a light chain variable region (“VL”) comprising SEQ ID NO: 511. Said VH and VL regions comprise the full complement of disclosed CDRs 1, 2 and 3 for the VH [SEQ ID NO: 193 (or SEQ ID NO: 195) as CDR1; SEQ ID NO: 72 (or SEQ ID NO: 74) as CDR2; and SEQ ID NO: 9 (or SEQ ID NO: 11) as CDR3)] and VL regions [SEQ ID NO: 349 (or SEQ ID NO: 351) as CDR1; SEQ ID NO: 339 (or SEQ ID NO: 341) as CDR2; and SEQ ID NO: 301 (or SEQ ID NO: 303) as CDR3], respectively. Examples of AX213 antibody molecules include without limitation: (i) a Fab which comprises a light chain comprising SEQ ID NO: 554 and an Fd chain comprising amino acids comprising amino acids 1-221 of SEQ ID NO: 562 (or SEQ ID NO: 562); (ii) a full length antibody molecule which comprises a light chain comprising SEQ ID NO: 566 and a heavy chain comprising SEQ ID NO: 564; and (iii) an antibody produced by the expression of SEQ ID NO: 569.
PCSK9-specific antagonists are effective in counteracting PCSK9-dependent inhibition of cellular LDL-uptake, and particularly human PCSK9-dependent inhibition of cellular LDL uptake. Repeatedly, PCSK9-specific antagonists as described herein have demonstrated dose-dependent inhibition of the effects of PCSK9 on LDL uptake. Accordingly, the disclosed PCSK9-specific antagonists are of import for lowering plasma LDL cholesterol levels. The disclosed antagonists also have utility for various diagnostic purposes, including the detection and quantification of PCSK9.
In particular embodiments, the present invention encompasses antibody molecules comprising the disclosed heavy and/or light chain variable regions, equivalents of said regions having one or more amino acid substitutions that do not substantially impact function, and homologs thereof. Select embodiments comprise isolated PCSK9-specific antagonists that comprise disclosed CDR domains or sets of the heavy and/or light chain CDR domains, and equivalents of such domains characterized as having one or more amino acid substitutions. As will be appreciated by those skilled in the art, fragments of PCSK9-specific antagonists that retain the ability to antagonize PCSK9 may be inserted into various frameworks; see, e.g., U.S. Pat. No. 6,818,418 and references contained therein, the collective disclosures of which are incorporated herein by reference, which discuss various scaffolds which may be used to display antibody loops previously selected on the basis of antigen binding. In the alternative, genes encoding for VL and VH may be joined, using recombinant methods, for example using a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules, otherwise known as single chain Fvs (“ScFVs”); see, e.g., Bird et al., 1988 Science 242: 423-426, and Huston et al., 1988 Proc. Natl. Acad. Sci. USA 85:5879-5883, the disclosures of which are incorporated herein by reference. In another alternative, the VH and VL may be fused with two interactive domains, and form a Fab-like molecule, see, e.g., ccFv, Wang et al., U.S. Pat. No. 6,833,441 and U.S. Pat. No. 7,429,652.
PCSK-9 specific antagonists and fragments may be in the form of various non-antibody-based scaffolds, including but not limited to avimers (Avidia); DARPins (Molecular Partners); Adnectins (Adnexus), Anticalins (Pieris) and Affibodies (Affibody). The use of alternative scaffolds for protein binding is well appreciated in the scientific literature, see, e.g., Binz & Plückthun, 2005 Curr. Opin. Biotech. 16:1-11; the disclosure of which is incorporated herein by reference.
Accordingly, any PCSK9-specific antagonist, including antibody molecules and non-antibody-based scaffolds comprising (i) the disclosed heavy and/or light chain variable region CDR3 sequences (heavy chain variable region CDR3 sequence selected from SEQ ID NOs: 1-5, 7, 9, 11, 13-63, and residues 4-12 of the foregoing sequences that are 15 amino acids in length; light chain variable region CDR3 sequence selected from SEQ ID NOs: 295-301, 303, 305-334, and residues 4-13 of the foregoing sequences that are 16 amino acids in length), (ii) the disclosed heavy and/or light chain variable region CDR2 sequences (heavy chain variable region CDR2 sequence selected from SEQ ID NOs: 64-68, 70, 72, 74, 76-182, and residues 4-20 of the foregoing sequences that are 23 amino acids in length; light chain variable region CDR2 sequence selected from SEQ ID NOs: 335-339, 341, 343-346 and residues 4-10 of the foregoing sequences that are 13 amino acids in length), (iii) the disclosed heavy and/or light chain variable region CDR1 sequences (heavy chain variable region CDR1 sequence selected from SEQ ID NOs: 183-189, 191, 193, 195, 197-294, and residues 4-13 of the foregoing sequences that are 16 amino acids in length; light chain variable region CDR1 sequence selected from SEQ ID NOs: 347-349, 351, 353-359 and residues 4-14 of the foregoing sequences that are 17 amino acids in length), (iv) the disclosed heavy chain variable CDR1, CDR2 and CDR3 sequences or the disclosed light chain variable CDR1, CDR2 and CDR3 sequences, (v) a full complement (CDRs 1, 2 and 3) of the disclosed heavy and light chain CDRs within a variable region framework of a human heavy and/or light chain sequence, respectively, or (vi) the disclosed heavy and/or light chain variable regions (heavy chain variable sequence selected from SEQ ID NOs: 360-510; light chain variable sequence selected from SEQ ID NOs: 511-549) form important embodiments of the present invention; where antagonists, antibody molecules or scaffolds exhibit selectivity for PCSK9 and counteract PCSK9-dependent inhibition of cellular LDL-uptake.
In another aspect, the present invention provides nucleic acid encoding the disclosed PCSK9-specific antagonists and, in particular embodiments, PCSK9-specific antagonists which comprise the disclosed heavy and light chains, the disclosed variable heavy and light regions and select components thereof (including CDRs 1, 2 and/or 3), particularly the disclosed respective CDR3 or CDR2 regions. In another aspect, the present invention provides vectors comprising said nucleic acid. The present invention, additionally, provides isolated cell(s) comprising nucleic acid encoding disclosed PCSK9-specific antagonists. In another aspect, the present invention provides isolated cell(s) comprising a polypeptide or vector of the present invention.
The present invention provides methods for making PCSK9-specific antagonists disclosed herein including but not limited to antibodies, antigen binding fragments, derivatives, chimeric molecules, fusions of any of the foregoing with another polypeptide, or alternative structures/compositions capable of specifically binding PCSK9 which comprise the disclosed sequences. The methods comprise: (i) incubating a cell comprising nucleic acid encoding the PCSK9-specific antagonist(s), or which comprises individual nucleic acids encoding one or more components thereof, said nucleic acids which, when expressed, collectively produce the antagonist(s), under conditions that allow for the expression and/or assembly of the PCSK9-specific antagonist(s), and (ii) isolating said antagonist(s) from the cell. One of skill in the art can obtain PCSK9-specific antagonists disclosed herein using standard recombinant DNA techniques as well.
The present invention provides a method for antagonizing the activity or function of PCSK9 or a noted effect of PCSK9 which comprises contacting a cell, population of cells, or tissue sample of interest expressing PCSK9 (or treated with or having therein human PCSK9) with a PCSK9-specific antagonist disclosed herein under conditions that allow said antagonist to bind to PCSK9. Specific embodiments of the present invention include such methods wherein the cell is a human cell. Additional embodiments are wherein the cell expresses human-derived PCSK9.
In another aspect, the present invention provides a method for antagonizing the activity or function of PCSK9 or a noted effect of PCSK9 in a subject exhibiting a condition associated with PCSK9 activity, or a condition where the functioning of PCSK9 is contraindicated for a particular subject, which comprises administering to the subject a therapeutically effective amount of a PCSK9-specific antagonist of the present invention in a pharmaceutical or other composition.
The present invention, thus, encompasses a method of treating a condition associated with PCSK9 activity, or a condition wherein the functioning of PCSK9 is contraindicated for a particular subject, which comprises administering to the subject a therapeutically effective amount of a PCSK9-specific antagonist of the present invention in a pharmaceutical or other composition. In select embodiments, the condition is hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related conditions.
In specific embodiments, the present invention encompasses a method of administering a disclosed PCSK9-specific antagonist to a subject which comprises delivering a therapeutically effective amount of a pharmaceutical or other composition comprising a PCSK9-specific antagonist as disclosed herein.
In another aspect, the present invention provides a pharmaceutical composition or other composition comprising a PCSK9-specific antagonist of the invention characterized as comprising a pharmaceutically acceptable carrier including but not limited to an excipient, diluent, stabilizer, buffer, or alternative designed to facilitate administration of the antagonist in the desired amount to the treated individual.
The following table offers a generalized outline of the sequences discussed in the present application. The Sequence Listing including all notations, sequences and features forms an express part of the disclosure hereof:








TABLE 1





SEQ ID NO:
DESCRIPTION







SEQ ID NOs: 1-5, 7, 9,
HEAVY CHAIN CDR3


11, 13-63


SEQ ID NOs: 6, 8, 10,
HEAVY CHAIN CDR3; NUCLEIC ACID


12


SEQ ID NOs: 64-68, 70,
HEAVY CHAIN CDR2


72, 74, 76-182


SEQ ID NOs: 69, 71, 73,
HEAVY CHAIN CDR2; NUCLEIC ACID


75


SEQ ID NOs: 183-189,
HEAVY CHAIN CDR1


191, 193, 195, 197-294


SEQ ID NOs: 190, 192,
HEAVY CHAIN CDR1; NUCLEIC ACID


194, 196


SEQ ID NOs: 295-301,
LIGHT CHAIN CDR3


303, 305-334


SEQ ID NOs: 302, 304
LIGHT CHAIN CDR3; NUCLEIC ACID


SEQ ID NOs: 335-339,
LIGHT CHAIN CDR2


341, 343-346


SEQ ID NOs: 340, 342
LIGHT CHAIN CDR2; NUCLEIC ACID


SEQ ID NOs: 347-349,
LIGHT CHAIN CDR1


351, 353-359


SEQ ID NOs: 350, 352
LIGHT CHAIN CDR1; NUCLEIC ACID


SEQ ID NOs: 360-510
VARIABLE HEAVY REGIONS


SEQ ID NOs: 550, 561
VARIABLE HEAVY REGIONS;



NUCLEIC ACID


SEQ ID NOs: 511-549
VARIABLE LIGHT REGIONS


SEQ ID NO: 551
VARIABLE LIGHT REGION;



NUCLEIC ACID


SEQ ID NOs: 552, 562
FAB HEAVY CHAIN


SEQ ID NOs: 553, 563
FAB HEAVY CHAIN; NUCLEIC ACID


SEQ ID NO: 554
FAB LIGHT CHAIN


SEQ ID NO: 555
FAB LIGHT CHAIN; NUCLEIC ACID


SEQ ID NOs: 556, 564
IGG2 HEAVY CHAIN


SEQ ID NOs: 557, 565
IGG2 HEAVY CHAIN; NUCLEIC ACID


SEQ ID NOs: 558, 566
IGG2 LIGHT CHAIN


SEQ ID NOs: 559, 567,
IGG2 LIGHT CHAIN; NUCLEIC ACID


568


SEQ ID NOs: 560, 569
ANTIBODY EXPRESSION



VECTOR SEQUENCE


SEQ ID NO: 570
FRAGMENT OF PROCESSING SITE


SEQ ID NO: 571
FRAGMENT OF PROCESSING SITE


SEQ ID NO: 572
Constant domain of IgG1


SEQ ID NO: 573
Constant domain of IgG2


SEQ ID NO: 574
Constant domain of IgG4


SEQ ID NO: 575
Constant domain of IgG2m4


SEQ ID NOs: 576-582
AX132 EPITOPES


SEQ ID NOs: 583-590
AX132 AND VARIANT FRAMEWORK



REGIONS


SEQ ID NO: 591-592
CONSENSUS VARIABLE HEAVY



AND VARIABLE LIGHT REGIONS,



RESPECTIVELY


SEQ ID NO: 593-641
FIGURE SEQUENCES


SEQ ID NO: 642
PCSK9


SEQ ID NOs: 643-644
AX132 CONTACT RESIDUES


SEQ ID NO: 645
EGF_AB PEPTIDE


SEQ ID NOs: 646-647
pMAB9-AX132; and complementary



sequence; respectively












BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates the impact of PDL1 Fabs on PCSK9—LDL receptor interaction. This Biacore-based assay shows that binding of AX1, AX9, and AX114 to PCSK9 inhibits the interaction of PCSK9-LDLR and PCSK9-EGF_AB domain. EGF_AB domain in LDLR involves the interaction with PCSK9.
FIG. 2 illustrates amino acid substitutions in VH-CDR1, 2, 3 regions from 134 AX114 variants, which were isolated from 10 optimization libraries.
FIG. 3 illustrates amino acid substitutions in VK-CDR1, 2, 3 regions from 134 AX114 variants, which were isolated from 10 optimization libraries.
FIGS. 4A-B illustrate the three possible binding bins proposed by computational docking program for the PCSK9 antagonist antibodies isolated from PDL1 library (A). The bin #1, which involves in the binding to EGF_AB domain of LDL receptor, is predicted to be the binding region for AX132 antibody. The surface amino acid residues are provided (B).
FIGS. 5A-B illustrate the structure of human PCSK9 chimeric mutant #1 with D192G and F379Y substitutions from rat PCSK9 in the Bin #1 (B). ELISA result shows that these substitutions in PCSK9 cause significant loss of binding activity to AX132 antibody (A). These data confirm the binding of AX132 to the Bin #1 as predicted.
FIG. 6 illustrate the HD exchange profiles for AX132 and AX213 antibodies. The PCSK9 peptic fragments that exhibit the greatest deuteration difference upon AX213 or AX132 binding are 155-PWNL-158 (SEQ ID NO: 576) and 364-PGEDIIGASSDCSTC-378 (SEQ ID NO: 577).
FIG. 7 shows PCSK9 with the two peptic fragments containing the AX132 and AX213 epitope highlighted. These peptic fragments are 155-PWNL-158 (SEQ ID NO: 576) and 364-PGEDIIGASSDCSTC-378 (SEQ ID NO: 577). The HD exchange data is consistent with the PCSK9 mutagenesis data in Example 7. Both 155- and 364-peptides are located in the epitope Bin #1 as shown in FIG. 4.
FIG. 8 depicts the crystal structure of PCSK9 bound to the AX132 antibody.
FIG. 9 shows the surface area representation of PCSK9 with AX132 epitope. FIG. 9 illustrates the involvement of F379 residue on PCSK9 in the AX132 binding.
FIGS. 10A-F illustrate the activities of AX114, AX132, AX210, AX211, AX212 and AX213 antibodies in a PCSK9-LDLR interaction TR-FRET format assay, respectively. All IgG2 antibodies tested are potent and inhibit the interaction of AF647-labeled wild type human PCSK9 and Eu8044-labeled LDL receptor [AF647 PCSK9=10 nM; [Eu 8044 sLDLR]  ̃5 nM (20,000 counts at F1620 nM).
FIGS. 11A-F illustrate AX114 and AX132 IgG's dose-dependent inhibition of human, murine and rhesus PCSK9-dependent loss of cellular LDL-uptake (FIGS. 11A, 11B and 11C, respectively for AX114; and FIGS. 11D, 11E and 11F, respectively for AX132). AX114 and AX132 IgGs cross-react with human, mouse and rhesus PCSK9.
FIGS. 12A-F illustrate AX210 and AX211 IgG's dose-dependent inhibition of human, murine and rhesus PCSK9-dependent loss of cellular LDL-uptake (FIGS. 12A, 12B and 12C, respectively for AX210; and FIGS. 12D, 12E and 12F, respectively for AX211). AX210 and AX211 IgGs cross-react with human, mouse and rhesus PCSK9.
FIGS. 13A-F illustrate AX212 and AX213 IgG's dose-dependent inhibition of human, murine and rhesus PCSK9-dependent loss of cellular LDL-uptake (FIGS. 13A, 13B and 13C, respectively for AX212; and FIGS. 13D, 13E and 13F, respectively for AX213). AX212 and AX213 IgGs cross-react with human, mouse and rhesus PCSK9.
FIGS. 14A-D illustrate binding of AX114, AX132, AX210 and AX211, respectively, to immobilized human FcRn with Biacore.
FIGS. 15A-B illustrate binding of AX212 and AX213, respectively, to immobilized human FcRn with Biacore.
FIGS. 16A-B illustrate the pharmacokinetic profile of AX132 and AX114, respectively, in human FcRn mice following a single 10 mg/kg IV administration.
FIG. 17 illustrates the results of pharmacodynamics study in rhesus monkeys. AX132 significantly lowered LDL cholesterol following a single dose, with a maximum mean reduction of 60%, and >25% LDL-C lowering for 42 days.
FIG. 18 illustrates size-exclusion chromatography for the time-zero product of monoclonal antibodies in the AX114 epitope bin.
FIG. 19 illustrates a vector map for expression of AX132 antibody.
FIGS. 20A-F illustrate a sequence for an expression plasmid for AX132 antibody.



DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to protein-specific antagonists of PCSK9 and, in particular embodiments, those antagonists that inhibit human PCSK9. Protein-specific antagonists of PCSK9 (or “PCSK9-specific antagonists”) in accordance herewith are effective in the selective binding to and inhibition of PCSK9 function and, thus, are of import in the treatment of conditions associated with or impacted by PCSK9 function, including, but not limited to, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome and related conditions. Use of the term “antagonist” refers to the fact that the subject molecule can antagonize the functioning of PCSK9. Use of the term “antagonizing” or derivatives thereof refers to the act of opposing, counteracting, inhibiting, neutralizing or curtailing one or more functions of PCSK9. Reference herein to PCSK9 function or PCSK9 activity refers to any function or activity that is driven by, requires, or is exacerbated or enhanced by PCSK9. PCSK9-specific antagonists as described herein have proven to be effective for counteracting human PCSK9-dependent inhibition of cellular LDL-uptake.
One important embodiment hereof relates to AX132 antibody molecules and variants thereof. Specific embodiments of the present invention include AX132 antibody molecules characterized as comprising a (i) heavy chain variable region (“VH”) comprising or consisting of SEQ ID NO: 360 or SEQ ID NO: 361; and (ii) a light chain variable region (“VL”) comprising SEQ ID NO: 511. Said VH and VL regions comprise the full complement of disclosed CDRs 1, 2 and 3 for the VH [SEQ ID NOs: 189 (or SEQ ID NO: 191) as CDR1; SEQ ID NO: 68 (or SEQ ID NO: 70) as CDR2; and SEQ ID NO: 5 (or SEQ ID NO: 7) as CDR3] and VL regions [SEQ ID NOs: 349 (or SEQ ID NO: 351) as CDR1; SEQ ID NO: 339 (or SEQ ID NO: 341) as CDR2; and SEQ ID NO: 301 (or SEQ ID NO: 303) as CDR3], respectively. Examples of AX132 antibody molecules include without limitation: (i) a Fab which comprises a light chain comprising SEQ ID NO: 554 and an Fd chain comprising amino acids comprising amino acids 1-221 of SEQ ID NO: 552 (or SEQ ID NO: 552); (ii) a full length antibody molecule which comprises a light chain comprising SEQ ID NO: 558 and a heavy chain comprising SEQ ID NO: 556; and (iii) an antibody produced by the expression of SEQ ID NO: 560.
In specific embodiments, AX132 variants comprise in contiguous order for one or both heavy or light chains: (a) framework 1 (FR1) sequence; (b) CDR1 sequence; (c) framework 2 (FR2) sequence; (d) CDR2 sequence; (e) framework 3 (FR3) sequence, (f) CDR3 sequence; and (g) framework 4 (FR4) sequence. In specific embodiments, the heavy chain comprises in contiguous order: (a) FR1 sequence SEQ ID NO: 583; (b) CDR1 sequence selected from the group consisting of: SEQ ID NOs: 183, 185, 187, 189, 193, and 197-294; (c) FR2 sequence SEQ ID NO: 584; (d) CDR2 sequence selected from the group consisting of: SEQ ID NOs: 64, 66, 68, 72, and 76-182; (e) FR3 sequence SEQ ID NO: 585; (f) CDR3 sequence selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 9, and 13-63; and (g) FR4 sequence SEQ ID NO: 586. In specific embodiments, the light chain comprises in contiguous order: (a) FR1 sequence SEQ ID NO: 587; (b) CDR1 sequence selected from the group consisting of: SEQ ID NOs: 347, 349 and 353-359; (c) FR2 sequence SEQ ID NO: 588; (d) CDR2 sequence selected from the group consisting of: SEQ ID NOs: 335, 337, 339, and 3430-346; (e) FR3 sequence SEQ ID NO: 589; (f) CDR3 sequence selected from the group consisting of: SEQ ID NOs: 295, 297, 299, 301, and 305-334; and (g) FR4 sequence SEQ ID NO: 590. The present invention includes antibody molecules have both heavy and light chains as described above and equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not reduce specificity for PCSK9 by more than 50% (in specific embodiments, by more than 60%, 70%, 80%, and 90%). The select group of AX132 antibodies exemplified demonstrate without limitation that PCSK9-specific antagonists as disclosed herein effectively inhibit human PCSK9.
One particular AX132 variant is AX213. AX213 antibody molecules are characterized as comprising a (i) heavy chain variable region (“VH”) comprising SEQ ID NO: 362 or SEQ ID NO: 363; and (ii) a light chain variable region (“VL”) comprising SEQ ID NO: 511. Said VH and VL regions comprise the full complement of disclosed CDRs 1, 2 and 3 for the VH [SEQ ID NO: 193 (or SEQ ID NO: 195) as CDR1; SEQ ID NO: 72 (or SEQ ID NO: 74) as CDR2; and SEQ ID NO: 9 (or SEQ ID NO: 11) as CDR3)] and VL regions [SEQ ID NO: 349 (or SEQ ID NO: 351) as CDR1; SEQ ID NO: 339 (or SEQ ID NO: 341) as CDR2; and SEQ ID NO: 301 (or SEQ ID NO: 303) as CDR3], respectively. Examples of AX213 antibody molecules include without limitation: (i) a Fab which comprises a light chain comprising SEQ ID NO: 554 and an Fd chain comprising amino acids comprising amino acids 1-221 of SEQ ID NO: 562 (or SEQ ID NO: 562); (ii) a full length antibody molecule which comprises a light chain comprising SEQ ID NO: 566 and a heavy chain comprising SEQ ID NO: 564; and (iii) an antibody produced by the expression of SEQ ID NO: 569.
The CDR definitions arrived at and disclosed herein were defined using the Abmaxis in-silico program, Luo et al., U.S. Pat. No. 7,117,096 and U.S. Patent Publication No. US2004/0010376 or WO03/099999. Applicants wish to note, however, that various other methods are also available to delineate and define the start and end points of the CDR sequences, including but not limited to Kabat, 1991 Sequences of Proteins of Immunological Interest, 5th edit., NIH Publication no. 91-3242 U.S. Department of Health and Human Services; Clothia et al., 1987 J. Mol. Biol. 196:901-917; Clothia et al., 1989 Nature 342:877-883; Lefranc, 1997 Immunol. Today, 18:509; and Chen et al., 1999 J. Mol. Biol. 293:865-881. These and other methods have been reviewed and are well within the realm of skills possessed by those in the art; see, e.g., Honegger & Plückthun, 2001 J. Mol. Biol. 309:657-670. While the current inventors have employed the Abmaxis program to define the CDRs, the present invention fully encompasses the different definitions around the sequences and the varying CDR delineations arrived at through use of any different analysis software or methods. For example, CDRs may also be defined as the component of the antibody molecules that binds an epitope or which is involved in binding the antigen. The CDR may comprise from 5-20 amino acids. In particular embodiments, the CDRs may further comprise from 2-6 flanking amino acids on each side of the CDR into the framework region. The above methods and resulting CDR definitions based on the presently disclosed sequences are fully within the scope of the present disclosure and anticipated herein.
PCSK9-specific molecules also have utility for various diagnostic purposes in the detection and quantification of PCSK9.
Disclosed PCSK9-specific antagonists are, furthermore, unique in that select embodiments have demonstrated a preferential recognition of processed PCSK9, the active form of PCSK9.
PCSK9-specific antagonists as disclosed herein are desirable molecules for lowering plasma LDL cholesterol levels and are of utility for any primate, mammal or vertebrate of commercial or domestic veterinary importance. PCSK9-specific antagonists are of utility as well to inhibit the activity of PCSK9 in any population of cells or tissues possessing the LDL receptor. The utility of the disclosed antagonists is directly measurable by assays readily available to the skilled artisan. Means for measuring LDL uptake are described in the literature; see, e.g., Barak & Webb, 1981 J. Cell Biol. 90:595-604, and Stephan & Yurachek, 1993 J. Lipid Res. 34:325330. In addition, means for measuring LDL cholesterol in plasma is well described in the literature; see, e.g., McNamara et al., 2006 Clinica Chimica Acta 369:158-167. The particular impact of the disclosed antagonists on cellular LDL uptake may also be measured through a method which comprises providing purified PCSK9 and labeled LDL particles to a cell sample; providing a PCSK9 antagonist to the cell sample; incubating said cell sample for a period of time sufficient to allow LDL particle uptake by the cells; quantifying the amount of label incorporated into the cell; and identifying those antagonists that result in an increase in the amount of quantified label taken up by the cells as compared with that observed when PCSK9 is administered alone. An additional method for measuring the impact of the disclosed antagonists comprises providing purified PCSK9 and labeled LDL particles to a cell sample; providing a PCSK9 antagonist to the cell sample; incubating said cell sample for a period of time sufficient to allow LDL particle uptake by the cells; isolating cells of the cell sample by removing the supernate; reducing non-specific association of labeled LDL particles (whether to the plate, the cells, or anything other than the LDL receptor); lysing the cells; quantifying the amount of label retained within the cell lysate; and identifying those antagonists that result in an increase in the amount of quantified label taken up by the cells as compared with that observed when PCSK9 is administered alone. Antagonists that result in an increase in the amount of quantified label are PCSK9 antagonists.
Any type of cell bearing the LDL receptor can be employed in the above methods including, but not limited to HEK cells, HepG2 cells, and CHO cells. LDL particles derived from any source are of use in the above-described assays. In particular assays, the LDL particles are fresh particles derived from blood. This can be accomplished by any method available to the skilled artisan including, but not limited to, the method of Havel et al., 1955 J. Clin. Invest. 34: 1345-1353. The LDL particles may be labeled with fluorescence. The labeled LDL particles may have incorporated therein visible wavelength excited fluorophore 3,3′-dioctadecylindocarbocyanine iodide (dil(3)) to form the highly fluorescent LDL derivative dil(3)-LDL. Any label which enables the skilled artisan to detect LDL in the cellular lysate may be used. An LDL analog may be used that would only become detectable (e.g., become fluorescent or fluoresce at a different wavelength, etc.) when metabolized intracellularly or, for instance, if it were to become associated with (or dissociated from) other molecules in the process of becoming internalized (e.g. a FRET assay, in which an LDL analog would become associated with a secondary fluor, or else be dissociated from a quencher). Any means available in the art for detecting internalization of labeled LDL particles can be employed. The incubation time for the LDL particles and PCSK9 with the cells is an amount of time sufficient to allow LDL particle uptake by the cells. This time may be within the range of 5 minutes to 360 minutes. The concentration of PCSK9 added to the cells may be in the range of 1 nM to 5 μM and, in specific methods, be in the range of 0.1 nM to 3 μM. One specific means by which the skilled artisan can determine a range of concentrations for a particular PCSK9 protein is to develop a dose response curve in the LDL-uptake assay. A concentration of PCSK9 can be selected that promotes close to maximal loss of LDL-uptake and is still in the linear range of the dose response curve. Typically, this concentration is  ̃5 times the EC-50 of the protein extracted from the dose response curve. The concentrations can vary by protein.
Broadly, PCSK9-specific antagonists as defined herein selectively recognize and specifically bind to PCSK9. An antibody is typically said to specifically bind an antigen when the dissociation constant is ≦1 μM, preferably ≦100 nM and most preferably ≦10 nM. Use of the terms “selective” or “specific” herein, further, refers to the fact that the disclosed antagonists do not show significant binding to proteins other than PCSK9, except in those specific instances where the antagonist is supplemented or designed to confer an additional, distinct specificity to the PCSK9-specific binding portion (as, for example, in bispecific or bifunctional molecules where the molecule is designed to bind two molecules or effect two functions, at least one of which is to specifically bind PCSK9). In specific embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1.2×10−6 M or less. In more specific embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 5×10−7 M or less, of 2×10−7 M or less, or of 1×10−7 M or less. In additional embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1×10−8 M or less. In further embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 5×10−9 M or less, or of 1×10−9 M or less. In select embodiments, PCSK9-specific antagonists bind to human PCSK9 with a KD of 1×10−10 M or less, a KD of 1×10−11 M or less, or a KD of 1×10−12 M or less. In specific embodiments, PCSK9-specific antagonists do not bind proteins other than PCSK9 at the above KDs. KD refers to the dissociation constant obtained from the ratio of Kd (the dissociation rate of a particular binding molecule-target protein interaction) to Ka (the association rate of the particular binding molecule-target protein interaction), or Kd/Ka which is expressed as a molar concentration (M). KD values can be determined using methods well established in the art. A preferred method for determining the KD of a binding molecule is by using surface plasmon resonance, for example employing a biosensor system such as a BiacoreTM (GE Healthcare Life Sciences) system.
PCSK9-specific antagonists disclosed herein have been shown to dose-dependently inhibit human PCSK9 dependent effects on LDL uptake. Accordingly, PCSK9-specific antagonists as disclosed herein are characterized by their ability to counteract PCSK9-dependent inhibition of LDL uptake into cells. This uptake of LDL into cells by the LDL receptor is referred to herein as “cellular LDL uptake”. In specific embodiments, PCSK9-specific antagonists counteract or antagonize human PCSK9-dependent inhibition of LDL uptake into cells, exhibiting an IC50 of less than 1.0×10−6 M, or, in order of preference, less than 1×10−7 M, 1×10−8 M, 1×10−9 M, 1×10−10 M, 1×10−11 M and 1×10−12 M. The extent of inhibition by any PCSK9-specific antagonist may be measured quantitatively in statistical comparison to a control, or via any alternative method available in the art for assessing a negative effect on, or inhibition of, PCSK9 function (i.e., any method capable of assessing antagonism of PCSK9 function). In specific embodiments, the inhibition is at least about 10% inhibition. In other embodiments, the inhibition is at least 20%, 30%, 40%, 50%, 60%, 70,%, 80%, 90%, or 95%. Accordingly, PCSK9-specific antagonists capable of effecting these levels of inhibition of PCSK9 function form particular embodiments hereof. Specific embodiments provide PCSK9 antagonists as described that, upon administration to a subject, lower LDL by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% and above. In specific embodiments, the PCSK9 antagonists lower LDL by those levels for a period of at least 7 days, 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days and longer. In particular embodiments, the percent lowering is greater than or equal to 10, 15, 20 and 25 for over 20, 30 or 40 days. Particular embodiments, provide lowering greater than or equal to 25% for over 40 days (see, e.g., Example 19 and FIG. 17). Specific embodiments also provide for PCSK9-specific antagonists that bind to human FcRn at approximately pH 6.0 and dissociate at approximately pH 7.3 (see, e.g., Example 17 and FIGS. 14-15). Particular embodiments are wherein the disclosed PCSK9-specific antagonists exhibit a dissociation of <5% (in specific embodiments, less than 3% or 1%) at neutral pH. Dissociation (or % bound) can be calculated as described in Example 17. Specific embodiments, also provide PCSK-9 specific antagonists as described herein that have a 1⁄2 life in mice of greater than 50, 60, 70, 80, 90 or 95 hours (see, e.g., Example 18 and FIG. 16). In particular embodiments, PCSK9-specific antagonists are provided that have a 1⁄2 life in primates of greater than 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 and 145 hours (see, e.g., Example 18). The present invention also provides, in specific embodiments, PCSK9-specific antagonists that, after 1 week of stress at 45° C. (under conditions similar to that described in Example 20), in pH 5, 6, 7 or 8 buffers have essentially no increase in oligomers, higher order aggregates and exhibit no clipping (see, e.g., Example 20 and Table 13). In specific embodiments, the above effects are as seen in humans and non-human primates (or where particularly specified, mice). In specific embodiments, the above effects are seen following intravenous or subcutaneous administration.
A PCSK9-specific antagonist in accordance herewith can be any binding molecule that specifically binds human PCSK9 protein including, but not limited to, antibody molecules as defined below, any PCSK9-specific binding structure, any polypeptide or nucleic acid structure that specifically binds PCSK9, and any of the foregoing incorporated into various protein scaffolds; including but not limited to, various non-antibody-based scaffolds, and various structures capable of affording or allowing for selective binding to PCSK9 including but not limited to small modular immunopharmaceuticals (or “SMIPs”; see, Haan & Maggos, 2004 Biocentury January 26); Immunity proteins (see, e.g., Chak et al., 1996 Proc. Natl. Acad. Sci. USA 93:6437-6442); cytochrome b562 (see Ku and Schultz, 1995 Proc. Natl. Acad. Sci. USA 92:6552-6556); the peptide α2p8 (see Barthe et al., 2000 Protein Sci. 9:942-955); avimers (Avidia; see Silverman et al., 2005 Nat. Biotechnol. 23:1556-1561); DARPins (Molecular Partners; see Binz et al., 2003 J. Mol. Biol. 332:489-503; and Forrer et al., 2003 FEBS Lett. 539:2-6); Tetranectins (see, Kastrup et al., 1998 Acta. Crystallogr. D. Biol. Crystallogr. 54:757-766); Adnectins (Adnexus; see, Xu et al., 2002 Chem. Biol. 9:933-942), Anticalins (Pieris; see Vogt & Skerra, 2004 Chemobiochem. 5:191-199; Beste et al., 1999 Proc. Natl. Acad. Sci. USA 96:1898-1903; Lamla & Erdmann, 2003 J. Mol. Biol. 329:381-388; and Lamla & Erdmann, 2004 Protein Expr. Purif. 33:39-47); A-domain proteins (see North & Blacklow, 1999 Biochemistry 38:3926-3935), Lipocalins (see Schlehuber & Skerra, 2005 Drug Discov. Today 10:23-33); Repeat-motif proteins such as Ankyrin repeat proteins (see Sedgwick & Smerdon, 1999 Trends Biochem. Sci. 24:311-316; Mosavi et al., 2002 Proc. Natl. Acad. Sci. USA 99:16029-16034; and Binz et al., 2004 Nat. Biotechnol. 22:575-582); Insect Defensin A (see Zhao et al., 2004 Peptides 25:629-635); Kunitz domains (see Roberts et al., 1992 Proc. Natl. Acad. Sci. USA 89:2429-2433; Roberts et al., 1992 Gene 121:9-15; Dennis & Lazarus, 1994 J. Biol. Chem. 269:22129-22136; and Dennis & Lazarus, 1994 J. Biol. Chem. 269:22137-22144); PDZ-Domains (see Schneider et al., 1999 Nat. Biotechnol. 17:170-175); Scorpion toxins such as Charybdotoxin (see Vita et al., 1998 Biopolymers 47:93-100); 10th fibronectin type III domain (or 10Fn3; see Koide et al., 1998 J. Mol. Biol. 284:1141-1151, and Xu et al., 2002 Chem. Biol. 9:933-942); CTLA-4 (extracellular domain; see Nuttall et al., 1999 Proteins 36:217-227; and Irving et al., 2001 J. Immunol. Methods 248:31-45); Knottins (see Souriau et al., 2005 Biochemistry 44:7143-7155 and Lehtio et al., 2000 Proteins 41:316-322); Neocarzinostatin (see Heyd et al. 2003 Biochemistry 42:5674-5683); carbohydrate binding module 4-2 (CBM4-2; see Cicortas et al., 2004 Protein Eng. Des. Sel. 17:213-221); Tendamistat (see McConnell & Hoess, 1995 J. Mol. Biol. 250:460-470, and Li et al., 2003 Protein Eng. 16:65-72); T cell receptor (see Holler et al., 2000 Proc. Natl. Acad. Sci. USA 97:5387-5392; Shusta et al., 2000 Nat. Biotechnol. 18:754-759; and Li et al., 2005 Nat. Biotechnol. 23:349-354); Affibodies (Affibody; see Nord et al., 1995 Protein Eng. 8:601-608; Nord et al., 1997 Nat. Biotechnol. 15:772-777; Gunneriusson et al., 1999 Protein Eng. 12:873-878); and other selective binding proteins or scaffolds recognized in the literature; see, e.g., Binz & Plückthun, 2005 Curr. Opin. Biotech. 16:1-11; Gill & Damle, 2006 Curr. Opin. Biotechnol. 17:1-6; Hosse et al., 2006 Protein Science 15:14-27; Binz et al., 2005 Nat. Biotechnol. 23:1257-1268; Hey et al., 2005 Trends in Biotechnol. 23:514-522; Binz & Plückthun, 2005 Curr. Opin. Biotech. 16:459-469; Nygren & Skerra, 2004 J. Immunolog. Methods 290:3-28; Nygren & Uhlen, 1997 Curr. Opin. Struct. Biol. 7:463-469; the disclosures of which are incorporated herein by reference. Antibodies and the use of antigen-binding fragments is well defined and understood in the literature. The use of alternative scaffolds for protein binding is well appreciated in the scientific literature as well, see, e.g., Binz & Plückthun, 2005 Curr. Opin. Biotech. 16:1-11; Gill & Damle, 2006 Curr. Opin. Biotechnol. 17:1-6; Hosse et al., 2006 Protein Science 15:14-27; Binz et al., 2005 Nat. Biotechnol. 23:1257-1268; Hey et al., 2005 Trends in Biotechnol. 23:514-522; Binz & Plückthun, 2005 Curr. Opin. Biotech. 16:459-469; Nygren & Skerra, 2004 J. Immunolog. Methods 290:3-28; Nygren & Uhlen, 1997 Curr. Opin. Struct. Biol. 7:463-469; the disclosures of which are incorporated herein by reference. Accordingly, non-antibody-based scaffolds or antagonist molecules in accordance herewith exhibiting selectivity for PCSK9 that counteract PCSK9-dependent inhibition of cellular LDL-uptake form important embodiments of the present invention. Aptamers (nucleic acid or peptide molecules capable of selectively binding a target molecule) are one specific example. They can be selected from random sequence pools or identified from natural sources such as riboswitches. Peptide aptamers, nucleic acid aptamers (e.g., structured nucleic acid, including both DNA and RNA-based structures) and nucleic acid decoys can be effective for selectively binding and inhibiting proteins of interest; see, e.g., Hoppe-Seyler & Butz, 2000 J. Mol. Med. 78:426-430; Bock et al., 1992 Nature 355:564-566; Bunka & Stockley, 2006 Nat. Rev. Microbiol. 4:588-596; Martell et al., 2002 Molec. Ther. 6:30-34; Jayasena, 1999 Clin. Chem. 45:1628-1650; the disclosures of which are incorporated herein by reference.
The three-dimensional structure of PCSK9 in complex with the AX132 FAb, determined using x-ray crystallography, revealed that a linear sequence of the light chain of this FAb encompassing residues 26-34 with a sequence of SQYVGSYLN (SEQ ID NO: 643) makes a specific interaction with the surface of PCSK9 used to bind the EGF-A domain of LDLR. This observation suggests that peptides, heterologous proteins, or other entities that include this sequence of amino acids could be designed and used to specifically disrupt the interaction between PCSK9 and LDLR. Smaller subsets of this sequence may also be useful, and the structural studies suggest that residues 28-32 (YVGSY) (SEQ ID NO: 644) appears to be the shortest such sequence that might confer specific recognition of the PCSK9 surface. Furthermore, the crystal structure of the PCSK9:AX132 Fab complex can be used to rationally design new chemical entities that embody similar interactions as that observed in the crystal structure. Accordingly, polypeptides or peptides comprising (or consisting essentially of: SEQ ID NO: 643 or SEQ ID NO: 644 are contemplated herein.
Given AX132's significant neutralizing activity and the activity of its variants, it is clearly of interest to identify other PCSK9-specific antagonists that bind to PCSK9 in the same manner as AX132 or one of its variants. One means of identifying antagonists and particularly antibodies that bind to the same region or epitope as AX132 or its variants, or an overlapping epitope is through a competition or similar assay where the candidate antibody or binding molecule would have to out-compete AX132 (or variant) for the epitope. Competitive antagonists encompassed herein are molecules that inhibit (i.e., prevent, or interfere with, AX132 (or variant) binding in comparison to a control) or reduce AX132 (or variant) binding by at least 50%, 60%, 70%, and 80% in order of increasing preference (even more preferably, at least 90% and, most preferably, at least 95%) at 1 μM or less with AX132 (or variant) at or below its KD, and in particular those molecules that antagonize (i) PCSK9 binding to the LDL receptor, (ii) PCSK9 internalization into cells, or (iii) both PCSK9 binding to the LDL receptor and PCSK9 internalization into cells. Competition between binding members may be readily assayed in vitro for example using ELISA and/or by monitoring the interaction of the antibodies with PCSK9 in solution. The exact means for conducting the analysis is not critical. PCSK9 may be immobilized to a 96-well plate or may be placed in a homogenous solution. In specific embodiments, the ability of unlabeled candidate antibody(ies) to block the binding of labeled AX132 (or variant) can be measured using radioactive, enzyme or other labels. In the reverse assay, the ability of unlabeled antibodies to interfere with the interaction of labeled AX132 (or variant) with PCSK9 wherein said AX132 (or variant) and PCSK9 are already bound is determined. In specific embodiments, (i) PCSK9 is contacted with labeled AX132 (or variant); (ii) PCSK9 is contacted with the candidate antibody or pool of antibodies; and (iii) antibodies capable of interrupting or preventing complexes between PCSK9 and AX132 (or variant) are identified. The readout in such an example is through measurement of bound label. AX132 (or variant) and the candidate antibody(ies) may be added in any order or at the same time.
Antibodies identified as AX132 (or variant) competitors in the above or other suitable assays may be tested for the ability to antagonize or neutralize (i) PCSK9 binding to the LDL receptor; and/or (ii) PCSK9 internalization into cells. These parameters may be measured through the use of assays similar to that employed or described in the current specification. In specific embodiments, the inhibition demonstrated by the competing antibody is at least about 10% inhibition. In other embodiments, the inhibition is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95%.
The present invention specifically encompasses PCSK9-specific antagonists and particularly monoclonal antibody molecules (and their corresponding amino acid and nucleic acid sequences) that selectively bind to the same epitope as AX132 (or variant) or an overlapping epitope interfering with AX132 (or variant)'s binding to PCSK9. Monoclonal antibodies that specifically bind to the epitope of AX132 (or variant), or an overlapping epitope antagonize or neutralize (i) PCSK9 binding to the LDL receptor; (ii) PCSK9 internalization into cells, or (iii) both. A monoclonal antibody molecule in accordance herewith may be an intact (complete or full length) antibody, a substantially intact antibody, or a portion or fragment of an antibody comprising an antigen-binding portion, e.g., a Fab fragment, Fab′ fragment or F(ab′)2 fragment of a murine antibody or of a chimeric antibody or of a humanized antibody or of a human antibody. Monoclonal, as used herein, refers to a homogeneous or substantially homogeneous (or pure) antibody population (i.e., at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, more preferably at least about 97% or 98%, or most preferably at least 99% of the antibodies in the population are identical and would compete in an ELISA assay for the same antigen or epitope). In specific embodiments of the present invention, the present invention provides monoclonal antibodies that (i) compete for binding to PCSK9 with a AX132 (or variant) antibody molecule, reducing AX132 (or variant) binding by at least 50% at 1 μM or less with AX132 (or variant) at or below its KD, (ii) block PCSK9 binding to the LDL receptor, (iii) inhibit PCSK9 internalization into the cell, and (iv) comprise a specific antigen-binding region, VH, VL, set of CDRs or heavy CDR3, heavy and/or light chain or any variant of these components as described herein.
In any of the above assays for identifying antibodies binding the same or overlapping epitope region as AX132 (or variant), binding of the known binder (i.e., AX132 (or variant) antibody molecule) as compared to the binding of the candidate binder should be distinguishable. This can (but need not) be accomplished through the use of labels on either or both molecules as will be readily appreciated by the skilled artisan. Labels, as used herein, refer to another molecule or agent incorporated into/affixed to the antibody molecule. In one embodiment, the label is a detectable marker, e.g., a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 90Y, 99Tc, 111In, 125I, 131I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), magnetic agents, such as gadolinium chelates, toxins such as pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
In particular embodiments, the present invention encompasses antagonists as described herein characterized as binding specifically to any epitope sequence selected from the group consisting of: SEQ ID NOs: 576, 577, 579-582 and 237-RDA, or regions therein such as 157-NL-158 or SEQ ID NO: 578. In particular embodiments, the epitope sequence is within SEQ ID NOs: 576 and/or 577, or sub-regions therein such as 157-NL-158 or SEQ ID NO: 578. In particular embodiments, the antagonists described herein bind to SEQ ID NOs: 579, 580, 581 and 582, as well as 237-RDA. These epitopes are described further in Example 8 and in FIG. 4. The numerical numbers provide the starting and/or ending position on human PCSK9.
In specific embodiments, binding of a PCSK9-specific antagonist is significantly reduced or a mutant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5 or more) mutations at the following residue positions: 192 and 379, as compared to a wild-type PCSK9 protein (SEQ ID NO: 642). In certain embodiments, binding of a PCSK9-specific antagonist is significantly reduced for a mutant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5 or more) of the following mutations: D192G and F379Y.
An AX132 (or variant) antibody used as the standard for the competition assays may be any antibody molecule described herein. Molecules (peptides, antagonists, antibody molecules, etc.) tested may be from any source or library. In particular embodiments, the molecules are selected from a phage display library. In specific embodiments the molecules are selected using an EGF_AB peptide (293-DKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQ RRCEDIDECQDPDTCSQLCVNLE-372; SEQ ID NO: 645) that competes with AX132 in a manner similar to that described in Example 11.
Expression and selection of any of the PCSK9-specific antagonists described in the present application may be achieved using suitable technologies including, but not limited to phage display (see, e.g., International Application Number WO 92/01047, Kay et al., 1996 Phage Display of Peptides and Proteins: A Laboratory Manual, San Diego: Academic Press), Wang et al., 2010 J. Mol. Biol. 1088-1101; Wang et al., U.S. Pat. No. 7,175,983, yeast display, bacterial display, T7 display, and ribosome display (see, e.g., Lowe & Jermutus, 2004 Curr. Pharm. Biotech. 517-527).
Particular PCSK9-specific antagonists forming part of the present invention are antibody molecules or antibodies. “Antibody molecule” or “Antibody” as described herein refers to an immunoglobulin-derived structure with selective binding to human PCSK9 including, but not limited to, a full length or whole antibody, an antigen binding fragment (a fragment derived, physically or conceptually, from an antibody structure), a derivative of any of the foregoing, a fusion of any of the foregoing with another polypeptide, or any alternative structure/composition which incorporates any of the foregoing for purposes of selectively binding to/inhibiting the function of PCSK9. Antibody molecules can exist, for example, as intact immunoglobulins or as a number of well characterized fragments produced by, for example, digestion with various peptidases. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as a myriad of immunoglobulin variable region genes. Light chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. “Whole” antibodies or “full length” antibodies often refers to proteins that comprise two heavy (H) and two light (L) chains inter-connected by disulfide bonds which comprise: (1) in terms of the heavy chains, a variable region (abbreviated herein as “VH”) and a heavy chain constant region which comprises three domains, CH1, CH2, and CH3; and (2) in terms of the light chains, a light chain variable region (abbreviated herein as “VL”) and a light chain constant region which comprises one domain, CL. Pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)′2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)′2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the F(ab)′2 dimer into an Fab′ monomer. The Fab′ monomer is essentially a Fab with part of the hinge region broken. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab′ fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies.
Antibody fragments and, more specifically, antigen binding fragments are molecules possessing an antibody variable region or segment thereof (which comprises one or more of the disclosed CDR 3 or CDR2 domains, heavy and/or light, within framework regions of heavy and/or light chains, as appropriate), which confers selective binding to PCSK9, and particularly human PCSK9. Antibody fragments containing such an antibody variable region include, but are not limited to the following antibody molecules: a Fab, a F(ab′)2, a Fd, a Fv, a scFv, ccFv, bispecific antibody molecules (antibody molecules comprising a PCSK9-specific antibody or antigen binding fragment as disclosed herein linked to a second functional moiety having a different binding specificity than the antibody, including, without limitation, another peptide or protein such as an antibody, or receptor ligand), a bispecific single chain Fv dimer, an isolated CDR3, a minibody, a ‘scAb’, a dAb fragment, a diabody, a triabody, a tetrabody, a minibody, and artificial antibodies based upon protein scaffolds, including but not limited to fibronectin type III polypeptide antibodies (see, e.g., U.S. Pat. No. 6,703,199 and International Application Numbers WO 02/32925 and WO 00/34784) or cytochrome B; see, e.g., Nygren et al., 1997 Curr. Opinion Struct. Biol. 7:463-469; the disclosures of which are incorporated herein by reference. The antibody portions or binding fragments may be natural, or partly or wholly synthetically produced. Such antibody portions can be prepared by various means known by one of skill in the art, including, but not limited to, conventional techniques, such as papain or pepsin digestion. One of skill in the art will, furthermore, appreciate that any of the above antibody molecules, including full length as well as the various antibody fragments, may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes full length antibodies and antibody fragments either produced by the generation or modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies.
The term “isolated” as used herein in reference to antibody molecules, PCSK9-specific antagonists in general, encoding nucleic acid or other describes a property as it pertains to the disclosed PCSK9-specific antagonists, nucleic acid or other that makes them different from that found in nature. The difference can be, for example, that they are of a different purity than that found in nature, or that they are of a different structure or form part of a different structure than that found in nature. A structure not found in nature, for example, includes recombinant human immunoglobulin structures including, but not limited to, recombinant human immunoglobulin structures with optimized CDRs. Other examples of structures not found in nature are PCSK9-specific antagonists or nucleic acid substantially free of other cellular material. Isolated PCSK9-specific antagonists are generally free of other protein-specific antagonists having different protein specificities (i.e., possess an affinity for other than PCSK9).
In one particular aspect, the present invention provides isolated PCSK9-specific antagonists which antagonize PCSK9 function. In particular embodiments, said PCSK9-specific antagonists inhibit human PCSK9's antagonism of cellular LDL uptake by interfering with PCSK9 binding to the LDL receptor and resultant PCSK9 cell internalization. Disclosed PCSK9-specific antagonists, thus, form desirable molecules for lowering plasma LDL-cholesterol levels; see, e.g., Cohen et al., 2005 Nat. Genet. 37:161-165 (wherein significantly lower plasma LDL cholesterol levels were noted in individuals heterozygous for a nonsense mutation in allele PCSK9); Rashid et al., 2005 Proc. Natl. Acad. Sci. USA 102:5374-5379 (wherein PCSK9-knockout mice evidenced increased numbers of LDLRs in hepatocytes, accelerated plasma LDL clearance, and significantly lower plasma cholesterol levels); and Cohen et al., 2006 N Engl. J. Med. 354:1264-1272 (wherein humans heterozygous for mutated, loss of function, PCSK9 exhibited a significant reduction in the long-term risk of developing atherosclerotic heart disease).
Through repeat experiments, antibody molecules tested herein herein dose-dependently inhibited the effects of both human PCSK9 on LDL uptake. In specific embodiments, the present invention, thus, encompasses isolated PCSK9-specific antagonists as described herein, as well as equivalents (characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions that do not degrade the PCSK9-selective property of the disclosed AX132 or variant antibody molecules) or homologs thereof. Particular embodiments comprise isolated PCSK9-specific antagonists that comprise the CDR domains disclosed herein or sets of heavy and/or light chain CDR domains disclosed herein, or equivalents thereof, characterized as having one or more amino acid substitutions.
Use of the terms “domain” or “region” herein simply refers to the respective portion of the antibody molecule wherein the sequence or segment at issue will reside or, in the alternative, currently resides.
In specific embodiments, the present invention provides isolated PCSK9-specific antagonists and, in more specific embodiments, antibody molecules that comprise (i) a heavy chain variable region selected from the group consisting of: SEQ ID NOs: 360-510 and/or (ii) a light chain variable region selected from the group consisting of: SEQ ID NOs: 511-549; equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions, and homologs thereof. This group also encompasses, for SEQ ID NOs: 360, 362, and 364-510, PCSK9 antibody molecules that do not have the last 3 amino acid residues in the sequence (see, e.g., SEQ ID NOs: 361 and 363); due to varying interpretations on variable region boundaries. The disclosed antagonists should counteract or inhibit human PCSK9-dependent inhibition of cellular LDL uptake. In specific embodiments, the present invention provides homologs of the disclosed antagonists characterized as comprising a heavy chain variable and/or a light chain variable region being at least 90% (or in specific embodiments, at least 95%, 97% or 99%) identical in sequence to either or both, respectively, of (i) a heavy chain variable region selected from the group consisting of: SEQ ID NOs: 360-510 and/or (ii) a light chain variable region selected from the group consisting of: SEQ ID NOs: 511-549; said antagonists which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
In particular embodiments, the present invention provides isolated PCSK9-specific antagonists and, in more specific embodiments, PCSK9 antibody molecules that comprise (i) variable heavy CDR3 sequence selected from the group consisting of: SEQ ID NOs: 1-5, 7, 9, 11, 13-63 and residues 4-12 of SEQ ID NOs: 1, 3, 5, 9 and 13-63 and/or (ii) variable light CDR3 sequence selected from the group consisting of: SEQ ID NOs: 295-301, 303, 305-334 and residues 4-13 of SEQ ID NOs: 295, 297, 299, 301 and 305-334; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions; specific embodiments of which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%. Specific embodiments provide isolated antagonists which additionally comprise in the heavy and/or light chain variable regions CDR1 and/or CDR2 sequences as described herein; or equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions in any one or more of the CDR sequences. In specific embodiments, the present invention provides homologs of the disclosed antagonists characterized as being at least 90% (in specific embodiments, 95%, 97%, or 99%) identical to the CDR3 sequences or within each of the CDR1, CDR2 and CDR3 sequences; said antagonists which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
In particular embodiments, the present invention provides isolated PCSK9-specific antagonists and, in more specific embodiments, PCSK9 antibody molecules that comprise (i) variable heavy CDR2 sequence selected from the group consisting of: SEQ ID NOs: 64-68, 70, 72, 74, 76-182 and residues 4-20 of SEQ ID NOs: 64, 66, 68, 72 and 76-182 and/or (ii) variable light CDR2 sequence selected from the group consisting of: SEQ ID NOs: 335-339, 341, 343-346, and residues 4-10 of SEQ ID NOs: 335, 337, 339 and 343-346; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions; specific embodiments of which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%. Specific embodiments provide isolated antagonists which additionally comprise heavy and/or light chain variable regions CDR1 and/or CDR3 sequences as described herein; or equivalents thereof characterized as having one or more (in specific embodiments, 1-5 or 1-3) amino acid substitutions in any one or more of the CDR sequences. In specific embodiments, the present invention provides homologs of the disclosed antagonists characterized as being at least 90% (in specific embodiments, 95%, 97%, or 99%) identical to the CDR2 sequences or within each of the CDR1, CDR2 and CDR3 sequences; said antagonists which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
Select variable heavy CDR1 regions comprise sequence selected from the group consisting of: SEQ ID NOs: 183-189, 191, 193, 195 197-294, and residues 4-13 of SEQ ID NOs: 183, 185, 187, 189, 193 and 197-294; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions.
Select variable light CDR1 regions comprise sequence selected from the group consisting of: SEQ ID NOs: 347-349, 351, 353-359, and residues 4-14 of SEQ ID NOs: 347, 349 and 353-359; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions.
Specific embodiments provide isolated PCSK9-specific antagonists and, in more specific embodiments, antibody molecules which comprise one or more (in particular embodiments, one of each CDR1, 2, and 3 regions) heavy chain variable region CDR1, CDR2, and CDR3 sequences and light chain variable region CDR1, CDR2, and CDR3 sequences as disclosed herein; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions in any one or more of the CDR sequences; specific embodiments of which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%. In specific embodiments, the present invention provides homologs of the disclosed antagonists characterized as being at least 90% (in specific embodiments, 95%, 97%, or 99%) identical over the disclosed heavy and light chain variable region CDR1, CDR2 and CDR3 sequences, respectively; said antagonists which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
One particular aspect of the present invention encompasses isolated PCSK9-specific antagonists and, in more specific embodiments, antibody molecules which are variants of that disclosed above which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
Additional distinct embodiments encompass isolated PCSK9-specific antagonists which comprise: (a) a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is selected from the group consisting of: SEQ ID NOs: 183-189, 191, 193, 195, 197-294, and residues 4-13 of SEQ ID NOs: 183, 185, 187, 189, 193, and 197-294; (ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NOs: 64-68, 70, 72, 74, 76-182 and residues 4-20 of SEQ ID NOs: 64, 66, 68, 72 and 76-182; and (iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NOs: 1-5, 7, 9, 11, 13-63, and residues 4-12 of SEQ ID NOs: 1, 3, 5, 9 and 13-63 and/or (b) a light chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is selected from the group consisting of: SEQ ID NOs: 347-349, 351, 353-359, and residues 4-14 of SEQ ID NOs: 347, 349 and 353-359; (ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NOs: 335-339, 341, 343-346 and residues 4-10 of SEQ ID NOs: 335, 337, 339, and 343-346; and (iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NOs: 295-301, 303, 305-334, and residues 4-13 of SEQ ID NOs: 295, 297, 299, 301 and 305-334; and equivalents thereof characterized as having one or more (in particular embodiments, 1-5 or 1-3) amino acid substitutions; specific embodiments of which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
In specific embodiments herein the CDRs are in place of the corresponding regions of AX132 (or disclosed variants) or alternative antagonist, antibody molecule or scaffold structure with or without amino acid substitutions (in specific embodiments, 1-5 or 1-3); specific embodiments of which inhibit human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
Particular embodiments are isolated PCSK9-specific antagonists which comprise the above-described VH and VL regions in a full length antibody. Specific embodiments herein further comprise a series of amino acids selected from the group consisting of: SEQ ID NO: 572 (IgG1), SEQ ID NO: 573 (IgG2), SEQ ID NO: 574 (IgG4) and SEQ ID NO: 575 (IgG2 m4).
Amino acid substitutions encompassed herein may be conservative or non-conservative amino acid substitutions. Amino acid substitutions, as one of ordinary skill in the art will appreciate, are substitutions that replace an amino acid residue with one imparting similar or better (for the intended purpose) functional and/or chemical characteristics. Antagonists bearing amino acid substitutions can be tested for retained or better activity using functional assays available in the art or described herein. PCSK9-specific antagonists possessing one or more amino acid substitutions which retain the ability to selectively bind to human PCSK9 and antagonize PCSK9 functioning at a level the same or better than AX132 (or variant) antibody molecules as described herein are referred to herein as “functional equivalents” of the disclosed antagonists and form specific embodiments of the present invention. Conservative amino acid substitutions are often ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Modifications as described above may or may not be designed to significantly alter the binding or functional inhibition characteristics of the PCSK9-specific antagonist, and may improve such properties. The purpose for making a substitution is not significant and can include, but is by no means limited to, replacing a residue with one better able to maintain or enhance the structure of the molecule, the charge or hydrophobicity of the molecule, or the size of the molecule. For instance, one may desire simply to substitute a less desired residue with one of the same polarity or charge. Such modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. One specific means by which those of skill in the art accomplish conservative amino acid substitutions is alanine scanning mutagenesis as discussed in, for example, MacLennan et al., 1998 Acta Physiol. Scand. Suppl. 643:55-67, and Sasaki et al., 1998 Adv. Biophys. 35:1-24.
In one specific embodiment of the present invention, a CDR disclosed herein is altered so as to generate a more stable variant or a variant that is recombinantly expressed at higher levels. For example, if Asn-Gly or Asp-Gly is in a CDR, the invention encompasses variants wherein the Asp or Asn is changed to Glu or Ala or wherein the Gly is changed to Ala. A benefit of such a change is removal of the potential for isoaspartate formation. Also, if a Met is in a CDR in an exposed position, the scope of the present invention includes variants wherein the Met is changed to Lys, Leu, Ala, or Phe. A benefit of such a change is removal of the potential for methionine oxidation. If an Asn is in a CDR of the invention, the scope of the present invention includes variants wherein Asn is changed to Gln or Ala. A benefit of such a change is removal of the potential for deamidation. Furthermore, if an Asn-Pro is in a CDR of the present invention, the present invention includes variants wherein Asn is changed to Gln or Ala or wherein Pro is changed to Ala. A benefit of such a change is removal of a possible scissile Asn-Pro peptide bond. The scope of the invention includes embodiments wherein the heavy or light chain CDRs of any of the disclosed antibody molecules are independently changed in one or more places as described above.
In another aspect, the present invention provides isolated PCSK9-specific antagonists and, in more specific embodiments, antibody molecules which comprise heavy and/or light chain variable regions comprising amino acid sequences that are homologous to the corresponding amino acid sequences of the disclosed antibodies, wherein the antibody molecules inhibit PCSK9-dependent inhibition of cellular LDL uptake. Specific embodiments are antagonists which comprise heavy and/or light chain variable regions which are at least 90% identical to disclosed heavy and/or light chain variable regions (or heavy and/or light chains), respectively. Reference to “at least 90% identical” includes at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100% identical sequences along the full length of the molecule disclosed herein.
PCSK9-specific antagonists with amino acid sequences homologous to the amino acid sequences of antagonists described herein are typically produced to improve one or more of the properties of the antagonist without negatively impacting its specificity for PCSK9. One method of obtaining such sequences, which is not the only method available to the skilled artisan, is to mutate sequence encoding the PCSK9-specific antagonist or specificity-determining region(s) thereof, express an antagonist comprising the mutated sequence(s), and test the encoded antagonist for retained function using available functional assays including those described herein. Mutation may be by site-directed or random mutagenesis. As one of skill in the art will appreciate, however, other methods of mutagenesis can readily bring about the same effect. For example, in certain methods, the spectrum of mutants are constrained by non-randomly targeting amino acid substitutions based on either amino acid chemical or structural characteristics, or else by protein structural considerations. In affinity maturation experiments, several such mutations may be found in a single selected molecule, whether they are randomly or non-randomly selected. There are also various structure-based approaches toward affinity maturation as demonstrated in, e.g., U.S. Pat. No. 7,117,096, PCT Pub. Nos.: WO 02/084277 and WO 03/099999; the disclosures of which are incorporated herein by reference.
As used herein, the percent homology between two amino acid or nucleic acid sequences is equivalent to the percent identity between the two sequences, and these two terms will be used interchangeably throughout. As used herein, % identity of two nucleic acid or amino acid sequences is determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990 J. Mol. Biol. 215:403-410. BLAST nucleotide searches are performed with the NBLAST program, score=100, wordlength=12, to obtain nucleic acid sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches are performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to an amino acid sequence disclosed herein. To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in Altschul et al., 1997 Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used.
Utilization of components of one or more disclosed PCSK9-specific molecules to produce other binding molecules with similar or better specificity is well within the realm of one skilled in the art. This can be accomplished, for example, using techniques of recombinant DNA technology. One specific example of this involves the introduction of DNA encoding the immunoglobulin variable region, or one or more of the CDRs, of an antibody to the variable region, constant region, or constant region plus framework regions, as appropriate, of a different immunoglobulin. Such molecules form important aspects of the present invention. Specific immunoglobulins or the corresponding sequences, into which particular disclosed sequences may be inserted or, in the alternative, form the essential part of, include but are not limited to the following antibody molecules which form particular embodiments of the present invention: a Fab (monovalent fragment with variable light (VL), variable heavy (VH), constant light (CL) and constant heavy 1 (CH1) domains), a F(ab′)2 (bivalent fragment comprising two Fab fragments linked by a disulfide bridge or alternative at the hinge region), a Fd (VH and CH1 domains), a Fv (VL and VH domains), a scFv (a single chain Fv where VL and VH are joined by a linker, e.g., a peptide linker, see, e.g., Bird et al., 1988 Science 242:423-426, Huston et al., 1988 PNAS USA 85:5879-5883), a bispecific antibody molecule (an antibody molecule comprising a PCSK9-specific antibody or antigen binding fragment as disclosed herein linked to a second functional moiety having a different binding specificity than the antibody, including, without limitation, another peptide or protein such as an antibody, or receptor ligand), a bispecific single chain Fv dimer (see, e.g., PCT/US92/09965), an isolated CDR3, a minibody (single chain-CH3 fusion that self assembles into a bivalent dimer of about 80 kDa), a ‘scAb’ (an antibody fragment containing VH and VL as well as either CL or CH1), a dAb fragment (VH domain, see, e.g., Ward et al., 1989 Nature 341:544-546, and McCafferty et al., 1990 Nature 348:552-554; or VL domain; Holt et al., 2003 Trends in Biotechnology 21:484-489), a diabody (see, e.g., Holliger et al., 1993 PNAS USA 90:6444-6448 and International Application Number WO 94/13804), a triabody, a tetrabody, a minibody (a scFv joined to a CH3; see, e.g., Hu et al., 1996 Cancer Res. 56:3055-3061), IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgD, IgA, IgE or any derivatives thereof, and artificial antibodies based upon protein scaffolds, including but not limited to fibronectin type III polypeptide antibodies (see, e.g., U.S. Pat. No. 6,703,199 and International Application Number WO 02/32925) or cytochrome B; see, e.g., Koide et al., 1998 J. Molec. Biol. 284:1141-1151, and Nygren et al., 1997 Current Opinion in Structural Biology 7:463-469; the disclosures of which are incorporated herein by reference. Certain antibody molecules including, but not limited to, Fv, scFv, diabody molecules or domain antibodies (Domantis) may be stabilized by incorporating disulfide bridges to line the VH and VL domains, see, e.g., Reiter et al., 1996 Nature Biotech. 14:1239-1245; the disclosure of which is incorporated herein by reference. Bispecific antibodies may be produced using conventional technologies (see, e.g., Holliger & Winter, 1993 Current Opinion Biotechnol. 4:446-449, specific methods of which include production chemically, or from hybrid hybridomas) and other technologies including, but not limited to, the BiTETM technology (molecules possessing antigen binding regions of different specificity with a peptide linker) and knobs-into-holes engineering (see, e.g., Ridgeway et al., 1996 Protein Eng. 9:616-621; the disclosure of which is incorporated herein by reference). Bispecific diabodies may be produced in E. coli, and these molecules as other PCSK9-specific antagonists, as one of skill in the art will appreciate, may be selected using phage display in the appropriate libraries (see, e.g., International Application Number WO 94/13804; the disclosure of which is incorporated herein by reference).
Variable domains, into which CDRs of interest are inserted, may be obtained from any germ-line or rearranged human variable domain. Variable domains may also be synthetically produced. The CDR regions can be introduced into the respective variable domains using recombinant DNA technology. One means by which this can be achieved is described in Marks et al., 1992 Bio/Technology 10:779-783; the disclosure of which is incorporated herein by reference. A variable heavy domain may be paired with a variable light domain to provide an antigen binding site. In addition, independent regions (e.g., a variable heavy domain alone) may be used to bind antigen. The artisan is well aware, as well, that two domains of an Fv fragment, VL and VH, while perhaps coded by separate genes, may be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (scFvs).
Specific embodiments provide the CDR(s) in germline framework regions. Framework regions, including but not limited to human framework regions, are known to those of skill in the art (e.g., a human or non-human framework). The framework regions may be naturally occurring or consensus framework regions. In one aspect, the framework region of an antibody of the invention is human (see, e.g., Clothia et al., 1998 J. Mol. Biol. 278:457-479 for a listing of human framework regions; said disclosure of which is incorporated herein by reference in its entirety). Specific embodiments herein provide the disclosed heavy and/or light chain variable CDR3 sequences into VH3 or VK3, respectively, in place of the relevant CDR. Specific embodiments herein provide the disclosed heavy and/or light chain variable CDR1, CDR2 and/or CDR3 sequences into VH3 or VK3, respectively, in place of the relevant CDRs.
The present invention encompasses antibody molecules that are human, humanized, deimmunized, chimeric and primatized. The invention also encompasses antibody molecules produced by the process of veneering; see, e.g., Mark et al., 1994 Handbook of Experimental Pharmacology, vol. 113: The pharmacology of monoclonal Antibodies, Springer-Verlag, pp. 105-134; the disclosure of which is incorporated herein by reference. “Human” in reference to the disclosed antibody molecules specifically refers to antibody molecules having variable and/or constant regions derived from human germline immunoglobulin sequences, wherein said sequences may, but need not, be modified/altered to have certain amino acid substitutions or residues that are not encoded by human germline immunoglobulin sequence. Such mutations can be introduced by methods including, but not limited to, random or site-specific mutagenesis in vitro, or by somatic mutation in vivo. Specific examples of mutation techniques discussed in the literature are that disclosed in Gram et al., 1992 PNAS USA 89:3576-3580; Barbas et al., 1994 PNAS USA 91:3809-3813, and Schier et al., 1996 J. Mol. Biol. 263:551-567; the disclosures of which are incorporated herein by reference. These are only specific examples and do not represent the only available techniques. There are a plethora of mutation techniques in the scientific literature which are available to, and widely appreciated by, the skilled artisan. “Humanized” in reference to the disclosed antibody molecules refers specifically to antibody molecules wherein CDR sequences derived from another mammalian species, such as a mouse, are grafted onto human framework sequences. “Primatized” in reference to the disclosed antibody molecules refers to antibody molecules wherein CDR sequences of a non-primate are inserted into primate framework sequences, see, e.g., WO 93/02108 and WO 99/55369; the disclosures of which are incorporated herein by reference.
Specific antibodies of the present invention are monoclonal antibodies and, in particular embodiments, are in one of the following antibody formats: IgD, IgA, IgE, IgM, IgG1, IgG2, IgG3, IgG4 or any derivative of any of the foregoing. The language “derivatives thereof” or “derivatives” in this respect includes, inter alia, (i) antibodies and antibody molecules with amino acid modifications in one or both variable regions (i.e., VH and/or VL), (ii) antibodies and antibody molecules with manipulations in the constant regions of the heavy and/or light chains, and/or (iii) antibodies and antibody molecules that contain additional chemical moieties which are not normally a part of the immunoglobulin molecule (e.g., pegylation).
Manipulations of the variable regions can be within one or more of the VH and/or VL CDR regions. Site-directed mutagenesis, random mutagenesis or other method for generating sequence or molecule diversity can be utilized to create mutants which can subsequently be tested for a particular functional property of interest in available in vitro or in vivo assays including those described herein.
Antibodies of the present invention also include those in which modifications have been made to the framework residues within VH and/or VL to improve one or more properties of the antibody of interest. Typically, such framework modifications are made to decrease the immunogenicity of the antibody. For example, one approach is to “backmutate” one or more framework residues to the corresponding germline sequence. More specifically, an antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived. Such “backmutated” antibodies are also intended to be encompassed by the invention. Another type of framework modification involves mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T cell epitopes to thereby reduce the potential immunogenicity of the antibody. This approach is also referred to as “deimmunization” and is described in further detail in U.S. Patent Publication No. 20030153043 by Carr et al; the disclosure of which is incorporated herein by reference.
In addition or alternative to modifications made within the framework or CDR regions, antibodies of the invention may be engineered to include modifications within the Fc or constant regions, where present, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity.
The concept of generating “hybrids” or “combinatorial” IgG forms comprising various antibody isotypes to hone in on desired effector functionality has generally been described; see, e.g., Tao et al., 1991 J. Exp. Med. 173:1025-1028. A specific embodiment of the present invention encompasses antibody molecules that possess specific manipulations in the Fc region which have been found to result in reduced or altered binding to FcγR receptors, C1q or FcRn on the part of the antibody. The present invention, therefore, encompasses antibodies in accordance with the present description that do not provoke (or provoke to a lesser extent) antibody-dependent cellular cytotoxicity (“ADCC”), complement-mediated cytotoxicity (“CMC”), or form immune complexes, while retaining normal pharmacokinetic (“PK”) properties. Specific embodiments of the present invention provide an antibody molecule as defined in accordance with the present invention which comprises, as part of its immunoglobulin structure, SEQ ID NO: 575 and, in particular embodiments, residues 107-326 of SEQ ID NO: 575 as part of the immunoglobulin structure. The present invention encompasses antibody molecules which comprise: (i) a light chain variable region selected from the group consisting of: SEQ ID NOs: 511-549 (and in specific embodiments, selected from the group consisting of: SEQ ID NOs: 511-518, 520-524 and 526-549), and (ii) a heavy chain variable region selected from the group consisting of: SEQ ID NOs: 360-510 in sequence with (adjacent to) or followed by a series of amino acids selected from the group consisting of: SEQ ID NO: 572 (IgG1), SEQ ID NO: 573 (IgG2), SEQ ID NO: 574 (IgG4) and SEQ ID NO: 575 (IgG2 m4). In particular embodiments, the light chain and heavy chain pairings of (i) and (ii) above are (a) SEQ ID NOs: 360 and 511, and (b) SEQ ID NOs: 362 and 511.
The present invention also encompasses crystals The present invention includes crystals comprising any PCSK9-specific antagonist of the invention complexed with PCSK9 or a peptide epitope thereof.
Several crystallization methods are known in the art (Giegé, et al., (1994) Acta Crystallogr. D50: 339-350; McPherson, (1990) Eur. J. Biochem. 189: 1-23). Such methods include microbatch, hanging drop, seeding and dialysis. Preferably, hanging-drop vapor diffusion (McPherson, (1976) J. Biol. Chem. 251: 6300-6303) or microbatch methods (Chayen (1997) Structure 5: 1269-1274) are used. In each of these methods, it is important to promote continued crystal growth after nucleation by maintaining a supersaturated solution. In the microbatch method, polypeptide is mixed with precipitants to achieve supersaturation, the vessel is sealed and set aside until crystals appear. In the dialysis method, polypeptide is retained in a sealed dialysis membrane which is placed into a solution containing precipitant. Equilibration across the membrane increases the precipitant concentration thereby causing the polypeptide to reach supersaturation levels.
Once a crystal of the present invention is grown, X-ray diffraction data can be collected. One method for determining structure with X-ray diffraction data includes use of synchrotron radiation, under standard cryogenic condition; however, alternative methods may also be used. For example, crystals can be characterized by using X-rays produced by a conventional source, such as a sealed tube or a rotating anode. Methods of characterization include, but are not limited to, precession photography, oscillation photography and diffractometer data collection.
The crystallizable compositions provided by this invention are amenable to X-ray crystallography for providing the three-dimensional structure of the PCSK9/PCSK9-specific antagonist complex. The present invention includes crystals which effectively diffract X-rays for the determination of the atomic coordinates of the PCSK9/PCSK9-specific antagonist complex to a resolution of greater than about 5.0 Ångströms (e.g., about 4.5 Å, about 4.0 Å, about 3 Å, about 2.5 Å, about 2 Å, about 1.95 Å, about 1 Å), preferably greater than about 4.0 Ångströms (e.g., about 3 Å, about 2.5 Å, about 2 Å, about 1.95 Å, about 1 Å), more preferably greater than about 2.8 Ångströms (e.g., about 2.5 Å, about 2 Å, about 1.95 Å, about 1 Å) and most preferably greater than about 2.0 Ångströms (e.g., about 1.95 Å, about 1.5 Å, about 1.0 Å).
The scope of the present invention also encompasses a crystalline complex between a PCSK9-specific antagonist of the present invention (e.g., a Fab comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 552 and the light chain amino acid sequence set forth in SEQ ID NO: 554) and PCSK9 in space group The complex of PCSK9 and the AX132 Fab fragment crystallized in space group P65 and comprising the unit cell dimensions a=155.946 Å, b=155.946 Å, c=160.037 Å and α=90°, β=90°, γ=120°, wherein the Fab is derived from the antibody AX132 as described herein.
The present invention includes PCSK9/PCSK9-specific antagonist complex crystals whose three-dimensional structure is described by the structure coordinates set forth in Table 14. The scope of the present invention also includes crystals that possess structural coordinates which are similar to those set forth in Table 14. Structural similarity between crystals is discussed in detail below.
The term “structure coordinates” refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a beam of X-rays by the atoms (scattering centers) of a molecule. The diffraction data are used to calculate electron density maps and to establish the positions of the individual atoms of the molecule.
Those of skill in the art will understand that a set of structure coordinates for an enzyme or an enzyme-complex or a portion thereof, is a relative set of points that define a shape in three dimensions. Thus, it is possible that an entirely different set of coordinates could define a similar or identical shape. Moreover, slight variations in the individual coordinates will have little effect on overall shape.
The present invention includes crystals exhibiting structural coordinates which are similar to those set forth in Table 14 but for crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, additions, subtractions, rotations or translations to sets of the structure coordinates or any combinations of the above.
Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal may also account for variations in structure coordinates. If such variations are within an acceptable standard error as compared to the coordinates of Table 14, the resulting three-dimensional shape is considered to be the same and, accordingly, the modified crystal is considered to be within the scope of the present invention.
Various computational analyses may be used to determine whether a crystal is sufficiently similar to the crystals whose structural coordinates are set forth in Table 14 as to be considered the same. Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, Calif.) version 4.1, and as described in the accompanying User's Guide.
The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. In general, the procedure used in Molecular Similarity to compare structures is divided into four steps: 1) input the structures to be compared; 2) define the atom equivalences in these structures; 3) perform a fitting operation; and 4) analyze the results. Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention we will define equivalent atoms as alpha carbon atoms (Cα) or all protein backbone atoms (N, Cα, C and O) for all conserved residues between the two structures being compared. When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses a least squares fitting algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in Ångströms, is reported by QUANTA.
The term “root mean square deviation” (RMSD) is a commonly known term in the art which, in general, means the square root of the arithmetic mean of the squares of the deviations from the mean distance of corresponding atoms. It is a way to express the deviation or variation from a trend or object.
The term “least squares” relates to a method based on the principle that the best estimate of a value is that in which the sum of the squares of the deviations of observed values is a minimum.
For the purpose of this invention, any crystalline molecule characterized by a set of structure coordinates that has a RMSD of conserved residue backbone atoms (N, Cα, C, O) or of alpha carbon atoms (Cα) only of less than about 1.5 Å when superimposed—using backbone atoms or alpha carbon atoms—on the relevant structure coordinates of Table 14 are considered identical and are within the scope of the present invention. In an embodiment, the root mean square deviation is about 1.5 Å or about 1.0 Å or about 0.75 Å or about 0.5 Å or about 0.25 Å or about 0.10 Å.
The present invention also encompasses any non-crystalline PCSK9-specific antagonist that, when converted to Fab format, binds to human PCSK9 in a manner characterized by a three dimensional structure which is characterized by a set of structure coordinates that has a RMSD of conserved residue backbone atoms (N, Cα, C, O) or of alpha carbon atoms (Cα) only of less than about 1.5 Å when superimposed—using backbone atoms or alpha carbon atoms—on the relevant structure coordinates of Table 14 are considered identical and are within the scope of the present invention. In an embodiment, the root mean square deviation is about 1.5 Å or about 1.0 Å or about 0.75 Å or about 0.5 Å or about 0.25 Å or about 0.10 Å.
In particular embodiments, the present invention encompasses PCSK9-specific antagonists that bind to PCSK9 within 10 Å or less from at least one (in specific embodiments, at least 2, 4, 10, 15, 20, 25, 30 or 35; or all) of the following residues on PCSK9: S153, I154, P155, W156, N157, L158, D192, H193, R194, E195, I196, E197, G198, R199, 5221, H229, G232, S235, G236, 8237, D238, A239, G240, K243, G244, D367, I368, I369, G370, A371, S372, S373, D374, C375, 5376, T377, C378, F379, V380, S381. In specific embodiments, the present invention encompasses PCSK9-specific antagonists that bind to PCSK9 within 5 Å or less from at least one (in specific embodiments, at least 2, 4 or 10; or all) of the following residues on PCSK9: S153, P155, R194, E195, R237, D238, A239, I369, D374, C375, S376, T377, C378, F379.
Specific PCSK9-specific antagonists may carry a detectable label, or may be conjugated to a toxin (e.g., a cytotoxin), a radioactive isotope, a radionuclide, a liposome, a targeting moiety, a biosensor, a cationic tail, or an enzyme (e.g., via a peptidyl bond or linker). Such PCSK9-specific antagonist compositions form an additional aspect of the present invention.
In another aspect, the present invention provides isolated nucleic acid encoding disclosed PCSK9-specific antagonists. “Isolated” as mentioned prior refers to the property of the thing referred to that makes them different from that found in nature. The difference can be, for example, that they are of a different purity than that found in nature, or that they are of a different structure or form part of a different structure than that found in nature. An example of nucleic acid not found in nature is, for example, nucleic acid substantially free of other cellular material. The nucleic acid may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. In specific instances, a nucleic acid may be isolated when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, for example, using standard techniques, including without limitation, alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and other suitable methods known in the art. The nucleic acid may include DNA (inclusive of cDNA) and/or RNA. Nucleic acids of the present invention can be obtained using standard molecular biology techniques. For antibodies expressed by hybridomas (e.g., hybridomas prepared from transgenic mice carrying human immunoglobulin genes), cDNAs encoding the light and heavy chains of the antibody made by the hybridoma can be obtained by standard PCR amplification or cDNA cloning techniques. For antibodies obtained from an immunoglobulin gene library (e.g., using phage display techniques), nucleic acid encoding the antibody can be recovered from the library.
The present invention encompasses isolated nucleic acid encoding disclosed variable heavy and/or light chains and select components thereof, particularly the disclosed variable or respective CDR regions. In specific embodiments hereof, the CDR(s) are provided within antibody framework regions and, in particular embodiments, human framework regions. Specific embodiments provide isolated nucleic acid encoding the CDR(s) into germline framework regions including, but not limited to, human germline framework regions. Specific embodiments herein provide isolated nucleic acid encoding heavy chain CDR3 sequence selected from the group consisting of: SEQ ID NOs: 1-5, 7, 9, 11, 13-63, and residues 4-12 of SEQ ID NOs: 1, 3, 5, 9, and 13-63 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 6, 8, 10 and 12). Specific embodiments herein provide isolated nucleic acid encoding heavy chain CDR2 sequence selected from the group consisting of: SEQ ID NOs: 64-68, 70, 72, 74, 76-182, and residues 4-20 of SEQ ID NOs: 64, 66, 68, 72 and 76-182 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 69, 71, 73 and 75). Specific embodiments herein provide isolated nucleic acid encoding heavy chain CDR1 sequence selected from the group consisting of: SEQ ID NOs: 183-189, 191, 193, 195, 197-294 and residues 4-13 of SEQ ID NOs: 183, 185, 187, 189, 193 and 197-294 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 190, 192, 194 and 196). Specific embodiments herein provide nucleic acid encoding the disclosed heavy chain variable CDR1, CDR2 and/or CDR3 sequences into VH3 in place of the relevant CDRs. Specific embodiments herein provide isolated nucleic acid encoding light chain CDR3 sequence selected from the group consisting of: SEQ ID NOs: 295-301, 303, 305-334, and residues 4-13 of SEQ ID NOs: 295, 297, 299, 301 and 305-334 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 302 and 304). Specific embodiments herein provide isolated nucleic acid encoding light chain CDR2 sequence selected from the group consisting of: SEQ ID NOs: 335-339, 341, 343-346, and residues 4-10 of SEQ ID NOs: 335, 337, 339 and 343-346 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 340 and 342). Specific embodiments herein provide isolated nucleic acid encoding light chain CDR1 sequence selected from the group consisting of: SEQ ID NOs: 347-349, 351, 353-359 and residues 4-14 of SEQ ID NOs: 347, 349 and 353-359 (in specific embodiments, said nucleic acid of which comprises a sequence selected from the group consisting of: SEQ ID NOs: 350 and 352). Specific embodiments herein provide nucleic acid encoding the disclosed light chain variable CDR1, CDR2 and/or CDR3 sequences into VK3 (or VK1) in place of the relevant CDRs. Specific embodiments provide both the heavy and light chain CDRs (1, 2 and 3) or some combination of one or more thereof.
The isolated nucleic acid encoding the variable regions can be provided within any desired antibody molecule format including, but not limited to, the following: F(ab′)2, a Fab, a Fv, a scFv, bispecific antibody molecules (antibody molecules comprising a PCSK9-specific antibody or antigen binding fragment as disclosed herein linked to a second functional moiety having a different binding specificity than the antibody, including, without limitation, another peptide or protein such as an antibody, or receptor ligand), a bispecific single chain Fv dimer, a minibody, a dAb fragment, diabody, triabody or tetrabody, a minibody, IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgD, IgA, IgE or any derivatives thereof.
Specific embodiments provide isolated nucleic acid which encodes PCSK9-specific antagonists and, in more specific embodiments, antibody molecules comprising (i) a heavy chain variable domain selected from the group consisting of: SEQ ID NOs: 360-510; specific embodiments of which comprise nucleic acid sequence SEQ ID NO: 550 or SEQ ID NO: 561; and/or (ii) a light chain variable domain selected from the group consisting of: SEQ ID NOs: 511-549; specific embodiments of which comprise nucleic acid sequence SEQ ID NO: 551. The present invention further provides in specific embodiments, homologs of the antagonists disclosed above, characterized as being at least 90% (in specific embodiments, 95%, 97% or 99%) identical through the heavy and/or light chain variable regions.
Additional embodiments provide isolated nucleic acid encoding PCSK9-specific antagonists and, in more specific embodiments, antibody molecules which comprise (i) a light chain selected from the group consisting of: SEQ ID NOs: 558, 566, and 554 (specific embodiments of which comprise nucleic acid selected from the group consisting of: SEQ ID NOs: 559, 567, 568 and 555); and/or (ii) a heavy chain or Fd chain selected from the group consisting of: SEQ ID NOs: 552, 562, 556, 564 and amino acids 1-221 of SEQ ID NOs: 562 and 552 (specific embodiments of which comprise nucleic acid selected from the group consisting of: SEQ ID NOs: 553, 563, 557, 565 and nucleotides 1-663 of SEQ ID NOs: 553 and 563. The present invention further provides in specific embodiments, homologs of the antagonists disclosed above, characterized as being at least 90% identical over the heavy and/or light chains.
Specific embodiments of the present invention encompass nucleic acid encoding antibody molecules that possess manipulations in the Fc region which result in reduced or altered binding to FcγR receptors, C1q or FcRn on the part of the antibody. One specific embodiment of the present invention is isolated nucleic acid which encodes for antibody molecules comprising as part of their immunoglobulin structure SEQ ID NO: 575 and, in particular embodiments, residues 107-326 of SEQ ID NO: 575. In specific embodiments, synthetic PCSK9-specific antagonists can be produced by expression from nucleic acid generated from oligonucleotides synthesized and assembled within suitable expression vectors; see, e.g., Knappick et al., 2000 J. Mol. Biol. 296:57-86, and Krebs et al., 2001 J. Immunol. Methods 254:67-84.
The present invention encompasses nucleic acid encoding antibody molecules which comprise: (i) the disclosed nucleic acid encoding the light chain variable region, and (ii) the disclosed nucleic acid encoding the heavy chain variable region, followed in sequence by (adjacent to) a set of nucleotides encoding for a set of amino acids selected from the group consisting of: SEQ ID NO: 572 (IgG1), SEQ ID NO: 573 (IgG2), SEQ ID NO: 574 (IgG4) and SEQ ID NO: 575 (IgG2 m4). Plasmid sequence comprising heavy and light chain AX132 anti-PCSK9 antibody molecule sequence can be found as SEQ ID NO: 560. Plasmid sequence comprising heavy and light chain AX213 anti-PCSK9 antibody molecule sequence can be found as SEQ ID NO: 569. Nucleic acid encoding such antibody molecules form important embodiments hereof. Additional plasmid sequences can be obtained by substituting the altered region for that present in the disclosed plasmid sequences.
Also included within the present invention are isolated nucleic acids comprising nucleotide sequences which are at least about 90% identical and more preferably at least about 95% identical to the full length of the nucleotide sequences described herein, and which nucleotide sequences encode PCSK9-specific antagonists which inhibit PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.
Reference to “at least about 90% identical” throughout the application includes at least about 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical.
The invention further provides isolated nucleic acid at least a portion of which hybridizes to the complement of nucleic acid encoding any one of the variable heavy, variable light, heavy chain, and light chain regions disclosed herein under stringent hybridization conditions, said nucleic acid of which confers upon antibody molecules the ability to specifically bind PCSK9 and antagonize PCSK9 function, and PCSK9-specific antagonists expressed employing said nucleic acid. Methods for hybridizing nucleic acids are well-known in the art; see, e.g., Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1989. Stringent hybridization conditions involve hybridizing at 68° C. in 5×SSC/5×Denhardt's solution (or equivalent)/1.0% SDS, and washing in 0.2×SSC/0.1% SDS at room temperature. Moderately stringent conditions include washing in 3×SSC at 42° C. The parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. The skilled artisan can manipulate various hybridization and/or washing conditions to specifically target nucleic acid in the hybridizing portion that is at least 80, 85, 90, 95, 98, or 99% identical to the variable heavy, variable light, heavy chain and/or light chain regions disclosed herein. Basic parameters affecting the choice of hybridization conditions and guidance for devising suitable conditions are set forth by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, 1989 and Ausubel et al. (eds), Current Protocols in Molecular Biology, John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, 1995 (the disclosures of which are incorporated herein by reference), and can be readily determined by those having ordinary skill in the art. PCSK9 antagonists having one or more regions comprising nucleic acid which hybridizes to the disclosed heavy chain, light chain, variable heavy or variable light regions under stringent hybridization conditions should be effective in antagonizing one or more functions of PCSK9. Said antagonists and encoding nucleic acid, thus, form important embodiments of the present invention.
In another aspect, the present invention provides vectors comprising the nucleic acid disclosed herein. Vectors in accordance with the present invention include, but are not limited to, plasmids and other expression constructs (e.g., phage or phagemid, as appropriate) suitable for the expression of the desired antibody molecule at the appropriate level for the intended purpose; see, e.g., Sambrook & Russell, Molecular Cloning: A Laboratory Manual: 3rd Edition, Cold Spring Harbor Laboratory Press; the disclosure of which is incorporated herein by reference. For most cloning purposes, DNA vectors may be used. Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast artificial chromosomes, bacterial artificial chromosomes, and other forms of episomal or integrated DNA. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer, generation of a recombinant PCSK9-specific antagonist, or other use. In specific embodiments, in addition to a recombinant gene, the vector may also contain an origin of replication for autonomous replication in a host cell, appropriate regulatory sequences, such as a promoter, a termination sequence, a polyadenylation sequence, an enhancer sequence, a selectable marker, a limited number of useful restriction enzyme sites, and/or other sequences as appropriate and the potential for high copy number. Examples of expression vectors for the production of protein-specific antagonists are well known in the art; see, e.g., Persic et al., 1997 Gene 187:9-18; Boel et al., 2000 J. Immunol. Methods 239:153-166, and Liang et al., 2001 J. Immunol. Methods 247:119-130; the disclosures of which are incorporated herein by reference. If desired, nucleic acid encoding the antagonist may be integrated into the host chromosome using techniques well known in the art; see, e.g., Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons, 1999, and Marks et al., International Application Number WO 95/17516. Nucleic acid may also be expressed on plasmids maintained episomally or incorporated into an artificial chromosome; see, e.g., Csonka et al., 2000 J. Cell Science 113:3207-3216; Vanderbyl et al., 2002 Molecular Therapy 5:10. Specifically with regards to antibody molecules, the antibody light chain gene and the antibody heavy chain gene can be inserted into separate vectors or, more typically, both genes may be inserted into the same expression vector. Nucleic acid encoding any PCSK9-specific antagonist or component thereof can be inserted into an expression vector using standard methods (e.g., ligation of complementary restriction sites on the nucleic acid fragment and vector, or blunt end ligation if no restriction sites are present). Another specific example of how this may be carried out is through use of recombinational methods, e.g. the Clontech “InFusion” system, or Invitrogen “TOPO” system (both in vitro), or intracellularly (e.g. the Cre-Lox system). Specifically with regards to antibody molecules, the light and heavy chain variable regions can be used to create full-length antibody genes of any antibody isotype by inserting them into expression vectors already encoding heavy chain constant and light chain constant regions of the desired isotype such that the VH segment is operatively linked to the CH segment(s) within the vector and the VL segment is operatively linked to the CL segment within the vector. Additionally or alternatively, the recombinant expression vector comprising nucleic acid encoding a PCSK9-specific antagonist can encode a signal peptide that facilitates secretion of the antagonist from a host cell. The nucleic acid can be cloned into the vector such that the nucleic acid encoding a signal peptide is linked in-frame adjacent to the PCSK9-specific antagonist-encoding nucleic acid. The signal peptide may be an immunoglobulin or a non-immunoglobulin signal peptide. Any technique available to the skilled artisan may be employed to introduce the nucleic acid into the host cell; see, e.g., Morrison, 1985 Science, 229:1202. Methods of subcloning nucleic acid molecules of interest into expression vectors, transforming or transfecting host cells containing the vectors, and methods of making substantially pure protein comprising the steps of introducing the respective expression vector into a host cell, and cultivating the host cell under appropriate conditions are well known. The PCSK9-specific antagonist so produced may be harvested from the host cells in conventional ways. Techniques suitable for the introduction of nucleic acid into cells of interest will depend on the type of cell being used. General techniques include, but are not limited to, calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using viruses appropriate to the cell line of interest (e.g., retrovirus, vaccinia, baculovirus, or bacteriophage).
In another aspect, the present invention provides isolated cell(s) comprising nucleic acid encoding disclosed PCSK9-specific antagonists. A variety of different cell lines are contemplated herein and can be used for the recombinant production of PCSK9-specific antagonists, including but not limited to those from prokaryotic organisms (e.g., E. coli, Bacillus, and Streptomyces) and from eukaryotic (e.g., yeast, Baculovirus, and mammalian); see, e.g., Breitling et al., Recombinant antibodies, John Wiley & Sons, Inc. and Spektrum Akademischer Verlag, 1999; the disclosure of which is incorporated herein by reference. Plant cells, including transgenic plants, and animal cells, including transgenic animals (other than humans), comprising the nucleic acid or antagonists disclosed herein are also contemplated as part of the present invention. Suitable mammalian cells or cell lines including, but not limited to, those derived from Chinese Hamster Ovary (CHO cells, including but not limited to DHFR-CHO cells (described in Urlaub and Chasin, 1980 Proc. Natl. Acad. Sci. USA 77:4216-4220) used, for example, with a DHFR selectable marker (e.g., as described in Kaufman and Sharp, 1982 Mol. Biol. 159:601-621), NS0 myeloma cells (where a GS expression system as described in WO 87/04462, WO 89/01036, and EP 338,841 may be used), COS cells, SP2 cells, HeLa cells, baby hamster kidney cells, YB2/0 rat myeloma cells, human embryonic kidney cells, human embryonic retina cells, and others comprising the nucleic acid or antagonists disclosed herein form additional embodiments of the present invention; the preceding cited disclosures of which are incorporated herein by reference. Specific embodiments of the present invention comprising nucleic acid encoding disclosed PCSK9-specific antagonists include, but are not limited to, E. coli; see, e.g., Plückthun, 1991 Bio/Technology 9:545-551, or yeast, such as Pichia, and recombinant derivatives thereof (see, e.g., Li et al., 2006 Nat. Biotechnol. 24:210-215); the preceding disclosures of which are incorporated herein by reference. Specific embodiments of the present invention relate to eukaryotic cells comprising nucleic acid encoding the disclosed PCSK9-specific antagonists, see, Chadd & Chamow, 2001 Current Opinion in Biotechnology 12:188-194, Andersen & Krummen, 2002 Current Opinion in Biotechnology 13:117, Larrick & Thomas, 2001 Current Opinion in Biotechnology 12:411-418; the disclosures of which are incorporated herein by reference. Specific embodiments of the present invention relate to mammalian cells comprising nucleic acid encoding the disclosed PCSK9-specific antagonists which are able to produce PCSK9-specific antagonists with proper post translational modifications. Post translational modifications include, but are by no means limited to, disulfide bond formation and glycosylation. Another type of post translational modification is signal peptide cleavage. Preferred embodiments herein have the appropriate glycosylation; see, e.g., Yoo et al., 2002 J. Immunol. Methods 261:1-20; the disclosure of which is incorporated herein by reference. Naturally occurring antibodies contain at least one N-linked carbohydrate attached to a heavy chain. Id. Different types of mammalian host cells can be used to provide for efficient post-translational modifications. Examples of such host cells include Chinese Hamster Ovary (CHO), HeLa, C6, PC12, and myeloma cells; see, Yoo et al., 2002 J. Immunol. Methods 261:1-20, and Persic et al., 1997 Gene 187:9-18; the disclosures of which are incorporated herein by reference.
In another aspect, the present invention provides isolated cell(s) comprising a polypeptide of the present invention.
In another aspect, the present invention provides a method of making a PCSK9-specific antagonist of the present invention, which comprises incubating a cell comprising nucleic acid encoding the PCSK9-specific antagonist, or a heavy and/or light chain or a fragment thereof (e.g., VH and/or VL, or one or more of the disclosed heavy and/or light chain variable region CDRs) of a desired PCSK9-specific antagonist (dictated by the desired antagonist) with specificity for human PCSK9 under conditions that allow the expression of the PCSK9-specific antagonist, or the expression and assembly of said heavy and/or light chains or fragment into a PCSK9-specific antagonist, and isolating said PCSK9-specific antagonist from the cell. One example by which to generate particular desired heavy and/or light chain sequence or fragment is to first amplify (and modify) the germline heavy and/or light chain variable sequences or fragment using PCR. Germline sequence for human heavy and/or light variable regions are readily available to the skilled artisan, see, e.g., the “Vbase” human germline sequence database, and Kabat, E. A. et al., 1991 Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; Tomlinson, I. M. et al., 1992 “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops” J. Mol. Biol. 227:776-798; and Cox, J. P. L. et al., 1994 “A Directory of Human Germ-line VK Segments Reveals a Strong Bias in their Usage” Eur. J. Immunol. 24:827-836; the disclosures of which are incorporated herein by reference. Mutagenesis of germline sequences may be carried out using standard methods, e.g., PCR-mediated mutagenesis where the mutations are incorporated into PCR primers, or site-directed mutagenesis. If full-length antibodies are desired, sequence is available for the human heavy chain constant region genes; see, e.g., Kabat. E. A. et al., 1991 Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242. Fragments containing these regions may be obtained, for example, by standard PCR amplification. Alternatively, the skilled artisan can avail him/herself of vectors already encoding heavy and/or light chain constant regions.
Fab expression and purification may be achieved in a number of ways. One common way is to perform papain digestion of whole IgG1s to release two equivalents of Fab and one equivalent of Fc region. However, for phage displayed libraries, which also needs to be expressed in E. coli, Fab is typically displayed via covalent linkage to a protein and also to a hexahistidine tag (His-tag). In a typical fashion, induction by IPTG is followed by intracellular expression of the Fab. Subsequently, whole cells are lysed and the desired Fab is purified using a nickel affinity column. Depending on the specific case, this can yield high background in analytical SE-HPLC, presumably from misfolded, partially folded, disulfide scrambled or proteolyzed Fabs containing the His-tag since His-tag does not discriminate between these and the correctly folded Fab. Thus, in specific embodiments, expression of Fabs is carried out as follows: the periplasmic transport signal from phage, such as pIII and pVIII coat protein leader sequences, are utilized in the expression vector to localize the Fab polypeptides into the oxidizing environment of the periplasmic space. There, chaperone-like enzymes can facilitate correct Fab folding and thus allow formation of correct disulfide bonds. The initial overnight growth phase may be set at 30° C. Subsequently, the bacterial culture can be induced into Fab production, using lower concentration of IPTG (1 mM, 0.5 mM, or 0.1 mM) to induce the lac operon and start translation of the Fab genes. The temperature can be lowered to 22-23° C. Both the low IPTG and low temperature slow the E. coli protein synthesis in order to avoid overloading the periplasmic folding machinery. Cells may then be harvested by low speed centrifugation ( ̃4000 g) and undergo periplasmic extraction. Periplasmic extraction is a gentle osmotic release process that primarily aims to make the outer bacterial cell wall leaky via mild osmotic shock, allowing Fabs to escape the periplasm into the surrounding media. After extraction, the cells can then be centrifuged at high speed (>15000 g) and the supernatant, containing released soluble Fab is saved for affinity chromatography.
In the specific embodiment above, affinity chromatography can be as follows: Affinity purification using protein G resin selectively binds folded constant region of the Fab at neutral pH (typically, using PBS or HBS at  ̃7.0-7.4). The bound Fab can be released under acidic pH (typically with glycine-HCl, pH 2.7-4.0) and eluted into a tube containing 1M Tris base at pH 9 to minimize exposure of the Fab to acidic pH. Alternatively, because the extract from the periplasmic extraction is relatively clean compared to a whole cell lysate, a nickel affinity column may be used to purify a Fab with a His-tag. In both cases, the eluted Fabs are buffer exchanged (e.g., by dialysis or centrifugal filtration using 30 kD MW cutoff filters) into the storage buffer, typically PBS or any preferred formulation buffer. The sample can be analyzed using analytical size exclusion (SE) HPLC generally show single peak consisting of >95% desired product. Additional polishing may be performed, if desired, using orthogonal methods, such as cation (CEX) or anion exchange (AEX) or hydrophobic interaction (HIC) chromatography.
Accordingly, in specific embodiments, the expression vector used for expression of the disclosed PCSK9-specific antagonists comprises sequence for phage coat protein pIII or pVIII leaders sequence or other export leader sequence to export the expressed antagonist into the bacterial periplasm. In specific embodiments, this is for the expression of Fab. In specific embodiments, the invention comprises a method for producing a PCSK9-specific antagonist which comprises: (a) inserting a vector as described herein into a cell (in particular embodiments, the vector encodes a Fab); wherein the vector comprises a phage coat protein PIII or pVIII leader sequence; (b) culturing the cell under conditions appropriate for production of the PCSK9-specific antagonist; and (c) isolating the PCSK9-specific antagonist produced by periplasmic extraction using gentle lysis conditions to disrupt primarily the outer cell wall to release periplasmic contents and minimize contamination by intracellular contents. In specific embodiments, this may further comprise purifying the PCSK9-specific antagonist by: (i) affinity of the constant domain to protein G to purify correctly folded PCSK9-specific antagonists (such as Fabs); (ii) affinity of the His-tag to a nickel affinity column; or (iii) other suitable purification technique. This may then be followed by analyzing the buffer-exchanged Fab or isolated PCSK9-specific antagonist using SDS-PAGE, analytical SE-HPLC, or mass spectrometry to QC the final product.
Available techniques exist to recombinantly produce other antibody molecules which retain the specificity of an original antibody. A specific example of this is where DNA encoding the immunoglobulin variable region or the CDRs is introduced into the constant regions, or constant regions and framework regions, or simply the framework regions, of another antibody molecule; see, e.g., EP-184,187, GB 2188638, and EP-239400; the disclosures of which are incorporated herein by reference. Cloning and expression of antibody molecules, including chimeric antibodies, are described in the literature; see, e.g., EP 0120694 and EP 0125023; the disclosures of which are incorporated herein by reference.
Antibody molecules in accordance with the present invention may, in one instance, be raised and then screened for characteristics identified herein using known techniques. Basic techniques for the preparation of monoclonal antibodies are described in the literature, see, e.g., Kohler and Milstein (1975, Nature 256:495-497); the disclosure of which is incorporated herein by reference. Fully human monoclonal antibodies can be produced by available methods. These methods include, but are by no means limited to, the use of genetically engineered mouse strains which possess an immune system whereby the mouse antibody genes have been inactivated and in turn replaced with a repertoire of functional human antibody genes, while leaving other components of the mouse immune system unchanged. Such genetically engineered mice allow for the natural in vivo immune response and affinity maturation process which results in high affinity, full human monoclonal antibodies. This technology is well known in the art and is fully detailed in various publications, including but not limited to U.S. Pat. Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; 5,770,249 (assigned to GenPharm International and available through Medarex, under the umbrella of the “UltraMab Human Antibody Development System”); as well as U.S. Pat. Nos. 5,939,598; 6,075,181; 6,114,598; 6,150,584 and related family members (assigned to Abgenix, disclosing their XenoMouse® technology); the disclosures of which are incorporated herein by reference. See also reviews from Kellerman and Green, 2002 Curr. Opinion in Biotechnology 13:593-597, and Kontermann & Stefan, 2001 Antibody Engineering, Springer Laboratory Manuals; the disclosures of which are incorporated herein by reference.
Alternatively, a library having potential PCSK9-specific antagonists or any library of antibody molecules may be brought into contact with PCSK9, and ones able to demonstrate specific binding selected. Functional studies can then be carried out to ensure proper functionality, e.g., inhibition of PCSK9-dependent inhibition of cellular LDL uptake. There are various techniques available to the skilled artisan for the selection of protein-specific molecules from libraries using enrichment technologies including, but not limited to, phage display (e.g., see technology from Abmaxis disclosed in U.S. Pat. Nos. 7,175,983 and 7,117,096, WO 03/099999, and Wang et al., 2010 J. Mol. Biol. 395:1088-1101 and Cambridge Antibody Technology (“CAT”) disclosed in U.S. Pat. Nos. 5,565,332; 5,733,743; 5,871,907; 5,872,215; 5,885,793; 5,962,255; 6,140,471; 6,225,447; 6,291,650; 6,492,160; 6,521,404; 6,544,731; 6,555,313; 6,582,915; 6,593,081, as well as other U.S. family members and/or applications which rely on priority filing GB 9206318, filed May 24, 1992; see also Vaughn et al., 1996, Nature Biotechnology 14:309-314), ribosome display (see, e.g., Hanes and Pluckthün, 1997 Proc. Natl. Acad. Sci. 94:4937-4942), bacterial display (see, e.g., Georgiou, et al., 1997 Nature Biotechnology 15:29-34) and/or yeast display (see, e.g., Kieke, et al., 1997 Protein Engineering 10:1303-1310, and Wang et al., 2010 J. Immunol. Methods 354:11-19); the preceding disclosures of which are incorporated herein by reference. A library, for example, can be displayed on the surface of bacteriophage particles, with nucleic acid encoding the PCSK9-specific antagonist or fragment thereof expressed and displayed on its surface. Nucleic acid may then be isolated from bacteriophage particles exhibiting the desired level of activity and the nucleic acid used in the development of desired antagonist. Phage display has been thoroughly described in the literature; see, e.g., Wang et al., 2010 J. Mol. Biol. 395:1088-1101, Kontermann & Stefan, supra, and International Application Number WO 92/01047; the disclosures of which are incorporated herein by reference. Specifically with regard to antibody molecules, individual heavy or light chain clones in accordance with the present invention may also be used to screen for complementary heavy or light chains, respectively, capable of interaction therewith to form a molecule of the combined heavy and light chains; see, e.g., International Application Number WO 92/01047. Any method of panning which is available to the skilled artisan may be used to identify PCSK9-specific antagonists. Another specific method for accomplishing this is to pan against the target antigen in solution, e.g. biotinylated, soluble PCSK9, and then capture the PCSK9-specific antagonist-phage complexes on streptavidin-coated magnetic beads, which are then washed to remove nonspecifically-bound phage. The captured phage can then be recovered from the beads in the same way they would be recovered from the surface of a plate, as described herein.
PCSK9-specific antagonists may be purified by techniques available to one of skill in the art. Titers of the relevant antagonist preparation, ascites, hybridoma culture fluids, or relevant sample may be determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (“ELISA”) techniques and radioimmunoassay (“RIA”) techniques.
The present invention relates in part to methods employing PCSK9-specific antagonists described herein for antagonizing PCSK9 function; said methods of which are further described below. Use of the term “antagonizing” throughout the present application refers to the act of opposing, inhibiting, counteracting, neutralizing or curtailing one or more functions of PCSK9. Inhibition or antagonism of one or more of PCSK9-associated functional properties can be readily determined according to methodologies known to the art (see, e.g., Barak & Webb, 1981 J. Cell Biol. 90:595-604; Stephan & Yurachek, 1993 J. Lipid Res. 34:325330; and McNamara et al., 2006 Clinica Chimica Acta 369:158-167) as well as those described herein. Inhibition or antagonism will effectuate a decrease in PCSK9 activity relative to that seen in the absence of the antagonist or, for example, that seen when a control antagonist of irrelevant specificity is present. Preferably, a PCSK9-specific antagonist in accordance with the present invention antagonizes PCSK9 functioning to the point that there is a decrease of at least 10%, of the measured parameter including but not limited to the activities disclosed herein, and more preferably, a decrease of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 95% of the measured parameter. Such inhibition/antagonism of PCSK9 functioning is particularly effective in those instances where PCSK9 functioning is contributing at least in part to a particular phenotype, disease, disorder or condition which is negatively impacting the subject.
In one aspect, the present invention provides a method for antagonizing the activity of PCSK9, which comprises contacting a cell, population of cells or tissue sample capable of being affected by PCSK9 (i.e., which expresses and/or comprises LDL receptors) with a PCSK9-specific antagonist disclosed herein under conditions that allow said antagonist to bind to PCSK9 when present and inhibit PCSK9's inhibition of cellular LDL uptake. Specific embodiments of the present invention include such methods wherein the cell is a human cell.
In another aspect, the present invention provides a method for antagonizing the activity of PCSK9 in a subject, which comprises administering to the subject a therapeutically effective amount of a PCSK9-specific antagonist of the present invention. In specific embodiments, the methods for antagonizing PCSK9 function are for the treatment of a PCSK9-associated disease, disorder or condition or, alternatively, a disease, disorder or condition that could benefit from the effects of a PCSK9 antagonist. The medicament would be useful in a subject(s) exhibiting a condition associated with PCSK9 activity, or a condition where the functioning of PCSK9 is contraindicated for a particular subject. In select embodiments, the condition may be hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related conditions.
The present invention, thus, contemplates the use of PCSK9-specific antagonists described herein in various methods of treatment where antagonizing PCSK9 function is desirable. The method of treatment can be prophylactic or therapeutic in nature. In specific embodiments, the present invention relates to a method of treatment for a condition associated with/attributed to PCSK9 activity, or a condition where the functioning of PCSK9 is contraindicated for a particular subject, which comprises administering to the subject a therapeutically effective amount of a PCSK9-specific antagonist of the present invention. In select embodiments, the condition may be hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related conditions.
Methods of treatment in accordance with the present invention comprise administering to an individual a therapeutically (or prophylactically) effective amount of a PCSK9-specific antagonist of the present invention. Use of the terms “therapeutically effective” or “prophylactically effective” in reference to an amount refers to the amount necessary at the intended dosage to achieve the desired therapeutic/prophylactic effect for the period of time desired. The desired effect may be, for example, amelioration of at least one symptom associated with the treated condition. These amounts will vary, as the skilled artisan will appreciate, according to various factors, including but not limited to the disease state, age, sex and weight of the individual, and the ability of the PCSK9-specific antagonist to elicit the desired effect in the individual. The response may be documented by in vitro assay, in vivo non-human animal studies, and/or further supported from clinical trials.
The present invention provides methods for treating or preventing disorders of cholesterol or lipid homeostasis and disorders and complications associated therewith, e.g., hypercholesterolemia, hyperlipidemia, hypertriglyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, metabolic syndrome, acute coronary syndrome, vascular inflammation, xanthoma and related conditions.
The present invention also provides methods for improving blood cholesterol markers associated with increased risk of heart disease. These markers include, but are not limited to, high total cholesterol, high LDL, high total cholesterol to HDL ratio and high LDL to HDL ratio.
In general, a total cholesterol of less than 200 mg/dL is considered desirable, 200-239 mg/dL is considered borderline high and 240 mg/dL and above is considered high. For example, the present invention comprises methods for reducing total cholesterol, e.g., to less than or equal to about 200 mg/dL by administering a therapeutically effective amount of a PCSK9-specific antagonist of the present invention.
In general, a blood LDL level of less than 100 mg/dL is considered optimal; 100-129 mg/dL is considered near optimal/above optimal, 130-159 mg/dL is considered borderline high, 160-189 mg/dL is considered high and 190 mg/dL and above is considered very high. For example, the present invention comprises methods for reducing LDL, e.g., to less than about 100 mg/dL by administering a therapeutically effective amount of a PCSK9-specific antagonist of the present invention.
In general, HDL levels considered normal are at least 35-40 mg/dL. For example, the present invention comprises methods for increasing HDL, e.g., to greater than or equal to about 35-40 mg/dL by administering a therapeutically effective amount of anti-PCSK9 antibody or antigen binding fragment thereof of the present invention.
Another indicator of heart disease risk is the ratio of total cholesterol to HDL. In general, a very low risk of heart disease correlates with a ratio of <3.4 (men) or <3.3 (women); a low risk is associated with a ratio of 4.0 (men) or 3.8 (women), an average risk is associated with a ratio of 5.0 (men) or 4.5 (women), a moderate risk is associated with a ratio of 9.5 (men) or 7.0 (women) and a high risk is associated with a ratio of >23 (men) or >11 (women). For example, the present invention comprises methods for reducing the ratio of total cholesterol to HDL, e.g., to less than about 4.5 or 5.0 by administering a therapeutically effective amount of a PCSK9-specific antagonist of the present invention.
A further indicator of heart disease risk is the ratio of LDL to HDL. In general, a very low risk is associated with a ratio of 1 (men) or 1.5 (women), an average risk is associated with a ratio of 3.6 (men) or 3.2 (women), a moderate risk is associated with a ratio of 6.3 (men) or 5.0 (women) and a high risk is associated with a ratio of 8 (men) or 6.1 (women). For example, the present invention comprises methods for the ratio of LDL to HDL, e.g., to less than or equal to about 3.2 or 3.6 by administering a therapeutically effective amount of a PCSK9-specific antagonist of the present invention.
The PCSK9-specific antagonist may be administered as a pharmaceutical composition. The present invention, thus, provides a pharmaceutically acceptable composition comprising a PCSK9-specific antagonist of the invention and a pharmaceutically acceptable carrier including but not limited to an excipient, diluent, stabilizer, buffer, or alternative designed to facilitate administration of the antagonist in the desired format and amount to the treated individual.
The pharmaceutical composition may be formulated by any number of strategies known in the art, see, e.g., McGoff and Scher, 2000 Solution Formulation of Proteins/Peptides: In—McNally, E. J., ed. Protein Formulation and Delivery. New York, N.Y.: Marcel Dekker; pp. 139-158; Akers & Defilippis, 2000, Peptides and Proteins as Parenteral Solutions. In—Pharmaceutical Formulation Development of Peptides and Proteins. Philadelphia, Pa.: Taylor and Francis; pp. 145-177; Akers et al., 2002, Pharm. Biotechnol. 14:47-127. A pharmaceutically acceptable composition suitable for patient administration will contain an effective amount of the PCSK9-specific antagonist in a formulation which both retains biological activity while also promoting maximal stability during storage within an acceptable temperature range.
The antagonist-based pharmaceutically acceptable composition may, in particular embodiments, be in liquid or solid form, or in the form of gas particles or aerosolized particles. Any technique for production of liquid or solid formulations may be utilized. Such techniques are well within the realm of the abilities of the skilled artisan. Solid formulations may be produced by any available method including, but not limited to, lyophilization, spray drying, or drying by supercritical fluid technology. Solid formulations for oral administration may be in any form rendering the antagonist accessible to the patient in the prescribed amount and within the prescribed period of time. The oral formulation can take the form of a number of solid formulations including, but not limited to, a tablet, capsule, or powder. Solid formulations may alternatively be lyophilized and brought into solution prior to administration for either single or multiple dosing according to methods well known to the skilled artisan. Antagonist compositions should generally be formulated within a biologically relevant pH range and may be buffered to maintain a proper pH range during storage. Both liquid and solid formulations generally require storage at lower temperatures (e.g., 2-8° C.) in order to retain stability for longer periods. Formulated antagonist compositions, especially liquid formulations, may contain a bacteriostat to prevent or minimize proteolysis during storage, including but not limited to effective concentrations (e.g., ≦1% w/v) of benzyl alcohol, phenol, m-cresol, chlorobutanol, methylparaben, and/or propylparaben. A bacteriostat may be contraindicated for some patients. Therefore, a lyophilized formulation may be reconstituted in a solution either containing or not containing such a component. Additional components may be added to either a buffered liquid or solid antagonist formulation, including but not limited to sugars as a cryoprotectant (including but not limited to polyhydroxy hydrocarbons such as sorbitol, mannitol, glycerol, and dulcitol and/or disaccharides such as sucrose, lactose, maltose, or trehalose) and, in some instances, a relevant salt (including but not limited to NaCl, KCl, or LiCl). Such antagonist formulations, especially liquid formulations slated for long term storage, will rely on a useful range of total osmolarity to both promote long term stability at temperatures of, for example, 2-8° C. or higher, while also making the formulation useful for parenteral injection. As appropriate, preservatives, stabilizers, buffers, antioxidants and/or other additives may be included. The formulations may contain a divalent cation (including but not limited to MgCl2, CaCl2, and MnCl2); and/or a non-ionic surfactant (including but not limited to Polysorbate-80 (Tween 80TM), Polysorbate-60 (Tween 60TM), Polysorbate-40 (Tween 40TM), and Polysorbate-20 (Tween 20TM), polyoxyethylene alkyl ethers, including but not limited to Brij 58TM, Brij35TM, as well as others such as Triton X-100TM, Triton X-114TM, NP40TM, Span 85 and the Pluronic series of non-ionic surfactants (e.g., Pluronic 121)). Any combination of such components form specific embodiments of the present invention.
Pharmaceutical compositions in liquid format may include a liquid carrier, e.g., water, petroleum, animal oil, vegetable oil, mineral oil, or synthetic oil. The liquid format may also include physiological saline solution, dextrose or other saccharide solution or glycols, such as ethylene glycol, propylene glycol or polyethylene glycol.
Preferably, the pharmaceutical composition may be in the form of a parenterally acceptable aqueous solution that is pyrogen-free with suitable pH, tonicity, and stability. Pharmaceutical compositions may be formulated for administration after dilution in isotonic vehicles, for example, Sodium Chloride Injection, Ringer's Injection, or Lactated Ringer's Injection.
One aspect of the present invention is a pharmaceutical composition which comprises: (i) about 50 to about 200 mg/mL of the PCSK9-specific antagonists described herein; (ii) a polyhydroxy hydrocarbon (including but not limited to sorbitol, mannitol, glycerol and dulcitol) and/or a disaccharide (including but not limited to sucrose, lactose, maltose and trehalose); the total of said polyhydroxy hydrocarbon and/or disaccharide being about 1% to about 6% weight per volume (“w/v”) of the formulation; (iii) about 5 mM to about 200 mM of histidine, imidazole, phosphate or acetic acid which serves as a buffering agent to prevent pH drift over the shelf life of the pharmaceutical composition and as a tonicity modifier; (iv) about 5 mM to about 200 mM of arginine, proline, phenylalanine, alanine, glycine, lysine, glutamic acid, aspartic acid or methionine to counteract aggregation; (v) about 0.01M to about 0.1M of hydrochloric acid (“HCl”) in an amount sufficient to achieve a pH in the range of about 5.5 to about 7.5; and (vi) a liquid carrier including but not limited to sterile water, petroleum, animal oil, vegetable oil, mineral oil, synthetic oil, physiological saline solution, dextrose or other saccharide solution or glycols, such as ethylene glycol, propylene glycol or polyethylene glycol; wherein said pharmaceutical composition has a pH in the range of about 5.5 to about 7.5; and wherein said pharmaceutical composition optionally comprises about 0.01% to about 1% w/v of the formulation of a non-ionic surfactant (including but not limited to Polysorbate-80 (Tween 80TM), Polysorbate-60 (Tween 60TM), Polysorbate-40 (Tween 40TM), and Polysorbate-20 (Tween 20TM), polyoxyethylene alkyl ethers, including but not limited to Brij 58TM, Brij35TM, as well as others such as Triton X-100TM, Triton X-114TM, NP40TM, Span 85 and the Pluronic series of non-ionic surfactants (e.g., Pluronic 121)).
HCl may be added as free acid, Histidine-HCl or Arginine-HCl. Where supplied as Histidine-HCl or Arginine-HCl, the total amounts of Histidine or Arginine in the HCl form should be that specified above. Accordingly, some or all of the HCl depending on the amounts of Histidine and/or Arginine may be supplied as Histidine-HCl and/or Arginine-HCl; as appropriate. Use of the term “about” with respect to amounts disclosed in the specification means within 10% of the specified numbers provided. A range provided as, for example” in “about 50 to about 200” expressly includes as distinct embodiments each number within said range. As such in the above example, embodiments including but not limited to those having 50, 100, 125, 150 and 200 form specific embodiments herein. Pharmaceutical compositions as disclosed herein have general applicability despite the mode of administration. In specific embodiments, the disclosed pharmaceutical compositions are useful for subcutaneous administration as a liquid or upon reconstitution of a lyophilized form. Proteins that can be employed in the disclosed formulations include any polymeric protein or polypeptide characterized as comprising covalently linked amino acid residues delivered for purposes of effecting a therapeutic benefit. Proteins of use in the present compositions include but are not limited to any antibody molecules as defined herein or any non-antibody or non-immunoglobulin proteins, peptides, pegylated proteins and fusion proteins.
Specific aspects of the present invention relate to the above disclosed pharmaceutical compositions which comprise: (i) about 50 to about 200 mg/mL of the PCSK9-specific antagonists described herein; (ii) about 1% to about 6% (in particular embodiments from about 2% to about 6%) w/v mannitol, trehalose or sucrose; (iii) about 10 mM to about 100 mM of histidine; (iv) about 25 mM to about 100 mM of arginine or proline; (v) about 0.02 M to about 0.05M of hydrochloric acid (“HCl”) in an amount sufficient to achieve a pH in the range of about 5.8 to about 7; and (vi) a liquid carrier including but not limited to sterile water, petroleum, animal oil, vegetable oil, mineral oil, synthetic oil, physiological saline solution, dextrose or other saccharide solution or glycols, such as ethylene glycol, propylene glycol or polyethylene glycol; wherein said pharmaceutical composition has a pH in the range of about 5.8 to about 7; and wherein said pharmaceutical composition optionally comprising about 0.01% to about 1% w/v of the formulation of a non-ionic surfactant (including but not limited to Polysorbate-80 (Tween 80TM), Polysorbate-60 (Tween 60TM), Polysorbate-40 (Tween 40TM), and Polysorbate-20 (Tween 20TM), polyoxyethylene alkyl ethers, including but not limited to Brij 58TM, Brij35TM, as well as others such as Triton X-100TM, Triton X-114TM, NP40TM, Span 85 and the Pluronic series of non-ionic surfactants (e.g., Pluronic 121)).
Specific embodiments provide pharmaceutical compositions which comprise: (i) 50 to 200 mg/mL of the PCSK9-specific antagonists described herein; (ii) about 1% to about 6% (in particular embodiments from about 2% to about 6%) w/v mannitol, trehalose or sucrose; (iii) about 10 mM to about 150 mM of histidine; (iv) about 10 mM to about 150 mM of arginine or proline; (v) about 0.03 M to about 0.05 M of hydrochloric acid (“HCl”) in an amount sufficient to achieve a pH in the range of about 5.8 to about 6.5; and (vi) a liquid carrier including but not limited to sterile water, petroleum, animal oil, vegetable oil, mineral oil, synthetic oil, physiological saline solution, dextrose or other saccharide solution or glycols, such as ethylene glycol, propylene glycol or polyethylene glycol; wherein said pharmaceutical composition has a pH in the range of about 5.8 to about 6.5; and wherein said pharmaceutical composition optionally comprising about 0.01% to about 1% w/v of Polysorbate-80 (Tween 80TM) or Polysorbate-20 (Tween 20TM).
Specific embodiments herein provide pharmaceutical compositions which comprise: (i) 50 to 200 mg/mL of the PCSK9-specific antagonists described herein; (ii) about 1% to about 6% (in particular embodiments from about 2% to about 6%) w/v sucrose; (iii) about 25 mM to about 100 mM of histidine; (iv) about 25 mM to about 100 mM of arginine; (v) about 0.040 M to about 0.045 M of hydrochloric acid (“HCl”) in an amount sufficient to achieve a pH of about 6; and (vi) sterile water; wherein said pharmaceutical composition has a pH of about 6; and wherein said pharmaceutical composition optionally comprising about 0.01% to about 1% w/v of Polysorbate-80 (Tween 80TM) or Polysorbate-20 (Tween 20TM). In specific embodiments thereof, the levels of histidine and arginine are within 25 mM of each other and, in other embodiments are the same.
Specific embodiments herein provide pharmaceutical compositions which comprise (i) 50 to 200 mg/mL of the PCSK9-specific antagonists described herein; (ii) sucrose, histidine and arginine in one of the following amounts: (a) about 1% w/v sucrose, about 10 mM histidine and about 25 mM arginine; (b) about 2% w/v sucrose, about 25 mM histidine and about 25 mM arginine; (c) about 3% w/v sucrose, about 50 mM histidine and about 50 mM arginine; or (d) about 6% w/v sucrose, about 100 mM histidine and about 100 mM arginine; (iii) about 0.04 mol or, alternatively, about 1.46 g of HCl; and (iv) sterile water; wherein said pharmaceutical composition has a pH of about 6; and wherein said pharmaceutical composition optionally comprising about 0.01% to about 1% w/v of Polysorbate-80 (Tween 80TM) or Polysorbate-20 (Tween 20TM). Specific embodiments herein are wherein the amounts of sucrose, histidine and arginine in (ii) above are that described in (c) or (d). Specific embodiments employing pharmaceutical formulations as described above wherein the amounts of sucrose, histidine and arginine are that specified in (ii) (c) were found to provide an osmolality similar to the physiological value of 300 mOsm and provided stability in both the liquid and lyophilized form.
Specific embodiments herein provide pharmaceutical compositions as described which comprise 50 to 200 mg/ml of any one of the various PCSK9-specific antagonists described herein. For purposes of exemplification of one distinct embodiment thereof, and not to be construed as a limitation, is the following: a pharmaceutical formulation as described above which comprises: a PCSK9-specific antagonist which comprises: (a) a light chain comprising SEQ ID NO: 558; and (b) a heavy chain comprising SEQ ID NO: 556; wherein said PCSK9-specific antagonist is an antibody molecule that antagonizes PCSK9's inhibition of cellular LDL uptake. An additional embodiment is a pharmaceutical formulation as described above which comprises: a PCSK9-specific antagonist which comprises: (a) a light chain comprising SEQ ID NO: 566; and (b) a heavy chain comprising SEQ ID NO: 564; wherein said PCSK9-specific antagonist is an antibody molecule that antagonizes PCSK9's inhibition of cellular LDL uptake.
Particular embodiments herein are pharmaceutical compositions according to the above description which are lyophilized and reconstituted. In specific embodiments, said protein concentration in said lyophilized and reconstituted solution is up to 2-fold higher than in the pre-lyophilized composition. In specific embodiments, the protein or PCSK9-specific antagonist concentration in the lyophilized and/or reconstituted pharmaceutical composition is in the range of about 50 mg/mL to about 300 mg/mL. Diluents useful for reconstituting the lyophilized pharmaceutical compositions include but are not limited to sterile water, bacteriostatic water for injection (“BWFI”), phosphate-buffered saline, a sterile saline solution, physiological saline solution, Ringer's solution or dextrose solution and may in specific embodiments contain 0.01-1% (w/v) of Polysorbate-80 (Tween 80TM) or Polysorbate-20 (Tween 20TM). In specific embodiments, lyophilized powder can be reconstituted with 1/60.2× original volume (or 0.167 mL) up to 1× (1 mL).
Exemplary embodiments of the present invention are pharmaceutical compositions as described herein which are stable. Other embodiments of the present invention are pharmaceutical compositions as described herein which are stable to lyophilization and reconstitution. Various methods are available to the skilled artisan to prepare lyophilized compositions; see, e.g., Martin & Mo, 2007 “Stability Considerations for Lyophilized Biologics” Amer. Pharm. Rev. “Stable” as used herein refers to the property of the protein or PCSK9-specific antagonist to retain its physical or chemical stability, conformational integrity, or its ability to exhibit less denaturation, protein clipping, aggregation, fragmentation, acidic variant formation or loss of biological activity compared with a control sample at a temperature in the range of 4-37° C. for at least about 30 days. Other embodiments remain stable for up to 3 months, 6 months, 12 months, 2 years or longer periods at the above temperatures. In specific embodiments the formulation exhibits no significant changes at 2-8° C. for at least 6 months, and preferably 12 months, 2 years or longer, in order of preference. Specific embodiments experience less than 10% or, in particular embodiments, less than 5% of denaturation, protein clipping, aggregation, fragmentation, acidic variant formation or loss of biological activity compared with a control sample at a temperature in the range of 25-45° C. (or alternatively 2-8° C.) for at least about 30 days, 3 months, 6 months, 12 months, 2 years or longer. Stability of the formulations can be tested via several means known to the skilled artisan including, but not limited to Size Exclusion Chromatography (SEC-HPLC) to measure aggregation and fragmentation, Dynamic Light Scattering (DLS) to measure particle size of concentrated samples, capillary SDS-PAGE to measure fragmentation and capillary iso-electric focusing (cIEF) or cation exchange chromatography (“CEX”) to measure acidic variants formation. Techniques suitable for the analysis of protein stability are well understood by those of skill in the art: see review in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, 1993 Adv. Drug Delivery Rev. 10:29-90.
Pharmaceutical compositions as described herein should be sterile. There are various techniques available to the skilled artisan to accomplish this including, but not limited to, filtration through sterile filtration membranes. In specific embodiments, employing lyophilized and reconstituted compositions, this may be done prior to or following lyophilization and reconstitution.
Dosing of antagonist therapeutics is well within the realm of the skilled artisan, see, e.g., Lederman et al., 1991 Int. J. Cancer 47:659-664; Bagshawe et al., 1991 Antibody, Immunoconjugates and Radiopharmaceuticals 4:915-922, and will vary based on a number of factors including but not limited to the particular PCSK9-specific antagonist utilized, the patient being treated, the condition of the patient, the area being treated, the route of administration, and the treatment desired. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective therapeutic amount of the antagonist. Dosage ranges may be from about 0.01 to 100 mg/kg, and more usually 0.05 to 25 mg/kg, of the host body weight. For example, dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg. For purposes of illustration, and not limitation, in specific embodiments, a dose of 5 mg to 2.0 g may be utilized to deliver the antagonist systemically. In specific embodiments, the concentration of the dose provided will be in the range of about 8 mg/mL to about 200 mg/mL. In other embodiments, a dose contemplated for use in the present invention is from about 50 mg/mL to about 150 mg/mL. In specific embodiments, the dose will be from about 0.1 mL to about 1.5 mL and in specific embodiments is 1 mL. Optimal precision in achieving concentrations of antagonist within a range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to the target site(s). This involves a consideration of the distribution, equilibrium, and elimination of the PCSK9-specific antagonist. Antagonists described herein may be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents may be desirable. It will be possible to present a therapeutic dosing regime for the PCSK9-specific antagonists of the present invention in conjunction with alternative treatment regimes. For example, PCSK9-specific antagonists may be used in combination or in conjunction with other drugs (therapeutic and/or prophylactic). In specific embodiments, the PCSK9-specific antagonists are used in combination or in conjunction with cholesterol-lowering drugs, for example, cholesterol absorption inhibitors (e.g., Zetia®) and cholesterol synthesis inhibitors (e.g., Zocor® and Vytorin®). The present invention contemplates such combinations and they form an important embodiment hereof. Accordingly, the present invention relates to methods of treatment as described above where the PCSK9-specific antagonist is administered/delivered simultaneously with, following or prior to another drug or drugs (therapeutic and/or prophylactic), including but not limited to cholesterol-lowering drugs, including cholesterol absorption inhibitors.
Individuals (subjects) capable of treatment as described herein include primates, human and non-human, and include any non-human mammal or vertebrate of commercial or domestic veterinary importance.
The PCSK9-specific antagonist may be administered to an individual by any route of administration appreciated in the art, including but not limited to oral administration, administration by injection (specific embodiments of which include intravenous, subcutaneous, intraperitoneal or intramuscular injection), or administration by inhalation, intranasal, or topical administration, either alone or in combination with other agents designed to assist in the treatment of the individual. The PCSK9-specific antagonist may also be administered by injection devices, injector pens, needleless devices; and subcutaneous patch delivery systems. The route of administration should be determined based on a number of considerations appreciated by the skilled artisan including, but not limited to, the desired physiochemical characteristics of the treatment. Treatment may be provided on a daily, weekly, biweekly, or monthly basis, or any other regimen that delivers the appropriate amount of PCSK9-specific antagonist to the individual at the prescribed times such that the desired treatment is effected and maintained. The formulations may be administered in a single dose or in more than one dose at separate times.
Also contemplated are methods of using the disclosed antagonists in the manufacture of a medicament for treatment of a PCSK9-associated disease, disorder or condition or, alternatively, a disease, disorder or condition that could benefit from the effects of a PCSK9 antagonist. The medicament would be useful in a subject(s) exhibiting a condition associated with PCSK9 activity, or a condition where the functioning of PCSK9 is contraindicated for a particular subject. In select embodiments, the condition may be hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related conditions.
PCSK9-specific antagonists disclosed herein may also be used as a method of diagnosis of PCSK9. In select embodiments, the present invention encompasses methods of identifying or quantifying the level of PCSK9 present in a sample (including but not limited to a biological sample, e.g., serum or blood) which comprises contacting the sample with a PCSK9-specific antagonist described herein and detecting or quantifying, respectively, binding to PCSK9. The PCSK9-specific antagonist may be used in various assay formats known to the skilled artisan and may form part of a kit (the general features of a kit of which are further described below).
The present invention further provides for the administration of disclosed anti-PCSK9 antagonists for purposes of gene therapy. Through such methods, cells of a subject are transformed with nucleic acid encoding a PCSK9-specific antagonist of the invention. Subjects comprising the nucleic acids then produce the PCSK9-specific antagonists endogenously. Previously, Alvarez, et al, Clinical Cancer Research 6:3081-3087, 2000, introduced single-chain anti-ErbB2 antibodies to subjects using a gene therapy approach. The methods disclosed by Alvarez, et al, supra, may be easily adapted for the introduction of nucleic acids encoding an anti-PCSK9 antibody of the invention to a subject.
Nucleic acids encoding any PCSK9-specific antagonist may be introduced to a subject.
The nucleic acids may be introduced to the cells of a subject by any means known in the art. In preferred embodiments, the nucleic acids are introduced as part of a viral vector. Examples of preferred viruses from which the vectors may be derived include lentiviruses, herpes viruses, adenoviruses, adeno-associated viruses, vaccinia virus, baculovirus, alphavirus, influenza virus, and other recombinant viruses with desirable cellular tropism.
Various companies produce viral vectors commercially, including, but by no means limited to, Avigen, Inc. (Alameda, Calif.; AAV vectors), Cell Genesys (Foster City, Calif.; retroviral, adenoviral, AAV vectors, and lentiviral vectors), Clontech (retroviral and baculoviral vectors), Genovo, Inc. (Sharon Hill, Pa.; adenoviral and AAV vectors), Genvec (adenoviral vectors), IntroGene (Leiden, Netherlands; adenoviral vectors), Molecular Medicine (retroviral, adenoviral, AAV, and herpes viral vectors), Norgen (adenoviral vectors), Oxford BioMedica (Oxford, United Kingdom; lentiviral vectors), and Transgene (Strasbourg, France; adenoviral, vaccinia, retroviral, and lentiviral vectors).
Methods for constructing and using viral vectors are known in the art (see, e.g., Miller, et al, BioTechniques 7:980-990, 1992). Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously, and thus are not infectious, in the target cell. Preferably, the replication defective virus is a minimal virus, i.e., it retains only the sequences of its genome which are necessary for encapsidating the genome to produce viral particles. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted.
Examples of vectors comprising attenuated or defective DNA virus sequences include, but are not limited to, a defective herpes virus vector (Kanno et al, Cancer Gen. Ther. 6:147-154, 1999; Kaplitt et al, J. Neurosci. Meth. 71:125-132, 1997 and Kaplitt et al, J. Neuro One. 19:137-147, 1994).
Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types. Attenuated adenovirus vectors, such as the vector described by Strafford-Perricaudet et al, J. Clin. Invest. 90:626-630, 1992 are desirable in some instances. Various replication defective adenovirus and minimum adenovirus vectors have been described (PCT Publication Nos. WO94/26914, WO94/28938, WO94/28152, WO94/12649, WO95/02697 and WO96/22378). The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to a person skilled in the art (Levrero et al, Gene 101:195, 1991; EP 185573; Graham, EMBO J. 3:2917, 1984; Graham et al, J. Gen. Virol. 36:59, 1977).
The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The use of vectors derived from the AAVs for transferring genes in vitro and in vivo has been described (see Daly, et al, Gene Ther. 8:1343-1346, 2001, Larson et al, Adv. Exp. Med. Bio. 489:45-57, 2001; PCT Publication Nos. WO 91/18088 and WO 93/09239; U.S. Pat. Nos. 4,797,368 and 5,139,941 and EP 488528B1).
In another embodiment, the gene can be introduced in a retroviral vector, e.g., as described in U.S. Pat. Nos. 5,399,346, 4,650,764, 4,980,289, and 5,124,263; Mann et al, Cell 33:153, 1983; Markowitz et al, J. Virol., 62:1120, 1988; EP 453242 and EP178220. The retroviruses are integrating viruses which infect dividing cells.
Lentiviral vectors can be used as agents for the direct delivery and sustained expression of nucleic acids encoding a PCSK9-specific antagonist of the invention in several tissue types, including brain, retina, muscle, liver and blood. The vectors can efficiently transduce dividing and nondividing cells in these tissues, and maintain long-term expression of the PCSK9-specific antagonist. For a review, see Zufferey et al, J. Virol. 72:9873-80, 1998 and Kafri et al, Curr. Opin. Mol. Ther. 3:316-326, 2001. Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy. An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line which can generate virus particles at titers greater than 106 IU/ml for at least 3 to 4 days; see Kafri et al, J. Virol. 73:576-584, 1999. The vector produced by the inducible cell line can be concentrated as needed for efficiently transducing nondividing cells in vitro and in vivo.
Sindbis virus is a member of the alphavirus genus and has been studied extensively since its discovery in various parts of the world beginning in 1953. Gene transduction based on alphavirus, particularly Sindbis virus, has been well-studied in vitro (see Straus et al, Microbiol. Rev., 58:491-562, 1994; Bredenbeek et al, J. Virol., 67:6439-6446, 1993; Ijima et al, Int. J. Cancer 80:110-118, 1999 and Sawai et al, Biochim. Biophyr. Res. Comm. 248:315-323, 1998. Many properties of alphavirus vectors make them a desirable alternative to other virus-derived vector systems being developed, including rapid engineering of expression constructs, production of high-titered stocks of infectious particles, infection of nondividing cells, and high levels of expression (Strauss et al, 1994 supra). Use of Sindbis virus for gene therapy has been described. (Wahlfors et al, Gene. Ther. 7:472-480, 2000 and Lundstrom, J. Recep. Sig. Transduct. Res. 19(1-4):673-686, 1999.
In another embodiment, a vector can be introduced to cells by lipofection or with other transfection facilitating agents (peptides, polymers, etc.). Synthetic cationic lipids can be used to prepare liposomes for in vivo and in vitro transfection of a gene encoding a marker (Feigner et al, Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987 and Wang et al, Proc. Natl. Acad. Sci. USA 84:7851-7855, 1987). Useful lipid compounds and compositions for transfer of nucleic acids are described in PCT Publication Nos. WO 95/18863 and WO 96/17823, and in U.S. Pat. No. 5,459,127.
It is also possible to introduce the vector in vivo as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, e.g., Wilson, et al, J. Biol. Chem. 267:963-967, 1992; Williams et al, Proc. Natl. Acad. Sci. USA 88:2726-2730, 1991). Other reagents commonly used for transfection of plasmids include, but are by no means limited to, FuGene, Lipofectin, and Lipofectamine Receptor-mediated DNA delivery approaches can also be used (Wu et al, J. Biol. Chem. 263:14621-14624, 1988). U.S. Pat. Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal Recently, a relatively low voltage, high efficiency in vivo DNA transfer technique, termed electrotransfer, has been described (Vilquin et al, Gene Ther. 8:1097, 2001; Payen et al, Exp. Hematol. 29:295-300, 2001; Mir, Bioelectrochemistry 53:1-10, 2001; PCT Publication Nos. WO 99/01157, WO 99/01158 and WO 99/01175).
Pharmaceutical compositions suitable for such gene therapy approaches and comprising nucleic acids encoding an anti-PCSK9 antagonist of the present invention are included within the scope of the present invention.
In another aspect, the present invention provides a method for identifying, isolating, quantifying or antagonizing PCSK9 in a sample of interest using a PCSK9-specific antagonist of the present invention. The PCSK9-specific antagonists may be utilized as research tools in immunochemical assays, such as Western blots, ELISAs, radioimmunoassay, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art (see, e.g., Immunological Techniques Laboratory Manual, ed. Goers, J. 1993, Academic Press) or various purification protocols. The antagonists may have a label incorporated therein or affixed thereto to facilitate ready identification or measurement of the activities associated therewith. One skilled in the art is readily familiar with the various types of detectable labels (e.g., enzymes, dyes, or other suitable molecules which are either readily detectable or cause some activity/result that is readily detectable) which are or may be useful in the above protocols.
An additional aspect of the present invention are kits comprising PCSK9-specific antagonists or pharmaceutical compositions disclosed herein and instructions for use. Kits typically but need not include a label indicating the intended use of the contents of the kit. The term label includes any writing, or recorded material supplied on or with the kit, or which otherwise accompanies the kit. In specific embodiments wherein the pharmaceutical composition is provided lyophilized, the kit may include sterile water or saline for reconstitution of the formulation into liquid form. In specific embodiments, the amount of water or saline is from about 0.1 ml to 1.0 ml.
The following examples are provided to illustrate the present invention without limiting the same hereto:
EXAMPLE 1
Abmaxis PDL1 Phage Library Panning Against PCSK9 Protein
A synthetic human Fab library was panned against human PCSK9. Antigen protein PCSK9 was coated on Maxisorp well stripe (Nunc-Immuno Modules) at a concentration of 1-10 μg/ml for overnight at 4° C. Multiple wells of antigen were prepared for each library. 5% milk in PBS was used to block the coated wells at room temperature for 1-2 hours. After a wash with PBS, 100 μl of phage library solution/well (usually 1-5×1012 in 2% milk-PBS) was added into 4 parallel wells, and incubated for designed length of time (usually 1-2 hours). After several washings with PBST and PBS, the bound phages were eluted from the wells with fresh-prepared 1.4% triethylamine in ddH2O (10 minutes incubation at room temperature), followed immediately with neutralization by adding 50 μl of 1M Tris-HCl (pH 6.8).
The eluted, enriched phage pool was further amplified through the following steps: First, TG1 cells were infected with eluted phages at 37° C. for 1 hour, then plated out on 2YT agar plates with 2% glucose and 100 μg/ml carbenicillin for overnight culture. Thus TG1 cells harboring enriched phagemid library were harvested from the plates, and infected with helper phage GMCT for 1 hour. The Fab-display phages were then generated from those TG1 cells harboring both library phagemids and GMCT helper phage genome by overnight growth in 2xYT/carbenicillin/Kanamycin at 22° C. The phagemid particles were purified from overnight culture supernatants by precipitation with PEG/NaCl, and re-suspended in PBS. The PEG-precipitation was repeated once. The phage concentration was determined by OD268 measurement.
With amplified first round phages, the panning process as described above was repeated twice for further enrichment of PCSK9-binding phages. The eluted phages from the third round panning were used to infect TG1 cells. The TG1 cells harboring phagemids from third round panning were picked from 2YT agar plates for Fab ELISA screening assay.
EXAMPLE 2
Fab ELISA Screening for PCSK9 Binders
Over 10,000 clones from third round panning were picked by MegaPix Picking Robot (Genetix), and inoculated into 384-well plates with 60 μl of 2YT/2% Glucose/carbenicillin for overnight culture at 30° C. with 450 rpm shaking. The duplicated plates were made by transferring  ̃1-3 μl overnight culture from each well into new plates with 50 μl/well of 2YT/0.1% Glucose/carbenicillin. The duplicated plates were incubated in a shaker at 30° C. for 6 hours, then 10 μl/well of IPTG was added for a final concentration of 1 mM. After overnight culture at 22° C., the soluble Fab in IPTG-induction plates were released by adding lysozyme into each well.
To detect the antigen binding activity of soluble Fabs generated from the above experiment, the antigen plates were generated by overnight coating of 5 μg/ml human PCSK9 antigen. After blocking with 5% milk-PBS and a wash with PBST, 15-20 μl of Fab samples from IPTG-induction plates was transferred into antigen plates for 1-2 hours incubation at room temperature. The plates were washed 5 times with PBS-T, and added with 1:2000 diluted goat anti-human Kappa-HRP (SouthernBiotech Cat. No. 2060-05) or 1:10,000 diluted goat anti-human Fab-HRP in 5% MPBS for 1 hour incubation. After washing away unbound HRP-conjugates with PBST, the substrate solution QuantaBlu WS (Pierce 15169) was then added to each well and incubated for 5-15 minutes. The relative fluorescence units (RFU) of each well was measured to determine the Fab binding activity by using excitation wavelength 330 nm and emission detection wavelength 410 nm.
The ELISA results showed 30 to 80% clones from third round panning of individual PDL1 sub-libraries bound to antigen PCSK9. The positive clones were then sent out for DNA sequencing. A total of 128 unique Fab sequences were identified from the PDL1 library.
One particular PCSK9 antagonist of interest, AX114, comprising the following variable heavy and variable light regions was identified from the PDL1-VH3/VK3 sub-library.







(AX114 VH)







SEQ 360







EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGW


 


IDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


 


YGYYFDYWGQGTLVTVSSAS


 


(AX114 VK)







SEQ 512







EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYD


 


ASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVAFG


 


GGTKVEIK






EXAMPLE 3
Fab Protein Expression and Purification from TG1 Cells
50 ml of overnight cultures for individual clones in 2YT/2% glucose/Carbenicillin 100 μg/ml were grown in 37° C. shaker incubator. In the second day, 750 mL to 1 L of 2YT/0.1% glucose/100 μg/mL Carbenicillin was inoculated for each clone by transferring 5-10 ml of the overnight culture. The cultures were grown at 30° C. with shaking for approximately 3-4 hours until OD600 ̃1. IPTG was added to the culture to reach the final concentration of 0.1-0.5 mM. After overnight IPTG induction at 22° C., the cells pellets were collected by centrifugation at 10,000 rpm for 10-15 minutes, to proceed for periplasmic preparation.
Soluble Fabs were extracted from cell periplasm. The periplasmic preparation was performed as follows. The TG1 pellet was re-suspended in 20 mL pre-chilled PPB buffer (20% Sucrose+2 mM EDTA+30 mM Tris, pH=8), and incubated on ice for 1 hour. The supernatant with soluble Fab was collected by centrifugation. Subsequently, the cell pellet was further re-suspended in 20 mL pre-chilled 5 mM magnesium sulfate with 1 hour incubation on ice. Two supernatants were combined for further Fab purification.
The soluble Fab from the periplasmic extraction was purified using a HiTrap Protein G HP column (GE Healthcare). The column was initially equilibrated with equilibration buffer (PBS or Tris, pH 7.3). The supernatant from periplasmic preparation was loaded onto a 1-ml or 5-mL protein-G column (HiTrap, GE healthcare). After wash with 10 column volumes (CVs) of equilibration buffer, Fab protein was eluted with 8 CVs of elution buffer (0.3 M acetic acid, pH3). The eluted fractions were collected, and neutralized with 0.5 volume of 1M Tris, pH 9 buffer. The Fab samples were buffer-exchanged into PBS using Amicon centrifugal filters with 10 kD molecular weight cutoff. The quality of purified Fab was analyzed using size exclusion HPLC (SE-HPLC). Purified Fab was also used for ELISA assay and Biacore assay (below). Overall, the summary of Fab yields is  ̃1-2 mg/L with high degree of variability, from less than 1 mg/L to well over 10 mg/L. All Fabs show single main peak by SE-HPLC. The ELISA assay results confirmed all Fabs isolated from PDL1 library bound to human PCSK9 antigen.
EXAMPLE 4
Biacore-Based PCSP9-LDL Receptor Interaction Assay
The LDL-Receptor (LDLR) and EGF_AB domain of LDLR (this domain involves the interaction with PCSK9) were immobilized on two different flow cells in the same CM5 chips by coupling of amine groups of LDLR or EGF_AB domain onto carboxylated surfaces of sensor chips according to the instruction of Amine Coupling Kit (GE/Biacore). Briefly, LDLR and EGF_AB were diluted to 20 μg/ml in pH 4.5 10 mM Acetate buffer and injected to two flow cells on the same CM5 chip to achieve an immobilization level of  ̃1500 RU. 100 nM human PCSK9 alone in running buffer (1×HBSP with 0.1 mM CaCl2) was injected into the flow cells (at 20 μl/minute for 2.5 minutes) to measure the interaction of PSK9 with LDLR and EGF_AB domain. After injection, the flow cells were regenerated by 10 mM HCl.
To determine the impact of the binding of Fab antibody to PCSK9, each purified Fab sample (1 μM in the running buffer) was incubated with human PCSK9 at the concentration of 100 nM for 30 minutes at room temperature. The prepared PCSK9/Fab samples were injected into the CM5 chip, and binding of PCSK9/Fab complex was measured. As shown in FIG. 1, human PCSK9 alone bound to both LDLR and EGF_AB domain. When the binding of Fab antibody did not inhibit the PCSK9-LDLR interaction, the binding of PCSK9/Fab complex to LDLR or EGF_AB resulted in higher binding RU then PCSK9 alone. Among the Fab antibodies tested, AX114 Fab showed significant inhibition on PCSK9 binding to LDLR or EGF_AB domain.
EXAMPLE 5
Biacore-Based Competition Assay for Binding Epitope Binning
Human PCSK9 protein was immobilized on CM5 chip by coupling primary amine groups of PCSK9 onto carboxylated surfaces of sensor chips according to the instruction of Amine Coupling Kit (GE/Biacore). Briefly, hPCSK9 protein was diluted to 50 μg/ml in pH 5.5/10 mM Acetate solution, and was injected onto the NHS/EDC activated surface to achieve an immobilization level of 1000-2000 RU, followed with surface inactivation by injection of Ethanolamine The Fab or IgG protein (1 μM in HBS-P buffer) was then injected for 3 minutes binding, followed by 5 minutes dissociation. In the binding epitope binning assay, two flow cells were immobilized with same amount of hPCSK9 protein to detect the binding competition between antibody 1 and antibody 2. On the flow cell 1, antibody 1 was injected twice to occupy its binding epitope, antibody 2 was then injected for binding. The flow cell 2 was setup as a reference, only antibody 2 was injected onto it for binding. To determine whether there was competition between antibody 1 and antibody 2, the sensorgrams of antibody 2 from both flow cells were overplayed. When two antibodies competed, pre-occupation of antibody 1 could significantly or totally inhibit the antibody 1 binding. Cross competition for 19 antibodies from PDL1 library was completed, and 3 independent epitope bins on human PCSK9 were identified, see table 2.











TABLE 2









Bin 1 binder
Bin 2 binder
Bin 3 binder







AX114
AX1
AX116



AX132
AX9



AX139
AX40



AX212
AX56



AX213
AX115



AX210
AX118



AX211
AX119




AX188




AX189




AX191















Bin 1 Binder
VH SEQ ID NO
VL SEQ ID NO







AX114
360
512



AX132
360
511



AX137
360
517



AX139
360
523



AX210
364
511



AX211
365
511



AX212
366
511



AX213
362
511










EXAMPLE 6
Optimization of AX114
Optimization libraries for AX114 were designed and constructed. All AX114 libraries were panned against PCSK9 antigen for 3-6 rounds as described in Example 1. The clones were picked for Fab ELISA screening as described in Example 2. The PCSK9 binding clones were expressed in TG1 cells for Fab secretion. Purified Fab proteins (Example 3) were run on Biacore for affinity measurements (see Example 14). From these libraries, a total of 135 AX114 variants (listed in table 3) that bind to human PCSK9 were identified, including AX132 (comprising VH and VL regions SEQ ID No: 360 and 511, respectively).







TABLE 3







sequence ID for AX114 and its variants










Sequences
SEQ ID NO:






VH
360-510



VK
511-549



VH_CDR1
189, 191 193, 195, 197-294



VH_CDR2
68, 70, 72, 74, 76-182



VH_CDR3
5, 7, 9, 11, 13-63



VK_CDR1
349, 351, 353-359



VK_CDR2
339, 341, 343-346



VK_CDR3
301, 303, 305-334










>SEQ ID NO: 360 (AX132 VH)


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWI


GWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCA


RERYGYYFDYWGQGTLVTVSSAS [in specific embodiments,


SEQ ID NO: 361]


 


>SEQ ID NO: 511 (AX132 VK)


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIY


DASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPP


VVFGGGTKVEIK


 


>SEQ ID NO: 362 (AX213 VH)


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWI


GRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCA


RANDGYSFDYWGQGTLVTVSSAS [in specific embodiments,


SEQ ID NO: 363]


 


>SEQ ID NO: 511 (AX213 VK)


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIY


DASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPP


VVFGGGTKVEIK









The sequence changes in the CDR regions for AX114 variants are illustrated in FIGS. 2 and 3.
EXAMPLE 7
Computational Docking and PCSK9 Mutagenesis for AX132 Epitope Mapping
Definitions: Given residue on the PCSK9 is counted as in contact with a given antibody, if Cα (see, e.g., “Introduction to Protein Structure” by Carl Branden & John Tooze, 2nd edition, 1999 Garland publishing) atom of PCSK9 residue is within 10 Angstroms from CA of that antibody. For X-ray structure, the residues in contact define the epitope. For docking poses within a given epitope bin, the residues in the contacts with frequency higher than threshold (>50-75%) define the epitope. Two proteins (e.g. AX114 with a control Fab that competes with AX114 to bind to EGF_AB domain of LDL receptor) are defined as compete based on their structural model if the distance between any Cα atoms of these proteins is shorter than 5 Å.
Docking procedure: To determine the epitope for AX132, docking was performed with a program involving rigid-body translation/rotation of one partner with respect to the other with optimization of side-chains; see, Gray, J J et al., 2003 J. Mol. Biol. 331:281-299. Since AX114 and AX132 compete with the control Fab, the initial configuration was started from the X-ray structure of control Fab with antibody pulled away approximately 15 Angstroms. The low scoring poses have been clustered and analyzed for contacts to determine the epitope. The epitope for AX213 is assumed similar to AX114/AX132 based on sequence similarity and competition data.
Based on computational docking studies, three bins have been determined, as shown in FIG. 4. Based on the AX132 binding differentiation between human and rat PCSK9 (table 4), human PCSK9 chimeric mutations to rat PCSK9 residues have been selected to differentiate and test epitope bins. Total 6 chimeric mutants have been designed. Each mutant represents a patch on PCSK9, see table 5. Mutant #1 is in bin 1 and is expected to abrogate binding of AX114/AX132/AX213 based on cross-species binding data. Mutant #2 (from bin 2) or mutant 3 (from bin 3) are expected to abrogate binding of other antibodies.







TABLE 4







binding affinities of AX132 variants to human, rhesus, mouse


and rat PCSK9














Human
Rhesus






PCSK9
PCSK9
Mouse 9
rat PCSK9


Molecule
Format
KD (M)
KD (M)
KD (M)
KD (M)





AX114
IgG2
2.40E−08
1.16E−08
1.12E−08
N/A


AX132
IgG2
6.16E−09
2.59E−09
2.76E−09
E−7


AX137
IgG2
9.98E−09
1.00E−08
no binding
N/A


AX210
IgG2
2.64E−09
9.44E−10
3.60E−09
N/A


AX211
IgG2
1.63E−09
4.93E−10
1.66E−09
N/A


AX212
IgG2
2.12E−09
7.74E−10
2.74E−09
N/A


AX213
IgG2
2.07E−09
1.89E−09
3.25E−09
N/A
















TABLE 5







human PCSK9 mutants with residues of rat PCSK9










Mutants
Residues of rat PCSK9







Mutant #1
192, 379



Mutant #2
366, 426



Mutant #3
201, 202, 206, 207, 247, 248



Mutant #4
245, 396, 405, 420, 440, 443



Mutant #5
177, 179, 277, 280



Mutant #6
162, 173










The human PCSK9 mutant proteins were produced from HEK293 cells. Briefly, the gene of a full-length human PCSK9 inside a mammalian expression vector with His-tag was modified by site-directed mutagenesis to induce the corresponding mutations based on table 5. Then the vectors of PCSK9 mutants were transiently transfected into human HEK293 cells for 7 to 10 days culture at 37° C. The His-tagged PCSK9 mutant proteins were purified from the culture supernatants by NTA column (GE Healthcare, Pittsburgh, Pa.). The quality of PCSK9 proteins were analyzed using 10% SDS-PAGE.
ELISA assays were performed to study the bindings of PCSK9 mutants to anti-PCSK9 antibody AX132. Briefly, the PCSK9 mutant proteins were diluted with PBS to the concentration of 5 μg/ml, and coated to a 96-well ELISA plate with 100 μl/each well for overnight at 4° C. After blocking with 5% milk-PBS, AX132 samples (in 5% milk-PBS with 1:2 serial dilution at start concentration of 4 nM) were added to the wells coated with individual PCSK9 mutants, and incubated for 1 hour at room temperature. After PBS wash, the anti-human K antibody conjugated with HRP was added and incubated for another hour. The TMB substrate solution (Thermo Scientific) was then added into PBS-washed plate for 10-20 minutes of development. After adding stop solution, the plates were measured for the absorbance at 450 nM.
The ELISA results shown in FIG. 5A indicated a significant loss of binding of PCSK9 mutant #1 to antibody AX132. This result suggested that AX132 binds to predicted Bin I. PCSK9 mutant #1 has the amino acid substitutions of D192G and F379Y (FIG. 5B). This region is involved in the binding to EGF_AB domain of LDL receptor.
EXAMPLE 8
Epitope Mapping by Hydrogen-Deuterium Exchange Mass Spectrometry (DXMS)
In order to identify the various epitope regions of PCSK9 recognized by anti-PCSK9 antibodies, hydrogen deuterium exchange was applied to PCSK9, followed by peptide digestion and mass spectrometry based on protocol of Wood and Hamuro (2001) and further developed and automated; see Hamuro et al., 2003 J. Biomolec. Tech. 14:171-182; and Coales et al., 2009 Rapid Comm. Mass Spectrom. 23:639-647. The multi-step procedure is described in the following.
Antibody affinity column preparation: Antibody was immobilized by overnight incubation with cyanogen bromide activated Poros AL resin followed by washing with PBS using a filter funnel. The reaction was capped by resuspending the dried resin in ethanolamine solution for 2 hours and followed with washing with PBS using a filter funnel. The resin was resuspended in PBS then packed into a column. Column was equilibrated with PBS with 2 mM NaCl pH 7 in exchange buffer H at 3° C. All column injections and incubations were done using a syringe pump.
On-solution and off-column deuterium exchange: Exchange H buffer was prepared as PBS in water. Exchange D buffer was prepared as PBS in D2O. Exchange HD buffer was prepared as PBS in 50% D2O. All exchange steps were conducted at 3° C. The mAb column was cleaned with 0.8% formic acid and washed and equilibrated with exchange HD buffer. On-solution exchange of deuterons was initiated by mixing PCSK9 sample 1:1 with exchange D buffer and incubated for predetermined times. The mixture was then injected into mAb column and washed with exchange HD buffer. Off-column exchange was initiated by washing with exchange H buffer and incubating for predetermined times. Off-column exchange was quenched and PCSK9 was eluted using 0.8% formic acid. Fractions were collected and analyzed.
On- and off-column deuterium exchange: All exchange steps were conducted at 3° C. The mAb column was cleaned with 0.8% formic acid and washed and equilibrated with exchange HD buffer. PCSK9 in exchange H buffer was loaded onto the mAb column and washed with exchange H buffer. On-column exchange of deuterons was initiated by the injection of exchange HD buffer and incubating for predetermined times. Off-column exchange was performed and quenched as above. Fractions were collected and analyzed.
Full deuteration of PCSK9: PCSK9 was equilibrated in PBS prepared in D2O and incubated at 60° C. for 3 hours. This was cooled to room temperature and stored on ice. Fully deuterated PCSK9 was loaded onto an antibody affinity column in HD exchange buffer and washed in same buffer. Elution and analysis were carried out the same as above.
Peptide Analysis by Mass Spectrometry: Eluted PCSK9 was injected into an immobilized pepsin column and then onto a C18 reversed-phase LC-MS to identify fragments. PCSK9 from eluted fractions was denatured and reduced in 2M urea, 1M TCEP, pH3, 0° C. for 2 minutes. The sample was then passed over immobilized pepsin column in buffer A (0.05% TFA in water). The peptic fragments were loaded onto a reversed phase trap column and desalted in buffer A. Peptic fragments were separated by a C18 column with a linear gradient of 13-40% Buffer B (95% acetonitrile, 5% water, 0.0025% TFA) in 23 minutes. Peptides were detected by mass spectrometry.
The shift in the masses of known peptic fragments detected by MS is used to determine the HD exchange level. The percent exchange is determined from ratio HD exchange of bound vs. unbound PCSK9 and indicates degree of epitope protection by the antibody. Percent deuteration change is cutoff at 5% as threshold to remove noise.
The HD exchange profiles for AX132 and AX213 antibodies are shown in FIG. 6. The PCSK9 peptic fragments that exhibit the greatest deuteration difference upon AX213 or AX132 binding are 155-PWNL-158 (SEQ ID NO: 576) and 364-PGEDIIGASSDCSTC-378 (SEQ ID NO: 577) where subfragments 157-NL-158 and 370-GASSDCSTC-378 (SEQ ID NO: 578) appear to contain the epitope. There may be other weakly interacting sites but these are below the cutoff threshold (5%) and are likely due to indirect or local structural perturbations.
FIG. 7 shows PCSK9 (PDB: 2PMW) with the two peptic fragments containing the AX132 and AX213 epitope highlighted. Grey corresponds to 155-PWNL-158 (SEQ ID NO: 576) and dark grey corresponds to 364-PGEDIIGASSDCSTC-378 (SEQ ID NO: 577). The auto cleaved prodomain is largely hidden from this view.
The HD exchange data is consistent with the PCSK9 mutagenesis data in Example 7. Both 155- and 364-peptides are located in the epitope bin #1 as shown in FIG. 4,
EXAMPLE 9
Fab Domain Thermostability
Thermostabilities of Fabs and Fab domains were determined from DSC experiments by analysis and deconvolution of excess heat capacity function in Origin 5.0. The melting transition temperatures (Tm) for Fabs or Fab domains are indicated in Table 6. The Tm of various Fabs and Fab domains range from 72 to 78° C. for PDL1 derived antibodies, which is consistent with well folded antibody Fab region.







TABLE 6







Thermostabilities of AX114 variants










IgG
Fab domain (Tm, ° C.)







Ax114-IgG1
76.7



AX114-IgG2
76.5



AX132-IgG2
77.4










EXAMPLE 10
AX132-FAB/PCS9 Crystal Structure
Expression
Nucleic acid expressing AX132 Fab was incorporated into a phage library display vector, and extraneous N- and C-terminal residues were removed from the vector prior to expression and purification of the Fab for crystallization, as follows:

    
    
        1) Codons expressing 3 extra amino acids (AGS) between the p3 leader and the H chain FR1 in the vector were removed, generating an authentic heavy chain N-terminus following cleavage of the p3 signal peptide in E. coli. 
        2) In order to facilitate Fab crystallization, the GR1 adaptor domain coding region at the heavy chain C-terminus in the vector was removed prior to Fab expression and purification, and a termination codon was introduced immediately following the coding sequences of the HA and His tags. This was accomplished by subcloning the light and heavy chain Fab expression cassette (HindIII-XhoI) into plasmid pMAB9, which carries those modifications.

The final expression plasmid for purification is illustrated in FIGS. 20A-E, and the vector map is illustrated in FIG. 19. The plasmid expresses both the light and heavy chains in a bicistronic message off the lac promoter. The light chain open reading frame is expressed at the 5′ end of the message following the p8 leader, and then the heavy chain follows after the p3 leader.

Purification of AX132

    
    


AX 132 was purified from E. coli over a nickel affinity column followed by SP Sepharose column chromatography,
Purification of PCSK9:
Secreted PCSK9 was captured from HEK 293 cell over a capto Q column. The bound protein was pooled and further purified over a nickel affinity column followed by size exclusion column (S200) chromatography
Complex-Generation:
Purified AX 132 was mixed with purified PCSK9 at a molar ratio of 1.5:1 and incubated for 12 hours at 4° C. The mixture was further fractionated on a 2× Superdex 200 (16-60) column to get rid of uncomplexed AX 132. The purified complex was concentrated to 10 mg/ml and crystallized without any freeze-thaws.
Crystallization
The PCSK9:AX132 complex yielded crystals in different crystallization conditions. Generally, the complex was frozen in the presence of cryoprotectant. The crystal diffracted up to 3.09 Å at synchrotron. The structure of PCSK9 bound to the AX132 Fab fragment was determined by a molecular replacement method. AX132 binds at the EGF-A binding site. The light chain of the antibody AX132 is mainly responsible for the interactions with PCSK9. Multiple hydrogen bonding and hydrophobic interactions are observed at the interface.
FIG. 8 depicts the crystal structure of PCSK9 bound to the AX132 antibody. FIG. 9 shows the surface area representation of PCSK9 with the AX132 epitope. The coordinates for the crystal structure discussed are presented in Table 14, Example 21.
The residues involved in the binding are identified by calculating the difference in accessible surface area between the AX132:PCSK9 crystal structure and PCSK9 structure alone. PCSK9 residues that show buried surface area upon complex formation with AX132 antibody are included as a part of the epitope. The solvent accessible surface of a protein is defined as the locus of the center of a probe sphere (representing a solvent molecule) as it rolls over the Van der Waals surface of the protein. The solvent accessible surface area was calculated by using the program AREAIMOL (see, Lee et al., 1997 J. Mol. Biol. 55:5-11 and Saff et al., 1997 The Mathematical Intelligencer 19:5-11), which generates surface points on an extended sphere about each atom (at a distance from the atom center equal to the sum of the atom and probe radii) and eliminates those that lie within equivalent spheres associated with neighboring atoms (Briggs, P. J. 2000, CCP4 Newsletter No. 38, CCLRC, Darebury).
EXAMPLE 11
Selection of Antibodies Binding to AX132 Epitope on PCSK9
The antibodies with AX132 binding epitope can also be selected out from a phage display antibody library using EGF_AB peptide that competes with AX132. After binding of phage library to human PCSK9 coated on plate, the EGF_AB protein can be added to elute the binding phages. The individual clones from the EGF_AB eluted phage pool can then be screened against human PCSK9 and PCSK9 mutant #1. As shown in FIG. 5A, AX132 bind to human PCSK9 with high affinity, but very low affinity to human PCSK9 mutant #1 (see, Example 7). The Fabs that bind to human PCSK9 can be subjected to a binding screening assay against PCSK9 mutant #1 protein, and the Fab with strong binding to human PCSK9 but weak binding to PCSK9 mutant #1 will share the AX132 binding epitope.
EXAMPLE 12
Anti-PCSK9 Monoclonal Antibody Expression and Purification From Mammalian Cells
The DNA sequence encoding the Vk1 or VK3 light chain variable region was amplified by polymerase chain reaction from plasmid template. The product of this amplification was cloned into plasmid pVUNSAGS-FB-LCK that had been previously digested with Fspl and Bmtl, using the InFusion cloning system (Clontech). The resulting plasmid was verified by DNA sequencing across the variable region. Endotoxin-free plasmid preparations were made using the Qiagen Endo-Free plasmid maxiprep kit. The DNA sequence encoding the heavy chain variable region of VH3 was amplified by polymerase chain reaction, and the amplified product was cloned into plasmid pVl JNSA-BF-HCG2M4 that had been previously digested with Fspl and Bmtl. The resulting plasmid was verified by DNA sequencing across the variable region. Endotoxin-free plasmid preparations were made using the Qiagen Endo-Free plasmid maxiprep kit.
The plasmid DNA for heavy and light chain was mixed at 1:3, and co-tranfected into HEK293 cells. After 5-7 days culture, the supernatant was harvested and proceeded for Protein-A column purification. Briefly, the cell free supernatant was loaded on to protein-A column pre-equilibrated with three column volume of 20 mM Tris-HCl pH7.0 at a flow rate of 5.0 mL/min. The column was washed with three column volumes of the 20 mM Tris-HCl pH7.0 followed by a five column volume wash with 20 mM Tris-HCl pH7.0 containing 1M NaCl to remove the host cell proteins. The anti-PCSK9 antibody was eluted with five column volume of 100 mM Glycine, 100 mM Arginine pH 3.0 and immediately neutralized with 1M Tris-HCl pH8.0.
EXAMPLE 13
ANTI-PCSK9 Monoclonal Antibody Expression and Purification from Glycoengineered Pichia pastoris 
Anti-PCSK9 IgG2 monoclonal antibodies were expressed in glyco-engineered Pichia pastoris GFI 5.0 host YGLY8316, which is capable of transferring terminal galactose at its complex N-linked glycan. Anti-PCSK9 heavy and light chains were codon optimized and expressed under methanol tightly inducible promoter AOX1 using Saccharomyces cerevisiae alpha mating factor presequence as secretion signal sequence. Anti-PCSK9 antibody from Pichia pastoris GFI 5.0 host YGLY8316 was captured from cell free supernatant media by affinity chromatography using MabSelectTM medium from GE Healthcare (Cat. #17-5199-01). The cell free supernatant was loaded on to Mabselect column (XK 16/20, 1.6 cm×10.0 cm) pre-equilibrated with three column volume of 20 mM Tris-HCl pH7.0 at a flow rate of 5.0 mL/min. The column was washed with three column volumes of the 20 mM Tris-HCl pH7.0 followed by a five column volume wash with 20 mM Tris-HCl pH7.0 containing 1M NaCl to remove the host cell proteins. The anti-PCSK9 antibody was eluted with five column volume of 100 mM Glycine, 100 mM Arginine pH 3.0 and immediately neutralized with 1M Tris-HCl pH8.0. AX213 antibody was well expressed in Pichia, yielding ca. 300-700 mg/L of protein in a small scale fermentation process. The yield for AX114 was 5 mg/L in small scale.
Strong Cation Exchange Chromatography employing Source 30S resin from GE Healthcare (Cat #17-1273-02) was used as the second step purification to remove the clipped species and aggregates. A MabSelectTM (GE Healthcare, Pittsburgh, Pa.) pool of the anti-PCSK9 antibody was 5× diluted with 25 mM Sodium acetate pH5.0 and loaded on to the Source 30S column pre-equilibrated with three column volume of 25 mM Sodium acetate pH5.0. After loading, the column was washed with three column volume of the 25 mM Sodium acetate pH5.0 and elution was performed by developing a linear gradient over ten column volume ranging from 100 mM to 150 mM Sodium chloride in 25 mM Sodium acetate pH5.0. The fractions containing good assembled anti-PCSK9 antibody was pooled together. The Source 30S pooled fractions that contained the anti-PCSK9 antibody was buffer exchanged into the formulation buffer containing 6% Sucrose, 100 mM Arginine, 100 mM Histidine pH6.0 (HyClone® Cat #RR10804.02) and sterile filtered using 0.2 μm PES (PolyEtherSulfone) membrane filter and stored @4° C. until release.
EXAMPLE 14
Biacore Assay for Affinity Measurement
To determine the binding affinity of Fab to PCSK9, Fab capture-based Biacore assay was developed. First, goat anti-Fab IgGs were immobilized onto CM5 chip by amine coupling as described above. The anti-Fab IgGs were diluted to 200 μg/ml in pH 5/10 mM Acetate solution, and injected onto the NHS/EDC activated surface to achieve an immobilization level of  ̃10,000 RU, followed with surface inactivation by injection of Ethanolamine. Then Fab samples at concentration of 2 μg/ml in HBS-P running buffer were injected for 3 minutes at flow speed of 20 ul/min, followed with K-injection (3 minutes injection for association and 6 minutes for dissociation) of PCSK9 at concentration of 10 to 100 nM. The sensor chip surface was regenerated by 30 second injection of 100 mM phosphoric acid. The binding sensorgrams were fitted with 1:1 Langmuir binding model to determine the binding affinity. The Fab affinities of AX114, AX132 and other variants are shown in table 7.







TABLE 7







Fab binding affinity










Fabs
Binding affinity to human PCSK9












Name
ka (1/Ms)
kd (1/s)
KD (M)







AX114
7.17E+04
3.48E−03
4.85E−08



AX132
9.11E+04
1.08E−03
1.18E−08



AX137
1.07E+05
2.08E−03
1.95E−08



AX139
8.97E+04
1.18E−03
1.32E−08



AX201
1.31E+05
1.02E−03
7.82E−09



AX202
1.09E+05
1.02E−03
9.43E−09



AX204
2.34E+05
9.87E−04
8.39E−09



AX205
1.04E+05
9.72E−04
9.45E−09



AX206
1.22E+05
1.03E−03
8.42E−09



AX207
1.11E+05
1.00E−03
9.23E−09



AX208
9.84E+04
2.59E−03
2.64E−08



AX209
1.12E+05
1.07E−03
9.60E−09



AX210
1.72E+05
2.87E−04
1.67E−09



Ax211
1.97E+05
3.29E−04
1.67E−09



AX212
1.59E+05
2.33E−04
1.47E−09



AX213
2.43E+05
3.29E−04
1.37E−09



AX214
1.92E+05
3.19E−04
1.60E−09



AX215
1.16E+05
3.76E−04
3.47E−09



AX216
1.15E+05
2.88E−04
2.51E−09



AX217
1.38E+05
3.40E−04
2.52E−09



AX239
3.03E+04
9.60E−04
3.16E−08



AX240
1.60E+05
1.66E−04
1.04E−09



AX241
1.97E+05
1.60E−04
8.13E−10



AX242
1.62E+05
1.93E−04
1.19E−09



AX243
1.31E+05
1.91E−04
1.46E−09



AX244
1.89E+05
2.03E−04
1.07E−09



AX245
1.12E+05
3.19E−04
2.84E−09



AX246
2.49E+05
2.01E−04
8.06E−10



AX247
1.86E+05
2.44E−04
1.31E−09



AX248
1.89E+05
2.07E−04
1.09E−09



AX249
1.90E+05
2.06E−04
1.08E−09



AX250
3.07E+05
2.40E−04
7.81E−10



AX251
2.54E+05
2.52E−04
9.93E−10



AX252
1.37E+05
4.67E−04
3.42E−09



AX253
1.61E+05
6.81E−04
4.23E−09



AX254
9.24E+04
2.95E−04
3.19E−09



AX255
9.61E+04
3.91E−04
4.07E−09



AX256
1.26E+05
3.65E−04
2.90E−09



AX257
2.53E+05
1.68E−04
6.64E−10



AX258
1.12E+05
6.30E−04
5.63E−09



AX259
6.92E+04
6.04E−04
8.73E−09



AX260
4.19E+04
5.20E−04
1.24E−08



AX260
2.64E+04
5.70E−04
2.16E−08



AX263
2.78E+04
1.70E−04
6.11E−09



AX267
1.29E+05
4.75E−04
3.70E−09



AX268
2.77E+04
4.17E−04
1.50E−08



AX269
1.13E+05
3.14E−04
2.77E−09



AX269
9.49E+04
3.20E−04
3.37E−09



AX299
1.03E+05
2.57E−04
2.51E−09



AX300
1.15E+05
3.12E−04
2.72E−09



AX301
1.28E+05
6.00E−04
4.67E−09



AX302
1.14E+05
6.68E−04
5.89E−09



AX303
7.37E+04
8.61E−04
1.17E−08



AX306
9.04E+04
4.47E−04
4.94E−09



AX307
8.88E+04
2.70E−03
3.03E−08



AX308
5.23E+04
2.59E−03
4.96E−08



AX310
1.09E+05
7.43E−04
6.79E−09



AX311
1.47E+05
4.98E−04
3.39E−09



AX312
1.58E+05
1.41E−03
8.94E−09



AX313
2.13E+05
7.35E−04
3.46E−09



AX314
1.09E+05
1.72E−03
1.58E−08



AX315
4.65E+04
2.31E−04
4.97E−09



AX316
1.57E+05
5.63E−04
3.59E−09



AX318
1.67E+05
2.71E−05
1.62E−10



AX319
2.59E+05
4.25E−05
1.64E−10



AX320
1.51E+05
2.62E−05
1.74E−10



AX322
1.19E+05
1.83E−04
1.54E−09



AX323
1.79E+05
8.36E−05
4.66E−10



AX325
1.39E+05
1.19E−04
8.53E−10



AX326
1.68E+05
6.52E−05
3.87E−10



AX329
1.33E+05
2.09E−04
1.57E−09










The Fabs which showed functional efficacy in the cell-base assays were converted into IgG molecules. The affinities of those IgG molecules were also measured by Biacore assay. Briefly, anti-human IgG monoclonal antibody form Human Antibody Capture Kit provided by Biacore was immobilized on CM5 chips at level of 8000 to 10000 RU. The IgG samples at concentration of  ̃0.4 μg/ml was injected onto a sensor chip for 2 minutes at a flow rate of 20 μl/min, then PCSK9 proteins at 5 concentrations (3.75 to 60 nM) were injected onto an IgG captured flow cell for binding kinetic analysis. After each round injection, the sensor chip surface was regenerated by 30 second injection of 3M Magnesium Chloride. The affinities of AX114, AX1213 and other variants are shown in table 8 and table 9.







TABLE 8







Purified IgGs against human PCSK9












Name
ka (1/Ms)
kd (1/s)
KD (M)







AX114
1.51E+05
3.61E−03
2.40E−08



AX132
2.48E+05
1.52E−03
6.16E−09



AX137
3.33E+05
3.32E−03
9.98E−09



AX210
2.35E+05
6.21E−04
2.64E−09



AX211
3.61E+05
5.89E−04
1.63E−09



AX212
1.53E+05
3.24E−04
2.12E−09



AX213
3.53E+05
7.30E−04
2.07E−09

















TABLE 9







Purified IgGs against rhesus PCSK9












Name
ka (1/Ms)
kd (1/s)
KD (M)







AX240
1.41E+06
3.09E−04
2.20E−10



AX241
1.56E+06
3.46E−04
2.22E−10



AX242
1.76E+06
3.25E−04
1.85E−10



AX243
7.71E+05
8.70E−04
1.13E−09



AX245
8.90E+05
1.05E−03
1.18E−09



AX246
1.48E+06
6.14E−04
4.16E−10



AX248
1.16E+06
4.58E−04
3.96E−10



AX249
1.22E+06
6.53E−04
5.35E−10



AX250
2.09E+06
6.23E−04
2.98E−10



AX253
1.62E+06
1.76E−03
1.09E−09



AX267
1.38E+06
1.26E−03
9.13E−10



AX277
9.99E+05
1.67E−03
1.67E−09



AX369
9.71E+05
2.30E−03
2.37E−09



AX370
1.01E+06
2.31E−03
2.28E−09



AX402
1.09E+06
2.32E−03
2.12E−09



AX406
8.86E+05
2.01E−03
2.27E−09



AX408
7.65E+05
1.50E−03
1.96E−09



AX415
7.50E+05
3.12E−03
4.15E−09



AX417
1.10E+06
9.04E−04
8.22E−10



AX419
1.25E+06
9.41E−04
7.51E−10



AX426
6.92E+05
6.28E−04
9.08E−10



AX427
7.45E+05
5.60E−04
7.51E−10



AX428
6.55E+05
4.43E−04
6.76E−10



AX429
7.25E+05
5.88E−04
8.11E−10



AX430
9.15E+05
8.52E−04
9.31E−10



AX432
7.39E+05
1.25E−03
1.69E−09



AX436
4.81E+05
7.93E−04
1.65E−09



AX439
7.40E+05
7.36E−04
9.94E−10



AX441
7.92E+05
8.22E−04
1.04E−09



AX444
7.08E+05
4.99E−04
7.06E−10










EXAMPLE 15
PCSK9-LDLR TR-FRET Assay
This assay is a variant of the one described in Fisher et al., 2007 J. Biol. Chem. 282:20502-20512. AlexaFluor647-labeled PCSK9 (final concentration 10 nM) was combined with varying amounts of AX132 and variants and to this was added Eu(8044)-labeled LDLR ectodomain to a final concentration of  ̃4 nM (sufficient to give  ̃20,000 counts at F1620 nM on the Rubystar) in 10 mM HEPES (pH 7.4), 150 mM NaCl, 0.1 mM CaCl2, 0.05% (w/v) BSA in a total volume of 50 μL using 96 well black Dynatech U bottom plates. After at least 90 minutes of equilibration, samples were read in a Rubystar reader (BMG Corp.) using 20 flashes per well, a 50 μsec integration delay, and a 200 μsec total integration time. Data were expressed as the ratio of (Fl665/Fl620×10000), and IC50s for AX132 and variants were determined from the inflection point of a sigmoidal dose-response curve using a standard four parameter fit.
FIG. 10 illustrates the activity of AX132 and its variants in the PCSK9-LDLR interaction TR-FRET assay. The IgG of AX132 and its variants are potent [with an IC50 of 2.4 to 5.9 nM] and inhibit the PCSK9-LDLR interaction fully.
EXAMPLE 16
Exopolar Assay: Effects of Exogenous PCSK9 on Cellular LDL Uptake
On day 1, 30,000 HepG2 or HEK cells/well were plated in a 96 well polyD-lysine coated plate. On day 2, the media was switched to no-serum containing DMEM media. On day 3, the media was removed and the cells were washed with OptiMEM. Purified PCSK9 was added in 100 μl of DMEM media containing LPDS and dI-LDL. The plates were incubated at 37° C. for 6.5 hours. The cells were washed quickly in TBS containing 2 mg/ml BSA; then washed in TBS-BSA for 2 minutes; and then washed twice (but quickly) with TBS. The cells were lysed in 100 μl RIPA buffer. Fluorescence was then measured in the plate using an Ex 520, Em 580 nm. The total cellular protein in each well was measured using a BCA Protein Assay and the fluorescence units were then normalized to total protein.
The Exopolar Assay is effective for characterizing variant effects on LDL uptake; see Table 10 below illustrating how the potencies of PCSK9 mutants correlate with plasma LDL-cholesterol in the Exopolar Assay.












TABLE 10










EC-50 (nM)



Mutation
Gain/Loss
LDL-C (mg/dI)
Exopolar





















S127R
Gain
277
14



D374Y
Gain
388
1.3



Wild-type

140
51



R46L
Loss
116
78










Results: 54 Fabs listed in table 11 inhibited the effect of human (“h”), rhesus (“rh”) and murine (“m”) PCSK9 on LDL uptake in a dose-dependent way, with IC50 (human PCSK9) ranging from 4 ̃178.7 nM.







TABLE 11







Inhibition of PCSK9 on LDL uptake by Fabs









Fab IC50 (nM)












Antibody
hPCSK9
rhPCSK9
mPCSK9
















AX114
178.7
194.0
326.0



AX132
62.2
N/A
26.9



AX137
74.4
N/A
27.4



AX139
37.7
N/A
22.9



AX201
36.0
N/A
N/A



AX202
31.2
N/A
N/A



AX204
26.7
N/A
N/A



AX205
26.1
N/A
N/A



AX206
30.3
N/A
N/A



AX207
25.6
N/A
N/A



AX209
35.4
N/A
N/A



AX210
26.8
N/A
N/A



AX211
12.6
N/A
N/A



AX212
13.8
N/A
N/A



AX213
14.7
N/A
N/A



AX214
15.1
N/A
N/A



AX215
19.3
N/A
N/A



AX216
17.1
N/A
N/A



AX217
21.4
N/A
N/A



AX240
65
N/A
N/A



AX241
5
N/A
N/A



AX242
9
N/A
N/A



AX243
17
N/A
N/A



AX244
13
N/A
N/A



AX245
28
N/A
N/A



AX246
17
N/A
N/A



AX248
29
N/A
N/A



AX249
25
N/A
N/A



AX250
11
N/A
N/A



AX254
11
N/A
N/A



AX255
4
N/A
N/A



AX256
18
N/A
N/A



AX257
13
N/A
N/A



AX258
11
N/A
N/A



AX259
9
N/A
N/A



AX267
11
N/A
N/A



AX268
12
N/A
N/A



AX269
22
N/A
N/A



AX272
19
N/A
N/A



AX273
10
N/A
N/A



AX277
20
N/A
N/A



AX302
20
N/A
N/A



AX303
19
N/A
N/A



AX304
23
N/A
N/A



AX305
42.0
N/A
N/A



AX318
7
N/A
N/A



AX319
7
N/A
N/A



AX320
9
N/A
N/A



AX322
26
N/A
N/A



AX323
13
N/A
N/A



AX325
4
N/A
N/A



AX326
11
N/A
N/A



AX329
9
N/A
N/A



AX330
20
N/A
N/A










For IgGs, 7 antibodies listed in table 12 dose-dependently inhibited the effects of both human and rhesus PCSK9 on LDL uptake (FIG. 11-13); an effect which was reproducibly observed. The amount of PCSK9 added to the cells was  ̃5-320 nM.







TABLE 12







inhibition of PCSK9 by IgGs









IgG2 IC50 (nM)












Antibody
hPCSK9
rhPCSK9
mPCSK9
















AX114
36.6
14.4
27.4



AX132
8.9
11.5
9.4



AX137
9.8
10.0
5.3



AX210
6.5
9.7
15.9



AX211
7.5
4.4
11.1



AX212
9.5
4.7
7.3



AX213
11.1
10.2
7.0










FIGS. 11A-F illustrate (i) AX114 or AX132 (IgG)'s dose-dependent inhibition of human PCSK9-dependent loss of cellular LDL-uptake (A, D); (ii) AX114 or Ax132 (IgG)'s dose-dependent inhibition of murine PCSK9-dependent loss of cellular LDL-uptake (B, E); and (iii) AX114 or AX132 (IgG)'s dose-dependent inhibition of rhesus PCSK9-dependent loss of cellular LDL-uptake (C, F).
FIGS. 12A-F illustrate (i) AX210 or AX211 (IgG)'s dose-dependent inhibition of human PCSK9-dependent loss of cellular LDL-uptake (A, D); (ii) AX210 or AX211 (IgG)'s dose-dependent inhibition of murine PCSK9-dependent loss of cellular LDL-uptake (B, E); and (iii) AX210 or AX211 (IgG)'s dose-dependent inhibition of rhesus PCSK9-dependent loss of cellular LDL-uptake (C, F).
FIGS. 13A-F illustrate (i) AX212 or AX213 (IgG)'s dose-dependent inhibition of human PCSK9-dependent loss of cellular LDL-uptake (A, D); (ii) AX212 or AX213 (IgG)'s dose-dependent inhibition of murine PCSK9-dependent loss of cellular LDL-uptake (B, E); and (iii) AX212 or AX213 (IgG)'s dose-dependent inhibition of rhesus PCSK9-dependent loss of cellular LDL-uptake (C, F).
EXAMPLE 17
In Vitro FcRn Dissociation Assay
Our internal data showed that monoclonal antibodies with identical Fc sequences but different Fab domains can bind FcRn with considerable differences. Moreover, an apparent correlation between dissociation at neutral pH and in vivo pharmacokinetics was observed: mAbs with slow dissociation (i.e. >5% “% bound” tend to show shorter terminal half life (t1⁄2) in vivo). This feature was used as an in vitro screening tool for antibody pharmacokinetics.
The neutral pH dissociation of mAbs from human FcRn was measured by SPR using a Biacore T-100 instrument. Briefly, purified FcRn protein was immobilized onto a Biacore CM5 biosensor chip and PBSP (50 mM NaPO4, 150 mM NaCl and 0.05% (v/v) Surfactant 20) pH 7.3 was used as running buffer. The mAbs were diluted with PBSP pH 6.0 to 100 nM, allowed to bind FcRn for 3 minutes to reach equilibrium and followed by 1 minute of dissociation in pH 7.3 running buffer. A report point (Stability) was inserted at 5 seconds after the end of mAb binding and the “% bound” was calculated as RUStability/RUBinding (%).
FIGS. 14-15 illustrate binding of AX114, AX132, AX210-213 to immobilized human FcRn with Biacore. The sensorgrams show both binding at pH 6.0 and dissociation at pH 7.3. A report point (Stability) was inserted at 5 seconds after then end of pH 6.0 binding and the “% bound” was calculated as RUStability/RUBinding(%).
EXAMPLE 18
Pharmacokinetics Study in Human FcRn Mice
The interaction between IgG and FcRn is species-specific. Human FcRn mice have recently been suggested as a valuable surrogate system for evaluating mAb pharmacokinetics; Petkova et al., 2006 Int. Immunol. 12:1759-69. The human FcRn mice (heterozygous Tg276) used in this study were obtained from Jackson Laboratory (Bar Harbor, Me.). They are deficient in mouse FcRn-α chain and carry a human FcRn-α chain gene. Id. Our internal data showed that unlike mouse or rat FcRn, this “hybrid” FcRn had comparable human IgG binding characteristics as that of human and monkey FcRn. In addition, good terminal half life correlation between this human FcRn mice and non-human primate was observed.
For pharmacokinetics studies, each animal (2-3/group) received a single intravenous injection of mAb at 10 mg/kg via tail vein. Series of 10 μL of blood was collected at specified time points. A validated anti-human IgG immunoassay was used to determine all mAb levels.
The pharmacokinetic profile of AX114, AX132 and AX213 were determined in human FcRn mice following a single 10 mg/kg IV administration. FIG. 16 illustrates the half-life of AX114 and AX132 determined to be 79.6 and 65.5 hours, respectively. The half-life of AX213 was determined to be 97 hours.
The pharmacokinetic profile of AX132 was also determined in rhesus monkey following a single 10 mg/kg IV administration. The half-life of AX132 was determined to be 147 hours.
EXAMPLE 19
Rhesus Pharmacodynamics Study
To characterize pharmacokinetics, pharmacodynamics and target engagement of AX132, a single dose study was conducted in 6 Rhesus monkeys at 1 mg/kg with subcutaneous route of administration. All Rhesus monkeys used in the study were naive to biologies. Blood samples were collected from the saphenous/femoral vessel at designated time points post dosing and the resulting plasma/serum was stored at −70° C. until analysis.
To generate lipoprotein profiles, plasma or serum was fractionated by chromatography over Superose-6 size exclusion column (GE LifeSciences, Inc.). Total cholesterol levels in the column effluent were continuously measured via in-line mixture with a commercially available enzymatic colorimetric cholesterol detection reagent (Total Cholesterol E, Wako USA) followed by downstream spectrophotometric detection of the reaction products at 600 nm absorbance. The first peak of cholesterol eluted from the column was attributed to VLDL, the second peak to LDL and the third to HDL; the area under each peak was calculated using software provided with the HPLC. To calculate the cholesterol concentration for each lipoprotein fraction, the ratio of the corresponding peak area to total peak area was multiplied by the total cholesterol concentration measured in the sample.
The lipoprotein analysis of the serum samples were carried out as described above. An anti-human IgG ELISA using commercially available reagents was used to quantify Ax132 levels.
As shown in FIG. 17, AX132 significantly lowered LDL cholesterol following a single dose, with a maximum mean reduction of 60%, and >25% LDL-C lowering for 42 days.
EXAMPLE 20
Analytical Size Exclusion Chromatography
High Performance-Size Exclusion Chromatography (HP-SEC) is an analytical method used to separate proteins based on order of decreasing size. This method was used to quantitate the level of aggregation and/or fragmentation of proteins after process and purification (time zero) and after accelerated stability studies. Size Exclusion Chromatography was performed with a Waters 2690 Separations Module/996 Photodiode Array Detector. Material was separated using a TSKgel G3000SWXL (4.6×300 mm) column with a Phenomenex pre-filter GFC 4000 (4×3 mm) The column was loaded with 10 μg of material and eluted with a 25 mM sodium phosphate 300 mM sodium chloride pH 7.0 mobile phase at a flow rate of 0.5 ml/min for 30 min. Data was acquired from 200-500 nm and 220 nm profiles were reported.
Monoclonal antibodies were formulated at 0.5 mg/ml in pH 5, 6, 7, and 8 buffers. The buffers contained 150 mM sodium chloride and 10 mM acetate, histidine, phosphate, and TRIS for pH 5, 6, 7, and 8 respectively. HP-SEC was used to characterize material purity at time zero and after one weak at 45° C. Stability results are summarized in Table 13 below. FIG. 18 shows time zero SEC profiles. The boxed labels in the figure define the approximate elution times of higher order aggregates (HOAs), oligomer, monomer, and clipped protein.







TABLE 13







Physical Stability data at time zero and after thermal stress (1 week 45 C.)









1 week stress at 45 C. in



pH 5, 6, 7, and 8 buffers











T0
Inc in






















Elution
Pre



Pre






Cell
Theoretical
time
Mon2



Mon2
Inc in
Inc in
Inc in


mAb1
line
pl
(min)
Peak
Olig3
HOA4
Clip5
Peak
Olig3
HOA4
Clip5





















AX114
HEK293
7.6815
16.1
no
<5%
No
no
na
no
no
no


AX132
HEK293
7.6815
16.0
no
<5%
No
no
na
no
no
1%













pH 8


AX210
HEK293
7.8225
16.1
no
<5%
No
no
na
≈2%
no
no


AX211
HEK293
7.9447
16.1
no
<5%
No
no
na
no
no
no


AX212
HEK293
7.8223
16.2
no
≈25%
No
no
na
no
no
no


AX213
HEK293
7.8231
16.1
no
<5%
No
no
na
no
no
no





1mAb: monoclonal antibody


2Mon: monomer


3Olig: Oligomer


4HOA: higher order aggregate


5Clip: Clipped protein






EXAMPLE 21
Crystal Coordinates
The coordinates for the crystal structures discussed in Example 10 are presented in Table 14 (full length PCSK9 and AX132 Fab).







TABLE 14





PCSK9 and AX132 Fab complex x-ray structure


























ATOM
17
CB
PRO
B
155
−82.132
20.346
−24.263
1.00
87.08
C


ATOM
1
N
SER
B
153
−87.150
14.839
−25.924
1.00
107.36
N


ATOM
2
CA
SER
B
153
−87.121
15.824
−27.023
1.00
107.09
C


ATOM
3
CB
SER
B
153
−88.455
16.570
−27.109
1.00
107.02
C


ATOM
4
OG
SER
B
153
−88.594
17.255
−28.345
1.00
107.56
O


ATOM
5
C
SER
B
153
−85.944
16.829
−26.896
1.00
106.67
C


ATOM
6
O
SER
B
153
−85.196
16.763
−25.908
1.00
107.20
O


ATOM
7
N
ILE
B
154
−85.791
17.752
−27.900
1.00
98.66
N


ATOM
8
CA
ILE
B
154
−84.757
18.804
−27.957
1.00
97.20
C


ATOM
9
CB
ILE
B
154
−84.874
19.708
−29.237
1.00
97.44
C


ATOM
10
CG1
ILE
B
154
−84.778
18.907
−30.560
1.00
97.90
C


ATOM
11
CD1
ILE
B
154
−83.348
18.623
−31.113
1.00
99.30
C


ATOM
12
CG2
ILE
B
154
−83.924
20.925
−29.210
1.00
97.05
C


ATOM
13
C
ILE
B
154
−84.794
19.659
−26.673
1.00
96.02
C


ATOM
14
O
ILE
B
154
−85.832
20.274
−26.366
1.00
96.01
O


ATOM
15
N
PRO
B
155
−83.657
19.697
−25.928
1.00
87.96
N


ATOM
16
CA
PRO
B
155
−83.593
20.523
−24.706
1.00
86.99
C


ATOM
18
CG
PRO
B
155
−81.704
19.043
−24.862
1.00
86.72
C


ATOM
19
CD
PRO
B
155
−82.363
19.027
−26.185
1.00
87.68
C


ATOM
20
C
PRO
B
155
−83.939
22.001
−24.985
1.00
85.91
C


ATOM
21
O
PRO
B
155
−83.438
22.547
−25.973
1.00
85.74
O


ATOM
22
N
TRP
B
156
−84.796
22.642
−24.145
1.00
79.85
N


ATOM
23
CA
TRP
B
156
−85.226
24.051
−24.327
1.00
79.03
C


ATOM
24
CB
TRP
B
156
−85.929
24.634
−23.078
1.00
78.53
C


ATOM
25
CG
TRP
B
156
−85.005
25.173
−22.022
1.00
77.29
C


ATOM
26
CD1
TRP
B
156
−84.573
24.522
−20.904
1.00
77.25
C


ATOM
27
NE1
TRP
B
156
−83.715
25.325
−20.186
1.00
76.73
N


ATOM
28
CE2
TRP
B
156
−83.578
26.525
−20.835
1.00
76.79
C


ATOM
29
CD2
TRP
B
156
−84.383
26.469
−21.995
1.00
77.04
C


ATOM
30
CE3
TRP
B
156
−84.414
27.588
−22.849
1.00
77.32
C


ATOM
31
CZ3
TRP
B
156
−83.643
28.695
−22.529
1.00
76.08
C


ATOM
32
CH2
TRP
B
156
−82.875
28.729
−21.359
1.00
76.36
C


ATOM
33
CZ2
TRP
B
156
−82.833
27.660
−20.494
1.00
76.64
C


ATOM
34
C
TRP
B
156
−84.141
25.004
−24.852
1.00
78.84
C


ATOM
35
O
TRP
B
156
−84.399
25.797
−25.755
1.00
78.45
O


ATOM
36
N
ASN
B
157
−82.937
24.912
−24.262
1.00
76.67
N


ATOM
37
CA
ASN
B
157
−81.762
25.708
−24.553
1.00
76.65
C


ATOM
38
CB
ASN
B
157
−80.649
25.360
−23.568
1.00
76.70
C


ATOM
39
CG
ASN
B
157
−80.500
23.895
−23.179
1.00
77.44
C


ATOM
40
OD1
ASN
B
157
−81.398
23.247
−22.587
1.00
78.09
O


ATOM
41
ND2
ASN
B
157
−79.332
23.336
−23.494
1.00
78.70
N


ATOM
42
C
ASN
B
157
−81.302
25.627
−26.021
1.00
76.86
C


ATOM
43
O
ASN
B
157
−80.858
26.632
−26.591
1.00
76.92
O


ATOM
44
N
LEU
B
158
−81.451
24.440
−26.641
1.00
78.20
N


ATOM
45
CA
LEU
B
158
−81.061
24.168
−28.028
1.00
78.40
C


ATOM
46
CB
LEU
B
158
−80.758
22.675
−28.179
1.00
78.20
C


ATOM
47
CG
LEU
B
158
−79.638
22.072
−27.335
1.00
77.54
C


ATOM
48
CD1
LEU
B
158
−79.387
20.643
−27.746
1.00
77.52
C


ATOM
49
CD2
LEU
B
158
−78.357
22.824
−27.511
1.00
77.42
C


ATOM
50
C
LEU
B
158
−82.081
24.636
−29.115
1.00
78.95
C


ATOM
51
O
LEU
B
158
−81.763
24.593
−30.320
1.00
78.73
O


ATOM
52
N
GLU
B
159
−83.291
25.099
−28.677
1.00
80.20
N


ATOM
53
CA
GLU
B
159
−84.392
25.571
−29.528
1.00
80.74
C


ATOM
54
CB
GLU
B
159
−85.654
25.870
−28.689
1.00
80.85
C


ATOM
55
CG
GLU
B
159
−86.337
24.617
−28.128
1.00
83.98
C


ATOM
56
CD
GLU
B
159
−87.623
24.729
−27.301
1.00
87.83
C


ATOM
57
OE1
GLU
B
159
−88.207
25.840
−27.214
1.00
89.05
O


ATOM
58
OE2
GLU
B
159
−88.049
23.686
−26.740
1.00
88.45
O


ATOM
59
C
GLU
B
159
−84.070
26.715
−30.528
1.00
80.76
C


ATOM
60
O
GLU
B
159
−84.777
26.852
−31.529
1.00
80.51
O


ATOM
61
N
ARG
B
160
−83.009
27.513
−30.275
1.00
79.37
N


ATOM
62
CA
ARG
B
160
−82.620
28.641
−31.131
1.00
79.76
C


ATOM
63
CB
ARG
B
160
−82.410
29.887
−30.277
1.00
79.64
C


ATOM
64
CG
ARG
B
160
−83.685
30.582
−29.832
1.00
79.80
C


ATOM
65
CD
ARG
B
160
−83.400
32.060
−29.603
1.00
80.11
C


ATOM
66
NE
ARG
B
160
−83.932
32.569
−28.335
1.00
79.71
N


ATOM
67
CZ
ARG
B
160
−85.105
33.176
−28.210
1.00
79.38
C


ATOM
68
NH1
ARG
B
160
−85.894
33.338
−29.269
1.00
80.19
N


ATOM
69
NH2
ARG
B
160
−85.506
33.617
−27.031
1.00
78.06
N


ATOM
70
C
ARG
B
160
−81.386
28.416
−32.041
1.00
80.50
C


ATOM
71
O
ARG
B
160
−80.926
29.378
−32.691
1.00
80.44
O


ATOM
72
N
ILE
B
161
−80.841
27.159
−32.081
1.00
82.33
N


ATOM
73
CA
ILE
B
161
−79.657
26.815
−32.892
1.00
83.00
C


ATOM
74
CB
ILE
B
161
−78.418
26.346
−32.057
1.00
82.95
C


ATOM
75
CG1
ILE
B
161
−78.717
25.103
−31.232
1.00
83.40
C


ATOM
76
CD1
ILE
B
161
−78.270
23.767
−31.910
1.00
85.12
C


ATOM
77
CG2
ILE
B
161
−77.847
27.458
−31.182
1.00
82.40
C


ATOM
78
C
ILE
B
161
−79.984
25.903
−34.106
1.00
83.49
C


ATOM
79
O
ILE
B
161
−80.884
25.057
−34.006
1.00
83.63
O


ATOM
80
N
THR
B
162
−79.224
26.091
−35.244
1.00
83.22
N


ATOM
81
CA
THR
B
162
−79.316
25.413
−36.559
1.00
83.35
C


ATOM
82
CB
THR
B
162
−78.521
24.057
−36.634
1.00
83.59
C


ATOM
83
OG1
THR
B
162
−77.332
24.237
−37.432
1.00
83.88
O


ATOM
84
CG2
THR
B
162
−79.360
22.854
−37.155
1.00
83.18
C


ATOM
85
C
THR
B
162
−80.735
25.516
−37.147
1.00
83.30
C


ATOM
86
O
THR
B
162
−81.293
26.622
−37.185
1.00
83.19
O


ATOM
87
N
GLY
B
176
−70.723
20.546
−35.205
1.00
140.14
N


ATOM
88
CA
GLY
B
176
−69.466
20.083
−35.782
1.00
140.14
C


ATOM
89
C
GLY
B
176
−68.282
21.003
−35.539
1.00
140.03
C


ATOM
90
O
GLY
B
176
−68.462
22.201
−35.295
1.00
140.10
O


ATOM
91
N
GLY
B
177
−67.073
20.432
−35.614
1.00
136.95
N


ATOM
92
CA
GLY
B
177
−65.807
21.142
−35.416
1.00
136.21
C


ATOM
93
C
GLY
B
177
−64.711
20.729
−36.389
1.00
135.59
C


ATOM
94
O
GLY
B
177
−64.029
19.720
−36.147
1.00
135.76
O


ATOM
95
N
SER
B
178
−64.539
21.534
−37.507
1.00
128.99
N


ATOM
96
CA
SER
B
178
−63.569
21.359
−38.622
1.00
127.64
C


ATOM
97
CB
SER
B
178
−64.250
21.579
−39.977
1.00
128.00
C


ATOM
98
OG
SER
B
178
−64.514
22.945
−40.265
1.00
128.21
O


ATOM
99
C
SER
B
178
−62.324
22.258
−38.493
1.00
126.31
C


ATOM
100
O
SER
B
178
−62.346
23.420
−38.931
1.00
126.19
O


ATOM
101
N
LEU
B
179
−61.235
21.706
−37.884
1.00
118.00
N


ATOM
102
CA
LEU
B
179
−59.969
22.406
−37.598
1.00
115.97
C


ATOM
103
CB
LEU
B
179
−59.268
22.923
−38.892
1.00
116.34
C


ATOM
104
CG
LEU
B
179
−57.735
22.921
−38.922
1.00
116.65
C


ATOM
105
CD1
LEU
B
179
−57.196
21.592
−39.416
1.00
116.41
C


ATOM
106
CD2
LEU
B
179
−57.216
24.022
−39.817
1.00
116.41
C


ATOM
107
C
LEU
B
179
−60.259
23.551
−36.573
1.00
114.12
C


ATOM
108
O
LEU
B
179
−59.376
24.361
−36.285
1.00
114.17
O


ATOM
109
N
VAL
B
180
−61.512
23.591
−36.026
1.00
105.44
N


ATOM
110
CA
VAL
B
180
−61.996
24.548
−35.027
1.00
102.74
C


ATOM
111
CB
VAL
B
180
−63.488
24.952
−35.144
1.00
102.92
C


ATOM
112
CG1
VAL
B
180
−63.808
26.126
−34.229
1.00
102.10
C


ATOM
113
CG2
VAL
B
180
−63.860
25.286
−36.568
1.00
103.04
C


ATOM
114
C
VAL
B
180
−61.737
23.899
−33.705
1.00
100.85
C


ATOM
115
O
VAL
B
180
−62.422
22.940
−33.302
1.00
100.51
O


ATOM
116
N
GLU
B
181
−60.725
24.429
−33.040
1.00
95.52
N


ATOM
117
CA
GLU
B
181
−60.286
23.968
−31.750
1.00
93.31
C


ATOM
118
CB
GLU
B
181
−58.754
23.963
−31.695
1.00
93.78
C


ATOM
119
CG
GLU
B
181
−58.163
22.856
−30.839
1.00
95.42
C


ATOM
120
CD
GLU
B
181
−58.611
21.438
−31.161
1.00
97.54
C


ATOM
121
OE1
GLU
B
181
−59.571
20.963
−30.510
1.00
98.37
O


ATOM
122
OE2
GLU
B
181
−58.003
20.801
−32.054
1.00
98.34
O


ATOM
123
C
GLU
B
181
−60.882
24.838
−30.661
1.00
91.24
C


ATOM
124
O
GLU
B
181
−60.742
26.058
−30.691
1.00
90.90
O


ATOM
125
N
VAL
B
182
−61.574
24.198
−29.720
1.00
83.34
N


ATOM
126
CA
VAL
B
182
−62.203
24.834
−28.581
1.00
80.42
C


ATOM
127
CB
VAL
B
182
−63.678
24.408
−28.435
1.00
80.28
C


ATOM
128
CG1
VAL
B
182
−64.275
24.918
−27.133
1.00
79.85
C


ATOM
129
CG2
VAL
B
182
−64.503
24.882
−29.616
1.00
79.66
C


ATOM
130
C
VAL
B
182
−61.385
24.448
−27.363
1.00
78.88
C


ATOM
131
O
VAL
B
182
−61.327
23.273
−27.006
1.00
78.56
O


ATOM
132
N
TYR
B
183
−60.732
25.424
−26.744
1.00
75.90
N


ATOM
133
CA
TYR
B
183
−59.945
25.203
−25.541
1.00
74.25
C


ATOM
134
CB
TYR
B
183
−58.703
26.075
−25.548
1.00
74.20
C


ATOM
135
CG
TYR
B
183
−57.561
25.512
−26.366
1.00
75.11
C


ATOM
136
CD1
TYR
B
183
−56.510
24.831
−25.756
1.00
75.82
C


ATOM
137
CE1
TYR
B
183
−55.436
24.342
−26.501
1.00
76.26
C


ATOM
138
CZ
TYR
B
183
−55.406
24.533
−27.875
1.00
76.26
C


ATOM
139
OH
TYR
B
183
−54.348
24.061
−28.624
1.00
77.47
O


ATOM
140
CE2
TYR
B
183
−56.453
25.187
−28.502
1.00
75.43
C


ATOM
141
CD2
TYR
B
183
−57.512
25.685
−27.746
1.00
75.11
C


ATOM
142
C
TYR
B
183
−60.805
25.516
−24.330
1.00
72.94
C


ATOM
143
O
TYR
B
183
−61.482
26.538
−24.300
1.00
73.00
O


ATOM
144
N
LEU
B
184
−60.802
24.650
−23.341
1.00
68.66
N


ATOM
145
CA
LEU
B
184
−61.598
24.882
−22.156
1.00
67.26
C


ATOM
146
CB
LEU
B
184
−62.680
23.801
−22.077
1.00
67.15
C


ATOM
147
CG
LEU
B
184
−63.354
23.530
−20.744
1.00
67.01
C


ATOM
148
CD1
LEU
B
184
−64.242
24.673
−20.322
1.00
67.88
C


ATOM
149
CD2
LEU
B
184
−64.171
22.290
−20.831
1.00
66.74
C


ATOM
150
C
LEU
B
184
−60.725
24.918
−20.906
1.00
66.66
C


ATOM
151
O
LEU
B
184
−60.114
23.913
−20.563
1.00
66.73
O


ATOM
152
N
LEU
B
185
−60.651
26.071
−20.240
1.00
65.50
N


ATOM
153
CA
LEU
B
185
−59.894
26.218
−19.007
1.00
65.04
C


ATOM
154
CB
LEU
B
185
−59.206
27.584
−18.911
1.00
64.85
C


ATOM
155
CG
LEU
B
185
−57.923
27.771
−19.677
1.00
63.72
C


ATOM
156
CD1
LEU
B
185
−58.192
28.459
−20.951
1.00
62.36
C


ATOM
157
CD2
LEU
B
185
−56.975
28.647
−18.914
1.00
62.83
C


ATOM
158
C
LEU
B
185
−60.943
26.118
−17.933
1.00
65.33
C


ATOM
159
O
LEU
B
185
−61.788
27.002
−17.826
1.00
65.52
O


ATOM
160
N
ASP
B
186
−60.923
25.033
−17.162
1.00
69.66
N


ATOM
161
CA
ASP
B
186
−61.877
24.787
−16.096
1.00
69.85
C


ATOM
162
CB
ASP
B
186
−63.224
24.309
−16.694
1.00
70.50
C


ATOM
163
CG
ASP
B
186
−64.456
24.744
−15.888
1.00
73.29
C


ATOM
164
OD1
ASP
B
186
−65.209
23.853
−15.411
1.00
74.50
O


ATOM
165
OD2
ASP
B
186
−64.666
25.982
−15.722
1.00
77.37
O


ATOM
166
C
ASP
B
186
−61.306
23.784
−15.098
1.00
69.28
C


ATOM
167
O
ASP
B
186
−60.110
23.791
−14.810
1.00
68.99
O


ATOM
168
N
THR
B
187
−62.175
22.937
−14.559
1.00
69.19
N


ATOM
169
CA
THR
B
187
−61.860
21.885
−13.606
1.00
68.93
C


ATOM
170
CB
THR
B
187
−63.157
21.450
−12.844
1.00
68.58
C


ATOM
171
OG1
THR
B
187
−64.084
20.833
−13.739
1.00
67.31
O


ATOM
172
CG2
THR
B
187
−63.827
22.585
−12.090
1.00
68.14
C


ATOM
173
C
THR
B
187
−61.353
20.698
−14.426
1.00
69.35
C


ATOM
174
O
THR
B
187
−61.200
20.799
−15.658
1.00
69.24
O


ATOM
175
N
SER
B
188
−61.133
19.564
−13.747
1.00
72.98
N


ATOM
176
CA
SER
B
188
−60.778
18.312
−14.397
1.00
73.83
C


ATOM
177
CB
SER
B
188
−60.395
17.274
−13.348
1.00
73.82
C


ATOM
178
OG
SER
B
188
−61.266
17.343
−12.228
1.00
75.61
O


ATOM
179
C
SER
B
188
−62.075
17.877
−15.146
1.00
73.93
C


ATOM
180
O
SER
B
188
−63.155
18.377
−14.828
1.00
74.16
O


ATOM
181
N
ILE
B
189
−61.974
17.023
−16.166
1.00
75.20
N


ATOM
182
CA
ILE
B
189
−63.160
16.595
−16.918
1.00
75.33
C


ATOM
183
CB
ILE
B
189
−63.315
17.325
−18.303
1.00
75.17
C


ATOM
184
CG1
ILE
B
189
−62.291
16.857
−19.328
1.00
74.91
C


ATOM
185
CD1
ILE
B
189
−62.849
16.079
−20.326
1.00
74.99
C


ATOM
186
CG2
ILE
B
189
−63.244
18.842
−18.208
1.00
74.89
C


ATOM
187
C
ILE
B
189
−63.173
15.060
−17.055
1.00
75.92
C


ATOM
188
O
ILE
B
189
−62.105
14.431
−17.112
1.00
76.37
O


ATOM
189
N
GLN
B
190
−64.377
14.464
−17.115
1.00
78.71
N


ATOM
190
CA
GLN
B
190
−64.573
13.031
−17.324
1.00
78.81
C


ATOM
191
CB
GLN
B
190
−65.935
12.599
−16.719
1.00
79.20
C


ATOM
192
CG
GLN
B
190
−66.291
11.106
−16.838
1.00
80.98
C


ATOM
193
CD
GLN
B
190
−65.218
10.268
−16.184
1.00
84.40
C


ATOM
194
OE1
GLN
B
190
−64.398
9.600
−16.863
1.00
85.93
O


ATOM
195
NE2
GLN
B
190
−65.178
10.319
−14.838
1.00
84.61
N


ATOM
196
C
GLN
B
190
−64.528
12.852
−18.868
1.00
78.44
C


ATOM
197
O
GLN
B
190
−65.557
12.986
−19.530
1.00
78.67
O


ATOM
198
N
SER
B
191
−63.335
12.619
−19.437
1.00
76.26
N


ATOM
199
CA
SER
B
191
−63.125
12.472
−20.886
1.00
76.40
C


ATOM
200
CB
SER
B
191
−61.641
12.584
−21.242
1.00
76.30
C


ATOM
201
OG
SER
B
191
−60.774
11.931
−20.321
1.00
76.89
O


ATOM
202
C
SER
B
191
−63.742
11.221
−21.507
1.00
76.56
C


ATOM
203
O
SER
B
191
−63.870
11.147
−22.735
1.00
76.51
O


ATOM
204
N
ASP
B
192
−64.123
10.249
−20.657
1.00
76.51
N


ATOM
205
CA
ASP
B
192
−64.731
8.972
−21.021
1.00
77.11
C


ATOM
206
CB
ASP
B
192
−64.437
7.919
−19.946
1.00
77.96
C


ATOM
207
CG
ASP
B
192
−62.956
7.651
−19.710
1.00
81.51
C


ATOM
208
OD1
ASP
B
192
−62.098
8.236
−20.470
1.00
85.26
O


ATOM
209
OD2
ASP
B
192
−62.633
6.861
−18.764
1.00
84.42
O


ATOM
210
C
ASP
B
192
−66.228
9.066
−21.249
1.00
76.46
C


ATOM
211
O
ASP
B
192
−66.799
8.171
−21.881
1.00
76.47
O


ATOM
212
N
HIS
B
193
−66.868
10.135
−20.742
1.00
71.48
N


ATOM
213
CA
HIS
B
193
−68.302
10.347
−20.896
1.00
70.66
C


ATOM
214
CB
HIS
B
193
−68.760
11.679
−20.308
1.00
69.92
C


ATOM
215
CG
HIS
B
193
−70.227
11.703
−20.063
1.00
67.58
C


ATOM
216
ND1
HIS
B
193
−70.738
11.592
−18.798
1.00
65.49
N


ATOM
217
CE1
HIS
B
193
−72.055
11.611
−18.938
1.00
65.26
C


ATOM
218
NE2
HIS
B
193
−72.408
11.730
−20.211
1.00
65.88
N


ATOM
219
CD2
HIS
B
193
−71.250
11.777
−20.942
1.00
66.29
C


ATOM
220
C
HIS
B
193
−68.702
10.216
−22.354
1.00
71.00
C


ATOM
221
O
HIS
B
193
−68.100
10.843
−23.217
1.00
70.97
O


ATOM
222
N
ARG
B
194
−69.698
9.364
−22.618
1.00
72.56
N


ATOM
223
CA
ARG
B
194
−70.195
9.035
−23.949
1.00
72.97
C


ATOM
224
CB
ARG
B
194
−71.371
8.065
−23.872
1.00
73.07
C


ATOM
225
CG
ARG
B
194
−71.020
6.680
−23.334
1.00
71.88
C


ATOM
226
CD
ARG
B
194
−70.534
5.692
−24.386
1.00
70.41
C


ATOM
227
NE
ARG
B
194
−71.239
5.796
−25.672
1.00
69.15
N


ATOM
228
CZ
ARG
B
194
−72.366
5.156
−25.988
1.00
67.53
C


ATOM
229
NH1
ARG
B
194
−72.916
5.324
−27.182
1.00
66.06
N


ATOM
230
NH2
ARG
B
194
−72.952
4.350
−25.110
1.00
66.67
N


ATOM
231
C
ARG
B
194
−70.530
10.244
−24.783
1.00
73.51
C


ATOM
232
O
ARG
B
194
−70.356
10.201
−25.999
1.00
73.71
O


ATOM
233
N
GLU
B
195
−70.984
11.321
−24.140
1.00
74.05
N


ATOM
234
CA
GLU
B
195
−71.321
12.577
−24.796
1.00
74.65
C


ATOM
235
CB
GLU
B
195
−71.857
13.566
−23.770
1.00
74.69
C


ATOM
236
CG
GLU
B
195
−73.312
13.345
−23.447
1.00
75.96
C


ATOM
237
CD
GLU
B
195
−74.199
14.009
−24.471
1.00
78.05
C


ATOM
238
OE1
GLU
B
195
−74.682
13.293
−25.377
1.00
78.92
O


ATOM
239
OE2
GLU
B
195
−74.397
15.244
−24.381
1.00
79.60
O


ATOM
240
C
GLU
B
195
−70.102
13.201
−25.436
1.00
74.65
C


ATOM
241
O
GLU
B
195
−70.190
13.725
−26.548
1.00
74.72
O


ATOM
242
N
ILE
B
196
−68.967
13.149
−24.730
1.00
73.62
N


ATOM
243
CA
ILE
B
196
−67.730
13.773
−25.156
1.00
73.67
C


ATOM
244
CB
ILE
B
196
−67.386
14.919
−24.181
1.00
73.39
C


ATOM
245
CG1
ILE
B
196
−67.087
14.413
−22.746
1.00
72.89
C


ATOM
246
CD1
ILE
B
196
−66.340
15.398
−21.869
1.00
71.68
C


ATOM
247
CG2
ILE
B
196
−68.451
16.011
−24.223
1.00
73.36
C


ATOM
248
C
ILE
B
196
−66.528
12.877
−25.455
1.00
74.30
C


ATOM
249
O
ILE
B
196
−65.459
13.403
−25.759
1.00
74.46
O


ATOM
250
N
GLU
B
197
−66.671
11.556
−25.367
1.00
77.64
N


ATOM
251
CA
GLU
B
197
−65.571
10.634
−25.623
1.00
78.11
C


ATOM
252
CB
GLU
B
197
−66.039
9.218
−25.284
1.00
78.29
C


ATOM
253
CG
GLU
B
197
−65.094
8.094
−25.675
1.00
80.67
C


ATOM
254
CD
GLU
B
197
−65.213
7.595
−27.109
1.00
84.14
C


ATOM
255
OE1
GLU
B
197
−64.154
7.241
−27.691
1.00
85.48
O


ATOM
256
OE2
GLU
B
197
−66.352
7.566
−27.652
1.00
84.38
O


ATOM
257
C
GLU
B
197
−65.078
10.775
−27.088
1.00
78.33
C


ATOM
258
O
GLU
B
197
−65.889
10.888
−28.006
1.00
77.70
O


ATOM
259
N
GLY
B
198
−63.760
10.805
−27.279
1.00
79.97
N


ATOM
260
CA
GLY
B
198
−63.155
10.931
−28.601
1.00
80.78
C


ATOM
261
C
GLY
B
198
−63.125
12.335
−29.184
1.00
81.70
C


ATOM
262
O
GLY
B
198
−62.354
12.594
−30.119
1.00
81.82
O


ATOM
263
N
ARG
B
199
−63.974
13.254
−28.657
1.00
82.07
N


ATOM
264
CA
ARG
B
199
−64.025
14.643
−29.107
1.00
82.71
C


ATOM
265
CB
ARG
B
199
−65.478
15.135
−29.363
1.00
83.22
C


ATOM
266
CG
ARG
B
199
−66.383
14.288
−30.315
1.00
85.09
C


ATOM
267
CD
ARG
B
199
−65.757
13.859
−31.646
1.00
88.67
C


ATOM
268
NE
ARG
B
199
−65.336
15.001
−32.478
1.00
93.40
N


ATOM
269
CZ
ARG
B
199
−64.332
14.985
−33.365
1.00
95.58
C


ATOM
270
NH1
ARG
B
199
−63.613
13.880
−33.552
1.00
96.91
N


ATOM
271
NH2
ARG
B
199
−64.033
16.080
−34.059
1.00
96.23
N


ATOM
272
C
ARG
B
199
−63.255
15.546
−28.128
1.00
82.57
C


ATOM
273
O
ARG
B
199
−62.553
16.450
−28.562
1.00
82.54
O


ATOM
274
N
VAL
B
200
−63.346
15.278
−26.823
1.00
81.88
N


ATOM
275
CA
VAL
B
200
−62.645
16.074
−25.811
1.00
82.39
C


ATOM
276
CB
VAL
B
200
−63.532
16.470
−24.599
1.00
82.30
C


ATOM
277
CG1
VAL
B
200
−62.754
17.342
−23.624
1.00
82.32
C


ATOM
278
CG2
VAL
B
200
−64.785
17.208
−25.063
1.00
82.80
C


ATOM
279
C
VAL
B
200
−61.318
15.438
−25.401
1.00
82.80
C


ATOM
280
O
VAL
B
200
−61.308
14.351
−24.833
1.00
83.26
O


ATOM
281
N
MET
B
201
−60.210
16.138
−25.687
1.00
81.97
N


ATOM
282
CA
MET
B
201
−58.824
15.754
−25.428
1.00
82.08
C


ATOM
283
CB
MET
B
201
−57.973
16.215
−26.633
1.00
82.67
C


ATOM
284
CG
MET
B
201
−56.563
15.650
−26.664
1.00
86.68
C


ATOM
285
SD
MET
B
201
−55.285
16.848
−26.166
1.00
94.50
S


ATOM
286
CE
MET
B
201
−53.765
15.772
−26.202
1.00
93.41
C


ATOM
287
C
MET
B
201
−58.299
16.402
−24.139
1.00
81.18
C


ATOM
288
O
MET
B
201
−58.375
17.613
−24.004
1.00
81.66
O


ATOM
289
N
VAL
B
202
−57.742
15.619
−23.207
1.00
76.40
N


ATOM
290
CA
VAL
B
202
−57.201
16.193
−21.968
1.00
75.21
C


ATOM
291
CB
VAL
B
202
−57.488
15.305
−20.727
1.00
74.80
C


ATOM
292
CG1
VAL
B
202
−56.634
15.704
−19.538
1.00
74.05
C


ATOM
293
CG2
VAL
B
202
−58.961
15.338
−20.355
1.00
74.22
C


ATOM
294
C
VAL
B
202
−55.714
16.527
−22.138
1.00
74.85
C


ATOM
295
O
VAL
B
202
−54.922
15.636
−22.431
1.00
74.77
O


ATOM
296
N
THR
B
203
−55.341
17.804
−21.957
1.00
76.16
N


ATOM
297
CA
THR
B
203
−53.939
18.230
−22.074
1.00
75.76
C


ATOM
298
CB
THR
B
203
−53.791
19.707
−22.484
1.00
75.68
C


ATOM
299
OG1
THR
B
203
−54.117
20.556
−21.381
1.00
75.47
O


ATOM
300
CG2
THR
B
203
−54.603
20.071
−23.730
1.00
75.36
C


ATOM
301
C
THR
B
203
−53.191
17.904
−20.784
1.00
75.63
C


ATOM
302
O
THR
B
203
−53.823
17.586
−19.767
1.00
75.46
O


ATOM
303
N
ASP
B
204
−51.847
17.984
−20.823
1.00
77.72
N


ATOM
304
CA
ASP
B
204
−51.004
17.699
−19.657
1.00
77.96
C


ATOM
305
CB
ASP
B
204
−49.553
17.422
−20.106
1.00
77.97
C


ATOM
306
C
ASP
B
204
−51.035
18.862
−18.648
1.00
78.07
C


ATOM
307
O
ASP
B
204
−50.476
18.734
−17.551
1.00
78.14
O


ATOM
308
N
PHE
B
205
−51.681
20.000
−19.026
1.00
77.35
N


ATOM
309
CA
PHE
B
205
−51.773
21.198
−18.201
1.00
77.05
C


ATOM
310
CB
PHE
B
205
−52.185
22.435
−19.014
1.00
76.92
C


ATOM
311
CG
PHE
B
205
−52.052
23.686
−18.184
1.00
76.42
C


ATOM
312
CD1
PHE
B
205
−50.846
24.370
−18.120
1.00
76.04
C


ATOM
313
CE1
PHE
B
205
−50.711
25.509
−17.322
1.00
76.41
C


ATOM
314
CZ
PHE
B
205
−51.770
25.942
−16.555
1.00
76.80
C


ATOM
315
CE2
PHE
B
205
−52.975
25.265
−16.595
1.00
76.24
C


ATOM
316
CD2
PHE
B
205
−53.117
24.147
−17.414
1.00
76.25
C


ATOM
317
C
PHE
B
205
−52.658
21.061
−16.999
1.00
77.20
C


ATOM
318
O
PHE
B
205
−53.790
20.576
−17.103
1.00
77.05
O


ATOM
319
N
GLU
B
206
−52.138
21.560
−15.861
1.00
78.14
N


ATOM
320
CA
GLU
B
206
−52.770
21.615
−14.550
1.00
78.71
C


ATOM
321
CB
GLU
B
206
−52.774
20.246
−13.895
1.00
78.73
C


ATOM
322
CG
GLU
B
206
−53.559
20.204
−12.606
1.00
80.94
C


ATOM
323
CD
GLU
B
206
−53.553
18.848
−11.930
1.00
83.15
C


ATOM
324
OE1
GLU
B
206
−54.647
18.256
−11.754
1.00
83.16
O


ATOM
325
OE2
GLU
B
206
−52.446
18.379
−11.573
1.00
85.09
O


ATOM
326
C
GLU
B
206
−52.023
22.608
−13.673
1.00
78.91
C


ATOM
327
O
GLU
B
206
−50.796
22.571
−13.591
1.00
78.97
O


ATOM
328
N
ASN
B
207
−52.771
23.509
−13.038
1.00
79.45
N


ATOM
329
CA
ASN
B
207
−52.290
24.546
−12.123
1.00
79.62
C


ATOM
330
CB
ASN
B
207
−51.621
25.721
−12.860
1.00
79.53
C


ATOM
331
CG
ASN
B
207
−50.999
26.739
−11.913
1.00
79.76
C


ATOM
332
OD1
ASN
B
207
−51.654
27.303
−11.010
1.00
81.14
O


ATOM
333
ND2
ASN
B
207
−49.712
27.006
−12.090
1.00
79.96
N


ATOM
334
C
ASN
B
207
−53.491
25.008
−11.308
1.00
79.67
C


ATOM
335
O
ASN
B
207
−54.229
25.903
−11.720
1.00
79.86
O


ATOM
336
N
VAL
B
208
−53.708
24.368
−10.169
1.00
77.92
N


ATOM
337
CA
VAL
B
208
−54.844
24.685
−9.309
1.00
78.49
C


ATOM
338
CB
VAL
B
208
−55.932
23.555
−9.333
1.00
78.44
C


ATOM
339
CG1
VAL
B
208
−56.307
23.167
−10.757
1.00
78.06
C


ATOM
340
CG2
VAL
B
208
−55.512
22.320
−8.537
1.00
78.22
C


ATOM
341
C
VAL
B
208
−54.378
25.014
−7.893
1.00
79.11
C


ATOM
342
O
VAL
B
208
−53.314
24.559
−7.507
1.00
79.41
O


ATOM
343
N
PRO
B
209
−55.135
25.755
−7.070
1.00
81.83
N


ATOM
344
CA
PRO
B
209
−54.683
25.979
−5.690
1.00
82.62
C


ATOM
345
CB
PRO
B
209
−55.588
27.115
−5.195
1.00
82.43
C


ATOM
346
CG
PRO
B
209
−56.400
27.543
−6.378
1.00
82.07
C


ATOM
347
CD
PRO
B
209
−56.440
26.399
−7.306
1.00
81.97
C


ATOM
348
C
PRO
B
209
−54.901
24.721
−4.848
1.00
83.65
C


ATOM
349
O
PRO
B
209
−55.779
23.915
−5.171
1.00
83.64
O


ATOM
350
N
GLU
B
210
−54.111
24.546
−3.768
1.00
88.20
N


ATOM
351
CA
GLU
B
210
−54.277
23.383
−2.889
1.00
89.74
C


ATOM
352
CB
GLU
B
210
−53.256
23.381
−1.729
1.00
89.55
C


ATOM
353
C
GLU
B
210
−55.719
23.435
−2.380
1.00
90.57
C


ATOM
354
O
GLU
B
210
−56.228
24.532
−2.087
1.00
90.41
O


ATOM
355
N
GLU
B
211
−56.397
22.265
−2.362
1.00
94.51
N


ATOM
356
CA
GLU
B
211
−57.792
22.170
−1.924
1.00
95.89
C


ATOM
357
CB
GLU
B
211
−58.384
20.760
−2.085
1.00
95.83
C


ATOM
358
CG
GLU
B
211
−59.166
20.582
−3.374
1.00
96.71
C


ATOM
359
CD
GLU
B
211
−58.341
20.326
−4.626
1.00
98.31
C


ATOM
360
OE1
GLU
B
211
−57.101
20.520
−4.597
1.00
99.53
O


ATOM
361
OE2
GLU
B
211
−58.943
19.930
−5.651
1.00
98.49
O


ATOM
362
C
GLU
B
211
−57.994
22.716
−0.527
1.00
96.75
C


ATOM
363
O
GLU
B
211
−57.235
22.401
0.402
1.00
96.76
O


ATOM
364
N
ASP
B
212
−59.002
23.594
−0.403
1.00
100.07
N


ATOM
365
CA
ASP
B
212
−59.353
24.245
0.855
1.00
100.92
C


ATOM
366
CB
ASP
B
212
−59.966
25.636
0.574
1.00
100.87
C


ATOM
367
C
ASP
B
212
−60.273
23.321
1.699
1.00
101.36
C


ATOM
368
O
ASP
B
212
−59.990
22.121
1.877
1.00
101.83
O


ATOM
369
N
ALA
B
220
−64.416
12.642
−5.714
1.00
107.90
N


ATOM
370
CA
ALA
B
220
−63.510
12.432
−6.856
1.00
108.17
C


ATOM
371
CB
ALA
B
220
−62.875
11.044
−6.803
1.00
108.18
C


ATOM
372
C
ALA
B
220
−64.175
12.680
−8.228
1.00
107.99
C


ATOM
373
O
ALA
B
220
−63.526
13.212
−9.133
1.00
108.10
O


ATOM
374
N
SER
B
221
−65.463
12.279
−8.380
1.00
105.36
N


ATOM
375
CA
SER
B
221
−66.286
12.492
−9.588
1.00
104.82
C


ATOM
376
CB
SER
B
221
−66.943
11.200
−10.083
1.00
104.98
C


ATOM
377
OG
SER
B
221
−66.303
10.735
−11.264
1.00
106.07
O


ATOM
378
C
SER
B
221
−67.299
13.640
−9.308
1.00
103.94
C


ATOM
379
O
SER
B
221
−68.445
13.644
−9.772
1.00
104.03
O


ATOM
380
N
LYS
B
222
−66.813
14.603
−8.502
1.00
97.73
N


ATOM
381
CA
LYS
B
222
−67.413
15.840
−8.056
1.00
96.15
C


ATOM
382
CB
LYS
B
222
−67.589
15.848
−6.533
1.00
96.42
C


ATOM
383
CG
LYS
B
222
−68.380
17.045
−5.993
1.00
97.85
C


ATOM
384
CD
LYS
B
222
−69.836
17.113
−6.522
1.00
100.51
C


ATOM
385
CE
LYS
B
222
−70.544
18.401
−6.165
1.00
101.09
C


ATOM
386
NZ
LYS
B
222
−71.729
18.637
−7.034
1.00
101.72
N


ATOM
387
C
LYS
B
222
−66.420
16.908
−8.498
1.00
94.80
C


ATOM
388
O
LYS
B
222
−66.796
18.070
−8.600
1.00
94.92
O


ATOM
389
N
CYS
B
223
−65.149
16.516
−8.779
1.00
89.06
N


ATOM
390
CA
CYS
B
223
−64.125
17.431
−9.279
1.00
87.39
C


ATOM
391
CB
CYS
B
223
−62.733
16.818
−9.218
1.00
87.43
C


ATOM
392
SG
CYS
B
223
−62.208
16.366
−7.551
1.00
90.01
S


ATOM
393
C
CYS
B
223
−64.506
17.717
−10.681
1.00
85.86
C


ATOM
394
O
CYS
B
223
−64.776
18.872
−11.006
1.00
86.32
O


ATOM
395
N
ASP
B
224
−64.594
16.660
−11.508
1.00
80.28
N


ATOM
396
CA
ASP
B
224
−64.974
16.782
−12.908
1.00
78.53
C


ATOM
397
CB
ASP
B
224
−64.517
15.581
−13.764
1.00
79.51
C


ATOM
398
CG
ASP
B
224
−64.381
14.211
−13.116
1.00
81.45
C


ATOM
399
OD1
ASP
B
224
−65.095
13.951
−12.105
1.00
83.11
O


ATOM
400
OD2
ASP
B
224
−63.569
13.382
−13.636
1.00
83.60
O


ATOM
401
C
ASP
B
224
−66.417
17.221
−13.200
1.00
76.34
C


ATOM
402
O
ASP
B
224
−66.799
17.373
−14.348
1.00
75.54
O


ATOM
403
N
SER
B
225
−67.176
17.481
−12.146
1.00
72.60
N


ATOM
404
CA
SER
B
225
−68.564
17.906
−12.142
1.00
70.75
C


ATOM
405
CB
SER
B
225
−68.948
18.338
−10.732
1.00
70.68
C


ATOM
406
OG
SER
B
225
−70.346
18.509
−10.593
1.00
71.29
O


ATOM
407
C
SER
B
225
−68.881
19.022
−13.134
1.00
69.45
C


ATOM
408
O
SER
B
225
−69.705
18.849
−14.037
1.00
69.51
O


ATOM
409
N
HIS
B
226
−68.213
20.152
−12.959
1.00
67.18
N


ATOM
410
CA
HIS
B
226
−68.384
21.368
−13.731
1.00
65.54
C


ATOM
411
CB
HIS
B
226
−67.775
22.527
−12.943
1.00
66.03
C


ATOM
412
CG
HIS
B
226
−68.050
23.885
−13.494
1.00
67.26
C


ATOM
413
ND1
HIS
B
226
−67.015
24.731
−13.866
1.00
68.03
N


ATOM
414
CE1
HIS
B
226
−67.596
25.843
−14.284
1.00
69.18
C


ATOM
415
NE2
HIS
B
226
−68.929
25.764
−14.196
1.00
68.94
N


ATOM
416
CD2
HIS
B
226
−69.229
24.521
−13.682
1.00
68.58
C


ATOM
417
C
HIS
B
226
−67.837
21.304
−15.152
1.00
64.16
C


ATOM
418
O
HIS
B
226
−68.570
21.600
−16.087
1.00
64.08
O


ATOM
419
N
GLY
B
227
−66.569
20.938
−15.308
1.00
59.89
N


ATOM
420
CA
GLY
B
227
−65.918
20.862
−16.606
1.00
57.91
C


ATOM
421
C
GLY
B
227
−66.559
19.870
−17.542
1.00
57.07
C


ATOM
422
O
GLY
B
227
−66.580
20.101
−18.749
1.00
56.80
O


ATOM
423
N
THR
B
228
−67.066
18.749
−16.997
1.00
56.49
N


ATOM
424
CA
THR
B
228
−67.718
17.703
−17.779
1.00
55.25
C


ATOM
425
CB
THR
B
228
−67.908
16.416
−16.945
1.00
55.36
C


ATOM
426
OG1
THR
B
228
−66.617
15.986
−16.499
1.00
55.00
O


ATOM
427
CG2
THR
B
228
−68.598
15.284
−17.718
1.00
54.69
C


ATOM
428
C
THR
B
228
−68.980
18.294
−18.344
1.00
54.71
C


ATOM
429
O
THR
B
228
−69.159
18.226
−19.558
1.00
54.21
O


ATOM
430
N
HIS
B
229
−69.822
18.921
−17.478
1.00
54.98
N


ATOM
431
CA
HIS
B
229
−71.068
19.581
−17.869
1.00
54.94
C


ATOM
432
CB
HIS
B
229
−71.761
20.249
−16.676
1.00
54.87
C


ATOM
433
CG
HIS
B
229
−73.182
20.612
−16.969
1.00
56.60
C


ATOM
434
ND1
HIS
B
229
−73.533
21.889
−17.344
1.00
58.44
N


ATOM
435
CE1
HIS
B
229
−74.838
21.861
−17.560
1.00
58.78
C


ATOM
436
NE2
HIS
B
229
−75.347
20.652
−17.328
1.00
59.04
N


ATOM
437
CD2
HIS
B
229
−74.295
19.839
−16.964
1.00
58.70
C


ATOM
438
C
HIS
B
229
−70.830
20.596
−18.986
1.00
54.67
C


ATOM
439
O
HIS
B
229
−71.518
20.524
−20.001
1.00
54.62
O


ATOM
440
N
LEU
B
230
−69.850
21.508
−18.831
1.00
54.53
N


ATOM
441
CA
LEU
B
230
−69.571
22.503
−19.852
1.00
54.58
C


ATOM
442
CB
LEU
B
230
−68.631
23.570
−19.340
1.00
54.42
C


ATOM
443
CG
LEU
B
230
−69.134
24.331
−18.137
1.00
54.76
C


ATOM
444
CD1
LEU
B
230
−68.075
25.189
−17.588
1.00
53.99
C


ATOM
445
CD2
LEU
B
230
−70.327
25.160
−18.468
1.00
54.36
C


ATOM
446
C
LEU
B
230
−69.079
21.900
−21.169
1.00
55.03
C


ATOM
447
O
LEU
B
230
−69.569
22.309
−22.234
1.00
55.41
O


ATOM
448
N
ALA
B
231
−68.146
20.920
−21.120
1.00
56.16
N


ATOM
449
CA
ALA
B
231
−67.674
20.261
−22.329
1.00
56.30
C


ATOM
450
CB
ALA
B
231
−66.598
19.260
−21.978
1.00
56.06
C


ATOM
451
C
ALA
B
231
−68.909
19.545
−22.980
1.00
56.96
C


ATOM
452
O
ALA
B
231
−69.020
19.449
−24.220
1.00
56.80
O


ATOM
453
N
GLY
B
232
−69.836
19.095
−22.121
1.00
59.26
N


ATOM
454
CA
GLY
B
232
−71.076
18.461
−22.529
1.00
59.55
C


ATOM
455
C
GLY
B
232
−71.926
19.502
−23.210
1.00
60.10
C


ATOM
456
O
GLY
B
232
−72.435
19.243
−24.292
1.00
60.36
O


ATOM
457
N
VAL
B
233
−72.041
20.710
−22.618
1.00
61.09
N


ATOM
458
CA
VAL
B
233
−72.819
21.810
−23.203
1.00
61.50
C


ATOM
459
CB
VAL
B
233
−72.984
23.009
−22.244
1.00
61.31
C


ATOM
460
CG1
VAL
B
233
−73.636
24.194
−22.945
1.00
60.60
C


ATOM
461
CG2
VAL
B
233
−73.789
22.612
−21.018
1.00
61.89
C


ATOM
462
C
VAL
B
233
−72.251
22.248
−24.573
1.00
61.96
C


ATOM
463
O
VAL
B
233
−73.034
22.489
−25.497
1.00
62.26
O


ATOM
464
N
VAL
B
234
−70.922
22.337
−24.714
1.00
60.75
N


ATOM
465
CA
VAL
B
234
−70.352
22.756
−25.989
1.00
61.40
C


ATOM
466
CB
VAL
B
234
−68.872
23.198
−25.877
1.00
61.51
C


ATOM
467
CG1
VAL
B
234
−68.288
23.565
−27.247
1.00
59.64
C


ATOM
468
CG2
VAL
B
234
−68.713
24.336
−24.879
1.00
61.44
C


ATOM
469
C
VAL
B
234
−70.522
21.730
−27.102
1.00
62.31
C


ATOM
470
O
VAL
B
234
−71.164
22.032
−28.107
1.00
62.51
O


ATOM
471
N
SER
B
235
−69.936
20.528
−26.924
1.00
65.08
N


ATOM
472
CA
SER
B
235
−69.889
19.474
−27.934
1.00
65.81
C


ATOM
473
CB
SER
B
235
−68.441
19.226
−28.329
1.00
65.94
C


ATOM
474
OG
SER
B
235
−67.686
18.789
−27.205
1.00
67.86
O


ATOM
475
C
SER
B
235
−70.558
18.146
−27.670
1.00
66.01
C


ATOM
476
O
SER
B
235
−70.314
17.225
−28.436
1.00
65.96
O


ATOM
477
N
GLY
B
236
−71.380
18.036
−26.636
1.00
66.49
N


ATOM
478
CA
GLY
B
236
−72.083
16.792
−26.322
1.00
67.15
C


ATOM
479
C
GLY
B
236
−72.830
16.189
−27.497
1.00
67.77
C


ATOM
480
O
GLY
B
236
−73.471
16.909
−28.263
1.00
67.70
O


ATOM
481
N
ARG
B
237
−72.720
14.860
−27.666
1.00
70.52
N


ATOM
482
CA
ARG
B
237
−73.357
14.101
−28.748
1.00
71.20
C


ATOM
483
CB
ARG
B
237
−72.983
12.613
−28.639
1.00
71.49
C


ATOM
484
CG
ARG
B
237
−71.768
12.239
−29.499
1.00
72.04
C


ATOM
485
CD
ARG
B
237
−71.175
10.847
−29.206
1.00
71.96
C


ATOM
486
NE
ARG
B
237
−69.909
10.643
−29.937
1.00
71.37
N


ATOM
487
CZ
ARG
B
237
−68.687
10.761
−29.415
1.00
71.09
C


ATOM
488
NH1
ARG
B
237
−68.531
11.077
−28.132
1.00
70.70
N


ATOM
489
NH2
ARG
B
237
−67.614
10.563
−30.171
1.00
71.58
N


ATOM
490
C
ARG
B
237
−74.892
14.283
−28.885
1.00
71.39
C


ATOM
491
O
ARG
B
237
−75.409
14.334
−30.007
1.00
71.19
O


ATOM
492
N
ASP
B
238
−75.601
14.382
−27.749
1.00
71.16
N


ATOM
493
CA
ASP
B
238
−77.054
14.516
−27.705
1.00
71.52
C


ATOM
494
CB
ASP
B
238
−77.650
13.479
−26.722
1.00
71.63
C


ATOM
495
CG
ASP
B
238
−77.532
12.031
−27.144
1.00
73.10
C


ATOM
496
OD1
ASP
B
238
−77.848
11.720
−28.334
1.00
75.60
O


ATOM
497
OD2
ASP
B
238
−77.149
11.198
−26.293
1.00
74.54
O


ATOM
498
C
ASP
B
238
−77.556
15.870
−27.282
1.00
71.43
C


ATOM
499
O
ASP
B
238
−78.565
16.337
−27.810
1.00
71.16
O


ATOM
500
N
ALA
B
239
−76.906
16.456
−26.268
1.00
69.73
N


ATOM
501
CA
ALA
B
239
−77.309
17.714
−25.671
1.00
69.78
C


ATOM
502
CB
ALA
B
239
−77.607
17.499
−24.192
1.00
69.61
C


ATOM
503
C
ALA
B
239
−76.339
18.888
−25.878
1.00
69.98
C


ATOM
504
O
ALA
B
239
−76.380
19.860
−25.117
1.00
70.14
O


ATOM
505
N
GLY
B
240
−75.507
18.809
−26.914
1.00
69.35
N


ATOM
506
CA
GLY
B
240
−74.540
19.858
−27.223
1.00
69.93
C


ATOM
507
C
GLY
B
240
−75.059
20.857
−28.230
1.00
70.35
C


ATOM
508
O
GLY
B
240
−75.989
20.552
−28.991
1.00
70.72
O


ATOM
509
N
VAL
B
241
−74.477
22.071
−28.227
1.00
68.65
N


ATOM
510
CA
VAL
B
241
−74.865
23.136
−29.153
1.00
68.57
C


ATOM
511
CB
VAL
B
241
−74.481
24.545
−28.611
1.00
68.64
C


ATOM
512
CG1
VAL
B
241
−74.415
25.596
−29.720
1.00
69.14
C


ATOM
513
CG2
VAL
B
241
−75.455
24.997
−27.535
1.00
68.83
C


ATOM
514
C
VAL
B
241
−74.203
22.769
−30.469
1.00
68.68
C


ATOM
515
O
VAL
B
241
−74.902
22.445
−31.431
1.00
68.58
O


ATOM
516
N
ALA
B
242
−72.849
22.751
−30.471
1.00
67.47
N


ATOM
517
CA
ALA
B
242
−71.997
22.391
−31.603
1.00
67.98
C


ATOM
518
CB
ALA
B
242
−70.755
23.270
−31.637
1.00
67.56
C


ATOM
519
C
ALA
B
242
−71.611
20.928
−31.472
1.00
68.56
C


ATOM
520
O
ALA
B
242
−70.426
20.625
−31.362
1.00
68.61
O


ATOM
521
N
LYS
B
243
−72.625
20.019
−31.484
1.00
70.17
N


ATOM
522
CA
LYS
B
243
−72.479
18.549
−31.373
1.00
70.58
C


ATOM
523
CB
LYS
B
243
−73.758
17.824
−31.839
1.00
70.40
C


ATOM
524
CG
LYS
B
243
−74.950
17.975
−30.932
1.00
70.91
C


ATOM
525
CD
LYS
B
243
−76.200
17.759
−31.720
1.00
72.46
C


ATOM
526
CE
LYS
B
243
−77.325
17.308
−30.848
1.00
73.73
C


ATOM
527
NZ
LYS
B
243
−78.202
18.439
−30.481
1.00
74.94
N


ATOM
528
C
LYS
B
243
−71.289
18.034
−32.199
1.00
70.80
C


ATOM
529
O
LYS
B
243
−71.208
18.312
−33.406
1.00
70.91
O


ATOM
530
N
GLY
B
244
−70.372
17.340
−31.532
1.00
71.40
N


ATOM
531
CA
GLY
B
244
−69.188
16.758
−32.149
1.00
71.80
C


ATOM
532
C
GLY
B
244
−67.989
17.656
−32.409
1.00
72.07
C


ATOM
533
O
GLY
B
244
−67.100
17.249
−33.170
1.00
72.10
O


ATOM
534
N
ALA
B
245
−67.931
18.881
−31.786
1.00
74.12
N


ATOM
535
CA
ALA
B
245
−66.802
19.826
−31.942
1.00
73.82
C


ATOM
536
CB
ALA
B
245
−67.190
21.205
−31.464
1.00
73.58
C


ATOM
537
C
ALA
B
245
−65.612
19.324
−31.149
1.00
73.72
C


ATOM
538
O
ALA
B
245
−65.804
18.821
−30.056
1.00
73.86
O


ATOM
539
N
SER
B
246
−64.390
19.405
−31.684
1.00
76.47
N


ATOM
540
CA
SER
B
246
−63.265
18.895
−30.892
1.00
76.25
C


ATOM
541
CB
SER
B
246
−62.144
18.310
−31.755
1.00
76.56
C


ATOM
542
OG
SER
B
246
−61.518
19.218
−32.647
1.00
77.19
O


ATOM
543
C
SER
B
246
−62.796
19.919
−29.879
1.00
75.82
C


ATOM
544
O
SER
B
246
−62.778
21.113
−30.174
1.00
75.68
O


ATOM
545
N
MET
B
247
−62.484
19.452
−28.664
1.00
75.61
N


ATOM
546
CA
MET
B
247
−62.064
20.290
−27.540
1.00
75.40
C


ATOM
547
CB
MET
B
247
−63.145
20.308
−26.465
1.00
75.44
C


ATOM
548
CG
MET
B
247
−64.413
20.931
−26.899
1.00
76.86
C


ATOM
549
SD
MET
B
247
−65.642
20.855
−25.589
1.00
79.70
S


ATOM
550
CE
MET
B
247
−64.971
22.118
−24.482
1.00
79.04
C


ATOM
551
C
MET
B
247
−60.806
19.822
−26.860
1.00
74.96
C


ATOM
552
O
MET
B
247
−60.548
18.620
−26.791
1.00
75.05
O


ATOM
553
N
ARG
B
248
−60.047
20.777
−26.312
1.00
75.49
N


ATOM
554
CA
ARG
B
248
−58.836
20.513
−25.545
1.00
74.89
C


ATOM
555
CB
ARG
B
248
−57.587
21.112
−26.198
1.00
75.20
C


ATOM
556
CG
ARG
B
248
−57.578
20.887
−27.698
1.00
77.26
C


ATOM
557
CD
ARG
B
248
−56.245
21.122
−28.343
1.00
79.96
C


ATOM
558
NE
ARG
B
248
−55.613
19.847
−28.644
1.00
81.95
N


ATOM
559
CZ
ARG
B
248
−54.391
19.515
−28.244
1.00
83.83
C


ATOM
560
NH1
ARG
B
248
−53.894
18.316
−28.540
1.00
84.54
N


ATOM
561
NH2
ARG
B
248
−53.653
20.376
−27.541
1.00
84.67
N


ATOM
562
C
ARG
B
248
−59.087
21.076
−24.158
1.00
74.04
C


ATOM
563
O
ARG
B
248
−59.463
22.232
−24.032
1.00
73.90
O


ATOM
564
N
SER
B
249
−58.950
20.239
−23.128
1.00
71.20
N


ATOM
565
CA
SER
B
249
−59.164
20.579
−21.729
1.00
70.17
C


ATOM
566
CB
SER
B
249
−59.736
19.366
−20.999
1.00
69.92
C


ATOM
567
OG
SER
B
249
−59.511
19.446
−19.602
1.00
68.99
O


ATOM
568
C
SER
B
249
−57.850
21.031
−21.050
1.00
69.89
C


ATOM
569
O
SER
B
249
−56.810
20.406
−21.278
1.00
70.14
O


ATOM
570
N
LEU
B
250
−57.916
22.099
−20.203
1.00
66.61
N


ATOM
571
CA
LEU
B
250
−56.812
22.648
−19.391
1.00
65.82
C


ATOM
572
CB
LEU
B
250
−56.351
23.994
−19.919
1.00
65.38
C


ATOM
573
CG
LEU
B
250
−55.208
23.974
−20.898
1.00
64.50
C


ATOM
574
CD1
LEU
B
250
−55.702
23.663
−22.312
1.00
64.17
C


ATOM
575
CD2
LEU
B
250
−54.523
25.306
−20.908
1.00
63.05
C


ATOM
576
C
LEU
B
250
−57.325
22.798
−17.956
1.00
65.75
C


ATOM
577
O
LEU
B
250
−58.399
23.350
−17.777
1.00
66.25
O


ATOM
578
N
ARG
B
251
−56.608
22.285
−16.937
1.00
67.20
N


ATOM
579
CA
ARG
B
251
−57.095
22.367
−15.552
1.00
67.06
C


ATOM
580
CB
ARG
B
251
−56.857
21.076
−14.773
1.00
66.51
C


ATOM
581
CG
ARG
B
251
−57.683
21.030
−13.516
1.00
65.46
C


ATOM
582
CD
ARG
B
251
−57.459
19.766
−12.738
1.00
65.04
C


ATOM
583
NE
ARG
B
251
−58.350
19.702
−11.575
1.00
65.85
N


ATOM
584
CZ
ARG
B
251
−57.945
19.431
−10.334
1.00
65.92
C


ATOM
585
NH1
ARG
B
251
−58.822
19.402
−9.332
1.00
66.09
N


ATOM
586
NH2
ARG
B
251
−56.658
19.186
−10.085
1.00
66.35
N


ATOM
587
C
ARG
B
251
−56.608
23.553
−14.764
1.00
67.70
C


ATOM
588
O
ARG
B
251
−55.438
23.587
−14.360
1.00
67.90
O


ATOM
589
N
VAL
B
252
−57.518
24.528
−14.524
1.00
67.49
N


ATOM
590
CA
VAL
B
252
−57.211
25.746
−13.756
1.00
67.57
C


ATOM
591
CB
VAL
B
252
−57.228
27.057
−14.566
1.00
67.13
C


ATOM
592
CG1
VAL
B
252
−56.161
27.053
−15.656
1.00
67.37
C


ATOM
593
CG2
VAL
B
252
−58.607
27.350
−15.131
1.00
66.31
C


ATOM
594
C
VAL
B
252
−58.046
25.845
−12.498
1.00
68.12
C


ATOM
595
O
VAL
B
252
−57.782
26.706
−11.650
1.00
68.43
O


ATOM
596
N
LEU
B
253
−59.048
24.968
−12.365
1.00
65.71
N


ATOM
597
CA
LEU
B
253
−59.889
24.997
−11.189
1.00
66.27
C


ATOM
598
CB
LEU
B
253
−61.365
25.338
−11.518
1.00
65.95
C


ATOM
599
CG
LEU
B
253
−61.632
26.540
−12.451
1.00
64.62
C


ATOM
600
CD1
LEU
B
253
−63.059
26.692
−12.730
1.00
63.03
C


ATOM
601
CD2
LEU
B
253
−61.039
27.832
−11.937
1.00
63.96
C


ATOM
602
C
LEU
B
253
−59.746
23.712
−10.404
1.00
67.24
C


ATOM
603
O
LEU
B
253
−59.663
22.636
−10.990
1.00
67.26
O


ATOM
604
N
ASN
B
254
−59.679
23.826
−9.070
1.00
72.03
N


ATOM
605
CA
ASN
B
254
−59.555
22.675
−8.196
1.00
73.18
C


ATOM
606
CB
ASN
B
254
−58.866
23.055
−6.882
1.00
73.11
C


ATOM
607
CG
ASN
B
254
−59.635
23.933
−5.921
1.00
73.35
C


ATOM
608
OD1
ASN
B
254
−60.873
23.945
−5.851
1.00
73.95
O


ATOM
609
ND2
ASN
B
254
−58.895
24.683
−5.117
1.00
73.40
N


ATOM
610
C
ASN
B
254
−60.929
22.017
−8.018
1.00
74.16
C


ATOM
611
O
ASN
B
254
−61.852
22.372
−8.732
1.00
74.14
O


ATOM
612
N
CYS
B
255
−61.074
21.070
−7.085
1.00
80.58
N


ATOM
613
CA
CYS
B
255
−62.333
20.370
−6.860
1.00
82.09
C


ATOM
614
CB
CYS
B
255
−62.127
19.108
−6.036
1.00
82.62
C


ATOM
615
SG
CYS
B
255
−61.022
17.905
−6.832
1.00
89.25
S


ATOM
616
C
CYS
B
255
−63.427
21.222
−6.329
1.00
81.75
C


ATOM
617
O
CYS
B
255
−64.589
20.917
−6.584
1.00
82.38
O


ATOM
618
N
GLN
B
256
−63.079
22.314
−5.639
1.00
77.66
N


ATOM
619
CA
GLN
B
256
−64.057
23.252
−5.091
1.00
77.30
C


ATOM
620
CB
GLN
B
256
−63.590
23.807
−3.733
1.00
77.93
C


ATOM
621
CG
GLN
B
256
−63.313
22.757
−2.649
1.00
81.07
C


ATOM
622
CD
GLN
B
256
−61.881
22.827
−2.088
1.00
87.25
C


ATOM
623
OE1
GLN
B
256
−61.041
23.719
−2.429
1.00
89.83
O


ATOM
624
NE2
GLN
B
256
−61.568
21.877
−1.194
1.00
88.70
N


ATOM
625
C
GLN
B
256
−64.361
24.387
−6.094
1.00
76.06
C


ATOM
626
O
GLN
B
256
−64.995
25.374
−5.747
1.00
76.16
O


ATOM
627
N
GLY
B
257
−63.912
24.223
−7.330
1.00
70.38
N


ATOM
628
CA
GLY
B
257
−64.100
25.186
−8.411
1.00
68.58
C


ATOM
629
C
GLY
B
257
−63.271
26.444
−8.277
1.00
67.40
C


ATOM
630
O
GLY
B
257
−63.500
27.409
−9.009
1.00
67.30
O


ATOM
631
N
LYS
B
258
−62.297
26.434
−7.349
1.00
63.96
N


ATOM
632
CA
LYS
B
258
−61.401
27.547
−7.062
1.00
62.84
C


ATOM
633
CB
LYS
B
258
−61.073
27.568
−5.566
1.00
62.59
C


ATOM
634
CG
LYS
B
258
−60.889
28.968
−5.004
1.00
63.89
C


ATOM
635
CD
LYS
B
258
−61.172
29.003
−3.504
1.00
66.19
C


ATOM
636
CE
LYS
B
258
−59.925
29.279
−2.696
1.00
68.11
C


ATOM
637
NZ
LYS
B
258
−59.951
28.592
−1.372
1.00
70.08
N


ATOM
638
C
LYS
B
258
−60.123
27.507
−7.911
1.00
62.15
C


ATOM
639
O
LYS
B
258
−59.550
26.452
−8.117
1.00
62.29
O


ATOM
640
N
GLY
B
259
−59.711
28.661
−8.409
1.00
62.62
N


ATOM
641
CA
GLY
B
259
−58.507
28.810
−9.211
1.00
61.64
C


ATOM
642
C
GLY
B
259
−57.771
30.085
−8.845
1.00
61.25
C


ATOM
643
O
GLY
B
259
−58.114
30.754
−7.853
1.00
61.08
O


ATOM
644
N
THR
B
260
−56.742
30.431
−9.633
1.00
60.84
N


ATOM
645
CA
THR
B
260
−55.981
31.658
−9.397
1.00
60.16
C


ATOM
646
CB
THR
B
260
−54.619
31.406
−8.736
1.00
59.90
C


ATOM
647
OG1
THR
B
260
−53.793
30.546
−9.540
1.00
60.29
O


ATOM
648
CG2
THR
B
260
−54.741
30.915
−7.327
1.00
58.45
C


ATOM
649
C
THR
B
260
−55.826
32.420
−10.684
1.00
60.24
C


ATOM
650
O
THR
B
260
−55.965
31.834
−11.759
1.00
60.08
O


ATOM
651
N
VAL
B
261
−55.559
33.736
−10.580
1.00
62.43
N


ATOM
652
CA
VAL
B
261
−55.346
34.609
−11.732
1.00
62.54
C


ATOM
653
CB
VAL
B
261
−55.159
36.076
−11.269
1.00
62.53
C


ATOM
654
CG1
VAL
B
261
−54.689
36.982
−12.411
1.00
62.52
C


ATOM
655
CG2
VAL
B
261
−56.443
36.614
−10.639
1.00
62.50
C


ATOM
656
C
VAL
B
261
−54.105
34.051
−12.435
1.00
62.77
C


ATOM
657
O
VAL
B
261
−54.156
33.687
−13.615
1.00
62.53
O


ATOM
658
N
SER
B
262
−53.013
33.932
−11.655
1.00
64.10
N


ATOM
659
CA
SER
B
262
−51.694
33.417
−12.028
1.00
63.98
C


ATOM
660
CB
SER
B
262
−50.844
33.245
−10.768
1.00
63.93
C


ATOM
661
OG
SER
B
262
−51.594
32.577
−9.765
1.00
63.42
O


ATOM
662
C
SER
B
262
−51.805
32.088
−12.800
1.00
63.70
C


ATOM
663
O
SER
B
262
−51.284
31.978
−13.911
1.00
63.66
O


ATOM
664
N
GLY
B
263
−52.499
31.118
−12.212
1.00
59.41
N


ATOM
665
CA
GLY
B
263
−52.699
29.818
−12.829
1.00
59.00
C


ATOM
666
C
GLY
B
263
−53.432
29.909
−14.148
1.00
58.77
C


ATOM
667
O
GLY
B
263
−53.094
29.199
−15.085
1.00
58.40
O


ATOM
668
N
THR
B
264
−54.435
30.800
−14.230
1.00
59.19
N


ATOM
669
CA
THR
B
264
−55.214
31.016
−15.446
1.00
59.40
C


ATOM
670
CB
THR
B
264
−56.492
31.846
−15.157
1.00
59.23
C


ATOM
671
OG1
THR
B
264
−57.212
31.270
−14.085
1.00
57.85
O


ATOM
672
CG2
THR
B
264
−57.407
31.974
−16.359
1.00
58.64
C


ATOM
673
C
THR
B
264
−54.255
31.654
−16.486
1.00
60.21
C


ATOM
674
O
THR
B
264
−54.314
31.273
−17.654
1.00
60.35
O


ATOM
675
N
LEU
B
265
−53.363
32.592
−16.064
1.00
60.92
N


ATOM
676
CA
LEU
B
265
−52.390
33.217
−16.968
1.00
61.51
C


ATOM
677
CB
LEU
B
265
−51.507
34.228
−16.242
1.00
61.56
C


ATOM
678
CG
LEU
B
265
−52.105
35.499
−15.796
1.00
61.07
C


ATOM
679
CD1
LEU
B
265
−51.031
36.384
−15.256
1.00
61.15
C


ATOM
680
CD2
LEU
B
265
−52.793
36.196
−16.930
1.00
61.14
C


ATOM
681
C
LEU
B
265
−51.475
32.148
−17.562
1.00
62.10
C


ATOM
682
O
LEU
B
265
−51.352
32.085
−18.782
1.00
62.27
O


ATOM
683
N
ILE
B
266
−50.845
31.306
−16.699
1.00
62.02
N


ATOM
684
CA
ILE
B
266
−49.958
30.220
−17.110
1.00
62.61
C


ATOM
685
CB
ILE
B
266
−49.356
29.498
−15.889
1.00
62.34
C


ATOM
686
CG1
ILE
B
266
−48.527
30.489
−15.077
1.00
61.21
C


ATOM
687
CD1
ILE
B
266
−48.121
30.072
−13.744
1.00
59.56
C


ATOM
688
CG2
ILE
B
266
−48.495
28.315
−16.321
1.00
62.82
C


ATOM
689
C
ILE
B
266
−50.668
29.297
−18.126
1.00
63.41
C


ATOM
690
O
ILE
B
266
−50.049
28.912
−19.122
1.00
63.60
O


ATOM
691
N
GLY
B
267
−51.962
29.030
−17.891
1.00
64.02
N


ATOM
692
CA
GLY
B
267
−52.840
28.261
−18.763
1.00
64.93
C


ATOM
693
C
GLY
B
267
−53.057
28.971
−20.086
1.00
66.04
C


ATOM
694
O
GLY
B
267
−53.084
28.326
−21.120
1.00
66.22
O


ATOM
695
N
LEU
B
268
−53.191
30.301
−20.091
1.00
68.50
N


ATOM
696
CA
LEU
B
268
−53.379
31.042
−21.340
1.00
69.85
C


ATOM
697
CB
LEU
B
268
−53.910
32.463
−21.083
1.00
69.65
C


ATOM
698
CG
LEU
B
268
−55.356
32.607
−20.643
1.00
68.47
C


ATOM
699
CD1
LEU
B
268
−55.673
34.048
−20.359
1.00
67.56
C


ATOM
700
CD2
LEU
B
268
−56.322
32.090
−21.679
1.00
67.17
C


ATOM
701
C
LEU
B
268
−52.068
31.097
−22.137
1.00
71.25
C


ATOM
702
O
LEU
B
268
−52.103
31.106
−23.374
1.00
71.19
O


ATOM
703
N
GLU
B
269
−50.918
31.140
−21.413
1.00
76.14
N


ATOM
704
CA
GLU
B
269
−49.556
31.179
−21.963
1.00
77.92
C


ATOM
705
CB
GLU
B
269
−48.522
31.419
−20.838
1.00
78.06
C


ATOM
706
CG
GLU
B
269
−47.137
31.853
−21.311
1.00
80.49
C


ATOM
707
CD
GLU
B
269
−45.980
31.559
−20.357
1.00
84.46
C


ATOM
708
OE1
GLU
B
269
−45.848
30.397
−19.901
1.00
85.61
O


ATOM
709
OE2
GLU
B
269
−45.191
32.492
−20.081
1.00
85.68
O


ATOM
710
C
GLU
B
269
−49.311
29.834
−22.667
1.00
78.53
C


ATOM
711
O
GLU
B
269
−48.644
29.787
−23.705
1.00
78.67
O


ATOM
712
N
PHE
B
270
−49.890
28.756
−22.102
1.00
77.08
N


ATOM
713
CA
PHE
B
270
−49.835
27.406
−22.618
1.00
77.95
C


ATOM
714
CB
PHE
B
270
−50.502
26.457
−21.619
1.00
77.76
C


ATOM
715
CG
PHE
B
270
−50.556
25.010
−22.025
1.00
77.89
C


ATOM
716
CD1
PHE
B
270
−49.751
24.066
−21.401
1.00
78.17
C


ATOM
717
CE1
PHE
B
270
−49.803
22.720
−21.779
1.00
78.00
C


ATOM
718
CZ
PHE
B
270
−50.656
22.319
−22.783
1.00
77.50
C


ATOM
719
CE2
PHE
B
270
−51.467
23.236
−23.408
1.00
77.66
C


ATOM
720
CD2
PHE
B
270
−51.426
24.579
−23.024
1.00
77.70
C


ATOM
721
C
PHE
B
270
−50.555
27.378
−23.977
1.00
78.85
C


ATOM
722
O
PHE
B
270
−49.995
26.856
−24.934
1.00
79.16
O


ATOM
723
N
ILE
B
271
−51.781
27.942
−24.067
1.00
78.91
N


ATOM
724
CA
ILE
B
271
−52.584
28.020
−25.297
1.00
79.98
C


ATOM
725
CB
ILE
B
271
−53.980
28.639
−25.023
1.00
79.66
C


ATOM
726
CG1
ILE
B
271
−54.744
27.834
−23.994
1.00
79.30
C


ATOM
727
CD1
ILE
B
271
−55.932
28.488
−23.539
1.00
79.71
C


ATOM
728
CG2
ILE
B
271
−54.806
28.767
−26.297
1.00
79.37
C


ATOM
729
C
ILE
B
271
−51.834
28.818
−26.364
1.00
81.30
C


ATOM
730
O
ILE
B
271
−51.953
28.499
−27.540
1.00
80.98
O


ATOM
731
N
ARG
B
272
−51.076
29.861
−25.957
1.00
89.76
N


ATOM
732
CA
ARG
B
272
−50.321
30.685
−26.897
1.00
91.79
C


ATOM
733
CB
ARG
B
272
−49.724
31.948
−26.240
1.00
91.99
C


ATOM
734
CG
ARG
B
272
−49.015
32.925
−27.212
1.00
93.58
C


ATOM
735
CD
ARG
B
272
−49.915
33.388
−28.356
1.00
96.32
C


ATOM
736
NE
ARG
B
272
−49.252
34.288
−29.309
1.00
98.43
N


ATOM
737
CZ
ARG
B
272
−49.192
34.072
−30.623
1.00
99.37
C


ATOM
738
NH1
ARG
B
272
−49.730
32.977
−31.149
1.00
99.79
N


ATOM
739
NH2
ARG
B
272
−48.586
34.946
−31.419
1.00
99.85
N


ATOM
740
C
ARG
B
272
−49.266
29.850
−27.565
1.00
92.79
C


ATOM
741
O
ARG
B
272
−49.134
29.938
−28.779
1.00
93.00
O


ATOM
742
N
LYS
B
273
−48.549
29.016
−26.788
1.00
96.33
N


ATOM
743
CA
LYS
B
273
−47.516
28.113
−27.295
1.00
97.71
C


ATOM
744
CB
LYS
B
273
−46.703
27.484
−26.153
1.00
97.59
C


ATOM
745
CG
LYS
B
273
−45.899
28.533
−25.361
1.00
99.09
C


ATOM
746
CD
LYS
B
273
−45.328
27.986
−24.044
1.00
100.65
C


ATOM
747
CE
LYS
B
273
−44.717
29.045
−23.148
1.00
100.83
C


ATOM
748
NZ
LYS
B
273
−44.250
28.449
−21.855
1.00
101.62
N


ATOM
749
C
LYS
B
273
−48.172
27.061
−28.176
1.00
98.53
C


ATOM
750
O
LYS
B
273
−47.726
26.863
−29.302
1.00
98.77
O


ATOM
751
N
SER
B
274
−49.273
26.449
−27.707
1.00
99.80
N


ATOM
752
CA
SER
B
274
−50.037
25.441
−28.450
1.00
101.05
C


ATOM
753
CB
SER
B
274
−51.272
25.015
−27.662
1.00
101.07
C


ATOM
754
OG
SER
B
274
−50.945
24.670
−26.328
1.00
102.23
O


ATOM
755
C
SER
B
274
−50.486
25.957
−29.809
1.00
101.70
C


ATOM
756
O
SER
B
274
−50.572
25.180
−30.755
1.00
101.92
O


ATOM
757
N
GLN
B
275
−50.789
27.259
−29.896
1.00
101.88
N


ATOM
758
CA
GLN
B
275
−51.251
27.923
−31.104
1.00
102.84
C


ATOM
759
CB
GLN
B
275
−51.856
29.289
−30.743
1.00
102.72
C


ATOM
760
CG
GLN
B
275
−52.759
29.880
−31.816
1.00
102.15
C


ATOM
761
CD
GLN
B
275
−52.885
31.385
−31.755
1.00
100.72
C


ATOM
762
OE1
GLN
B
275
−52.233
32.074
−30.964
1.00
100.81
O


ATOM
763
NE2
GLN
B
275
−53.735
31.931
−32.605
1.00
100.53
N


ATOM
764
C
GLN
B
275
−50.100
28.079
−32.082
1.00
103.88
C


ATOM
765
O
GLN
B
275
−50.283
27.824
−33.272
1.00
104.18
O


ATOM
766
N
LEU
B
276
−48.920
28.490
−31.583
1.00
107.99
N


ATOM
767
CA
LEU
B
276
−47.721
28.700
−32.391
1.00
109.33
C


ATOM
768
CB
LEU
B
276
−46.615
29.395
−31.577
1.00
109.22
C


ATOM
769
CG
LEU
B
276
−46.896
30.833
−31.126
1.00
109.42
C


ATOM
770
CD1
LEU
B
276
−46.028
31.208
−29.954
1.00
109.47
C


ATOM
771
CD2
LEU
B
276
−46.742
31.838
−32.268
1.00
109.48
C


ATOM
772
C
LEU
B
276
−47.221
27.386
−32.974
1.00
110.36
C


ATOM
773
O
LEU
B
276
−47.159
27.245
−34.202
1.00
110.44
O


ATOM
774
N
VAL
B
277
−46.894
26.416
−32.080
1.00
116.52
N


ATOM
775
CA
VAL
B
277
−46.396
25.061
−32.383
1.00
117.56
C


ATOM
776
CB
VAL
B
277
−46.286
24.164
−31.102
1.00
117.53
C


ATOM
777
CG1
VAL
B
277
−46.084
22.685
−31.446
1.00
117.63
C


ATOM
778
CG2
VAL
B
277
−45.172
24.662
−30.182
1.00
117.65
C


ATOM
779
C
VAL
B
277
−47.229
24.437
−33.507
1.00
118.10
C


ATOM
780
O
VAL
B
277
−46.736
24.368
−34.636
1.00
118.31
O


ATOM
781
N
GLN
B
278
−48.489
24.045
−33.207
1.00
120.99
N


ATOM
782
CA
GLN
B
278
−49.422
23.455
−34.161
1.00
121.66
C


ATOM
783
CB
GLN
B
278
−50.691
22.919
−33.450
1.00
121.92
C


ATOM
784
CG
GLN
B
278
−50.444
21.903
−32.324
1.00
123.58
C


ATOM
785
CD
GLN
B
278
−51.715
21.462
−31.608
1.00
126.12
C


ATOM
786
OE1
GLN
B
278
−52.738
22.166
−31.571
1.00
127.28
O


ATOM
787
NE2
GLN
B
278
−51.677
20.276
−31.009
1.00
126.75
N


ATOM
788
C
GLN
B
278
−49.803
24.535
−35.196
1.00
121.49
C


ATOM
789
O
GLN
B
278
−50.590
25.429
−34.855
1.00
121.77
O


ATOM
790
N
PRO
B
279
−49.239
24.526
−36.443
1.00
122.36
N


ATOM
791
CA
PRO
B
279
−49.655
25.544
−37.427
1.00
121.69
C


ATOM
792
CB
PRO
B
279
−48.575
25.458
−38.532
1.00
121.88
C


ATOM
793
CG
PRO
B
279
−47.539
24.434
−38.030
1.00
122.28
C


ATOM
794
CD
PRO
B
279
−48.296
23.566
−37.058
1.00
122.41
C


ATOM
795
C
PRO
B
279
−51.051
25.080
−37.864
1.00
120.73
C


ATOM
796
O
PRO
B
279
−51.204
24.135
−38.659
1.00
120.92
O


ATOM
797
N
VAL
B
280
−52.071
25.680
−37.228
1.00
115.26
N


ATOM
798
CA
VAL
B
280
−53.465
25.315
−37.445
1.00
113.52
C


ATOM
799
CB
VAL
B
280
−54.075
24.563
−36.204
1.00
113.87
C


ATOM
800
CG1
VAL
B
280
−53.477
23.156
−36.042
1.00
113.62
C


ATOM
801
CG2
VAL
B
280
−53.941
25.378
−34.907
1.00
113.84
C


ATOM
802
C
VAL
B
280
−54.311
26.493
−37.970
1.00
112.03
C


ATOM
803
O
VAL
B
280
−53.749
27.428
−38.557
1.00
111.92
O


ATOM
804
N
GLY
B
281
−55.637
26.408
−37.767
1.00
105.64
N


ATOM
805
CA
GLY
B
281
−56.626
27.405
−38.168
1.00
102.84
C


ATOM
806
C
GLY
B
281
−57.292
28.151
−37.017
1.00
100.46
C


ATOM
807
O
GLY
B
281
−56.594
28.825
−36.246
1.00
100.89
O


ATOM
808
N
PRO
B
282
−58.652
28.074
−36.883
1.00
91.19
N


ATOM
809
CA
PRO
B
282
−59.336
28.813
−35.810
1.00
89.14
C


ATOM
810
CB
PRO
B
282
−60.793
28.825
−36.263
1.00
89.19
C


ATOM
811
CG
PRO
B
282
−60.943
27.627
−37.050
1.00
89.93
C


ATOM
812
CD
PRO
B
282
−59.628
27.349
−37.717
1.00
91.00
C


ATOM
813
C
PRO
B
282
−59.167
28.240
−34.408
1.00
87.01
C


ATOM
814
O
PRO
B
282
−58.887
27.050
−34.242
1.00
86.82
O


ATOM
815
N
LEU
B
283
−59.339
29.115
−33.401
1.00
80.72
N


ATOM
816
CA
LEU
B
283
−59.198
28.804
−31.981
1.00
78.15
C


ATOM
817
CB
LEU
B
283
−57.789
29.242
−31.551
1.00
78.20
C


ATOM
818
CG
LEU
B
283
−57.040
28.350
−30.582
1.00
78.62
C


ATOM
819
CD1
LEU
B
283
−56.323
27.223
−31.317
1.00
79.96
C


ATOM
820
CD2
LEU
B
283
−56.004
29.145
−29.848
1.00
78.44
C


ATOM
821
C
LEU
B
283
−60.248
29.532
−31.107
1.00
76.26
C


ATOM
822
O
LEU
B
283
−60.404
30.746
−31.215
1.00
76.25
O


ATOM
823
N
VAL
B
284
−60.948
28.794
−30.240
1.00
69.65
N


ATOM
824
CA
VAL
B
284
−61.933
29.344
−29.306
1.00
66.85
C


ATOM
825
CB
VAL
B
284
−63.381
28.841
−29.550
1.00
66.64
C


ATOM
826
CG1
VAL
B
284
−64.343
29.377
−28.497
1.00
65.54
C


ATOM
827
CG2
VAL
B
284
−63.863
29.209
−30.942
1.00
65.81
C


ATOM
828
C
VAL
B
284
−61.444
29.024
−27.895
1.00
65.45
C


ATOM
829
O
VAL
B
284
−61.199
27.872
−27.592
1.00
65.31
O


ATOM
830
N
VAL
B
285
−61.270
30.022
−27.047
1.00
64.37
N


ATOM
831
CA
VAL
B
285
−60.844
29.783
−25.674
1.00
63.25
C


ATOM
832
CB
VAL
B
285
−59.605
30.599
−25.256
1.00
63.09
C


ATOM
833
CG1
VAL
B
285
−59.359
30.481
−23.766
1.00
62.67
C


ATOM
834
CG2
VAL
B
285
−58.371
30.144
−26.020
1.00
63.08
C


ATOM
835
C
VAL
B
285
−62.045
30.077
−24.809
1.00
62.71
C


ATOM
836
O
VAL
B
285
−62.540
31.205
−24.818
1.00
62.92
O


ATOM
837
N
LEU
B
286
−62.545
29.067
−24.097
1.00
63.34
N


ATOM
838
CA
LEU
B
286
−63.694
29.235
−23.217
1.00
62.71
C


ATOM
839
CB
LEU
B
286
−64.766
28.183
−23.501
1.00
62.52
C


ATOM
840
CG
LEU
B
286
−65.735
27.853
−22.392
1.00
62.69
C


ATOM
841
CD1
LEU
B
286
−66.769
28.949
−22.197
1.00
62.31
C


ATOM
842
CD2
LEU
B
286
−66.418
26.550
−22.686
1.00
63.41
C


ATOM
843
C
LEU
B
286
−63.215
29.258
−21.743
1.00
62.46
C


ATOM
844
O
LEU
B
286
−62.615
28.292
−21.246
1.00
62.37
O


ATOM
845
N
LEU
B
287
−63.451
30.412
−21.082
1.00
62.84
N


ATOM
846
CA
LEU
B
287
−63.089
30.686
−19.698
1.00
62.24
C


ATOM
847
CB
LEU
B
287
−62.236
31.948
−19.625
1.00
62.14
C


ATOM
848
CG
LEU
B
287
−60.959
31.917
−20.414
1.00
61.78
C


ATOM
849
CD1
LEU
B
287
−60.962
33.019
−21.408
1.00
61.94
C


ATOM
850
CD2
LEU
B
287
−59.779
32.050
−19.518
1.00
60.79
C


ATOM
851
C
LEU
B
287
−64.385
30.871
−18.905
1.00
62.08
C


ATOM
852
O
LEU
B
287
−64.886
31.998
−18.807
1.00
62.29
O


ATOM
853
N
PRO
B
288
−64.966
29.773
−18.353
1.00
63.14
N


ATOM
854
CA
PRO
B
288
−66.243
29.892
−17.615
1.00
62.63
C


ATOM
855
CB
PRO
B
288
−66.932
28.565
−17.937
1.00
62.45
C


ATOM
856
CG
PRO
B
288
−65.820
27.623
−18.305
1.00
62.93
C


ATOM
857
CD
PRO
B
288
−64.524
28.370
−18.394
1.00
63.06
C


ATOM
858
C
PRO
B
288
−66.010
30.119
−16.112
1.00
62.16
C


ATOM
859
O
PRO
B
288
−66.469
29.365
−15.245
1.00
62.44
O


ATOM
860
N
LEU
B
289
−65.265
31.183
−15.823
1.00
62.09
N


ATOM
861
CA
LEU
B
289
−64.851
31.538
−14.492
1.00
61.42
C


ATOM
862
CB
LEU
B
289
−63.469
30.909
−14.214
1.00
61.52
C


ATOM
863
CG
LEU
B
289
−62.367
31.084
−15.278
1.00
60.95
C


ATOM
864
CD1
LEU
B
289
−61.614
32.401
−15.094
1.00
59.80
C


ATOM
865
CD2
LEU
B
289
−61.395
29.911
−15.247
1.00
60.26
C


ATOM
866
C
LEU
B
289
−64.805
33.038
−14.291
1.00
61.25
C


ATOM
867
O
LEU
B
289
−64.786
33.797
−15.256
1.00
61.35
O


ATOM
868
N
ALA
B
290
−64.756
33.473
−13.038
1.00
61.46
N


ATOM
869
CA
ALA
B
290
−64.732
34.884
−12.737
1.00
61.26
C


ATOM
870
CB
ALA
B
290
−66.158
35.363
−12.513
1.00
61.09
C


ATOM
871
C
ALA
B
290
−63.893
35.186
−11.516
1.00
61.37
C


ATOM
872
O
ALA
B
290
−63.746
34.334
−10.649
1.00
61.38
O


ATOM
873
N
GLY
B
291
−63.370
36.398
−11.459
1.00
60.73
N


ATOM
874
CA
GLY
B
291
−62.595
36.936
−10.351
1.00
61.16
C


ATOM
875
C
GLY
B
291
−62.833
38.433
−10.364
1.00
61.50
C


ATOM
876
O
GLY
B
291
−63.539
38.924
−11.244
1.00
61.91
O


ATOM
877
N
GLY
B
292
−62.253
39.175
−9.432
1.00
61.91
N


ATOM
878
CA
GLY
B
292
−62.401
40.623
−9.436
1.00
62.03
C


ATOM
879
C
GLY
B
292
−61.699
41.185
−10.660
1.00
62.38
C


ATOM
880
O
GLY
B
292
−60.960
40.443
−11.327
1.00
62.27
O


ATOM
881
N
TYR
B
293
−61.909
42.493
−10.987
1.00
64.79
N


ATOM
882
CA
TYR
B
293
−61.232
43.050
−12.157
1.00
64.90
C


ATOM
883
CB
TYR
B
293
−61.637
44.508
−12.443
1.00
64.83
C


ATOM
884
CG
TYR
B
293
−60.623
45.227
−13.312
1.00
65.53
C


ATOM
885
CD1
TYR
B
293
−60.693
45.163
−14.700
1.00
66.24
C


ATOM
886
CE1
TYR
B
293
−59.739
45.790
−15.502
1.00
67.57
C


ATOM
887
CZ
TYR
B
293
−58.686
46.482
−14.913
1.00
68.84
C


ATOM
888
OH
TYR
B
293
−57.712
47.094
−15.680
1.00
71.12
O


ATOM
889
CE2
TYR
B
293
−58.592
46.543
−13.534
1.00
67.77
C


ATOM
890
CD2
TYR
B
293
−59.563
45.929
−12.746
1.00
66.45
C


ATOM
891
C
TYR
B
293
−59.714
42.903
−11.993
1.00
64.84
C


ATOM
892
O
TYR
B
293
−59.172
43.323
−10.968
1.00
64.89
O


ATOM
893
N
SER
B
294
−59.048
42.287
−12.987
1.00
64.99
N


ATOM
894
CA
SER
B
294
−57.600
42.074
−13.014
1.00
65.59
C


ATOM
895
CB
SER
B
294
−57.289
40.586
−13.096
1.00
65.66
C


ATOM
896
OG
SER
B
294
−55.979
40.351
−13.585
1.00
65.02
O


ATOM
897
C
SER
B
294
−56.990
42.734
−14.231
1.00
66.16
C


ATOM
898
O
SER
B
294
−57.414
42.428
−15.345
1.00
66.20
O


ATOM
899
N
ARG
B
295
−55.970
43.597
−14.041
1.00
68.26
N


ATOM
900
CA
ARG
B
295
−55.282
44.255
−15.158
1.00
68.63
C


ATOM
901
CB
ARG
B
295
−54.300
45.317
−14.636
1.00
68.95
C


ATOM
902
CG
ARG
B
295
−53.713
46.206
−15.724
1.00
69.57
C


ATOM
903
CD
ARG
B
295
−52.767
47.221
−15.138
1.00
70.03
C


ATOM
904
NE
ARG
B
295
−52.075
47.948
−16.200
1.00
72.60
N


ATOM
905
CZ
ARG
B
295
−51.133
48.873
−16.008
1.00
73.70
C


ATOM
906
NH1
ARG
B
295
−50.745
49.194
−14.778
1.00
74.10
N


ATOM
907
NH2
ARG
B
295
−50.562
49.472
−17.047
1.00
74.62
N


ATOM
908
C
ARG
B
295
−54.538
43.203
−15.999
1.00
68.50
C


ATOM
909
O
ARG
B
295
−54.693
43.179
−17.217
1.00
68.72
O


ATOM
910
N
VAL
B
296
−53.761
42.326
−15.333
1.00
66.22
N


ATOM
911
CA
VAL
B
296
−52.969
41.263
−15.956
1.00
65.91
C


ATOM
912
CB
VAL
B
296
−51.887
40.658
−15.025
1.00
65.76
C


ATOM
913
CG1
VAL
B
296
−52.460
39.654
−14.039
1.00
64.52
C


ATOM
914
CG2
VAL
B
296
−50.778
40.031
−15.833
1.00
65.21
C


ATOM
915
C
VAL
B
296
−53.767
40.230
−16.733
1.00
66.07
C


ATOM
916
O
VAL
B
296
−53.389
39.925
−17.846
1.00
66.43
O


ATOM
917
N
LEU
B
297
−54.848
39.698
−16.172
1.00
64.68
N


ATOM
918
CA
LEU
B
297
−55.660
38.716
−16.865
1.00
64.85
C


ATOM
919
CB
LEU
B
297
−56.741
38.146
−15.935
1.00
64.83
C


ATOM
920
CG
LEU
B
297
−57.642
37.028
−16.456
1.00
64.77
C


ATOM
921
CD1
LEU
B
297
−56.857
35.817
−16.880
1.00
64.90
C


ATOM
922
CD2
LEU
B
297
−58.574
36.588
−15.382
1.00
65.00
C


ATOM
923
C
LEU
B
297
−56.255
39.385
−18.090
1.00
65.24
C


ATOM
924
O
LEU
B
297
−56.053
38.885
−19.184
1.00
65.29
O


ATOM
925
N
ASN
B
298
−56.909
40.548
−17.928
1.00
65.33
N


ATOM
926
CA
ASN
B
298
−57.491
41.310
−19.030
1.00
65.69
C


ATOM
927
CB
ASN
B
298
−58.071
42.609
−18.523
1.00
65.52
C


ATOM
928
CG
ASN
B
298
−59.430
42.467
−17.930
1.00
65.42
C


ATOM
929
OD1
ASN
B
298
−59.889
41.361
−17.614
1.00
64.87
O


ATOM
930
ND2
ASN
B
298
−60.108
43.588
−17.769
1.00
64.99
N


ATOM
931
C
ASN
B
298
−56.485
41.616
−20.137
1.00
66.28
C


ATOM
932
O
ASN
B
298
−56.849
41.546
−21.314
1.00
66.62
O


ATOM
933
N
ALA
B
299
−55.237
41.965
−19.760
1.00
64.24
N


ATOM
934
CA
ALA
B
299
−54.166
42.287
−20.679
1.00
64.70
C


ATOM
935
CB
ALA
B
299
−52.941
42.711
−19.895
1.00
64.65
C


ATOM
936
C
ALA
B
299
−53.842
41.079
−21.527
1.00
65.39
C


ATOM
937
O
ALA
B
299
−53.663
41.214
−22.735
1.00
65.12
O


ATOM
938
N
ALA
B
300
−53.773
39.898
−20.882
1.00
66.94
N


ATOM
939
CA
ALA
B
300
−53.476
38.603
−21.477
1.00
68.02
C


ATOM
940
CB
ALA
B
300
−53.287
37.563
−20.386
1.00
67.68
C


ATOM
941
C
ALA
B
300
−54.589
38.172
−22.428
1.00
68.95
C


ATOM
942
O
ALA
B
300
−54.325
37.566
−23.455
1.00
69.09
O


ATOM
943
N
CYS
B
301
−55.824
38.491
−22.105
1.00
74.05
N


ATOM
944
CA
CYS
B
301
−56.923
38.122
−22.970
1.00
75.78
C


ATOM
945
CB
CYS
B
301
−58.244
38.228
−22.222
1.00
75.64
C


ATOM
946
SG
CYS
B
301
−58.381
37.099
−20.810
1.00
78.21
S


ATOM
947
C
CYS
B
301
−56.895
39.004
−24.200
1.00
76.78
C


ATOM
948
O
CYS
B
301
−57.223
38.542
−25.298
1.00
77.13
O


ATOM
949
N
GLN
B
302
−56.467
40.269
−24.019
1.00
81.35
N


ATOM
950
CA
GLN
B
302
−56.351
41.259
−25.081
1.00
82.53
C


ATOM
951
CB
GLN
B
302
−56.133
42.670
−24.496
1.00
82.87
C


ATOM
952
CG
GLN
B
302
−55.970
43.814
−25.507
1.00
84.29
C


ATOM
953
CD
GLN
B
302
−54.565
44.367
−25.477
1.00
87.06
C


ATOM
954
OE1
GLN
B
302
−53.874
44.430
−26.512
1.00
89.24
O


ATOM
955
NE2
GLN
B
302
−54.092
44.774
−24.290
1.00
87.85
N


ATOM
956
C
GLN
B
302
−55.236
40.840
−26.022
1.00
82.94
C


ATOM
957
O
GLN
B
302
−55.491
40.793
−27.216
1.00
83.12
O


ATOM
958
N
ARG
B
303
−54.033
40.495
−25.499
1.00
83.14
N


ATOM
959
CA
ARG
B
303
−52.901
40.065
−26.319
1.00
83.88
C


ATOM
960
CB
ARG
B
303
−51.648
39.825
−25.459
1.00
84.35
C


ATOM
961
CG
ARG
B
303
−50.440
39.294
−26.239
1.00
87.43
C


ATOM
962
CD
ARG
B
303
−49.226
40.219
−26.312
1.00
92.85
C


ATOM
963
NE
ARG
B
303
−48.042
39.479
−26.791
1.00
96.60
N


ATOM
964
CZ
ARG
B
303
−46.772
39.876
−26.661
1.00
98.59
C


ATOM
965
NH1
ARG
B
303
−46.484
41.029
−26.055
1.00
99.18
N


ATOM
966
NH2
ARG
B
303
−45.783
39.123
−27.133
1.00
99.96
N


ATOM
967
C
ARG
B
303
−53.262
38.840
−27.190
1.00
83.75
C


ATOM
968
O
ARG
B
303
−52.950
38.815
−28.387
1.00
84.03
O


ATOM
969
N
LEU
B
304
−53.945
37.853
−26.592
1.00
79.66
N


ATOM
970
CA
LEU
B
304
−54.403
36.617
−27.227
1.00
79.27
C


ATOM
971
CB
LEU
B
304
−55.014
35.732
−26.133
1.00
79.28
C


ATOM
972
CG
LEU
B
304
−54.840
34.216
−26.188
1.00
79.49
C


ATOM
973
CD1
LEU
B
304
−53.393
33.793
−26.419
1.00
79.48
C


ATOM
974
CD2
LEU
B
304
−55.271
33.617
−24.883
1.00
80.20
C


ATOM
975
C
LEU
B
304
−55.433
36.891
−28.332
1.00
79.16
C


ATOM
976
O
LEU
B
304
−55.456
36.190
−29.332
1.00
78.82
O


ATOM
977
N
ALA
B
305
−56.274
37.915
−28.150
1.00
78.62
N


ATOM
978
CA
ALA
B
305
−57.295
38.302
−29.116
1.00
78.76
C


ATOM
979
CB
ALA
B
305
−58.250
39.295
−28.483
1.00
78.61
C


ATOM
980
C
ALA
B
305
−56.650
38.889
−30.371
1.00
78.89
C


ATOM
981
O
ALA
B
305
−57.161
38.683
−31.473
1.00
78.50
O


ATOM
982
N
ARG
B
306
−55.513
39.607
−30.182
1.00
82.77
N


ATOM
983
CA
ARG
B
306
−54.686
40.219
−31.233
1.00
83.19
C


ATOM
984
CB
ARG
B
306
−53.537
41.096
−30.666
1.00
83.62
C


ATOM
985
CG
ARG
B
306
−53.958
42.091
−29.584
1.00
86.19
C


ATOM
986
CD
ARG
B
306
−53.874
43.551
−29.983
1.00
90.92
C


ATOM
987
NE
ARG
B
306
−55.167
44.216
−29.792
1.00
93.38
N


ATOM
988
CZ
ARG
B
306
−55.325
45.431
−29.268
1.00
94.24
C


ATOM
989
NH1
ARG
B
306
−54.266
46.135
−28.868
1.00
94.00
N


ATOM
990
NH2
ARG
B
306
−56.545
45.950
−29.137
1.00
94.74
N


ATOM
991
C
ARG
B
306
−54.096
39.059
−32.014
1.00
82.50
C


ATOM
992
O
ARG
B
306
−54.136
39.084
−33.241
1.00
82.73
O


ATOM
993
N
ALA
B
307
−53.612
38.009
−31.307
1.00
79.21
N


ATOM
994
CA
ALA
B
307
−53.081
36.802
−31.941
1.00
78.26
C


ATOM
995
CB
ALA
B
307
−52.368
35.919
−30.916
1.00
78.38
C


ATOM
996
C
ALA
B
307
−54.190
36.012
−32.675
1.00
77.40
C


ATOM
997
O
ALA
B
307
−53.981
34.858
−33.022
1.00
77.54
O


ATOM
998
N
GLY
B
308
−55.342
36.649
−32.902
1.00
76.27
N


ATOM
999
CA
GLY
B
308
−56.490
36.098
−33.620
1.00
75.00
C


ATOM
1000
C
GLY
B
308
−57.519
35.267
−32.875
1.00
74.15
C


ATOM
1001
O
GLY
B
308
−58.621
35.044
−33.392
1.00
74.25
O


ATOM
1002
N
VAL
B
309
−57.170
34.798
−31.665
1.00
74.16
N


ATOM
1003
CA
VAL
B
309
−58.005
33.952
−30.798
1.00
72.79
C


ATOM
1004
CB
VAL
B
309
−57.222
33.470
−29.545
1.00
72.94
C


ATOM
1005
CG1
VAL
B
309
−57.930
32.303
−28.879
1.00
73.15
C


ATOM
1006
CG2
VAL
B
309
−55.775
33.092
−29.876
1.00
72.80
C


ATOM
1007
C
VAL
B
309
−59.361
34.588
−30.403
1.00
71.77
C


ATOM
1008
O
VAL
B
309
−59.451
35.794
−30.139
1.00
71.89
O


ATOM
1009
N
VAL
B
310
−60.404
33.751
−30.354
1.00
67.70
N


ATOM
1010
CA
VAL
B
310
−61.773
34.115
−29.964
1.00
65.94
C


ATOM
1011
CB
VAL
B
310
−62.806
33.548
−30.985
1.00
66.01
C


ATOM
1012
CG1
VAL
B
310
−64.228
33.545
−30.432
1.00
65.64
C


ATOM
1013
CG2
VAL
B
310
−62.732
34.304
−32.304
1.00
64.95
C


ATOM
1014
C
VAL
B
310
−61.973
33.586
−28.526
1.00
64.79
C


ATOM
1015
O
VAL
B
310
−61.924
32.389
−28.309
1.00
64.43
O


ATOM
1016
N
LEU
B
311
−62.136
34.484
−27.548
1.00
65.24
N


ATOM
1017
CA
LEU
B
311
−62.322
34.107
−26.141
1.00
64.15
C


ATOM
1018
CB
LEU
B
311
−61.370
34.859
−25.202
1.00
63.97
C


ATOM
1019
CG
LEU
B
311
−59.878
34.536
−25.347
1.00
64.52
C


ATOM
1020
CD1
LEU
B
311
−59.187
35.472
−26.313
1.00
65.02
C


ATOM
1021
CD2
LEU
B
311
−59.174
34.704
−24.056
1.00
64.24
C


ATOM
1022
C
LEU
B
311
−63.759
34.342
−25.734
1.00
63.45
C


ATOM
1023
O
LEU
B
311
−64.360
35.368
−26.100
1.00
63.75
O


ATOM
1024
N
VAL
B
312
−64.337
33.365
−25.016
1.00
61.15
N


ATOM
1025
CA
VAL
B
312
−65.720
33.450
−24.529
1.00
59.55
C


ATOM
1026
CB
VAL
B
312
−66.698
32.496
−25.240
1.00
59.24
C


ATOM
1027
CG1
VAL
B
312
−68.120
32.761
−24.793
1.00
58.49
C


ATOM
1028
CG2
VAL
B
312
−66.583
32.632
−26.757
1.00
58.14
C


ATOM
1029
C
VAL
B
312
−65.665
33.287
−23.028
1.00
59.03
C


ATOM
1030
O
VAL
B
312
−64.942
32.420
−22.542
1.00
59.28
O


ATOM
1031
N
THR
B
313
−66.364
34.159
−22.298
1.00
60.50
N


ATOM
1032
CA
THR
B
313
−66.337
34.186
−20.834
1.00
59.73
C


ATOM
1033
CB
THR
B
313
−65.370
35.307
−20.388
1.00
59.82
C


ATOM
1034
OG1
THR
B
313
−65.293
35.342
−18.954
1.00
61.73
O


ATOM
1035
CG2
THR
B
313
−65.781
36.664
−20.889
1.00
59.54
C


ATOM
1036
C
THR
B
313
−67.686
34.306
−20.124
1.00
58.80
C


ATOM
1037
O
THR
B
313
−68.658
34.806
−20.700
1.00
58.72
O


ATOM
1038
N
ALA
B
314
−67.739
33.872
−18.854
1.00
56.48
N


ATOM
1039
CA
ALA
B
314
−68.978
33.997
−18.079
1.00
56.09
C


ATOM
1040
CB
ALA
B
314
−68.988
33.039
−16.893
1.00
55.49
C


ATOM
1041
C
ALA
B
314
−69.050
35.440
−17.593
1.00
55.97
C


ATOM
1042
O
ALA
B
314
−68.021
36.021
−17.215
1.00
56.24
O


ATOM
1043
N
ALA
B
315
−70.247
36.036
−17.626
1.00
54.10
N


ATOM
1044
CA
ALA
B
315
−70.388
37.397
−17.154
1.00
53.49
C


ATOM
1045
CB
ALA
B
315
−71.734
37.952
−17.549
1.00
53.36
C


ATOM
1046
C
ALA
B
315
−70.200
37.440
−15.627
1.00
53.40
C


ATOM
1047
O
ALA
B
315
−69.737
38.460
−15.106
1.00
53.51
O


ATOM
1048
N
GLY
B
316
−70.496
36.326
−14.944
1.00
50.96
N


ATOM
1049
CA
GLY
B
316
−70.407
36.221
−13.500
1.00
51.09
C


ATOM
1050
C
GLY
B
316
−71.795
36.017
−12.933
1.00
51.70
C


ATOM
1051
O
GLY
B
316
−72.798
36.418
−13.540
1.00
51.47
O


ATOM
1052
N
ASN
B
317
−71.873
35.369
−11.775
1.00
53.82
N


ATOM
1053
CA
ASN
B
317
−73.149
35.071
−11.126
1.00
54.21
C


ATOM
1054
CB
ASN
B
317
−73.183
33.588
−10.795
1.00
53.67
C


ATOM
1055
CG
ASN
B
317
−72.945
32.681
−11.969
1.00
53.09
C


ATOM
1056
OD1
ASN
B
317
−73.258
32.996
−13.112
1.00
52.07
O


ATOM
1057
ND2
ASN
B
317
−72.392
31.521
−11.710
1.00
53.94
N


ATOM
1058
C
ASN
B
317
−73.322
35.916
−9.866
1.00
55.00
C


ATOM
1059
O
ASN
B
317
−73.792
35.435
−8.843
1.00
55.03
O


ATOM
1060
N
PHE
B
318
−72.957
37.174
−9.939
1.00
57.87
N


ATOM
1061
CA
PHE
B
318
−73.018
38.000
−8.759
1.00
59.18
C


ATOM
1062
CB
PHE
B
318
−71.639
38.625
−8.558
1.00
59.07
C


ATOM
1063
CG
PHE
B
318
−70.543
37.591
−8.502
1.00
60.43
C


ATOM
1064
CD1
PHE
B
318
−70.408
36.753
−7.397
1.00
60.99
C


ATOM
1065
CE1
PHE
B
318
−69.408
35.784
−7.353
1.00
61.38
C


ATOM
1066
CZ
PHE
B
318
−68.543
35.638
−8.418
1.00
62.04
C


ATOM
1067
CE2
PHE
B
318
−68.652
36.469
−9.513
1.00
61.99
C


ATOM
1068
CD2
PHE
B
318
−69.664
37.433
−9.562
1.00
61.64
C


ATOM
1069
C
PHE
B
318
−74.093
39.053
−8.750
1.00
59.93
C


ATOM
1070
O
PHE
B
318
−74.101
39.886
−7.840
1.00
60.27
O


ATOM
1071
N
ARG
B
319
−75.009
39.028
−9.748
1.00
62.41
N


ATOM
1072
CA
ARG
B
319
−76.081
40.020
−9.913
1.00
63.19
C


ATOM
1073
CB
ARG
B
319
−77.305
39.725
−9.016
1.00
63.23
C


ATOM
1074
CG
ARG
B
319
−78.540
40.496
−9.473
1.00
64.48
C


ATOM
1075
CD
ARG
B
319
−79.855
39.992
−8.921
1.00
67.70
C


ATOM
1076
NE
ARG
B
319
−80.960
40.830
−9.410
1.00
71.37
N


ATOM
1077
CZ
ARG
B
319
−82.248
40.501
−9.322
1.00
72.76
C


ATOM
1078
NH1
ARG
B
319
−82.612
39.345
−8.777
1.00
73.52
N


ATOM
1079
NH2
ARG
B
319
−83.183
41.314
−9.813
1.00
72.41
N


ATOM
1080
C
ARG
B
319
−75.479
41.435
−9.704
1.00
63.42
C


ATOM
1081
O
ARG
B
319
−76.033
42.268
−8.989
1.00
63.73
O


ATOM
1082
N
ASP
B
320
−74.312
41.662
−10.320
1.00
60.42
N


ATOM
1083
CA
ASP
B
320
−73.530
42.873
−10.230
1.00
60.55
C


ATOM
1084
CB
ASP
B
320
−72.304
42.552
−9.364
1.00
60.60
C


ATOM
1085
CG
ASP
B
320
−71.544
43.741
−8.807
1.00
61.89
C


ATOM
1086
OD1
ASP
B
320
−72.018
44.900
−8.997
1.00
63.22
O


ATOM
1087
OD2
ASP
B
320
−70.464
43.523
−8.172
1.00
63.66
O


ATOM
1088
C
ASP
B
320
−73.091
43.307
−11.623
1.00
60.89
C


ATOM
1089
O
ASP
B
320
−73.323
42.608
−12.596
1.00
60.80
O


ATOM
1090
N
ASP
B
321
−72.457
44.456
−11.723
1.00
62.47
N


ATOM
1091
CA
ASP
B
321
−71.955
44.980
−12.973
1.00
63.25
C


ATOM
1092
CB
ASP
B
321
−71.748
46.490
−12.827
1.00
63.52
C


ATOM
1093
CG
ASP
B
321
−70.868
47.151
−13.863
1.00
66.23
C


ATOM
1094
OD1
ASP
B
321
−70.991
46.787
−15.099
1.00
68.25
O


ATOM
1095
OD2
ASP
B
321
−70.047
48.029
−13.466
1.00
69.51
O


ATOM
1096
C
ASP
B
321
−70.664
44.203
−13.367
1.00
63.26
C


ATOM
1097
O
ASP
B
321
−69.640
44.266
−12.668
1.00
63.00
O


ATOM
1098
N
ALA
B
322
−70.742
43.466
−14.505
1.00
63.34
N


ATOM
1099
CA
ALA
B
322
−69.678
42.617
−15.058
1.00
63.47
C


ATOM
1100
CB
ALA
B
322
−70.135
41.973
−16.351
1.00
63.32
C


ATOM
1101
C
ALA
B
322
−68.329
43.277
−15.249
1.00
63.71
C


ATOM
1102
O
ALA
B
322
−67.333
42.599
−15.461
1.00
63.80
O


ATOM
1103
N
CYS
B
323
−68.293
44.587
−15.157
1.00
65.81
N


ATOM
1104
CA
CYS
B
323
−67.083
45.376
−15.328
1.00
66.30
C


ATOM
1105
CB
CYS
B
323
−67.449
46.810
−15.689
1.00
66.41
C


ATOM
1106
SG
CYS
B
323
−68.421
46.951
−17.215
1.00
71.16
S


ATOM
1107
C
CYS
B
323
−66.222
45.326
−14.114
1.00
65.76
C


ATOM
1108
O
CYS
B
323
−65.083
45.788
−14.154
1.00
66.03
O


ATOM
1109
N
LEU
B
324
−66.755
44.785
−13.022
1.00
60.42
N


ATOM
1110
CA
LEU
B
324
−66.002
44.698
−11.774
1.00
60.17
C


ATOM
1111
CB
LEU
B
324
−66.902
44.989
−10.549
1.00
59.89
C


ATOM
1112
CG
LEU
B
324
−67.731
46.250
−10.542
1.00
57.86
C


ATOM
1113
CD1
LEU
B
324
−68.629
46.254
−9.347
1.00
56.82
C


ATOM
1114
CD2
LEU
B
324
−66.874
47.477
−10.635
1.00
54.79
C


ATOM
1115
C
LEU
B
324
−65.353
43.332
−11.636
1.00
60.54
C


ATOM
1116
O
LEU
B
324
−64.750
43.051
−10.593
1.00
60.71
O


ATOM
1117
N
TYR
B
325
−65.481
42.497
−12.694
1.00
60.77
N


ATOM
1118
CA
TYR
B
325
−64.988
41.133
−12.770
1.00
61.44
C


ATOM
1119
CB
TYR
B
325
−66.184
40.173
−12.748
1.00
61.31
C


ATOM
1120
CG
TYR
B
325
−67.056
40.381
−11.534
1.00
61.96
C


ATOM
1121
CD1
TYR
B
325
−66.831
39.667
−10.359
1.00
62.39
C


ATOM
1122
CE1
TYR
B
325
−67.591
39.901
−9.216
1.00
63.69
C


ATOM
1123
CZ
TYR
B
325
−68.614
40.841
−9.250
1.00
64.04
C


ATOM
1124
OH
TYR
B
325
−69.381
41.077
−8.135
1.00
65.21
O


ATOM
1125
CE2
TYR
B
325
−68.855
41.563
−10.408
1.00
63.14
C


ATOM
1126
CD2
TYR
B
325
−68.082
41.324
−11.542
1.00
62.84
C


ATOM
1127
C
TYR
B
325
−64.132
40.863
−13.994
1.00
62.04
C


ATOM
1128
O
TYR
B
325
−64.366
41.428
−15.044
1.00
61.85
O


ATOM
1129
N
SER
B
326
−63.156
39.989
−13.873
1.00
62.89
N


ATOM
1130
CA
SER
B
326
−62.288
39.610
−14.988
1.00
63.61
C


ATOM
1131
CB
SER
B
326
−60.863
40.095
−14.774
1.00
63.85
C


ATOM
1132
OG
SER
B
326
−60.802
41.499
−14.935
1.00
64.07
O


ATOM
1133
C
SER
B
326
−62.317
38.100
−15.085
1.00
63.80
C


ATOM
1134
O
SER
B
326
−62.452
37.444
−14.051
1.00
64.86
O


ATOM
1135
N
PRO
B
327
−62.235
37.505
−16.286
1.00
65.20
N


ATOM
1136
CA
PRO
B
327
−62.054
38.141
−17.592
1.00
64.67
C


ATOM
1137
CB
PRO
B
327
−61.389
37.029
−18.418
1.00
64.01
C


ATOM
1138
CG
PRO
B
327
−61.990
35.765
−17.876
1.00
65.29
C


ATOM
1139
CD
PRO
B
327
−62.281
36.032
−16.410
1.00
64.99
C


ATOM
1140
C
PRO
B
327
−63.287
38.808
−18.223
1.00
64.37
C


ATOM
1141
O
PRO
B
327
−63.144
39.327
−19.323
1.00
64.00
O


ATOM
1142
N
ALA
B
328
−64.462
38.849
−17.542
1.00
62.54
N


ATOM
1143
CA
ALA
B
328
−65.677
39.500
−18.072
1.00
62.61
C


ATOM
1144
CB
ALA
B
328
−66.788
39.500
−17.029
1.00
62.46
C


ATOM
1145
C
ALA
B
328
−65.443
40.936
−18.573
1.00
62.77
C


ATOM
1146
O
ALA
B
328
−65.986
41.317
−19.615
1.00
62.83
O


ATOM
1147
N
SER
B
329
−64.635
41.719
−17.839
1.00
62.16
N


ATOM
1148
CA
SER
B
329
−64.330
43.111
−18.152
1.00
62.02
C


ATOM
1149
CB
SER
B
329
−63.787
43.835
−16.930
1.00
61.96
C


ATOM
1150
OG
SER
B
329
−62.597
43.229
−16.448
1.00
61.98
O


ATOM
1151
C
SER
B
329
−63.422
43.347
−19.347
1.00
62.28
C


ATOM
1152
O
SER
B
329
−63.419
44.473
−19.854
1.00
62.32
O


ATOM
1153
N
ALA
B
330
−62.636
42.327
−19.796
1.00
65.17
N


ATOM
1154
CA
ALA
B
330
−61.765
42.458
−20.969
1.00
65.63
C


ATOM
1155
CB
ALA
B
330
−60.979
41.177
−21.200
1.00
65.46
C


ATOM
1156
C
ALA
B
330
−62.722
42.749
−22.153
1.00
66.41
C


ATOM
1157
O
ALA
B
330
−63.680
41.992
−22.382
1.00
66.58
O


ATOM
1158
N
PRO
B
331
−62.585
43.907
−22.844
1.00
73.00
N


ATOM
1159
CA
PRO
B
331
−63.554
44.219
−23.923
1.00
73.50
C


ATOM
1160
CB
PRO
B
331
−63.334
45.714
−24.166
1.00
73.46
C


ATOM
1161
CG
PRO
B
331
−61.916
45.944
−23.767
1.00
72.99
C


ATOM
1162
CD
PRO
B
331
−61.573
44.978
−22.687
1.00
72.92
C


ATOM
1163
C
PRO
B
331
−63.366
43.369
−25.188
1.00
73.88
C


ATOM
1164
O
PRO
B
331
−64.265
43.259
−26.028
1.00
74.31
O


ATOM
1165
N
GLU
B
332
−62.191
42.757
−25.294
1.00
77.27
N


ATOM
1166
CA
GLU
B
332
−61.781
41.912
−26.398
1.00
77.53
C


ATOM
1167
CB
GLU
B
332
−60.258
41.718
−26.367
1.00
78.10
C


ATOM
1168
CG
GLU
B
332
−59.474
43.022
−26.258
1.00
81.67
C


ATOM
1169
CD
GLU
B
332
−59.396
43.680
−24.879
1.00
86.35
C


ATOM
1170
OE1
GLU
B
332
−59.799
43.043
−23.874
1.00
86.76
O


ATOM
1171
OE2
GLU
B
332
−58.924
44.841
−24.807
1.00
88.63
O


ATOM
1172
C
GLU
B
332
−62.503
40.562
−26.373
1.00
76.52
C


ATOM
1173
O
GLU
B
332
−62.771
39.986
−27.436
1.00
77.06
O


ATOM
1174
N
VAL
B
333
−62.818
40.060
−25.164
1.00
70.74
N


ATOM
1175
CA
VAL
B
333
−63.481
38.769
−24.964
1.00
68.74
C


ATOM
1176
CB
VAL
B
333
−63.067
38.120
−23.622
1.00
68.83
C


ATOM
1177
CG1
VAL
B
333
−61.556
38.105
−23.460
1.00
68.45
C


ATOM
1178
CG2
VAL
B
333
−63.708
38.838
−22.453
1.00
68.60
C


ATOM
1179
C
VAL
B
333
−64.993
38.873
−25.115
1.00
67.53
C


ATOM
1180
O
VAL
B
333
−65.553
39.955
−24.914
1.00
67.70
O


ATOM
1181
N
ILE
B
334
−65.654
37.763
−25.476
1.00
62.01
N


ATOM
1182
CA
ILE
B
334
−67.101
37.785
−25.621
1.00
60.41
C


ATOM
1183
CB
ILE
B
334
−67.598
36.945
−26.826
1.00
60.26
C


ATOM
1184
CG1
ILE
B
334
−67.270
37.654
−28.123
1.00
60.39
C


ATOM
1185
CD1
ILE
B
334
−66.925
36.721
−29.207
1.00
62.55
C


ATOM
1186
CG2
ILE
B
334
−69.098
36.676
−26.764
1.00
59.89
C


ATOM
1187
C
ILE
B
334
−67.676
37.401
−24.267
1.00
59.53
C


ATOM
1188
O
ILE
B
334
−67.498
36.266
−23.833
1.00
59.35
O


ATOM
1189
N
THR
B
335
−68.313
38.373
−23.578
1.00
57.48
N


ATOM
1190
CA
THR
B
335
−68.887
38.225
−22.242
1.00
56.89
C


ATOM
1191
CB
THR
B
335
−68.621
39.466
−21.384
1.00
56.86
C


ATOM
1192
OG1
THR
B
335
−67.231
39.840
−21.464
1.00
57.03
O


ATOM
1193
CG2
THR
B
335
−69.005
39.267
−19.945
1.00
56.65
C


ATOM
1194
C
THR
B
335
−70.320
37.833
−22.344
1.00
56.75
C


ATOM
1195
O
THR
B
335
−71.130
38.558
−22.901
1.00
56.71
O


ATOM
1196
N
VAL
B
336
−70.640
36.665
−21.808
1.00
55.91
N


ATOM
1197
CA
VAL
B
336
−71.988
36.106
−21.868
1.00
55.24
C


ATOM
1198
CB
VAL
B
336
−71.927
34.722
−22.551
1.00
55.29
C


ATOM
1199
CG1
VAL
B
336
−73.309
34.265
−22.994
1.00
55.31
C


ATOM
1200
CG2
VAL
B
336
−70.941
34.717
−23.721
1.00
55.00
C


ATOM
1201
C
VAL
B
336
−72.746
36.041
−20.532
1.00
55.10
C


ATOM
1202
O
VAL
B
336
−72.345
35.348
−19.588
1.00
54.55
O


ATOM
1203
N
GLY
B
337
−73.860
36.744
−20.491
1.00
54.20
N


ATOM
1204
CA
GLY
B
337
−74.765
36.737
−19.350
1.00
54.32
C


ATOM
1205
C
GLY
B
337
−75.665
35.524
−19.514
1.00
54.86
C


ATOM
1206
O
GLY
B
337
−75.630
34.863
−20.568
1.00
54.77
O


ATOM
1207
N
ALA
B
338
−76.478
35.199
−18.499
1.00
55.32
N


ATOM
1208
CA
ALA
B
338
−77.341
34.029
−18.609
1.00
55.65
C


ATOM
1209
CB
ALA
B
338
−76.927
32.989
−17.593
1.00
55.37
C


ATOM
1210
C
ALA
B
338
−78.802
34.362
−18.439
1.00
56.20
C


ATOM
1211
O
ALA
B
338
−79.153
35.135
−17.537
1.00
56.29
O


ATOM
1212
N
THR
B
339
−79.660
33.766
−19.304
1.00
57.13
N


ATOM
1213
CA
THR
B
339
−81.121
33.916
−19.264
1.00
57.44
C


ATOM
1214
CB
THR
B
339
−81.695
34.682
−20.460
1.00
57.24
C


ATOM
1215
OG1
THR
B
339
−81.399
33.995
−21.678
1.00
56.49
O


ATOM
1216
CG2
THR
B
339
−81.275
36.110
−20.491
1.00
57.07
C


ATOM
1217
C
THR
B
339
−81.804
32.556
−19.161
1.00
58.11
C


ATOM
1218
O
THR
B
339
−81.255
31.538
−19.589
1.00
58.12
O


ATOM
1219
N
ASN
B
340
−83.013
32.544
−18.609
1.00
61.87
N


ATOM
1220
CA
ASN
B
340
−83.762
31.311
−18.486
1.00
62.65
C


ATOM
1221
CB
ASN
B
340
−84.601
31.300
−17.235
1.00
62.41
C


ATOM
1222
CG
ASN
B
340
−85.516
32.464
−17.167
1.00
62.27
C


ATOM
1223
OD1
ASN
B
340
−86.269
32.767
−18.103
1.00
60.60
O


ATOM
1224
ND2
ASN
B
340
−85.447
33.145
−16.043
1.00
62.99
N


ATOM
1225
C
ASN
B
340
−84.609
31.019
−19.714
1.00
63.43
C


ATOM
1226
O
ASN
B
340
−84.453
31.674
−20.758
1.00
63.12
O


ATOM
1227
N
ALA
B
341
−85.494
29.995
−19.584
1.00
66.06
N


ATOM
1228
CA
ALA
B
341
−86.365
29.522
−20.647
1.00
67.26
C


ATOM
1229
CB
ALA
B
341
−87.083
28.264
−20.224
1.00
66.99
C


ATOM
1230
C
ALA
B
341
−87.329
30.561
−21.175
1.00
68.26
C


ATOM
1231
O
ALA
B
341
−87.692
30.499
−22.356
1.00
68.61
O


ATOM
1232
N
GLN
B
342
−87.703
31.537
−20.315
1.00
69.30
N


ATOM
1233
CA
GLN
B
342
−88.617
32.635
−20.628
1.00
70.34
C


ATOM
1234
CB
GLN
B
342
−89.531
32.965
−19.440
1.00
70.57
C


ATOM
1235
CG
GLN
B
342
−90.370
31.805
−18.937
1.00
72.94
C


ATOM
1236
CD
GLN
B
342
−89.597
30.971
−17.945
1.00
76.85
C


ATOM
1237
OE1
GLN
B
342
−89.030
31.481
−16.957
1.00
77.98
O


ATOM
1238
NE2
GLN
B
342
−89.547
29.660
−18.195
1.00
77.87
N


ATOM
1239
C
GLN
B
342
−87.824
33.860
−21.006
1.00
70.57
C


ATOM
1240
O
GLN
B
342
−88.361
34.961
−20.998
1.00
70.82
O


ATOM
1241
N
ASP
B
343
−86.543
33.673
−21.330
1.00
71.09
N


ATOM
1242
CA
ASP
B
343
−85.611
34.727
−21.727
1.00
71.24
C


ATOM
1243
CB
ASP
B
343
−85.893
35.218
−23.147
1.00
71.51
C


ATOM
1244
CG
ASP
B
343
−85.819
34.036
−24.078
1.00
74.17
C


ATOM
1245
OD1
ASP
B
343
−84.666
33.581
−24.392
1.00
76.97
O


ATOM
1246
OD2
ASP
B
343
−86.896
33.516
−24.459
1.00
78.55
O


ATOM
1247
C
ASP
B
343
−85.408
35.815
−20.705
1.00
70.72
C


ATOM
1248
O
ASP
B
343
−85.076
36.951
−21.036
1.00
70.59
O


ATOM
1249
N
GLN
B
344
−85.570
35.442
−19.442
1.00
67.52
N


ATOM
1250
CA
GLN
B
344
−85.422
36.350
−18.324
1.00
67.56
C


ATOM
1251
CB
GLN
B
344
−86.637
36.247
−17.404
1.00
67.61
C


ATOM
1252
CG
GLN
B
344
−87.911
36.741
−18.088
1.00
68.31
C


ATOM
1253
CD
GLN
B
344
−87.688
38.051
−18.840
1.00
70.11
C


ATOM
1254
OE1
GLN
B
344
−87.908
38.154
−20.067
1.00
68.92
O


ATOM
1255
NE2
GLN
B
344
−87.223
39.082
−18.113
1.00
71.30
N


ATOM
1256
C
GLN
B
344
−84.085
36.159
−17.625
1.00
67.41
C


ATOM
1257
O
GLN
B
344
−83.588
35.027
−17.597
1.00
67.29
O


ATOM
1258
N
PRO
B
345
−83.429
37.242
−17.131
1.00
66.24
N


ATOM
1259
CA
PRO
B
345
−82.117
37.052
−16.496
1.00
66.31
C


ATOM
1260
CB
PRO
B
345
−81.731
38.445
−16.016
1.00
66.17
C


ATOM
1261
CG
PRO
B
345
−82.587
39.369
−16.736
1.00
66.05
C


ATOM
1262
CD
PRO
B
345
−83.849
38.653
−17.080
1.00
66.08
C


ATOM
1263
C
PRO
B
345
−82.240
36.042
−15.371
1.00
66.57
C


ATOM
1264
O
PRO
B
345
−83.214
36.098
−14.591
1.00
66.73
O


ATOM
1265
N
VAL
B
346
−81.297
35.076
−15.336
1.00
67.36
N


ATOM
1266
CA
VAL
B
346
−81.278
33.987
−14.364
1.00
67.43
C


ATOM
1267
CB
VAL
B
346
−80.250
32.896
−14.756
1.00
67.44
C


ATOM
1268
CG1
VAL
B
346
−80.161
31.789
−13.712
1.00
67.51
C


ATOM
1269
CG2
VAL
B
346
−80.601
32.291
−16.095
1.00
67.50
C


ATOM
1270
C
VAL
B
346
−81.105
34.456
−12.936
1.00
67.73
C


ATOM
1271
O
VAL
B
346
−80.188
35.216
−12.646
1.00
67.53
O


ATOM
1272
N
THR
B
347
−81.994
33.994
−12.041
1.00
73.64
N


ATOM
1273
CA
THR
B
347
−81.890
34.274
−10.610
1.00
74.69
C


ATOM
1274
CB
THR
B
347
−83.182
34.813
−10.024
1.00
74.30
C


ATOM
1275
OG1
THR
B
347
−83.446
36.056
−10.662
1.00
74.34
O


ATOM
1276
CG2
THR
B
347
−83.080
35.038
−8.534
1.00
74.12
C


ATOM
1277
C
THR
B
347
−81.330
32.997
−9.955
1.00
75.60
C


ATOM
1278
O
THR
B
347
−81.999
31.954
−9.960
1.00
76.22
O


ATOM
1279
N
LEU
B
348
−80.064
33.083
−9.471
1.00
80.17
N


ATOM
1280
CA
LEU
B
348
−79.281
32.008
−8.826
1.00
80.74
C


ATOM
1281
CB
LEU
B
348
−77.863
31.912
−9.460
1.00
80.52
C


ATOM
1282
CG
LEU
B
348
−77.772
31.673
−10.954
1.00
80.04
C


ATOM
1283
CD1
LEU
B
348
−76.563
32.385
−11.548
1.00
78.71
C


ATOM
1284
CD2
LEU
B
348
−77.802
30.199
−11.271
1.00
80.04
C


ATOM
1285
C
LEU
B
348
−79.159
32.383
−7.349
1.00
81.10
C


ATOM
1286
O
LEU
B
348
−78.241
33.132
−6.972
1.00
81.74
O


ATOM
1287
N
GLY
B
349
−80.108
31.914
−6.545
1.00
80.68
N


ATOM
1288
CA
GLY
B
349
−80.145
32.243
−5.127
1.00
80.71
C


ATOM
1289
C
GLY
B
349
−80.483
33.700
−4.864
1.00
80.56
C


ATOM
1290
O
GLY
B
349
−81.431
34.254
−5.447
1.00
80.70
O


ATOM
1291
N
THR
B
350
−79.697
34.337
−3.978
1.00
80.62
N


ATOM
1292
CA
THR
B
350
−79.888
35.763
−3.619
1.00
80.69
C


ATOM
1293
CB
THR
B
350
−79.344
36.046
−2.201
1.00
80.96
C


ATOM
1294
OG1
THR
B
350
−77.978
35.604
−2.099
1.00
82.21
O


ATOM
1295
CG2
THR
B
350
−80.205
35.381
−1.117
1.00
81.74
C


ATOM
1296
C
THR
B
350
−79.277
36.677
−4.689
1.00
79.69
C


ATOM
1297
O
THR
B
350
−79.548
37.877
−4.748
1.00
79.91
O


ATOM
1298
N
LEU
B
351
−78.453
36.061
−5.531
1.00
74.98
N


ATOM
1299
CA
LEU
B
351
−77.746
36.657
−6.628
1.00
73.84
C


ATOM
1300
CB
LEU
B
351
−76.284
36.235
−6.512
1.00
74.24
C


ATOM
1301
CG
LEU
B
351
−75.557
36.676
−5.255
1.00
74.58
C


ATOM
1302
CD1
LEU
B
351
−74.238
36.009
−5.168
1.00
75.49
C


ATOM
1303
CD2
LEU
B
351
−75.356
38.179
−5.229
1.00
75.38
C


ATOM
1304
C
LEU
B
351
−78.381
36.247
−7.983
1.00
72.90
C


ATOM
1305
O
LEU
B
351
−79.607
36.113
−8.083
1.00
73.12
O


ATOM
1306
N
GLY
B
352
−77.553
36.090
−9.004
1.00
68.29
N


ATOM
1307
CA
GLY
B
352
−77.976
35.757
−10.354
1.00
66.37
C


ATOM
1308
C
GLY
B
352
−77.007
36.329
−11.365
1.00
65.12
C


ATOM
1309
O
GLY
B
352
−75.901
36.746
−10.992
1.00
64.78
O


ATOM
1310
N
THR
B
353
−77.407
36.367
−12.648
1.00
62.17
N


ATOM
1311
CA
THR
B
353
−76.532
36.867
−13.713
1.00
61.44
C


ATOM
1312
CB
THR
B
353
−77.124
36.662
−15.111
1.00
61.66
C


ATOM
1313
OG1
THR
B
353
−76.054
36.868
−16.040
1.00
61.54
O


ATOM
1314
CG2
THR
B
353
−78.303
37.631
−15.429
1.00
61.65
C


ATOM
1315
C
THR
B
353
−76.077
38.298
−13.587
1.00
61.03
C


ATOM
1316
O
THR
B
353
−76.855
39.160
−13.168
1.00
60.67
O


ATOM
1317
N
ASN
B
354
−74.824
38.558
−14.015
1.00
58.04
N


ATOM
1318
CA
ASN
B
354
−74.276
39.903
−14.038
1.00
57.12
C


ATOM
1319
CB
ASN
B
354
−72.749
39.874
−14.104
1.00
57.05
C


ATOM
1320
CG
ASN
B
354
−72.064
39.672
−12.776
1.00
56.66
C


ATOM
1321
OD1
ASN
B
354
−72.706
39.594
−11.736
1.00
57.85
O


ATOM
1322
ND2
ASN
B
354
−70.743
39.579
−12.765
1.00
55.21
N


ATOM
1323
C
ASN
B
354
−74.893
40.594
−15.265
1.00
57.09
C


ATOM
1324
O
ASN
B
354
−75.561
39.948
−16.068
1.00
56.51
O


ATOM
1325
N
PHE
B
355
−74.684
41.902
−15.396
1.00
58.97
N


ATOM
1326
CA
PHE
B
355
−75.226
42.761
−16.455
1.00
58.97
C


ATOM
1327
CB
PHE
B
355
−76.600
43.333
−15.984
1.00
58.89
C


ATOM
1328
CG
PHE
B
355
−76.642
43.671
−14.500
1.00
58.25
C


ATOM
1329
CD1
PHE
B
355
−77.335
42.862
−13.605
1.00
56.71
C


ATOM
1330
CE1
PHE
B
355
−77.323
43.140
−12.238
1.00
56.45
C


ATOM
1331
CZ
PHE
B
355
−76.618
44.223
−11.758
1.00
56.46
C


ATOM
1332
CE2
PHE
B
355
−75.933
45.039
−12.626
1.00
57.61
C


ATOM
1333
CD2
PHE
B
355
−75.922
44.753
−13.991
1.00
57.66
C


ATOM
1334
C
PHE
B
355
−74.251
43.911
−16.701
1.00
59.20
C


ATOM
1335
O
PHE
B
355
−73.104
43.883
−16.238
1.00
59.27
O


ATOM
1336
N
GLY
B
356
−74.725
44.932
−17.385
1.00
60.17
N


ATOM
1337
CA
GLY
B
356
−73.904
46.095
−17.649
1.00
60.92
C


ATOM
1338
C
GLY
B
356
−73.343
46.069
−19.034
1.00
61.66
C


ATOM
1339
O
GLY
B
356
−73.620
45.134
−19.790
1.00
61.68
O


ATOM
1340
N
ARG
B
357
−72.579
47.127
−19.367
1.00
64.73
N


ATOM
1341
CA
ARG
B
357
−71.935
47.380
−20.662
1.00
65.38
C


ATOM
1342
CB
ARG
B
357
−71.306
48.777
−20.705
1.00
65.63
C


ATOM
1343
CG
ARG
B
357
−70.518
49.113
−19.467
1.00
66.74
C


ATOM
1344
CD
ARG
B
357
−69.864
50.459
−19.552
1.00
68.76
C


ATOM
1345
NE
ARG
B
357
−68.612
50.445
−18.800
1.00
69.87
N


ATOM
1346
CZ
ARG
B
357
−67.437
50.189
−19.354
1.00
70.36
C


ATOM
1347
NH1
ARG
B
357
−67.346
49.960
−20.662
1.00
70.41
N


ATOM
1348
NH2
ARG
B
357
−66.340
50.161
−18.608
1.00
71.53
N


ATOM
1349
C
ARG
B
357
−70.919
46.329
−21.055
1.00
65.47
C


ATOM
1350
O
ARG
B
357
−70.777
46.056
−22.249
1.00
65.45
O


ATOM
1351
N
CYS
B
358
−70.244
45.716
−20.067
1.00
67.67
N


ATOM
1352
CA
CYS
B
358
−69.251
44.680
−20.337
1.00
68.19
C


ATOM
1353
CB
CYS
B
358
−68.303
44.504
−19.162
1.00
68.27
C


ATOM
1354
SG
CYS
B
358
−67.381
46.018
−18.746
1.00
70.93
S


ATOM
1355
C
CYS
B
358
−69.827
43.353
−20.848
1.00
68.00
C


ATOM
1356
O
CYS
B
358
−69.128
42.613
−21.543
1.00
68.04
O


ATOM
1357
N
VAL
B
359
−71.118
43.091
−20.558
1.00
67.04
N


ATOM
1358
CA
VAL
B
359
−71.850
41.916
−21.035
1.00
66.98
C


ATOM
1359
CB
VAL
B
359
−73.146
41.644
−20.231
1.00
66.79
C


ATOM
1360
CG1
VAL
B
359
−73.978
40.544
−20.865
1.00
66.32
C


ATOM
1361
CG2
VAL
B
359
−72.828
41.290
−18.800
1.00
66.58
C


ATOM
1362
C
VAL
B
359
−72.156
42.215
−22.506
1.00
67.34
C


ATOM
1363
O
VAL
B
359
−72.738
43.273
−22.817
1.00
68.24
O


ATOM
1364
N
ASP
B
360
−71.728
41.309
−23.407
1.00
67.45
N


ATOM
1365
CA
ASP
B
360
−71.927
41.451
−24.838
1.00
67.13
C


ATOM
1366
CB
ASP
B
360
−70.766
40.803
−25.610
1.00
67.44
C


ATOM
1367
CG
ASP
B
360
−69.434
41.534
−25.368
1.00
70.71
C


ATOM
1368
OD1
ASP
B
360
−69.374
42.758
−25.618
1.00
74.94
O


ATOM
1369
OD2
ASP
B
360
−68.444
40.878
−24.919
1.00
73.47
O


ATOM
1370
C
ASP
B
360
−73.303
40.935
−25.240
1.00
66.55
C


ATOM
1371
O
ASP
B
360
−73.968
41.539
−26.091
1.00
66.82
O


ATOM
1372
N
LEU
B
361
−73.754
39.849
−24.602
1.00
62.14
N


ATOM
1373
CA
LEU
B
361
−75.047
39.220
−24.876
1.00
61.50
C


ATOM
1374
CB
LEU
B
361
−75.059
38.557
−26.280
1.00
61.27
C


ATOM
1375
CG
LEU
B
361
−74.367
37.179
−26.492
1.00
61.28
C


ATOM
1376
CD1
LEU
B
361
−74.698
36.631
−27.854
1.00
60.90
C


ATOM
1377
CD2
LEU
B
361
−72.831
37.244
−26.309
1.00
60.87
C


ATOM
1378
C
LEU
B
361
−75.373
38.192
−23.815
1.00
61.29
C


ATOM
1379
O
LEU
B
361
−74.502
37.803
−23.045
1.00
61.49
O


ATOM
1380
N
PHE
B
362
−76.611
37.747
−23.789
1.00
61.00
N


ATOM
1381
CA
PHE
B
362
−77.075
36.747
−22.863
1.00
61.06
C


ATOM
1382
CB
PHE
B
362
−78.384
37.205
−22.234
1.00
60.86
C


ATOM
1383
CG
PHE
B
362
−78.173
38.342
−21.274
1.00
60.86
C


ATOM
1384
CD1
PHE
B
362
−78.162
38.120
−19.906
1.00
59.91
C


ATOM
1385
CE1
PHE
B
362
−77.950
39.175
−19.018
1.00
58.68
C


ATOM
1386
CZ
PHE
B
362
−77.733
40.449
−19.495
1.00
58.51
C


ATOM
1387
CE2
PHE
B
362
−77.725
40.689
−20.847
1.00
59.36
C


ATOM
1388
CD2
PHE
B
362
−77.951
39.637
−21.737
1.00
61.08
C


ATOM
1389
C
PHE
B
362
−77.261
35.479
−23.667
1.00
61.49
C


ATOM
1390
O
PHE
B
362
−77.217
35.536
−24.895
1.00
61.81
O


ATOM
1391
N
ALA
B
363
−77.445
34.343
−23.003
1.00
62.20
N


ATOM
1392
CA
ALA
B
363
−77.624
33.047
−23.648
1.00
62.13
C


ATOM
1393
CB
ALA
B
363
−76.264
32.485
−24.055
1.00
62.04
C


ATOM
1394
C
ALA
B
363
−78.261
32.122
−22.617
1.00
62.26
C


ATOM
1395
O
ALA
B
363
−78.217
32.436
−21.416
1.00
62.48
O


ATOM
1396
N
PRO
B
364
−78.824
30.971
−23.028
1.00
60.56
N


ATOM
1397
CA
PRO
B
364
−79.418
30.053
−22.046
1.00
60.70
C


ATOM
1398
CB
PRO
B
364
−79.785
28.853
−22.896
1.00
60.33
C


ATOM
1399
CG
PRO
B
364
−79.975
29.394
−24.223
1.00
59.88
C


ATOM
1400
CD
PRO
B
364
−78.984
30.455
−24.396
1.00
60.34
C


ATOM
1401
C
PRO
B
364
−78.468
29.647
−20.917
1.00
61.27
C


ATOM
1402
O
PRO
B
364
−77.380
29.150
−21.194
1.00
61.78
O


ATOM
1403
N
GLY
B
365
−78.885
29.866
−19.666
1.00
63.45
N


ATOM
1404
CA
GLY
B
365
−78.091
29.540
−18.481
1.00
63.91
C


ATOM
1405
C
GLY
B
365
−78.856
29.033
−17.268
1.00
64.44
C


ATOM
1406
O
GLY
B
365
−78.378
29.171
−16.142
1.00
64.33
O


ATOM
1407
N
GLU
B
366
−80.033
28.444
−17.474
1.00
66.98
N


ATOM
1408
CA
GLU
B
366
−80.819
27.923
−16.367
1.00
68.00
C


ATOM
1409
CB
GLU
B
366
−81.943
28.894
−15.962
1.00
68.37
C


ATOM
1410
CG
GLU
B
366
−82.522
28.588
−14.592
1.00
71.56
C


ATOM
1411
CD
GLU
B
366
−83.672
29.463
−14.135
1.00
76.80
C


ATOM
1412
OE1
GLU
B
366
−83.399
30.568
−13.599
1.00
79.89
O


ATOM
1413
OE2
GLU
B
366
−84.845
29.045
−14.306
1.00
78.54
O


ATOM
1414
C
GLU
B
366
−81.388
26.570
−16.715
1.00
67.88
C


ATOM
1415
O
GLU
B
366
−81.985
26.415
−17.777
1.00
67.93
O


ATOM
1416
N
ASP
B
367
−81.234
25.598
−15.799
1.00
68.26
N


ATOM
1417
CA
ASP
B
367
−81.717
24.241
−15.963
1.00
68.38
C


ATOM
1418
CB
ASP
B
367
−83.232
24.160
−15.669
1.00
69.02
C


ATOM
1419
CG
ASP
B
367
−84.035
23.000
−16.269
1.00
72.86
C


ATOM
1420
OD1
ASP
B
367
−83.614
21.803
−16.083
1.00
77.07
O


ATOM
1421
OD2
ASP
B
367
−85.099
23.275
−16.919
1.00
76.42
O


ATOM
1422
C
ASP
B
367
−81.239
23.723
−17.325
1.00
67.72
C


ATOM
1423
O
ASP
B
367
−82.011
23.400
−18.220
1.00
67.13
O


ATOM
1424
N
ILE
B
368
−79.919
23.728
−17.483
1.00
64.65
N


ATOM
1425
CA
ILE
B
368
−79.262
23.289
−18.692
1.00
64.75
C


ATOM
1426
CB
ILE
B
368
−78.073
24.205
−19.070
1.00
64.52
C


ATOM
1427
CG1
ILE
B
368
−78.462
25.700
−19.157
1.00
64.19
C


ATOM
1428
CD1
ILE
B
368
−79.483
26.137
−20.261
1.00
63.84
C


ATOM
1429
CG2
ILE
B
368
−77.334
23.692
−20.320
1.00
63.95
C


ATOM
1430
C
ILE
B
368
−78.851
21.836
−18.541
1.00
65.40
C


ATOM
1431
O
ILE
B
368
−77.982
21.492
−17.728
1.00
65.45
O


ATOM
1432
N
ILE
B
369
−79.479
20.983
−19.342
1.00
68.85
N


ATOM
1433
CA
ILE
B
369
−79.184
19.564
−19.310
1.00
69.23
C


ATOM
1434
CB
ILE
B
369
−80.406
18.721
−19.759
1.00
69.28
C


ATOM
1435
CG1
ILE
B
369
−80.376
17.337
−19.141
1.00
70.78
C


ATOM
1436
CD1
ILE
B
369
−80.909
17.246
−17.682
1.00
73.48
C


ATOM
1437
CG2
ILE
B
369
−80.594
18.651
−21.256
1.00
69.21
C


ATOM
1438
C
ILE
B
369
−77.888
19.296
−20.049
1.00
69.27
C


ATOM
1439
O
ILE
B
369
−77.704
19.817
−21.152
1.00
69.70
O


ATOM
1440
N
GLY
B
370
−76.991
18.544
−19.414
1.00
67.64
N


ATOM
1441
CA
GLY
B
370
−75.678
18.200
−19.957
1.00
67.43
C


ATOM
1442
C
GLY
B
370
−74.966
17.113
−19.179
1.00
67.40
C


ATOM
1443
O
GLY
B
370
−75.383
16.770
−18.075
1.00
67.49
O


ATOM
1444
N
ALA
B
371
−73.878
16.575
−19.748
1.00
67.13
N


ATOM
1445
CA
ALA
B
371
−73.044
15.510
−19.191
1.00
66.88
C


ATOM
1446
CB
ALA
B
371
−71.784
15.340
−20.020
1.00
66.63
C


ATOM
1447
C
ALA
B
371
−72.685
15.559
−17.699
1.00
67.05
C


ATOM
1448
O
ALA
B
371
−71.899
16.414
−17.248
1.00
67.24
O


ATOM
1449
N
SER
B
372
−73.234
14.587
−16.935
1.00
69.52
N


ATOM
1450
CA
SER
B
372
−72.948
14.425
−15.507
1.00
69.69
C


ATOM
1451
CB
SER
B
372
−74.163
13.888
−14.773
1.00
69.34
C


ATOM
1452
OG
SER
B
372
−73.778
13.661
−13.432
1.00
68.66
O


ATOM
1453
C
SER
B
372
−71.789
13.435
−15.337
1.00
70.18
C


ATOM
1454
O
SER
B
372
−71.873
12.313
−15.834
1.00
70.36
O


ATOM
1455
N
SER
B
373
−70.712
13.842
−14.640
1.00
74.56
N


ATOM
1456
CA
SER
B
373
−69.540
12.991
−14.390
1.00
74.78
C


ATOM
1457
CB
SER
B
373
−68.397
13.804
−13.788
1.00
74.54
C


ATOM
1458
OG
SER
B
373
−68.850
14.486
−12.629
1.00
74.19
O


ATOM
1459
C
SER
B
373
−69.893
11.784
−13.489
1.00
75.14
C


ATOM
1460
O
SER
B
373
−69.060
10.880
−13.352
1.00
75.75
O


ATOM
1461
N
ASP
B
374
−71.121
11.761
−12.898
1.00
76.21
N


ATOM
1462
CA
ASP
B
374
−71.622
10.677
−12.050
1.00
76.51
C


ATOM
1463
CB
ASP
B
374
−73.078
10.926
−11.658
1.00
76.87
C


ATOM
1464
CG
ASP
B
374
−73.278
11.831
−10.456
1.00
77.21
C


ATOM
1465
OD1
ASP
B
374
−72.258
12.144
−9.768
1.00
77.96
O


ATOM
1466
OD2
ASP
B
374
−74.471
12.237
−10.193
1.00
76.93
O


ATOM
1467
C
ASP
B
374
−71.489
9.273
−12.686
1.00
76.86
C


ATOM
1468
O
ASP
B
374
−71.069
8.341
−11.998
1.00
77.61
O


ATOM
1469
N
CYS
B
375
−71.848
9.121
−13.977
1.00
73.83
N


ATOM
1470
CA
CYS
B
375
−71.746
7.884
−14.756
1.00
73.51
C


ATOM
1471
CB
CYS
B
375
−72.947
6.965
−14.529
1.00
73.63
C


ATOM
1472
SG
CYS
B
375
−74.337
7.199
−15.678
1.00
76.02
S


ATOM
1473
C
CYS
B
375
−71.561
8.290
−16.221
1.00
73.03
C


ATOM
1474
O
CYS
B
375
−71.981
9.388
−16.577
1.00
73.09
O


ATOM
1475
N
SER
B
376
−70.912
7.455
−17.064
1.00
68.20
N


ATOM
1476
CA
SER
B
376
−70.627
7.806
−18.467
1.00
67.70
C


ATOM
1477
CB
SER
B
376
−69.542
6.924
−19.071
1.00
67.82
C


ATOM
1478
OG
SER
B
376
−70.072
5.678
−19.480
1.00
68.81
O


ATOM
1479
C
SER
B
376
−71.787
8.094
−19.439
1.00
67.35
C


ATOM
1480
O
SER
B
376
−71.529
8.558
−20.554
1.00
66.71
O


ATOM
1481
N
THR
B
377
−73.055
7.869
−19.012
1.00
66.32
N


ATOM
1482
CA
THR
B
377
−74.239
8.165
−19.829
1.00
66.42
C


ATOM
1483
CB
THR
B
377
−74.876
6.901
−20.383
1.00
66.19
C


ATOM
1484
OG1
THR
B
377
−75.281
6.064
−19.314
1.00
65.85
O


ATOM
1485
CG2
THR
B
377
−73.982
6.162
−21.326
1.00
66.15
C


ATOM
1486
C
THR
B
377
−75.243
9.045
−19.074
1.00
66.82
C


ATOM
1487
O
THR
B
377
−76.346
9.295
−19.570
1.00
67.04
O


ATOM
1488
N
CYS
B
378
−74.857
9.523
−17.882
1.00
69.75
N


ATOM
1489
CA
CYS
B
378
−75.691
10.360
−17.010
1.00
70.60
C


ATOM
1490
CB
CYS
B
378
−75.242
10.253
−15.553
1.00
70.72
C


ATOM
1491
SG
CYS
B
378
−75.535
8.635
−14.779
1.00
76.79
S


ATOM
1492
C
CYS
B
378
−75.737
11.815
−17.436
1.00
69.95
C


ATOM
1493
O
CYS
B
378
−74.714
12.384
−17.826
1.00
69.93
O


ATOM
1494
N
PHE
B
379
−76.914
12.435
−17.273
1.00
68.10
N


ATOM
1495
CA
PHE
B
379
−77.121
13.845
−17.529
1.00
67.31
C


ATOM
1496
CB
PHE
B
379
−78.233
14.050
−18.545
1.00
67.28
C


ATOM
1497
CG
PHE
B
379
−77.766
13.764
−19.933
1.00
67.51
C


ATOM
1498
CD1
PHE
B
379
−77.097
14.732
−20.668
1.00
67.75
C


ATOM
1499
CE1
PHE
B
379
−76.638
14.459
−21.959
1.00
67.92
C


ATOM
1500
CZ
PHE
B
379
−76.858
13.219
−22.517
1.00
68.53
C


ATOM
1501
CE2
PHE
B
379
−77.516
12.243
−21.796
1.00
69.39
C


ATOM
1502
CD2
PHE
B
379
−77.972
12.519
−20.505
1.00
68.25
C


ATOM
1503
C
PHE
B
379
−77.485
14.553
−16.242
1.00
66.84
C


ATOM
1504
O
PHE
B
379
−78.048
13.957
−15.328
1.00
66.88
O


ATOM
1505
N
VAL
B
380
−77.182
15.831
−16.174
1.00
66.05
N


ATOM
1506
CA
VAL
B
380
−77.512
16.661
−15.029
1.00
65.75
C


ATOM
1507
CB
VAL
B
380
−76.405
16.742
−13.944
1.00
65.44
C


ATOM
1508
CG1
VAL
B
380
−75.179
17.514
−14.436
1.00
65.48
C


ATOM
1509
CG2
VAL
B
380
−76.945
17.343
−12.653
1.00
64.28
C


ATOM
1510
C
VAL
B
380
−77.930
18.021
−15.542
1.00
65.90
C


ATOM
1511
O
VAL
B
380
−77.429
18.493
−16.573
1.00
66.20
O


ATOM
1512
N
SER
B
381
−78.840
18.649
−14.816
1.00
65.11
N


ATOM
1513
CA
SER
B
381
−79.308
19.958
−15.153
1.00
64.86
C


ATOM
1514
CB
SER
B
381
−80.818
20.000
−14.994
1.00
64.84
C


ATOM
1515
OG
SER
B
381
−81.278
21.322
−14.804
1.00
65.85
O


ATOM
1516
C
SER
B
381
−78.584
20.962
−14.261
1.00
64.52
C


ATOM
1517
O
SER
B
381
−78.762
20.938
−13.051
1.00
64.12
O


ATOM
1518
N
GLN
B
382
−77.738
21.818
−14.859
1.00
65.97
N


ATOM
1519
CA
GLN
B
382
−76.989
22.857
−14.125
1.00
66.38
C


ATOM
1520
CB
GLN
B
382
−75.483
22.638
−14.200
1.00
66.64
C


ATOM
1521
CG
GLN
B
382
−75.010
21.530
−13.285
1.00
68.46
C


ATOM
1522
CD
GLN
B
382
−73.504
21.374
−13.324
1.00
71.37
C


ATOM
1523
OE1
GLN
B
382
−72.728
22.346
−13.165
1.00
73.24
O


ATOM
1524
NE2
GLN
B
382
−73.052
20.136
−13.508
1.00
71.55
N


ATOM
1525
C
GLN
B
382
−77.347
24.270
−14.559
1.00
65.83
C


ATOM
1526
O
GLN
B
382
−78.046
24.421
−15.560
1.00
66.06
O


ATOM
1527
N
SER
B
383
−76.907
25.303
−13.804
1.00
64.06
N


ATOM
1528
CA
SER
B
383
−77.200
26.709
−14.136
1.00
63.37
C


ATOM
1529
CB
SER
B
383
−78.417
27.208
−13.363
1.00
63.26
C


ATOM
1530
OG
SER
B
383
−79.509
26.312
−13.464
1.00
63.66
O


ATOM
1531
C
SER
B
383
−76.005
27.650
−13.911
1.00
62.65
C


ATOM
1532
O
SER
B
383
−75.120
27.339
−13.109
1.00
63.21
O


ATOM
1533
N
GLY
B
384
−75.972
28.782
−14.610
1.00
61.71
N


ATOM
1534
CA
GLY
B
384
−74.884
29.739
−14.426
1.00
60.72
C


ATOM
1535
C
GLY
B
384
−74.402
30.424
−15.675
1.00
60.19
C


ATOM
1536
O
GLY
B
384
−74.737
30.001
−16.775
1.00
60.26
O


ATOM
1537
N
THR
B
385
−73.606
31.484
−15.527
1.00
60.84
N


ATOM
1538
CA
THR
B
385
−73.095
32.176
−16.696
1.00
60.30
C


ATOM
1539
CB
THR
B
385
−72.612
33.595
−16.392
1.00
60.29
C


ATOM
1540
OG1
THR
B
385
−71.719
33.599
−15.282
1.00
60.49
O


ATOM
1541
CG2
THR
B
385
−73.734
34.539
−16.152
1.00
60.32
C


ATOM
1542
C
THR
B
385
−72.096
31.285
−17.414
1.00
60.14
C


ATOM
1543
O
THR
B
385
−71.858
31.498
−18.600
1.00
60.76
O


ATOM
1544
N
SER
B
386
−71.538
30.259
−16.718
1.00
59.68
N


ATOM
1545
CA
SER
B
386
−70.610
29.290
−17.308
1.00
58.69
C


ATOM
1546
CB
SER
B
386
−70.208
28.255
−16.276
1.00
58.66
C


ATOM
1547
OG
SER
B
386
−69.090
28.756
−15.570
1.00
59.58
O


ATOM
1548
C
SER
B
386
−71.328
28.575
−18.415
1.00
58.08
C


ATOM
1549
O
SER
B
386
−70.886
28.598
−19.560
1.00
57.08
O


ATOM
1550
N
GLN
B
387
−72.474
27.969
−18.068
1.00
57.98
N


ATOM
1551
CA
GLN
B
387
−73.350
27.253
−18.974
1.00
58.10
C


ATOM
1552
CB
GLN
B
387
−74.580
26.756
−18.211
1.00
58.10
C


ATOM
1553
CG
GLN
B
387
−74.321
25.450
−17.479
1.00
59.28
C


ATOM
1554
CD
GLN
B
387
−73.438
25.567
−16.264
1.00
62.12
C


ATOM
1555
OE1
GLN
B
387
−73.404
26.591
−15.573
1.00
64.35
O


ATOM
1556
NE2
GLN
B
387
−72.688
24.512
−15.964
1.00
63.82
N


ATOM
1557
C
GLN
B
387
−73.706
28.133
−20.185
1.00
57.84
C


ATOM
1558
O
GLN
B
387
−73.647
27.665
−21.320
1.00
57.46
O


ATOM
1559
N
ALA
B
388
−73.996
29.413
−19.940
1.00
57.44
N


ATOM
1560
CA
ALA
B
388
−74.321
30.379
−20.971
1.00
57.87
C


ATOM
1561
CB
ALA
B
388
−74.751
31.670
−20.321
1.00
58.03
C


ATOM
1562
C
ALA
B
388
−73.137
30.628
−21.913
1.00
58.24
C


ATOM
1563
O
ALA
B
388
−73.307
30.586
−23.137
1.00
58.05
O


ATOM
1564
N
ALA
B
389
−71.932
30.874
−21.330
1.00
59.19
N


ATOM
1565
CA
ALA
B
389
−70.680
31.119
−22.054
1.00
59.09
C


ATOM
1566
CB
ALA
B
389
−69.537
31.386
−21.083
1.00
58.69
C


ATOM
1567
C
ALA
B
389
−70.379
29.920
−22.949
1.00
59.41
C


ATOM
1568
O
ALA
B
389
−70.090
30.121
−24.127
1.00
59.39
O


ATOM
1569
N
ALA
B
390
−70.536
28.675
−22.417
1.00
59.10
N


ATOM
1570
CA
ALA
B
390
−70.335
27.416
−23.148
1.00
59.27
C


ATOM
1571
CB
ALA
B
390
−70.634
26.231
−22.246
1.00
59.50
C


ATOM
1572
C
ALA
B
390
−71.223
27.368
−24.389
1.00
59.18
C


ATOM
1573
O
ALA
B
390
−70.762
27.016
−25.465
1.00
58.96
O


ATOM
1574
N
HIS
B
391
−72.466
27.771
−24.245
1.00
59.70
N


ATOM
1575
CA
HIS
B
391
−73.437
27.824
−25.327
1.00
60.45
C


ATOM
1576
CB
HIS
B
391
−74.748
28.343
−24.754
1.00
60.64
C


ATOM
1577
CG
HIS
B
391
−75.881
28.349
−25.711
1.00
61.44
C


ATOM
1578
ND1
HIS
B
391
−76.895
27.390
−25.638
1.00
62.58
N


ATOM
1579
CE1
HIS
B
391
−77.758
27.717
−26.591
1.00
62.78
C


ATOM
1580
NE2
HIS
B
391
−77.364
28.815
−27.263
1.00
61.77
N


ATOM
1581
CD2
HIS
B
391
−76.170
29.229
−26.701
1.00
60.82
C


ATOM
1582
C
HIS
B
391
−72.941
28.752
−26.446
1.00
60.78
C


ATOM
1583
O
HIS
B
391
−73.011
28.394
−27.626
1.00
60.82
O


ATOM
1584
N
VAL
B
392
−72.431
29.940
−26.073
1.00
60.26
N


ATOM
1585
CA
VAL
B
392
−71.934
30.895
−27.048
1.00
60.56
C


ATOM
1586
CB
VAL
B
392
−71.837
32.337
−26.501
1.00
60.49
C


ATOM
1587
CG1
VAL
B
392
−70.866
33.192
−27.316
1.00
59.89
C


ATOM
1588
CG2
VAL
B
392
−73.219
32.987
−26.456
1.00
60.00
C


ATOM
1589
C
VAL
B
392
−70.675
30.361
−27.706
1.00
60.89
C


ATOM
1590
O
VAL
B
392
−70.504
30.544
−28.910
1.00
61.08
O


ATOM
1591
N
ALA
B
393
−69.822
29.658
−26.943
1.00
60.20
N


ATOM
1592
CA
ALA
B
393
−68.610
29.042
−27.496
1.00
60.46
C


ATOM
1593
CB
ALA
B
393
−67.728
28.480
−26.381
1.00
60.29
C


ATOM
1594
C
ALA
B
393
−69.051
27.932
−28.506
1.00
60.76
C


ATOM
1595
O
ALA
B
393
−68.423
27.773
−29.542
1.00
60.67
O


ATOM
1596
N
GLY
B
394
−70.158
27.237
−28.218
1.00
60.47
N


ATOM
1597
CA
GLY
B
394
−70.731
26.231
−29.105
1.00
60.83
C


ATOM
1598
C
GLY
B
394
−71.095
26.913
−30.409
1.00
61.49
C


ATOM
1599
O
GLY
B
394
−70.561
26.545
−31.452
1.00
61.48
O


ATOM
1600
N
ILE
B
395
−71.940
27.986
−30.350
1.00
59.97
N


ATOM
1601
CA
ILE
B
395
−72.324
28.798
−31.517
1.00
60.21
C


ATOM
1602
CB
ILE
B
395
−73.238
29.997
−31.149
1.00
59.85
C


ATOM
1603
CG1
ILE
B
395
−74.560
29.509
−30.540
1.00
59.07
C


ATOM
1604
CD1
ILE
B
395
−75.597
30.517
−30.318
1.00
56.08
C


ATOM
1605
CG2
ILE
B
395
−73.496
30.836
−32.396
1.00
58.99
C


ATOM
1606
C
ILE
B
395
−71.075
29.268
−32.270
1.00
60.82
C


ATOM
1607
O
ILE
B
395
−70.963
29.023
−33.459
1.00
60.79
O


ATOM
1608
N
ALA
B
396
−70.132
29.901
−31.572
1.00
62.66
N


ATOM
1609
CA
ALA
B
396
−68.893
30.389
−32.166
1.00
63.99
C


ATOM
1610
CB
ALA
B
396
−67.994
30.993
−31.104
1.00
63.67
C


ATOM
1611
C
ALA
B
396
−68.144
29.297
−32.910
1.00
65.18
C


ATOM
1612
O
ALA
B
396
−67.522
29.590
−33.929
1.00
65.64
O


ATOM
1613
N
ALA
B
397
−68.192
28.046
−32.420
1.00
66.67
N


ATOM
1614
CA
ALA
B
397
−67.481
26.966
−33.077
1.00
67.47
C


ATOM
1615
CB
ALA
B
397
−67.364
25.760
−32.167
1.00
67.14
C


ATOM
1616
C
ALA
B
397
−68.193
26.611
−34.351
1.00
68.29
C


ATOM
1617
O
ALA
B
397
−67.538
26.383
−35.358
1.00
68.46
O


ATOM
1618
N
MET
B
398
−69.518
26.615
−34.346
1.00
70.12
N


ATOM
1619
CA
MET
B
398
−70.253
26.291
−35.562
1.00
71.55
C


ATOM
1620
CB
MET
B
398
−71.707
26.108
−35.259
1.00
71.19
C


ATOM
1621
CG
MET
B
398
−72.011
24.717
−34.979
1.00
71.23
C


ATOM
1622
SD
MET
B
398
−73.527
24.713
−34.090
1.00
72.01
S


ATOM
1623
CE
MET
B
398
−74.705
24.947
−35.431
1.00
72.24
C


ATOM
1624
C
MET
B
398
−70.068
27.307
−36.668
1.00
72.80
C


ATOM
1625
O
MET
B
398
−70.022
26.937
−37.845
1.00
73.11
O


ATOM
1626
N
MET
B
399
−69.950
28.584
−36.276
1.00
75.45
N


ATOM
1627
CA
MET
B
399
−69.737
29.715
−37.153
1.00
76.60
C


ATOM
1628
CB
MET
B
399
−69.784
30.998
−36.335
1.00
76.93
C


ATOM
1629
CG
MET
B
399
−71.138
31.385
−35.885
1.00
78.25
C


ATOM
1630
SD
MET
B
399
−71.060
33.142
−35.460
1.00
81.74
S


ATOM
1631
CE
MET
B
399
−72.769
33.407
−35.066
1.00
81.33
C


ATOM
1632
C
MET
B
399
−68.353
29.584
−37.760
1.00
77.22
C


ATOM
1633
O
MET
B
399
−68.220
29.669
−38.974
1.00
77.23
O


ATOM
1634
N
LEU
B
400
−67.325
29.365
−36.915
1.00
76.33
N


ATOM
1635
CA
LEU
B
400
−65.936
29.226
−37.346
1.00
77.44
C


ATOM
1636
CB
LEU
B
400
−64.965
29.365
−36.170
1.00
77.12
C


ATOM
1637
CG
LEU
B
400
−64.811
30.729
−35.539
1.00
76.49
C


ATOM
1638
CD1
LEU
B
400
−64.013
30.617
−34.295
1.00
76.33
C


ATOM
1639
CD2
LEU
B
400
−64.101
31.702
−36.459
1.00
75.61
C


ATOM
1640
C
LEU
B
400
−65.679
27.928
−38.104
1.00
78.55
C


ATOM
1641
O
LEU
B
400
−64.640
27.811
−38.754
1.00
78.47
O


ATOM
1642
N
SER
B
401
−66.614
26.951
−38.008
1.00
83.21
N


ATOM
1643
CA
SER
B
401
−66.532
25.676
−38.712
1.00
84.86
C


ATOM
1644
CB
SER
B
401
−67.538
24.675
−38.161
1.00
85.02
C


ATOM
1645
OG
SER
B
401
−66.854
23.694
−37.400
1.00
86.31
O


ATOM
1646
C
SER
B
401
−66.806
25.932
−40.171
1.00
85.71
C


ATOM
1647
O
SER
B
401
−66.036
25.489
−41.022
1.00
85.97
O


ATOM
1648
N
ALA
B
402
−67.881
26.692
−40.453
1.00
87.49
N


ATOM
1649
CA
ALA
B
402
−68.301
27.071
−41.792
1.00
88.50
C


ATOM
1650
CB
ALA
B
402
−69.740
27.534
−41.756
1.00
88.32
C


ATOM
1651
C
ALA
B
402
−67.408
28.157
−42.437
1.00
89.39
C


ATOM
1652
O
ALA
B
402
−67.193
28.122
−43.651
1.00
90.05
O


ATOM
1653
N
GLU
B
403
−66.905
29.121
−41.654
1.00
88.89
N


ATOM
1654
CA
GLU
B
403
−66.093
30.194
−42.210
1.00
89.62
C


ATOM
1655
CB
GLU
B
403
−66.934
31.483
−42.301
1.00
89.85
C


ATOM
1656
CG
GLU
B
403
−68.060
31.403
−43.317
1.00
91.79
C


ATOM
1657
CD
GLU
B
403
−69.147
32.466
−43.267
1.00
94.98
C


ATOM
1658
OE1
GLU
B
403
−70.339
32.075
−43.285
1.00
96.52
O


ATOM
1659
OE2
GLU
B
403
−68.822
33.679
−43.231
1.00
95.76
O


ATOM
1660
C
GLU
B
403
−64.809
30.399
−41.401
1.00
89.80
C


ATOM
1661
O
GLU
B
403
−64.673
31.415
−40.722
1.00
89.82
O


ATOM
1662
N
PRO
B
404
−63.837
29.467
−41.471
1.00
88.89
N


ATOM
1663
CA
PRO
B
404
−62.587
29.614
−40.692
1.00
89.06
C


ATOM
1664
CB
PRO
B
404
−61.704
28.485
−41.210
1.00
88.92
C


ATOM
1665
CG
PRO
B
404
−62.379
27.990
−42.431
1.00
89.10
C


ATOM
1666
CD
PRO
B
404
−63.827
28.207
−42.225
1.00
88.89
C


ATOM
1667
C
PRO
B
404
−61.843
30.937
−40.746
1.00
89.38
C


ATOM
1668
O
PRO
B
404
−61.071
31.243
−39.833
1.00
89.29
O


ATOM
1669
N
GLU
B
405
−62.077
31.724
−41.800
1.00
94.03
N


ATOM
1670
CA
GLU
B
405
−61.424
33.021
−41.962
1.00
94.48
C


ATOM
1671
CB
GLU
B
405
−60.953
33.222
−43.414
1.00
94.82
C


ATOM
1672
CG
GLU
B
405
−59.644
32.488
−43.697
1.00
97.73
C


ATOM
1673
CD
GLU
B
405
−59.402
32.015
−45.125
1.00
102.06
C


ATOM
1674
OE1
GLU
B
405
−59.461
32.859
−46.057
1.00
103.17
O


ATOM
1675
OE2
GLU
B
405
−59.138
30.798
−45.309
1.00
103.58
O


ATOM
1676
C
GLU
B
405
−62.212
34.217
−41.358
1.00
93.93
C


ATOM
1677
O
GLU
B
405
−61.967
35.374
−41.720
1.00
94.12
O


ATOM
1678
N
LEU
B
406
−63.146
33.927
−40.414
1.00
90.47
N


ATOM
1679
CA
LEU
B
406
−63.928
34.956
−39.725
1.00
89.50
C


ATOM
1680
CB
LEU
B
406
−65.167
34.369
−39.024
1.00
89.48
C


ATOM
1681
CG
LEU
B
406
−66.506
34.396
−39.753
1.00
88.84
C


ATOM
1682
CD1
LEU
B
406
−67.483
33.473
−39.089
1.00
88.84
C


ATOM
1683
CD2
LEU
B
406
−67.102
35.767
−39.764
1.00
87.85
C


ATOM
1684
C
LEU
B
406
−63.031
35.560
−38.669
1.00
89.00
C


ATOM
1685
O
LEU
B
406
−62.284
34.841
−37.990
1.00
89.04
O


ATOM
1686
N
THR
B
407
−63.094
36.872
−38.523
1.00
88.63
N


ATOM
1687
CA
THR
B
407
−62.281
37.526
−37.512
1.00
87.98
C


ATOM
1688
CB
THR
B
407
−61.776
38.896
−37.998
1.00
88.20
C


ATOM
1689
OG1
THR
B
407
−62.718
39.924
−37.660
1.00
88.82
O


ATOM
1690
CG2
THR
B
407
−61.437
38.917
−39.497
1.00
88.11
C


ATOM
1691
C
THR
B
407
−63.112
37.632
−36.240
1.00
87.20
C


ATOM
1692
O
THR
B
407
−64.333
37.469
−36.293
1.00
87.26
O


ATOM
1693
N
LEU
B
408
−62.461
37.926
−35.104
1.00
83.82
N


ATOM
1694
CA
LEU
B
408
−63.150
38.086
−33.837
1.00
82.78
C


ATOM
1695
CB
LEU
B
408
−62.143
38.376
−32.722
1.00
82.53
C


ATOM
1696
CG
LEU
B
408
−62.696
38.851
−31.380
1.00
82.25
C


ATOM
1697
CD1
LEU
B
408
−63.598
37.798
−30.727
1.00
82.62
C


ATOM
1698
CD2
LEU
B
408
−61.576
39.199
−30.436
1.00
82.94
C


ATOM
1699
C
LEU
B
408
−64.180
39.215
−33.955
1.00
82.54
C


ATOM
1700
O
LEU
B
408
−65.314
39.051
−33.489
1.00
82.55
O


ATOM
1701
N
ALA
B
409
−63.795
40.344
−34.605
1.00
81.97
N


ATOM
1702
CA
ALA
B
409
−64.659
41.516
−34.779
1.00
81.35
C


ATOM
1703
CB
ALA
B
409
−63.871
42.672
−35.361
1.00
81.52
C


ATOM
1704
C
ALA
B
409
−65.874
41.213
−35.633
1.00
80.96
C


ATOM
1705
O
ALA
B
409
−66.945
41.771
−35.386
1.00
80.76
O


ATOM
1706
N
GLU
B
410
−65.699
40.309
−36.617
1.00
80.96
N


ATOM
1707
CA
GLU
B
410
−66.710
39.842
−37.567
1.00
80.62
C


ATOM
1708
CB
GLU
B
410
−66.014
39.093
−38.711
1.00
80.93
C


ATOM
1709
CG
GLU
B
410
−65.963
39.834
−40.033
1.00
83.23
C


ATOM
1710
CD
GLU
B
410
−64.677
39.602
−40.809
1.00
87.13
C


ATOM
1711
OE1
GLU
B
410
−64.421
38.451
−41.248
1.00
88.89
O


ATOM
1712
OE2
GLU
B
410
−63.915
40.584
−40.969
1.00
89.23
O


ATOM
1713
C
GLU
B
410
−67.650
38.891
−36.874
1.00
79.82
C


ATOM
1714
O
GLU
B
410
−68.822
38.779
−37.234
1.00
79.68
O


ATOM
1715
N
LEU
B
411
−67.113
38.187
−35.889
1.00
78.35
N


ATOM
1716
CA
LEU
B
411
−67.839
37.207
−35.119
1.00
77.79
C


ATOM
1717
CB
LEU
B
411
−66.867
36.153
−34.596
1.00
77.78
C


ATOM
1718
CG
LEU
B
411
−67.515
34.903
−34.097
1.00
78.03
C


ATOM
1719
CD1
LEU
B
411
−67.345
33.767
−35.086
1.00
78.21
C


ATOM
1720
CD2
LEU
B
411
−66.983
34.561
−32.737
1.00
79.18
C


ATOM
1721
C
LEU
B
411
−68.681
37.847
−34.001
1.00
77.24
C


ATOM
1722
O
LEU
B
411
−69.831
37.441
−33.802
1.00
77.27
O


ATOM
1723
N
ARG
B
412
−68.130
38.849
−33.291
1.00
76.11
N


ATOM
1724
CA
ARG
B
412
−68.868
39.539
−32.231
1.00
75.55
C


ATOM
1725
CB
ARG
B
412
−68.009
40.629
−31.581
1.00
75.61
C


ATOM
1726
CG
ARG
B
412
−68.578
41.165
−30.270
1.00
75.68
C


ATOM
1727
CD
ARG
B
412
−67.779
42.318
−29.686
1.00
76.09
C


ATOM
1728
NE
ARG
B
412
−66.410
41.948
−29.333
1.00
76.59
N


ATOM
1729
CZ
ARG
B
412
−65.366
42.123
−30.143
1.00
78.24
C


ATOM
1730
NH1
ARG
B
412
−65.535
42.649
−31.357
1.00
78.09
N


ATOM
1731
NH2
ARG
B
412
−64.146
41.775
−29.749
1.00
79.25
N


ATOM
1732
C
ARG
B
412
−70.114
40.149
−32.851
1.00
75.03
C


ATOM
1733
O
ARG
B
412
−71.220
39.914
−32.358
1.00
75.17
O


ATOM
1734
N
GLN
B
413
−69.921
40.886
−33.966
1.00
74.22
N


ATOM
1735
CA
GLN
B
413
−70.953
41.540
−34.766
1.00
73.43
C


ATOM
1736
CB
GLN
B
413
−70.301
42.219
−35.965
1.00
73.44
C


ATOM
1737
CG
GLN
B
413
−69.415
43.393
−35.576
1.00
73.24
C


ATOM
1738
CD
GLN
B
413
−70.167
44.690
−35.561
1.00
72.45
C


ATOM
1739
OE1
GLN
B
413
−71.411
44.719
−35.704
1.00
72.48
O


ATOM
1740
NE2
GLN
B
413
−69.425
45.783
−35.373
1.00
70.30
N


ATOM
1741
C
GLN
B
413
−72.012
40.539
−35.229
1.00
73.02
C


ATOM
1742
O
GLN
B
413
−73.201
40.787
−35.048
1.00
72.86
O


ATOM
1743
N
ARG
B
414
−71.571
39.396
−35.800
1.00
75.91
N


ATOM
1744
CA
ARG
B
414
−72.421
38.300
−36.272
1.00
75.71
C


ATOM
1745
CB
ARG
B
414
−71.555
37.219
−36.942
1.00
76.10
C


ATOM
1746
CG
ARG
B
414
−72.166
36.681
−38.235
1.00
79.15
C


ATOM
1747
CD
ARG
B
414
−71.243
35.718
−38.987
1.00
85.28
C


ATOM
1748
NE
ARG
B
414
−71.509
35.701
−40.431
1.00
88.74
N


ATOM
1749
CZ
ARG
B
414
−71.101
36.643
−41.287
1.00
91.15
C


ATOM
1750
NH1
ARG
B
414
−71.403
36.551
−42.578
1.00
92.85
N


ATOM
1751
NH2
ARG
B
414
−70.399
37.695
−40.851
1.00
91.02
N


ATOM
1752
C
ARG
B
414
−73.325
37.712
−35.133
1.00
74.46
C


ATOM
1753
O
ARG
B
414
−74.515
37.478
−35.356
1.00
74.04
O


ATOM
1754
N
LEU
B
415
−72.759
37.512
−33.921
1.00
68.09
N


ATOM
1755
CA
LEU
B
415
−73.501
37.017
−32.764
1.00
67.32
C


ATOM
1756
CB
LEU
B
415
−72.561
36.841
−31.577
1.00
67.07
C


ATOM
1757
CG
LEU
B
415
−71.715
35.604
−31.538
1.00
66.56
C


ATOM
1758
CD1
LEU
B
415
−70.568
35.777
−30.549
1.00
66.03
C


ATOM
1759
CD2
LEU
B
415
−72.554
34.350
−31.266
1.00
65.00
C


ATOM
1760
C
LEU
B
415
−74.591
38.032
−32.381
1.00
67.36
C


ATOM
1761
O
LEU
B
415
−75.722
37.642
−32.052
1.00
67.10
O


ATOM
1762
N
ILE
B
416
−74.234
39.348
−32.425
1.00
68.45
N


ATOM
1763
CA
ILE
B
416
−75.152
40.442
−32.127
1.00
68.32
C


ATOM
1764
CB
ILE
B
416
−74.435
41.815
−32.035
1.00
67.86
C


ATOM
1765
CG1
ILE
B
416
−73.425
41.848
−30.881
1.00
67.10
C


ATOM
1766
CD1
ILE
B
416
−72.503
43.080
−30.854
1.00
65.57
C


ATOM
1767
CG2
ILE
B
416
−75.453
42.945
−31.889
1.00
66.91
C


ATOM
1768
C
ILE
B
416
−76.298
40.439
−33.154
1.00
68.96
C


ATOM
1769
O
ILE
B
416
−77.454
40.451
−32.752
1.00
68.93
O


ATOM
1770
N
HIS
B
417
−75.975
40.390
−34.462
1.00
74.14
N


ATOM
1771
CA
HIS
B
417
−76.957
40.405
−35.536
1.00
75.34
C


ATOM
1772
CB
HIS
B
417
−76.288
40.576
−36.912
1.00
76.00
C


ATOM
1773
CG
HIS
B
417
−77.281
40.887
−37.995
1.00
79.28
C


ATOM
1774
ND1
HIS
B
417
−77.849
42.162
−38.121
1.00
82.13
N


ATOM
1775
CE1
HIS
B
417
−78.699
42.080
−39.137
1.00
82.76
C


ATOM
1776
NE2
HIS
B
417
−78.727
40.842
−39.657
1.00
83.50
N


ATOM
1777
CD2
HIS
B
417
−77.825
40.071
−38.935
1.00
81.69
C


ATOM
1778
C
HIS
B
417
−77.945
39.241
−35.522
1.00
75.44
C


ATOM
1779
O
HIS
B
417
−79.073
39.401
−35.971
1.00
75.49
O


ATOM
1780
N
PHE
B
418
−77.541
38.085
−35.001
1.00
76.60
N


ATOM
1781
CA
PHE
B
418
−78.407
36.912
−34.952
1.00
76.73
C


ATOM
1782
CB
PHE
B
418
−77.574
35.642
−35.078
1.00
77.20
C


ATOM
1783
CG
PHE
B
418
−76.787
35.408
−36.338
1.00
79.44
C


ATOM
1784
CD1
PHE
B
418
−76.803
36.338
−37.377
1.00
81.12
C


ATOM
1785
CE1
PHE
B
418
−76.056
36.129
−38.533
1.00
82.00
C


ATOM
1786
CZ
PHE
B
418
−75.304
34.976
−38.667
1.00
82.73
C


ATOM
1787
CE2
PHE
B
418
−75.286
34.034
−37.656
1.00
82.54
C


ATOM
1788
CD2
PHE
B
418
−76.022
34.254
−36.491
1.00
81.60
C


ATOM
1789
C
PHE
B
418
−79.206
36.813
−33.663
1.00
76.39
C


ATOM
1790
O
PHE
B
418
−80.242
36.139
−33.646
1.00
76.28
O


ATOM
1791
N
SER
B
419
−78.701
37.427
−32.578
1.00
73.74
N


ATOM
1792
CA
SER
B
419
−79.308
37.404
−31.256
1.00
73.75
C


ATOM
1793
CB
SER
B
419
−78.556
38.338
−30.314
1.00
73.84
C


ATOM
1794
OG
SER
B
419
−77.436
37.727
−29.700
1.00
74.19
O


ATOM
1795
C
SER
B
419
−80.734
37.853
−31.302
1.00
73.84
C


ATOM
1796
O
SER
B
419
−81.040
38.766
−32.061
1.00
73.99
O


ATOM
1797
N
ALA
B
420
−81.605
37.240
−30.484
1.00
71.93
N


ATOM
1798
CA
ALA
B
420
−83.005
37.625
−30.365
1.00
72.07
C


ATOM
1799
CB
ALA
B
420
−83.745
36.590
−29.542
1.00
71.93
C


ATOM
1800
C
ALA
B
420
−83.013
38.999
−29.644
1.00
72.40
C


ATOM
1801
O
ALA
B
420
−82.185
39.205
−28.751
1.00
72.46
O


ATOM
1802
N
LYS
B
421
−83.897
39.937
−30.051
1.00
74.23
N


ATOM
1803
CA
LYS
B
421
−83.988
41.299
−29.487
1.00
74.62
C


ATOM
1804
CB
LYS
B
421
−83.947
42.338
−30.610
1.00
74.66
C


ATOM
1805
CG
LYS
B
421
−82.547
42.783
−30.946
1.00
76.25
C


ATOM
1806
CD
LYS
B
421
−81.924
41.947
−32.054
1.00
78.94
C


ATOM
1807
CE
LYS
B
421
−80.544
42.425
−32.471
1.00
79.71
C


ATOM
1808
NZ
LYS
B
421
−79.899
41.465
−33.406
1.00
80.33
N


ATOM
1809
C
LYS
B
421
−85.189
41.583
−28.572
1.00
74.71
C


ATOM
1810
O
LYS
B
421
−86.234
40.961
−28.717
1.00
74.88
O


ATOM
1811
N
ASP
B
422
−85.035
42.533
−27.638
1.00
75.41
N


ATOM
1812
CA
ASP
B
422
−86.057
42.990
−26.672
1.00
75.73
C


ATOM
1813
CB
ASP
B
422
−87.007
44.040
−27.285
1.00
76.30
C


ATOM
1814
CG
ASP
B
422
−86.437
44.958
−28.360
1.00
78.13
C


ATOM
1815
OD1
ASP
B
422
−85.237
45.372
−28.230
1.00
78.71
O


ATOM
1816
OD2
ASP
B
422
−87.193
45.274
−29.336
1.00
80.16
O


ATOM
1817
C
ASP
B
422
−86.846
41.924
−25.868
1.00
75.29
C


ATOM
1818
O
ASP
B
422
−87.839
42.245
−25.206
1.00
75.54
O


ATOM
1819
N
VAL
B
423
−86.389
40.677
−25.899
1.00
72.35
N


ATOM
1820
CA
VAL
B
423
−87.045
39.568
−25.209
1.00
71.53
C


ATOM
1821
CB
VAL
B
423
−86.847
38.225
−25.933
1.00
71.50
C


ATOM
1822
CG1
VAL
B
423
−87.586
38.219
−27.275
1.00
71.38
C


ATOM
1823
CG2
VAL
B
423
−85.370
37.910
−26.124
1.00
71.72
C


ATOM
1824
C
VAL
B
423
−86.777
39.517
−23.713
1.00
71.24
C


ATOM
1825
O
VAL
B
423
−87.544
38.891
−22.980
1.00
71.04
O


ATOM
1826
N
ILE
B
424
−85.710
40.192
−23.253
1.00
69.40
N


ATOM
1827
CA
ILE
B
424
−85.372
40.256
−21.831
1.00
69.33
C


ATOM
1828
CB
ILE
B
424
−83.852
40.479
−21.624
1.00
69.22
C


ATOM
1829
CG1
ILE
B
424
−82.966
39.459
−22.357
1.00
68.76
C


ATOM
1830
CD1
ILE
B
424
−81.464
39.930
−22.473
1.00
67.42
C


ATOM
1831
CG2
ILE
B
424
−83.513
40.562
−20.155
1.00
69.12
C


ATOM
1832
C
ILE
B
424
−86.142
41.435
−21.246
1.00
69.45
C


ATOM
1833
O
ILE
B
424
−86.150
42.493
−21.869
1.00
69.43
O


ATOM
1834
N
ASN
B
425
−86.764
41.278
−20.062
1.00
72.98
N


ATOM
1835
CA
ASN
B
425
−87.468
42.374
−19.397
1.00
73.43
C


ATOM
1836
CB
ASN
B
425
−88.543
41.841
−18.432
1.00
73.75
C


ATOM
1837
CG
ASN
B
425
−89.486
42.891
−17.818
1.00
75.20
C


ATOM
1838
OD1
ASN
B
425
−89.341
44.124
−18.010
1.00
77.09
O


ATOM
1839
ND2
ASN
B
425
−90.491
42.419
−17.056
1.00
75.14
N


ATOM
1840
C
ASN
B
425
−86.405
43.217
−18.656
1.00
73.62
C


ATOM
1841
O
ASN
B
425
−85.893
42.785
−17.618
1.00
73.33
O


ATOM
1842
N
GLU
B
426
−86.061
44.408
−19.211
1.00
76.51
N


ATOM
1843
CA
GLU
B
426
−85.051
45.338
−18.671
1.00
76.99
C


ATOM
1844
CB
GLU
B
426
−84.946
46.653
−19.505
1.00
77.36
C


ATOM
1845
CG
GLU
B
426
−84.451
46.494
−20.946
1.00
80.58
C


ATOM
1846
CD
GLU
B
426
−82.965
46.603
−21.329
1.00
85.39
C


ATOM
1847
OE1
GLU
B
426
−82.675
47.253
−22.367
1.00
86.18
O


ATOM
1848
OE2
GLU
B
426
−82.097
46.025
−20.625
1.00
86.84
O


ATOM
1849
C
GLU
B
426
−85.252
45.650
−17.181
1.00
76.56
C


ATOM
1850
O
GLU
B
426
−84.302
46.052
−16.515
1.00
76.36
O


ATOM
1851
N
ALA
B
427
−86.480
45.442
−16.667
1.00
75.86
N


ATOM
1852
CA
ALA
B
427
−86.903
45.679
−15.282
1.00
75.92
C


ATOM
1853
CB
ALA
B
427
−88.383
45.409
−15.137
1.00
75.89
C


ATOM
1854
C
ALA
B
427
−86.121
44.920
−14.195
1.00
75.95
C


ATOM
1855
O
ALA
B
427
−85.977
45.442
−13.089
1.00
76.02
O


ATOM
1856
N
TRP
B
428
−85.611
43.715
−14.505
1.00
75.20
N


ATOM
1857
CA
TRP
B
428
−84.837
42.878
−13.588
1.00
75.04
C


ATOM
1858
CB
TRP
B
428
−84.603
41.511
−14.243
1.00
75.43
C


ATOM
1859
CG
TRP
B
428
−83.974
40.446
−13.377
1.00
77.09
C


ATOM
1860
CD1
TRP
B
428
−84.627
39.444
−12.722
1.00
78.40
C


ATOM
1861
NE1
TRP
B
428
−83.720
38.604
−12.105
1.00
78.60
N


ATOM
1862
CE2
TRP
B
428
−82.445
39.035
−12.383
1.00
77.96
C


ATOM
1863
CD2
TRP
B
428
−82.560
40.204
−13.171
1.00
78.20
C


ATOM
1864
CE3
TRP
B
428
−81.382
40.862
−13.572
1.00
77.89
C


ATOM
1865
CZ3
TRP
B
428
−80.160
40.346
−13.171
1.00
77.32
C


ATOM
1866
CH2
TRP
B
428
−80.081
39.181
−12.399
1.00
76.83
C


ATOM
1867
CZ2
TRP
B
428
−81.206
38.518
−11.981
1.00
77.51
C


ATOM
1868
C
TRP
B
428
−83.502
43.533
−13.263
1.00
74.49
C


ATOM
1869
O
TRP
B
428
−82.938
43.281
−12.201
1.00
74.39
O


ATOM
1870
N
PHE
B
429
−82.992
44.352
−14.180
1.00
71.16
N


ATOM
1871
CA
PHE
B
429
−81.722
45.030
−14.002
1.00
71.13
C


ATOM
1872
CB
PHE
B
429
−81.100
45.403
−15.369
1.00
70.85
C


ATOM
1873
CG
PHE
B
429
−80.897
44.253
−16.314
1.00
70.76
C


ATOM
1874
CD1
PHE
B
429
−80.117
43.159
−15.949
1.00
71.06
C


ATOM
1875
CE1
PHE
B
429
−79.955
42.075
−16.812
1.00
70.57
C


ATOM
1876
CZ
PHE
B
429
−80.551
42.090
−18.052
1.00
70.73
C


ATOM
1877
CE2
PHE
B
429
−81.311
43.175
−18.440
1.00
70.60
C


ATOM
1878
CD2
PHE
B
429
−81.482
44.257
−17.571
1.00
70.51
C


ATOM
1879
C
PHE
B
429
−81.861
46.287
−13.170
1.00
71.33
C


ATOM
1880
O
PHE
B
429
−82.913
46.900
−13.188
1.00
71.38
O


ATOM
1881
N
PRO
B
430
−80.807
46.735
−12.470
1.00
73.47
N


ATOM
1882
CA
PRO
B
430
−80.905
48.014
−11.761
1.00
73.85
C


ATOM
1883
CB
PRO
B
430
−79.493
48.199
−11.175
1.00
73.71
C


ATOM
1884
CG
PRO
B
430
−78.873
46.883
−11.199
1.00
73.53
C


ATOM
1885
CD
PRO
B
430
−79.454
46.157
−12.353
1.00
73.62
C


ATOM
1886
C
PRO
B
430
−81.189
49.125
−12.788
1.00
74.59
C


ATOM
1887
O
PRO
B
430
−80.551
49.129
−13.836
1.00
74.54
O


ATOM
1888
N
GLU
B
431
−82.130
50.055
−12.498
1.00
80.83
N


ATOM
1889
CA
GLU
B
431
−82.507
51.176
−13.378
1.00
81.60
C


ATOM
1890
CB
GLU
B
431
−83.287
52.266
−12.613
1.00
82.19
C


ATOM
1891
CG
GLU
B
431
−84.205
51.738
−11.499
1.00
86.77
C


ATOM
1892
CD
GLU
B
431
−85.528
52.458
−11.219
1.00
91.61
C


ATOM
1893
OE1
GLU
B
431
−85.495
53.696
−11.002
1.00
93.91
O


ATOM
1894
OE2
GLU
B
431
−86.592
51.781
−11.204
1.00
92.08
O


ATOM
1895
C
GLU
B
431
−81.322
51.797
−14.118
1.00
81.10
C


ATOM
1896
O
GLU
B
431
−81.396
52.006
−15.332
1.00
81.11
O


ATOM
1897
N
ASP
B
432
−80.212
52.054
−13.405
1.00
79.98
N


ATOM
1898
CA
ASP
B
432
−79.032
52.650
−14.039
1.00
79.83
C


ATOM
1899
CB
ASP
B
432
−78.114
53.367
−13.030
1.00
80.23
C


ATOM
1900
CG
ASP
B
432
−77.464
52.452
−12.013
1.00
82.98
C


ATOM
1901
OD1
ASP
B
432
−76.200
52.487
−11.896
1.00
85.48
O


ATOM
1902
OD2
ASP
B
432
−78.211
51.687
−11.327
1.00
85.86
O


ATOM
1903
C
ASP
B
432
−78.266
51.729
−14.994
1.00
79.05
C


ATOM
1904
O
ASP
B
432
−77.451
52.233
−15.759
1.00
79.13
O


ATOM
1905
N
GLN
B
433
−78.530
50.388
−14.964
1.00
74.87
N


ATOM
1906
CA
GLN
B
433
−77.887
49.397
−15.849
1.00
73.54
C


ATOM
1907
CB
GLN
B
433
−77.585
48.078
−15.128
1.00
73.41
C


ATOM
1908
CG
GLN
B
433
−76.494
48.154
−14.079
1.00
73.19
C


ATOM
1909
CD
GLN
B
433
−75.246
48.854
−14.525
1.00
72.32
C


ATOM
1910
OE1
GLN
B
433
−74.502
48.395
−15.396
1.00
72.62
O


ATOM
1911
NE2
GLN
B
433
−74.996
50.003
−13.925
1.00
72.78
N


ATOM
1912
C
GLN
B
433
−78.673
49.113
−17.124
1.00
72.69
C


ATOM
1913
O
GLN
B
433
−78.066
48.758
−18.122
1.00
72.79
O


ATOM
1914
N
ARG
B
434
−80.001
49.284
−17.096
1.00
70.39
N


ATOM
1915
CA
ARG
B
434
−80.933
49.043
−18.202
1.00
69.41
C


ATOM
1916
CB
ARG
B
434
−82.350
49.503
−17.846
1.00
69.21
C


ATOM
1917
CG
ARG
B
434
−82.790
49.107
−16.459
1.00
69.34
C


ATOM
1918
CD
ARG
B
434
−84.272
48.914
−16.404
1.00
72.35
C


ATOM
1919
NE
ARG
B
434
−84.937
49.688
−15.347
1.00
74.41
N


ATOM
1920
CZ
ARG
B
434
−85.379
49.180
−14.198
1.00
74.96
C


ATOM
1921
NH1
ARG
B
434
−85.209
47.899
−13.924
1.00
75.62
N


ATOM
1922
NH2
ARG
B
434
−85.997
49.954
−13.318
1.00
75.15
N


ATOM
1923
C
ARG
B
434
−80.487
49.584
−19.565
1.00
68.75
C


ATOM
1924
O
ARG
B
434
−80.503
48.863
−20.567
1.00
68.68
O


ATOM
1925
N
VAL
B
435
−80.063
50.824
−19.605
1.00
69.69
N


ATOM
1926
CA
VAL
B
435
−79.630
51.434
−20.859
1.00
69.16
C


ATOM
1927
CB
VAL
B
435
−79.319
52.950
−20.680
1.00
69.68
C


ATOM
1928
CG1
VAL
B
435
−79.223
53.634
−22.034
1.00
69.67
C


ATOM
1929
CG2
VAL
B
435
−80.336
53.662
−19.758
1.00
70.48
C


ATOM
1930
C
VAL
B
435
−78.405
50.727
−21.446
1.00
68.06
C


ATOM
1931
O
VAL
B
435
−78.319
50.560
−22.659
1.00
68.42
O


ATOM
1932
N
LEU
B
436
−77.455
50.355
−20.583
1.00
62.44
N


ATOM
1933
CA
LEU
B
436
−76.184
49.748
−20.936
1.00
61.31
C


ATOM
1934
CB
LEU
B
436
−75.187
50.001
−19.814
1.00
61.19
C


ATOM
1935
CG
LEU
B
436
−75.048
51.449
−19.364
1.00
60.52
C


ATOM
1936
CD1
LEU
B
436
−75.019
51.546
−17.855
1.00
58.88
C


ATOM
1937
CD2
LEU
B
436
−73.804
52.074
−19.923
1.00
59.40
C


ATOM
1938
C
LEU
B
436
−76.227
48.265
−21.243
1.00
60.83
C


ATOM
1939
O
LEU
B
436
−75.425
47.798
−22.044
1.00
60.74
O


ATOM
1940
N
THR
B
437
−77.122
47.523
−20.600
1.00
61.21
N


ATOM
1941
CA
THR
B
437
−77.254
46.086
−20.776
1.00
60.77
C


ATOM
1942
CB
THR
B
437
−77.896
45.475
−19.558
1.00
60.68
C


ATOM
1943
OG1
THR
B
437
−77.178
45.957
−18.448
1.00
60.46
O


ATOM
1944
CG2
THR
B
437
−77.811
43.977
−19.557
1.00
60.66
C


ATOM
1945
C
THR
B
437
−77.946
45.730
−22.094
1.00
60.69
C


ATOM
1946
O
THR
B
437
−79.155
46.032
−22.257
1.00
60.93
O


ATOM
1947
N
PRO
B
438
−77.186
45.075
−23.030
1.00
59.45
N


ATOM
1948
CA
PRO
B
438
−77.763
44.714
−24.323
1.00
59.43
C


ATOM
1949
CB
PRO
B
438
−76.575
44.148
−25.106
1.00
59.07
C


ATOM
1950
CG
PRO
B
438
−75.608
43.738
−24.113
1.00
59.06
C


ATOM
1951
CD
PRO
B
438
−75.772
44.650
−22.948
1.00
59.53
C


ATOM
1952
C
PRO
B
438
−78.874
43.715
−24.166
1.00
59.80
C


ATOM
1953
O
PRO
B
438
−78.681
42.690
−23.504
1.00
59.99
O


ATOM
1954
N
ASN
B
439
−80.048
44.031
−24.734
1.00
61.38
N


ATOM
1955
CA
ASN
B
439
−81.202
43.156
−24.666
1.00
61.71
C


ATOM
1956
CB
ASN
B
439
−82.453
43.972
−24.765
1.00
61.56
C


ATOM
1957
CG
ASN
B
439
−83.616
43.278
−24.141
1.00
62.42
C


ATOM
1958
OD1
ASN
B
439
−83.963
42.129
−24.488
1.00
64.09
O


ATOM
1959
ND2
ASN
B
439
−84.250
43.957
−23.198
1.00
62.21
N


ATOM
1960
C
ASN
B
439
−81.103
42.097
−25.788
1.00
61.96
C


ATOM
1961
O
ASN
B
439
−81.911
42.076
−26.722
1.00
62.22
O


ATOM
1962
N
LEU
B
440
−80.090
41.216
−25.678
1.00
61.01
N


ATOM
1963
CA
LEU
B
440
−79.773
40.158
−26.642
1.00
61.13
C


ATOM
1964
CB
LEU
B
440
−78.401
40.491
−27.264
1.00
61.11
C


ATOM
1965
CG
LEU
B
440
−78.293
41.836
−27.960
1.00
59.46
C


ATOM
1966
CD1
LEU
B
440
−76.926
42.042
−28.476
1.00
58.29
C


ATOM
1967
CD2
LEU
B
440
−79.271
41.930
−29.105
1.00
58.76
C


ATOM
1968
C
LEU
B
440
−79.736
38.721
−26.091
1.00
61.57
C


ATOM
1969
O
LEU
B
440
−79.230
38.491
−24.994
1.00
61.27
O


ATOM
1970
N
VAL
B
441
−80.247
37.758
−26.862
1.00
62.02
N


ATOM
1971
CA
VAL
B
441
−80.214
36.328
−26.483
1.00
62.90
C


ATOM
1972
CB
VAL
B
441
−81.570
35.746
−26.017
1.00
62.40
C


ATOM
1973
CG1
VAL
B
441
−81.444
34.252
−25.761
1.00
62.92
C


ATOM
1974
CG2
VAL
B
441
−82.092
36.460
−24.775
1.00
61.58
C


ATOM
1975
C
VAL
B
441
−79.655
35.552
−27.680
1.00
63.94
C


ATOM
1976
O
VAL
B
441
−80.283
35.579
−28.737
1.00
64.07
O


ATOM
1977
N
ALA
B
442
−78.496
34.882
−27.524
1.00
63.55
N


ATOM
1978
CA
ALA
B
442
−77.838
34.123
−28.593
1.00
65.18
C


ATOM
1979
CB
ALA
B
442
−76.643
33.361
−28.056
1.00
64.97
C


ATOM
1980
C
ALA
B
442
−78.740
33.182
−29.379
1.00
66.71
C


ATOM
1981
O
ALA
B
442
−79.629
32.497
−28.839
1.00
66.50
O


ATOM
1982
N
ALA
B
443
−78.506
33.180
−30.688
1.00
72.51
N


ATOM
1983
CA
ALA
B
443
−79.223
32.337
−31.630
1.00
74.74
C


ATOM
1984
CB
ALA
B
443
−80.508
33.007
−32.070
1.00
74.63
C


ATOM
1985
C
ALA
B
443
−78.323
32.072
−32.820
1.00
76.48
C


ATOM
1986
O
ALA
B
443
−77.381
32.839
−33.082
1.00
76.64
O


ATOM
1987
N
LEU
B
444
−78.576
30.936
−33.489
1.00
83.55
N


ATOM
1988
CA
LEU
B
444
−77.880
30.481
−34.689
1.00
85.83
C


ATOM
1989
CB
LEU
B
444
−76.964
29.278
−34.398
1.00
85.77
C


ATOM
1990
CG
LEU
B
444
−75.812
29.013
−35.370
1.00
85.71
C


ATOM
1991
CD1
LEU
B
444
−76.248
28.122
−36.509
1.00
85.91
C


ATOM
1992
CD2
LEU
B
444
−75.150
30.303
−35.853
1.00
85.83
C


ATOM
1993
C
LEU
B
444
−79.042
30.122
−35.619
1.00
87.65
C


ATOM
1994
O
LEU
B
444
−79.531
28.979
−35.621
1.00
87.86
O


ATOM
1995
N
PRO
B
445
−79.562
31.140
−36.347
1.00
91.99
N


ATOM
1996
CA
PRO
B
445
−80.728
30.905
−37.201
1.00
93.36
C


ATOM
1997
CB
PRO
B
445
−81.401
32.282
−37.238
1.00
93.34
C


ATOM
1998
CG
PRO
B
445
−80.375
33.270
−36.705
1.00
92.71
C


ATOM
1999
CD
PRO
B
445
−79.122
32.545
−36.433
1.00
91.94
C


ATOM
2000
C
PRO
B
445
−80.406
30.379
−38.603
1.00
94.82
C


ATOM
2001
O
PRO
B
445
−79.243
30.442
−39.030
1.00
95.02
O


ATOM
2002
N
PRO
B
446
−81.423
29.864
−39.339
1.00
100.30
N


ATOM
2003
CA
PRO
B
446
−81.172
29.360
−40.707
1.00
101.67
C


ATOM
2004
CB
PRO
B
446
−82.565
28.945
−41.192
1.00
101.62
C


ATOM
2005
CG
PRO
B
446
−83.513
29.671
−40.290
1.00
100.98
C


ATOM
2006
CD
PRO
B
446
−82.841
29.705
−38.971
1.00
100.26
C


ATOM
2007
C
PRO
B
446
−80.494
30.374
−41.646
1.00
103.06
C


ATOM
2008
O
PRO
B
446
−81.112
31.345
−42.102
1.00
103.50
O


ATOM
2009
N
SER
B
447
−79.193
30.120
−41.908
1.00
108.30
N


ATOM
2010
CA
SER
B
447
−78.239
30.894
−42.717
1.00
109.79
C


ATOM
2011
CB
SER
B
447
−77.048
30.038
−43.148
1.00
109.70
C


ATOM
2012
OG
SER
B
447
−77.472
28.871
−43.833
1.00
110.07
O


ATOM
2013
C
SER
B
447
−78.721
31.820
−43.859
1.00
110.65
C


ATOM
2014
O
SER
B
447
−78.629
33.043
−43.691
1.00
110.94
O


ATOM
2015
N
THR
B
448
−79.205
31.263
−45.007
1.00
111.76
N


ATOM
2016
CA
THR
B
448
−79.627
32.021
−46.211
1.00
112.95
C


ATOM
2017
CB
THR
B
448
−81.051
32.675
−46.122
1.00
113.38
C


ATOM
2018
OG1
THR
B
448
−81.534
32.935
−47.451
1.00
114.43
O


ATOM
2019
CG2
THR
B
448
−81.088
33.990
−45.303
1.00
113.43
C


ATOM
2020
C
THR
B
448
−78.504
32.906
−46.819
1.00
113.06
C


ATOM
2021
O
THR
B
448
−77.312
32.666
−46.587
1.00
113.35
O


ATOM
2022
N
GLY
B
452
−75.461
38.623
−50.141
1.00
127.63
N


ATOM
2023
CA
GLY
B
452
−74.322
39.520
−50.305
1.00
127.36
C


ATOM
2024
C
GLY
B
452
−73.994
40.335
−49.067
1.00
127.27
C


ATOM
2025
O
GLY
B
452
−74.774
40.335
−48.104
1.00
127.36
O


ATOM
2026
N
TRP
B
453
−72.829
41.046
−49.090
1.00
122.80
N


ATOM
2027
CA
TRP
B
453
−72.319
41.891
−47.987
1.00
122.17
C


ATOM
2028
CB
TRP
B
453
−70.949
42.535
−48.332
1.00
122.48
C


ATOM
2029
CG
TRP
B
453
−70.383
43.388
−47.225
1.00
124.10
C


ATOM
2030
CD1
TRP
B
453
−69.563
42.980
−46.214
1.00
125.45
C


ATOM
2031
NE1
TRP
B
453
−69.277
44.037
−45.377
1.00
125.89
N


ATOM
2032
CE2
TRP
B
453
−69.926
45.156
−45.830
1.00
126.02
C


ATOM
2033
CD2
TRP
B
453
−70.633
44.786
−46.998
1.00
125.51
C


ATOM
2034
CE3
TRP
B
453
−71.391
45.766
−47.669
1.00
126.21
C


ATOM
2035
CZ3
TRP
B
453
−71.418
47.056
−47.160
1.00
126.79
C


ATOM
2036
CH2
TRP
B
453
−70.706
47.393
−45.998
1.00
127.19
C


ATOM
2037
CZ2
TRP
B
453
−69.963
46.457
−45.312
1.00
126.61
C


ATOM
2038
C
TRP
B
453
−73.304
42.963
−47.472
1.00
121.09
C


ATOM
2039
O
TRP
B
453
−73.843
43.745
−48.267
1.00
121.09
O


ATOM
2040
N
GLN
B
454
−73.493
43.010
−46.132
1.00
112.45
N


ATOM
2041
CA
GLN
B
454
−74.348
43.982
−45.450
1.00
110.83
C


ATOM
2042
CB
GLN
B
454
−75.655
43.349
−44.953
1.00
111.06
C


ATOM
2043
CG
GLN
B
454
−76.547
42.747
−46.064
1.00
112.66
C


ATOM
2044
CD
GLN
B
454
−76.778
43.590
−47.325
1.00
114.86
C


ATOM
2045
OE1
GLN
B
454
−77.171
44.775
−47.288
1.00
116.38
O


ATOM
2046
NE2
GLN
B
454
−76.544
42.975
−48.487
1.00
115.50
N


ATOM
2047
C
GLN
B
454
−73.595
44.729
−44.337
1.00
109.32
C


ATOM
2048
O
GLN
B
454
−72.538
44.271
−43.875
1.00
109.03
O


ATOM
2049
N
LEU
B
455
−74.120
45.907
−43.938
1.00
102.05
N


ATOM
2050
CA
LEU
B
455
−73.486
46.731
−42.907
1.00
100.09
C


ATOM
2051
CB
LEU
B
455
−73.601
48.239
−43.203
1.00
99.99
C


ATOM
2052
CG
LEU
B
455
−72.755
49.173
−42.336
1.00
99.59
C


ATOM
2053
CD1
LEU
B
455
−71.273
48.977
−42.577
1.00
98.61
C


ATOM
2054
CD2
LEU
B
455
−73.148
50.606
−42.538
1.00
99.38
C


ATOM
2055
C
LEU
B
455
−73.909
46.390
−41.474
1.00
98.78
C


ATOM
2056
O
LEU
B
455
−75.098
46.445
−41.116
1.00
98.56
O


ATOM
2057
N
PHE
B
456
−72.909
46.036
−40.657
1.00
93.82
N


ATOM
2058
CA
PHE
B
456
−73.130
45.694
−39.266
1.00
92.42
C


ATOM
2059
CB
PHE
B
456
−72.575
44.301
−38.925
1.00
92.95
C


ATOM
2060
CG
PHE
B
456
−73.280
43.119
−39.552
1.00
94.75
C


ATOM
2061
CD1
PHE
B
456
−74.642
43.167
−39.835
1.00
96.82
C


ATOM
2062
CE1
PHE
B
456
−75.290
42.077
−40.415
1.00
97.51
C


ATOM
2063
CZ
PHE
B
456
−74.586
40.924
−40.684
1.00
98.15
C


ATOM
2064
CE2
PHE
B
456
−73.240
40.850
−40.395
1.00
97.34
C


ATOM
2065
CD2
PHE
B
456
−72.590
41.946
−39.826
1.00
96.09
C


ATOM
2066
C
PHE
B
456
−72.531
46.742
−38.370
1.00
90.96
C


ATOM
2067
O
PHE
B
456
−71.347
47.078
−38.502
1.00
90.49
O


ATOM
2068
N
CYS
B
457
−73.373
47.247
−37.450
1.00
87.32
N


ATOM
2069
CA
CYS
B
457
−73.034
48.272
−36.478
1.00
85.52
C


ATOM
2070
CB
CYS
B
457
−73.687
49.596
−36.852
1.00
85.99
C


ATOM
2071
SG
CYS
B
457
−73.007
50.355
−38.340
1.00
87.56
S


ATOM
2072
C
CYS
B
457
−73.413
47.873
−35.088
1.00
83.67
C


ATOM
2073
O
CYS
B
457
−74.446
47.243
−34.870
1.00
83.32
O


ATOM
2074
N
ARG
B
458
−72.595
48.290
−34.140
1.00
77.84
N


ATOM
2075
CA
ARG
B
458
−72.821
48.044
−32.733
1.00
76.05
C


ATOM
2076
CB
ARG
B
458
−72.061
46.810
−32.248
1.00
75.58
C


ATOM
2077
CG
ARG
B
458
−70.567
46.915
−32.358
1.00
73.81
C


ATOM
2078
CD
ARG
B
458
−69.871
45.766
−31.679
1.00
72.65
C


ATOM
2079
NE
ARG
B
458
−68.418
45.964
−31.645
1.00
71.73
N


ATOM
2080
CZ
ARG
B
458
−67.708
46.168
−30.542
1.00
70.47
C


ATOM
2081
NH1
ARG
B
458
−68.301
46.188
−29.357
1.00
69.87
N


ATOM
2082
NH2
ARG
B
458
−66.402
46.355
−30.615
1.00
71.94
N


ATOM
2083
C
ARG
B
458
−72.488
49.289
−31.914
1.00
75.38
C


ATOM
2084
O
ARG
B
458
−71.528
50.012
−32.201
1.00
75.32
O


ATOM
2085
N
THR
B
459
−73.298
49.526
−30.897
1.00
74.97
N


ATOM
2086
CA
THR
B
459
−73.165
50.632
−29.970
1.00
74.11
C


ATOM
2087
CB
THR
B
459
−74.576
50.978
−29.470
1.00
74.25
C


ATOM
2088
OG1
THR
B
459
−75.305
51.553
−30.549
1.00
75.21
O


ATOM
2089
CG2
THR
B
459
−74.583
51.928
−28.291
1.00
74.38
C


ATOM
2090
C
THR
B
459
−72.233
50.216
−28.829
1.00
73.34
C


ATOM
2091
O
THR
B
459
−72.508
49.232
−28.140
1.00
73.34
O


ATOM
2092
N
VAL
B
460
−71.143
50.946
−28.626
1.00
71.16
N


ATOM
2093
CA
VAL
B
460
−70.229
50.646
−27.524
1.00
70.53
C


ATOM
2094
CB
VAL
B
460
−68.835
50.047
−27.892
1.00
70.38
C


ATOM
2095
CG1
VAL
B
460
−68.605
50.023
−29.385
1.00
70.18
C


ATOM
2096
CG2
VAL
B
460
−67.669
50.708
−27.151
1.00
70.10
C


ATOM
2097
C
VAL
B
460
−70.219
51.769
−26.496
1.00
70.41
C


ATOM
2098
O
VAL
B
460
−69.932
52.922
−26.831
1.00
70.49
O


ATOM
2099
N
TRP
B
461
−70.587
51.449
−25.256
1.00
71.19
N


ATOM
2100
CA
TRP
B
461
−70.600
52.468
−24.220
1.00
71.20
C


ATOM
2101
CB
TRP
B
461
−71.716
52.230
−23.222
1.00
70.38
C


ATOM
2102
CG
TRP
B
461
−73.086
52.530
−23.725
1.00
68.32
C


ATOM
2103
CD1
TRP
B
461
−73.821
51.788
−24.600
1.00
66.23
C


ATOM
2104
NE1
TRP
B
461
−75.082
52.327
−24.739
1.00
65.16
N


ATOM
2105
CE2
TRP
B
461
−75.176
53.441
−23.950
1.00
65.89
C


ATOM
2106
CD2
TRP
B
461
−73.944
53.582
−23.271
1.00
67.24
C


ATOM
2107
CE3
TRP
B
461
−73.789
54.645
−22.363
1.00
66.29
C


ATOM
2108
CZ3
TRP
B
461
−74.852
55.511
−22.164
1.00
65.24
C


ATOM
2109
CH2
TRP
B
461
−76.054
55.355
−22.858
1.00
64.31
C


ATOM
2110
CZ2
TRP
B
461
−76.233
54.336
−23.768
1.00
64.76
C


ATOM
2111
C
TRP
B
461
−69.271
52.531
−23.493
1.00
72.30
C


ATOM
2112
O
TRP
B
461
−68.647
51.506
−23.189
1.00
72.67
O


ATOM
2113
N
SER
B
462
−68.861
53.744
−23.181
1.00
74.24
N


ATOM
2114
CA
SER
B
462
−67.647
53.992
−22.450
1.00
75.66
C


ATOM
2115
CB
SER
B
462
−67.283
55.462
−22.583
1.00
75.63
C


ATOM
2116
OG
SER
B
462
−67.969
56.222
−21.593
1.00
75.96
O


ATOM
2117
C
SER
B
462
−67.941
53.748
−20.995
1.00
76.81
C


ATOM
2118
O
SER
B
462
−69.083
53.488
−20.615
1.00
76.78
O


ATOM
2119
N
ALA
B
463
−66.913
53.899
−20.169
1.00
83.59
N


ATOM
2120
CA
ALA
B
463
−67.059
53.845
−18.733
1.00
85.46
C


ATOM
2121
CB
ALA
B
463
−65.747
53.449
−18.103
1.00
85.21
C


ATOM
2122
C
ALA
B
463
−67.388
55.321
−18.382
1.00
86.93
C


ATOM
2123
O
ALA
B
463
−66.940
56.237
−19.096
1.00
87.12
O


ATOM
2124
N
HIS
B
464
−68.181
55.542
−17.317
1.00
91.57
N


ATOM
2125
CA
HIS
B
464
−68.569
56.865
−16.837
1.00
93.29
C


ATOM
2126
CB
HIS
B
464
−69.353
56.682
−15.550
1.00
93.19
C


ATOM
2127
CG
HIS
B
464
−70.259
57.811
−15.222
1.00
94.40
C


ATOM
2128
ND1
HIS
B
464
−70.153
58.482
−14.026
1.00
95.91
N


ATOM
2129
CE1
HIS
B
464
−71.114
59.398
−14.042
1.00
96.37
C


ATOM
2130
NE2
HIS
B
464
−71.815
59.356
−15.177
1.00
96.33
N


ATOM
2131
CD2
HIS
B
464
−71.279
58.342
−15.938
1.00
95.65
C


ATOM
2132
C
HIS
B
464
−67.316
57.718
−16.583
1.00
94.53
C


ATOM
2133
O
HIS
B
464
−66.354
57.220
−16.007
1.00
94.76
O


ATOM
2134
N
SER
B
465
−67.299
58.973
−17.040
1.00
98.33
N


ATOM
2135
CA
SER
B
465
−66.131
59.856
−16.882
1.00
100.02
C


ATOM
2136
CB
SER
B
465
−66.287
61.104
−17.743
1.00
99.96
C


ATOM
2137
OG
SER
B
465
−67.287
61.959
−17.209
1.00
100.90
O


ATOM
2138
C
SER
B
465
−65.818
60.262
−15.426
1.00
101.11
C


ATOM
2139
O
SER
B
465
−64.683
60.648
−15.123
1.00
101.22
O


ATOM
2140
N
GLY
B
466
−66.819
60.185
−14.555
1.00
105.25
N


ATOM
2141
CA
GLY
B
466
−66.659
60.566
−13.161
1.00
106.92
C


ATOM
2142
C
GLY
B
466
−67.039
62.020
−12.944
1.00
108.18
C


ATOM
2143
O
GLY
B
466
−67.212
62.759
−13.923
1.00
108.28
O


ATOM
2144
N
PRO
B
467
−67.153
62.482
−11.672
1.00
110.29
N


ATOM
2145
CA
PRO
B
467
−67.595
63.862
−11.426
1.00
110.92
C


ATOM
2146
CB
PRO
B
467
−68.260
63.783
−10.037
1.00
110.81
C


ATOM
2147
CG
PRO
B
467
−68.208
62.298
−9.634
1.00
110.68
C


ATOM
2148
CD
PRO
B
467
−67.043
61.752
−10.399
1.00
110.39
C


ATOM
2149
C
PRO
B
467
−66.599
65.015
−11.571
1.00
111.61
C


ATOM
2150
O
PRO
B
467
−66.978
66.145
−11.229
1.00
111.89
O


ATOM
2151
N
THR
B
468
−65.366
64.776
−12.095
1.00
112.93
N


ATOM
2152
CA
THR
B
468
−64.389
65.867
−12.288
1.00
113.63
C


ATOM
2153
CB
THR
B
468
−63.022
65.346
−12.752
1.00
113.72
C


ATOM
2154
OG1
THR
B
468
−62.623
64.204
−11.980
1.00
114.00
O


ATOM
2155
CG2
THR
B
468
−61.943
66.443
−12.763
1.00
113.06
C


ATOM
2156
C
THR
B
468
−64.931
66.818
−13.341
1.00
114.18
C


ATOM
2157
O
THR
B
468
−65.436
66.351
−14.358
1.00
114.47
O


ATOM
2158
N
ARG
B
469
−64.854
68.139
−13.109
1.00
116.36
N


ATOM
2159
CA
ARG
B
469
−65.353
69.118
−14.087
1.00
116.78
C


ATOM
2160
CB
ARG
B
469
−65.519
70.513
−13.460
1.00
116.61
C


ATOM
2161
C
ARG
B
469
−64.473
69.131
−15.377
1.00
117.02
C


ATOM
2162
O
ARG
B
469
−64.922
69.595
−16.431
1.00
117.28
O


ATOM
2163
N
MET
B
470
−63.235
68.594
−15.286
1.00
115.47
N


ATOM
2164
CA
MET
B
470
−62.323
68.485
−16.418
1.00
115.35
C


ATOM
2165
CB
MET
B
470
−61.003
69.219
−16.122
1.00
115.40
C


ATOM
2166
C
MET
B
470
−62.120
66.978
−16.703
1.00
115.23
C


ATOM
2167
O
MET
B
470
−60.997
66.521
−16.945
1.00
115.36
O


ATOM
2168
N
ALA
B
471
−63.240
66.207
−16.656
1.00
112.94
N


ATOM
2169
CA
ALA
B
471
−63.279
64.754
−16.886
1.00
112.30
C


ATOM
2170
CB
ALA
B
471
−64.280
64.082
−15.953
1.00
112.14
C


ATOM
2171
C
ALA
B
471
−63.595
64.378
−18.328
1.00
111.87
C


ATOM
2172
O
ALA
B
471
−64.359
65.075
−19.019
1.00
111.95
O


ATOM
2173
N
THR
B
472
−63.013
63.245
−18.764
1.00
108.06
N


ATOM
2174
CA
THR
B
472
−63.203
62.708
−20.104
1.00
107.28
C


ATOM
2175
CB
THR
B
472
−62.134
63.281
−21.061
1.00
107.44
C


ATOM
2176
OG1
THR
B
472
−62.624
63.256
−22.403
1.00
107.35
O


ATOM
2177
CG2
THR
B
472
−60.753
62.607
−20.918
1.00
107.39
C


ATOM
2178
C
THR
B
472
−63.468
61.169
−20.148
1.00
106.42
C


ATOM
2179
O
THR
B
472
−62.699
60.386
−19.579
1.00
106.26
O


ATOM
2180
N
ALA
B
473
−64.578
60.768
−20.808
1.00
100.03
N


ATOM
2181
CA
ALA
B
473
−64.996
59.380
−21.021
1.00
98.90
C


ATOM
2182
CB
ALA
B
473
−66.484
59.238
−20.767
1.00
98.99
C


ATOM
2183
C
ALA
B
473
−64.674
59.012
−22.481
1.00
98.11
C


ATOM
2184
O
ALA
B
473
−65.074
59.735
−23.392
1.00
97.85
O


ATOM
2185
N
ILE
B
474
−63.934
57.908
−22.701
1.00
94.49
N


ATOM
2186
CA
ILE
B
474
−63.512
57.467
−24.042
1.00
93.51
C


ATOM
2187
CB
ILE
B
474
−61.943
57.470
−24.185
1.00
93.53
C


ATOM
2188
CG1
ILE
B
474
−61.326
58.856
−23.878
1.00
93.64
C


ATOM
2189
CD1
ILE
B
474
−60.862
59.102
−22.394
1.00
94.37
C


ATOM
2190
CG2
ILE
B
474
−61.478
57.016
−25.563
1.00
93.58
C


ATOM
2191
C
ILE
B
474
−64.149
56.122
−24.419
1.00
92.67
C


ATOM
2192
O
ILE
B
474
−64.214
55.218
−23.588
1.00
92.53
O


ATOM
2193
N
ALA
B
475
−64.619
56.010
−25.670
1.00
89.81
N


ATOM
2194
CA
ALA
B
475
−65.227
54.810
−26.233
1.00
89.14
C


ATOM
2195
CB
ALA
B
475
−66.705
55.038
−26.489
1.00
88.89
C


ATOM
2196
C
ALA
B
475
−64.489
54.415
−27.532
1.00
88.97
C


ATOM
2197
O
ALA
B
475
−64.430
55.202
−28.478
1.00
88.77
O


ATOM
2198
N
ARG
B
476
−63.899
53.202
−27.555
1.00
91.20
N


ATOM
2199
CA
ARG
B
476
−63.126
52.687
−28.694
1.00
91.05
C


ATOM
2200
CB
ARG
B
476
−61.694
52.324
−28.252
1.00
91.07
C


ATOM
2201
CG
ARG
B
476
−60.980
53.406
−27.489
1.00
91.51
C


ATOM
2202
CD
ARG
B
476
−59.652
52.942
−26.945
1.00
93.16
C


ATOM
2203
NE
ARG
B
476
−58.894
54.061
−26.366
1.00
95.08
N


ATOM
2204
CZ
ARG
B
476
−58.959
54.441
−25.086
1.00
95.78
C


ATOM
2205
NH1
ARG
B
476
−59.744
53.793
−24.230
1.00
96.38
N


ATOM
2206
NH2
ARG
B
476
−58.241
55.476
−24.657
1.00
95.88
N


ATOM
2207
C
ARG
B
476
−63.785
51.463
−29.343
1.00
90.94
C


ATOM
2208
O
ARG
B
476
−64.694
50.868
−28.758
1.00
90.98
O


ATOM
2209
N
CYS
B
477
−63.304
51.083
−30.552
1.00
88.88
N


ATOM
2210
CA
CYS
B
477
−63.772
49.922
−31.321
1.00
88.83
C


ATOM
2211
CB
CYS
B
477
−64.138
50.326
−32.744
1.00
88.48
C


ATOM
2212
SG
CYS
B
477
−65.297
51.695
−32.860
1.00
87.32
S


ATOM
2213
C
CYS
B
477
−62.704
48.862
−31.359
1.00
89.31
C


ATOM
2214
O
CYS
B
477
−61.568
49.075
−30.903
1.00
89.18
O


ATOM
2215
N
ALA
B
478
−63.054
47.733
−31.983
1.00
94.15
N


ATOM
2216
CA
ALA
B
478
−62.116
46.645
−32.192
1.00
94.86
C


ATOM
2217
CB
ALA
B
478
−62.863
45.389
−32.620
1.00
95.20
C


ATOM
2218
C
ALA
B
478
−61.164
47.106
−33.316
1.00
95.16
C


ATOM
2219
O
ALA
B
478
−61.631
47.763
−34.248
1.00
95.16
O


ATOM
2220
N
PRO
B
479
−59.846
46.811
−33.249
1.00
97.02
N


ATOM
2221
CA
PRO
B
479
−58.929
47.265
−34.309
1.00
97.37
C


ATOM
2222
CB
PRO
B
479
−57.707
46.383
−34.097
1.00
97.36
C


ATOM
2223
CG
PRO
B
479
−57.687
46.161
−32.634
1.00
97.31
C


ATOM
2224
CD
PRO
B
479
−59.118
46.070
−32.201
1.00
97.04
C


ATOM
2225
C
PRO
B
479
−59.451
47.186
−35.747
1.00
97.84
C


ATOM
2226
O
PRO
B
479
−59.298
48.148
−36.511
1.00
98.32
O


ATOM
2227
N
ASP
B
480
−60.100
46.072
−36.106
1.00
98.53
N


ATOM
2228
CA
ASP
B
480
−60.631
45.901
−37.448
1.00
98.64
C


ATOM
2229
CB
ASP
B
480
−60.437
44.456
−37.960
1.00
99.11
C


ATOM
2230
CG
ASP
B
480
−60.712
43.321
−36.971
1.00
101.51
C


ATOM
2231
OD1
ASP
B
480
−60.634
43.567
−35.723
1.00
103.08
O


ATOM
2232
OD2
ASP
B
480
−60.994
42.179
−37.436
1.00
103.88
O


ATOM
2233
C
ASP
B
480
−62.046
46.457
−37.642
1.00
98.13
C


ATOM
2234
O
ASP
B
480
−62.797
45.971
−38.492
1.00
98.13
O


ATOM
2235
N
GLU
B
481
−62.394
47.501
−36.867
1.00
95.63
N


ATOM
2236
CA
GLU
B
481
−63.689
48.187
−36.919
1.00
95.12
C


ATOM
2237
CB
GLU
B
481
−64.466
48.026
−35.600
1.00
94.98
C


ATOM
2238
CG
GLU
B
481
−65.174
46.694
−35.404
1.00
93.55
C


ATOM
2239
CD
GLU
B
481
−66.047
46.588
−34.164
1.00
91.31
C


ATOM
2240
OE1
GLU
B
481
−65.681
47.169
−33.115
1.00
89.30
O


ATOM
2241
OE2
GLU
B
481
−67.097
45.909
−34.240
1.00
90.31
O


ATOM
2242
C
GLU
B
481
−63.471
49.667
−37.174
1.00
95.14
C


ATOM
2243
O
GLU
B
481
−62.396
50.193
−36.855
1.00
95.26
O


ATOM
2244
N
GLU
B
482
−64.501
50.343
−37.733
1.00
96.88
N


ATOM
2245
CA
GLU
B
482
−64.494
51.782
−38.033
1.00
96.69
C


ATOM
2246
CB
GLU
B
482
−64.755
52.040
−39.542
1.00
97.05
C


ATOM
2247
CG
GLU
B
482
−63.538
51.866
−40.458
1.00
98.77
C


ATOM
2248
CD
GLU
B
482
−62.350
52.817
−40.312
1.00
100.97
C


ATOM
2249
OE1
GLU
B
482
−62.551
54.010
−39.973
1.00
101.66
O


ATOM
2250
OE2
GLU
B
482
−61.208
52.359
−40.555
1.00
101.54
O


ATOM
2251
C
GLU
B
482
−65.510
52.552
−37.160
1.00
95.97
C


ATOM
2252
O
GLU
B
482
−66.665
52.138
−37.067
1.00
96.15
O


ATOM
2253
N
LEU
B
483
−65.086
53.661
−36.525
1.00
94.44
N


ATOM
2254
CA
LEU
B
483
−65.987
54.467
−35.695
1.00
93.65
C


ATOM
2255
CB
LEU
B
483
−65.188
55.264
−34.656
1.00
93.65
C


ATOM
2256
CG
LEU
B
483
−65.994
55.805
−33.488
1.00
92.96
C


ATOM
2257
CD1
LEU
B
483
−65.282
55.536
−32.197
1.00
92.61
C


ATOM
2258
CD2
LEU
B
483
−66.223
57.289
−33.628
1.00
92.74
C


ATOM
2259
C
LEU
B
483
−66.763
55.413
−36.611
1.00
93.20
C


ATOM
2260
O
LEU
B
483
−66.282
56.505
−36.919
1.00
92.99
O


ATOM
2261
N
LEU
B
484
−67.948
54.990
−37.057
1.00
91.03
N


ATOM
2262
CA
LEU
B
484
−68.770
55.780
−37.969
1.00
90.35
C


ATOM
2263
CB
LEU
B
484
−69.846
54.914
−38.623
1.00
90.12
C


ATOM
2264
CG
LEU
B
484
−69.384
53.855
−39.611
1.00
90.20
C


ATOM
2265
CD1
LEU
B
484
−70.429
53.636
−40.680
1.00
89.15
C


ATOM
2266
CD2
LEU
B
484
−67.994
54.169
−40.221
1.00
89.63
C


ATOM
2267
C
LEU
B
484
−69.424
56.993
−37.337
1.00
90.26
C


ATOM
2268
O
LEU
B
484
−69.623
58.010
−38.005
1.00
90.42
O


ATOM
2269
N
SER
B
485
−69.800
56.877
−36.073
1.00
90.25
N


ATOM
2270
CA
SER
B
485
−70.469
57.948
−35.371
1.00
89.82
C


ATOM
2271
CB
SER
B
485
−71.974
57.816
−35.544
1.00
89.68
C


ATOM
2272
OG
SER
B
485
−72.718
57.958
−34.345
1.00
89.43
O


ATOM
2273
C
SER
B
485
−70.095
57.962
−33.916
1.00
89.74
C


ATOM
2274
O
SER
B
485
−69.499
57.017
−33.401
1.00
89.92
O


ATOM
2275
N
CYS
B
486
−70.447
59.055
−33.257
1.00
89.97
N


ATOM
2276
CA
CYS
B
486
−70.186
59.279
−31.850
1.00
89.87
C


ATOM
2277
CB
CYS
B
486
−68.778
59.840
−31.644
1.00
90.20
C


ATOM
2278
SG
CYS
B
486
−68.445
60.453
−29.975
1.00
93.44
S


ATOM
2279
C
CYS
B
486
−71.276
60.219
−31.339
1.00
88.92
C


ATOM
2280
O
CYS
B
486
−71.765
61.088
−32.076
1.00
88.97
O


ATOM
2281
N
SER
B
487
−71.697
59.966
−30.095
1.00
83.57
N


ATOM
2282
CA
SER
B
487
−72.712
60.680
−29.337
1.00
82.49
C


ATOM
2283
CB
SER
B
487
−74.099
60.102
−29.605
1.00
82.58
C


ATOM
2284
OG
SER
B
487
−74.369
58.914
−28.880
1.00
82.74
O


ATOM
2285
C
SER
B
487
−72.306
60.585
−27.861
1.00
81.85
C


ATOM
2286
O
SER
B
487
−71.257
60.001
−27.570
1.00
81.86
O


ATOM
2287
N
SER
B
488
−73.086
61.194
−26.942
1.00
79.82
N


ATOM
2288
CA
SER
B
488
−72.791
61.200
−25.502
1.00
79.19
C


ATOM
2289
CB
SER
B
488
−71.826
62.331
−25.148
1.00
79.19
C


ATOM
2290
OG
SER
B
488
−72.426
63.603
−25.331
1.00
79.03
O


ATOM
2291
C
SER
B
488
−74.054
61.326
−24.675
1.00
78.79
C


ATOM
2292
O
SER
B
488
−75.085
61.775
−25.188
1.00
78.90
O


ATOM
2293
N
PHE
B
489
−73.974
60.952
−23.391
1.00
75.75
N


ATOM
2294
CA
PHE
B
489
−75.117
61.012
−22.485
1.00
75.43
C


ATOM
2295
CB
PHE
B
489
−75.921
59.717
−22.597
1.00
75.12
C


ATOM
2296
CG
PHE
B
489
−77.093
59.529
−21.677
1.00
73.56
C


ATOM
2297
CD1
PHE
B
489
−78.318
60.123
−21.958
1.00
71.80
C


ATOM
2298
CE1
PHE
B
489
−79.419
59.928
−21.123
1.00
70.76
C


ATOM
2299
CZ
PHE
B
489
−79.303
59.114
−20.020
1.00
70.83
C


ATOM
2300
CE2
PHE
B
489
−78.095
58.500
−19.732
1.00
70.74
C


ATOM
2301
CD2
PHE
B
489
−76.993
58.704
−20.563
1.00
71.60
C


ATOM
2302
C
PHE
B
489
−74.686
61.267
−21.056
1.00
75.85
C


ATOM
2303
O
PHE
B
489
−73.584
60.884
−20.653
1.00
75.64
O


ATOM
2304
N
SER
B
490
−75.571
61.918
−20.305
1.00
79.05
N


ATOM
2305
CA
SER
B
490
−75.419
62.298
−18.911
1.00
79.93
C


ATOM
2306
CB
SER
B
490
−74.873
63.722
−18.835
1.00
80.03
C


ATOM
2307
OG
SER
B
490
−75.315
64.449
−17.699
1.00
81.51
O


ATOM
2308
C
SER
B
490
−76.810
62.206
−18.296
1.00
80.40
C


ATOM
2309
O
SER
B
490
−77.742
62.767
−18.856
1.00
80.25
O


ATOM
2310
N
ARG
B
491
−76.964
61.477
−17.170
1.00
84.03
N


ATOM
2311
CA
ARG
B
491
−78.258
61.283
−16.500
1.00
85.04
C


ATOM
2312
CB
ARG
B
491
−78.178
60.137
−15.482
1.00
84.72
C


ATOM
2313
C
ARG
B
491
−78.840
62.573
−15.886
1.00
86.05
C


ATOM
2314
O
ARG
B
491
−80.022
62.591
−15.560
1.00
86.32
O


ATOM
2315
N
SER
B
492
−78.013
63.650
−15.761
1.00
91.60
N


ATOM
2316
CA
SER
B
492
−78.324
64.991
−15.218
1.00
92.72
C


ATOM
2317
CB
SER
B
492
−77.248
65.420
−14.212
1.00
92.72
C


ATOM
2318
OG
SER
B
492
−76.036
65.860
−14.812
1.00
92.51
O


ATOM
2319
C
SER
B
492
−78.477
66.092
−16.313
1.00
93.57
C


ATOM
2320
O
SER
B
492
−78.938
67.198
−16.019
1.00
94.01
O


ATOM
2321
N
GLY
B
493
−78.053
65.788
−17.540
1.00
96.27
N


ATOM
2322
CA
GLY
B
493
−78.109
66.709
−18.671
1.00
96.99
C


ATOM
2323
C
GLY
B
493
−76.892
67.606
−18.788
1.00
97.51
C


ATOM
2324
O
GLY
B
493
−76.600
68.118
−19.876
1.00
97.74
O


ATOM
2325
N
LYS
B
494
−76.173
67.795
−17.661
1.00
98.26
N


ATOM
2326
CA
LYS
B
494
−74.973
68.633
−17.543
1.00
98.74
C


ATOM
2327
CB
LYS
B
494
−74.570
68.799
−16.055
1.00
98.94
C


ATOM
2328
CG
LYS
B
494
−75.584
69.547
−15.192
1.00
100.15
C


ATOM
2329
CD
LYS
B
494
−75.531
69.091
−13.731
1.00
102.35
C


ATOM
2330
CE
LYS
B
494
−76.668
69.652
−12.887
1.00
103.47
C


ATOM
2331
NZ
LYS
B
494
−78.005
69.083
−13.257
1.00
103.97
N


ATOM
2332
C
LYS
B
494
−73.784
68.125
−18.385
1.00
98.61
C


ATOM
2333
O
LYS
B
494
−72.873
67.487
−17.851
1.00
98.84
O


ATOM
2334
N
ARG
B
495
−73.792
68.407
−19.695
1.00
96.50
N


ATOM
2335
CA
ARG
B
495
−72.702
67.973
−20.574
1.00
96.64
C


ATOM
2336
CB
ARG
B
495
−73.033
66.666
−21.333
1.00
96.79
C


ATOM
2337
CG
ARG
B
495
−74.345
66.675
−22.085
1.00
96.15
C


ATOM
2338
CD
ARG
B
495
−74.561
65.412
−22.880
1.00
95.77
C


ATOM
2339
NE
ARG
B
495
−75.702
65.601
−23.773
1.00
96.50
N


ATOM
2340
CZ
ARG
B
495
−75.601
65.836
−25.078
1.00
96.55
C


ATOM
2341
NH1
ARG
B
495
−76.692
66.036
−25.808
1.00
96.40
N


ATOM
2342
NH2
ARG
B
495
−74.410
65.868
−25.666
1.00
96.96
N


ATOM
2343
C
ARG
B
495
−72.171
69.040
−21.503
1.00
96.85
C


ATOM
2344
O
ARG
B
495
−72.881
69.988
−21.831
1.00
96.81
O


ATOM
2345
N
ARG
B
496
−70.912
68.882
−21.915
1.00
96.61
N


ATOM
2346
CA
ARG
B
496
−70.236
69.795
−22.829
1.00
97.36
C


ATOM
2347
CB
ARG
B
496
−68.947
70.374
−22.207
1.00
97.76
C


ATOM
2348
CG
ARG
B
496
−69.188
71.646
−21.366
1.00
99.31
C


ATOM
2349
CD
ARG
B
496
−67.969
72.560
−21.228
1.00
101.85
C


ATOM
2350
NE
ARG
B
496
−66.832
71.927
−20.546
1.00
104.10
N


ATOM
2351
CZ
ARG
B
496
−65.770
71.399
−21.157
1.00
104.55
C


ATOM
2352
NH1
ARG
B
496
−65.676
71.420
−22.485
1.00
104.86
N


ATOM
2353
NH2
ARG
B
496
−64.797
70.845
−20.446
1.00
104.83
N


ATOM
2354
C
ARG
B
496
−69.997
69.133
−24.191
1.00
97.42
C


ATOM
2355
O
ARG
B
496
−69.019
69.439
−24.880
1.00
97.20
O


ATOM
2356
N
GLY
B
497
−70.911
68.232
−24.552
1.00
97.26
N


ATOM
2357
CA
GLY
B
497
−70.893
67.497
−25.810
1.00
97.69
C


ATOM
2358
C
GLY
B
497
−69.932
66.331
−25.891
1.00
98.14
C


ATOM
2359
O
GLY
B
497
−69.592
65.716
−24.876
1.00
98.09
O


ATOM
2360
N
GLU
B
498
−69.501
66.026
−27.130
1.00
99.98
N


ATOM
2361
CA
GLU
B
498
−68.601
64.928
−27.490
1.00
100.60
C


ATOM
2362
CB
GLU
B
498
−69.422
63.637
−27.690
1.00
100.54
C


ATOM
2363
CG
GLU
B
498
−70.232
63.578
−28.982
1.00
99.77
C


ATOM
2364
CD
GLU
B
498
−71.598
64.247
−29.036
1.00
99.78
C


ATOM
2365
OE1
GLU
B
498
−72.349
64.209
−28.031
1.00
99.38
O


ATOM
2366
OE2
GLU
B
498
−71.933
64.781
−30.118
1.00
99.93
O


ATOM
2367
C
GLU
B
498
−67.810
65.231
−28.770
1.00
101.27
C


ATOM
2368
O
GLU
B
498
−68.208
66.105
−29.542
1.00
101.37
O


ATOM
2369
N
ARG
B
499
−66.720
64.488
−29.015
1.00
102.02
N


ATOM
2370
CA
ARG
B
499
−65.915
64.670
−30.220
1.00
103.16
C


ATOM
2371
CB
ARG
B
499
−64.914
65.838
−30.075
1.00
103.36
C


ATOM
2372
CG
ARG
B
499
−63.771
65.661
−29.066
1.00
104.82
C


ATOM
2373
CD
ARG
B
499
−63.010
66.968
−28.889
1.00
107.27
C


ATOM
2374
NE
ARG
B
499
−61.560
66.786
−28.803
1.00
108.74
N


ATOM
2375
CZ
ARG
B
499
−60.748
66.743
−29.859
1.00
110.20
C


ATOM
2376
NH1
ARG
B
499
−61.237
66.848
−31.091
1.00
110.76
N


ATOM
2377
NH2
ARG
B
499
−59.440
66.584
−29.690
1.00
110.74
N


ATOM
2378
C
ARG
B
499
−65.212
63.403
−30.683
1.00
103.63
C


ATOM
2379
O
ARG
B
499
−64.716
62.654
−29.843
1.00
103.79
O


ATOM
2380
N
MET
B
500
−65.166
63.166
−32.016
1.00
104.97
N


ATOM
2381
CA
MET
B
500
−64.464
62.024
−32.618
1.00
105.67
C


ATOM
2382
CB
MET
B
500
−65.081
61.555
−33.951
1.00
105.49
C


ATOM
2383
CG
MET
B
500
−66.574
61.518
−33.996
1.00
105.68
C


ATOM
2384
SD
MET
B
500
−67.135
61.048
−35.655
1.00
106.00
S


ATOM
2385
CE
MET
B
500
−68.702
61.924
−35.734
1.00
106.42
C


ATOM
2386
C
MET
B
500
−63.063
62.545
−32.907
1.00
106.25
C


ATOM
2387
O
MET
B
500
−62.922
63.593
−33.548
1.00
106.65
O


ATOM
2388
N
GLU
B
501
−62.032
61.841
−32.436
1.00
108.32
N


ATOM
2389
CA
GLU
B
501
−60.643
62.261
−32.642
1.00
108.99
C


ATOM
2390
CB
GLU
B
501
−60.233
63.351
−31.631
1.00
109.08
C


ATOM
2391
CG
GLU
B
501
−60.598
63.038
−30.191
1.00
109.68
C


ATOM
2392
CD
GLU
B
501
−59.428
63.072
−29.234
1.00
111.33
C


ATOM
2393
OE1
GLU
B
501
−58.397
62.407
−29.499
1.00
112.50
O


ATOM
2394
OE2
GLU
B
501
−59.550
63.768
−28.203
1.00
111.64
O


ATOM
2395
C
GLU
B
501
−59.677
61.091
−32.599
1.00
109.25
C


ATOM
2396
O
GLU
B
501
−59.884
60.161
−31.813
1.00
109.40
O


ATOM
2397
N
ALA
B
502
−58.619
61.134
−33.439
1.00
110.32
N


ATOM
2398
CA
ALA
B
502
−57.623
60.066
−33.487
1.00
110.50
C


ATOM
2399
CB
ALA
B
502
−56.732
60.212
−34.706
1.00
110.43
C


ATOM
2400
C
ALA
B
502
−56.799
60.056
−32.206
1.00
110.60
C


ATOM
2401
O
ALA
B
502
−56.305
61.106
−31.785
1.00
110.53
O


ATOM
2402
N
GLN
B
503
−56.705
58.877
−31.556
1.00
111.55
N


ATOM
2403
CA
GLN
B
503
−55.966
58.704
−30.301
1.00
111.77
C


ATOM
2404
CB
GLN
B
503
−56.926
58.536
−29.112
1.00
111.82
C


ATOM
2405
CG
GLN
B
503
−56.555
59.397
−27.905
1.00
112.75
C


ATOM
2406
CD
GLN
B
503
−56.913
58.792
−26.555
1.00
113.67
C


ATOM
2407
OE1
GLN
B
503
−57.487
59.470
−25.683
1.00
113.67
O


ATOM
2408
NE2
GLN
B
503
−56.572
57.514
−26.337
1.00
113.24
N


ATOM
2409
C
GLN
B
503
−54.970
57.548
−30.402
1.00
111.66
C


ATOM
2410
O
GLN
B
503
−54.878
56.702
−29.506
1.00
111.55
O


ATOM
2411
N
GLY
B
504
−54.226
57.547
−31.504
1.00
110.07
N


ATOM
2412
CA
GLY
B
504
−53.219
56.544
−31.810
1.00
109.96
C


ATOM
2413
C
GLY
B
504
−53.490
55.899
−33.147
1.00
109.86
C


ATOM
2414
O
GLY
B
504
−53.667
54.682
−33.219
1.00
110.09
O


ATOM
2415
N
GLY
B
505
−53.547
56.727
−34.193
1.00
107.76
N


ATOM
2416
CA
GLY
B
505
−53.794
56.312
−35.574
1.00
107.17
C


ATOM
2417
C
GLY
B
505
−55.244
55.983
−35.853
1.00
106.75
C


ATOM
2418
O
GLY
B
505
−55.739
56.207
−36.966
1.00
106.70
O


ATOM
2419
N
LYS
B
506
−55.921
55.438
−34.817
1.00
103.97
N


ATOM
2420
CA
LYS
B
506
−57.319
55.021
−34.795
1.00
103.43
C


ATOM
2421
CB
LYS
B
506
−57.475
53.707
−34.009
1.00
103.22
C


ATOM
2422
C
LYS
B
506
−58.195
56.119
−34.201
1.00
102.98
C


ATOM
2423
O
LYS
B
506
−57.736
56.916
−33.374
1.00
102.94
O


ATOM
2424
N
LEU
B
507
−59.462
56.138
−34.640
1.00
100.19
N


ATOM
2425
CA
LEU
B
507
−60.488
57.086
−34.243
1.00
99.60
C


ATOM
2426
CB
LEU
B
507
−61.489
57.283
−35.389
1.00
99.62
C


ATOM
2427
CG
LEU
B
507
−61.238
58.461
−36.300
1.00
99.92
C


ATOM
2428
CD1
LEU
B
507
−62.162
58.412
−37.512
1.00
99.81
C


ATOM
2429
CD2
LEU
B
507
−61.374
59.779
−35.541
1.00
100.26
C


ATOM
2430
C
LEU
B
507
−61.244
56.677
−33.010
1.00
99.14
C


ATOM
2431
O
LEU
B
507
−62.007
55.710
−33.045
1.00
99.30
O


ATOM
2432
N
VAL
B
508
−61.059
57.418
−31.926
1.00
97.74
N


ATOM
2433
CA
VAL
B
508
−61.807
57.153
−30.702
1.00
97.21
C


ATOM
2434
CB
VAL
B
508
−60.965
57.106
−29.391
1.00
97.40
C


ATOM
2435
CG1
VAL
B
508
−59.822
56.097
−29.491
1.00
97.46
C


ATOM
2436
CG2
VAL
B
508
−60.459
58.492
−28.979
1.00
97.58
C


ATOM
2437
C
VAL
B
508
−62.985
58.151
−30.656
1.00
96.62
C


ATOM
2438
O
VAL
B
508
−63.221
58.856
−31.633
1.00
96.62
O


ATOM
2439
N
CYS
B
509
−63.723
58.190
−29.551
1.00
95.28
N


ATOM
2440
CA
CYS
B
509
−64.854
59.076
−29.355
1.00
94.70
C


ATOM
2441
CB
CYS
B
509
−66.158
58.379
−29.765
1.00
94.39
C


ATOM
2442
SG
CYS
B
509
−67.660
58.918
−28.888
1.00
93.73
S


ATOM
2443
C
CYS
B
509
−64.799
59.439
−27.882
1.00
94.85
C


ATOM
2444
O
CYS
B
509
−64.850
58.556
−27.023
1.00
94.75
O


ATOM
2445
N
ARG
B
510
−64.580
60.734
−27.590
1.00
98.66
N


ATOM
2446
CA
ARG
B
510
−64.523
61.210
−26.214
1.00
98.77
C


ATOM
2447
CB
ARG
B
510
−63.126
61.622
−25.716
1.00
98.96
C


ATOM
2448
CG
ARG
B
510
−62.429
62.761
−26.441
1.00
99.61
C


ATOM
2449
CD
ARG
B
510
−61.444
63.535
−25.547
1.00
101.26
C


ATOM
2450
NE
ARG
B
510
−60.647
62.705
−24.625
1.00
101.83
N


ATOM
2451
CZ
ARG
B
510
−59.442
62.197
−24.891
1.00
102.45
C


ATOM
2452
NH1
ARG
B
510
−58.866
62.412
−26.068
1.00
102.46
N


ATOM
2453
NH2
ARG
B
510
−58.806
61.463
−23.979
1.00
102.87
N


ATOM
2454
C
ARG
B
510
−65.574
62.221
−25.907
1.00
98.65
C


ATOM
2455
O
ARG
B
510
−65.911
63.044
−26.755
1.00
98.46
O


ATOM
2456
N
ALA
B
511
−66.129
62.119
−24.704
1.00
99.45
N


ATOM
2457
CA
ALA
B
511
−67.163
63.007
−24.210
1.00
99.87
C


ATOM
2458
CB
ALA
B
511
−68.338
62.210
−23.677
1.00
99.79
C


ATOM
2459
C
ALA
B
511
−66.569
63.865
−23.118
1.00
100.26
C


ATOM
2460
O
ALA
B
511
−65.663
63.428
−22.394
1.00
100.16
O


ATOM
2461
N
HIS
B
512
−67.062
65.104
−23.017
1.00
103.56
N


ATOM
2462
CA
HIS
B
512
−66.572
66.038
−22.022
1.00
103.97
C


ATOM
2463
CB
HIS
B
512
−66.059
67.328
−22.680
1.00
104.15
C


ATOM
2464
CG
HIS
B
512
−65.158
67.086
−23.851
1.00
104.58
C


ATOM
2465
ND1
HIS
B
512
−63.836
66.696
−23.679
1.00
104.80
N


ATOM
2466
CE1
HIS
B
512
−63.344
66.555
−24.901
1.00
105.05
C


ATOM
2467
NE2
HIS
B
512
−64.263
66.828
−25.833
1.00
104.85
N


ATOM
2468
CD2
HIS
B
512
−65.424
67.166
−25.176
1.00
104.75
C


ATOM
2469
C
HIS
B
512
−67.647
66.339
−21.017
1.00
104.07
C


ATOM
2470
O
HIS
B
512
−68.814
66.544
−21.377
1.00
103.94
O


ATOM
2471
N
ASN
B
513
−67.249
66.344
−19.745
1.00
108.70
N


ATOM
2472
CA
ASN
B
513
−68.135
66.661
−18.637
1.00
109.06
C


ATOM
2473
CB
ASN
B
513
−67.662
65.942
−17.371
1.00
108.93
C


ATOM
2474
CG
ASN
B
513
−68.626
66.037
−16.216
1.00
109.02
C


ATOM
2475
OD1
ASN
B
513
−69.822
65.727
−16.324
1.00
108.87
O


ATOM
2476
ND2
ASN
B
513
−68.118
66.469
−15.077
1.00
109.30
N


ATOM
2477
C
ASN
B
513
−68.090
68.195
−18.458
1.00
109.45
C


ATOM
2478
O
ASN
B
513
−67.032
68.806
−18.668
1.00
109.67
O


ATOM
2479
N
ALA
B
514
−69.225
68.822
−18.102
1.00
112.49
N


ATOM
2480
CA
ALA
B
514
−69.271
70.277
−17.905
1.00
112.56
C


ATOM
2481
CB
ALA
B
514
−70.691
70.785
−18.130
1.00
112.61
C


ATOM
2482
C
ALA
B
514
−68.781
70.659
−16.492
1.00
112.54
C


ATOM
2483
O
ALA
B
514
−68.324
69.783
−15.741
1.00
112.68
O


ATOM
2484
N
PHE
B
515
−68.862
71.962
−16.126
1.00
112.66
N


ATOM
2485
CA
PHE
B
515
−68.475
72.372
−14.779
1.00
112.19
C


ATOM
2486
CB
PHE
B
515
−68.331
73.903
−14.673
1.00
112.23
C


ATOM
2487
C
PHE
B
515
−69.586
71.830
−13.844
1.00
111.78
C


ATOM
2488
O
PHE
B
515
−70.780
72.017
−14.123
1.00
111.67
O


ATOM
2489
N
GLY
B
516
−69.175
71.100
−12.804
1.00
110.55
N


ATOM
2490
CA
GLY
B
516
−70.078
70.509
−11.817
1.00
109.70
C


ATOM
2491
C
GLY
B
516
−71.000
69.405
−12.305
1.00
109.14
C


ATOM
2492
O
GLY
B
516
−71.985
69.068
−11.632
1.00
109.15
O


ATOM
2493
N
GLY
B
517
−70.672
68.842
−13.468
1.00
107.91
N


ATOM
2494
CA
GLY
B
517
−71.421
67.753
−14.079
1.00
106.83
C


ATOM
2495
C
GLY
B
517
−71.141
66.421
−13.414
1.00
106.05
C


ATOM
2496
O
GLY
B
517
−69.981
66.074
−13.178
1.00
105.89
O


ATOM
2497
N
GLU
B
518
−72.218
65.673
−13.112
1.00
104.44
N


ATOM
2498
CA
GLU
B
518
−72.240
64.353
−12.468
1.00
103.79
C


ATOM
2499
CB
GLU
B
518
−73.714
63.883
−12.390
1.00
104.31
C


ATOM
2500
CG
GLU
B
518
−73.988
62.379
−12.342
1.00
107.59
C


ATOM
2501
CD
GLU
B
518
−74.554
61.735
−13.604
1.00
111.39
C


ATOM
2502
OE1
GLU
B
518
−74.894
62.473
−14.563
1.00
112.80
O


ATOM
2503
OE2
GLU
B
518
−74.652
60.483
−13.630
1.00
112.20
O


ATOM
2504
C
GLU
B
518
−71.289
63.314
−13.137
1.00
102.42
C


ATOM
2505
O
GLU
B
518
−70.720
62.456
−12.452
1.00
102.42
O


ATOM
2506
N
GLY
B
519
−71.128
63.434
−14.456
1.00
95.77
N


ATOM
2507
CA
GLY
B
519
−70.298
62.569
−15.288
1.00
93.38
C


ATOM
2508
C
GLY
B
519
−70.952
62.276
−16.624
1.00
91.71
C


ATOM
2509
O
GLY
B
519
−72.173
62.415
−16.775
1.00
91.45
O


ATOM
2510
N
VAL
B
520
−70.136
61.873
−17.604
1.00
85.33
N


ATOM
2511
CA
VAL
B
520
−70.610
61.549
−18.953
1.00
83.96
C


ATOM
2512
CB
VAL
B
520
−70.257
62.615
−20.026
1.00
83.84
C


ATOM
2513
CG1
VAL
B
520
−71.053
63.895
−19.825
1.00
84.23
C


ATOM
2514
CG2
VAL
B
520
−68.762
62.878
−20.107
1.00
82.88
C


ATOM
2515
C
VAL
B
520
−70.246
60.147
−19.455
1.00
83.10
C


ATOM
2516
O
VAL
B
520
−69.364
59.482
−18.903
1.00
82.93
O


ATOM
2517
N
TYR
B
521
−70.927
59.734
−20.542
1.00
77.36
N


ATOM
2518
CA
TYR
B
521
−70.719
58.483
−21.248
1.00
76.11
C


ATOM
2519
CB
TYR
B
521
−72.014
57.659
−21.271
1.00
75.84
C


ATOM
2520
CG
TYR
B
521
−72.279
56.875
−20.014
1.00
74.40
C


ATOM
2521
CD1
TYR
B
521
−71.496
55.778
−19.678
1.00
73.61
C


ATOM
2522
CE1
TYR
B
521
−71.726
55.057
−18.514
1.00
73.69
C


ATOM
2523
CZ
TYR
B
521
−72.783
55.405
−17.690
1.00
73.71
C


ATOM
2524
OH
TYR
B
521
−73.029
54.664
−16.560
1.00
75.02
O


ATOM
2525
CE2
TYR
B
521
−73.591
56.480
−18.016
1.00
73.04
C


ATOM
2526
CD2
TYR
B
521
−73.333
57.208
−19.172
1.00
73.38
C


ATOM
2527
C
TYR
B
521
−70.376
58.817
−22.676
1.00
75.67
C


ATOM
2528
O
TYR
B
521
−71.056
59.644
−23.272
1.00
75.79
O


ATOM
2529
N
ALA
B
522
−69.352
58.187
−23.236
1.00
75.50
N


ATOM
2530
CA
ALA
B
522
−69.011
58.380
−24.644
1.00
75.36
C


ATOM
2531
CB
ALA
B
522
−67.509
58.343
−24.849
1.00
75.31
C


ATOM
2532
C
ALA
B
522
−69.682
57.201
−25.354
1.00
75.24
C


ATOM
2533
O
ALA
B
522
−69.425
56.045
−25.017
1.00
75.54
O


ATOM
2534
N
ILE
B
523
−70.584
57.471
−26.280
1.00
75.34
N


ATOM
2535
CA
ILE
B
523
−71.266
56.367
−26.911
1.00
75.13
C


ATOM
2536
CB
ILE
B
523
−72.780
56.459
−26.667
1.00
74.87
C


ATOM
2537
CG1
ILE
B
523
−73.084
56.834
−25.200
1.00
74.58
C


ATOM
2538
CD1
ILE
B
523
−74.213
57.663
−25.036
1.00
74.23
C


ATOM
2539
CG2
ILE
B
523
−73.447
55.142
−27.051
1.00
74.99
C


ATOM
2540
C
ILE
B
523
−70.871
56.188
−28.372
1.00
75.66
C


ATOM
2541
O
ILE
B
523
−71.472
56.794
−29.261
1.00
75.68
O


ATOM
2542
N
ALA
B
524
−69.855
55.338
−28.624
1.00
77.17
N


ATOM
2543
CA
ALA
B
524
−69.367
55.050
−29.976
1.00
77.63
C


ATOM
2544
CB
ALA
B
524
−67.969
54.457
−29.905
1.00
77.24
C


ATOM
2545
C
ALA
B
524
−70.312
54.102
−30.761
1.00
78.11
C


ATOM
2546
O
ALA
B
524
−70.984
53.267
−30.151
1.00
78.12
O


ATOM
2547
N
ARG
B
525
−70.370
54.249
−32.104
1.00
78.26
N


ATOM
2548
CA
ARG
B
525
−71.152
53.387
−32.983
1.00
79.17
C


ATOM
2549
CB
ARG
B
525
−72.256
54.140
−33.724
1.00
78.49
C


ATOM
2550
CG
ARG
B
525
−73.134
53.238
−34.584
1.00
77.19
C


ATOM
2551
CD
ARG
B
525
−74.204
52.490
−33.806
1.00
74.80
C


ATOM
2552
NE
ARG
B
525
−75.051
51.713
−34.710
1.00
71.66
N


ATOM
2553
CZ
ARG
B
525
−76.000
50.870
−34.324
1.00
69.01
C


ATOM
2554
NH1
ARG
B
525
−76.228
50.663
−33.034
1.00
68.93
N


ATOM
2555
NH2
ARG
B
525
−76.730
50.224
−35.224
1.00
67.79
N


ATOM
2556
C
ARG
B
525
−70.131
52.755
−33.927
1.00
80.77
C


ATOM
2557
O
ARG
B
525
−69.737
53.366
−34.930
1.00
81.03
O


ATOM
2558
N
CYS
B
526
−69.661
51.534
−33.550
1.00
84.10
N


ATOM
2559
CA
CYS
B
526
−68.646
50.752
−34.245
1.00
85.63
C


ATOM
2560
CB
CYS
B
526
−67.808
49.986
−33.240
1.00
85.67
C


ATOM
2561
SG
CYS
B
526
−67.028
51.045
−32.001
1.00
86.73
S


ATOM
2562
C
CYS
B
526
−69.216
49.854
−35.307
1.00
86.72
C


ATOM
2563
O
CYS
B
526
−70.177
49.127
−35.059
1.00
86.85
O


ATOM
2564
N
CYS
B
527
−68.638
49.930
−36.517
1.00
86.58
N


ATOM
2565
CA
CYS
B
527
−69.110
49.182
−37.679
1.00
88.11
C


ATOM
2566
CB
CYS
B
527
−69.933
50.094
−38.590
1.00
87.81
C


ATOM
2567
SG
CYS
B
527
−71.199
51.072
−37.722
1.00
87.72
S


ATOM
2568
C
CYS
B
527
−68.031
48.439
−38.457
1.00
89.37
C


ATOM
2569
O
CYS
B
527
−66.840
48.717
−38.310
1.00
89.09
O


ATOM
2570
N
LEU
B
528
−68.464
47.481
−39.284
1.00
91.74
N


ATOM
2571
CA
LEU
B
528
−67.579
46.684
−40.136
1.00
94.12
C


ATOM
2572
CB
LEU
B
528
−67.845
45.175
−39.990
1.00
93.84
C


ATOM
2573
CG
LEU
B
528
−67.467
44.499
−38.679
1.00
93.16
C


ATOM
2574
CD1
LEU
B
528
−67.902
43.074
−38.710
1.00
92.63
C


ATOM
2575
CD2
LEU
B
528
−65.968
44.576
−38.403
1.00
92.08
C


ATOM
2576
C
LEU
B
528
−67.726
47.142
−41.604
1.00
96.20
C


ATOM
2577
O
LEU
B
528
−68.639
46.703
−42.330
1.00
96.27
O


ATOM
2578
N
LEU
B
529
−66.826
48.060
−42.013
1.00
101.19
N


ATOM
2579
CA
LEU
B
529
−66.801
48.654
−43.341
1.00
103.82
C


ATOM
2580
CB
LEU
B
529
−67.066
50.162
−43.241
1.00
103.71
C


ATOM
2581
CG
LEU
B
529
−67.526
50.876
−44.500
1.00
103.99
C


ATOM
2582
CD1
LEU
B
529
−68.929
50.463
−44.903
1.00
103.65
C


ATOM
2583
CD2
LEU
B
529
−67.502
52.368
−44.292
1.00
104.17
C


ATOM
2584
C
LEU
B
529
−65.463
48.354
−43.998
1.00
105.85
C


ATOM
2585
O
LEU
B
529
−64.440
48.938
−43.629
1.00
105.85
O


ATOM
2586
N
PRO
B
530
−65.462
47.394
−44.950
1.00
113.01
N


ATOM
2587
CA
PRO
B
530
−64.207
47.020
−45.619
1.00
114.85
C


ATOM
2588
CB
PRO
B
530
−64.560
45.707
−46.324
1.00
114.74
C


ATOM
2589
CG
PRO
B
530
−66.027
45.796
−46.581
1.00
114.03
C


ATOM
2590
CD
PRO
B
530
−66.609
46.618
−45.471
1.00
113.18
C


ATOM
2591
C
PRO
B
530
−63.733
48.104
−46.587
1.00
116.79
C


ATOM
2592
O
PRO
B
530
−64.550
48.652
−47.352
1.00
117.04
O


ATOM
2593
N
GLN
B
531
−62.405
48.413
−46.538
1.00
120.37
N


ATOM
2594
CA
GLN
B
531
−61.736
49.449
−47.339
1.00
122.30
C


ATOM
2595
CB
GLN
B
531
−61.674
49.073
−48.844
1.00
122.37
C


ATOM
2596
CG
GLN
B
531
−60.765
47.872
−49.170
1.00
123.50
C


ATOM
2597
CD
GLN
B
531
−61.035
47.202
−50.518
1.00
125.13
C


ATOM
2598
OE1
GLN
B
531
−61.895
47.613
−51.314
1.00
125.49
O


ATOM
2599
NE2
GLN
B
531
−60.297
46.132
−50.803
1.00
125.67
N


ATOM
2600
C
GLN
B
531
−62.456
50.797
−47.061
1.00
123.38
C


ATOM
2601
O
GLN
B
531
−63.323
51.236
−47.832
1.00
123.60
O


ATOM
2602
N
ALA
B
532
−62.136
51.406
−45.908
1.00
124.93
N


ATOM
2603
CA
ALA
B
532
−62.755
52.653
−45.485
1.00
126.34
C


ATOM
2604
CB
ALA
B
532
−63.765
52.379
−44.380
1.00
126.15
C


ATOM
2605
C
ALA
B
532
−61.735
53.690
−45.027
1.00
127.47
C


ATOM
2606
O
ALA
B
532
−60.935
53.423
−44.123
1.00
127.79
O


ATOM
2607
N
ASN
B
533
−61.760
54.874
−45.667
1.00
129.58
N


ATOM
2608
CA
ASN
B
533
−60.896
56.006
−45.335
1.00
130.77
C


ATOM
2609
CB
ASN
B
533
−60.371
56.707
−46.611
1.00
130.82
C


ATOM
2610
CG
ASN
B
533
−59.372
55.919
−47.435
1.00
131.44
C


ATOM
2611
OD1
ASN
B
533
−58.173
55.852
−47.120
1.00
132.13
O


ATOM
2612
ND2
ASN
B
533
−59.841
55.321
−48.530
1.00
131.80
N


ATOM
2613
C
ASN
B
533
−61.818
56.929
−44.539
1.00
131.52
C


ATOM
2614
O
ASN
B
533
−62.575
57.704
−45.132
1.00
131.65
O


ATOM
2615
N
CYS
B
534
−61.818
56.803
−43.207
1.00
132.79
N


ATOM
2616
CA
CYS
B
534
−62.710
57.648
−42.419
1.00
133.86
C


ATOM
2617
CB
CYS
B
534
−63.591
56.830
−41.481
1.00
133.93
C


ATOM
2618
SG
CYS
B
534
−64.768
55.741
−42.336
1.00
135.03
S


ATOM
2619
C
CYS
B
534
−62.004
58.801
−41.720
1.00
134.34
C


ATOM
2620
O
CYS
B
534
−60.982
58.585
−41.062
1.00
134.48
O


ATOM
2621
N
SER
B
535
−62.545
60.034
−41.898
1.00
133.21
N


ATOM
2622
CA
SER
B
535
−61.988
61.287
−41.371
1.00
133.80
C


ATOM
2623
CB
SER
B
535
−61.343
62.075
−42.512
1.00
133.78
C


ATOM
2624
OG
SER
B
535
−62.285
62.439
−43.512
1.00
134.38
O


ATOM
2625
C
SER
B
535
−62.971
62.205
−40.630
1.00
134.13
C


ATOM
2626
O
SER
B
535
−64.168
62.208
−40.920
1.00
133.92
O


ATOM
2627
N
VAL
B
536
−62.436
63.018
−39.704
1.00
133.66
N


ATOM
2628
CA
VAL
B
536
−63.204
63.990
−38.926
1.00
134.48
C


ATOM
2629
CB
VAL
B
536
−62.823
64.004
−37.423
1.00
134.45
C


ATOM
2630
CG1
VAL
B
536
−63.703
64.970
−36.626
1.00
134.41
C


ATOM
2631
CG2
VAL
B
536
−62.907
62.610
−36.834
1.00
134.51
C


ATOM
2632
C
VAL
B
536
−63.047
65.372
−39.554
1.00
135.15
C


ATOM
2633
O
VAL
B
536
−61.924
65.824
−39.800
1.00
135.25
O


ATOM
2634
N
HIS
B
537
−64.176
66.039
−39.809
1.00
136.24
N


ATOM
2635
CA
HIS
B
537
−64.192
67.375
−40.380
1.00
137.05
C


ATOM
2636
CB
HIS
B
537
−65.002
67.415
−41.688
1.00
137.20
C


ATOM
2637
CG
HIS
B
537
−64.287
66.848
−42.883
1.00
138.47
C


ATOM
2638
ND1
HIS
B
537
−64.571
67.293
−44.171
1.00
139.63
N


ATOM
2639
CE1
HIS
B
537
−63.786
66.590
−44.974
1.00
139.83
C


ATOM
2640
NE2
HIS
B
537
−63.020
65.733
−44.288
1.00
139.91
N


ATOM
2641
CD2
HIS
B
537
−63.331
65.887
−42.955
1.00
139.28
C


ATOM
2642
C
HIS
B
537
−64.690
68.370
−39.330
1.00
137.40
C


ATOM
2643
O
HIS
B
537
−65.864
68.736
−39.305
1.00
137.42
O


ATOM
2644
N
THR
B
538
−63.777
68.780
−38.441
1.00
136.73
N


ATOM
2645
CA
THR
B
538
−64.031
69.734
−37.362
1.00
137.31
C


ATOM
2646
CB
THR
B
538
−62.838
69.736
−36.391
1.00
137.31
C


ATOM
2647
OG1
THR
B
538
−62.335
68.410
−36.237
1.00
137.37
O


ATOM
2648
CG2
THR
B
538
−63.182
70.320
−35.032
1.00
137.41
C


ATOM
2649
C
THR
B
538
−64.244
71.142
−37.951
1.00
137.73
C


ATOM
2650
O
THR
B
538
−63.608
71.494
−38.949
1.00
137.83
O


ATOM
2651
N
ALA
B
539
−65.130
71.940
−37.328
1.00
137.80
N


ATOM
2652
CA
ALA
B
539
−65.430
73.316
−37.741
1.00
138.09
C


ATOM
2653
CB
ALA
B
539
−66.688
73.353
−38.607
1.00
137.95
C


ATOM
2654
C
ALA
B
539
−65.597
74.208
−36.488
1.00
138.39
C


ATOM
2655
O
ALA
B
539
−66.600
74.053
−35.789
1.00
138.43
O


ATOM
2656
N
PRO
B
540
−64.639
75.124
−36.163
1.00
137.90
N


ATOM
2657
CA
PRO
B
540
−64.789
75.965
−34.955
1.00
138.18
C


ATOM
2658
CB
PRO
B
540
−63.554
76.868
−35.000
1.00
138.11
C


ATOM
2659
CG
PRO
B
540
−62.563
76.098
−35.784
1.00
138.04
C


ATOM
2660
CD
PRO
B
540
−63.372
75.428
−36.854
1.00
137.89
C


ATOM
2661
C
PRO
B
540
−66.092
76.771
−34.890
1.00
138.52
C


ATOM
2662
O
PRO
B
540
−66.703
77.001
−35.937
1.00
138.52
O


ATOM
2663
N
PRO
B
541
−66.550
77.190
−33.683
1.00
140.26
N


ATOM
2664
CA
PRO
B
541
−67.822
77.938
−33.594
1.00
140.69
C


ATOM
2665
CB
PRO
B
541
−67.994
78.175
−32.090
1.00
140.62
C


ATOM
2666
CG
PRO
B
541
−67.103
77.184
−31.430
1.00
140.29
C


ATOM
2667
CD
PRO
B
541
−65.952
76.993
−32.347
1.00
140.16
C


ATOM
2668
C
PRO
B
541
−67.874
79.243
−34.397
1.00
141.21
C


ATOM
2669
O
PRO
B
541
−66.997
80.103
−34.245
1.00
141.24
O


ATOM
2670
N
ALA
B
542
−68.902
79.372
−35.269
1.00
143.91
N


ATOM
2671
CA
ALA
B
542
−69.118
80.543
−36.131
1.00
144.42
C


ATOM
2672
CB
ALA
B
542
−69.882
80.143
−37.381
1.00
144.31
C


ATOM
2673
C
ALA
B
542
−69.822
81.712
−35.419
1.00
144.79
C


ATOM
2674
O
ALA
B
542
−69.664
82.863
−35.843
1.00
144.89
O


ATOM
2675
N
GLU
B
543
−70.603
81.409
−34.344
1.00
146.53
N


ATOM
2676
CA
GLU
B
543
−71.364
82.347
−33.488
1.00
146.91
C


ATOM
2677
CB
GLU
B
543
−70.434
83.292
−32.689
1.00
146.88
C


ATOM
2678
CG
GLU
B
543
−69.338
82.595
−31.894
1.00
147.35
C


ATOM
2679
CD
GLU
B
543
−67.935
83.145
−32.090
1.00
147.98
C


ATOM
2680
OE1
GLU
B
543
−67.271
83.452
−31.072
1.00
148.23
O


ATOM
2681
OE2
GLU
B
543
−67.497
83.270
−33.258
1.00
148.17
O


ATOM
2682
C
GLU
B
543
−72.480
83.137
−34.206
1.00
147.16
C


ATOM
2683
O
GLU
B
543
−73.279
83.804
−33.539
1.00
147.21
O


ATOM
2684
N
ALA
B
544
−72.538
83.042
−35.553
1.00
149.04
N


ATOM
2685
CA
ALA
B
544
−73.493
83.719
−36.434
1.00
149.34
C


ATOM
2686
CB
ALA
B
544
−72.873
83.882
−37.817
1.00
149.30
C


ATOM
2687
C
ALA
B
544
−74.877
83.025
−36.540
1.00
149.62
C


ATOM
2688
O
ALA
B
544
−75.082
81.958
−35.948
1.00
149.52
O


ATOM
2689
N
SER
B
545
−75.827
83.658
−37.299
1.00
151.45
N


ATOM
2690
CA
SER
B
545
−77.200
83.181
−37.566
1.00
151.69
C


ATOM
2691
CB
SER
B
545
−78.032
84.266
−38.246
1.00
151.68
C


ATOM
2692
OG
SER
B
545
−78.545
85.206
−37.317
1.00
151.78
O


ATOM
2693
C
SER
B
545
−77.176
81.923
−38.437
1.00
151.85
C


ATOM
2694
O
SER
B
545
−78.085
81.092
−38.348
1.00
151.87
O


ATOM
2695
N
MET
B
546
−76.114
81.791
−39.272
1.00
153.34
N


ATOM
2696
CA
MET
B
546
−75.849
80.651
−40.155
1.00
153.39
C


ATOM
2697
CB
MET
B
546
−74.703
80.994
−41.125
1.00
153.18
C


ATOM
2698
C
MET
B
546
−75.479
79.409
−39.301
1.00
153.47
C


ATOM
2699
O
MET
B
546
−75.531
78.278
−39.800
1.00
153.61
O


ATOM
2700
N
GLY
B
547
−75.123
79.654
−38.028
1.00
153.18
N


ATOM
2701
CA
GLY
B
547
−74.730
78.652
−37.042
1.00
152.83
C


ATOM
2702
C
GLY
B
547
−73.400
78.010
−37.378
1.00
152.65
C


ATOM
2703
O
GLY
B
547
−72.613
78.582
−38.144
1.00
152.76
O


ATOM
2704
N
THR
B
548
−73.138
76.812
−36.812
1.00
150.47
N


ATOM
2705
CA
THR
B
548
−71.906
76.068
−37.091
1.00
149.88
C


ATOM
2706
CB
THR
B
548
−71.132
75.686
−35.821
1.00
149.84
C


ATOM
2707
OG1
THR
B
548
−71.382
76.632
−34.786
1.00
149.65
O


ATOM
2708
CG2
THR
B
548
−69.648
75.634
−36.061
1.00
149.67
C


ATOM
2709
C
THR
B
548
−72.256
74.903
−38.018
1.00
149.55
C


ATOM
2710
O
THR
B
548
−73.048
74.028
−37.651
1.00
149.53
O


ATOM
2711
N
ARG
B
549
−71.690
74.925
−39.238
1.00
147.12
N


ATOM
2712
CA
ARG
B
549
−71.929
73.922
−40.278
1.00
146.62
C


ATOM
2713
CB
ARG
B
549
−72.792
74.529
−41.403
1.00
146.51
C


ATOM
2714
CG
ARG
B
549
−74.211
74.886
−40.969
1.00
146.04
C


ATOM
2715
CD
ARG
B
549
−74.934
75.740
−41.987
1.00
145.51
C


ATOM
2716
NE
ARG
B
549
−76.346
75.935
−41.643
1.00
144.95
N


ATOM
2717
CZ
ARG
B
549
−77.362
75.291
−42.217
1.00
144.63
C


ATOM
2718
NH1
ARG
B
549
−77.136
74.398
−43.175
1.00
144.47
N


ATOM
2719
NH2
ARG
B
549
−78.611
75.536
−41.840
1.00
144.53
N


ATOM
2720
C
ARG
B
549
−70.622
73.340
−40.844
1.00
146.42
C


ATOM
2721
O
ARG
B
549
−69.584
74.009
−40.816
1.00
146.41
O


ATOM
2722
N
VAL
B
550
−70.684
72.080
−41.337
1.00
145.57
N


ATOM
2723
CA
VAL
B
550
−69.584
71.312
−41.954
1.00
145.24
C


ATOM
2724
CB
VAL
B
550
−68.425
70.923
−40.987
1.00
145.19
C


ATOM
2725
CG1
VAL
B
550
−68.861
69.903
−39.940
1.00
145.05
C


ATOM
2726
CG2
VAL
B
550
−67.199
70.440
−41.753
1.00
145.00
C


ATOM
2727
C
VAL
B
550
−70.151
70.126
−42.755
1.00
145.09
C


ATOM
2728
O
VAL
B
550
−71.102
69.486
−42.295
1.00
145.05
O


ATOM
2729
N
HIS
B
551
−69.587
69.850
−43.956
1.00
145.41
N


ATOM
2730
CA
HIS
B
551
−70.079
68.758
−44.798
1.00
145.22
C


ATOM
2731
CB
HIS
B
551
−71.275
69.187
−45.673
1.00
145.55
C


ATOM
2732
CG
HIS
B
551
−70.979
70.102
−46.819
1.00
146.57
C


ATOM
2733
ND1
HIS
B
551
−70.529
71.399
−46.618
1.00
147.29
N


ATOM
2734
CE1
HIS
B
551
−70.406
71.925
−47.826
1.00
147.67
C


ATOM
2735
NE2
HIS
B
551
−70.775
71.061
−48.778
1.00
147.78
N


ATOM
2736
CD2
HIS
B
551
−71.158
69.900
−48.147
1.00
147.30
C


ATOM
2737
C
HIS
B
551
−69.075
67.895
−45.558
1.00
144.66
C


ATOM
2738
O
HIS
B
551
−67.962
68.337
−45.874
1.00
144.55
O


ATOM
2739
N
CYS
B
552
−69.501
66.638
−45.833
1.00
142.01
N


ATOM
2740
CA
CYS
B
552
−68.746
65.621
−46.566
1.00
141.40
C


ATOM
2741
CB
CYS
B
552
−69.012
64.216
−46.023
1.00
141.22
C


ATOM
2742
SG
CYS
B
552
−68.536
63.969
−44.292
1.00
139.76
S


ATOM
2743
C
CYS
B
552
−69.128
65.732
−48.037
1.00
141.30
C


ATOM
2744
O
CYS
B
552
−70.177
65.231
−48.462
1.00
141.33
O


ATOM
2745
N
HIS
B
553
−68.278
66.420
−48.799
1.00
140.49
N


ATOM
2746
CA
HIS
B
553
−68.472
66.649
−50.224
1.00
140.01
C


ATOM
2747
CB
HIS
B
553
−68.969
68.077
−50.447
1.00
140.00
C


ATOM
2748
C
HIS
B
553
−67.175
66.373
−50.985
1.00
139.66
C


ATOM
2749
O
HIS
B
553
−66.997
66.840
−52.114
1.00
139.69
O


ATOM
2750
N
GLN
B
554
−66.277
65.584
−50.354
1.00
137.93
N


ATOM
2751
CA
GLN
B
554
−64.980
65.160
−50.881
1.00
137.37
C


ATOM
2752
CB
GLN
B
554
−64.135
64.574
−49.728
1.00
137.42
C


ATOM
2753
CG
GLN
B
554
−62.657
64.982
−49.707
1.00
137.46
C


ATOM
2754
CD
GLN
B
554
−61.878
64.336
−48.570
1.00
137.87
C


ATOM
2755
OE1
GLN
B
554
−62.354
64.218
−47.431
1.00
138.13
O


ATOM
2756
NE2
GLN
B
554
−60.652
63.905
−48.848
1.00
137.66
N


ATOM
2757
C
GLN
B
554
−65.214
64.123
−52.013
1.00
136.96
C


ATOM
2758
O
GLN
B
554
−66.355
63.942
−52.465
1.00
136.89
O


ATOM
2759
N
GLN
B
555
−64.140
63.455
−52.472
1.00
136.84
N


ATOM
2760
CA
GLN
B
555
−64.193
62.457
−53.544
1.00
136.32
C


ATOM
2761
CB
GLN
B
555
−62.766
62.050
−53.968
1.00
136.30
C


ATOM
2762
C
GLN
B
555
−65.084
61.219
−53.223
1.00
135.91
C


ATOM
2763
O
GLN
B
555
−64.559
60.153
−52.872
1.00
136.01
O


ATOM
2764
N
GLY
B
556
−66.413
61.384
−53.354
1.00
133.72
N


ATOM
2765
CA
GLY
B
556
−67.408
60.339
−53.098
1.00
132.66
C


ATOM
2766
C
GLY
B
556
−67.532
59.892
−51.649
1.00
131.92
C


ATOM
2767
O
GLY
B
556
−68.062
58.806
−51.374
1.00
131.89
O


ATOM
2768
N
HIS
B
557
−67.022
60.734
−50.718
1.00
130.00
N


ATOM
2769
CA
HIS
B
557
−67.022
60.539
−49.268
1.00
129.20
C


ATOM
2770
CB
HIS
B
557
−66.075
61.560
−48.601
1.00
129.39
C


ATOM
2771
CG
HIS
B
557
−64.616
61.179
−48.582
1.00
130.76
C


ATOM
2772
ND1
HIS
B
557
−63.909
60.921
−49.757
1.00
131.87
N


ATOM
2773
CE1
HIS
B
557
−62.667
60.645
−49.378
1.00
131.98
C


ATOM
2774
NE2
HIS
B
557
−62.530
60.719
−48.050
1.00
132.18
N


ATOM
2775
CD2
HIS
B
557
−63.762
61.075
−47.531
1.00
131.65
C


ATOM
2776
C
HIS
B
557
−68.452
60.738
−48.744
1.00
128.37
C


ATOM
2777
O
HIS
B
557
−69.127
61.687
−49.166
1.00
128.41
O


ATOM
2778
N
VAL
B
558
−68.922
59.845
−47.833
1.00
123.42
N


ATOM
2779
CA
VAL
B
558
−70.278
59.929
−47.252
1.00
122.31
C


ATOM
2780
CB
VAL
B
558
−71.199
58.691
−47.485
1.00
122.30
C


ATOM
2781
CG1
VAL
B
558
−72.624
59.133
−47.810
1.00
122.05
C


ATOM
2782
CG2
VAL
B
558
−70.663
57.762
−48.573
1.00
122.17
C


ATOM
2783
C
VAL
B
558
−70.256
60.358
−45.777
1.00
121.63
C


ATOM
2784
O
VAL
B
558
−69.283
60.081
−45.068
1.00
121.34
O


ATOM
2785
N
LEU
B
559
−71.327
61.051
−45.332
1.00
117.23
N


ATOM
2786
CA
LEU
B
559
−71.486
61.517
−43.958
1.00
116.45
C


ATOM
2787
CB
LEU
B
559
−72.326
62.806
−43.897
1.00
116.37
C


ATOM
2788
CG
LEU
B
559
−72.570
63.383
−42.503
1.00
115.80
C


ATOM
2789
CD1
LEU
B
559
−71.488
64.347
−42.122
1.00
115.41
C


ATOM
2790
CD2
LEU
B
559
−73.930
64.037
−42.415
1.00
115.21
C


ATOM
2791
C
LEU
B
559
−72.162
60.397
−43.186
1.00
116.11
C


ATOM
2792
O
LEU
B
559
−73.250
59.945
−43.567
1.00
115.98
O


ATOM
2793
N
THR
B
560
−71.501
59.946
−42.109
1.00
114.52
N


ATOM
2794
CA
THR
B
560
−71.975
58.856
−41.261
1.00
114.17
C


ATOM
2795
CB
THR
B
560
−70.936
57.742
−41.193
1.00
114.04
C


ATOM
2796
OG1
THR
B
560
−69.707
58.299
−40.747
1.00
113.63
O


ATOM
2797
CG2
THR
B
560
−70.738
57.039
−42.529
1.00
113.63
C


ATOM
2798
C
THR
B
560
−72.408
59.303
−39.877
1.00
114.27
C


ATOM
2799
O
THR
B
560
−73.401
58.785
−39.366
1.00
114.13
O


ATOM
2800
N
GLY
B
561
−71.673
60.243
−39.282
1.00
117.40
N


ATOM
2801
CA
GLY
B
561
−71.985
60.734
−37.945
1.00
117.64
C


ATOM
2802
C
GLY
B
561
−71.793
62.211
−37.677
1.00
117.75
C


ATOM
2803
O
GLY
B
561
−70.841
62.828
−38.169
1.00
117.59
O


ATOM
2804
N
CYS
B
562
−72.706
62.763
−36.849
1.00
121.48
N


ATOM
2805
CA
CYS
B
562
−72.740
64.161
−36.417
1.00
121.78
C


ATOM
2806
CB
CYS
B
562
−74.093
64.807
−36.735
1.00
122.20
C


ATOM
2807
SG
CYS
B
562
−74.284
65.432
−38.438
1.00
124.74
S


ATOM
2808
C
CYS
B
562
−72.408
64.282
−34.924
1.00
121.24
C


ATOM
2809
O
CYS
B
562
−73.171
63.821
−34.071
1.00
121.19
O


ATOM
2810
N
SER
B
563
−71.279
64.913
−34.617
1.00
117.71
N


ATOM
2811
CA
SER
B
563
−70.834
65.153
−33.246
1.00
117.39
C


ATOM
2812
CB
SER
B
563
−69.533
64.413
−32.958
1.00
117.54
C


ATOM
2813
OG
SER
B
563
−69.786
63.090
−32.517
1.00
117.97
O


ATOM
2814
C
SER
B
563
−70.649
66.651
−33.033
1.00
116.99
C


ATOM
2815
O
SER
B
563
−70.457
67.375
−34.006
1.00
116.83
O


ATOM
2816
N
SER
B
564
−70.711
67.120
−31.773
1.00
114.82
N


ATOM
2817
CA
SER
B
564
−70.551
68.535
−31.436
1.00
114.48
C


ATOM
2818
CB
SER
B
564
−71.828
69.317
−31.734
1.00
114.59
C


ATOM
2819
OG
SER
B
564
−71.646
70.710
−31.531
1.00
114.76
O


ATOM
2820
C
SER
B
564
−70.180
68.741
−29.992
1.00
114.22
C


ATOM
2821
O
SER
B
564
−70.838
68.191
−29.107
1.00
114.08
O


ATOM
2822
N
HIS
B
565
−69.151
69.574
−29.749
1.00
113.98
N


ATOM
2823
CA
HIS
B
565
−68.708
69.894
−28.392
1.00
113.78
C


ATOM
2824
CB
HIS
B
565
−67.494
69.057
−27.985
1.00
113.77
C


ATOM
2825
CG
HIS
B
565
−66.183
69.733
−28.190
1.00
113.56
C


ATOM
2826
ND1
HIS
B
565
−65.582
69.762
−29.427
1.00
113.36
N


ATOM
2827
CE1
HIS
B
565
−64.445
70.415
−29.253
1.00
113.77
C


ATOM
2828
NE2
HIS
B
565
−64.295
70.814
−27.985
1.00
113.71
N


ATOM
2829
CD2
HIS
B
565
−65.397
70.382
−27.297
1.00
113.47
C


ATOM
2830
C
HIS
B
565
−68.514
71.397
−28.124
1.00
113.61
C


ATOM
2831
O
HIS
B
565
−68.098
72.138
−29.014
1.00
113.77
O


ATOM
2832
N
TRP
B
566
−68.811
71.832
−26.887
1.00
111.53
N


ATOM
2833
CA
TRP
B
566
−68.699
73.226
−26.459
1.00
111.30
C


ATOM
2834
CB
TRP
B
566
−70.073
73.892
−26.382
1.00
110.76
C


ATOM
2835
CG
TRP
B
566
−71.099
73.138
−25.594
1.00
108.53
C


ATOM
2836
CD1
TRP
B
566
−71.464
73.367
−24.303
1.00
107.11
C


ATOM
2837
NE1
TRP
B
566
−72.470
72.505
−23.934
1.00
106.14
N


ATOM
2838
CE2
TRP
B
566
−72.776
71.694
−24.996
1.00
105.83
C


ATOM
2839
CD2
TRP
B
566
−71.936
72.070
−26.065
1.00
106.56
C


ATOM
2840
CE3
TRP
B
566
−72.043
71.377
−27.284
1.00
105.74
C


ATOM
2841
CZ3
TRP
B
566
−72.978
70.362
−27.399
1.00
104.64
C


ATOM
2842
CH2
TRP
B
566
−73.805
70.015
−26.323
1.00
104.70
C


ATOM
2843
CZ2
TRP
B
566
−73.721
70.664
−25.111
1.00
105.03
C


ATOM
2844
C
TRP
B
566
−67.886
73.431
−25.176
1.00
111.98
C


ATOM
2845
O
TRP
B
566
−67.531
72.456
−24.509
1.00
111.85
O


ATOM
2846
N
GLU
B
567
−67.561
74.707
−24.858
1.00
114.23
N


ATOM
2847
CA
GLU
B
567
−66.761
75.104
−23.688
1.00
115.12
C


ATOM
2848
CB
GLU
B
567
−65.441
75.762
−24.139
1.00
115.08
C


ATOM
2849
CG
GLU
B
567
−64.472
74.828
−24.866
1.00
115.87
C


ATOM
2850
CD
GLU
B
567
−64.594
74.654
−26.379
1.00
117.42
C


ATOM
2851
OE1
GLU
B
567
−63.621
74.151
−26.991
1.00
118.08
O


ATOM
2852
OE2
GLU
B
567
−65.652
75.009
−26.953
1.00
117.83
O


ATOM
2853
C
GLU
B
567
−67.542
75.993
−22.684
1.00
115.59
C


ATOM
2854
O
GLU
B
567
−67.103
76.191
−21.549
1.00
115.56
O


ATOM
2855
N
VAL
B
568
−68.716
76.482
−23.111
1.00
117.31
N


ATOM
2856
CA
VAL
B
568
−69.635
77.344
−22.368
1.00
118.32
C


ATOM
2857
CB
VAL
B
568
−70.463
78.177
−23.408
1.00
118.29
C


ATOM
2858
CG1
VAL
B
568
−71.539
77.344
−24.110
1.00
118.30
C


ATOM
2859
CG2
VAL
B
568
−71.051
79.447
−22.803
1.00
118.56
C


ATOM
2860
C
VAL
B
568
−70.501
76.567
−21.313
1.00
119.01
C


ATOM
2861
O
VAL
B
568
−70.265
75.385
−21.061
1.00
119.09
O


ATOM
2862
N
GLU
B
569
−71.477
77.251
−20.693
1.00
122.68
N


ATOM
2863
CA
GLU
B
569
−72.409
76.693
−19.717
1.00
123.60
C


ATOM
2864
CB
GLU
B
569
−72.467
77.576
−18.453
1.00
123.70
C


ATOM
2865
CG
GLU
B
569
−73.180
76.948
−17.254
1.00
124.32
C


ATOM
2866
CD
GLU
B
569
−74.701
77.019
−17.209
1.00
125.29
C


ATOM
2867
OE1
GLU
B
569
−75.277
78.004
−17.728
1.00
125.60
O


ATOM
2868
OE2
GLU
B
569
−75.319
76.086
−16.644
1.00
125.58
O


ATOM
2869
C
GLU
B
569
−73.802
76.581
−20.364
1.00
124.11
C


ATOM
2870
O
GLU
B
569
−74.515
75.611
−20.085
1.00
124.23
O


ATOM
2871
N
ASP
B
570
−74.194
77.564
−21.219
1.00
125.99
N


ATOM
2872
CA
ASP
B
570
−75.518
77.548
−21.864
1.00
126.58
C


ATOM
2873
CB
ASP
B
570
−76.498
78.498
−21.136
1.00
126.73
C


ATOM
2874
CG
ASP
B
570
−77.684
77.795
−20.486
1.00
127.25
C


ATOM
2875
OD1
ASP
B
570
−77.472
77.067
−19.479
1.00
127.50
O


ATOM
2876
OD2
ASP
B
570
−78.825
77.974
−20.980
1.00
127.65
O


ATOM
2877
C
ASP
B
570
−75.590
77.646
−23.424
1.00
126.73
C


ATOM
2878
O
ASP
B
570
−74.856
76.924
−24.118
1.00
126.77
O


ATOM
2879
N
LEU
B
571
−76.516
78.506
−23.954
1.00
124.61
N


ATOM
2880
CA
LEU
B
571
−76.769
78.734
−25.387
1.00
124.78
C


ATOM
2881
CB
LEU
B
571
−77.398
77.485
−26.034
1.00
124.75
C


ATOM
2882
C
LEU
B
571
−77.608
80.015
−25.697
1.00
124.83
C


ATOM
2883
O
LEU
B
571
−77.023
81.037
−26.069
1.00
125.00
O


ATOM
2884
N
GLY
B
572
−78.945
79.933
−25.562
1.00
119.93
N


ATOM
2885
CA
GLY
B
572
−79.876
81.033
−25.819
1.00
119.70
C


ATOM
2886
C
GLY
B
572
−80.172
81.292
−27.285
1.00
119.66
C


ATOM
2887
O
GLY
B
572
−81.252
81.776
−27.636
1.00
119.48
O


ATOM
2888
N
GLN
B
584
−78.485
72.651
−48.615
1.00
150.06
N


ATOM
2889
CA
GLN
B
584
−77.758
72.137
−47.448
1.00
150.10
C


ATOM
2890
CB
GLN
B
584
−78.497
72.514
−46.135
1.00
150.24
C


ATOM
2891
CG
GLN
B
584
−79.016
73.963
−46.047
1.00
150.44
C


ATOM
2892
CD
GLN
B
584
−80.441
74.074
−45.527
1.00
150.94
C


ATOM
2893
OE1
GLN
B
584
−80.989
73.160
−44.898
1.00
151.33
O


ATOM
2894
NE2
GLN
B
584
−81.078
75.207
−45.777
1.00
150.78
N


ATOM
2895
C
GLN
B
584
−77.532
70.583
−47.559
1.00
149.91
C


ATOM
2896
O
GLN
B
584
−78.009
69.837
−46.690
1.00
149.95
O


ATOM
2897
N
PRO
B
585
−76.804
70.067
−48.596
1.00
147.52
N


ATOM
2898
CA
PRO
B
585
−76.641
68.600
−48.725
1.00
147.11
C


ATOM
2899
CB
PRO
B
585
−76.683
68.379
−50.247
1.00
147.20
C


ATOM
2900
CG
PRO
B
585
−76.395
69.773
−50.875
1.00
147.42
C


ATOM
2901
CD
PRO
B
585
−76.181
70.757
−49.746
1.00
147.59
C


ATOM
2902
C
PRO
B
585
−75.394
67.962
−48.090
1.00
146.51
C


ATOM
2903
O
PRO
B
585
−74.286
68.507
−48.215
1.00
146.59
O


ATOM
2904
N
ASN
B
586
−75.584
66.773
−47.437
1.00
140.53
N


ATOM
2905
CA
ASN
B
586
−74.557
65.960
−46.745
1.00
139.64
C


ATOM
2906
CB
ASN
B
586
−73.540
65.361
−47.762
1.00
139.67
C


ATOM
2907
CG
ASN
B
586
−73.382
63.848
−47.758
1.00
139.54
C


ATOM
2908
OD1
ASN
B
586
−72.264
63.324
−47.760
1.00
139.19
O


ATOM
2909
ND2
ASN
B
586
−74.483
63.103
−47.775
1.00
139.50
N


ATOM
2910
C
ASN
B
586
−73.854
66.757
−45.611
1.00
139.03
C


ATOM
2911
O
ASN
B
586
−72.642
66.614
−45.420
1.00
138.94
O


ATOM
2912
N
GLN
B
587
−74.640
67.573
−44.850
1.00
133.89
N


ATOM
2913
CA
GLN
B
587
−74.172
68.457
−43.772
1.00
133.19
C


ATOM
2914
CB
GLN
B
587
−74.544
69.920
−44.107
1.00
133.41
C


ATOM
2915
CG
GLN
B
587
−73.611
70.981
−43.503
1.00
134.10
C


ATOM
2916
CD
GLN
B
587
−73.858
72.385
−44.004
1.00
135.07
C


ATOM
2917
OE1
GLN
B
587
−74.969
72.928
−43.898
1.00
135.42
O


ATOM
2918
NE2
GLN
B
587
−72.812
73.011
−44.542
1.00
135.30
N


ATOM
2919
C
GLN
B
587
−74.564
68.125
−42.319
1.00
132.46
C


ATOM
2920
O
GLN
B
587
−75.651
67.611
−42.038
1.00
132.24
O


ATOM
2921
N
CYS
B
588
−73.642
68.469
−41.404
1.00
127.56
N


ATOM
2922
CA
CYS
B
588
−73.739
68.333
−39.955
1.00
126.80
C


ATOM
2923
CB
CYS
B
588
−72.441
67.765
−39.381
1.00
126.59
C


ATOM
2924
SG
CYS
B
588
−72.434
65.971
−39.116
1.00
125.32
S


ATOM
2925
C
CYS
B
588
−73.998
69.737
−39.413
1.00
126.66
C


ATOM
2926
O
CYS
B
588
−73.106
70.597
−39.478
1.00
126.58
O


ATOM
2927
N
VAL
B
589
−75.203
69.979
−38.882
1.00
125.88
N


ATOM
2928
CA
VAL
B
589
−75.524
71.301
−38.350
1.00
125.64
C


ATOM
2929
CB
VAL
B
589
−76.688
71.994
−39.099
1.00
125.70
C


ATOM
2930
CG1
VAL
B
589
−76.844
73.445
−38.646
1.00
125.90
C


ATOM
2931
CG2
VAL
B
589
−76.497
71.921
−40.615
1.00
125.82
C


ATOM
2932
C
VAL
B
589
−75.699
71.334
−36.832
1.00
125.41
C


ATOM
2933
O
VAL
B
589
−76.718
70.880
−36.312
1.00
125.19
O


ATOM
2934
N
GLY
B
590
−74.703
71.898
−36.154
1.00
127.02
N


ATOM
2935
CA
GLY
B
590
−74.688
72.066
−34.705
1.00
126.97
C


ATOM
2936
C
GLY
B
590
−74.906
73.513
−34.301
1.00
126.94
C


ATOM
2937
O
GLY
B
590
−74.917
74.401
−35.162
1.00
126.90
O


ATOM
2938
N
HIS
B
591
−75.077
73.763
−32.980
1.00
128.31
N


ATOM
2939
CA
HIS
B
591
−75.290
75.093
−32.382
1.00
128.33
C


ATOM
2940
CB
HIS
B
591
−75.465
74.964
−30.851
1.00
128.36
C


ATOM
2941
CG
HIS
B
591
−75.848
76.229
−30.138
1.00
128.50
C


ATOM
2942
ND1
HIS
B
591
−74.894
77.149
−29.728
1.00
128.48
N


ATOM
2943
CE1
HIS
B
591
−75.564
78.124
−29.135
1.00
128.57
C


ATOM
2944
NE2
HIS
B
591
−76.874
77.883
−29.131
1.00
128.60
N


ATOM
2945
CD2
HIS
B
591
−77.068
76.670
−29.754
1.00
128.45
C


ATOM
2946
C
HIS
B
591
−74.140
76.070
−32.735
1.00
128.35
C


ATOM
2947
O
HIS
B
591
−72.996
75.638
−32.916
1.00
128.27
O


ATOM
2948
N
ARG
B
592
−74.464
77.382
−32.845
1.00
130.35
N


ATOM
2949
CA
ARG
B
592
−73.526
78.465
−33.174
1.00
130.16
C


ATOM
2950
CB
ARG
B
592
−74.251
79.820
−33.346
1.00
130.23
C


ATOM
2951
CG
ARG
B
592
−75.283
80.125
−32.268
1.00
130.52
C


ATOM
2952
CD
ARG
B
592
−75.698
81.590
−32.219
1.00
131.28
C


ATOM
2953
NE
ARG
B
592
−76.802
81.788
−31.269
1.00
131.92
N


ATOM
2954
CZ
ARG
B
592
−76.657
82.148
−29.993
1.00
131.97
C


ATOM
2955
NH1
ARG
B
592
−75.446
82.385
−29.494
1.00
131.94
N


ATOM
2956
NH2
ARG
B
592
−77.723
82.283
−29.209
1.00
131.77
N


ATOM
2957
C
ARG
B
592
−72.293
78.564
−32.238
1.00
129.90
C


ATOM
2958
O
ARG
B
592
−71.166
78.662
−32.736
1.00
129.80
O


ATOM
2959
N
GLU
B
593
−72.513
78.509
−30.898
1.00
127.81
N


ATOM
2960
CA
GLU
B
593
−71.474
78.591
−29.854
1.00
127.53
C


ATOM
2961
CB
GLU
B
593
−72.107
78.883
−28.475
1.00
127.55
C


ATOM
2962
CG
GLU
B
593
−72.567
80.316
−28.243
1.00
127.44
C


ATOM
2963
CD
GLU
B
593
−72.865
80.663
−26.791
1.00
127.43
C


ATOM
2964
OE1
GLU
B
593
−74.035
80.521
−26.362
1.00
127.08
O


ATOM
2965
OE2
GLU
B
593
−71.921
81.080
−26.081
1.00
127.50
O


ATOM
2966
C
GLU
B
593
−70.550
77.346
−29.750
1.00
127.34
C


ATOM
2967
O
GLU
B
593
−69.465
77.438
−29.160
1.00
127.36
O


ATOM
2968
N
ALA
B
594
−70.987
76.191
−30.309
1.00
125.85
N


ATOM
2969
CA
ALA
B
594
−70.270
74.904
−30.279
1.00
125.30
C


ATOM
2970
CB
ALA
B
594
−71.239
73.797
−29.915
1.00
125.28
C


ATOM
2971
C
ALA
B
594
−69.558
74.534
−31.580
1.00
124.94
C


ATOM
2972
O
ALA
B
594
−70.001
74.939
−32.656
1.00
124.87
O


ATOM
2973
N
SER
B
595
−68.465
73.739
−31.475
1.00
122.91
N


ATOM
2974
CA
SER
B
595
−67.691
73.248
−32.625
1.00
122.59
C


ATOM
2975
CB
SER
B
595
−66.283
72.828
−32.211
1.00
122.36
C


ATOM
2976
OG
SER
B
595
−65.804
73.570
−31.103
1.00
122.18
O


ATOM
2977
C
SER
B
595
−68.431
72.034
−33.200
1.00
122.55
C


ATOM
2978
O
SER
B
595
−68.960
71.224
−32.432
1.00
122.50
O


ATOM
2979
N
ILE
B
596
−68.489
71.920
−34.541
1.00
122.51
N


ATOM
2980
CA
ILE
B
596
−69.152
70.812
−35.234
1.00
122.52
C


ATOM
2981
CB
ILE
B
596
−70.392
71.213
−36.108
1.00
122.49
C


ATOM
2982
CG1
ILE
B
596
−71.112
69.996
−36.722
1.00
122.49
C


ATOM
2983
CD1
ILE
B
596
−72.218
69.408
−35.909
1.00
122.57
C


ATOM
2984
CG2
ILE
B
596
−70.043
72.208
−37.194
1.00
122.93
C


ATOM
2985
C
ILE
B
596
−68.140
69.889
−35.916
1.00
122.55
C


ATOM
2986
O
ILE
B
596
−67.267
70.340
−36.662
1.00
122.43
O


ATOM
2987
N
HIS
B
597
−68.254
68.592
−35.601
1.00
123.80
N


ATOM
2988
CA
HIS
B
597
−67.429
67.504
−36.118
1.00
123.82
C


ATOM
2989
CB
HIS
B
597
−66.876
66.643
−34.975
1.00
123.73
C


ATOM
2990
CG
HIS
B
597
−66.178
67.399
−33.892
1.00
123.54
C


ATOM
2991
ND1
HIS
B
597
−64.810
67.319
−33.731
1.00
123.54
N


ATOM
2992
CE1
HIS
B
597
−64.529
68.074
−32.682
1.00
123.72
C


ATOM
2993
NE2
HIS
B
597
−65.631
68.621
−32.165
1.00
123.77
N


ATOM
2994
CD2
HIS
B
597
−66.689
68.189
−32.919
1.00
123.49
C


ATOM
2995
C
HIS
B
597
−68.322
66.643
−37.008
1.00
123.91
C


ATOM
2996
O
HIS
B
597
−69.529
66.534
−36.760
1.00
123.96
O


ATOM
2997
N
ALA
B
598
−67.737
66.040
−38.043
1.00
126.34
N


ATOM
2998
CA
ALA
B
598
−68.474
65.191
−38.969
1.00
126.61
C


ATOM
2999
CB
ALA
B
598
−68.871
65.991
−40.196
1.00
126.45
C


ATOM
3000
C
ALA
B
598
−67.612
64.022
−39.379
1.00
126.91
C


ATOM
3001
O
ALA
B
598
−66.396
64.193
−39.509
1.00
126.98
O


ATOM
3002
N
SER
B
599
−68.216
62.835
−39.584
1.00
130.56
N


ATOM
3003
CA
SER
B
599
−67.431
61.686
−40.022
1.00
130.97
C


ATOM
3004
CB
SER
B
599
−67.738
60.438
−39.210
1.00
131.14
C


ATOM
3005
OG
SER
B
599
−66.822
59.400
−39.528
1.00
132.04
O


ATOM
3006
C
SER
B
599
−67.633
61.448
−41.505
1.00
131.08
C


ATOM
3007
O
SER
B
599
−68.756
61.189
−41.947
1.00
130.93
O


ATOM
3008
N
CYS
B
600
−66.536
61.585
−42.275
1.00
136.15
N


ATOM
3009
CA
CYS
B
600
−66.507
61.421
−43.728
1.00
136.70
C


ATOM
3010
CB
CYS
B
600
−65.754
62.571
−44.403
1.00
137.12
C


ATOM
3011
SG
CYS
B
600
−66.513
64.211
−44.198
1.00
139.29
S


ATOM
3012
C
CYS
B
600
−65.893
60.079
−44.067
1.00
136.36
C


ATOM
3013
O
CYS
B
600
−64.730
59.836
−43.734
1.00
136.42
O


ATOM
3014
N
CYS
B
601
−66.665
59.207
−44.720
1.00
136.31
N


ATOM
3015
CA
CYS
B
601
−66.163
57.888
−45.071
1.00
136.05
C


ATOM
3016
CB
CYS
B
601
−66.877
56.799
−44.274
1.00
135.96
C


ATOM
3017
SG
CYS
B
601
−66.493
56.808
−42.505
1.00
135.19
S


ATOM
3018
C
CYS
B
601
−66.175
57.599
−46.557
1.00
136.06
C


ATOM
3019
O
CYS
B
601
−67.227
57.682
−47.201
1.00
136.04
O


ATOM
3020
N
HIS
B
602
−64.999
57.250
−47.104
1.00
139.94
N


ATOM
3021
CA
HIS
B
602
−64.915
56.900
−48.510
1.00
139.95
C


ATOM
3022
CB
HIS
B
602
−63.577
57.301
−49.168
1.00
140.20
C


ATOM
3023
CG
HIS
B
602
−63.501
56.998
−50.648
1.00
141.34
C


ATOM
3024
ND1
HIS
B
602
−64.637
57.006
−51.463
1.00
142.03
N


ATOM
3025
CE1
HIS
B
602
−64.212
56.698
−52.679
1.00
142.05
C


ATOM
3026
NE2
HIS
B
602
−62.890
56.501
−52.703
1.00
142.35
N


ATOM
3027
CD2
HIS
B
602
−62.425
56.689
−51.413
1.00
142.20
C


ATOM
3028
C
HIS
B
602
−65.202
55.412
−48.652
1.00
139.62
C


ATOM
3029
O
HIS
B
602
−64.468
54.562
−48.125
1.00
139.50
O


ATOM
3030
N
ALA
B
603
−66.317
55.124
−49.341
1.00
139.92
N


ATOM
3031
CA
ALA
B
603
−66.846
53.804
−49.666
1.00
139.45
C


ATOM
3032
CB
ALA
B
603
−67.448
53.142
−48.433
1.00
139.37
C


ATOM
3033
C
ALA
B
603
−67.911
54.017
−50.764
1.00
139.05
C


ATOM
3034
O
ALA
B
603
−69.043
54.427
−50.468
1.00
139.15
O


ATOM
3035
N
PRO
B
604
−67.543
53.796
−52.055
1.00
138.26
N


ATOM
3036
CA
PRO
B
604
−68.514
54.008
−53.149
1.00
137.56
C


ATOM
3037
CB
PRO
B
604
−67.654
53.930
−54.425
1.00
137.66
C


ATOM
3038
CG
PRO
B
604
−66.209
53.965
−53.954
1.00
137.98
C


ATOM
3039
CD
PRO
B
604
−66.241
53.345
−52.586
1.00
138.32
C


ATOM
3040
C
PRO
B
604
−69.671
53.007
−53.167
1.00
136.75
C


ATOM
3041
O
PRO
B
604
−70.647
53.224
−53.896
1.00
136.87
O


ATOM
3042
N
GLY
B
605
−69.552
51.938
−52.370
1.00
132.29
N


ATOM
3043
CA
GLY
B
605
−70.575
50.907
−52.240
1.00
130.75
C


ATOM
3044
C
GLY
B
605
−71.601
51.257
−51.180
1.00
129.57
C


ATOM
3045
O
GLY
B
605
−72.657
50.619
−51.101
1.00
129.70
O


ATOM
3046
N
LEU
B
606
−71.288
52.296
−50.365
1.00
124.93
N


ATOM
3047
CA
LEU
B
606
−72.087
52.803
−49.246
1.00
123.32
C


ATOM
3048
CB
LEU
B
606
−71.135
53.282
−48.127
1.00
123.34
C


ATOM
3049
CG
LEU
B
606
−71.403
52.923
−46.648
1.00
123.22
C


ATOM
3050
CD1
LEU
B
606
−71.064
54.097
−45.742
1.00
122.43
C


ATOM
3051
CD2
LEU
B
606
−72.825
52.421
−46.395
1.00
123.19
C


ATOM
3052
C
LEU
B
606
−72.996
53.963
−49.617
1.00
122.22
C


ATOM
3053
O
LEU
B
606
−72.507
54.983
−50.120
1.00
122.10
O


ATOM
3054
N
GLU
B
607
−74.310
53.820
−49.322
1.00
118.39
N


ATOM
3055
CA
GLU
B
607
−75.315
54.853
−49.553
1.00
116.97
C


ATOM
3056
CB
GLU
B
607
−76.260
54.530
−50.732
1.00
116.99
C


ATOM
3057
CG
GLU
B
607
−77.272
53.410
−50.532
1.00
117.68
C


ATOM
3058
CD
GLU
B
607
−78.624
53.643
−51.193
1.00
118.47
C


ATOM
3059
OE1
GLU
B
607
−79.321
52.643
−51.483
1.00
118.49
O


ATOM
3060
OE2
GLU
B
607
−78.992
54.821
−51.417
1.00
118.52
O


ATOM
3061
C
GLU
B
607
−76.030
55.270
−48.246
1.00
115.91
C


ATOM
3062
O
GLU
B
607
−76.739
54.465
−47.637
1.00
116.06
O


ATOM
3063
N
CYS
B
608
−75.802
56.530
−47.807
1.00
112.37
N


ATOM
3064
CA
CYS
B
608
−76.366
57.102
−46.574
1.00
110.58
C


ATOM
3065
CB
CYS
B
608
−75.259
57.654
−45.681
1.00
110.79
C


ATOM
3066
SG
CYS
B
608
−74.059
56.409
−45.131
1.00
112.17
S


ATOM
3067
C
CYS
B
608
−77.498
58.127
−46.762
1.00
108.94
C


ATOM
3068
O
CYS
B
608
−77.508
58.886
−47.732
1.00
108.93
O


ATOM
3069
N
LYS
B
609
−78.442
58.147
−45.816
1.00
100.85
N


ATOM
3070
CA
LYS
B
609
−79.581
59.057
−45.811
1.00
98.69
C


ATOM
3071
CB
LYS
B
609
−80.818
58.412
−46.448
1.00
98.51
C


ATOM
3072
CG
LYS
B
609
−81.449
57.310
−45.646
1.00
97.62
C


ATOM
3073
CD
LYS
B
609
−82.927
57.350
−45.822
1.00
97.09
C


ATOM
3074
CE
LYS
B
609
−83.510
55.972
−45.802
1.00
97.54
C


ATOM
3075
NZ
LYS
B
609
−84.954
56.009
−46.121
1.00
98.08
N


ATOM
3076
C
LYS
B
609
−79.857
59.592
−44.402
1.00
97.61
C


ATOM
3077
O
LYS
B
609
−79.117
59.264
−43.477
1.00
97.62
O


ATOM
3078
N
VAL
B
610
−80.895
60.441
−44.239
1.00
95.01
N


ATOM
3079
CA
VAL
B
610
−81.250
61.021
−42.937
1.00
93.13
C


ATOM
3080
CB
VAL
B
610
−80.857
62.524
−42.796
1.00
92.98
C


ATOM
3081
CG1
VAL
B
610
−81.313
63.089
−41.457
1.00
92.75
C


ATOM
3082
CG2
VAL
B
610
−79.350
62.739
−42.970
1.00
92.08
C


ATOM
3083
C
VAL
B
610
−82.722
60.786
−42.671
1.00
92.11
C


ATOM
3084
O
VAL
B
610
−83.506
60.775
−43.609
1.00
92.08
O


ATOM
3085
N
LYS
B
611
−83.083
60.557
−41.404
1.00
91.38
N


ATOM
3086
CA
LYS
B
611
−84.454
60.370
−40.941
1.00
90.39
C


ATOM
3087
CB
LYS
B
611
−84.782
58.907
−40.668
1.00
90.56
C


ATOM
3088
CG
LYS
B
611
−86.289
58.613
−40.749
1.00
91.05
C


ATOM
3089
CD
LYS
B
611
−86.626
57.145
−41.098
1.00
92.07
C


ATOM
3090
CE
LYS
B
611
−86.088
56.691
−42.456
1.00
92.88
C


ATOM
3091
NZ
LYS
B
611
−86.867
57.237
−43.622
1.00
93.51
N


ATOM
3092
C
LYS
B
611
−84.597
61.214
−39.687
1.00
89.60
C


ATOM
3093
O
LYS
B
611
−83.626
61.343
−38.933
1.00
89.74
O


ATOM
3094
N
GLU
B
612
−85.772
61.833
−39.483
1.00
87.15
N


ATOM
3095
CA
GLU
B
612
−86.002
62.705
−38.337
1.00
86.15
C


ATOM
3096
CB
GLU
B
612
−85.823
64.171
−38.749
1.00
86.59
C


ATOM
3097
CG
GLU
B
612
−84.395
64.674
−38.837
1.00
88.33
C


ATOM
3098
CD
GLU
B
612
−84.229
66.187
−38.948
1.00
90.95
C


ATOM
3099
OE1
GLU
B
612
−85.200
66.927
−38.645
1.00
91.46
O


ATOM
3100
OE2
GLU
B
612
−83.120
66.633
−39.340
1.00
92.27
O


ATOM
3101
C
GLU
B
612
−87.386
62.586
−37.773
1.00
84.94
C


ATOM
3102
O
GLU
B
612
−88.346
62.351
−38.505
1.00
85.08
O


ATOM
3103
N
HIS
B
613
−87.510
62.805
−36.478
1.00
80.41
N


ATOM
3104
CA
HIS
B
613
−88.797
62.818
−35.798
1.00
79.40
C


ATOM
3105
CB
HIS
B
613
−89.366
61.441
−35.482
1.00
78.55
C


ATOM
3106
CG
HIS
B
613
−90.704
61.500
−34.811
1.00
76.10
C


ATOM
3107
ND1
HIS
B
613
−90.843
61.259
−33.460
1.00
74.15
N


ATOM
3108
CE1
HIS
B
613
−92.141
61.369
−33.200
1.00
72.72
C


ATOM
3109
NE2
HIS
B
613
−92.832
61.678
−34.297
1.00
72.67
N


ATOM
3110
CD2
HIS
B
613
−91.926
61.770
−35.332
1.00
73.99
C


ATOM
3111
C
HIS
B
613
−88.613
63.585
−34.552
1.00
79.83
C


ATOM
3112
O
HIS
B
613
−87.692
63.295
−33.791
1.00
80.05
O


ATOM
3113
N
GLY
B
614
−89.459
64.585
−34.375
1.00
82.49
N


ATOM
3114
CA
GLY
B
614
−89.444
65.441
−33.208
1.00
82.79
C


ATOM
3115
C
GLY
B
614
−90.823
65.612
−32.638
1.00
83.07
C


ATOM
3116
O
GLY
B
614
−91.803
65.424
−33.362
1.00
82.78
O


ATOM
3117
N
ILE
B
615
−90.911
65.966
−31.346
1.00
88.23
N


ATOM
3118
CA
ILE
B
615
−92.196
66.213
−30.683
1.00
89.18
C


ATOM
3119
CB
ILE
B
615
−93.076
64.985
−30.329
1.00
89.23
C


ATOM
3120
CG1
ILE
B
615
−92.261
63.813
−29.798
1.00
88.59
C


ATOM
3121
CD1
ILE
B
615
−92.242
63.843
−28.398
1.00
88.33
C


ATOM
3122
CG2
ILE
B
615
−94.050
64.602
−31.489
1.00
89.10
C


ATOM
3123
C
ILE
B
615
−92.141
67.291
−29.596
1.00
89.92
C


ATOM
3124
O
ILE
B
615
−91.193
67.289
−28.815
1.00
90.14
O


ATOM
3125
N
PRO
B
616
−93.132
68.230
−29.591
1.00
92.46
N


ATOM
3126
CA
PRO
B
616
−93.155
69.352
−28.639
1.00
92.93
C


ATOM
3127
CB
PRO
B
616
−94.598
69.867
−28.758
1.00
92.90
C


ATOM
3128
CG
PRO
B
616
−95.310
68.911
−29.645
1.00
92.45
C


ATOM
3129
CD
PRO
B
616
−94.277
68.348
−30.508
1.00
92.34
C


ATOM
3130
C
PRO
B
616
−92.673
69.260
−27.175
1.00
93.54
C


ATOM
3131
O
PRO
B
616
−91.577
69.768
−26.866
1.00
93.58
O


ATOM
3132
N
ALA
B
617
−93.519
68.703
−26.269
1.00
96.94
N


ATOM
3133
CA
ALA
B
617
−93.242
68.553
−24.839
1.00
97.57
C


ATOM
3134
CB
ALA
B
617
−94.431
69.057
−24.028
1.00
97.36
C


ATOM
3135
C
ALA
B
617
−93.013
67.053
−24.597
1.00
97.97
C


ATOM
3136
O
ALA
B
617
−93.990
66.330
−24.307
1.00
98.46
O


ATOM
3137
N
PRO
B
618
−91.751
66.545
−24.766
1.00
98.47
N


ATOM
3138
CA
PRO
B
618
−91.525
65.101
−24.623
1.00
98.62
C


ATOM
3139
CB
PRO
B
618
−90.209
64.854
−25.377
1.00
98.31
C


ATOM
3140
CG
PRO
B
618
−89.803
66.158
−25.913
1.00
98.18
C


ATOM
3141
CD
PRO
B
618
−90.498
67.217
−25.140
1.00
98.25
C


ATOM
3142
C
PRO
B
618
−91.446
64.630
−23.191
1.00
98.94
C


ATOM
3143
O
PRO
B
618
−90.715
65.232
−22.386
1.00
99.07
O


ATOM
3144
N
GLN
B
619
−92.203
63.530
−22.893
1.00
100.32
N


ATOM
3145
CA
GLN
B
619
−92.267
62.858
−21.590
1.00
100.41
C


ATOM
3146
CB
GLN
B
619
−93.209
61.620
−21.646
1.00
100.77
C


ATOM
3147
CG
GLN
B
619
−94.720
61.924
−21.757
1.00
102.64
C


ATOM
3148
CD
GLN
B
619
−95.221
62.146
−23.187
1.00
105.52
C


ATOM
3149
OE1
GLN
B
619
−95.170
61.245
−24.049
1.00
106.91
O


ATOM
3150
NE2
GLN
B
619
−95.732
63.351
−23.468
1.00
105.63
N


ATOM
3151
C
GLN
B
619
−90.813
62.447
−21.227
1.00
99.99
C


ATOM
3152
O
GLN
B
619
−90.130
63.183
−20.494
1.00
100.29
O


ATOM
3153
N
GLU
B
620
−90.318
61.323
−21.796
1.00
94.10
N


ATOM
3154
CA
GLU
B
620
−88.954
60.893
−21.519
1.00
92.71
C


ATOM
3155
CB
GLU
B
620
−88.935
59.482
−20.901
1.00
92.50
C


ATOM
3156
C
GLU
B
620
−88.053
60.992
−22.752
1.00
91.86
C


ATOM
3157
O
GLU
B
620
−86.984
61.626
−22.694
1.00
91.83
O


ATOM
3158
N
GLN
B
621
−88.487
60.374
−23.872
1.00
85.55
N


ATOM
3159
CA
GLN
B
621
−87.670
60.349
−25.080
1.00
84.47
C


ATOM
3160
CB
GLN
B
621
−86.844
59.042
−25.162
1.00
84.60
C


ATOM
3161
CG
GLN
B
621
−87.462
57.832
−24.461
1.00
84.63
C


ATOM
3162
CD
GLN
B
621
−87.643
56.685
−25.402
1.00
84.43
C


ATOM
3163
OE1
GLN
B
621
−86.689
55.973
−25.708
1.00
85.62
O


ATOM
3164
NE2
GLN
B
621
−88.871
56.482
−25.882
1.00
84.34
N


ATOM
3165
C
GLN
B
621
−88.374
60.638
−26.386
1.00
83.76
C


ATOM
3166
O
GLN
B
621
−89.598
60.733
−26.423
1.00
83.59
O


ATOM
3167
N
VAL
B
622
−87.563
60.800
−27.458
1.00
79.91
N


ATOM
3168
CA
VAL
B
622
−87.932
61.064
−28.848
1.00
79.67
C


ATOM
3169
CB
VAL
B
622
−87.664
62.526
−29.281
1.00
79.63
C


ATOM
3170
CG1
VAL
B
622
−87.873
62.702
−30.771
1.00
79.21
C


ATOM
3171
CG2
VAL
B
622
−88.559
63.495
−28.516
1.00
79.49
C


ATOM
3172
C
VAL
B
622
−87.170
60.043
−29.682
1.00
79.82
C


ATOM
3173
O
VAL
B
622
−85.939
59.991
−29.653
1.00
79.77
O


ATOM
3174
N
THR
B
623
−87.927
59.218
−30.410
1.00
82.55
N


ATOM
3175
CA
THR
B
623
−87.419
58.107
−31.207
1.00
82.68
C


ATOM
3176
CB
THR
B
623
−87.976
56.814
−30.555
1.00
82.61
C


ATOM
3177
OG1
THR
B
623
−87.045
56.385
−29.562
1.00
82.15
O


ATOM
3178
CG2
THR
B
623
−88.326
55.694
−31.553
1.00
82.02
C


ATOM
3179
C
THR
B
623
−87.629
58.197
−32.723
1.00
83.06
C


ATOM
3180
O
THR
B
623
−88.686
58.617
−33.191
1.00
83.23
O


ATOM
3181
N
VAL
B
624
−86.622
57.744
−33.474
1.00
85.14
N


ATOM
3182
CA
VAL
B
624
−86.620
57.659
−34.935
1.00
85.55
C


ATOM
3183
CB
VAL
B
624
−86.190
58.982
−35.648
1.00
85.38
C


ATOM
3184
CG1
VAL
B
624
−84.702
59.294
−35.472
1.00
85.50
C


ATOM
3185
CG2
VAL
B
624
−86.563
58.962
−37.122
1.00
85.18
C


ATOM
3186
C
VAL
B
624
−85.823
56.397
−35.353
1.00
86.01
C


ATOM
3187
O
VAL
B
624
−84.642
56.262
−35.013
1.00
85.58
O


ATOM
3188
N
ALA
B
625
−86.483
55.463
−36.046
1.00
89.04
N


ATOM
3189
CA
ALA
B
625
−85.810
54.229
−36.462
1.00
90.03
C


ATOM
3190
CB
ALA
B
625
−86.573
53.019
−35.942
1.00
89.71
C


ATOM
3191
C
ALA
B
625
−85.616
54.118
−37.974
1.00
90.84
C


ATOM
3192
O
ALA
B
625
−86.465
54.600
−38.730
1.00
91.18
O


ATOM
3193
N
CYS
B
626
−84.519
53.467
−38.416
1.00
92.62
N


ATOM
3194
CA
CYS
B
626
−84.249
53.242
−39.833
1.00
93.74
C


ATOM
3195
CB
CYS
B
626
−82.845
52.686
−40.028
1.00
93.68
C


ATOM
3196
SG
CYS
B
626
−81.521
53.825
−39.563
1.00
96.55
S


ATOM
3197
C
CYS
B
626
−85.294
52.278
−40.417
1.00
94.25
C


ATOM
3198
O
CYS
B
626
−85.991
51.581
−39.670
1.00
94.23
O


ATOM
3199
N
GLU
B
627
−85.397
52.224
−41.750
1.00
99.01
N


ATOM
3200
CA
GLU
B
627
−86.313
51.280
−42.372
1.00
99.57
C


ATOM
3201
CB
GLU
B
627
−86.699
51.724
−43.779
1.00
99.82
C


ATOM
3202
CG
GLU
B
627
−87.846
52.708
−43.822
1.00
101.35
C


ATOM
3203
CD
GLU
B
627
−87.453
54.073
−44.351
1.00
103.72
C


ATOM
3204
OE1
GLU
B
627
−86.269
54.258
−44.725
1.00
104.08
O


ATOM
3205
OE2
GLU
B
627
−88.334
54.965
−44.379
1.00
105.10
O


ATOM
3206
C
GLU
B
627
−85.575
49.950
−42.474
1.00
99.72
C


ATOM
3207
O
GLU
B
627
−84.331
49.916
−42.454
1.00
99.64
O


ATOM
3208
N
GLU
B
628
−86.347
48.852
−42.602
1.00
99.87
N


ATOM
3209
CA
GLU
B
628
−85.806
47.503
−42.759
1.00
99.87
C


ATOM
3210
CB
GLU
B
628
−86.981
46.504
−42.940
1.00
100.27
C


ATOM
3211
CG
GLU
B
628
−86.774
45.326
−43.885
1.00
102.66
C


ATOM
3212
CD
GLU
B
628
−85.816
44.225
−43.459
1.00
105.44
C


ATOM
3213
OE1
GLU
B
628
−85.760
43.908
−42.246
1.00
106.67
O


ATOM
3214
OE2
GLU
B
628
−85.130
43.664
−44.348
1.00
106.45
O


ATOM
3215
C
GLU
B
628
−84.797
47.549
−43.934
1.00
99.03
C


ATOM
3216
O
GLU
B
628
−85.098
48.102
−44.990
1.00
98.78
O


ATOM
3217
N
GLY
B
629
−83.593
47.065
−43.694
1.00
97.03
N


ATOM
3218
CA
GLY
B
629
−82.544
47.072
−44.706
1.00
96.58
C


ATOM
3219
C
GLY
B
629
−81.530
48.174
−44.506
1.00
96.44
C


ATOM
3220
O
GLY
B
629
−80.403
48.111
−45.014
1.00
96.39
O


ATOM
3221
N
TRP
B
630
−81.928
49.190
−43.757
1.00
99.26
N


ATOM
3222
CA
TRP
B
630
−81.056
50.308
−43.456
1.00
99.05
C


ATOM
3223
CB
TRP
B
630
−81.851
51.611
−43.533
1.00
99.48
C


ATOM
3224
CG
TRP
B
630
−82.241
51.986
−44.934
1.00
100.47
C


ATOM
3225
CD1
TRP
B
630
−83.413
51.692
−45.576
1.00
100.68
C


ATOM
3226
NE1
TRP
B
630
−83.394
52.210
−46.852
1.00
100.42
N


ATOM
3227
CE2
TRP
B
630
−82.198
52.855
−47.054
1.00
100.71
C


ATOM
3228
CD2
TRP
B
630
−81.443
52.723
−45.868
1.00
100.98
C


ATOM
3229
CE3
TRP
B
630
−80.163
53.307
−45.809
1.00
101.56
C


ATOM
3230
CZ3
TRP
B
630
−79.684
53.996
−46.915
1.00
101.51
C


ATOM
3231
CH2
TRP
B
630
−80.444
54.095
−48.085
1.00
101.62
C


ATOM
3232
CZ2
TRP
B
630
−81.710
53.541
−48.175
1.00
101.13
C


ATOM
3233
C
TRP
B
630
−80.456
50.094
−42.074
1.00
98.40
C


ATOM
3234
O
TRP
B
630
−81.127
49.576
−41.181
1.00
98.36
O


ATOM
3235
N
THR
B
631
−79.197
50.479
−41.910
1.00
95.20
N


ATOM
3236
CA
THR
B
631
−78.443
50.347
−40.667
1.00
94.44
C


ATOM
3237
CB
THR
B
631
−77.185
49.515
−40.966
1.00
94.47
C


ATOM
3238
OG1
THR
B
631
−77.579
48.155
−41.135
1.00
94.93
O


ATOM
3239
CG2
THR
B
631
−76.114
49.624
−39.898
1.00
94.21
C


ATOM
3240
C
THR
B
631
−78.164
51.727
−40.033
1.00
93.85
C


ATOM
3241
O
THR
B
631
−77.579
52.598
−40.681
1.00
93.88
O


ATOM
3242
N
LEU
B
632
−78.569
51.919
−38.772
1.00
91.41
N


ATOM
3243
CA
LEU
B
632
−78.332
53.177
−38.074
1.00
90.60
C


ATOM
3244
CB
LEU
B
632
−79.138
53.227
−36.766
1.00
90.50
C


ATOM
3245
CG
LEU
B
632
−78.971
54.451
−35.885
1.00
89.65
C


ATOM
3246
CD1
LEU
B
632
−79.409
55.660
−36.593
1.00
89.50
C


ATOM
3247
CD2
LEU
B
632
−79.817
54.334
−34.678
1.00
89.05
C


ATOM
3248
C
LEU
B
632
−76.849
53.315
−37.798
1.00
90.39
C


ATOM
3249
O
LEU
B
632
−76.288
52.506
−37.062
1.00
90.51
O


ATOM
3250
N
THR
B
633
−76.208
54.313
−38.411
1.00
90.81
N


ATOM
3251
CA
THR
B
633
−74.772
54.565
−38.232
1.00
90.43
C


ATOM
3252
CB
THR
B
633
−74.066
54.794
−39.567
1.00
90.45
C


ATOM
3253
OG1
THR
B
633
−74.591
55.988
−40.166
1.00
91.14
O


ATOM
3254
CG2
THR
B
633
−74.184
53.604
−40.500
1.00
90.51
C


ATOM
3255
C
THR
B
633
−74.524
55.759
−37.317
1.00
90.16
C


ATOM
3256
O
THR
B
633
−73.538
55.764
−36.582
1.00
90.12
O


ATOM
3257
N
GLY
B
634
−75.394
56.763
−37.396
1.00
87.09
N


ATOM
3258
CA
GLY
B
634
−75.267
57.961
−36.581
1.00
86.65
C


ATOM
3259
C
GLY
B
634
−76.542
58.364
−35.880
1.00
86.41
C


ATOM
3260
O
GLY
B
634
−77.612
58.389
−36.502
1.00
86.54
O


ATOM
3261
N
CYS
B
635
−76.438
58.699
−34.585
1.00
82.25
N


ATOM
3262
CA
CYS
B
635
−77.609
59.131
−33.820
1.00
82.04
C


ATOM
3263
CB
CYS
B
635
−78.076
58.027
−32.879
1.00
81.41
C


ATOM
3264
SG
CYS
B
635
−79.434
58.486
−31.778
1.00
79.97
S


ATOM
3265
C
CYS
B
635
−77.254
60.442
−33.099
1.00
82.61
C


ATOM
3266
O
CYS
B
635
−76.128
60.590
−32.595
1.00
82.41
O


ATOM
3267
N
SER
B
636
−78.190
61.428
−33.153
1.00
83.71
N


ATOM
3268
CA
SER
B
636
−78.043
62.796
−32.610
1.00
84.47
C


ATOM
3269
CB
SER
B
636
−77.178
63.631
−33.551
1.00
84.28
C


ATOM
3270
OG
SER
B
636
−77.693
63.523
−34.868
1.00
84.69
O


ATOM
3271
C
SER
B
636
−79.369
63.520
−32.421
1.00
84.91
C


ATOM
3272
O
SER
B
636
−80.422
62.986
−32.751
1.00
84.87
O


ATOM
3273
N
ALA
B
637
−79.306
64.751
−31.900
1.00
87.69
N


ATOM
3274
CA
ALA
B
637
−80.478
65.601
−31.676
1.00
88.87
C


ATOM
3275
CB
ALA
B
637
−80.790
65.706
−30.192
1.00
88.44
C


ATOM
3276
C
ALA
B
637
−80.287
66.994
−32.279
1.00
89.84
C


ATOM
3277
O
ALA
B
637
−79.159
67.500
−32.334
1.00
90.01
O


ATOM
3278
N
LEU
B
638
−81.395
67.603
−32.745
1.00
95.18
N


ATOM
3279
CA
LEU
B
638
−81.383
68.934
−33.337
1.00
96.41
C


ATOM
3280
CB
LEU
B
638
−82.722
69.272
−34.006
1.00
96.25
C


ATOM
3281
CG
LEU
B
638
−82.911
68.746
−35.428
1.00
95.86
C


ATOM
3282
CD1
LEU
B
638
−84.116
69.356
−36.057
1.00
95.51
C


ATOM
3283
CD2
LEU
B
638
−81.710
69.046
−36.310
1.00
94.65
C


ATOM
3284
C
LEU
B
638
−80.990
69.951
−32.267
1.00
97.73
C


ATOM
3285
O
LEU
B
638
−81.656
70.016
−31.223
1.00
97.77
O


ATOM
3286
N
PRO
B
639
−79.864
70.688
−32.494
1.00
105.30
N


ATOM
3287
CA
PRO
B
639
−79.352
71.634
−31.482
1.00
106.33
C


ATOM
3288
CB
PRO
B
639
−78.161
72.308
−32.178
1.00
106.24
C


ATOM
3289
CG
PRO
B
639
−78.327
72.005
−33.615
1.00
105.87
C


ATOM
3290
CD
PRO
B
639
−78.974
70.662
−33.669
1.00
105.46
C


ATOM
3291
C
PRO
B
639
−80.325
72.645
−30.907
1.00
107.40
C


ATOM
3292
O
PRO
B
639
−80.205
73.000
−29.722
1.00
107.75
O


ATOM
3293
N
GLY
B
640
−81.274
73.081
−31.741
1.00
113.40
N


ATOM
3294
CA
GLY
B
640
−82.310
74.042
−31.372
1.00
114.55
C


ATOM
3295
C
GLY
B
640
−83.280
73.426
−30.393
1.00
115.12
C


ATOM
3296
O
GLY
B
640
−84.423
73.114
−30.755
1.00
115.42
O


ATOM
3297
N
THR
B
641
−82.800
73.215
−29.150
1.00
117.71
N


ATOM
3298
CA
THR
B
641
−83.559
72.584
−28.075
1.00
118.36
C


ATOM
3299
CB
THR
B
641
−83.562
71.037
−28.234
1.00
118.30
C


ATOM
3300
OG1
THR
B
641
−84.491
70.483
−27.300
1.00
118.10
O


ATOM
3301
CG2
THR
B
641
−82.167
70.408
−28.050
1.00
118.37
C


ATOM
3302
C
THR
B
641
−83.112
73.048
−26.691
1.00
118.77
C


ATOM
3303
O
THR
B
641
−82.100
73.750
−26.555
1.00
119.16
O


ATOM
3304
N
SER
B
642
−83.885
72.626
−25.671
1.00
118.42
N


ATOM
3305
CA
SER
B
642
−83.692
72.923
−24.260
1.00
118.43
C


ATOM
3306
CB
SER
B
642
−85.050
73.128
−23.585
1.00
118.78
C


ATOM
3307
OG
SER
B
642
−85.914
73.957
−24.352
1.00
119.68
O


ATOM
3308
C
SER
B
642
−82.882
71.797
−23.600
1.00
117.89
C


ATOM
3309
O
SER
B
642
−81.844
71.394
−24.144
1.00
117.93
O


ATOM
3310
N
HIS
B
643
−83.345
71.289
−22.444
1.00
114.82
N


ATOM
3311
CA
HIS
B
643
−82.631
70.240
−21.720
1.00
114.07
C


ATOM
3312
CB
HIS
B
643
−82.906
70.289
−20.189
1.00
114.71
C


ATOM
3313
CG
HIS
B
643
−81.719
69.984
−19.295
1.00
116.80
C


ATOM
3314
ND1
HIS
B
643
−80.426
70.430
−19.601
1.00
118.25
N


ATOM
3315
CE1
HIS
B
643
−79.653
70.006
−18.607
1.00
118.56
C


ATOM
3316
NE2
HIS
B
643
−80.355
69.336
−17.686
1.00
118.87
N


ATOM
3317
CD2
HIS
B
643
−81.677
69.321
−18.109
1.00
118.39
C


ATOM
3318
C
HIS
B
643
−82.757
68.829
−22.313
1.00
112.56
C


ATOM
3319
O
HIS
B
643
−83.777
68.140
−22.151
1.00
112.68
O


ATOM
3320
N
VAL
B
644
−81.695
68.422
−23.023
1.00
102.35
N


ATOM
3321
CA
VAL
B
644
−81.587
67.090
−23.585
1.00
100.09
C


ATOM
3322
CB
VAL
B
644
−81.702
66.933
−25.117
1.00
100.10
C


ATOM
3323
CG1
VAL
B
644
−82.987
67.561
−25.623
1.00
99.99
C


ATOM
3324
CG2
VAL
B
644
−80.491
67.488
−25.854
1.00
99.85
C


ATOM
3325
C
VAL
B
644
−80.366
66.454
−22.963
1.00
98.62
C


ATOM
3326
O
VAL
B
644
−79.243
66.985
−23.051
1.00
98.76
O


ATOM
3327
N
LEU
B
645
−80.619
65.347
−22.262
1.00
90.02
N


ATOM
3328
CA
LEU
B
645
−79.643
64.550
−21.532
1.00
87.53
C


ATOM
3329
CB
LEU
B
645
−80.385
63.455
−20.757
1.00
87.46
C


ATOM
3330
CG
LEU
B
645
−81.162
63.901
−19.502
1.00
86.73
C


ATOM
3331
CD1
LEU
B
645
−82.312
64.792
−19.839
1.00
86.67
C


ATOM
3332
CD2
LEU
B
645
−81.741
62.719
−18.779
1.00
86.22
C


ATOM
3333
C
LEU
B
645
−78.572
63.976
−22.465
1.00
85.94
C


ATOM
3334
O
LEU
B
645
−77.389
64.002
−22.136
1.00
85.72
O


ATOM
3335
N
GLY
B
646
−78.999
63.512
−23.633
1.00
81.27
N


ATOM
3336
CA
GLY
B
646
−78.124
62.949
−24.655
1.00
78.79
C


ATOM
3337
C
GLY
B
646
−78.847
62.091
−25.670
1.00
77.11
C


ATOM
3338
O
GLY
B
646
−80.079
62.007
−25.682
1.00
76.86
O


ATOM
3339
N
ALA
B
647
−78.075
61.445
−26.532
1.00
74.90
N


ATOM
3340
CA
ALA
B
647
−78.608
60.554
−27.563
1.00
73.60
C


ATOM
3341
CB
ALA
B
647
−78.740
61.280
−28.888
1.00
73.68
C


ATOM
3342
C
ALA
B
647
−77.744
59.328
−27.734
1.00
72.61
C


ATOM
3343
O
ALA
B
647
−76.515
59.395
−27.653
1.00
72.32
O


ATOM
3344
N
TYR
B
648
−78.402
58.202
−27.970
1.00
71.64
N


ATOM
3345
CA
TYR
B
648
−77.731
56.920
−28.182
1.00
70.40
C


ATOM
3346
CB
TYR
B
648
−77.415
56.200
−26.842
1.00
69.77
C


ATOM
3347
CG
TYR
B
648
−78.580
56.130
−25.876
1.00
67.74
C


ATOM
3348
CD1
TYR
B
648
−78.712
57.058
−24.843
1.00
66.20
C


ATOM
3349
CE1
TYR
B
648
−79.797
57.015
−23.964
1.00
64.71
C


ATOM
3350
CZ
TYR
B
648
−80.767
56.030
−24.113
1.00
64.68
C


ATOM
3351
OH
TYR
B
648
−81.835
55.960
−23.239
1.00
63.83
O


ATOM
3352
CE2
TYR
B
648
−80.647
55.092
−25.132
1.00
64.61
C


ATOM
3353
CD2
TYR
B
648
−79.555
55.145
−26.000
1.00
65.13
C


ATOM
3354
C
TYR
B
648
−78.543
56.035
−29.123
1.00
70.18
C


ATOM
3355
O
TYR
B
648
−79.767
56.174
−29.210
1.00
70.19
O


ATOM
3356
N
ALA
B
649
−77.859
55.118
−29.813
1.00
71.65
N


ATOM
3357
CA
ALA
B
649
−78.512
54.174
−30.718
1.00
71.10
C


ATOM
3358
CB
ALA
B
649
−77.614
53.899
−31.910
1.00
71.27
C


ATOM
3359
C
ALA
B
649
−78.831
52.869
−30.005
1.00
70.52
C


ATOM
3360
O
ALA
B
649
−78.006
52.355
−29.249
1.00
70.51
O


ATOM
3361
N
VAL
B
650
−80.019
52.347
−30.226
1.00
70.69
N


ATOM
3362
CA
VAL
B
650
−80.446
51.073
−29.657
1.00
70.72
C


ATOM
3363
CB
VAL
B
650
−81.517
51.182
−28.569
1.00
70.58
C


ATOM
3364
CG1
VAL
B
650
−81.723
49.839
−27.885
1.00
70.02
C


ATOM
3365
CG2
VAL
B
650
−81.146
52.245
−27.549
1.00
70.80
C


ATOM
3366
C
VAL
B
650
−80.897
50.209
−30.814
1.00
71.06
C


ATOM
3367
O
VAL
B
650
−82.092
50.194
−31.175
1.00
70.88
O


ATOM
3368
N
ASP
B
651
−79.911
49.492
−31.401
1.00
74.95
N


ATOM
3369
CA
ASP
B
651
−80.052
48.625
−32.559
1.00
75.66
C


ATOM
3370
CB
ASP
B
651
−81.277
47.685
−32.445
1.00
76.16
C


ATOM
3371
CG
ASP
B
651
−81.529
46.758
−33.626
1.00
78.41
C


ATOM
3372
OD1
ASP
B
651
−80.530
46.195
−34.180
1.00
80.78
O


ATOM
3373
OD2
ASP
B
651
−82.727
46.584
−34.003
1.00
80.71
O


ATOM
3374
C
ASP
B
651
−80.132
49.596
−33.710
1.00
75.69
C


ATOM
3375
O
ASP
B
651
−79.143
50.298
−33.950
1.00
75.69
O


ATOM
3376
N
ASN
B
652
−81.294
49.702
−34.387
1.00
77.61
N


ATOM
3377
CA
ASN
B
652
−81.461
50.629
−35.493
1.00
77.68
C


ATOM
3378
CB
ASN
B
652
−81.874
49.898
−36.775
1.00
77.48
C


ATOM
3379
CG
ASN
B
652
−80.748
49.236
−37.560
1.00
77.93
C


ATOM
3380
OD1
ASN
B
652
−79.540
49.314
−37.242
1.00
78.69
O


ATOM
3381
ND2
ASN
B
652
−81.135
48.552
−38.626
1.00
78.67
N


ATOM
3382
C
ASN
B
652
−82.435
51.728
−35.091
1.00
77.91
C


ATOM
3383
O
ASN
B
652
−83.069
52.348
−35.940
1.00
78.35
O


ATOM
3384
N
THR
B
653
−82.551
51.977
−33.791
1.00
75.16
N


ATOM
3385
CA
THR
B
653
−83.417
53.015
−33.281
1.00
75.21
C


ATOM
3386
CB
THR
B
653
−84.473
52.452
−32.330
1.00
75.26
C


ATOM
3387
OG1
THR
B
653
−85.255
51.464
−33.006
1.00
75.72
O


ATOM
3388
CG2
THR
B
653
−85.399
53.526
−31.794
1.00
74.72
C


ATOM
3389
C
THR
B
653
−82.546
54.045
−32.635
1.00
75.52
C


ATOM
3390
O
THR
B
653
−81.665
53.697
−31.861
1.00
75.87
O


ATOM
3391
N
CYS
B
654
−82.767
55.319
−32.972
1.00
76.26
N


ATOM
3392
CA
CYS
B
654
−82.038
56.437
−32.405
1.00
76.22
C


ATOM
3393
CB
CYS
B
654
−81.803
57.509
−33.454
1.00
76.68
C


ATOM
3394
SG
CYS
B
654
−81.111
59.037
−32.794
1.00
79.21
S


ATOM
3395
C
CYS
B
654
−82.871
56.956
−31.255
1.00
75.66
C


ATOM
3396
O
CYS
B
654
−84.076
57.208
−31.421
1.00
75.66
O


ATOM
3397
N
VAL
B
655
−82.248
57.048
−30.064
1.00
70.52
N


ATOM
3398
CA
VAL
B
655
−82.914
57.520
−28.847
1.00
69.96
C


ATOM
3399
CB
VAL
B
655
−82.983
56.490
−27.703
1.00
69.62
C


ATOM
3400
CG1
VAL
B
655
−83.639
57.095
−26.464
1.00
68.37
C


ATOM
3401
CG2
VAL
B
655
−83.715
55.226
−28.147
1.00
69.18
C


ATOM
3402
C
VAL
B
655
−82.292
58.801
−28.392
1.00
70.24
C


ATOM
3403
O
VAL
B
655
−81.069
58.871
−28.242
1.00
69.75
O


ATOM
3404
N
VAL
B
656
−83.151
59.819
−28.201
1.00
71.61
N


ATOM
3405
CA
VAL
B
656
−82.816
61.150
−27.714
1.00
72.11
C


ATOM
3406
CB
VAL
B
656
−83.183
62.263
−28.729
1.00
72.14
C


ATOM
3407
CG1
VAL
B
656
−83.344
63.625
−28.055
1.00
72.22
C


ATOM
3408
CG2
VAL
B
656
−82.148
62.334
−29.843
1.00
71.57
C


ATOM
3409
C
VAL
B
656
−83.560
61.248
−26.401
1.00
72.63
C


ATOM
3410
O
VAL
B
656
−84.772
61.054
−26.372
1.00
72.38
O


ATOM
3411
N
ARG
B
657
−82.825
61.480
−25.304
1.00
78.59
N


ATOM
3412
CA
ARG
B
657
−83.387
61.567
−23.953
1.00
79.74
C


ATOM
3413
CB
ARG
B
657
−82.539
60.731
−22.976
1.00
79.78
C


ATOM
3414
CG
ARG
B
657
−82.737
59.207
−23.123
1.00
80.65
C


ATOM
3415
CD
ARG
B
657
−83.820
58.623
−22.204
1.00
82.56
C


ATOM
3416
NE
ARG
B
657
−83.525
58.905
−20.795
1.00
85.35
N


ATOM
3417
CZ
ARG
B
657
−82.733
58.168
−20.003
1.00
87.81
C


ATOM
3418
NH1
ARG
B
657
−82.173
57.043
−20.459
1.00
88.85
N


ATOM
3419
NH2
ARG
B
657
−82.504
58.544
−18.748
1.00
88.39
N


ATOM
3420
C
ARG
B
657
−83.533
63.037
−23.534
1.00
80.41
C


ATOM
3421
O
ARG
B
657
−82.609
63.828
−23.747
1.00
80.41
O


ATOM
3422
N
SER
B
658
−84.706
63.407
−22.982
1.00
83.27
N


ATOM
3423
CA
SER
B
658
−85.011
64.791
−22.589
1.00
84.33
C


ATOM
3424
CB
SER
B
658
−85.972
65.406
−23.597
1.00
84.44
C


ATOM
3425
OG
SER
B
658
−87.160
64.623
−23.627
1.00
85.47
O


ATOM
3426
C
SER
B
658
−85.614
64.919
−21.181
1.00
84.82
C


ATOM
3427
O
SER
B
658
−86.333
64.018
−20.728
1.00
85.31
O


ATOM
3428
N
ARG
B
659
−85.349
66.076
−20.511
1.00
83.80
N


ATOM
3429
CA
ARG
B
659
−85.794
66.403
−19.147
1.00
83.94
C


ATOM
3430
CB
ARG
B
659
−84.813
67.394
−18.504
1.00
83.98
C


ATOM
3431
C
ARG
B
659
−87.216
66.937
−19.109
1.00
83.92
C


ATOM
3432
O
ARG
B
659
−88.139
66.240
−19.535
1.00
84.37
O


ATOM
3433
N
GLU
B
670
−90.617
74.494
−28.169
1.00
107.03
N


ATOM
3434
CA
GLU
B
670
−90.150
73.859
−29.399
1.00
107.20
C


ATOM
3435
CB
GLU
B
670
−88.867
74.517
−29.912
1.00
107.28
C


ATOM
3436
CG
GLU
B
670
−88.726
74.422
−31.425
1.00
108.21
C


ATOM
3437
CD
GLU
B
670
−87.325
74.535
−31.995
1.00
109.40
C


ATOM
3438
OE1
GLU
B
670
−86.487
75.246
−31.390
1.00
109.72
O


ATOM
3439
OE2
GLU
B
670
−87.068
73.917
−33.056
1.00
109.72
O


ATOM
3440
C
GLU
B
670
−89.976
72.318
−29.299
1.00
107.16
C


ATOM
3441
O
GLU
B
670
−89.705
71.776
−28.212
1.00
107.43
O


ATOM
3442
N
ALA
B
671
−90.138
71.624
−30.458
1.00
103.50
N


ATOM
3443
CA
ALA
B
671
−90.045
70.172
−30.584
1.00
102.63
C


ATOM
3444
CB
ALA
B
671
−90.734
69.700
−31.852
1.00
102.68
C


ATOM
3445
C
ALA
B
671
−88.626
69.671
−30.551
1.00
102.05
C


ATOM
3446
O
ALA
B
671
−87.751
70.194
−31.255
1.00
101.78
O


ATOM
3447
N
VAL
B
672
−88.409
68.639
−29.715
1.00
98.57
N


ATOM
3448
CA
VAL
B
672
−87.128
67.956
−29.538
1.00
97.51
C


ATOM
3449
CB
VAL
B
672
−87.063
67.254
−28.166
1.00
97.29
C


ATOM
3450
CG1
VAL
B
672
−85.709
66.595
−27.963
1.00
97.24
C


ATOM
3451
CG2
VAL
B
672
−87.360
68.223
−27.039
1.00
96.37
C


ATOM
3452
C
VAL
B
672
−87.071
66.945
−30.680
1.00
97.19
C


ATOM
3453
O
VAL
B
672
−87.936
66.062
−30.741
1.00
97.15
O


ATOM
3454
N
THR
B
673
−86.084
67.082
−31.590
1.00
93.85
N


ATOM
3455
CA
THR
B
673
−86.007
66.179
−32.738
1.00
93.22
C


ATOM
3456
CB
THR
B
673
−86.082
66.971
−34.055
1.00
93.20
C


ATOM
3457
OG1
THR
B
673
−87.252
67.789
−34.046
1.00
93.18
O


ATOM
3458
CG2
THR
B
673
−86.115
66.071
−35.288
1.00
93.30
C


ATOM
3459
C
THR
B
673
−84.862
65.181
−32.725
1.00
92.78
C


ATOM
3460
O
THR
B
673
−83.703
65.600
−32.638
1.00
92.70
O


ATOM
3461
N
ALA
B
674
−85.193
63.863
−32.857
1.00
85.71
N


ATOM
3462
CA
ALA
B
674
−84.223
62.776
−32.942
1.00
85.33
C


ATOM
3463
CB
ALA
B
674
−84.859
61.471
−32.509
1.00
85.28
C


ATOM
3464
C
ALA
B
674
−83.760
62.709
−34.412
1.00
85.29
C


ATOM
3465
O
ALA
B
674
−84.589
62.797
−35.317
1.00
85.26
O


ATOM
3466
N
VAL
B
675
−82.442
62.626
−34.650
1.00
81.79
N


ATOM
3467
CA
VAL
B
675
−81.863
62.631
−35.999
1.00
82.25
C


ATOM
3468
CB
VAL
B
675
−81.074
63.949
−36.260
1.00
82.10
C


ATOM
3469
CG1
VAL
B
675
−80.323
63.902
−37.582
1.00
81.84
C


ATOM
3470
CG2
VAL
B
675
−81.986
65.173
−36.207
1.00
81.53
C


ATOM
3471
C
VAL
B
675
−81.012
61.389
−36.259
1.00
82.96
C


ATOM
3472
O
VAL
B
675
−79.932
61.222
−35.671
1.00
82.87
O


ATOM
3473
N
ALA
B
676
−81.483
60.541
−37.182
1.00
83.86
N


ATOM
3474
CA
ALA
B
676
−80.804
59.298
−37.538
1.00
84.66
C


ATOM
3475
CB
ALA
B
676
−81.787
58.148
−37.422
1.00
84.58
C


ATOM
3476
C
ALA
B
676
−80.159
59.282
−38.926
1.00
85.33
C


ATOM
3477
O
ALA
B
676
−80.844
59.573
−39.898
1.00
85.57
O


ATOM
3478
N
ILE
B
677
−78.866
58.922
−39.027
1.00
85.93
N


ATOM
3479
CA
ILE
B
677
−78.177
58.793
−40.309
1.00
87.29
C


ATOM
3480
CB
ILE
B
677
−76.731
59.365
−40.279
1.00
87.10
C


ATOM
3481
CG1
ILE
B
677
−76.739
60.894
−40.163
1.00
86.31
C


ATOM
3482
CD1
ILE
B
677
−75.397
61.517
−39.806
1.00
85.43
C


ATOM
3483
CG2
ILE
B
677
−75.901
58.886
−41.506
1.00
87.10
C


ATOM
3484
C
ILE
B
677
−78.200
57.285
−40.643
1.00
88.69
C


ATOM
3485
O
ILE
B
677
−77.514
56.508
−39.976
1.00
88.82
O


ATOM
3486
N
CYS
B
678
−78.983
56.879
−41.662
1.00
95.76
N


ATOM
3487
CA
CYS
B
678
−79.116
55.479
−42.075
1.00
97.30
C


ATOM
3488
CB
CYS
B
678
−80.583
55.115
−42.238
1.00
96.90
C


ATOM
3489
SG
CYS
B
678
−81.590
55.474
−40.783
1.00
96.44
S


ATOM
3490
C
CYS
B
678
−78.311
55.090
−43.309
1.00
98.81
C


ATOM
3491
O
CYS
B
678
−78.330
55.806
−44.300
1.00
98.90
O


ATOM
3492
N
CYS
B
679
−77.630
53.935
−43.265
1.00
107.42
N


ATOM
3493
CA
CYS
B
679
−76.839
53.458
−44.401
1.00
109.62
C


ATOM
3494
CB
CYS
B
679
−75.362
53.759
−44.203
1.00
109.63
C


ATOM
3495
SG
CYS
B
679
−75.035
55.440
−43.622
1.00
112.09
S


ATOM
3496
C
CYS
B
679
−77.080
51.998
−44.779
1.00
110.70
C


ATOM
3497
O
CYS
B
679
−77.664
51.247
−43.996
1.00
110.76
O


ATOM
3498
N
ARG
B
680
−76.668
51.620
−46.014
1.00
115.73
N


ATOM
3499
CA
ARG
B
680
−76.780
50.274
−46.602
1.00
117.24
C


ATOM
3500
CB
ARG
B
680
−78.259
49.884
−46.889
1.00
117.32
C


ATOM
3501
CG
ARG
B
680
−78.910
50.627
−48.051
1.00
118.28
C


ATOM
3502
CD
ARG
B
680
−80.001
49.809
−48.728
1.00
120.20
C


ATOM
3503
NE
ARG
B
680
−80.512
50.497
−49.921
1.00
121.55
N


ATOM
3504
CZ
ARG
B
680
−81.798
50.736
−50.181
1.00
121.99
C


ATOM
3505
NH1
ARG
B
680
−82.742
50.334
−49.335
1.00
122.32
N


ATOM
3506
NH2
ARG
B
680
−82.148
51.381
−51.288
1.00
122.33
N


ATOM
3507
C
ARG
B
680
−75.906
50.131
−47.873
1.00
118.03
C


ATOM
3508
O
ARG
B
680
−75.131
51.036
−48.200
1.00
117.95
O


ATOM
3509
N
SER
B
681
−76.034
48.972
−48.568
1.00
120.44
N


ATOM
3510
CA
SER
B
681
−75.376
48.656
−49.838
1.00
121.18
C


ATOM
3511
CB
SER
B
681
−74.457
47.442
−49.711
1.00
121.11
C


ATOM
3512
OG
SER
B
681
−73.359
47.574
−50.602
1.00
121.38
O


ATOM
3513
C
SER
B
681
−76.549
48.417
−50.821
1.00
121.58
C


ATOM
3514
O
SER
B
681
−77.264
47.411
−50.695
1.00
121.71
O


ATOM
3515
N
ARG
B
682
−76.777
49.412
−51.737
1.00
120.01
N


ATOM
3516
CA
ARG
B
682
−77.837
49.537
−52.769
1.00
120.22
C


ATOM
3517
CB
ARG
B
682
−77.387
50.442
−53.933
1.00
120.08
C


ATOM
3518
C
ARG
B
682
−78.603
48.269
−53.249
1.00
120.27
C


ATOM
3519
O
ARG
B
682
−78.104
47.460
−54.034
1.00
120.40
O


TER
3520

ARG
B
682


ATOM
3521
N
THR
A
61
−42.992
55.146
−11.374
1.00
94.08
N


ATOM
3522
CA
THR
A
61
−43.825
54.985
−12.583
1.00
94.03
C


ATOM
3523
CB
THR
A
61
−43.011
55.185
−13.899
1.00
94.36
C


ATOM
3524
OG1
THR
A
61
−41.662
55.588
−13.626
1.00
95.12
O


ATOM
3525
CG2
THR
A
61
−43.697
56.150
−14.889
1.00
94.34
C


ATOM
3526
C
THR
A
61
−44.554
53.625
−12.600
1.00
93.40
C


ATOM
3527
O
THR
A
61
−45.562
53.477
−13.300
1.00
93.63
O


ATOM
3528
N
ALA
A
62
−44.025
52.632
−11.841
1.00
86.60
N


ATOM
3529
CA
ALA
A
62
−44.604
51.293
−11.751
1.00
85.19
C


ATOM
3530
CB
ALA
A
62
−43.541
50.270
−11.387
1.00
85.12
C


ATOM
3531
C
ALA
A
62
−45.728
51.292
−10.735
1.00
84.17
C


ATOM
3532
O
ALA
A
62
−45.572
51.771
−9.607
1.00
84.03
O


ATOM
3533
N
THR
A
63
−46.872
50.770
−11.152
1.00
78.31
N


ATOM
3534
CA
THR
A
63
−48.064
50.711
−10.314
1.00
77.03
C


ATOM
3535
CB
THR
A
63
−49.247
51.320
−11.047
1.00
77.14
C


ATOM
3536
OG1
THR
A
63
−49.183
50.975
−12.444
1.00
77.22
O


ATOM
3537
CG2
THR
A
63
−49.309
52.826
−10.855
1.00
77.10
C


ATOM
3538
C
THR
A
63
−48.358
49.331
−9.758
1.00
75.91
C


ATOM
3539
O
THR
A
63
−47.909
48.323
−10.298
1.00
75.80
O


ATOM
3540
N
PHE
A
64
−49.094
49.294
−8.667
1.00
69.45
N


ATOM
3541
CA
PHE
A
64
−49.457
48.047
−8.055
1.00
68.44
C


ATOM
3542
CB
PHE
A
64
−48.972
47.998
−6.617
1.00
68.44
C


ATOM
3543
CG
PHE
A
64
−49.525
46.873
−5.781
1.00
68.49
C


ATOM
3544
CD1
PHE
A
64
−48.948
45.612
−5.815
1.00
68.43
C


ATOM
3545
CE1
PHE
A
64
−49.459
44.576
−5.029
1.00
68.32
C


ATOM
3546
CZ
PHE
A
64
−50.539
44.802
−4.201
1.00
68.09
C


ATOM
3547
CE2
PHE
A
64
−51.113
46.050
−4.146
1.00
67.74
C


ATOM
3548
CD2
PHE
A
64
−50.610
47.083
−4.936
1.00
67.80
C


ATOM
3549
C
PHE
A
64
−50.961
47.864
−8.183
1.00
67.94
C


ATOM
3550
O
PHE
A
64
−51.731
48.822
−8.140
1.00
67.79
O


ATOM
3551
N
HIS
A
65
−51.371
46.616
−8.385
1.00
70.21
N


ATOM
3552
CA
HIS
A
65
−52.759
46.236
−8.570
1.00
69.19
C


ATOM
3553
CB
HIS
A
65
−53.006
45.898
−10.048
1.00
69.21
C


ATOM
3554
CG
HIS
A
65
−52.742
47.070
−10.939
1.00
70.70
C


ATOM
3555
ND1
HIS
A
65
−51.443
47.456
−11.268
1.00
72.28
N


ATOM
3556
CE1
HIS
A
65
−51.562
48.539
−12.014
1.00
71.06
C


ATOM
3557
NE2
HIS
A
65
−52.840
48.865
−12.190
1.00
71.69
N


ATOM
3558
CD2
HIS
A
65
−53.606
47.942
−11.501
1.00
71.22
C


ATOM
3559
C
HIS
A
65
−53.114
45.081
−7.683
1.00
68.59
C


ATOM
3560
O
HIS
A
65
−52.321
44.163
−7.508
1.00
68.49
O


ATOM
3561
N
ARG
A
66
−54.295
45.143
−7.099
1.00
67.78
N


ATOM
3562
CA
ARG
A
66
−54.830
44.100
−6.240
1.00
67.53
C


ATOM
3563
CB
ARG
A
66
−54.410
44.260
−4.762
1.00
67.50
C


ATOM
3564
CG
ARG
A
66
−54.777
45.560
−4.108
1.00
68.39
C


ATOM
3565
CD
ARG
A
66
−55.971
45.345
−3.237
1.00
70.95
C


ATOM
3566
NE
ARG
A
66
−56.472
46.607
−2.707
1.00
72.19
N


ATOM
3567
CZ
ARG
A
66
−57.602
46.744
−2.019
1.00
72.89
C


ATOM
3568
NH1
ARG
A
66
−58.362
45.682
−1.752
1.00
73.37
N


ATOM
3569
NH2
ARG
A
66
−57.984
47.942
−1.595
1.00
74.64
N


ATOM
3570
C
ARG
A
66
−56.332
43.981
−6.436
1.00
67.14
C


ATOM
3571
O
ARG
A
66
−56.961
44.864
−7.024
1.00
67.05
O


ATOM
3572
N
CYS
A
67
−56.902
42.877
−5.981
1.00
67.36
N


ATOM
3573
CA
CYS
A
67
−58.323
42.631
−6.127
1.00
66.60
C


ATOM
3574
CB
CYS
A
67
−58.642
41.169
−5.830
1.00
66.74
C


ATOM
3575
SG
CYS
A
67
−60.357
40.701
−6.178
1.00
67.75
S


ATOM
3576
C
CYS
A
67
−59.103
43.565
−5.237
1.00
65.89
C


ATOM
3577
O
CYS
A
67
−58.732
43.748
−4.081
1.00
65.55
O


ATOM
3578
N
ALA
A
68
−60.173
44.168
−5.780
1.00
65.52
N


ATOM
3579
CA
ALA
A
68
−61.061
45.076
−5.044
1.00
64.94
C


ATOM
3580
CB
ALA
A
68
−61.968
45.802
−6.008
1.00
64.52
C


ATOM
3581
C
ALA
A
68
−61.884
44.292
−3.995
1.00
64.88
C


ATOM
3582
O
ALA
A
68
−62.169
44.823
−2.928
1.00
64.74
O


ATOM
3583
N
LYS
A
69
−62.228
43.024
−4.286
1.00
67.62
N


ATOM
3584
CA
LYS
A
69
−62.968
42.154
−3.366
1.00
68.11
C


ATOM
3585
CB
LYS
A
69
−63.802
41.076
−4.116
1.00
68.34
C


ATOM
3586
CG
LYS
A
69
−64.420
41.527
−5.465
1.00
70.40
C


ATOM
3587
CD
LYS
A
69
−65.785
42.295
−5.349
1.00
73.07
C


ATOM
3588
CE
LYS
A
69
−66.163
43.111
−6.579
1.00
73.40
C


ATOM
3589
NZ
LYS
A
69
−67.238
44.114
−6.294
1.00
73.28
N


ATOM
3590
C
LYS
A
69
−61.946
41.533
−2.403
1.00
68.01
C


ATOM
3591
O
LYS
A
69
−61.297
40.544
−2.732
1.00
67.83
O


ATOM
3592
N
ASP
A
70
−61.781
42.142
−1.225
1.00
72.25
N


ATOM
3593
CA
ASP
A
70
−60.823
41.685
−0.221
1.00
72.93
C


ATOM
3594
CB
ASP
A
70
−60.900
42.495
1.069
1.00
73.96
C


ATOM
3595
CG
ASP
A
70
−60.314
43.895
0.917
1.00
78.57
C


ATOM
3596
OD1
ASP
A
70
−59.122
44.095
1.329
1.00
82.61
O


ATOM
3597
OD2
ASP
A
70
−61.038
44.802
0.379
1.00
81.92
O


ATOM
3598
C
ASP
A
70
−60.733
40.191
0.053
1.00
72.06
C


ATOM
3599
O
ASP
A
70
−59.614
39.696
0.074
1.00
72.62
O


ATOM
3600
N
PRO
A
71
−61.835
39.425
0.219
1.00
65.61
N


ATOM
3601
CA
PRO
A
71
−61.692
37.979
0.491
1.00
64.69
C


ATOM
3602
CB
PRO
A
71
−63.120
37.531
0.763
1.00
64.75
C


ATOM
3603
CG
PRO
A
71
−63.888
38.762
1.004
1.00
65.16
C


ATOM
3604
CD
PRO
A
71
−63.251
39.825
0.221
1.00
65.34
C


ATOM
3605
C
PRO
A
71
−61.110
37.126
−0.629
1.00
64.06
C


ATOM
3606
O
PRO
A
71
−60.814
35.951
−0.395
1.00
64.26
O


ATOM
3607
N
TRP
A
72
−60.970
37.698
−1.847
1.00
62.84
N


ATOM
3608
CA
TRP
A
72
−60.442
37.025
−3.029
1.00
61.80
C


ATOM
3609
CB
TRP
A
72
−61.200
37.473
−4.272
1.00
61.49
C


ATOM
3610
CG
TRP
A
72
−62.596
36.957
−4.323
1.00
60.52
C


ATOM
3611
CD1
TRP
A
72
−63.195
36.113
−3.434
1.00
60.19
C


ATOM
3612
NE1
TRP
A
72
−64.489
35.863
−3.815
1.00
59.75
N


ATOM
3613
CE2
TRP
A
72
−64.758
36.559
−4.967
1.00
59.41
C


ATOM
3614
CD2
TRP
A
72
−63.577
37.249
−5.323
1.00
59.63
C


ATOM
3615
CE3
TRP
A
72
−63.583
38.042
−6.481
1.00
59.30
C


ATOM
3616
CZ3
TRP
A
72
−64.748
38.123
−7.226
1.00
58.49
C


ATOM
3617
CH2
TRP
A
72
−65.891
37.403
−6.863
1.00
57.68
C


ATOM
3618
CZ2
TRP
A
72
−65.922
36.618
−5.741
1.00
57.93
C


ATOM
3619
C
TRP
A
72
−58.977
37.271
−3.205
1.00
61.81
C


ATOM
3620
O
TRP
A
72
−58.348
36.600
−4.020
1.00
61.74
O


ATOM
3621
N
ARG
A
73
−58.419
38.234
−2.453
1.00
63.78
N


ATOM
3622
CA
ARG
A
73
−56.999
38.583
−2.518
1.00
63.69
C


ATOM
3623
CB
ARG
A
73
−56.719
39.805
−1.667
1.00
63.71
C


ATOM
3624
CG
ARG
A
73
−57.297
41.081
−2.210
1.00
64.55
C


ATOM
3625
CD
ARG
A
73
−57.007
42.217
−1.260
1.00
66.07
C


ATOM
3626
NE
ARG
A
73
−55.585
42.541
−1.253
1.00
67.02
N


ATOM
3627
CZ
ARG
A
73
−55.066
43.593
−0.634
1.00
67.26
C


ATOM
3628
NH1
ARG
A
73
−53.756
43.823
−0.688
1.00
67.03
N


ATOM
3629
NH2
ARG
A
73
−55.856
44.444
0.021
1.00
68.05
N


ATOM
3630
C
ARG
A
73
−56.125
37.442
−2.039
1.00
63.44
C


ATOM
3631
O
ARG
A
73
−56.520
36.701
−1.125
1.00
63.26
O


ATOM
3632
N
LEU
A
74
−54.938
37.299
−2.660
1.00
62.91
N


ATOM
3633
CA
LEU
A
74
−53.974
36.250
−2.301
1.00
63.06
C


ATOM
3634
CB
LEU
A
74
−53.932
35.125
−3.349
1.00
62.90
C


ATOM
3635
CG
LEU
A
74
−55.224
34.373
−3.584
1.00
61.25
C


ATOM
3636
CD1
LEU
A
74
−55.053
33.386
−4.668
1.00
59.62
C


ATOM
3637
CD2
LEU
A
74
−55.713
33.711
−2.332
1.00
59.04
C


ATOM
3638
C
LEU
A
74
−52.586
36.842
−2.076
1.00
63.27
C


ATOM
3639
O
LEU
A
74
−51.678
36.573
−2.875
1.00
63.60
O


ATOM
3640
N
PRO
A
75
−52.399
37.647
−0.988
1.00
64.69
N


ATOM
3641
CA
PRO
A
75
−51.076
38.265
−0.739
1.00
64.81
C


ATOM
3642
CB
PRO
A
75
−51.294
39.086
0.528
1.00
64.47
C


ATOM
3643
CG
PRO
A
75
−52.506
38.486
1.148
1.00
64.57
C


ATOM
3644
CD
PRO
A
75
−53.370
38.037
0.053
1.00
64.42
C


ATOM
3645
C
PRO
A
75
−49.965
37.240
−0.582
1.00
64.82
C


ATOM
3646
O
PRO
A
75
−50.240
36.119
−0.168
1.00
65.20
O


ATOM
3647
N
GLY
A
76
−48.747
37.611
−0.953
1.00
65.10
N


ATOM
3648
CA
GLY
A
76
−47.627
36.689
−0.893
1.00
65.15
C


ATOM
3649
C
GLY
A
76
−47.257
36.182
−2.270
1.00
65.43
C


ATOM
3650
O
GLY
A
76
−46.132
35.730
−2.481
1.00
65.75
O


ATOM
3651
N
THR
A
77
−48.185
36.258
−3.225
1.00
66.14
N


ATOM
3652
CA
THR
A
77
−47.894
35.832
−4.588
1.00
66.17
C


ATOM
3653
CB
THR
A
77
−48.593
34.534
−4.943
1.00
66.36
C


ATOM
3654
OG1
THR
A
77
−48.498
33.644
−3.813
1.00
67.43
O


ATOM
3655
CG2
THR
A
77
−47.989
33.881
−6.188
1.00
65.71
C


ATOM
3656
C
THR
A
77
−48.193
36.989
−5.481
1.00
66.17
C


ATOM
3657
O
THR
A
77
−49.247
37.602
−5.356
1.00
66.06
O


ATOM
3658
N
TYR
A
78
−47.234
37.335
−6.338
1.00
65.71
N


ATOM
3659
CA
TYR
A
78
−47.327
38.487
−7.228
1.00
66.03
C


ATOM
3660
CB
TYR
A
78
−46.449
39.646
−6.681
1.00
65.51
C


ATOM
3661
CG
TYR
A
78
−46.823
40.011
−5.260
1.00
64.46
C


ATOM
3662
CD1
TYR
A
78
−47.766
41.000
−5.000
1.00
62.96
C


ATOM
3663
CE1
TYR
A
78
−48.169
41.290
−3.702
1.00
61.90
C


ATOM
3664
CZ
TYR
A
78
−47.643
40.571
−2.642
1.00
62.48
C


ATOM
3665
OH
TYR
A
78
−48.064
40.836
−1.367
1.00
62.90
O


ATOM
3666
CE2
TYR
A
78
−46.707
39.580
−2.871
1.00
63.20
C


ATOM
3667
CD2
TYR
A
78
−46.294
39.311
−4.175
1.00
63.76
C


ATOM
3668
C
TYR
A
78
−46.927
38.144
−8.640
1.00
67.03
C


ATOM
3669
O
TYR
A
78
−46.096
37.260
−8.858
1.00
67.43
O


ATOM
3670
N
VAL
A
79
−47.515
38.844
−9.603
1.00
66.76
N


ATOM
3671
CA
VAL
A
79
−47.203
38.667
−11.018
1.00
67.72
C


ATOM
3672
CB
VAL
A
79
−48.450
38.357
−11.887
1.00
67.49
C


ATOM
3673
CG1
VAL
A
79
−48.165
38.537
−13.373
1.00
66.92
C


ATOM
3674
CG2
VAL
A
79
−48.959
36.957
−11.613
1.00
67.53
C


ATOM
3675
C
VAL
A
79
−46.494
39.959
−11.411
1.00
68.95
C


ATOM
3676
O
VAL
A
79
−47.116
41.031
−11.473
1.00
69.13
O


ATOM
3677
N
VAL
A
80
−45.173
39.860
−11.623
1.00
68.33
N


ATOM
3678
CA
VAL
A
80
−44.388
41.016
−12.002
1.00
69.38
C


ATOM
3679
CB
VAL
A
80
−42.947
40.931
−11.485
1.00
69.16
C


ATOM
3680
CG1
VAL
A
80
−42.137
42.144
−11.942
1.00
69.16
C


ATOM
3681
CG2
VAL
A
80
−42.934
40.808
−9.964
1.00
69.15
C


ATOM
3682
C
VAL
A
80
−44.485
41.158
−13.504
1.00
70.51
C


ATOM
3683
O
VAL
A
80
−44.064
40.271
−14.242
1.00
70.63
O


ATOM
3684
N
VAL
A
81
−45.088
42.250
−13.943
1.00
71.08
N


ATOM
3685
CA
VAL
A
81
−45.278
42.520
−15.352
1.00
72.85
C


ATOM
3686
CB
VAL
A
81
−46.738
42.913
−15.672
1.00
72.46
C


ATOM
3687
CG1
VAL
A
81
−46.901
43.266
−17.136
1.00
71.97
C


ATOM
3688
CG2
VAL
A
81
−47.690
41.790
−15.294
1.00
72.64
C


ATOM
3689
C
VAL
A
81
−44.264
43.564
−15.788
1.00
74.56
C


ATOM
3690
O
VAL
A
81
−44.175
44.653
−15.203
1.00
74.54
O


ATOM
3691
N
LEU
A
82
−43.489
43.207
−16.818
1.00
80.31
N


ATOM
3692
CA
LEU
A
82
−42.454
44.045
−17.403
1.00
82.53
C


ATOM
3693
CB
LEU
A
82
−41.202
43.217
−17.733
1.00
82.15
C


ATOM
3694
CG
LEU
A
82
−40.653
42.348
−16.593
1.00
82.16
C


ATOM
3695
CD1
LEU
A
82
−39.625
41.406
−17.092
1.00
81.74
C


ATOM
3696
CD2
LEU
A
82
−40.070
43.178
−15.458
1.00
81.41
C


ATOM
3697
C
LEU
A
82
−42.980
44.810
−18.618
1.00
84.46
C


ATOM
3698
O
LEU
A
82
−43.996
44.420
−19.204
1.00
84.83
O


ATOM
3699
N
LYS
A
83
−42.301
45.919
−18.974
1.00
91.85
N


ATOM
3700
CA
LYS
A
83
−42.649
46.806
−20.083
1.00
94.25
C


ATOM
3701
CB
LYS
A
83
−41.678
47.993
−20.147
1.00
94.21
C


ATOM
3702
CG
LYS
A
83
−41.986
49.105
−19.144
1.00
95.08
C


ATOM
3703
CD
LYS
A
83
−40.695
49.669
−18.537
1.00
97.23
C


ATOM
3704
CE
LYS
A
83
−40.735
51.157
−18.255
1.00
97.94
C


ATOM
3705
NZ
LYS
A
83
−40.546
51.984
−19.491
1.00
98.59
N


ATOM
3706
C
LYS
A
83
−42.769
46.063
−21.424
1.00
95.90
C


ATOM
3707
O
LYS
A
83
−42.054
45.079
−21.642
1.00
95.76
O


ATOM
3708
N
GLU
A
84
−43.701
46.526
−22.296
1.00
102.18
N


ATOM
3709
CA
GLU
A
84
−44.037
45.957
−23.611
1.00
104.41
C


ATOM
3710
CB
GLU
A
84
−44.691
47.000
−24.543
1.00
104.70
C


ATOM
3711
CG
GLU
A
84
−46.054
46.597
−25.108
1.00
106.90
C


ATOM
3712
CD
GLU
A
84
−46.181
45.235
−25.779
1.00
109.87
C


ATOM
3713
OE1
GLU
A
84
−45.523
45.012
−26.824
1.00
111.52
O


ATOM
3714
OE2
GLU
A
84
−46.950
44.392
−25.259
1.00
110.62
O


ATOM
3715
C
GLU
A
84
−42.984
45.117
−24.364
1.00
105.41
C


ATOM
3716
O
GLU
A
84
−43.124
43.886
−24.441
1.00
105.62
O


ATOM
3717
N
GLU
A
85
−41.941
45.786
−24.914
1.00
107.79
N


ATOM
3718
CA
GLU
A
85
−40.879
45.175
−25.728
1.00
108.91
C


ATOM
3719
CB
GLU
A
85
−40.238
46.222
−26.663
1.00
109.11
C


ATOM
3720
CG
GLU
A
85
−41.150
46.605
−27.827
1.00
111.00
C


ATOM
3721
CD
GLU
A
85
−40.772
47.798
−28.696
1.00
113.16
C


ATOM
3722
OE1
GLU
A
85
−40.359
48.847
−28.145
1.00
114.02
O


ATOM
3723
OE2
GLU
A
85
−40.916
47.685
−29.938
1.00
113.67
O


ATOM
3724
C
GLU
A
85
−39.828
44.309
−25.030
1.00
109.16
C


ATOM
3725
O
GLU
A
85
−38.950
43.780
−25.710
1.00
109.04
O


ATOM
3726
N
THR
A
86
−39.924
44.140
−23.697
1.00
109.04
N


ATOM
3727
CA
THR
A
86
−38.972
43.356
−22.899
1.00
109.80
C


ATOM
3728
CB
THR
A
86
−39.355
43.350
−21.403
1.00
109.80
C


ATOM
3729
OG1
THR
A
86
−39.577
44.693
−20.962
1.00
110.29
O


ATOM
3730
CG2
THR
A
86
−38.298
42.692
−20.513
1.00
109.32
C


ATOM
3731
C
THR
A
86
−38.697
41.965
−23.462
1.00
110.40
C


ATOM
3732
O
THR
A
86
−39.616
41.260
−23.882
1.00
110.56
O


ATOM
3733
N
HIS
A
87
−37.417
41.600
−23.490
1.00
111.60
N


ATOM
3734
CA
HIS
A
87
−36.944
40.308
−23.955
1.00
112.22
C


ATOM
3735
CB
HIS
A
87
−35.651
40.479
−24.764
1.00
112.64
C


ATOM
3736
CG
HIS
A
87
−35.087
39.185
−25.249
1.00
115.04
C


ATOM
3737
ND1
HIS
A
87
−34.097
38.517
−24.538
1.00
116.61
N


ATOM
3738
CE1
HIS
A
87
−33.845
37.413
−25.224
1.00
116.85
C


ATOM
3739
NE2
HIS
A
87
−34.616
37.325
−26.312
1.00
117.28
N


ATOM
3740
CD2
HIS
A
87
−35.421
38.447
−26.334
1.00
116.55
C


ATOM
3741
C
HIS
A
87
−36.743
39.422
−22.712
1.00
111.92
C


ATOM
3742
O
HIS
A
87
−36.530
39.955
−21.617
1.00
111.91
O


ATOM
3743
N
LEU
A
88
−36.834
38.083
−22.879
1.00
108.74
N


ATOM
3744
CA
LEU
A
88
−36.707
37.080
−21.815
1.00
108.42
C


ATOM
3745
CB
LEU
A
88
−36.914
35.664
−22.370
1.00
108.37
C


ATOM
3746
CG
LEU
A
88
−36.940
34.493
−21.376
1.00
108.37
C


ATOM
3747
CD1
LEU
A
88
−37.980
34.690
−20.308
1.00
108.28
C


ATOM
3748
CD2
LEU
A
88
−37.214
33.194
−22.089
1.00
108.49
C


ATOM
3749
C
LEU
A
88
−35.449
37.179
−20.951
1.00
108.39
C


ATOM
3750
O
LEU
A
88
−35.524
36.925
−19.745
1.00
108.36
O


ATOM
3751
N
SER
A
89
−34.306
37.554
−21.554
1.00
107.40
N


ATOM
3752
CA
SER
A
89
−33.040
37.724
−20.841
1.00
107.18
C


ATOM
3753
CB
SER
A
89
−31.958
38.227
−21.791
1.00
107.30
C


ATOM
3754
OG
SER
A
89
−32.389
39.349
−22.545
1.00
107.73
O


ATOM
3755
C
SER
A
89
−33.226
38.702
−19.669
1.00
106.89
C


ATOM
3756
O
SER
A
89
−32.757
38.414
−18.572
1.00
106.96
O


ATOM
3757
N
GLN
A
90
−33.954
39.828
−19.900
1.00
105.98
N


ATOM
3758
CA
GLN
A
90
−34.269
40.851
−18.899
1.00
105.55
C


ATOM
3759
CB
GLN
A
90
−34.803
42.130
−19.540
1.00
105.69
C


ATOM
3760
CG
GLN
A
90
−33.738
42.972
−20.218
1.00
106.15
C


ATOM
3761
CD
GLN
A
90
−34.174
43.457
−21.582
1.00
106.52
C


ATOM
3762
OE1
GLN
A
90
−34.701
42.699
−22.415
1.00
106.51
O


ATOM
3763
NE2
GLN
A
90
−33.953
44.737
−21.845
1.00
106.74
N


ATOM
3764
C
GLN
A
90
−35.279
40.333
−17.894
1.00
105.10
C


ATOM
3765
O
GLN
A
90
−35.180
40.702
−16.723
1.00
105.02
O


ATOM
3766
N
SER
A
91
−36.256
39.491
−18.343
1.00
102.39
N


ATOM
3767
CA
SER
A
91
−37.274
38.889
−17.470
1.00
101.79
C


ATOM
3768
CB
SER
A
91
−38.193
37.948
−18.249
1.00
101.84
C


ATOM
3769
OG
SER
A
91
−39.238
38.596
−18.954
1.00
102.28
O


ATOM
3770
C
SER
A
91
−36.561
38.108
−16.373
1.00
101.27
C


ATOM
3771
O
SER
A
91
−36.857
38.277
−15.189
1.00
101.03
O


ATOM
3772
N
GLU
A
92
−35.586
37.287
−16.783
1.00
100.39
N


ATOM
3773
CA
GLU
A
92
−34.776
36.464
−15.894
1.00
100.06
C


ATOM
3774
CB
GLU
A
92
−34.044
35.389
−16.698
1.00
100.14
C


ATOM
3775
CG
GLU
A
92
−34.964
34.502
−17.515
1.00
101.12
C


ATOM
3776
CD
GLU
A
92
−34.249
33.372
−18.225
1.00
102.83
C


ATOM
3777
OE1
GLU
A
92
−33.476
33.651
−19.174
1.00
103.80
O


ATOM
3778
OE2
GLU
A
92
−34.457
32.204
−17.823
1.00
103.76
O


ATOM
3779
C
GLU
A
92
−33.796
37.332
−15.093
1.00
99.64
C


ATOM
3780
O
GLU
A
92
−33.559
37.054
−13.917
1.00
99.53
O


ATOM
3781
N
ARG
A
93
−33.252
38.391
−15.728
1.00
98.20
N


ATOM
3782
CA
ARG
A
93
−32.324
39.345
−15.129
1.00
97.82
C


ATOM
3783
CB
ARG
A
93
−31.948
40.416
−16.180
1.00
98.13
C


ATOM
3784
CG
ARG
A
93
−30.644
41.194
−15.937
1.00
99.80
C


ATOM
3785
CD
ARG
A
93
−30.129
41.910
−17.197
1.00
101.97
C


ATOM
3786
NE
ARG
A
93
−29.467
40.988
−18.135
1.00
103.42
N


ATOM
3787
CZ
ARG
A
93
−29.900
40.713
−19.368
1.00
104.31
C


ATOM
3788
NH1
ARG
A
93
−30.993
41.300
−19.844
1.00
104.87
N


ATOM
3789
NH2
ARG
A
93
−29.237
39.857
−20.137
1.00
104.19
N


ATOM
3790
C
ARG
A
93
−33.000
39.981
−13.894
1.00
97.21
C


ATOM
3791
O
ARG
A
93
−32.505
39.807
−12.772
1.00
96.98
O


ATOM
3792
N
THR
A
94
−34.167
40.664
−14.112
1.00
93.34
N


ATOM
3793
CA
THR
A
94
−34.986
41.337
−13.089
1.00
92.40
C


ATOM
3794
CB
THR
A
94
−36.149
42.137
−13.722
1.00
92.32
C


ATOM
3795
OG1
THR
A
94
−35.743
42.711
−14.963
1.00
91.98
O


ATOM
3796
CG2
THR
A
94
−36.642
43.246
−12.826
1.00
92.59
C


ATOM
3797
C
THR
A
94
−35.426
40.359
−11.987
1.00
91.90
C


ATOM
3798
O
THR
A
94
−35.417
40.728
−10.813
1.00
91.73
O


ATOM
3799
N
ALA
A
95
−35.776
39.111
−12.367
1.00
90.39
N


ATOM
3800
CA
ALA
A
95
−36.178
38.065
−11.428
1.00
89.91
C


ATOM
3801
CB
ALA
A
95
−36.591
36.809
−12.176
1.00
89.80
C


ATOM
3802
C
ALA
A
95
−35.030
37.763
−10.478
1.00
89.75
C


ATOM
3803
O
ALA
A
95
−35.226
37.805
−9.263
1.00
89.56
O


ATOM
3804
N
ARG
A
96
−33.819
37.503
−11.036
1.00
91.58
N


ATOM
3805
CA
ARG
A
96
−32.603
37.207
−10.270
1.00
91.34
C


ATOM
3806
CB
ARG
A
96
−31.462
36.736
−11.179
1.00
91.22
C


ATOM
3807
C
ARG
A
96
−32.214
38.424
−9.448
1.00
91.23
C


ATOM
3808
O
ARG
A
96
−31.926
38.264
−8.264
1.00
91.23
O


ATOM
3809
N
ARG
A
97
−32.279
39.640
−10.048
1.00
92.37
N


ATOM
3810
CA
ARG
A
97
−31.984
40.908
−9.365
1.00
92.44
C


ATOM
3811
CB
ARG
A
97
−32.107
42.115
−10.334
1.00
92.70
C


ATOM
3812
CG
ARG
A
97
−31.829
43.487
−9.690
1.00
94.77
C


ATOM
3813
CD
ARG
A
97
−31.046
44.479
−10.557
1.00
99.05
C


ATOM
3814
NE
ARG
A
97
−30.156
45.347
−9.762
1.00
102.58
N


ATOM
3815
CZ
ARG
A
97
−28.901
45.033
−9.409
1.00
104.00
C


ATOM
3816
NH1
ARG
A
97
−28.367
43.869
−9.779
1.00
104.30
N


ATOM
3817
NH2
ARG
A
97
−28.174
45.881
−8.685
1.00
104.49
N


ATOM
3818
C
ARG
A
97
−32.900
41.071
−8.132
1.00
92.06
C


ATOM
3819
O
ARG
A
97
−32.456
41.576
−7.090
1.00
91.94
O


ATOM
3820
N
LEU
A
98
−34.168
40.614
−8.249
1.00
89.01
N


ATOM
3821
CA
LEU
A
98
−35.133
40.692
−7.161
1.00
88.35
C


ATOM
3822
CB
LEU
A
98
−36.565
40.441
−7.675
1.00
88.23
C


ATOM
3823
CG
LEU
A
98
−37.717
40.358
−6.657
1.00
86.92
C


ATOM
3824
CD1
LEU
A
98
−37.893
41.650
−5.897
1.00
85.51
C


ATOM
3825
CD2
LEU
A
98
−38.990
39.987
−7.346
1.00
85.38
C


ATOM
3826
C
LEU
A
98
−34.767
39.743
−6.033
1.00
88.29
C


ATOM
3827
O
LEU
A
98
−34.586
40.197
−4.903
1.00
88.02
O


ATOM
3828
N
GLN
A
99
−34.634
38.440
−6.343
1.00
89.27
N


ATOM
3829
CA
GLN
A
99
−34.303
37.381
−5.382
1.00
89.54
C


ATOM
3830
CB
GLN
A
99
−33.991
36.078
−6.121
1.00
89.39
C


ATOM
3831
CG
GLN
A
99
−35.159
35.469
−6.851
1.00
89.38
C


ATOM
3832
CD
GLN
A
99
−35.074
33.967
−6.829
1.00
89.63
C


ATOM
3833
OE1
GLN
A
99
−34.580
33.333
−7.783
1.00
89.30
O


ATOM
3834
NE2
GLN
A
99
−35.562
33.360
−5.734
1.00
88.93
N


ATOM
3835
C
GLN
A
99
−33.104
37.765
−4.510
1.00
89.87
C


ATOM
3836
O
GLN
A
99
−33.076
37.461
−3.305
1.00
89.84
O


ATOM
3837
N
ALA
A
100
−32.126
38.454
−5.158
1.00
92.62
N


ATOM
3838
CA
ALA
A
100
−30.861
38.948
−4.632
1.00
92.57
C


ATOM
3839
CB
ALA
A
100
−29.977
39.414
−5.779
1.00
92.48
C


ATOM
3840
C
ALA
A
100
−31.049
40.073
−3.639
1.00
92.61
C


ATOM
3841
O
ALA
A
100
−30.585
39.950
−2.501
1.00
92.73
O


ATOM
3842
N
GLN
A
101
−31.713
41.170
−4.062
1.00
91.54
N


ATOM
3843
CA
GLN
A
101
−31.960
42.316
−3.201
1.00
91.53
C


ATOM
3844
CB
GLN
A
101
−32.680
43.415
−3.967
1.00
91.53
C


ATOM
3845
CG
GLN
A
101
−31.748
44.103
−4.951
1.00
92.66
C


ATOM
3846
CD
GLN
A
101
−32.418
45.048
−5.921
1.00
93.49
C


ATOM
3847
OE1
GLN
A
101
−33.454
45.666
−5.642
1.00
94.00
O


ATOM
3848
NE2
GLN
A
101
−31.820
45.198
−7.088
1.00
93.98
N


ATOM
3849
C
GLN
A
101
−32.727
41.902
−1.947
1.00
91.42
C


ATOM
3850
O
GLN
A
101
−32.433
42.403
−0.864
1.00
91.36
O


ATOM
3851
N
ALA
A
102
−33.656
40.943
−2.095
1.00
89.40
N


ATOM
3852
CA
ALA
A
102
−34.489
40.393
−1.032
1.00
89.26
C


ATOM
3853
CB
ALA
A
102
−35.525
39.462
−1.639
1.00
89.34
C


ATOM
3854
C
ALA
A
102
−33.670
39.643
0.016
1.00
89.33
C


ATOM
3855
O
ALA
A
102
−33.893
39.807
1.226
1.00
88.78
O


ATOM
3856
N
ALA
A
103
−32.726
38.810
−0.471
1.00
91.22
N


ATOM
3857
CA
ALA
A
103
−31.824
37.998
0.339
1.00
91.41
C


ATOM
3858
CB
ALA
A
103
−30.920
37.189
−0.559
1.00
91.23
C


ATOM
3859
C
ALA
A
103
−30.993
38.867
1.290
1.00
91.64
C


ATOM
3860
O
ALA
A
103
−30.890
38.530
2.476
1.00
91.67
O


ATOM
3861
N
ARG
A
104
−30.449
40.012
0.799
1.00
94.32
N


ATOM
3862
CA
ARG
A
104
−29.663
40.899
1.654
1.00
94.63
C


ATOM
3863
CB
ARG
A
104
−28.583
41.665
0.885
1.00
94.83
C


ATOM
3864
CG
ARG
A
104
−29.067
42.802
0.027
1.00
96.25
C


ATOM
3865
CD
ARG
A
104
−27.874
43.433
−0.654
1.00
99.40
C


ATOM
3866
NE
ARG
A
104
−27.452
42.662
−1.828
1.00
101.85
N


ATOM
3867
CZ
ARG
A
104
−27.671
43.032
−3.088
1.00
103.05
C


ATOM
3868
NH1
ARG
A
104
−28.292
44.181
−3.356
1.00
103.65
N


ATOM
3869
NH2
ARG
A
104
−27.261
42.264
−4.092
1.00
103.39
N


ATOM
3870
C
ARG
A
104
−30.469
41.734
2.686
1.00
94.43
C


ATOM
3871
O
ARG
A
104
−30.007
42.773
3.178
1.00
94.68
O


ATOM
3872
N
ARG
A
105
−31.691
41.250
3.002
1.00
92.86
N


ATOM
3873
CA
ARG
A
105
−32.636
41.790
3.982
1.00
92.14
C


ATOM
3874
CB
ARG
A
105
−33.644
42.787
3.381
1.00
91.95
C


ATOM
3875
CG
ARG
A
105
−33.428
43.105
1.915
1.00
92.08
C


ATOM
3876
CD
ARG
A
105
−33.438
44.586
1.583
1.00
92.24
C


ATOM
3877
NE
ARG
A
105
−32.759
44.822
0.305
1.00
93.09
N


ATOM
3878
CZ
ARG
A
105
−32.665
46.001
−0.304
1.00
93.45
C


ATOM
3879
NH1
ARG
A
105
−32.019
46.108
−1.462
1.00
93.87
N


ATOM
3880
NH2
ARG
A
105
−33.218
47.084
0.239
1.00
92.83
N


ATOM
3881
C
ARG
A
105
−33.305
40.591
4.655
1.00
91.76
C


ATOM
3882
O
ARG
A
105
−34.331
40.718
5.320
1.00
91.78
O


ATOM
3883
N
GLY
A
106
−32.669
39.435
4.481
1.00
92.07
N


ATOM
3884
CA
GLY
A
106
−33.080
38.152
5.033
1.00
91.54
C


ATOM
3885
C
GLY
A
106
−34.368
37.585
4.478
1.00
91.23
C


ATOM
3886
O
GLY
A
106
−35.000
36.770
5.159
1.00
91.33
O


ATOM
3887
N
TYR
A
107
−34.772
37.993
3.236
1.00
91.05
N


ATOM
3888
CA
TYR
A
107
−36.023
37.498
2.641
1.00
90.30
C


ATOM
3889
CB
TYR
A
107
−36.851
38.620
1.995
1.00
90.38
C


ATOM
3890
CG
TYR
A
107
−37.421
39.660
2.931
1.00
90.13
C


ATOM
3891
CD1
TYR
A
107
−38.543
39.389
3.706
1.00
90.22
C


ATOM
3892
CE1
TYR
A
107
−39.084
40.353
4.552
1.00
90.37
C


ATOM
3893
CZ
TYR
A
107
−38.527
41.620
4.595
1.00
90.32
C


ATOM
3894
OH
TYR
A
107
−39.056
42.597
5.402
1.00
90.92
O


ATOM
3895
CE2
TYR
A
107
−37.433
41.920
3.808
1.00
90.06
C


ATOM
3896
CD2
TYR
A
107
−36.888
40.942
2.984
1.00
90.34
C


ATOM
3897
C
TYR
A
107
−35.904
36.341
1.654
1.00
89.73
C


ATOM
3898
O
TYR
A
107
−35.287
36.483
0.584
1.00
89.59
O


ATOM
3899
N
LEU
A
108
−36.553
35.210
2.000
1.00
89.78
N


ATOM
3900
CA
LEU
A
108
−36.596
34.024
1.147
1.00
89.15
C


ATOM
3901
CB
LEU
A
108
−37.005
32.768
1.945
1.00
89.21
C


ATOM
3902
C
LEU
A
108
−37.615
34.303
0.044
1.00
88.57
C


ATOM
3903
O
LEU
A
108
−38.684
34.859
0.306
1.00
88.75
O


ATOM
3904
N
THR
A
109
−37.271
33.969
−1.194
1.00
88.76
N


ATOM
3905
CA
THR
A
109
−38.167
34.182
−2.334
1.00
87.99
C


ATOM
3906
CB
THR
A
109
−37.788
35.446
−3.139
1.00
87.90
C


ATOM
3907
OG1
THR
A
109
−36.479
35.304
−3.706
1.00
88.28
O


ATOM
3908
CG2
THR
A
109
−37.888
36.713
−2.328
1.00
87.68
C


ATOM
3909
C
THR
A
109
−38.200
32.924
−3.208
1.00
87.61
C


ATOM
3910
O
THR
A
109
−37.363
32.029
−3.042
1.00
87.87
O


ATOM
3911
N
LYS
A
110
−39.173
32.852
−4.121
1.00
84.64
N


ATOM
3912
CA
LYS
A
110
−39.291
31.738
−5.026
1.00
83.87
C


ATOM
3913
CB
LYS
A
110
−40.053
30.557
−4.399
1.00
84.18
C


ATOM
3914
CG
LYS
A
110
−39.846
29.262
−5.196
1.00
86.24
C


ATOM
3915
CD
LYS
A
110
−40.683
28.061
−4.705
1.00
88.77
C


ATOM
3916
CE
LYS
A
110
−40.382
26.772
−5.466
1.00
90.05
C


ATOM
3917
NZ
LYS
A
110
−40.771
26.822
−6.914
1.00
91.41
N


ATOM
3918
C
LYS
A
110
−39.923
32.192
−6.318
1.00
82.95
C


ATOM
3919
O
LYS
A
110
−41.078
32.611
−6.311
1.00
83.40
O


ATOM
3920
N
ILE
A
111
−39.167
32.133
−7.434
1.00
78.43
N


ATOM
3921
CA
ILE
A
111
−39.712
32.489
−8.736
1.00
77.08
C


ATOM
3922
CB
ILE
A
111
−38.652
32.868
−9.795
1.00
76.80
C


ATOM
3923
CG1
ILE
A
111
−37.712
33.990
−9.317
1.00
76.57
C


ATOM
3924
CD1
ILE
A
111
−38.290
35.430
−9.093
1.00
77.16
C


ATOM
3925
CG2
ILE
A
111
−39.300
33.187
−11.155
1.00
76.13
C


ATOM
3926
C
ILE
A
111
−40.459
31.232
−9.106
1.00
76.77
C


ATOM
3927
O
ILE
A
111
−39.839
30.180
−9.312
1.00
77.12
O


ATOM
3928
N
LEU
A
112
−41.787
31.319
−9.123
1.00
75.11
N


ATOM
3929
CA
LEU
A
112
−42.641
30.175
−9.424
1.00
74.58
C


ATOM
3930
CB
LEU
A
112
−44.014
30.333
−8.758
1.00
74.58
C


ATOM
3931
CG
LEU
A
112
−44.028
30.542
−7.254
1.00
74.49
C


ATOM
3932
CD1
LEU
A
112
−45.400
30.996
−6.785
1.00
74.48
C


ATOM
3933
CD2
LEU
A
112
−43.653
29.296
−6.541
1.00
74.31
C


ATOM
3934
C
LEU
A
112
−42.795
29.870
−10.921
1.00
74.27
C


ATOM
3935
O
LEU
A
112
−43.036
28.704
−11.278
1.00
74.36
O


ATOM
3936
N
HIS
A
113
−42.668
30.895
−11.787
1.00
70.23
N


ATOM
3937
CA
HIS
A
113
−42.822
30.737
−13.228
1.00
70.12
C


ATOM
3938
CB
HIS
A
113
−44.303
30.468
−13.557
1.00
69.91
C


ATOM
3939
CG
HIS
A
113
−44.636
30.283
−15.001
1.00
69.54
C


ATOM
3940
ND1
HIS
A
113
−44.687
31.363
−15.878
1.00
68.93
N


ATOM
3941
CE1
HIS
A
113
−45.038
30.863
−17.050
1.00
68.78
C


ATOM
3942
NE2
HIS
A
113
−45.249
29.546
−16.975
1.00
69.46
N


ATOM
3943
CD2
HIS
A
113
−45.012
29.165
−15.663
1.00
69.45
C


ATOM
3944
C
HIS
A
113
−42.332
31.997
−13.912
1.00
70.51
C


ATOM
3945
O
HIS
A
113
−42.406
33.083
−13.331
1.00
70.03
O


ATOM
3946
N
VAL
A
114
−41.808
31.843
−15.152
1.00
73.95
N


ATOM
3947
CA
VAL
A
114
−41.298
32.949
−15.962
1.00
74.60
C


ATOM
3948
CB
VAL
A
114
−39.759
32.926
−16.188
1.00
74.41
C


ATOM
3949
CG1
VAL
A
114
−39.344
33.815
−17.351
1.00
74.28
C


ATOM
3950
CG2
VAL
A
114
−39.009
33.334
−14.922
1.00
74.15
C


ATOM
3951
C
VAL
A
114
−42.111
33.067
−17.228
1.00
75.54
C


ATOM
3952
O
VAL
A
114
−42.191
32.135
−18.031
1.00
75.89
O


ATOM
3953
N
PHE
A
115
−42.731
34.227
−17.376
1.00
80.92
N


ATOM
3954
CA
PHE
A
115
−43.586
34.562
−18.486
1.00
81.92
C


ATOM
3955
CB
PHE
A
115
−44.639
35.607
−18.064
1.00
81.57
C


ATOM
3956
CG
PHE
A
115
−45.657
35.047
−17.087
1.00
80.39
C


ATOM
3957
CD1
PHE
A
115
−46.708
34.249
−17.530
1.00
79.09
C


ATOM
3958
CE1
PHE
A
115
−47.632
33.719
−16.628
1.00
78.02
C


ATOM
3959
CZ
PHE
A
115
−47.499
33.970
−15.279
1.00
77.62
C


ATOM
3960
CE2
PHE
A
115
−46.454
34.737
−14.818
1.00
78.07
C


ATOM
3961
CD2
PHE
A
115
−45.540
35.285
−15.722
1.00
78.92
C


ATOM
3962
C
PHE
A
115
−42.843
34.933
−19.751
1.00
83.07
C


ATOM
3963
O
PHE
A
115
−41.997
35.835
−19.758
1.00
83.24
O


ATOM
3964
N
HIS
A
116
−43.160
34.207
−20.824
1.00
90.64
N


ATOM
3965
CA
HIS
A
116
−42.624
34.381
−22.174
1.00
92.40
C


ATOM
3966
CB
HIS
A
116
−41.201
33.785
−22.337
1.00
93.28
C


ATOM
3967
CG
HIS
A
116
−41.077
32.299
−22.140
1.00
97.26
C


ATOM
3968
ND1
HIS
A
116
−41.478
31.674
−20.953
1.00
100.73
N


ATOM
3969
CE1
HIS
A
116
−41.215
30.384
−21.115
1.00
101.46
C


ATOM
3970
NE2
HIS
A
116
−40.660
30.144
−22.310
1.00
102.09
N


ATOM
3971
CD2
HIS
A
116
−40.558
31.361
−22.969
1.00
100.23
C


ATOM
3972
C
HIS
A
116
−43.634
33.829
−23.188
1.00
92.48
C


ATOM
3973
O
HIS
A
116
−44.050
32.662
−23.105
1.00
92.81
O


ATOM
3974
N
GLY
A
117
−44.051
34.691
−24.102
1.00
90.93
N


ATOM
3975
CA
GLY
A
117
−45.027
34.327
−25.113
1.00
90.80
C


ATOM
3976
C
GLY
A
117
−46.240
35.218
−25.019
1.00
91.00
C


ATOM
3977
O
GLY
A
117
−46.557
35.937
−25.982
1.00
91.62
O


ATOM
3978
N
LEU
A
118
−46.927
35.201
−23.852
1.00
87.58
N


ATOM
3979
CA
LEU
A
118
−48.088
36.078
−23.718
1.00
87.01
C


ATOM
3980
CB
LEU
A
118
−49.182
35.470
−22.839
1.00
87.19
C


ATOM
3981
CG
LEU
A
118
−50.491
35.037
−23.510
1.00
87.82
C


ATOM
3982
CD1
LEU
A
118
−51.568
34.849
−22.472
1.00
87.94
C


ATOM
3983
CD2
LEU
A
118
−50.967
36.030
−24.575
1.00
87.14
C


ATOM
3984
C
LEU
A
118
−47.705
37.470
−23.214
1.00
86.38
C


ATOM
3985
O
LEU
A
118
−47.981
38.459
−23.880
1.00
86.36
O


ATOM
3986
N
LEU
A
119
−47.074
37.540
−22.041
1.00
83.97
N


ATOM
3987
CA
LEU
A
119
−46.673
38.791
−21.420
1.00
83.10
C


ATOM
3988
CB
LEU
A
119
−47.568
39.056
−20.183
1.00
83.27
C


ATOM
3989
CG
LEU
A
119
−49.077
39.314
−20.409
1.00
84.36
C


ATOM
3990
CD1
LEU
A
119
−49.871
39.090
−19.137
1.00
84.64
C


ATOM
3991
CD2
LEU
A
119
−49.371
40.720
−21.008
1.00
85.48
C


ATOM
3992
C
LEU
A
119
−45.229
38.688
−20.952
1.00
82.38
C


ATOM
3993
O
LEU
A
119
−44.767
37.580
−20.689
1.00
82.51
O


ATOM
3994
N
PRO
A
120
−44.499
39.813
−20.789
1.00
79.41
N


ATOM
3995
CA
PRO
A
120
−43.127
39.709
−20.275
1.00
78.62
C


ATOM
3996
CB
PRO
A
120
−42.417
40.903
−20.935
1.00
78.79
C


ATOM
3997
CG
PRO
A
120
−43.545
41.870
−21.375
1.00
79.03
C


ATOM
3998
CD
PRO
A
120
−44.864
41.224
−21.052
1.00
79.38
C


ATOM
3999
C
PRO
A
120
−43.121
39.827
−18.745
1.00
77.86
C


ATOM
4000
O
PRO
A
120
−43.469
40.869
−18.194
1.00
77.99
O


ATOM
4001
N
GLY
A
121
−42.747
38.776
−18.051
1.00
74.71
N


ATOM
4002
CA
GLY
A
121
−42.714
38.879
−16.603
1.00
73.64
C


ATOM
4003
C
GLY
A
121
−42.383
37.594
−15.901
1.00
73.19
C


ATOM
4004
O
GLY
A
121
−41.774
36.705
−16.493
1.00
73.07
O


ATOM
4005
N
PHE
A
122
−42.783
37.497
−14.629
1.00
72.55
N


ATOM
4006
CA
PHE
A
122
−42.575
36.315
−13.794
1.00
72.16
C


ATOM
4007
CB
PHE
A
122
−41.104
36.163
−13.373
1.00
71.78
C


ATOM
4008
CG
PHE
A
122
−40.538
37.359
−12.656
1.00
70.60
C


ATOM
4009
CD1
PHE
A
122
−39.948
38.400
−13.367
1.00
69.65
C


ATOM
4010
CE1
PHE
A
122
−39.431
39.512
−12.706
1.00
69.74
C


ATOM
4011
CZ
PHE
A
122
−39.504
39.590
−11.329
1.00
69.97
C


ATOM
4012
CE2
PHE
A
122
−40.080
38.561
−10.605
1.00
69.86
C


ATOM
4013
CD2
PHE
A
122
−40.589
37.446
−11.268
1.00
70.03
C


ATOM
4014
C
PHE
A
122
−43.485
36.339
−12.575
1.00
72.41
C


ATOM
4015
O
PHE
A
122
−43.845
37.417
−12.079
1.00
72.62
O


ATOM
4016
N
LEU
A
123
−43.850
35.146
−12.102
1.00
71.35
N


ATOM
4017
CA
LEU
A
123
−44.689
34.938
−10.928
1.00
71.32
C


ATOM
4018
CB
LEU
A
123
−45.588
33.706
−11.156
1.00
71.45
C


ATOM
4019
CG
LEU
A
123
−46.407
33.184
−9.985
1.00
71.79
C


ATOM
4020
CD1
LEU
A
123
−47.567
34.116
−9.673
1.00
72.22
C


ATOM
4021
CD2
LEU
A
123
−46.943
31.817
−10.296
1.00
71.36
C


ATOM
4022
C
LEU
A
123
−43.749
34.746
−9.743
1.00
71.15
C


ATOM
4023
O
LEU
A
123
−42.853
33.910
−9.801
1.00
71.24
O


ATOM
4024
N
VAL
A
124
−43.921
35.526
−8.684
1.00
71.84
N


ATOM
4025
CA
VAL
A
124
−43.021
35.422
−7.534
1.00
71.78
C


ATOM
4026
CB
VAL
A
124
−41.969
36.576
−7.520
1.00
71.84
C


ATOM
4027
CG1
VAL
A
124
−42.624
37.963
−7.403
1.00
71.15
C


ATOM
4028
CG2
VAL
A
124
−40.911
36.361
−6.441
1.00
71.27
C


ATOM
4029
C
VAL
A
124
−43.701
35.243
−6.192
1.00
71.82
C


ATOM
4030
O
VAL
A
124
−44.545
36.053
−5.816
1.00
71.98
O


ATOM
4031
N
LYS
A
125
−43.316
34.205
−5.462
1.00
73.15
N


ATOM
4032
CA
LYS
A
125
−43.822
33.981
−4.117
1.00
73.52
C


ATOM
4033
CB
LYS
A
125
−43.860
32.480
−3.785
1.00
73.77
C


ATOM
4034
CG
LYS
A
125
−44.453
32.158
−2.419
1.00
75.03
C


ATOM
4035
CD
LYS
A
125
−44.431
30.659
−2.133
1.00
77.65
C


ATOM
4036
CE
LYS
A
125
−45.562
30.252
−1.220
1.00
78.44
C


ATOM
4037
NZ
LYS
A
125
−46.906
30.461
−1.868
1.00
80.43
N


ATOM
4038
C
LYS
A
125
−42.824
34.738
−3.213
1.00
73.44
C


ATOM
4039
O
LYS
A
125
−41.657
34.367
−3.168
1.00
73.50
O


ATOM
4040
N
MET
A
126
−43.263
35.815
−2.547
1.00
74.18
N


ATOM
4041
CA
MET
A
126
−42.411
36.649
−1.681
1.00
74.20
C


ATOM
4042
CB
MET
A
126
−41.531
37.602
−2.516
1.00
74.36
C


ATOM
4043
CG
MET
A
126
−42.316
38.391
−3.520
1.00
75.18
C


ATOM
4044
SD
MET
A
126
−41.581
39.962
−3.943
1.00
78.44
S


ATOM
4045
CE
MET
A
126
−42.995
41.032
−3.741
1.00
77.19
C


ATOM
4046
C
MET
A
126
−43.241
37.473
−0.711
1.00
74.00
C


ATOM
4047
O
MET
A
126
−44.452
37.577
−0.868
1.00
74.18
O


ATOM
4048
N
SER
A
127
−42.586
38.085
0.273
1.00
74.27
N


ATOM
4049
CA
SER
A
127
−43.271
38.900
1.260
1.00
74.17
C


ATOM
4050
CB
SER
A
127
−42.361
39.142
2.454
1.00
74.01
C


ATOM
4051
OG
SER
A
127
−42.917
40.117
3.314
1.00
73.62
O


ATOM
4052
C
SER
A
127
−43.756
40.228
0.663
1.00
74.70
C


ATOM
4053
O
SER
A
127
−43.087
40.813
−0.197
1.00
75.08
O


ATOM
4054
N
GLY
A
128
−44.916
40.688
1.132
1.00
76.07
N


ATOM
4055
CA
GLY
A
128
−45.507
41.948
0.709
1.00
75.96
C


ATOM
4056
C
GLY
A
128
−44.600
43.117
1.025
1.00
76.12
C


ATOM
4057
O
GLY
A
128
−44.691
44.161
0.382
1.00
76.50
O


ATOM
4058
N
ASP
A
129
−43.679
42.932
1.994
1.00
75.99
N


ATOM
4059
CA
ASP
A
129
−42.690
43.931
2.407
1.00
75.71
C


ATOM
4060
CB
ASP
A
129
−41.849
43.373
3.561
1.00
75.74
C


ATOM
4061
CG
ASP
A
129
−42.588
43.212
4.879
1.00
76.66
C


ATOM
4062
OD1
ASP
A
129
−43.780
43.637
4.959
1.00
77.70
O


ATOM
4063
OD2
ASP
A
129
−41.978
42.661
5.843
1.00
77.23
O


ATOM
4064
C
ASP
A
129
−41.756
44.310
1.262
1.00
75.35
C


ATOM
4065
O
ASP
A
129
−41.245
45.427
1.225
1.00
75.27
O


ATOM
4066
N
LEU
A
130
−41.532
43.372
0.334
1.00
72.31
N


ATOM
4067
CA
LEU
A
130
−40.650
43.577
−0.796
1.00
72.16
C


ATOM
4068
CB
LEU
A
130
−40.086
42.234
−1.248
1.00
72.44
C


ATOM
4069
CG
LEU
A
130
−39.214
41.518
−0.227
1.00
73.24
C


ATOM
4070
CD1
LEU
A
130
−39.243
39.998
−0.443
1.00
74.34
C


ATOM
4071
CD2
LEU
A
130
−37.794
42.090
−0.214
1.00
73.18
C


ATOM
4072
C
LEU
A
130
−41.283
44.327
−1.957
1.00
71.98
C


ATOM
4073
O
LEU
A
130
−40.645
44.495
−2.997
1.00
71.98
O


ATOM
4074
N
LEU
A
131
−42.515
44.805
−1.782
1.00
72.28
N


ATOM
4075
CA
LEU
A
131
−43.224
45.519
−2.841
1.00
72.36
C


ATOM
4076
CB
LEU
A
131
−44.713
45.607
−2.556
1.00
72.27
C


ATOM
4077
CG
LEU
A
131
−45.490
44.354
−2.851
1.00
72.00
C


ATOM
4078
CD1
LEU
A
131
−46.830
44.400
−2.152
1.00
72.02
C


ATOM
4079
CD2
LEU
A
131
−45.624
44.126
−4.382
1.00
71.72
C


ATOM
4080
C
LEU
A
131
−42.669
46.861
−3.291
1.00
72.59
C


ATOM
4081
O
LEU
A
131
−42.585
47.090
−4.495
1.00
72.42
O


ATOM
4082
N
GLU
A
132
−42.300
47.743
−2.345
1.00
74.85
N


ATOM
4083
CA
GLU
A
132
−41.749
49.072
−2.623
1.00
75.47
C


ATOM
4084
CB
GLU
A
132
−41.481
49.822
−1.313
1.00
75.52
C


ATOM
4085
CG
GLU
A
132
−40.977
51.238
−1.542
1.00
75.63
C


ATOM
4086
CD
GLU
A
132
−40.813
52.067
−0.286
1.00
76.52
C


ATOM
4087
OE1
GLU
A
132
−40.124
51.581
0.643
1.00
76.99
O


ATOM
4088
OE2
GLU
A
132
−41.367
53.195
−0.226
1.00
76.49
O


ATOM
4089
C
GLU
A
132
−40.461
48.935
−3.416
1.00
75.73
C


ATOM
4090
O
GLU
A
132
−40.226
49.689
−4.372
1.00
75.85
O


ATOM
4091
N
LEU
A
133
−39.651
47.942
−3.003
1.00
75.20
N


ATOM
4092
CA
LEU
A
133
−38.358
47.552
−3.558
1.00
75.36
C


ATOM
4093
CB
LEU
A
133
−37.824
46.454
−2.620
1.00
75.46
C


ATOM
4094
CG
LEU
A
133
−36.419
45.899
−2.779
1.00
75.90
C


ATOM
4095
CD1
LEU
A
133
−36.028
45.162
−1.510
1.00
76.47
C


ATOM
4096
CD2
LEU
A
133
−36.344
44.882
−3.913
1.00
76.30
C


ATOM
4097
C
LEU
A
133
−38.510
47.025
−5.002
1.00
75.29
C


ATOM
4098
O
LEU
A
133
−37.793
47.484
−5.891
1.00
75.23
O


ATOM
4099
N
ALA
A
134
−39.425
46.041
−5.205
1.00
73.18
N


ATOM
4100
CA
ALA
A
134
−39.725
45.403
−6.480
1.00
73.41
C


ATOM
4101
CB
ALA
A
134
−40.666
44.241
−6.271
1.00
73.33
C


ATOM
4102
C
ALA
A
134
−40.315
46.385
−7.497
1.00
73.84
C


ATOM
4103
O
ALA
A
134
−39.999
46.301
−8.690
1.00
73.72
O


ATOM
4104
N
LEU
A
135
−41.153
47.329
−7.043
1.00
74.72
N


ATOM
4105
CA
LEU
A
135
−41.733
48.309
−7.956
1.00
75.35
C


ATOM
4106
CB
LEU
A
135
−42.880
49.050
−7.283
1.00
75.03
C


ATOM
4107
CG
LEU
A
135
−44.174
48.289
−7.229
1.00
74.09
C


ATOM
4108
CD1
LEU
A
135
−44.935
48.673
−6.047
1.00
74.22
C


ATOM
4109
CD2
LEU
A
135
−45.020
48.559
−8.423
1.00
73.06
C


ATOM
4110
C
LEU
A
135
−40.663
49.285
−8.486
1.00
76.31
C


ATOM
4111
O
LEU
A
135
−40.848
49.909
−9.546
1.00
76.40
O


ATOM
4112
N
LYS
A
136
−39.530
49.390
−7.735
1.00
78.69
N


ATOM
4113
CA
LYS
A
136
−38.383
50.232
−8.049
1.00
79.02
C


ATOM
4114
CB
LYS
A
136
−37.654
50.652
−6.763
1.00
78.89
C


ATOM
4115
CG
LYS
A
136
−38.294
51.859
−6.084
1.00
79.70
C


ATOM
4116
CD
LYS
A
136
−37.604
52.235
−4.755
1.00
80.63
C


ATOM
4117
CE
LYS
A
136
−38.268
53.405
−4.035
1.00
81.81
C


ATOM
4118
NZ
LYS
A
136
−37.773
53.576
−2.632
1.00
81.67
N


ATOM
4119
C
LYS
A
136
−37.440
49.570
−9.071
1.00
79.35
C


ATOM
4120
O
LYS
A
136
−36.595
50.260
−9.640
1.00
79.86
O


ATOM
4121
N
LEU
A
137
−37.598
48.261
−9.335
1.00
78.98
N


ATOM
4122
CA
LEU
A
137
−36.766
47.543
−10.309
1.00
79.57
C


ATOM
4123
CB
LEU
A
137
−36.973
46.013
−10.249
1.00
79.67
C


ATOM
4124
CG
LEU
A
137
−36.719
45.300
−8.926
1.00
80.16
C


ATOM
4125
CD1
LEU
A
137
−37.285
43.908
−8.960
1.00
79.93
C


ATOM
4126
CD2
LEU
A
137
−35.244
45.291
−8.560
1.00
80.74
C


ATOM
4127
C
LEU
A
137
−36.988
48.020
−11.752
1.00
79.92
C


ATOM
4128
O
LEU
A
137
−38.106
48.396
−12.132
1.00
79.79
O


ATOM
4129
N
PRO
A
138
−35.927
47.997
−12.583
1.00
85.61
N


ATOM
4130
CA
PRO
A
138
−36.094
48.415
−13.981
1.00
85.93
C


ATOM
4131
CB
PRO
A
138
−34.656
48.580
−14.466
1.00
85.97
C


ATOM
4132
CG
PRO
A
138
−33.896
47.564
−13.677
1.00
86.02
C


ATOM
4133
CD
PRO
A
138
−34.531
47.583
−12.315
1.00
85.82
C


ATOM
4134
C
PRO
A
138
−36.835
47.367
−14.807
1.00
85.94
C


ATOM
4135
O
PRO
A
138
−36.753
46.152
−14.541
1.00
85.89
O


ATOM
4136
N
HIS
A
139
−37.530
47.868
−15.838
1.00
87.14
N


ATOM
4137
CA
HIS
A
139
−38.343
47.136
−16.809
1.00
87.20
C


ATOM
4138
CB
HIS
A
139
−37.661
45.869
−17.395
1.00
87.77
C


ATOM
4139
CG
HIS
A
139
−36.221
46.038
−17.807
1.00
90.16
C


ATOM
4140
ND1
HIS
A
139
−35.740
47.238
−18.334
1.00
91.35
N


ATOM
4141
CE1
HIS
A
139
−34.455
47.029
−18.573
1.00
92.08
C


ATOM
4142
NE2
HIS
A
139
−34.091
45.780
−18.259
1.00
92.76
N


ATOM
4143
CD2
HIS
A
139
−35.206
45.140
−17.768
1.00
91.72
C


ATOM
4144
C
HIS
A
139
−39.743
46.848
−16.295
1.00
86.38
C


ATOM
4145
O
HIS
A
139
−40.634
46.652
−17.113
1.00
86.53
O


ATOM
4146
N
VAL
A
140
−39.952
46.860
−14.964
1.00
82.97
N


ATOM
4147
CA
VAL
A
140
−41.242
46.617
−14.312
1.00
81.89
C


ATOM
4148
CB
VAL
A
140
−41.074
46.509
−12.780
1.00
81.92
C


ATOM
4149
CG1
VAL
A
140
−42.392
46.161
−12.109
1.00
81.92
C


ATOM
4150
CG2
VAL
A
140
−39.993
45.497
−12.411
1.00
81.73
C


ATOM
4151
C
VAL
A
140
−42.304
47.673
−14.712
1.00
81.26
C


ATOM
4152
O
VAL
A
140
−42.130
48.869
−14.454
1.00
81.13
O


ATOM
4153
N
ASP
A
141
−43.395
47.212
−15.357
1.00
80.40
N


ATOM
4154
CA
ASP
A
141
−44.498
48.058
−15.821
1.00
79.27
C


ATOM
4155
CB
ASP
A
141
−45.162
47.427
−17.057
1.00
79.20
C


ATOM
4156
CG
ASP
A
141
−46.093
48.336
−17.844
1.00
79.58
C


ATOM
4157
OD1
ASP
A
141
−46.144
49.555
−17.541
1.00
80.20
O


ATOM
4158
OD2
ASP
A
141
−46.766
47.834
−18.766
1.00
81.10
O


ATOM
4159
C
ASP
A
141
−45.503
48.266
−14.682
1.00
78.54
C


ATOM
4160
O
ASP
A
141
−45.864
49.411
−14.374
1.00
78.85
O


ATOM
4161
N
TYR
A
142
−45.948
47.135
−14.067
1.00
74.15
N


ATOM
4162
CA
TYR
A
142
−46.852
47.015
−12.924
1.00
72.68
C


ATOM
4163
CB
TYR
A
142
−48.324
47.248
−13.287
1.00
72.37
C


ATOM
4164
CG
TYR
A
142
−48.906
46.336
−14.344
1.00
71.40
C


ATOM
4165
CD1
TYR
A
142
−48.805
46.654
−15.697
1.00
70.30
C


ATOM
4166
CE1
TYR
A
142
−49.380
45.843
−16.681
1.00
70.62
C


ATOM
4167
CZ
TYR
A
142
−50.076
44.695
−16.316
1.00
70.61
C


ATOM
4168
OH
TYR
A
142
−50.623
43.913
−17.321
1.00
68.55
O


ATOM
4169
CE2
TYR
A
142
−50.212
44.369
−14.967
1.00
70.46
C


ATOM
4170
CD2
TYR
A
142
−49.636
45.196
−13.991
1.00
70.99
C


ATOM
4171
C
TYR
A
142
−46.641
45.671
−12.245
1.00
72.14
C


ATOM
4172
O
TYR
A
142
−46.001
44.789
−12.813
1.00
71.87
O


ATOM
4173
N
ILE
A
143
−47.138
45.537
−11.013
1.00
69.96
N


ATOM
4174
CA
ILE
A
143
−47.067
44.325
−10.193
1.00
69.49
C


ATOM
4175
CB
ILE
A
143
−46.063
44.457
−9.008
1.00
69.68
C


ATOM
4176
CG1
ILE
A
143
−44.666
44.972
−9.483
1.00
69.49
C


ATOM
4177
CD1
ILE
A
143
−43.375
44.443
−8.782
1.00
68.82
C


ATOM
4178
CG2
ILE
A
143
−46.013
43.161
−8.154
1.00
68.95
C


ATOM
4179
C
ILE
A
143
−48.482
44.029
−9.699
1.00
69.45
C


ATOM
4180
O
ILE
A
143
−49.113
44.897
−9.098
1.00
69.21
O


ATOM
4181
N
GLU
A
144
−48.979
42.807
−9.956
1.00
71.72
N


ATOM
4182
CA
GLU
A
144
−50.317
42.405
−9.528
1.00
71.53
C


ATOM
4183
CB
GLU
A
144
−51.202
41.960
−10.708
1.00
71.48
C


ATOM
4184
CG
GLU
A
144
−52.658
42.320
−10.459
1.00
73.34
C


ATOM
4185
CD
GLU
A
144
−53.734
41.708
−11.339
1.00
75.76
C


ATOM
4186
OE1
GLU
A
144
−53.849
42.145
−12.509
1.00
75.42
O


ATOM
4187
OE2
GLU
A
144
−54.475
40.812
−10.852
1.00
76.83
O


ATOM
4188
C
GLU
A
144
−50.307
41.347
−8.449
1.00
70.91
C


ATOM
4189
O
GLU
A
144
−49.687
40.305
−8.615
1.00
71.23
O


ATOM
4190
N
GLU
A
145
−50.998
41.610
−7.348
1.00
69.74
N


ATOM
4191
CA
GLU
A
145
−51.142
40.646
−6.271
1.00
69.59
C


ATOM
4192
CB
GLU
A
145
−51.809
41.320
−5.059
1.00
69.65
C


ATOM
4193
CG
GLU
A
145
−52.061
40.413
−3.866
1.00
71.57
C


ATOM
4194
CD
GLU
A
145
−52.590
41.153
−2.648
1.00
74.80
C


ATOM
4195
OE1
GLU
A
145
−53.829
41.212
−2.480
1.00
77.48
O


ATOM
4196
OE2
GLU
A
145
−51.765
41.678
−1.863
1.00
74.22
O


ATOM
4197
C
GLU
A
145
−52.051
39.535
−6.823
1.00
69.32
C


ATOM
4198
O
GLU
A
145
−53.051
39.824
−7.485
1.00
69.54
O


ATOM
4199
N
ASP
A
146
−51.707
38.277
−6.574
1.00
69.08
N


ATOM
4200
CA
ASP
A
146
−52.530
37.166
−7.028
1.00
68.70
C


ATOM
4201
CB
ASP
A
146
−51.882
35.831
−6.636
1.00
69.08
C


ATOM
4202
CG
ASP
A
146
−52.124
34.665
−7.594
1.00
70.22
C


ATOM
4203
OD1
ASP
A
146
−52.938
34.827
−8.551
1.00
70.06
O


ATOM
4204
OD2
ASP
A
146
−51.496
33.578
−7.388
1.00
71.69
O


ATOM
4205
C
ASP
A
146
−53.926
37.280
−6.397
1.00
68.15
C


ATOM
4206
O
ASP
A
146
−54.077
37.892
−5.329
1.00
68.20
O


ATOM
4207
N
SER
A
147
−54.946
36.735
−7.080
1.00
66.95
N


ATOM
4208
CA
SER
A
147
−56.331
36.746
−6.607
1.00
66.13
C


ATOM
4209
CB
SER
A
147
−57.129
37.895
−7.208
1.00
65.93
C


ATOM
4210
OG
SER
A
147
−56.293
38.909
−7.736
1.00
66.81
O


ATOM
4211
C
SER
A
147
−56.976
35.441
−6.993
1.00
65.51
C


ATOM
4212
O
SER
A
147
−56.466
34.728
−7.864
1.00
65.59
O


ATOM
4213
N
SER
A
148
−58.094
35.123
−6.349
1.00
62.34
N


ATOM
4214
CA
SER
A
148
−58.833
33.915
−6.614
1.00
61.23
C


ATOM
4215
CB
SER
A
148
−59.607
33.509
−5.369
1.00
61.20
C


ATOM
4216
OG
SER
A
148
−58.747
32.994
−4.365
1.00
61.41
O


ATOM
4217
C
SER
A
148
−59.803
34.109
−7.767
1.00
60.82
C


ATOM
4218
O
SER
A
148
−60.365
35.198
−7.938
1.00
61.26
O


ATOM
4219
N
VAL
A
149
−59.990
33.049
−8.563
1.00
58.81
N


ATOM
4220
CA
VAL
A
149
−60.944
32.967
−9.672
1.00
58.28
C


ATOM
4221
CB
VAL
A
149
−60.356
32.896
−11.110
1.00
58.18
C


ATOM
4222
CG1
VAL
A
149
−59.501
34.111
−11.425
1.00
57.52
C


ATOM
4223
CG2
VAL
A
149
−59.594
31.603
−11.364
1.00
58.33
C


ATOM
4224
C
VAL
A
149
−61.855
31.779
−9.329
1.00
58.22
C


ATOM
4225
O
VAL
A
149
−61.413
30.884
−8.601
1.00
58.28
O


ATOM
4226
N
PHE
A
150
−63.110
31.768
−9.804
1.00
57.53
N


ATOM
4227
CA
PHE
A
150
−64.024
30.697
−9.449
1.00
57.21
C


ATOM
4228
CB
PHE
A
150
−64.996
31.178
−8.378
1.00
56.45
C


ATOM
4229
CG
PHE
A
150
−64.355
31.762
−7.158
1.00
55.56
C


ATOM
4230
CD1
PHE
A
150
−63.975
30.952
−6.100
1.00
54.34
C


ATOM
4231
CE1
PHE
A
150
−63.397
31.504
−4.956
1.00
54.41
C


ATOM
4232
CZ
PHE
A
150
−63.176
32.864
−4.878
1.00
54.23
C


ATOM
4233
CE2
PHE
A
150
−63.537
33.677
−5.921
1.00
54.50
C


ATOM
4234
CD2
PHE
A
150
−64.146
33.132
−7.053
1.00
55.55
C


ATOM
4235
C
PHE
A
150
−64.878
30.262
−10.570
1.00
57.91
C


ATOM
4236
O
PHE
A
150
−65.321
31.089
−11.351
1.00
58.22
O


ATOM
4237
N
ALA
A
151
−65.213
28.966
−10.586
1.00
59.21
N


ATOM
4238
CA
ALA
A
151
−66.127
28.355
−11.532
1.00
59.60
C


ATOM
4239
CB
ALA
A
151
−66.339
26.901
−11.148
1.00
59.54
C


ATOM
4240
C
ALA
A
151
−67.445
29.108
−11.409
1.00
60.14
C


ATOM
4241
O
ALA
A
151
−67.848
29.444
−10.283
1.00
60.22
O


ATOM
4242
N
GLN
A
152
−68.099
29.394
−12.558
1.00
61.34
N


ATOM
4243
CA
GLN
A
152
−69.375
30.113
−12.638
1.00
61.85
C


ATOM
4244
CB
GLN
A
152
−69.204
31.376
−13.490
1.00
61.59
C


ATOM
4245
CG
GLN
A
152
−68.267
32.380
−12.889
1.00
61.62
C


ATOM
4246
CD
GLN
A
152
−68.775
32.876
−11.557
1.00
62.64
C


ATOM
4247
OE1
GLN
A
152
−69.726
33.667
−11.461
1.00
63.19
O


ATOM
4248
NE2
GLN
A
152
−68.163
32.412
−10.476
1.00
64.63
N


ATOM
4249
C
GLN
A
152
−70.545
29.222
−13.155
1.00
62.70
C


ATOM
4250
O
GLN
A
152
−71.461
29.742
−13.838
1.00
63.04
O


ATOM
4251
OXT
GLN
A
152
−70.552
27.993
−12.901
1.00
90.28
O


TER
4252

GLN
A
152


ATOM
4253
N
GLU
H
1
−66.128
−17.371
−29.550
1.00
84.16
N


ATOM
4254
CA
GLU
H
1
−67.436
−17.005
−29.032
1.00
84.28
C


ATOM
4255
CB
GLU
H
1
−68.491
−18.106
−29.309
1.00
84.57
C


ATOM
4256
CG
GLU
H
1
−68.364
−19.339
−28.418
1.00
86.38
C


ATOM
4257
CD
GLU
H
1
−69.088
−20.603
−28.841
1.00
88.58
C


ATOM
4258
OE1
GLU
H
1
−68.431
−21.670
−28.871
1.00
88.46
O


ATOM
4259
OE2
GLU
H
1
−70.308
−20.532
−29.125
1.00
89.92
O


ATOM
4260
C
GLU
H
1
−67.333
−16.729
−27.549
1.00
83.78
C


ATOM
4261
O
GLU
H
1
−66.461
−17.307
−26.870
1.00
83.95
O


ATOM
4262
N
VAL
H
2
−68.228
−15.850
−27.047
1.00
78.94
N


ATOM
4263
CA
VAL
H
2
−68.256
−15.530
−25.632
1.00
78.30
C


ATOM
4264
CB
VAL
H
2
−68.442
−14.028
−25.340
1.00
78.19
C


ATOM
4265
CG1
VAL
H
2
−68.813
−13.772
−23.882
1.00
78.05
C


ATOM
4266
CG2
VAL
H
2
−67.170
−13.270
−25.684
1.00
77.93
C


ATOM
4267
C
VAL
H
2
−69.246
−16.451
−24.938
1.00
78.07
C


ATOM
4268
O
VAL
H
2
−70.267
−16.801
−25.524
1.00
78.24
O


ATOM
4269
N
GLN
H
3
−68.914
−16.889
−23.708
1.00
77.82
N


ATOM
4270
CA
GLN
H
3
−69.763
−17.773
−22.925
1.00
77.65
C


ATOM
4271
CB
GLN
H
3
−69.436
−19.213
−23.262
1.00
78.12
C


ATOM
4272
CG
GLN
H
3
−70.619
−19.947
−23.853
1.00
80.90
C


ATOM
4273
CD
GLN
H
3
−70.144
−20.979
−24.833
1.00
84.72
C


ATOM
4274
OE1
GLN
H
3
−70.363
−20.839
−26.047
1.00
86.45
O


ATOM
4275
NE2
GLN
H
3
−69.473
−22.032
−24.330
1.00
85.45
N


ATOM
4276
C
GLN
H
3
−69.640
−17.567
−21.436
1.00
76.67
C


ATOM
4277
O
GLN
H
3
−68.525
−17.477
−20.924
1.00
76.75
O


ATOM
4278
N
LEU
H
4
−70.787
−17.506
−20.739
1.00
72.16
N


ATOM
4279
CA
LEU
H
4
−70.837
−17.368
−19.280
1.00
71.64
C


ATOM
4280
CB
LEU
H
4
−71.524
−16.069
−18.818
1.00
71.33
C


ATOM
4281
CG
LEU
H
4
−71.195
−14.757
−19.523
1.00
70.60
C


ATOM
4282
CD1
LEU
H
4
−71.913
−13.625
−18.864
1.00
70.01
C


ATOM
4283
CD2
LEU
H
4
−69.718
−14.463
−19.528
1.00
69.61
C


ATOM
4284
C
LEU
H
4
−71.535
−18.618
−18.675
1.00
71.52
C


ATOM
4285
O
LEU
H
4
−72.709
−18.888
−18.974
1.00
71.75
O


ATOM
4286
N
LEU
H
5
−70.803
−19.384
−17.846
1.00
69.57
N


ATOM
4287
CA
LEU
H
5
−71.323
−20.591
−17.235
1.00
69.42
C


ATOM
4288
CB
LEU
H
5
−70.438
−21.787
−17.545
1.00
69.66
C


ATOM
4289
CG
LEU
H
5
−70.935
−22.587
−18.733
1.00
70.41
C


ATOM
4290
CD1
LEU
H
5
−69.780
−22.973
−19.690
1.00
70.09
C


ATOM
4291
CD2
LEU
H
5
−71.834
−23.750
−18.291
1.00
70.19
C


ATOM
4292
C
LEU
H
5
−71.668
−20.530
−15.770
1.00
69.40
C


ATOM
4293
O
LEU
H
5
−70.805
−20.593
−14.907
1.00
69.27
O


ATOM
4294
N
GLU
H
6
−72.943
−20.461
−15.482
1.00
71.71
N


ATOM
4295
CA
GLU
H
6
−73.380
−20.435
−14.106
1.00
72.24
C


ATOM
4296
CB
GLU
H
6
−74.742
−19.783
−14.004
1.00
72.34
C


ATOM
4297
CG
GLU
H
6
−74.678
−18.300
−14.254
1.00
74.24
C


ATOM
4298
CD
GLU
H
6
−75.966
−17.699
−14.760
1.00
76.78
C


ATOM
4299
OE1
GLU
H
6
−76.028
−16.458
−14.856
1.00
78.16
O


ATOM
4300
OE2
GLU
H
6
−76.912
−18.459
−15.059
1.00
78.55
O


ATOM
4301
C
GLU
H
6
−73.445
−21.839
−13.519
1.00
72.29
C


ATOM
4302
O
GLU
H
6
−73.777
−22.802
−14.225
1.00
72.74
O


ATOM
4303
N
SER
H
7
−73.152
−21.946
−12.218
1.00
69.48
N


ATOM
4304
CA
SER
H
7
−73.205
−23.184
−11.462
1.00
69.09
C


ATOM
4305
CB
SER
H
7
−71.933
−23.982
−11.661
1.00
68.95
C


ATOM
4306
OG
SER
H
7
−70.817
−23.156
−11.416
1.00
69.86
O


ATOM
4307
C
SER
H
7
−73.429
−22.835
−10.005
1.00
68.98
C


ATOM
4308
O
SER
H
7
−73.028
−21.760
−9.569
1.00
69.18
O


ATOM
4309
N
GLY
H
8
−74.130
−23.692
−9.279
1.00
69.93
N


ATOM
4310
CA
GLY
H
8
−74.400
−23.446
−7.871
1.00
69.86
C


ATOM
4311
C
GLY
H
8
−75.861
−23.338
−7.508
1.00
69.99
C


ATOM
4312
O
GLY
H
8
−76.206
−23.020
−6.357
1.00
70.57
O


ATOM
4313
N
GLY
H
9
−76.723
−23.574
−8.483
1.00
70.65
N


ATOM
4314
CA
GLY
H
9
−78.159
−23.495
−8.255
1.00
70.59
C


ATOM
4315
C
GLY
H
9
−78.664
−24.743
−7.563
1.00
70.37
C


ATOM
4316
O
GLY
H
9
−78.070
−25.815
−7.714
1.00
70.41
O


ATOM
4317
N
GLY
H
10
−79.748
−24.604
−6.812
1.00
67.78
N


ATOM
4318
CA
GLY
H
10
−80.338
−25.717
−6.099
1.00
67.44
C


ATOM
4319
C
GLY
H
10
−81.143
−25.309
−4.900
1.00
67.59
C


ATOM
4320
O
GLY
H
10
−81.720
−24.214
−4.870
1.00
67.31
O


ATOM
4321
N
LEU
H
11
−81.196
−26.202
−3.904
1.00
69.83
N


ATOM
4322
CA
LEU
H
11
−81.963
−25.902
−2.713
1.00
70.67
C


ATOM
4323
CB
LEU
H
11
−82.755
−27.099
−2.219
1.00
70.63
C


ATOM
4324
CG
LEU
H
11
−84.051
−27.363
−2.918
1.00
70.82
C


ATOM
4325
CD1
LEU
H
11
−84.469
−28.777
−2.695
1.00
71.32
C


ATOM
4326
CD2
LEU
H
11
−85.144
−26.348
−2.511
1.00
71.57
C


ATOM
4327
C
LEU
H
11
−81.134
−25.361
−1.602
1.00
71.27
C


ATOM
4328
O
LEU
H
11
−80.059
−25.887
−1.300
1.00
71.33
O


ATOM
4329
N
VAL
H
12
−81.636
−24.293
−0.985
1.00
77.04
N


ATOM
4330
CA
VAL
H
12
−80.974
−23.659
0.152
1.00
77.83
C


ATOM
4331
CB
VAL
H
12
−80.394
−22.247
−0.154
1.00
77.74
C


ATOM
4332
CG1
VAL
H
12
−79.444
−21.815
0.949
1.00
77.50
C


ATOM
4333
CG2
VAL
H
12
−79.676
−22.202
−1.502
1.00
76.57
C


ATOM
4334
C
VAL
H
12
−82.020
−23.624
1.262
1.00
78.58
C


ATOM
4335
O
VAL
H
12
−83.201
−23.385
0.982
1.00
78.68
O


ATOM
4336
N
GLN
H
13
−81.603
−23.892
2.508
1.00
82.84
N


ATOM
4337
CA
GLN
H
13
−82.524
−23.873
3.644
1.00
83.70
C


ATOM
4338
CB
GLN
H
13
−81.931
−24.645
4.835
1.00
83.95
C


ATOM
4339
CG
GLN
H
13
−81.539
−26.106
4.538
1.00
86.04
C


ATOM
4340
CD
GLN
H
13
−82.707
−26.981
4.115
1.00
88.73
C


ATOM
4341
OE1
GLN
H
13
−82.682
−27.649
3.048
1.00
89.35
O


ATOM
4342
NE2
GLN
H
13
−83.766
−26.985
4.935
1.00
89.33
N


ATOM
4343
C
GLN
H
13
−82.738
−22.430
4.052
1.00
83.88
C


ATOM
4344
O
GLN
H
13
−81.774
−21.673
3.978
1.00
83.93
O


ATOM
4345
N
PRO
H
14
−83.946
−21.995
4.478
1.00
84.30
N


ATOM
4346
CA
PRO
H
14
−84.102
−20.599
4.921
1.00
84.50
C


ATOM
4347
CB
PRO
H
14
−85.560
−20.519
5.377
1.00
84.18
C


ATOM
4348
CG
PRO
H
14
−85.967
−21.904
5.600
1.00
84.55
C


ATOM
4349
CD
PRO
H
14
−85.207
−22.732
4.625
1.00
84.42
C


ATOM
4350
C
PRO
H
14
−83.101
−20.312
6.049
1.00
84.71
C


ATOM
4351
O
PRO
H
14
−82.966
−21.105
6.995
1.00
85.21
O


ATOM
4352
N
GLY
H
15
−82.351
−19.227
5.880
1.00
84.98
N


ATOM
4353
CA
GLY
H
15
−81.285
−18.815
6.782
1.00
84.47
C


ATOM
4354
C
GLY
H
15
−79.928
−19.168
6.199
1.00
84.16
C


ATOM
4355
O
GLY
H
15
−78.915
−18.539
6.533
1.00
84.38
O


ATOM
4356
N
GLY
H
16
−79.916
−20.164
5.311
1.00
82.42
N


ATOM
4357
CA
GLY
H
16
−78.720
−20.637
4.622
1.00
82.29
C


ATOM
4358
C
GLY
H
16
−78.183
−19.668
3.589
1.00
82.05
C


ATOM
4359
O
GLY
H
16
−78.700
−18.556
3.439
1.00
82.21
O


ATOM
4360
N
SER
H
17
−77.142
−20.072
2.863
1.00
80.66
N


ATOM
4361
CA
SER
H
17
−76.571
−19.159
1.888
1.00
80.48
C


ATOM
4362
CB
SER
H
17
−75.275
−18.544
2.425
1.00
80.55
C


ATOM
4363
OG
SER
H
17
−74.139
−19.386
2.286
1.00
80.34
O


ATOM
4364
C
SER
H
17
−76.367
−19.745
0.497
1.00
80.27
C


ATOM
4365
O
SER
H
17
−75.852
−20.859
0.369
1.00
80.77
O


ATOM
4366
N
LEU
H
18
−76.747
−18.988
−0.550
1.00
76.11
N


ATOM
4367
CA
LEU
H
18
−76.545
−19.440
−1.921
1.00
75.09
C


ATOM
4368
CB
LEU
H
18
−77.591
−18.880
−2.916
1.00
75.04
C


ATOM
4369
CG
LEU
H
18
−77.659
−17.363
−3.144
1.00
75.02
C


ATOM
4370
CD1
LEU
H
18
−76.848
−16.963
−4.328
1.00
75.68
C


ATOM
4371
CD2
LEU
H
18
−79.075
−16.892
−3.389
1.00
74.44
C


ATOM
4372
C
LEU
H
18
−75.139
−19.051
−2.317
1.00
74.76
C


ATOM
4373
O
LEU
H
18
−74.662
−17.972
−1.969
1.00
74.41
O


ATOM
4374
N
ARG
H
19
−74.469
−19.938
−3.019
1.00
74.61
N


ATOM
4375
CA
ARG
H
19
−73.126
−19.699
−3.480
1.00
74.54
C


ATOM
4376
CB
ARG
H
19
−72.095
−20.339
−2.549
1.00
74.56
C


ATOM
4377
CG
ARG
H
19
−72.184
−19.622
−1.214
1.00
77.55
C


ATOM
4378
CD
ARG
H
19
−71.373
−20.123
−0.058
1.00
83.29
C


ATOM
4379
NE
ARG
H
19
−69.959
−20.310
−0.377
1.00
88.54
N


ATOM
4380
CZ
ARG
H
19
−69.093
−19.351
−0.709
1.00
90.54
C


ATOM
4381
NH1
ARG
H
19
−69.494
−18.085
−0.809
1.00
88.60
N


ATOM
4382
NH2
ARG
H
19
−67.824
−19.655
−0.965
1.00
92.32
N


ATOM
4383
C
ARG
H
19
−73.095
−20.139
−4.912
1.00
74.06
C


ATOM
4384
O
ARG
H
19
−73.229
−21.330
−5.216
1.00
74.25
O


ATOM
4385
N
LEU
H
20
−73.043
−19.123
−5.804
1.00
72.96
N


ATOM
4386
CA
LEU
H
20
−73.058
−19.247
−7.263
1.00
72.22
C


ATOM
4387
CB
LEU
H
20
−74.155
−18.353
−7.833
1.00
71.98
C


ATOM
4388
CG
LEU
H
20
−75.551
−18.561
−7.313
1.00
72.09
C


ATOM
4389
CD1
LEU
H
20
−76.477
−17.556
−7.895
1.00
72.12
C


ATOM
4390
CD2
LEU
H
20
−76.073
−19.910
−7.662
1.00
73.03
C


ATOM
4391
C
LEU
H
20
−71.739
−18.889
−7.927
1.00
71.91
C


ATOM
4392
O
LEU
H
20
−70.989
−18.053
−7.424
1.00
72.10
O


ATOM
4393
N
SER
H
21
−71.471
−19.504
−9.064
1.00
70.87
N


ATOM
4394
CA
SER
H
21
−70.270
−19.236
−9.818
1.00
70.98
C


ATOM
4395
CB
SER
H
21
−69.358
−20.450
−9.838
1.00
70.95
C


ATOM
4396
OG
SER
H
21
−68.806
−20.617
−8.545
1.00
72.22
O


ATOM
4397
C
SER
H
21
−70.667
−18.909
−11.205
1.00
71.06
C


ATOM
4398
O
SER
H
21
−71.741
−19.314
−11.637
1.00
71.48
O


ATOM
4399
N
CYS
H
22
−69.800
−18.180
−11.917
1.00
72.15
N


ATOM
4400
CA
CYS
H
22
−70.004
−17.784
−13.300
1.00
71.80
C


ATOM
4401
CB
CYS
H
22
−70.666
−16.416
−13.379
1.00
71.77
C


ATOM
4402
SG
CYS
H
22
−70.891
−15.818
−15.071
1.00
73.52
S


ATOM
4403
C
CYS
H
22
−68.658
−17.809
−13.994
1.00
71.24
C


ATOM
4404
O
CYS
H
22
−67.748
−17.129
−13.552
1.00
71.34
O


ATOM
4405
N
LYS
H
23
−68.516
−18.612
−15.042
1.00
70.46
N


ATOM
4406
CA
LYS
H
23
−67.258
−18.740
−15.754
1.00
70.46
C


ATOM
4407
CB
LYS
H
23
−66.749
−20.185
−15.748
1.00
70.57
C


ATOM
4408
CG
LYS
H
23
−65.377
−20.323
−16.393
1.00
71.74
C


ATOM
4409
CD
LYS
H
23
−64.644
−21.565
−15.971
1.00
73.39
C


ATOM
4410
CE
LYS
H
23
−63.311
−21.675
−16.687
1.00
74.92
C


ATOM
4411
NZ
LYS
H
23
−62.357
−20.557
−16.371
1.00
76.84
N


ATOM
4412
C
LYS
H
23
−67.265
−18.169
−17.158
1.00
70.28
C


ATOM
4413
O
LYS
H
23
−67.860
−18.748
−18.079
1.00
70.43
O


ATOM
4414
N
ALA
H
24
−66.532
−17.064
−17.331
1.00
68.97
N


ATOM
4415
CA
ALA
H
24
−66.411
−16.386
−18.606
1.00
68.52
C


ATOM
4416
CB
ALA
H
24
−66.065
−14.937
−18.374
1.00
68.52
C


ATOM
4417
C
ALA
H
24
−65.376
−17.041
−19.532
1.00
68.37
C


ATOM
4418
O
ALA
H
24
−64.365
−17.608
−19.075
1.00
68.38
O


ATOM
4419
N
SER
H
25
−65.639
−16.951
−20.850
1.00
67.81
N


ATOM
4420
CA
SER
H
25
−64.741
−17.502
−21.852
1.00
67.76
C


ATOM
4421
CB
SER
H
25
−65.021
−18.992
−22.075
1.00
67.84
C


ATOM
4422
OG
SER
H
25
−66.129
−19.288
−22.919
1.00
68.84
O


ATOM
4423
C
SER
H
25
−64.789
−16.748
−23.172
1.00
67.61
C


ATOM
4424
O
SER
H
25
−65.830
−16.243
−23.557
1.00
67.59
O


ATOM
4425
N
GLY
H
26
−63.665
−16.714
−23.862
1.00
69.08
N


ATOM
4426
CA
GLY
H
26
−63.575
−16.119
−25.181
1.00
69.03
C


ATOM
4427
C
GLY
H
26
−63.341
−14.638
−25.287
1.00
69.20
C


ATOM
4428
O
GLY
H
26
−63.493
−14.092
−26.386
1.00
69.36
O


ATOM
4429
N
TYR
H
27
−62.995
−13.970
−24.164
1.00
69.63
N


ATOM
4430
CA
TYR
H
27
−62.726
−12.530
−24.121
1.00
69.19
C


ATOM
4431
CB
TYR
H
27
−64.031
−11.724
−23.993
1.00
69.19
C


ATOM
4432
CG
TYR
H
27
−64.705
−11.748
−22.638
1.00
68.24
C


ATOM
4433
CD1
TYR
H
27
−64.480
−10.736
−21.708
1.00
68.05
C


ATOM
4434
CE1
TYR
H
27
−65.106
−10.744
−20.461
1.00
68.69
C


ATOM
4435
CZ
TYR
H
27
−66.016
−11.747
−20.153
1.00
68.90
C


ATOM
4436
OH
TYR
H
27
−66.662
−11.746
−18.934
1.00
68.89
O


ATOM
4437
CE2
TYR
H
27
−66.286
−12.739
−21.084
1.00
68.63
C


ATOM
4438
CD2
TYR
H
27
−65.633
−12.730
−22.318
1.00
68.29
C


ATOM
4439
C
TYR
H
27
−61.719
−12.216
−23.023
1.00
69.14
C


ATOM
4440
O
TYR
H
27
−61.306
−13.141
−22.321
1.00
69.30
O


ATOM
4441
N
THR
H
28
−61.305
−10.937
−22.865
1.00
69.86
N


ATOM
4442
CA
THR
H
28
−60.364
−10.551
−21.809
1.00
69.57
C


ATOM
4443
CB
THR
H
28
−59.416
−9.454
−22.290
1.00
69.64
C


ATOM
4444
OG1
THR
H
28
−58.599
−10.020
−23.328
1.00
70.12
O


ATOM
4445
CG2
THR
H
28
−58.490
−8.947
−21.164
1.00
70.18
C


ATOM
4446
C
THR
H
28
−61.190
−10.249
−20.594
1.00
69.14
C


ATOM
4447
O
THR
H
28
−61.860
−9.228
−20.548
1.00
69.14
O


ATOM
4448
N
PHE
H
29
−61.191
−11.175
−19.641
1.00
66.46
N


ATOM
4449
CA
PHE
H
29
−61.992
−11.133
−18.418
1.00
66.27
C


ATOM
4450
CB
PHE
H
29
−61.609
−12.272
−17.465
1.00
65.85
C


ATOM
4451
CG
PHE
H
29
−62.516
−12.405
−16.266
1.00
64.34
C


ATOM
4452
CD1
PHE
H
29
−63.828
−12.828
−16.411
1.00
62.78
C


ATOM
4453
CE1
PHE
H
29
−64.669
−12.936
−15.307
1.00
62.24
C


ATOM
4454
CZ
PHE
H
29
−64.202
−12.634
−14.053
1.00
62.61
C


ATOM
4455
CE2
PHE
H
29
−62.901
−12.214
−13.883
1.00
63.53
C


ATOM
4456
CD2
PHE
H
29
−62.058
−12.100
−14.991
1.00
64.31
C


ATOM
4457
C
PHE
H
29
−62.113
−9.794
−17.703
1.00
66.91
C


ATOM
4458
O
PHE
H
29
−63.226
−9.389
−17.324
1.00
67.42
O


ATOM
4459
N
SER
H
30
−60.974
−9.101
−17.559
1.00
70.34
N


ATOM
4460
CA
SER
H
30
−60.817
−7.798
−16.892
1.00
70.63
C


ATOM
4461
CB
SER
H
30
−59.363
−7.584
−16.504
1.00
70.51
C


ATOM
4462
OG
SER
H
30
−58.532
−8.272
−17.429
1.00
71.36
O


ATOM
4463
C
SER
H
30
−61.348
−6.570
−17.645
1.00
70.64
C


ATOM
4464
O
SER
H
30
−61.698
−5.591
−16.981
1.00
71.00
O


ATOM
4465
N
SER
H
31
−61.415
−6.611
−18.999
1.00
70.40
N


ATOM
4466
CA
SER
H
31
−61.896
−5.500
−19.836
1.00
70.53
C


ATOM
4467
CB
SER
H
31
−61.750
−5.815
−21.322
1.00
70.69
C


ATOM
4468
OG
SER
H
31
−60.508
−6.406
−21.666
1.00
73.12
O


ATOM
4469
C
SER
H
31
−63.350
−5.120
−19.587
1.00
70.40
C


ATOM
4470
O
SER
H
31
−63.729
−3.961
−19.838
1.00
71.01
O


ATOM
4471
N
TYR
H
32
−64.174
−6.086
−19.129
1.00
68.08
N


ATOM
4472
CA
TYR
H
32
−65.602
−5.849
−18.906
1.00
67.28
C


ATOM
4473
CB
TYR
H
32
−66.415
−6.861
−19.719
1.00
66.88
C


ATOM
4474
CG
TYR
H
32
−66.227
−6.729
−21.207
1.00
65.13
C


ATOM
4475
CD1
TYR
H
32
−65.053
−7.163
−21.824
1.00
64.22
C


ATOM
4476
CE1
TYR
H
32
−64.867
−7.035
−23.201
1.00
63.90
C


ATOM
4477
CZ
TYR
H
32
−65.885
−6.510
−23.985
1.00
64.65
C


ATOM
4478
OH
TYR
H
32
−65.720
−6.373
−25.344
1.00
64.76
O


ATOM
4479
CE2
TYR
H
32
−67.076
−6.102
−23.394
1.00
65.21
C


ATOM
4480
CD2
TYR
H
32
−67.233
−6.204
−22.010
1.00
65.21
C


ATOM
4481
C
TYR
H
32
−65.999
−5.939
−17.443
1.00
67.37
C


ATOM
4482
O
TYR
H
32
−65.254
−6.497
−16.667
1.00
67.35
O


ATOM
4483
N
GLY
H
33
−67.157
−5.396
−17.092
1.00
65.63
N


ATOM
4484
CA
GLY
H
33
−67.692
−5.452
−15.746
1.00
66.06
C


ATOM
4485
C
GLY
H
33
−68.749
−6.530
−15.700
1.00
66.58
C


ATOM
4486
O
GLY
H
33
−69.274
−6.910
−16.749
1.00
66.80
O


ATOM
4487
N
MET
H
34
−69.065
−7.046
−14.499
1.00
66.52
N


ATOM
4488
CA
MET
H
34
−70.046
−8.104
−14.319
1.00
66.65
C


ATOM
4489
CB
MET
H
34
−69.394
−9.345
−13.737
1.00
67.09
C


ATOM
4490
CG
MET
H
34
−68.225
−9.905
−14.497
1.00
69.58
C


ATOM
4491
SD
MET
H
34
−68.573
−10.522
−16.142
1.00
75.28
S


ATOM
4492
CE
MET
H
34
−70.078
−11.560
−15.865
1.00
73.82
C


ATOM
4493
C
MET
H
34
−71.076
−7.717
−13.313
1.00
66.50
C


ATOM
4494
O
MET
H
34
−70.731
−7.254
−12.228
1.00
66.14
O


ATOM
4495
N
TYR
H
35
−72.347
−7.964
−13.641
1.00
64.67
N


ATOM
4496
CA
TYR
H
35
−73.482
−7.743
−12.760
1.00
64.82
C


ATOM
4497
CB
TYR
H
35
−74.594
−6.958
−13.494
1.00
65.00
C


ATOM
4498
CG
TYR
H
35
−74.530
−5.446
−13.399
1.00
65.80
C


ATOM
4499
CD1
TYR
H
35
−75.447
−4.732
−12.621
1.00
66.36
C


ATOM
4500
CE1
TYR
H
35
−75.405
−3.339
−12.546
1.00
66.85
C


ATOM
4501
CZ
TYR
H
35
−74.443
−2.644
−13.266
1.00
68.42
C


ATOM
4502
OH
TYR
H
35
−74.340
−1.268
−13.236
1.00
67.78
O


ATOM
4503
CE2
TYR
H
35
−73.537
−3.337
−14.058
1.00
68.00
C


ATOM
4504
CD2
TYR
H
35
−73.595
−4.725
−14.130
1.00
66.03
C


ATOM
4505
C
TYR
H
35
−74.038
−9.135
−12.369
1.00
64.88
C


ATOM
4506
O
TYR
H
35
−73.866
−10.119
−13.088
1.00
64.57
O


ATOM
4507
N
TRP
H
36
−74.697
−9.208
−11.227
1.00
65.02
N


ATOM
4508
CA
TRP
H
36
−75.374
−10.413
−10.792
1.00
65.39
C


ATOM
4509
CB
TRP
H
36
−74.875
−10.937
−9.433
1.00
65.09
C


ATOM
4510
CG
TRP
H
36
−73.758
−11.924
−9.543
1.00
64.98
C


ATOM
4511
CD1
TRP
H
36
−72.449
−11.700
−9.255
1.00
65.63
C


ATOM
4512
NE1
TRP
H
36
−71.710
−12.843
−9.467
1.00
65.37
N


ATOM
4513
CE2
TRP
H
36
−72.537
−13.828
−9.937
1.00
65.27
C


ATOM
4514
CD2
TRP
H
36
−73.844
−13.292
−9.976
1.00
65.14
C


ATOM
4515
CE3
TRP
H
36
−74.891
−14.110
−10.421
1.00
64.75
C


ATOM
4516
CZ3
TRP
H
36
−74.605
−15.413
−10.800
1.00
64.19
C


ATOM
4517
CH2
TRP
H
36
−73.296
−15.915
−10.750
1.00
63.74
C


ATOM
4518
CZ2
TRP
H
36
−72.250
−15.143
−10.321
1.00
64.26
C


ATOM
4519
C
TRP
H
36
−76.798
−9.886
−10.721
1.00
65.98
C


ATOM
4520
O
TRP
H
36
−77.055
−8.937
−9.981
1.00
66.19
O


ATOM
4521
N
VAL
H
37
−77.686
−10.396
−11.569
1.00
69.64
N


ATOM
4522
CA
VAL
H
37
−79.080
−9.940
−11.610
1.00
70.22
C


ATOM
4523
CB
VAL
H
37
−79.428
−9.296
−12.987
1.00
70.35
C


ATOM
4524
CG1
VAL
H
37
−80.856
−8.750
−13.008
1.00
70.21
C


ATOM
4525
CG2
VAL
H
37
−78.425
−8.208
−13.382
1.00
70.26
C


ATOM
4526
C
VAL
H
37
−79.956
−11.161
−11.350
1.00
70.46
C


ATOM
4527
O
VAL
H
37
−79.578
−12.261
−11.754
1.00
70.87
O


ATOM
4528
N
ARG
H
38
−81.112
−10.980
−10.694
1.00
71.70
N


ATOM
4529
CA
ARG
H
38
−82.038
−12.072
−10.437
1.00
71.83
C


ATOM
4530
CB
ARG
H
38
−82.063
−12.479
−8.962
1.00
71.52
C


ATOM
4531
CG
ARG
H
38
−82.784
−11.516
−8.019
1.00
70.95
C


ATOM
4532
CD
ARG
H
38
−82.776
−12.049
−6.600
1.00
70.37
C


ATOM
4533
NE
ARG
H
38
−83.622
−11.259
−5.700
1.00
69.30
N


ATOM
4534
CZ
ARG
H
38
−83.680
−11.458
−4.385
1.00
69.01
C


ATOM
4535
NH1
ARG
H
38
−82.938
−12.401
−3.815
1.00
69.40
N


ATOM
4536
NH2
ARG
H
38
−84.473
−10.703
−3.626
1.00
68.45
N


ATOM
4537
C
ARG
H
38
−83.424
−11.737
−10.958
1.00
72.40
C


ATOM
4538
O
ARG
H
38
−83.737
−10.563
−11.168
1.00
72.42
O


ATOM
4539
N
GLN
H
39
−84.261
−12.761
−11.175
1.00
74.58
N


ATOM
4540
CA
GLN
H
39
−85.621
−12.539
−11.653
1.00
75.17
C


ATOM
4541
CB
GLN
H
39
−85.635
−12.551
−13.173
1.00
74.95
C


ATOM
4542
CG
GLN
H
39
−86.998
−12.352
−13.788
1.00
73.81
C


ATOM
4543
CD
GLN
H
39
−86.864
−12.405
−15.275
1.00
72.62
C


ATOM
4544
OE1
GLN
H
39
−86.133
−13.251
−15.833
1.00
72.71
O


ATOM
4545
NE2
GLN
H
39
−87.566
−11.505
−15.945
1.00
71.94
N


ATOM
4546
C
GLN
H
39
−86.554
−13.585
−11.070
1.00
75.87
C


ATOM
4547
O
GLN
H
39
−86.428
−14.765
−11.400
1.00
76.00
O


ATOM
4548
N
ALA
H
40
−87.468
−13.157
−10.179
1.00
79.68
N


ATOM
4549
CA
ALA
H
40
−88.437
−14.055
−9.557
1.00
80.51
C


ATOM
4550
CB
ALA
H
40
−89.123
−13.369
−8.400
1.00
80.27
C


ATOM
4551
C
ALA
H
40
−89.450
−14.438
−10.628
1.00
81.37
C


ATOM
4552
O
ALA
H
40
−89.762
−13.580
−11.452
1.00
81.84
O


ATOM
4553
N
PRO
H
41
−89.930
−15.711
−10.671
1.00
85.05
N


ATOM
4554
CA
PRO
H
41
−90.859
−16.153
−11.737
1.00
85.30
C


ATOM
4555
CB
PRO
H
41
−91.486
−17.431
−11.164
1.00
85.19
C


ATOM
4556
CG
PRO
H
41
−90.921
−17.572
−9.757
1.00
85.38
C


ATOM
4557
CD
PRO
H
41
−89.629
−16.838
−9.771
1.00
85.27
C


ATOM
4558
C
PRO
H
41
−91.864
−15.170
−12.361
1.00
85.47
C


ATOM
4559
O
PRO
H
41
−91.797
−14.903
−13.573
1.00
85.58
O


ATOM
4560
N
GLY
H
42
−92.765
−14.631
−11.549
1.00
86.15
N


ATOM
4561
CA
GLY
H
42
−93.730
−13.665
−12.056
1.00
86.25
C


ATOM
4562
C
GLY
H
42
−93.048
−12.352
−12.411
1.00
86.19
C


ATOM
4563
O
GLY
H
42
−93.180
−11.852
−13.535
1.00
86.40
O


ATOM
4564
N
LYS
H
43
−92.278
−11.819
−11.440
1.00
82.73
N


ATOM
4565
CA
LYS
H
43
−91.509
−10.583
−11.480
1.00
81.98
C


ATOM
4566
CB
LYS
H
43
−90.766
−10.431
−10.140
1.00
82.07
C


ATOM
4567
C
LYS
H
43
−90.538
−10.346
−12.691
1.00
81.47
C


ATOM
4568
O
LYS
H
43
−90.332
−11.213
−13.556
1.00
81.20
O


ATOM
4569
N
GLY
H
44
−89.976
−9.138
−12.705
1.00
76.91
N


ATOM
4570
CA
GLY
H
44
−89.006
−8.663
−13.671
1.00
76.29
C


ATOM
4571
C
GLY
H
44
−87.603
−8.677
−13.092
1.00
75.96
C


ATOM
4572
O
GLY
H
44
−87.377
−9.231
−12.008
1.00
76.24
O


ATOM
4573
N
LEU
H
45
−86.651
−8.057
−13.813
1.00
71.99
N


ATOM
4574
CA
LEU
H
45
−85.230
−7.989
−13.471
1.00
71.27
C


ATOM
4575
CB
LEU
H
45
−84.412
−7.534
−14.691
1.00
70.96
C


ATOM
4576
CG
LEU
H
45
−84.619
−8.373
−15.941
1.00
70.10
C


ATOM
4577
CD1
LEU
H
45
−84.088
−7.696
−17.142
1.00
69.71
C


ATOM
4578
CD2
LEU
H
45
−83.974
−9.728
−15.812
1.00
69.93
C


ATOM
4579
C
LEU
H
45
−84.886
−7.181
−12.223
1.00
71.13
C


ATOM
4580
O
LEU
H
45
−85.286
−6.030
−12.107
1.00
71.44
O


ATOM
4581
N
GLU
H
46
−84.145
−7.788
−11.286
1.00
73.29
N


ATOM
4582
CA
GLU
H
46
−83.716
−7.147
−10.043
1.00
73.28
C


ATOM
4583
CB
GLU
H
46
−84.414
−7.770
−8.821
1.00
73.31
C


ATOM
4584
CG
GLU
H
46
−83.727
−7.488
−7.486
1.00
75.03
C


ATOM
4585
CD
GLU
H
46
−84.613
−7.644
−6.265
1.00
77.42
C


ATOM
4586
OE1
GLU
H
46
−84.689
−6.677
−5.471
1.00
78.48
O


ATOM
4587
OE2
GLU
H
46
−85.241
−8.720
−6.107
1.00
79.58
O


ATOM
4588
C
GLU
H
46
−82.200
−7.225
−9.934
1.00
72.99
C


ATOM
4589
O
GLU
H
46
−81.642
−8.316
−9.826
1.00
73.27
O


ATOM
4590
N
TRP
H
47
−81.522
−6.072
−9.987
1.00
71.13
N


ATOM
4591
CA
TRP
H
47
−80.064
−6.082
−9.906
1.00
70.33
C


ATOM
4592
CB
TRP
H
47
−79.464
−4.756
−10.410
1.00
70.46
C


ATOM
4593
CG
TRP
H
47
−79.220
−3.703
−9.368
1.00
70.46
C


ATOM
4594
CD1
TRP
H
47
−80.151
−2.919
−8.759
1.00
70.13
C


ATOM
4595
NE1
TRP
H
47
−79.540
−2.068
−7.863
1.00
70.12
N


ATOM
4596
CE2
TRP
H
47
−78.188
−2.281
−7.895
1.00
69.84
C


ATOM
4597
CD2
TRP
H
47
−77.948
−3.305
−8.834
1.00
70.37
C


ATOM
4598
CE3
TRP
H
47
−76.626
−3.732
−9.042
1.00
70.17
C


ATOM
4599
CZ3
TRP
H
47
−75.611
−3.129
−8.320
1.00
69.26
C


ATOM
4600
CH2
TRP
H
47
−75.884
−2.125
−7.388
1.00
67.91
C


ATOM
4601
CZ2
TRP
H
47
−77.162
−1.681
−7.167
1.00
69.50
C


ATOM
4602
C
TRP
H
47
−79.628
−6.443
−8.497
1.00
69.74
C


ATOM
4603
O
TRP
H
47
−80.275
−6.030
−7.534
1.00
69.62
O


ATOM
4604
N
ILE
H
48
−78.575
−7.253
−8.373
1.00
67.17
N


ATOM
4605
CA
ILE
H
48
−78.067
−7.669
−7.064
1.00
66.52
C


ATOM
4606
CB
ILE
H
48
−77.870
−9.212
−6.979
1.00
66.45
C


ATOM
4607
CG1
ILE
H
48
−79.214
−9.941
−7.101
1.00
66.20
C


ATOM
4608
CD1
ILE
H
48
−79.091
−11.089
−7.877
1.00
66.59
C


ATOM
4609
CG2
ILE
H
48
−77.080
−9.657
−5.735
1.00
66.23
C


ATOM
4610
C
ILE
H
48
−76.832
−6.845
−6.727
1.00
66.16
C


ATOM
4611
O
ILE
H
48
−76.856
−6.080
−5.767
1.00
65.97
O


ATOM
4612
N
GLY
H
49
−75.792
−6.990
−7.535
1.00
65.65
N


ATOM
4613
CA
GLY
H
49
−74.543
−6.282
−7.350
1.00
65.29
C


ATOM
4614
C
GLY
H
49
−73.689
−6.230
−8.598
1.00
65.45
C


ATOM
4615
O
GLY
H
49
−73.948
−6.930
−9.586
1.00
65.27
O


ATOM
4616
N
TRP
H
50
−72.642
−5.399
−8.540
1.00
66.73
N


ATOM
4617
CA
TRP
H
50
−71.678
−5.202
−9.622
1.00
66.82
C


ATOM
4618
CB
TRP
H
50
−71.910
−3.831
−10.298
1.00
66.43
C


ATOM
4619
CG
TRP
H
50
−70.814
−3.413
−11.230
1.00
63.90
C


ATOM
4620
CD1
TRP
H
50
−70.646
−3.800
−12.527
1.00
62.55
C


ATOM
4621
NE1
TRP
H
50
−69.511
−3.235
−13.050
1.00
61.58
N


ATOM
4622
CE2
TRP
H
50
−68.897
−2.487
−12.073
1.00
62.09
C


ATOM
4623
CD2
TRP
H
50
−69.698
−2.580
−10.909
1.00
62.02
C


ATOM
4624
CE3
TRP
H
50
−69.267
−1.930
−9.734
1.00
61.51
C


ATOM
4625
CZ3
TRP
H
50
−68.091
−1.193
−9.768
1.00
59.88
C


ATOM
4626
CH2
TRP
H
50
−67.316
−1.118
−10.934
1.00
60.16
C


ATOM
4627
CZ2
TRP
H
50
−67.695
−1.755
−12.100
1.00
60.79
C


ATOM
4628
C
TRP
H
50
−70.229
−5.335
−9.111
1.00
67.37
C


ATOM
4629
O
TRP
H
50
−69.966
−5.052
−7.941
1.00
67.16
O


ATOM
4630
N
ILE
H
51
−69.307
−5.748
−9.997
1.00
65.38
N


ATOM
4631
CA
ILE
H
51
−67.901
−5.890
−9.687
1.00
66.71
C


ATOM
4632
CB
ILE
H
51
−67.561
−7.267
−9.077
1.00
66.78
C


ATOM
4633
CG1
ILE
H
51
−66.179
−7.234
−8.328
1.00
66.43
C


ATOM
4634
CD1
ILE
H
51
−65.274
−8.456
−8.481
1.00
64.32
C


ATOM
4635
CG2
ILE
H
51
−67.671
−8.400
−10.138
1.00
66.18
C


ATOM
4636
C
ILE
H
51
−67.044
−5.617
−10.913
1.00
67.98
C


ATOM
4637
O
ILE
H
51
−67.364
−6.085
−12.009
1.00
68.13
O


ATOM
4638
N
ASP
H
52
−65.936
−4.884
−10.726
1.00
73.76
N


ATOM
4639
CA
ASP
H
52
−65.022
−4.621
−11.812
1.00
75.48
C


ATOM
4640
CB
ASP
H
52
−64.515
−3.183
−11.781
1.00
75.68
C


ATOM
4641
CG
ASP
H
52
−63.282
−2.949
−12.637
1.00
77.20
C


ATOM
4642
OD1
ASP
H
52
−62.384
−2.192
−12.178
1.00
78.73
O


ATOM
4643
OD2
ASP
H
52
−63.202
−3.543
−13.781
1.00
76.29
O


ATOM
4644
C
ASP
H
52
−63.879
−5.644
−11.705
1.00
76.31
C


ATOM
4645
O
ASP
H
52
−63.042
−5.534
−10.801
1.00
76.43
O


ATOM
4646
N
PRO
H
53
−63.823
−6.653
−12.614
1.00
78.05
N


ATOM
4647
CA
PRO
H
53
−62.752
−7.660
−12.543
1.00
78.76
C


ATOM
4648
CB
PRO
H
53
−63.074
−8.626
−13.689
1.00
78.77
C


ATOM
4649
CG
PRO
H
53
−64.483
−8.421
−13.982
1.00
78.29
C


ATOM
4650
CD
PRO
H
53
−64.746
−6.957
−13.720
1.00
78.12
C


ATOM
4651
C
PRO
H
53
−61.357
−7.071
−12.678
1.00
79.46
C


ATOM
4652
O
PRO
H
53
−60.378
−7.777
−12.418
1.00
80.25
O


ATOM
4653
N
GLY
H
54
−61.281
−5.799
−13.079
1.00
78.39
N


ATOM
4654
CA
GLY
H
54
−60.023
−5.083
−13.210
1.00
78.15
C


ATOM
4655
C
GLY
H
54
−59.461
−4.803
−11.832
1.00
77.68
C


ATOM
4656
O
GLY
H
54
−58.483
−5.434
−11.420
1.00
77.62
O


ATOM
4657
N
SER
H
55
−60.121
−3.897
−11.099
1.00
77.03
N


ATOM
4658
CA
SER
H
55
−59.740
−3.476
−9.757
1.00
76.83
C


ATOM
4659
CB
SER
H
55
−60.242
−2.065
−9.479
1.00
76.80
C


ATOM
4660
OG
SER
H
55
−61.658
−1.999
−9.501
1.00
77.10
O


ATOM
4661
C
SER
H
55
−60.208
−4.397
−8.646
1.00
76.83
C


ATOM
4662
O
SER
H
55
−59.390
−4.929
−7.895
1.00
77.56
O


ATOM
4663
N
GLY
H
56
−61.515
−4.563
−8.547
1.00
75.37
N


ATOM
4664
CA
GLY
H
56
−62.203
−5.325
−7.517
1.00
74.42
C


ATOM
4665
C
GLY
H
56
−63.294
−4.422
−6.966
1.00
74.06
C


ATOM
4666
O
GLY
H
56
−63.938
−4.746
−5.961
1.00
73.96
O


ATOM
4667
N
GLY
H
57
−63.480
−3.279
−7.643
1.00
70.98
N


ATOM
4668
CA
GLY
H
57
−64.487
−2.277
−7.332
1.00
70.53
C


ATOM
4669
C
GLY
H
57
−65.847
−2.934
−7.303
1.00
70.34
C


ATOM
4670
O
GLY
H
57
−66.218
−3.660
−8.226
1.00
70.61
O


ATOM
4671
N
THR
H
58
−66.588
−2.704
−6.243
1.00
68.48
N


ATOM
4672
CA
THR
H
58
−67.841
−3.386
−6.090
1.00
67.80
C


ATOM
4673
CB
THR
H
58
−67.484
−4.512
−5.112
1.00
67.50
C


ATOM
4674
OG1
THR
H
58
−67.790
−5.788
−5.635
1.00
68.57
O


ATOM
4675
CG2
THR
H
58
−67.909
−4.281
−3.694
1.00
67.36
C


ATOM
4676
C
THR
H
58
−69.012
−2.480
−5.715
1.00
67.57
C


ATOM
4677
O
THR
H
58
−68.824
−1.568
−4.922
1.00
67.91
O


ATOM
4678
N
LYS
H
59
−70.215
−2.712
−6.273
1.00
66.54
N


ATOM
4679
CA
LYS
H
59
−71.445
−1.942
−5.922
1.00
66.37
C


ATOM
4680
CB
LYS
H
59
−71.880
−0.954
−7.023
1.00
65.94
C


ATOM
4681
CG
LYS
H
59
−70.839
0.083
−7.387
1.00
65.87
C


ATOM
4682
CD
LYS
H
59
−71.473
1.258
−8.101
1.00
65.73
C


ATOM
4683
CE
LYS
H
59
−70.641
1.831
−9.224
1.00
63.88
C


ATOM
4684
NZ
LYS
H
59
−71.283
1.617
−10.566
1.00
63.65
N


ATOM
4685
C
LYS
H
59
−72.578
−2.953
−5.633
1.00
66.37
C


ATOM
4686
O
LYS
H
59
−72.665
−3.953
−6.343
1.00
66.46
O


ATOM
4687
N
TYR
H
60
−73.409
−2.725
−4.601
1.00
65.94
N


ATOM
4688
CA
TYR
H
60
−74.512
−3.641
−4.260
1.00
66.27
C


ATOM
4689
CB
TYR
H
60
−74.252
−4.386
−2.949
1.00
65.68
C


ATOM
4690
CG
TYR
H
60
−72.987
−5.203
−2.907
1.00
65.72
C


ATOM
4691
CD1
TYR
H
60
−73.000
−6.567
−3.200
1.00
66.37
C


ATOM
4692
CE1
TYR
H
60
−71.828
−7.332
−3.145
1.00
66.03
C


ATOM
4693
CZ
TYR
H
60
−70.635
−6.732
−2.776
1.00
65.40
C


ATOM
4694
OH
TYR
H
60
−69.455
−7.428
−2.716
1.00
65.30
O


ATOM
4695
CE2
TYR
H
60
−70.618
−5.390
−2.444
1.00
65.92
C


ATOM
4696
CD2
TYR
H
60
−71.786
−4.635
−2.514
1.00
65.58
C


ATOM
4697
C
TYR
H
60
−75.861
−2.946
−4.124
1.00
66.96
C


ATOM
4698
O
TYR
H
60
−75.927
−1.776
−3.747
1.00
66.93
O


ATOM
4699
N
ASN
H
61
−76.945
−3.676
−4.408
1.00
74.07
N


ATOM
4700
CA
ASN
H
61
−78.296
−3.147
−4.254
1.00
75.29
C


ATOM
4701
CB
ASN
H
61
−79.308
−4.131
−4.838
1.00
75.03
C


ATOM
4702
CG
ASN
H
61
−80.745
−3.687
−4.798
1.00
75.28
C


ATOM
4703
OD1
ASN
H
61
−81.168
−2.881
−3.969
1.00
76.17
O


ATOM
4704
ND2
ASN
H
61
−81.556
−4.221
−5.695
1.00
75.49
N


ATOM
4705
C
ASN
H
61
−78.496
−2.964
−2.728
1.00
76.55
C


ATOM
4706
O
ASN
H
61
−78.137
−3.869
−1.957
1.00
76.87
O


ATOM
4707
N
GLU
H
62
−79.025
−1.791
−2.287
1.00
79.72
N


ATOM
4708
CA
GLU
H
62
−79.246
−1.525
−0.867
1.00
80.72
C


ATOM
4709
CB
GLU
H
62
−79.777
−0.116
−0.635
1.00
80.60
C


ATOM
4710
C
GLU
H
62
−80.103
−2.614
−0.172
1.00
81.74
C


ATOM
4711
O
GLU
H
62
−79.878
−2.866
1.017
1.00
82.04
O


ATOM
4712
N
LYS
H
63
−81.036
−3.298
−0.914
1.00
83.34
N


ATOM
4713
CA
LYS
H
63
−81.869
−4.389
−0.382
1.00
84.18
C


ATOM
4714
CB
LYS
H
63
−82.757
−5.008
−1.483
1.00
83.83
C


ATOM
4715
C
LYS
H
63
−80.984
−5.473
0.302
1.00
85.07
C


ATOM
4716
O
LYS
H
63
−81.297
−5.897
1.409
1.00
85.46
O


ATOM
4717
N
PHE
H
64
−79.859
−5.868
−0.328
1.00
87.41
N


ATOM
4718
CA
PHE
H
64
−78.931
−6.878
0.200
1.00
88.13
C


ATOM
4719
CB
PHE
H
64
−78.508
−7.839
−0.932
1.00
87.91
C


ATOM
4720
CG
PHE
H
64
−79.520
−8.037
−2.037
1.00
87.18
C


ATOM
4721
CD1
PHE
H
64
−79.311
−7.497
−3.295
1.00
86.67
C


ATOM
4722
CE1
PHE
H
64
−80.249
−7.678
−4.311
1.00
85.39
C


ATOM
4723
CZ
PHE
H
64
−81.392
−8.399
−4.074
1.00
84.32
C


ATOM
4724
CE2
PHE
H
64
−81.614
−8.940
−2.836
1.00
84.40
C


ATOM
4725
CD2
PHE
H
64
−80.684
−8.757
−1.817
1.00
85.74
C


ATOM
4726
C
PHE
H
64
−77.685
−6.241
0.902
1.00
89.03
C


ATOM
4727
O
PHE
H
64
−76.527
−6.644
0.650
1.00
89.44
O


ATOM
4728
N
LYS
H
65
−77.934
−5.234
1.784
1.00
91.91
N


ATOM
4729
CA
LYS
H
65
−76.890
−4.511
2.534
1.00
91.95
C


ATOM
4730
CB
LYS
H
65
−77.490
−3.335
3.342
1.00
92.18
C


ATOM
4731
C
LYS
H
65
−76.126
−5.469
3.448
1.00
91.81
C


ATOM
4732
O
LYS
H
65
−76.642
−5.894
4.490
1.00
91.86
O


ATOM
4733
N
GLY
H
66
−74.923
−5.832
3.012
1.00
91.10
N


ATOM
4734
CA
GLY
H
66
−74.065
−6.752
3.746
1.00
90.88
C


ATOM
4735
C
GLY
H
66
−74.492
−8.201
3.618
1.00
90.89
C


ATOM
4736
O
GLY
H
66
−73.743
−9.096
4.020
1.00
91.20
O


ATOM
4737
N
LYS
H
67
−75.705
−8.450
3.056
1.00
90.67
N


ATOM
4738
CA
LYS
H
67
−76.247
−9.793
2.832
1.00
90.02
C


ATOM
4739
CB
LYS
H
67
−77.753
−9.724
2.558
1.00
89.88
C


ATOM
4740
C
LYS
H
67
−75.497
−10.467
1.667
1.00
89.63
C


ATOM
4741
O
LYS
H
67
−75.191
−11.654
1.742
1.00
89.64
O


ATOM
4742
N
ALA
H
68
−75.170
−9.683
0.615
1.00
88.82
N


ATOM
4743
CA
ALA
H
68
−74.462
−10.118
−0.595
1.00
88.21
C


ATOM
4744
CB
ALA
H
68
−75.108
−9.486
−1.819
1.00
88.14
C


ATOM
4745
C
ALA
H
68
−72.935
−9.842
−0.588
1.00
87.72
C


ATOM
4746
O
ALA
H
68
−72.471
−8.920
0.093
1.00
88.14
O


ATOM
4747
N
THR
H
69
−72.163
−10.654
−1.350
1.00
84.50
N


ATOM
4748
CA
THR
H
69
−70.708
−10.544
−1.477
1.00
83.53
C


ATOM
4749
CB
THR
H
69
−69.985
−11.394
−0.401
1.00
83.59
C


ATOM
4750
OG1
THR
H
69
−70.545
−11.172
0.899
1.00
83.87
O


ATOM
4751
CG2
THR
H
69
−68.457
−11.205
−0.407
1.00
82.58
C


ATOM
4752
C
THR
H
69
−70.303
−11.027
−2.862
1.00
83.16
C


ATOM
4753
O
THR
H
69
−70.386
−12.231
−3.146
1.00
83.89
O


ATOM
4754
N
ILE
H
70
−69.850
−10.106
−3.719
1.00
77.88
N


ATOM
4755
CA
ILE
H
70
−69.410
−10.456
−5.071
1.00
76.85
C


ATOM
4756
CB
ILE
H
70
−70.094
−9.611
−6.180
1.00
76.87
C


ATOM
4757
CG1
ILE
H
70
−71.608
−9.667
−6.025
1.00
76.68
C


ATOM
4758
CD1
ILE
H
70
−72.269
−8.566
−6.573
1.00
76.66
C


ATOM
4759
CG2
ILE
H
70
−69.696
−10.099
−7.589
1.00
76.64
C


ATOM
4760
C
ILE
H
70
−67.894
−10.426
−5.147
1.00
76.29
C


ATOM
4761
O
ILE
H
70
−67.276
−9.485
−4.649
1.00
76.21
O


ATOM
4762
N
SER
H
71
−67.303
−11.463
−5.768
1.00
73.60
N


ATOM
4763
CA
SER
H
71
−65.858
−11.583
−5.946
1.00
73.32
C


ATOM
4764
CB
SER
H
71
−65.213
−12.345
−4.791
1.00
73.02
C


ATOM
4765
OG
SER
H
71
−65.483
−13.734
−4.787
1.00
72.63
O


ATOM
4766
C
SER
H
71
−65.472
−12.142
−7.311
1.00
73.44
C


ATOM
4767
O
SER
H
71
−66.354
−12.477
−8.098
1.00
73.35
O


ATOM
4768
N
ARG
H
72
−64.170
−12.201
−7.605
1.00
75.48
N


ATOM
4769
CA
ARG
H
72
−63.661
−12.700
−8.875
1.00
76.24
C


ATOM
4770
CB
ARG
H
72
−63.371
−11.515
−9.819
1.00
76.60
C


ATOM
4771
CG
ARG
H
72
−61.963
−10.932
−9.644
1.00
78.47
C


ATOM
4772
CD
ARG
H
72
−61.921
−9.442
−9.758
1.00
82.25
C


ATOM
4773
NE
ARG
H
72
−61.252
−8.815
−8.620
1.00
83.67
N


ATOM
4774
CZ
ARG
H
72
−60.030
−8.300
−8.661
1.00
84.64
C


ATOM
4775
NH1
ARG
H
72
−59.317
−8.353
−9.783
1.00
85.32
N


ATOM
4776
NH2
ARG
H
72
−59.506
−7.731
−7.582
1.00
85.79
N


ATOM
4777
C
ARG
H
72
−62.388
−13.538
−8.670
1.00
76.09
C


ATOM
4778
O
ARG
H
72
−61.857
−13.605
−7.562
1.00
76.37
O


ATOM
4779
N
ASP
H
73
−61.883
−14.140
−9.747
1.00
77.73
N


ATOM
4780
CA
ASP
H
73
−60.662
−14.929
−9.737
1.00
77.99
C


ATOM
4781
CB
ASP
H
73
−60.971
−16.362
−9.276
1.00
78.21
C


ATOM
4782
CG
ASP
H
73
−59.812
−17.175
−8.705
1.00
78.48
C


ATOM
4783
OD1
ASP
H
73
−58.651
−16.988
−9.181
1.00
76.53
O


ATOM
4784
OD2
ASP
H
73
−60.075
−18.043
−7.806
1.00
80.10
O


ATOM
4785
C
ASP
H
73
−60.098
−14.881
−11.160
1.00
78.17
C


ATOM
4786
O
ASP
H
73
−60.113
−15.882
−11.877
1.00
77.98
O


ATOM
4787
N
ASN
H
74
−59.616
−13.692
−11.568
1.00
77.75
N


ATOM
4788
CA
ASN
H
74
−59.066
−13.424
−12.893
1.00
77.93
C


ATOM
4789
CB
ASN
H
74
−58.226
−12.155
−12.872
1.00
78.15
C


ATOM
4790
CG
ASN
H
74
−59.031
−10.887
−12.827
1.00
79.65
C


ATOM
4791
OD1
ASN
H
74
−59.705
−10.592
−11.843
1.00
81.86
O


ATOM
4792
ND2
ASN
H
74
−58.965
−10.105
−13.894
1.00
80.65
N


ATOM
4793
C
ASN
H
74
−58.281
−14.578
−13.525
1.00
77.75
C


ATOM
4794
O
ASN
H
74
−58.295
−14.729
−14.753
1.00
77.58
O


ATOM
4795
N
SER
H
75
−57.597
−15.383
−12.681
1.00
77.01
N


ATOM
4796
CA
SER
H
75
−56.783
−16.530
−13.091
1.00
76.66
C


ATOM
4797
CB
SER
H
75
−55.966
−17.040
−11.919
1.00
76.52
C


ATOM
4798
OG
SER
H
75
−56.841
−17.302
−10.835
1.00
77.70
O


ATOM
4799
C
SER
H
75
−57.635
−17.658
−13.638
1.00
76.26
C


ATOM
4800
O
SER
H
75
−57.148
−18.418
−14.476
1.00
76.65
O


ATOM
4801
N
LYS
H
76
−58.892
−17.778
−13.161
1.00
73.56
N


ATOM
4802
CA
LYS
H
76
−59.837
−18.808
−13.593
1.00
72.90
C


ATOM
4803
CB
LYS
H
76
−60.073
−19.891
−12.521
1.00
72.97
C


ATOM
4804
CG
LYS
H
76
−60.109
−19.394
−11.094
1.00
73.34
C


ATOM
4805
CD
LYS
H
76
−60.812
−20.371
−10.118
1.00
74.83
C


ATOM
4806
CE
LYS
H
76
−59.884
−21.119
−9.187
1.00
75.51
C


ATOM
4807
NZ
LYS
H
76
−59.171
−22.235
−9.885
1.00
76.07
N


ATOM
4808
C
LYS
H
76
−61.131
−18.218
−14.154
1.00
72.42
C


ATOM
4809
O
LYS
H
76
−62.174
−18.882
−14.187
1.00
72.36
O


ATOM
4810
N
ASN
H
77
−61.053
−16.942
−14.599
1.00
72.21
N


ATOM
4811
CA
ASN
H
77
−62.142
−16.171
−15.213
1.00
71.28
C


ATOM
4812
CB
ASN
H
77
−62.280
−16.601
−16.669
1.00
70.88
C


ATOM
4813
CG
ASN
H
77
−61.140
−16.232
−17.561
1.00
70.31
C


ATOM
4814
OD1
ASN
H
77
−61.354
−15.894
−18.724
1.00
70.39
O


ATOM
4815
ND2
ASN
H
77
−59.916
−16.293
−17.071
1.00
70.87
N


ATOM
4816
C
ASN
H
77
−63.491
−16.338
−14.497
1.00
71.06
C


ATOM
4817
O
ASN
H
77
−64.552
−16.213
−15.119
1.00
71.17
O


ATOM
4818
N
THR
H
78
−63.457
−16.641
−13.209
1.00
67.84
N


ATOM
4819
CA
THR
H
78
−64.706
−16.851
−12.516
1.00
67.61
C


ATOM
4820
CB
THR
H
78
−64.782
−18.234
−11.818
1.00
67.66
C


ATOM
4821
OG1
THR
H
78
−63.489
−18.573
−11.370
1.00
68.59
O


ATOM
4822
CG2
THR
H
78
−65.170
−19.328
−12.744
1.00
67.39
C


ATOM
4823
C
THR
H
78
−65.160
−15.666
−11.724
1.00
67.05
C


ATOM
4824
O
THR
H
78
−64.359
−14.867
−11.264
1.00
66.86
O


ATOM
4825
N
LEU
H
79
−66.455
−15.564
−11.581
1.00
65.03
N


ATOM
4826
CA
LEU
H
79
−67.135
−14.527
−10.853
1.00
64.84
C


ATOM
4827
CB
LEU
H
79
−68.018
−13.799
−11.856
1.00
64.81
C


ATOM
4828
CG
LEU
H
79
−68.966
−12.782
−11.324
1.00
65.04
C


ATOM
4829
CD1
LEU
H
79
−68.254
−11.520
−11.026
1.00
66.20
C


ATOM
4830
CD2
LEU
H
79
−70.119
−12.567
−12.297
1.00
64.91
C


ATOM
4831
C
LEU
H
79
−67.964
−15.271
−9.823
1.00
65.02
C


ATOM
4832
O
LEU
H
79
−68.577
−16.281
−10.162
1.00
65.22
O


ATOM
4833
N
TYR
H
80
−67.953
−14.829
−8.568
1.00
64.32
N


ATOM
4834
CA
TYR
H
80
−68.694
−15.535
−7.532
1.00
64.62
C


ATOM
4835
CB
TYR
H
80
−67.752
−16.122
−6.458
1.00
64.08
C


ATOM
4836
CG
TYR
H
80
−66.626
−17.007
−6.950
1.00
64.44
C


ATOM
4837
CD1
TYR
H
80
−65.364
−16.481
−7.220
1.00
64.70
C


ATOM
4838
CE1
TYR
H
80
−64.320
−17.289
−7.668
1.00
64.48
C


ATOM
4839
CZ
TYR
H
80
−64.520
−18.650
−7.812
1.00
65.60
C


ATOM
4840
OH
TYR
H
80
−63.491
−19.448
−8.253
1.00
66.92
O


ATOM
4841
CE2
TYR
H
80
−65.758
−19.203
−7.516
1.00
65.49
C


ATOM
4842
CD2
TYR
H
80
−66.802
−18.380
−7.093
1.00
64.95
C


ATOM
4843
C
TYR
H
80
−69.660
−14.609
−6.841
1.00
65.53
C


ATOM
4844
O
TYR
H
80
−69.348
−13.437
−6.613
1.00
65.93
O


ATOM
4845
N
LEU
H
81
−70.823
−15.144
−6.473
1.00
68.48
N


ATOM
4846
CA
LEU
H
81
−71.832
−14.431
−5.709
1.00
69.08
C


ATOM
4847
CB
LEU
H
81
−73.130
−14.187
−6.522
1.00
68.98
C


ATOM
4848
CG
LEU
H
81
−74.458
−13.954
−5.745
1.00
68.46
C


ATOM
4849
CD1
LEU
H
81
−74.497
−12.601
−5.103
1.00
67.63
C


ATOM
4850
CD2
LEU
H
81
−75.635
−14.096
−6.645
1.00
68.63
C


ATOM
4851
C
LEU
H
81
−72.114
−15.283
−4.473
1.00
69.89
C


ATOM
4852
O
LEU
H
81
−72.090
−16.521
−4.544
1.00
69.50
O


ATOM
4853
N
GLN
H
82
−72.370
−14.604
−3.347
1.00
77.02
N


ATOM
4854
CA
GLN
H
82
−72.741
−15.211
−2.086
1.00
78.47
C


ATOM
4855
CB
GLN
H
82
−71.554
−15.328
−1.145
1.00
78.56
C


ATOM
4856
CG
GLN
H
82
−71.958
−16.041
0.147
1.00
81.03
C


ATOM
4857
CD
GLN
H
82
−70.901
−16.019
1.216
1.00
83.34
C


ATOM
4858
OE1
GLN
H
82
−70.408
−17.081
1.631
1.00
84.08
O


ATOM
4859
NE2
GLN
H
82
−70.538
−14.812
1.684
1.00
84.60
N


ATOM
4860
C
GLN
H
82
−73.840
−14.384
−1.440
1.00
79.23
C


ATOM
4861
O
GLN
H
82
−73.697
−13.170
−1.306
1.00
79.44
O


ATOM
4862
N
MET
H
83
−74.924
−15.037
−1.039
1.00
79.50
N


ATOM
4863
CA
MET
H
83
−76.023
−14.364
−0.377
1.00
80.56
C


ATOM
4864
CB
MET
H
83
−77.223
−14.186
−1.301
1.00
80.59
C


ATOM
4865
CG
MET
H
83
−77.063
−13.048
−2.260
1.00
81.48
C


ATOM
4866
SD
MET
H
83
−78.606
−12.506
−3.041
1.00
83.98
S


ATOM
4867
CE
MET
H
83
−79.683
−12.206
−1.544
1.00
82.79
C


ATOM
4868
C
MET
H
83
−76.373
−15.165
0.842
1.00
81.17
C


ATOM
4869
O
MET
H
83
−76.792
−16.308
0.725
1.00
81.21
O


ATOM
4870
N
ASN
H
84
−76.171
−14.561
2.014
1.00
83.17
N


ATOM
4871
CA
ASN
H
84
−76.391
−15.144
3.332
1.00
84.11
C


ATOM
4872
CB
ASN
H
84
−75.286
−14.659
4.258
1.00
84.31
C


ATOM
4873
CG
ASN
H
84
−73.927
−14.697
3.596
1.00
85.99
C


ATOM
4874
OD1
ASN
H
84
−73.459
−15.742
3.103
1.00
87.19
O


ATOM
4875
ND2
ASN
H
84
−73.261
−13.545
3.552
1.00
88.48
N


ATOM
4876
C
ASN
H
84
−77.774
−14.819
3.899
1.00
84.38
C


ATOM
4877
O
ASN
H
84
−78.430
−13.895
3.412
1.00
84.40
O


ATOM
4878
N
SER
H
85
−78.219
−15.591
4.922
1.00
86.21
N


ATOM
4879
CA
SER
H
85
−79.510
−15.426
5.625
1.00
86.62
C


ATOM
4880
CB
SER
H
85
−79.454
−14.250
6.608
1.00
86.59
C


ATOM
4881
OG
SER
H
85
−78.255
−14.235
7.371
1.00
87.47
O


ATOM
4882
C
SER
H
85
−80.736
−15.325
4.686
1.00
86.64
C


ATOM
4883
O
SER
H
85
−81.513
−14.367
4.769
1.00
86.92
O


ATOM
4884
N
LEU
H
86
−80.904
−16.326
3.804
1.00
83.88
N


ATOM
4885
CA
LEU
H
86
−81.992
−16.360
2.828
1.00
83.85
C


ATOM
4886
CB
LEU
H
86
−81.655
−17.283
1.646
1.00
83.52
C


ATOM
4887
CG
LEU
H
86
−80.321
−17.018
0.942
1.00
82.64
C


ATOM
4888
CD1
LEU
H
86
−79.953
−18.143
0.069
1.00
80.79
C


ATOM
4889
CD2
LEU
H
86
−80.341
−15.740
0.154
1.00
82.74
C


ATOM
4890
C
LEU
H
86
−83.391
−16.631
3.388
1.00
84.25
C


ATOM
4891
O
LEU
H
86
−83.540
−17.250
4.432
1.00
84.08
O


ATOM
4892
N
ARG
H
87
−84.408
−16.117
2.692
1.00
87.49
N


ATOM
4893
CA
ARG
H
87
−85.833
−16.239
2.996
1.00
87.95
C


ATOM
4894
CB
ARG
H
87
−86.424
−14.875
3.359
1.00
88.25
C


ATOM
4895
CG
ARG
H
87
−85.590
−14.081
4.356
1.00
90.00
C


ATOM
4896
CD
ARG
H
87
−86.349
−12.904
4.913
1.00
93.13
C


ATOM
4897
NE
ARG
H
87
−86.517
−11.838
3.924
1.00
95.49
N


ATOM
4898
CZ
ARG
H
87
−86.363
−10.540
4.182
1.00
97.17
C


ATOM
4899
NH1
ARG
H
87
−86.542
−9.639
3.220
1.00
97.17
N


ATOM
4900
NH2
ARG
H
87
−86.028
−10.132
5.406
1.00
98.62
N


ATOM
4901
C
ARG
H
87
−86.476
−16.753
1.724
1.00
87.88
C


ATOM
4902
O
ARG
H
87
−85.829
−16.724
0.680
1.00
88.02
O


ATOM
4903
N
ALA
H
88
−87.727
−17.223
1.777
1.00
89.65
N


ATOM
4904
CA
ALA
H
88
−88.388
−17.752
0.580
1.00
89.55
C


ATOM
4905
CB
ALA
H
88
−89.723
−18.371
0.940
1.00
89.60
C


ATOM
4906
C
ALA
H
88
−88.531
−16.737
−0.573
1.00
89.59
C


ATOM
4907
O
ALA
H
88
−88.712
−17.146
−1.719
1.00
89.56
O


ATOM
4908
N
GLU
H
89
−88.407
−15.422
−0.274
1.00
92.07
N


ATOM
4909
CA
GLU
H
89
−88.474
−14.325
−1.253
1.00
91.99
C


ATOM
4910
CB
GLU
H
89
−88.520
−12.960
−0.564
1.00
92.37
C


ATOM
4911
CG
GLU
H
89
−89.657
−12.783
0.418
1.00
95.67
C


ATOM
4912
CD
GLU
H
89
−89.184
−12.521
1.834
1.00
100.06
C


ATOM
4913
OE1
GLU
H
89
−89.344
−13.430
2.688
1.00
101.77
O


ATOM
4914
OE2
GLU
H
89
−88.648
−11.411
2.085
1.00
101.51
O


ATOM
4915
C
GLU
H
89
−87.246
−14.337
−2.146
1.00
91.13
C


ATOM
4916
O
GLU
H
89
−87.320
−13.892
−3.296
1.00
91.47
O


ATOM
4917
N
ASP
H
90
−86.105
−14.827
−1.614
1.00
88.34
N


ATOM
4918
CA
ASP
H
90
−84.853
−14.908
−2.353
1.00
86.96
C


ATOM
4919
CB
ASP
H
90
−83.650
−14.902
−1.408
1.00
87.15
C


ATOM
4920
CG
ASP
H
90
−83.592
−13.651
−0.532
1.00
88.39
C


ATOM
4921
OD1
ASP
H
90
−83.867
−12.532
−1.056
1.00
89.29
O


ATOM
4922
OD2
ASP
H
90
−83.279
−13.783
0.679
1.00
90.20
O


ATOM
4923
C
ASP
H
90
−84.831
−16.019
−3.410
1.00
85.83
C


ATOM
4924
O
ASP
H
90
−83.819
−16.208
−4.082
1.00
85.71
O


ATOM
4925
N
THR
H
91
−85.976
−16.717
−3.596
1.00
81.43
N


ATOM
4926
CA
THR
H
91
−86.138
−17.750
−4.618
1.00
79.99
C


ATOM
4927
CB
THR
H
91
−87.349
−18.647
−4.339
1.00
80.13
C


ATOM
4928
OG1
THR
H
91
−87.316
−19.113
−2.991
1.00
80.98
O


ATOM
4929
CG2
THR
H
91
−87.457
−19.804
−5.322
1.00
78.80
C


ATOM
4930
C
THR
H
91
−86.352
−17.032
−5.938
1.00
78.71
C


ATOM
4931
O
THR
H
91
−87.298
−16.237
−6.059
1.00
78.84
O


ATOM
4932
N
ALA
H
92
−85.475
−17.309
−6.914
1.00
73.98
N


ATOM
4933
CA
ALA
H
92
−85.505
−16.731
−8.254
1.00
72.60
C


ATOM
4934
CB
ALA
H
92
−85.247
−15.231
−8.182
1.00
72.66
C


ATOM
4935
C
ALA
H
92
−84.441
−17.367
−9.120
1.00
71.70
C


ATOM
4936
O
ALA
H
92
−83.702
−18.250
−8.682
1.00
72.05
O


ATOM
4937
N
VAL
H
93
−84.360
−16.903
−10.361
1.00
68.26
N


ATOM
4938
CA
VAL
H
93
−83.351
−17.341
−11.306
1.00
66.99
C


ATOM
4939
CB
VAL
H
93
−83.925
−17.581
−12.704
1.00
66.60
C


ATOM
4940
CG1
VAL
H
93
−82.815
−17.806
−13.705
1.00
66.29
C


ATOM
4941
CG2
VAL
H
93
−84.839
−18.779
−12.672
1.00
65.83
C


ATOM
4942
C
VAL
H
93
−82.247
−16.264
−11.243
1.00
66.74
C


ATOM
4943
O
VAL
H
93
−82.529
−15.062
−11.295
1.00
66.88
O


ATOM
4944
N
TYR
H
94
−81.015
−16.707
−11.080
1.00
65.99
N


ATOM
4945
CA
TYR
H
94
−79.873
−15.853
−10.929
1.00
64.93
C


ATOM
4946
CB
TYR
H
94
−79.072
−16.318
−9.710
1.00
65.01
C


ATOM
4947
CG
TYR
H
94
−79.755
−15.960
−8.407
1.00
65.23
C


ATOM
4948
CD1
TYR
H
94
−79.333
−14.870
−7.655
1.00
64.68
C


ATOM
4949
CE1
TYR
H
94
−79.985
−14.506
−6.480
1.00
64.28
C


ATOM
4950
CZ
TYR
H
94
−81.081
−15.233
−6.046
1.00
64.51
C


ATOM
4951
OH
TYR
H
94
−81.723
−14.863
−4.893
1.00
65.03
O


ATOM
4952
CE2
TYR
H
94
−81.526
−16.321
−6.779
1.00
64.86
C


ATOM
4953
CD2
TYR
H
94
−80.859
−16.683
−7.948
1.00
65.33
C


ATOM
4954
C
TYR
H
94
−79.051
−15.838
−12.178
1.00
64.74
C


ATOM
4955
O
TYR
H
94
−78.686
−16.889
−12.708
1.00
64.40
O


ATOM
4956
N
TYR
H
95
−78.764
−14.622
−12.658
1.00
63.64
N


ATOM
4957
CA
TYR
H
95
−77.994
−14.382
−13.859
1.00
63.12
C


ATOM
4958
CB
TYR
H
95
−78.812
−13.503
−14.829
1.00
62.92
C


ATOM
4959
CG
TYR
H
95
−80.064
−14.156
−15.365
1.00
61.93
C


ATOM
4960
CD1
TYR
H
95
−80.006
−15.057
−16.429
1.00
61.03
C


ATOM
4961
CE1
TYR
H
95
−81.152
−15.685
−16.905
1.00
61.11
C


ATOM
4962
CZ
TYR
H
95
−82.384
−15.383
−16.346
1.00
61.42
C


ATOM
4963
OH
TYR
H
95
−83.528
−15.996
−16.814
1.00
61.35
O


ATOM
4964
CE2
TYR
H
95
−82.467
−14.466
−15.309
1.00
60.44
C


ATOM
4965
CD2
TYR
H
95
−81.309
−13.863
−14.824
1.00
60.20
C


ATOM
4966
C
TYR
H
95
−76.738
−13.643
−13.582
1.00
63.30
C


ATOM
4967
O
TYR
H
95
−76.719
−12.802
−12.701
1.00
63.44
O


ATOM
4968
N
CYS
H
96
−75.701
−13.910
−14.359
1.00
67.44
N


ATOM
4969
CA
CYS
H
96
−74.483
−13.120
−14.364
1.00
68.48
C


ATOM
4970
CB
CYS
H
96
−73.190
−13.894
−14.097
1.00
68.59
C


ATOM
4971
SG
CYS
H
96
−72.852
−15.230
−15.268
1.00
73.30
S


ATOM
4972
C
CYS
H
96
−74.556
−12.530
−15.791
1.00
68.14
C


ATOM
4973
O
CYS
H
96
−75.032
−13.201
−16.720
1.00
68.02
O


ATOM
4974
N
ALA
H
97
−74.221
−11.241
−15.927
1.00
67.03
N


ATOM
4975
CA
ALA
H
97
−74.282
−10.541
−17.191
1.00
66.44
C


ATOM
4976
CB
ALA
H
97
−75.520
−9.668
−17.251
1.00
66.41
C


ATOM
4977
C
ALA
H
97
−73.063
−9.706
−17.338
1.00
66.28
C


ATOM
4978
O
ALA
H
97
−72.676
−8.995
−16.413
1.00
66.42
O


ATOM
4979
N
ARG
H
98
−72.447
−9.788
−18.500
1.00
65.71
N


ATOM
4980
CA
ARG
H
98
−71.268
−9.014
−18.822
1.00
65.78
C


ATOM
4981
CB
ARG
H
98
−70.573
−9.689
−19.983
1.00
65.49
C


ATOM
4982
CG
ARG
H
98
−69.167
−9.269
−20.286
1.00
62.95
C


ATOM
4983
CD
ARG
H
98
−69.244
−9.112
−21.758
1.00
60.25
C


ATOM
4984
NE
ARG
H
98
−68.042
−9.526
−22.443
1.00
59.34
N


ATOM
4985
CZ
ARG
H
98
−67.847
−9.378
−23.752
1.00
59.47
C


ATOM
4986
NH1
ARG
H
98
−68.779
−8.817
−24.511
1.00
57.40
N


ATOM
4987
NH2
ARG
H
98
−66.713
−9.776
−24.306
1.00
59.29
N


ATOM
4988
C
ARG
H
98
−71.754
−7.628
−19.209
1.00
66.54
C


ATOM
4989
O
ARG
H
98
−72.796
−7.506
−19.850
1.00
66.86
O


ATOM
4990
N
GLU
H
99
−71.022
−6.582
−18.789
1.00
70.53
N


ATOM
4991
CA
GLU
H
99
−71.356
−5.177
−19.043
1.00
71.00
C


ATOM
4992
CB
GLU
H
99
−71.418
−4.405
−17.703
1.00
70.96
C


ATOM
4993
CG
GLU
H
99
−71.527
−2.885
−17.795
1.00
72.27
C


ATOM
4994
CD
GLU
H
99
−71.137
−2.115
−16.540
1.00
74.67
C


ATOM
4995
OE1
GLU
H
99
−71.774
−1.072
−16.248
1.00
75.05
O


ATOM
4996
OE2
GLU
H
99
−70.195
−2.560
−15.841
1.00
75.63
O


ATOM
4997
C
GLU
H
99
−70.333
−4.548
−19.946
1.00
71.25
C


ATOM
4998
O
GLU
H
99
−69.143
−4.641
−19.659
1.00
71.38
O


ATOM
4999
N
ARG
H
100
−70.792
−3.911
−21.039
1.00
72.41
N


ATOM
5000
CA
ARG
H
100
−69.919
−3.163
−21.943
1.00
72.84
C


ATOM
5001
CB
ARG
H
100
−70.354
−3.224
−23.414
1.00
72.83
C


ATOM
5002
CG
ARG
H
100
−69.329
−2.517
−24.278
1.00
72.50
C


ATOM
5003
CD
ARG
H
100
−69.664
−2.380
−25.740
1.00
72.55
C


ATOM
5004
NE
ARG
H
100
−68.761
−1.403
−26.352
1.00
73.88
N


ATOM
5005
CZ
ARG
H
100
−68.848
−0.952
−27.601
1.00
74.27
C


ATOM
5006
NH1
ARG
H
100
−69.805
−1.397
−28.413
1.00
73.63
N


ATOM
5007
NH2
ARG
H
100
−67.977
−0.057
−28.049
1.00
74.01
N


ATOM
5008
C
ARG
H
100
−70.093
−1.768
−21.397
1.00
73.26
C


ATOM
5009
O
ARG
H
100
−71.149
−1.165
−21.573
1.00
73.35
O


ATOM
5010
N
TYR
H
101
−69.107
−1.285
−20.662
1.00
75.23
N


ATOM
5011
CA
TYR
H
101
−69.181
0.023
−20.022
1.00
75.75
C


ATOM
5012
CB
TYR
H
101
−67.837
0.402
−19.426
1.00
76.28
C


ATOM
5013
CG
TYR
H
101
−67.339
−0.535
−18.344
1.00
79.85
C


ATOM
5014
CD1
TYR
H
101
−66.172
−1.282
−18.522
1.00
82.83
C


ATOM
5015
CE1
TYR
H
101
−65.661
−2.084
−17.502
1.00
84.43
C


ATOM
5016
CZ
TYR
H
101
−66.329
−2.162
−16.288
1.00
85.43
C


ATOM
5017
OH
TYR
H
101
−65.820
−2.948
−15.284
1.00
86.44
O


ATOM
5018
CE2
TYR
H
101
−67.496
−1.437
−16.089
1.00
84.58
C


ATOM
5019
CD2
TYR
H
101
−67.992
−0.626
−17.113
1.00
82.47
C


ATOM
5020
C
TYR
H
101
−69.764
1.160
−20.866
1.00
74.82
C


ATOM
5021
O
TYR
H
101
−69.277
1.443
−21.961
1.00
74.74
O


ATOM
5022
N
GLY
H
102
−70.823
1.772
−20.346
1.00
71.45
N


ATOM
5023
CA
GLY
H
102
−71.510
2.890
−20.985
1.00
70.66
C


ATOM
5024
C
GLY
H
102
−72.424
2.481
−22.117
1.00
70.17
C


ATOM
5025
O
GLY
H
102
−73.112
3.327
−22.700
1.00
70.31
O


ATOM
5026
N
TYR
H
103
−72.451
1.166
−22.417
1.00
67.53
N


ATOM
5027
CA
TYR
H
103
−73.238
0.609
−23.497
1.00
66.65
C


ATOM
5028
CB
TYR
H
103
−72.334
−0.117
−24.495
1.00
66.73
C


ATOM
5029
CG
TYR
H
103
−71.616
0.826
−25.428
1.00
67.87
C


ATOM
5030
CD1
TYR
H
103
−72.107
1.082
−26.705
1.00
68.67
C


ATOM
5031
CE1
TYR
H
103
−71.450
1.956
−27.571
1.00
67.79
C


ATOM
5032
CZ
TYR
H
103
−70.303
2.604
−27.151
1.00
67.83
C


ATOM
5033
OH
TYR
H
103
−69.666
3.479
−27.994
1.00
69.69
O


ATOM
5034
CE2
TYR
H
103
−69.808
2.381
−25.877
1.00
67.02
C


ATOM
5035
CD2
TYR
H
103
−70.454
1.481
−25.032
1.00
67.47
C


ATOM
5036
C
TYR
H
103
−74.426
−0.225
−23.116
1.00
65.83
C


ATOM
5037
O
TYR
H
103
−75.530
0.291
−23.102
1.00
65.67
O


ATOM
5038
N
TYR
H
104
−74.219
−1.512
−22.833
1.00
63.53
N


ATOM
5039
CA
TYR
H
104
−75.274
−2.500
−22.568
1.00
62.64
C


ATOM
5040
CB
TYR
H
104
−75.902
−2.908
−23.950
1.00
62.17
C


ATOM
5041
CG
TYR
H
104
−74.866
−3.054
−25.055
1.00
61.14
C


ATOM
5042
CD1
TYR
H
104
−73.904
−4.065
−25.013
1.00
61.33
C


ATOM
5043
CE1
TYR
H
104
−72.921
−4.175
−25.999
1.00
60.48
C


ATOM
5044
CZ
TYR
H
104
−72.888
−3.265
−27.041
1.00
58.82
C


ATOM
5045
OH
TYR
H
104
−71.911
−3.370
−28.007
1.00
56.93
O


ATOM
5046
CE2
TYR
H
104
−73.833
−2.249
−27.097
1.00
59.35
C


ATOM
5047
CD2
TYR
H
104
−74.813
−2.153
−26.109
1.00
60.02
C


ATOM
5048
C
TYR
H
104
−74.712
−3.786
−21.964
1.00
62.35
C


ATOM
5049
O
TYR
H
104
−73.491
−3.944
−21.821
1.00
62.32
O


ATOM
5050
N
PHE
H
105
−75.626
−4.738
−21.697
1.00
60.95
N


ATOM
5051
CA
PHE
H
105
−75.321
−6.081
−21.233
1.00
60.08
C


ATOM
5052
CB
PHE
H
105
−76.422
−6.581
−20.308
1.00
59.40
C


ATOM
5053
CG
PHE
H
105
−76.500
−5.899
−18.968
1.00
58.42
C


ATOM
5054
CD1
PHE
H
105
−77.665
−5.252
−18.564
1.00
56.91
C


ATOM
5055
CE1
PHE
H
105
−77.752
−4.655
−17.301
1.00
56.33
C


ATOM
5056
CZ
PHE
H
105
−76.677
−4.698
−16.441
1.00
56.75
C


ATOM
5057
CE2
PHE
H
105
−75.519
−5.337
−16.822
1.00
57.86
C


ATOM
5058
CD2
PHE
H
105
−75.432
−5.951
−18.079
1.00
57.85
C


ATOM
5059
C
PHE
H
105
−75.312
−6.912
−22.504
1.00
60.10
C


ATOM
5060
O
PHE
H
105
−76.378
−7.137
−23.084
1.00
60.18
O


ATOM
5061
N
ASP
H
106
−74.139
−7.310
−22.982
1.00
62.16
N


ATOM
5062
CA
ASP
H
106
−74.102
−8.089
−24.215
1.00
63.03
C


ATOM
5063
CB
ASP
H
106
−72.863
−7.804
−25.072
1.00
63.28
C


ATOM
5064
CG
ASP
H
106
−71.598
−7.570
−24.296
1.00
65.40
C


ATOM
5065
OD1
ASP
H
106
−71.564
−7.925
−23.086
1.00
67.53
O


ATOM
5066
OD2
ASP
H
106
−70.634
−7.024
−24.887
1.00
66.52
O


ATOM
5067
C
ASP
H
106
−74.312
−9.586
−24.020
1.00
63.00
C


ATOM
5068
O
ASP
H
106
−75.097
−10.196
−24.752
1.00
63.66
O


ATOM
5069
N
TYR
H
107
−73.647
−10.168
−23.027
1.00
62.37
N


ATOM
5070
CA
TYR
H
107
−73.737
−11.583
−22.724
1.00
62.23
C


ATOM
5071
CB
TYR
H
107
−72.371
−12.194
−22.904
1.00
62.04
C


ATOM
5072
CG
TYR
H
107
−71.963
−12.148
−24.360
1.00
61.88
C


ATOM
5073
CD1
TYR
H
107
−72.543
−13.003
−25.290
1.00
61.17
C


ATOM
5074
CE1
TYR
H
107
−72.181
−12.969
−26.629
1.00
61.06
C


ATOM
5075
CZ
TYR
H
107
−71.227
−12.071
−27.061
1.00
61.23
C


ATOM
5076
OH
TYR
H
107
−70.917
−12.079
−28.399
1.00
61.91
O


ATOM
5077
CE2
TYR
H
107
−70.647
−11.186
−26.160
1.00
61.81
C


ATOM
5078
CD2
TYR
H
107
−71.025
−11.223
−24.818
1.00
62.31
C


ATOM
5079
C
TYR
H
107
−74.322
−11.875
−21.359
1.00
62.66
C


ATOM
5080
O
TYR
H
107
−74.063
−11.130
−20.410
1.00
62.89
O


ATOM
5081
N
TRP
H
108
−75.144
−12.946
−21.268
1.00
63.37
N


ATOM
5082
CA
TRP
H
108
−75.808
−13.377
−20.032
1.00
63.55
C


ATOM
5083
CB
TRP
H
108
−77.321
−13.169
−20.130
1.00
63.40
C


ATOM
5084
CG
TRP
H
108
−77.792
−11.753
−20.274
1.00
63.22
C


ATOM
5085
CD1
TRP
H
108
−77.723
−10.970
−21.390
1.00
63.42
C


ATOM
5086
NE1
TRP
H
108
−78.324
−9.757
−21.155
1.00
63.16
N


ATOM
5087
CE2
TRP
H
108
−78.811
−9.742
−19.873
1.00
61.71
C


ATOM
5088
CD2
TRP
H
108
−78.521
−10.999
−19.298
1.00
62.25
C


ATOM
5089
CE3
TRP
H
108
−78.912
−11.245
−17.974
1.00
61.41
C


ATOM
5090
CZ3
TRP
H
108
−79.556
−10.244
−17.279
1.00
62.45
C


ATOM
5091
CH2
TRP
H
108
−79.838
−9.007
−17.880
1.00
61.71
C


ATOM
5092
CZ2
TRP
H
108
−79.478
−8.738
−19.173
1.00
60.73
C


ATOM
5093
C
TRP
H
108
−75.560
−14.857
−19.782
1.00
64.14
C


ATOM
5094
O
TRP
H
108
−75.353
−15.610
−20.730
1.00
64.01
O


ATOM
5095
N
GLY
H
109
−75.600
−15.271
−18.519
1.00
66.93
N


ATOM
5096
CA
GLY
H
109
−75.436
−16.674
−18.144
1.00
67.80
C


ATOM
5097
C
GLY
H
109
−76.725
−17.385
−18.497
1.00
68.72
C


ATOM
5098
O
GLY
H
109
−77.722
−16.721
−18.806
1.00
68.99
O


ATOM
5099
N
GLN
H
110
−76.726
−18.726
−18.483
1.00
71.11
N


ATOM
5100
CA
GLN
H
110
−77.903
−19.541
−18.838
1.00
71.79
C


ATOM
5101
CB
GLN
H
110
−77.539
−21.035
−18.947
1.00
72.34
C


ATOM
5102
CG
GLN
H
110
−77.089
−21.720
−17.625
1.00
75.60
C


ATOM
5103
CD
GLN
H
110
−75.597
−21.586
−17.254
1.00
80.03
C


ATOM
5104
OE1
GLN
H
110
−74.927
−20.544
−17.468
1.00
81.28
O


ATOM
5105
NE2
GLN
H
110
−75.050
−22.650
−16.662
1.00
80.71
N


ATOM
5106
C
GLN
H
110
−79.129
−19.331
−17.951
1.00
71.61
C


ATOM
5107
O
GLN
H
110
−80.256
−19.487
−18.415
1.00
71.64
O


ATOM
5108
N
GLY
H
111
−78.888
−18.964
−16.700
1.00
69.26
N


ATOM
5109
CA
GLY
H
111
−79.910
−18.755
−15.687
1.00
69.55
C


ATOM
5110
C
GLY
H
111
−79.862
−19.902
−14.703
1.00
69.85
C


ATOM
5111
O
GLY
H
111
−80.013
−21.050
−15.114
1.00
70.20
O


ATOM
5112
N
THR
H
112
−79.605
−19.619
−13.410
1.00
67.06
N


ATOM
5113
CA
THR
H
112
−79.543
−20.649
−12.355
1.00
66.93
C


ATOM
5114
CB
THR
H
112
−78.146
−20.856
−11.717
1.00
66.96
C


ATOM
5115
OG1
THR
H
112
−77.302
−19.782
−12.092
1.00
68.20
O


ATOM
5116
CG2
THR
H
112
−77.479
−22.189
−12.133
1.00
67.65
C


ATOM
5117
C
THR
H
112
−80.638
−20.458
−11.341
1.00
66.57
C


ATOM
5118
O
THR
H
112
−80.784
−19.391
−10.759
1.00
66.47
O


ATOM
5119
N
LEU
H
113
−81.422
−21.502
−11.140
1.00
66.57
N


ATOM
5120
CA
LEU
H
113
−82.509
−21.442
−10.191
1.00
66.09
C


ATOM
5121
CB
LEU
H
113
−83.640
−22.395
−10.589
1.00
65.95
C


ATOM
5122
CG
LEU
H
113
−84.753
−22.495
−9.569
1.00
66.57
C


ATOM
5123
CD1
LEU
H
113
−85.585
−21.204
−9.506
1.00
65.93
C


ATOM
5124
CD2
LEU
H
113
−85.578
−23.706
−9.806
1.00
67.95
C


ATOM
5125
C
LEU
H
113
−82.033
−21.766
−8.794
1.00
65.67
C


ATOM
5126
O
LEU
H
113
−81.336
−22.771
−8.593
1.00
65.82
O


ATOM
5127
N
VAL
H
114
−82.422
−20.921
−7.836
1.00
62.65
N


ATOM
5128
CA
VAL
H
114
−82.107
−21.118
−6.438
1.00
62.66
C


ATOM
5129
CB
VAL
H
114
−81.151
−20.031
−5.865
1.00
62.38
C


ATOM
5130
CG1
VAL
H
114
−81.011
−20.153
−4.352
1.00
61.88
C


ATOM
5131
CG2
VAL
H
114
−79.779
−20.090
−6.514
1.00
62.63
C


ATOM
5132
C
VAL
H
114
−83.477
−21.141
−5.743
1.00
63.09
C


ATOM
5133
O
VAL
H
114
−84.211
−20.145
−5.793
1.00
62.87
O


ATOM
5134
N
THR
H
115
−83.835
−22.298
−5.138
1.00
66.30
N


ATOM
5135
CA
THR
H
115
−85.096
−22.454
−4.406
1.00
66.71
C


ATOM
5136
CB
THR
H
115
−86.002
−23.586
−4.957
1.00
66.71
C


ATOM
5137
OG1
THR
H
115
−86.136
−23.455
−6.375
1.00
65.99
O


ATOM
5138
CG2
THR
H
115
−87.399
−23.542
−4.358
1.00
66.36
C


ATOM
5139
C
THR
H
115
−84.799
−22.474
−2.911
1.00
67.37
C


ATOM
5140
O
THR
H
115
−83.917
−23.222
−2.441
1.00
67.19
O


ATOM
5141
N
VAL
H
116
−85.518
−21.615
−2.178
1.00
70.14
N


ATOM
5142
CA
VAL
H
116
−85.344
−21.459
−0.735
1.00
71.22
C


ATOM
5143
CB
VAL
H
116
−85.010
−19.986
−0.351
1.00
71.13
C


ATOM
5144
CG1
VAL
H
116
−83.751
−19.498
−1.085
1.00
71.19
C


ATOM
5145
CG2
VAL
H
116
−84.834
−19.835
1.150
1.00
71.12
C


ATOM
5146
C
VAL
H
116
−86.503
−22.093
0.058
1.00
71.93
C


ATOM
5147
O
VAL
H
116
−87.568
−21.501
0.188
1.00
72.15
O


ATOM
5148
N
SER
H
117
−86.281
−23.311
0.571
1.00
75.85
N


ATOM
5149
CA
SER
H
117
−87.269
−24.072
1.325
1.00
76.81
C


ATOM
5150
CB
SER
H
117
−88.179
−24.851
0.378
1.00
76.95
C


ATOM
5151
OG
SER
H
117
−89.002
−25.799
1.043
1.00
77.25
O


ATOM
5152
C
SER
H
117
−86.648
−25.048
2.307
1.00
77.41
C


ATOM
5153
O
SER
H
117
−85.645
−25.715
2.005
1.00
77.73
O


ATOM
5154
N
SER
H
118
−87.311
−25.159
3.476
1.00
79.00
N


ATOM
5155
CA
SER
H
118
−86.988
−26.050
4.599
1.00
79.39
C


ATOM
5156
CB
SER
H
118
−87.461
−25.432
5.911
1.00
79.16
C


ATOM
5157
OG
SER
H
118
−88.754
−24.877
5.731
1.00
80.04
O


ATOM
5158
C
SER
H
118
−87.660
−27.426
4.387
1.00
79.64
C


ATOM
5159
O
SER
H
118
−87.480
−28.330
5.218
1.00
80.15
O


ATOM
5160
N
ALA
H
119
−88.417
−27.587
3.266
1.00
73.07
N


ATOM
5161
CA
ALA
H
119
−89.074
−28.836
2.926
1.00
72.98
C


ATOM
5162
CB
ALA
H
119
−90.050
−28.632
1.784
1.00
73.09
C


ATOM
5163
C
ALA
H
119
−88.066
−29.956
2.607
1.00
73.10
C


ATOM
5164
O
ALA
H
119
−86.893
−29.696
2.305
1.00
72.72
O


ATOM
5165
N
SER
H
120
−88.550
−31.209
2.716
1.00
72.01
N


ATOM
5166
CA
SER
H
120
−87.807
−32.453
2.522
1.00
72.04
C


ATOM
5167
CB
SER
H
120
−87.893
−33.299
3.782
1.00
71.83
C


ATOM
5168
OG
SER
H
120
−87.997
−32.449
4.913
1.00
72.64
O


ATOM
5169
C
SER
H
120
−88.343
−33.239
1.343
1.00
72.00
C


ATOM
5170
O
SER
H
120
−89.547
−33.176
1.060
1.00
71.77
O


ATOM
5171
N
THR
H
121
−87.434
−33.976
0.654
1.00
70.38
N


ATOM
5172
CA
THR
H
121
−87.764
−34.779
−0.515
1.00
70.68
C


ATOM
5173
CB
THR
H
121
−86.523
−35.458
−1.138
1.00
70.30
C


ATOM
5174
OG1
THR
H
121
−85.504
−34.491
−1.375
1.00
69.93
O


ATOM
5175
CG2
THR
H
121
−86.829
−36.146
−2.451
1.00
69.49
C


ATOM
5176
C
THR
H
121
−88.901
−35.717
−0.151
1.00
71.62
C


ATOM
5177
O
THR
H
121
−88.827
−36.431
0.851
1.00
72.00
O


ATOM
5178
N
LYS
H
122
−89.972
−35.653
−0.936
1.00
72.71
N


ATOM
5179
CA
LYS
H
122
−91.168
−36.441
−0.774
1.00
73.30
C


ATOM
5180
CB
LYS
H
122
−92.131
−35.708
0.189
1.00
73.06
C


ATOM
5181
CG
LYS
H
122
−93.643
−35.827
−0.089
1.00
73.63
C


ATOM
5182
CD
LYS
H
122
−94.355
−36.996
0.603
1.00
73.39
C


ATOM
5183
CE
LYS
H
122
−95.860
−36.793
0.652
1.00
73.30
C


ATOM
5184
NZ
LYS
H
122
−96.591
−37.550
−0.418
1.00
74.03
N


ATOM
5185
C
LYS
H
122
−91.754
−36.731
−2.177
1.00
74.13
C


ATOM
5186
O
LYS
H
122
−91.985
−35.802
−2.956
1.00
74.29
O


ATOM
5187
N
GLY
H
123
−91.933
−38.022
−2.490
1.00
76.46
N


ATOM
5188
CA
GLY
H
123
−92.503
−38.498
−3.745
1.00
77.46
C


ATOM
5189
C
GLY
H
123
−93.959
−38.081
−3.787
1.00
78.54
C


ATOM
5190
O
GLY
H
123
−94.538
−37.830
−2.723
1.00
78.57
O


ATOM
5191
N
PRO
H
124
−94.605
−37.960
−4.972
1.00
80.93
N


ATOM
5192
CA
PRO
H
124
−96.000
−37.518
−4.987
1.00
81.90
C


ATOM
5193
CB
PRO
H
124
−96.172
−37.027
−6.418
1.00
81.54
C


ATOM
5194
CG
PRO
H
124
−95.326
−37.916
−7.208
1.00
80.73
C


ATOM
5195
CD
PRO
H
124
−94.124
−38.210
−6.346
1.00
80.84
C


ATOM
5196
C
PRO
H
124
−97.007
−38.620
−4.701
1.00
83.35
C


ATOM
5197
O
PRO
H
124
−96.687
−39.819
−4.762
1.00
83.63
O


ATOM
5198
N
SER
H
125
−98.240
−38.183
−4.426
1.00
86.85
N


ATOM
5199
CA
SER
H
125
−99.417
−39.010
−4.201
1.00
88.24
C


ATOM
5200
CB
SER
H
125
−100.136
−38.587
−2.915
1.00
88.05
C


ATOM
5201
OG
SER
H
125
−99.245
−38.444
−1.816
1.00
88.30
O


ATOM
5202
C
SER
H
125
−100.277
−38.707
−5.446
1.00
89.31
C


ATOM
5203
O
SER
H
125
−100.723
−37.571
−5.615
1.00
89.76
O


ATOM
5204
N
VAL
H
126
−100.456
−39.694
−6.343
1.00
90.66
N


ATOM
5205
CA
VAL
H
126
−101.241
−39.522
−7.578
1.00
91.88
C


ATOM
5206
CB
VAL
H
126
−100.536
−40.090
−8.832
1.00
91.55
C


ATOM
5207
CG1
VAL
H
126
−101.344
−39.818
−10.089
1.00
91.30
C


ATOM
5208
CG2
VAL
H
126
−99.146
−39.507
−8.971
1.00
91.37
C


ATOM
5209
C
VAL
H
126
−102.703
−39.986
−7.448
1.00
93.21
C


ATOM
5210
O
VAL
H
126
−102.989
−41.177
−7.310
1.00
93.26
O


ATOM
5211
N
PHE
H
127
−103.619
−39.023
−7.514
1.00
97.08
N


ATOM
5212
CA
PHE
H
127
−105.053
−39.266
−7.430
1.00
98.63
C


ATOM
5213
CB
PHE
H
127
−105.664
−38.352
−6.381
1.00
98.32
C


ATOM
5214
CG
PHE
H
127
−105.044
−38.479
−5.018
1.00
98.24
C


ATOM
5215
CD1
PHE
H
127
−104.950
−39.715
−4.392
1.00
97.94
C


ATOM
5216
CE1
PHE
H
127
−104.411
−39.829
−3.112
1.00
98.10
C


ATOM
5217
CZ
PHE
H
127
−103.972
−38.708
−2.451
1.00
98.37
C


ATOM
5218
CE2
PHE
H
127
−104.059
−37.473
−3.056
1.00
98.37
C


ATOM
5219
CD2
PHE
H
127
−104.590
−37.361
−4.340
1.00
97.97
C


ATOM
5220
C
PHE
H
127
−105.733
−39.022
−8.783
1.00
100.17
C


ATOM
5221
O
PHE
H
127
−105.388
−38.041
−9.446
1.00
100.19
O


ATOM
5222
N
PRO
H
128
−106.701
−39.871
−9.224
1.00
105.15
N


ATOM
5223
CA
PRO
H
128
−107.348
−39.619
−10.525
1.00
106.35
C


ATOM
5224
CB
PRO
H
128
−108.033
−40.949
−10.828
1.00
106.09
C


ATOM
5225
CG
PRO
H
128
−108.388
−41.479
−9.482
1.00
105.49
C


ATOM
5226
CD
PRO
H
128
−107.246
−41.088
−8.584
1.00
105.11
C


ATOM
5227
C
PRO
H
128
−108.372
−38.485
−10.473
1.00
107.79
C


ATOM
5228
O
PRO
H
128
−108.853
−38.108
−9.396
1.00
108.04
O


ATOM
5229
N
LEU
H
129
−108.703
−37.948
−11.649
1.00
110.12
N


ATOM
5230
CA
LEU
H
129
−109.708
−36.904
−11.827
1.00
111.66
C


ATOM
5231
CB
LEU
H
129
−109.089
−35.597
−12.368
1.00
111.44
C


ATOM
5232
CG
LEU
H
129
−108.038
−34.916
−11.497
1.00
110.89
C


ATOM
5233
CD1
LEU
H
129
−107.266
−33.891
−12.296
1.00
110.21
C


ATOM
5234
CD2
LEU
H
129
−108.651
−34.321
−10.217
1.00
109.59
C


ATOM
5235
C
LEU
H
129
−110.686
−37.551
−12.809
1.00
112.94
C


ATOM
5236
O
LEU
H
129
−110.593
−37.359
−14.028
1.00
113.16
O


ATOM
5237
N
ALA
H
130
−111.573
−38.399
−12.242
1.00
116.25
N


ATOM
5238
CA
ALA
H
130
−112.592
−39.223
−12.898
1.00
117.58
C


ATOM
5239
CB
ALA
H
130
−113.404
−39.975
−11.851
1.00
117.55
C


ATOM
5240
C
ALA
H
130
−113.530
−38.511
−13.889
1.00
118.57
C


ATOM
5241
O
ALA
H
130
−114.213
−37.554
−13.498
1.00
118.42
O


ATOM
5242
N
PRO
H
131
−113.593
−38.985
−15.168
1.00
122.13
N


ATOM
5243
CA
PRO
H
131
−114.505
−38.351
−16.137
1.00
123.31
C


ATOM
5244
CB
PRO
H
131
−114.164
−39.038
−17.468
1.00
123.07
C


ATOM
5245
CG
PRO
H
131
−113.532
−40.323
−17.098
1.00
122.46
C


ATOM
5246
CD
PRO
H
131
−112.864
−40.124
−15.769
1.00
122.18
C


ATOM
5247
C
PRO
H
131
−115.957
−38.570
−15.707
1.00
124.68
C


ATOM
5248
O
PRO
H
131
−116.427
−39.716
−15.642
1.00
125.03
O


ATOM
5249
N
SER
H
132
−116.648
−37.466
−15.356
1.00
128.46
N


ATOM
5250
CA
SER
H
132
−118.036
−37.475
−14.896
1.00
129.79
C


ATOM
5251
CB
SER
H
132
−118.581
−36.055
−14.767
1.00
129.75
C


ATOM
5252
OG
SER
H
132
−118.974
−35.502
−16.015
1.00
129.83
O


ATOM
5253
C
SER
H
132
−118.948
−38.294
−15.792
1.00
130.80
C


ATOM
5254
O
SER
H
132
−118.817
−38.263
−17.026
1.00
130.81
O


ATOM
5255
N
SER
H
133
−119.871
−39.028
−15.145
1.00
135.47
N


ATOM
5256
CA
SER
H
133
−120.893
−39.875
−15.765
1.00
136.57
C


ATOM
5257
CB
SER
H
133
−121.600
−40.707
−14.693
1.00
136.61
C


ATOM
5258
OG
SER
H
133
−120.690
−41.259
−13.752
1.00
136.55
O


ATOM
5259
C
SER
H
133
−121.896
−38.958
−16.527
1.00
137.33
C


ATOM
5260
O
SER
H
133
−122.243
−39.245
−17.680
1.00
137.30
O


ATOM
5261
N
ALA
H
134
−122.313
−37.834
−15.873
1.00
140.39
N


ATOM
5262
CA
ALA
H
134
−123.211
−36.795
−16.395
1.00
141.31
C


ATOM
5263
CB
ALA
H
134
−123.830
−36.020
−15.237
1.00
141.10
C


ATOM
5264
C
ALA
H
134
−122.409
−35.838
−17.305
1.00
142.01
C


ATOM
5265
O
ALA
H
134
−121.176
−35.913
−17.327
1.00
142.33
O


ATOM
5266
N
SER
H
135
−123.104
−34.956
−18.069
1.00
145.31
N


ATOM
5267
CA
SER
H
135
−122.515
−33.965
−18.999
1.00
145.93
C


ATOM
5268
CB
SER
H
135
−121.745
−32.877
−18.238
1.00
145.96
C


ATOM
5269
OG
SER
H
135
−121.187
−31.874
−19.076
1.00
146.36
O


ATOM
5270
C
SER
H
135
−121.673
−34.557
−20.168
1.00
146.25
C


ATOM
5271
O
SER
H
135
−121.344
−33.818
−21.109
1.00
146.30
O


ATOM
5272
N
THR
H
136
−121.350
−35.883
−20.106
1.00
147.23
N


ATOM
5273
CA
THR
H
136
−120.552
−36.654
−21.078
1.00
147.51
C


ATOM
5274
CB
THR
H
136
−120.503
−38.158
−20.698
1.00
147.62
C


ATOM
5275
OG1
THR
H
136
−119.503
−38.812
−21.484
1.00
147.69
O


ATOM
5276
CG2
THR
H
136
−121.855
−38.872
−20.851
1.00
147.57
C


ATOM
5277
C
THR
H
136
−120.818
−36.342
−22.577
1.00
147.51
C


ATOM
5278
O
THR
H
136
−119.865
−36.256
−23.367
1.00
147.44
O


ATOM
5279
N
SER
H
137
−122.115
−36.144
−22.939
1.00
146.29
N


ATOM
5280
CA
SER
H
137
−122.646
−35.828
−24.276
1.00
146.19
C


ATOM
5281
CB
SER
H
137
−122.269
−34.406
−24.720
1.00
146.28
C


ATOM
5282
OG
SER
H
137
−120.871
−34.156
−24.769
1.00
146.61
O


ATOM
5283
C
SER
H
137
−122.398
−36.918
−25.353
1.00
145.85
C


ATOM
5284
O
SER
H
137
−122.723
−38.090
−25.127
1.00
145.77
O


ATOM
5285
N
GLY
H
138
−121.852
−36.505
−26.498
1.00
144.07
N


ATOM
5286
CA
GLY
H
138
−121.516
−37.350
−27.641
1.00
143.40
C


ATOM
5287
C
GLY
H
138
−120.173
−36.970
−28.240
1.00
142.93
C


ATOM
5288
O
GLY
H
138
−119.533
−37.782
−28.923
1.00
142.93
O


ATOM
5289
N
GLY
H
139
−119.759
−35.729
−27.966
1.00
140.56
N


ATOM
5290
CA
GLY
H
139
−118.500
−35.162
−28.426
1.00
139.72
C


ATOM
5291
C
GLY
H
139
−117.340
−35.626
−27.576
1.00
139.13
C


ATOM
5292
O
GLY
H
139
−117.018
−36.819
−27.566
1.00
139.16
O


ATOM
5293
N
THR
H
140
−116.719
−34.680
−26.844
1.00
135.91
N


ATOM
5294
CA
THR
H
140
−115.571
−34.936
−25.964
1.00
134.98
C


ATOM
5295
CB
THR
H
140
−114.324
−34.106
−26.390
1.00
135.14
C


ATOM
5296
OG1
THR
H
140
−114.688
−32.735
−26.576
1.00
134.94
O


ATOM
5297
CG2
THR
H
140
−113.635
−34.656
−27.649
1.00
134.96
C


ATOM
5298
C
THR
H
140
−115.892
−34.858
−24.455
1.00
134.14
C


ATOM
5299
O
THR
H
140
−116.939
−34.337
−24.050
1.00
134.03
O


ATOM
5300
N
ALA
H
141
−114.969
−35.393
−23.638
1.00
130.14
N


ATOM
5301
CA
ALA
H
141
−115.025
−35.437
−22.178
1.00
128.96
C


ATOM
5302
CB
ALA
H
141
−115.462
−36.821
−21.724
1.00
129.08
C


ATOM
5303
C
ALA
H
141
−113.639
−35.110
−21.603
1.00
128.00
C


ATOM
5304
O
ALA
H
141
−112.625
−35.341
−22.273
1.00
127.86
O


ATOM
5305
N
ALA
H
142
−113.592
−34.570
−20.370
1.00
124.07
N


ATOM
5306
CA
ALA
H
142
−112.317
−34.238
−19.735
1.00
122.79
C


ATOM
5307
CB
ALA
H
142
−112.213
−32.751
−19.459
1.00
122.91
C


ATOM
5308
C
ALA
H
142
−112.031
−35.037
−18.471
1.00
121.84
C


ATOM
5309
O
ALA
H
142
−112.859
−35.113
−17.563
1.00
121.72
O


ATOM
5310
N
LEU
H
143
−110.845
−35.643
−18.440
1.00
118.17
N


ATOM
5311
CA
LEU
H
143
−110.325
−36.452
−17.342
1.00
116.96
C


ATOM
5312
CB
LEU
H
143
−110.519
−37.958
−17.618
1.00
116.97
C


ATOM
5313
CG
LEU
H
143
−109.759
−38.579
−18.793
1.00
117.14
C


ATOM
5314
CD1
LEU
H
143
−108.530
−39.301
−18.321
1.00
117.80
C


ATOM
5315
CD2
LEU
H
143
−110.608
−39.563
−19.497
1.00
117.95
C


ATOM
5316
C
LEU
H
143
−108.845
−36.130
−17.138
1.00
115.95
C


ATOM
5317
O
LEU
H
143
−108.161
−35.694
−18.073
1.00
115.91
O


ATOM
5318
N
GLY
H
144
−108.362
−36.374
−15.933
1.00
112.56
N


ATOM
5319
CA
GLY
H
144
−106.967
−36.137
−15.605
1.00
110.59
C


ATOM
5320
C
GLY
H
144
−106.543
−36.856
−14.352
1.00
109.20
C


ATOM
5321
O
GLY
H
144
−107.200
−37.808
−13.928
1.00
109.35
O


ATOM
5322
N
CYS
H
145
−105.433
−36.418
−13.762
1.00
104.64
N


ATOM
5323
CA
CYS
H
145
−104.937
−36.963
−12.503
1.00
102.92
C


ATOM
5324
CB
CYS
H
145
−104.190
−38.296
−12.643
1.00
102.96
C


ATOM
5325
SG
CYS
H
145
−102.651
−38.216
−13.596
1.00
103.88
S


ATOM
5326
C
CYS
H
145
−104.155
−35.917
−11.747
1.00
101.35
C


ATOM
5327
O
CYS
H
145
−103.278
−35.281
−12.320
1.00
100.90
O


ATOM
5328
N
LEU
H
146
−104.545
−35.685
−10.484
1.00
97.25
N


ATOM
5329
CA
LEU
H
146
−103.920
−34.733
−9.570
1.00
95.86
C


ATOM
5330
CB
LEU
H
146
−104.934
−34.217
−8.530
1.00
95.89
C


ATOM
5331
CG
LEU
H
146
−104.393
−33.386
−7.349
1.00
96.05
C


ATOM
5332
CD1
LEU
H
146
−103.887
−32.001
−7.806
1.00
97.22
C


ATOM
5333
CD2
LEU
H
146
−105.440
−33.233
−6.263
1.00
95.05
C


ATOM
5334
C
LEU
H
146
−102.705
−35.392
−8.879
1.00
94.95
C


ATOM
5335
O
LEU
H
146
−102.849
−36.416
−8.189
1.00
94.83
O


ATOM
5336
N
VAL
H
147
−101.509
−34.790
−9.092
1.00
91.45
N


ATOM
5337
CA
VAL
H
147
−100.210
−35.192
−8.550
1.00
89.84
C


ATOM
5338
CB
VAL
H
147
−99.138
−35.042
−9.638
1.00
89.60
C


ATOM
5339
CG1
VAL
H
147
−97.805
−35.572
−9.154
1.00
90.04
C


ATOM
5340
CG2
VAL
H
147
−99.556
−35.762
−10.904
1.00
88.81
C


ATOM
5341
C
VAL
H
147
−100.003
−34.275
−7.337
1.00
89.01
C


ATOM
5342
O
VAL
H
147
−99.572
−33.133
−7.472
1.00
88.83
O


ATOM
5343
N
LYS
H
148
−100.400
−34.759
−6.162
1.00
88.49
N


ATOM
5344
CA
LYS
H
148
−100.378
−33.988
−4.925
1.00
87.97
C


ATOM
5345
CB
LYS
H
148
−101.753
−34.128
−4.213
1.00
87.92
C


ATOM
5346
CG
LYS
H
148
−102.260
−32.874
−3.503
1.00
87.57
C


ATOM
5347
CD
LYS
H
148
−102.671
−33.147
−2.062
1.00
87.09
C


ATOM
5348
CE
LYS
H
148
−103.187
−31.899
−1.371
1.00
87.40
C


ATOM
5349
NZ
LYS
H
148
−103.089
−31.965
0.119
1.00
87.10
N


ATOM
5350
C
LYS
H
148
−99.254
−34.345
−3.964
1.00
87.69
C


ATOM
5351
O
LYS
H
148
−98.770
−35.482
−3.947
1.00
87.61
O


ATOM
5352
N
ASP
H
149
−98.870
−33.353
−3.140
1.00
87.66
N


ATOM
5353
CA
ASP
H
149
−97.877
−33.460
−2.087
1.00
87.23
C


ATOM
5354
CB
ASP
H
149
−98.495
−34.184
−0.875
1.00
87.43
C


ATOM
5355
CG
ASP
H
149
−99.611
−33.408
−0.191
1.00
88.64
C


ATOM
5356
OD1
ASP
H
149
−99.662
−32.147
−0.356
1.00
89.99
O


ATOM
5357
OD2
ASP
H
149
−100.428
−34.047
0.524
1.00
89.69
O


ATOM
5358
C
ASP
H
149
−96.559
−34.084
−2.510
1.00
86.55
C


ATOM
5359
O
ASP
H
149
−96.368
−35.292
−2.350
1.00
86.72
O


ATOM
5360
N
TYR
H
150
−95.665
−33.256
−3.087
1.00
82.33
N


ATOM
5361
CA
TYR
H
150
−94.323
−33.634
−3.552
1.00
81.28
C


ATOM
5362
CB
TYR
H
150
−94.313
−34.227
−4.996
1.00
80.95
C


ATOM
5363
CG
TYR
H
150
−94.522
−33.233
−6.118
1.00
79.79
C


ATOM
5364
CD1
TYR
H
150
−93.468
−32.449
−6.590
1.00
79.35
C


ATOM
5365
CE1
TYR
H
150
−93.659
−31.499
−7.595
1.00
78.26
C


ATOM
5366
CZ
TYR
H
150
−94.914
−31.342
−8.160
1.00
77.80
C


ATOM
5367
OH
TYR
H
150
−95.084
−30.431
−9.178
1.00
76.14
O


ATOM
5368
CE2
TYR
H
150
−95.971
−32.137
−7.729
1.00
78.33
C


ATOM
5369
CD2
TYR
H
150
−95.768
−33.077
−6.714
1.00
78.62
C


ATOM
5370
C
TYR
H
150
−93.338
−32.481
−3.397
1.00
81.02
C


ATOM
5371
O
TYR
H
150
−93.745
−31.318
−3.379
1.00
80.65
O


ATOM
5372
N
PHE
H
151
−92.041
−32.808
−3.298
1.00
80.24
N


ATOM
5373
CA
PHE
H
151
−90.930
−31.858
−3.173
1.00
80.24
C


ATOM
5374
CB
PHE
H
151
−90.891
−31.234
−1.772
1.00
80.03
C


ATOM
5375
CG
PHE
H
151
−89.858
−30.152
−1.607
1.00
79.36
C


ATOM
5376
CD1
PHE
H
151
−88.574
−30.455
−1.154
1.00
78.48
C


ATOM
5377
CE1
PHE
H
151
−87.613
−29.455
−1.002
1.00
77.04
C


ATOM
5378
CZ
PHE
H
151
−87.935
−28.147
−1.286
1.00
76.80
C


ATOM
5379
CE2
PHE
H
151
−89.205
−27.825
−1.724
1.00
77.16
C


ATOM
5380
CD2
PHE
H
151
−90.163
−28.830
−1.896
1.00
77.48
C


ATOM
5381
C
PHE
H
151
−89.630
−32.607
−3.477
1.00
80.47
C


ATOM
5382
O
PHE
H
151
−89.544
−33.745
−3.037
1.00
80.63
O


ATOM
5383
N
PRO
H
152
−88.606
−32.081
−4.209
1.00
83.43
N


ATOM
5384
CA
PRO
H
152
−88.427
−30.756
−4.834
1.00
83.19
C


ATOM
5385
CB
PRO
H
152
−86.933
−30.718
−5.186
1.00
83.10
C


ATOM
5386
CG
PRO
H
152
−86.322
−31.871
−4.473
1.00
83.56
C


ATOM
5387
CD
PRO
H
152
−87.398
−32.888
−4.413
1.00
83.45
C


ATOM
5388
C
PRO
H
152
−89.355
−30.408
−5.988
1.00
83.21
C


ATOM
5389
O
PRO
H
152
−90.542
−30.634
−5.855
1.00
83.44
O


ATOM
5390
N
GLU
H
153
−88.869
−29.838
−7.092
1.00
85.80
N


ATOM
5391
CA
GLU
H
153
−89.855
−29.416
−8.056
1.00
85.87
C


ATOM
5392
CB
GLU
H
153
−89.952
−27.900
−8.138
1.00
85.58
C


ATOM
5393
CG
GLU
H
153
−91.374
−27.408
−7.948
1.00
85.41
C


ATOM
5394
CD
GLU
H
153
−92.111
−26.963
−9.195
1.00
85.00
C


ATOM
5395
OE1
GLU
H
153
−92.597
−27.837
−9.955
1.00
84.39
O


ATOM
5396
OE2
GLU
H
153
−92.222
−25.729
−9.398
1.00
84.81
O


ATOM
5397
C
GLU
H
153
−90.029
−30.019
−9.406
1.00
86.38
C


ATOM
5398
O
GLU
H
153
−91.154
−29.908
−9.891
1.00
87.16
O


ATOM
5399
N
PRO
H
154
−89.067
−30.641
−10.075
1.00
82.97
N


ATOM
5400
CA
PRO
H
154
−89.363
−31.178
−11.422
1.00
82.81
C


ATOM
5401
CB
PRO
H
154
−88.144
−31.998
−11.761
1.00
82.87
C


ATOM
5402
CG
PRO
H
154
−87.059
−31.343
−10.977
1.00
83.12
C


ATOM
5403
CD
PRO
H
154
−87.664
−30.849
−9.699
1.00
82.87
C


ATOM
5404
C
PRO
H
154
−90.708
−31.866
−11.752
1.00
82.98
C


ATOM
5405
O
PRO
H
154
−91.522
−31.184
−12.391
1.00
83.54
O


ATOM
5406
N
VAL
H
155
−90.973
−33.154
−11.339
1.00
80.51
N


ATOM
5407
CA
VAL
H
155
−92.198
−33.952
−11.670
1.00
80.32
C


ATOM
5408
CB
VAL
H
155
−93.380
−33.981
−10.663
1.00
80.32
C


ATOM
5409
CG1
VAL
H
155
−94.519
−33.072
−11.087
1.00
80.02
C


ATOM
5410
CG2
VAL
H
155
−93.909
−35.403
−10.518
1.00
81.10
C


ATOM
5411
C
VAL
H
155
−92.678
−33.935
−13.151
1.00
80.22
C


ATOM
5412
O
VAL
H
155
−93.103
−32.900
−13.645
1.00
80.15
O


ATOM
5413
N
THR
H
156
−92.635
−35.088
−13.837
1.00
82.36
N


ATOM
5414
CA
THR
H
156
−93.051
−35.181
−15.241
1.00
82.95
C


ATOM
5415
CB
THR
H
156
−91.871
−35.400
−16.183
1.00
82.72
C


ATOM
5416
OG1
THR
H
156
−91.085
−36.512
−15.749
1.00
83.41
O


ATOM
5417
CG2
THR
H
156
−91.007
−34.163
−16.312
1.00
83.21
C


ATOM
5418
C
THR
H
156
−94.217
−36.094
−15.553
1.00
83.35
C


ATOM
5419
O
THR
H
156
−94.100
−37.315
−15.448
1.00
83.44
O


ATOM
5420
N
VAL
H
157
−95.335
−35.494
−15.987
1.00
84.88
N


ATOM
5421
CA
VAL
H
157
−96.543
−36.220
−16.367
1.00
85.29
C


ATOM
5422
CB
VAL
H
157
−97.852
−35.527
−15.929
1.00
85.05
C


ATOM
5423
CG1
VAL
H
157
−99.047
−36.460
−16.116
1.00
85.24
C


ATOM
5424
CG2
VAL
H
157
−97.766
−35.038
−14.485
1.00
85.07
C


ATOM
5425
C
VAL
H
157
−96.560
−36.494
−17.862
1.00
85.97
C


ATOM
5426
O
VAL
H
157
−96.249
−35.624
−18.682
1.00
86.10
O


ATOM
5427
N
SER
H
158
−96.942
−37.713
−18.198
1.00
88.64
N


ATOM
5428
CA
SER
H
158
−97.084
−38.197
−19.559
1.00
89.64
C


ATOM
5429
CB
SER
H
158
−95.836
−38.971
−19.993
1.00
89.51
C


ATOM
5430
OG
SER
H
158
−96.025
−40.372
−20.126
1.00
88.95
O


ATOM
5431
C
SER
H
158
−98.323
−39.091
−19.553
1.00
90.56
C


ATOM
5432
O
SER
H
158
−98.538
−39.794
−18.561
1.00
90.78
O


ATOM
5433
N
TRP
H
159
−99.144
−39.060
−20.633
1.00
92.59
N


ATOM
5434
CA
TRP
H
159
−100.333
−39.907
−20.723
1.00
92.98
C


ATOM
5435
CB
TRP
H
159
−101.561
−39.104
−21.090
1.00
92.58
C


ATOM
5436
CG
TRP
H
159
−102.045
−38.260
−19.953
1.00
91.88
C


ATOM
5437
CD1
TRP
H
159
−101.611
−37.013
−19.616
1.00
91.55
C


ATOM
5438
NE1
TRP
H
159
−102.312
−36.542
−18.527
1.00
91.01
N


ATOM
5439
CE2
TRP
H
159
−103.198
−37.503
−18.119
1.00
90.69
C


ATOM
5440
CD2
TRP
H
159
−103.060
−38.602
−18.998
1.00
91.08
C


ATOM
5441
CE3
TRP
H
159
−103.876
−39.729
−18.805
1.00
90.75
C


ATOM
5442
CZ3
TRP
H
159
−104.781
−39.726
−17.754
1.00
91.05
C


ATOM
5443
CH2
TRP
H
159
−104.885
−38.627
−16.889
1.00
91.05
C


ATOM
5444
CZ2
TRP
H
159
−104.101
−37.505
−17.052
1.00
90.75
C


ATOM
5445
C
TRP
H
159
−100.114
−41.115
−21.635
1.00
93.84
C


ATOM
5446
O
TRP
H
159
−99.360
−41.028
−22.620
1.00
93.86
O


ATOM
5447
N
ASN
H
160
−100.749
−42.254
−21.261
1.00
97.57
N


ATOM
5448
CA
ASN
H
160
−100.698
−43.567
−21.922
1.00
98.31
C


ATOM
5449
CB
ASN
H
160
−101.820
−43.740
−22.950
1.00
98.36
C


ATOM
5450
CG
ASN
H
160
−103.205
−43.845
−22.348
1.00
99.33
C


ATOM
5451
OD1
ASN
H
160
−103.408
−44.390
−21.255
1.00
100.83
O


ATOM
5452
ND2
ASN
H
160
−104.203
−43.325
−23.048
1.00
100.10
N


ATOM
5453
C
ASN
H
160
−99.332
−43.897
−22.492
1.00
98.70
C


ATOM
5454
O
ASN
H
160
−99.196
−44.110
−23.694
1.00
98.51
O


ATOM
5455
N
SER
H
161
−98.311
−43.901
−21.613
1.00
100.95
N


ATOM
5456
CA
SER
H
161
−96.899
−44.191
−21.914
1.00
101.67
C


ATOM
5457
CB
SER
H
161
−96.663
−45.691
−22.072
1.00
101.66
C


ATOM
5458
OG
SER
H
161
−97.176
−46.390
−20.948
1.00
102.13
O


ATOM
5459
C
SER
H
161
−96.307
−43.382
−23.078
1.00
102.05
C


ATOM
5460
O
SER
H
161
−95.469
−43.878
−23.843
1.00
102.08
O


ATOM
5461
N
GLY
H
162
−96.748
−42.131
−23.177
1.00
103.84
N


ATOM
5462
CA
GLY
H
162
−96.291
−41.207
−24.204
1.00
104.22
C


ATOM
5463
C
GLY
H
162
−96.960
−41.387
−25.546
1.00
104.40
C


ATOM
5464
O
GLY
H
162
−96.344
−41.119
−26.583
1.00
104.66
O


ATOM
5465
N
ALA
H
163
−98.223
−41.842
−25.536
1.00
105.13
N


ATOM
5466
CA
ALA
H
163
−99.000
−42.038
−26.755
1.00
105.10
C


ATOM
5467
CB
ALA
H
163
−99.670
−43.401
−26.755
1.00
105.12
C


ATOM
5468
C
ALA
H
163
−100.036
−40.918
−26.873
1.00
104.95
C


ATOM
5469
O
ALA
H
163
−100.053
−40.227
−27.897
1.00
105.29
O


ATOM
5470
N
LEU
H
164
−100.872
−40.717
−25.829
1.00
102.14
N


ATOM
5471
CA
LEU
H
164
−101.883
−39.664
−25.819
1.00
101.80
C


ATOM
5472
CB
LEU
H
164
−103.008
−40.001
−24.814
1.00
101.61
C


ATOM
5473
CG
LEU
H
164
−103.991
−38.899
−24.407
1.00
101.38
C


ATOM
5474
CD1
LEU
H
164
−104.862
−38.446
−25.572
1.00
101.25
C


ATOM
5475
CD2
LEU
H
164
−104.847
−39.360
−23.263
1.00
100.62
C


ATOM
5476
C
LEU
H
164
−101.200
−38.296
−25.553
1.00
101.92
C


ATOM
5477
O
LEU
H
164
−100.692
−38.055
−24.450
1.00
102.13
O


ATOM
5478
N
THR
H
165
−101.171
−37.427
−26.599
1.00
102.51
N


ATOM
5479
CA
THR
H
165
−100.559
−36.088
−26.619
1.00
102.09
C


ATOM
5480
CB
THR
H
165
−99.382
−36.040
−27.600
1.00
102.06
C


ATOM
5481
OG1
THR
H
165
−99.135
−34.668
−27.916
1.00
102.39
O


ATOM
5482
CG2
THR
H
165
−99.656
−36.816
−28.901
1.00
102.11
C


ATOM
5483
C
THR
H
165
−101.542
−34.931
−26.897
1.00
101.78
C


ATOM
5484
O
THR
H
165
−101.409
−33.860
−26.296
1.00
101.69
O


ATOM
5485
N
SER
H
166
−102.483
−35.126
−27.834
1.00
100.47
N


ATOM
5486
CA
SER
H
166
−103.452
−34.095
−28.178
1.00
99.92
C


ATOM
5487
CB
SER
H
166
−104.168
−34.428
−29.484
1.00
99.96
C


ATOM
5488
OG
SER
H
166
−103.821
−33.519
−30.519
1.00
100.95
O


ATOM
5489
C
SER
H
166
−104.447
−33.894
−27.055
1.00
99.35
C


ATOM
5490
O
SER
H
166
−104.954
−34.865
−26.485
1.00
99.39
O


ATOM
5491
N
GLY
H
167
−104.692
−32.625
−26.739
1.00
98.50
N


ATOM
5492
CA
GLY
H
167
−105.620
−32.206
−25.695
1.00
97.67
C


ATOM
5493
C
GLY
H
167
−105.093
−32.351
−24.284
1.00
97.17
C


ATOM
5494
O
GLY
H
167
−105.836
−32.081
−23.340
1.00
97.21
O


ATOM
5495
N
VAL
H
168
−103.801
−32.767
−24.126
1.00
95.72
N


ATOM
5496
CA
VAL
H
168
−103.112
−32.965
−22.840
1.00
94.89
C


ATOM
5497
CB
VAL
H
168
−101.922
−33.953
−22.958
1.00
94.85
C


ATOM
5498
CG1
VAL
H
168
−101.187
−34.094
−21.632
1.00
94.65
C


ATOM
5499
CG2
VAL
H
168
−102.370
−35.317
−23.462
1.00
95.14
C


ATOM
5500
C
VAL
H
168
−102.645
−31.616
−22.294
1.00
94.37
C


ATOM
5501
O
VAL
H
168
−101.856
−30.933
−22.952
1.00
94.37
O


ATOM
5502
N
HIS
H
169
−103.114
−31.250
−21.089
1.00
91.67
N


ATOM
5503
CA
HIS
H
169
−102.761
−29.997
−20.436
1.00
91.22
C


ATOM
5504
CB
HIS
H
169
−103.975
−29.060
−20.360
1.00
91.22
C


ATOM
5505
CG
HIS
H
169
−104.261
−28.301
−21.616
1.00
91.46
C


ATOM
5506
ND1
HIS
H
169
−103.604
−28.577
−22.806
1.00
91.91
N


ATOM
5507
CE1
HIS
H
169
−104.112
−27.742
−23.700
1.00
91.47
C


ATOM
5508
NE2
HIS
H
169
−105.044
−26.954
−23.158
1.00
91.76
N


ATOM
5509
CD2
HIS
H
169
−105.152
−27.306
−21.831
1.00
91.43
C


ATOM
5510
C
HIS
H
169
−102.183
−30.178
−19.056
1.00
91.04
C


ATOM
5511
O
HIS
H
169
−102.940
−30.139
−18.074
1.00
90.98
O


ATOM
5512
N
THR
H
170
−100.839
−30.341
−18.963
1.00
89.21
N


ATOM
5513
CA
THR
H
170
−100.155
−30.465
−17.665
1.00
88.80
C


ATOM
5514
CB
THR
H
170
−98.889
−31.300
−17.749
1.00
88.65
C


ATOM
5515
OG1
THR
H
170
−99.131
−32.484
−18.516
1.00
88.62
O


ATOM
5516
CG2
THR
H
170
−98.359
−31.656
−16.376
1.00
88.55
C


ATOM
5517
C
THR
H
170
−99.927
−29.048
−17.116
1.00
88.66
C


ATOM
5518
O
THR
H
170
−99.163
−28.267
−17.694
1.00
88.44
O


ATOM
5519
N
PHE
H
171
−100.631
−28.712
−16.028
1.00
89.66
N


ATOM
5520
CA
PHE
H
171
−100.588
−27.393
−15.418
1.00
89.85
C


ATOM
5521
CB
PHE
H
171
−101.810
−27.185
−14.518
1.00
90.12
C


ATOM
5522
CG
PHE
H
171
−103.058
−26.965
−15.322
1.00
91.71
C


ATOM
5523
CD1
PHE
H
171
−103.897
−28.028
−15.638
1.00
92.97
C


ATOM
5524
CE1
PHE
H
171
−105.041
−27.833
−16.406
1.00
93.11
C


ATOM
5525
CZ
PHE
H
171
−105.350
−26.577
−16.863
1.00
93.49
C


ATOM
5526
CE2
PHE
H
171
−104.526
−25.512
−16.568
1.00
93.17
C


ATOM
5527
CD2
PHE
H
171
−103.377
−25.706
−15.806
1.00
92.71
C


ATOM
5528
C
PHE
H
171
−99.363
−27.130
−14.609
1.00
89.75
C


ATOM
5529
O
PHE
H
171
−98.851
−28.065
−13.978
1.00
90.18
O


ATOM
5530
N
PRO
H
172
−98.904
−25.849
−14.542
1.00
87.98
N


ATOM
5531
CA
PRO
H
172
−97.760
−25.525
−13.674
1.00
87.45
C


ATOM
5532
CB
PRO
H
172
−97.648
−24.001
−13.796
1.00
87.33
C


ATOM
5533
CG
PRO
H
172
−98.322
−23.665
−15.037
1.00
87.68
C


ATOM
5534
CD
PRO
H
172
−99.420
−24.639
−15.210
1.00
87.92
C


ATOM
5535
C
PRO
H
172
−98.071
−25.903
−12.220
1.00
86.77
C


ATOM
5536
O
PRO
H
172
−99.229
−25.810
−11.797
1.00
86.77
O


ATOM
5537
N
ALA
H
173
−97.053
−26.340
−11.457
1.00
83.63
N


ATOM
5538
CA
ALA
H
173
−97.233
−26.716
−10.051
1.00
83.04
C


ATOM
5539
CB
ALA
H
173
−95.950
−27.329
−9.510
1.00
82.99
C


ATOM
5540
C
ALA
H
173
−97.657
−25.522
−9.184
1.00
82.58
C


ATOM
5541
O
ALA
H
173
−97.655
−24.373
−9.636
1.00
82.40
O


ATOM
5542
N
VAL
H
174
−98.029
−25.797
−7.948
1.00
82.52
N


ATOM
5543
CA
VAL
H
174
−98.410
−24.751
−7.019
1.00
82.63
C


ATOM
5544
CB
VAL
H
174
−99.915
−24.380
−7.047
1.00
82.71
C


ATOM
5545
CG1
VAL
H
174
−100.815
−25.563
−6.700
1.00
83.00
C


ATOM
5546
CG2
VAL
H
174
−100.205
−23.192
−6.140
1.00
83.07
C


ATOM
5547
C
VAL
H
174
−97.897
−25.120
−5.657
1.00
82.53
C


ATOM
5548
O
VAL
H
174
−98.127
−26.240
−5.209
1.00
82.89
O


ATOM
5549
N
LEU
H
175
−97.177
−24.202
−5.010
1.00
81.53
N


ATOM
5550
CA
LEU
H
175
−96.615
−24.424
−3.680
1.00
81.33
C


ATOM
5551
CB
LEU
H
175
−95.444
−23.472
−3.417
1.00
80.93
C


ATOM
5552
CG
LEU
H
175
−94.733
−23.605
−2.103
1.00
80.42
C


ATOM
5553
CD1
LEU
H
175
−94.223
−25.004
−1.892
1.00
81.14
C


ATOM
5554
CD2
LEU
H
175
−93.606
−22.641
−2.031
1.00
79.66
C


ATOM
5555
C
LEU
H
175
−97.701
−24.258
−2.644
1.00
81.61
C


ATOM
5556
O
LEU
H
175
−98.313
−23.193
−2.550
1.00
81.55
O


ATOM
5557
N
GLN
H
176
−97.954
−25.321
−1.883
1.00
85.15
N


ATOM
5558
CA
GLN
H
176
−98.989
−25.317
−0.856
1.00
85.67
C


ATOM
5559
CB
GLN
H
176
−99.579
−26.711
−0.689
1.00
85.64
C


ATOM
5560
CG
GLN
H
176
−100.237
−27.269
−1.931
1.00
85.96
C


ATOM
5561
CD
GLN
H
176
−100.703
−28.657
−1.616
1.00
87.03
C


ATOM
5562
OE1
GLN
H
176
−101.887
−28.871
−1.313
1.00
88.32
O


ATOM
5563
NE2
GLN
H
176
−99.783
−29.632
−1.655
1.00
86.68
N


ATOM
5564
C
GLN
H
176
−98.428
−24.839
0.469
1.00
86.04
C


ATOM
5565
O
GLN
H
176
−97.205
−24.852
0.652
1.00
86.10
O


ATOM
5566
N
SER
H
177
−99.324
−24.426
1.399
1.00
88.86
N


ATOM
5567
CA
SER
H
177
−98.974
−23.948
2.742
1.00
89.53
C


ATOM
5568
CB
SER
H
177
−100.230
−23.631
3.542
1.00
89.52
C


ATOM
5569
OG
SER
H
177
−101.138
−24.715
3.455
1.00
90.38
O


ATOM
5570
C
SER
H
177
−98.094
−24.979
3.474
1.00
89.80
C


ATOM
5571
O
SER
H
177
−97.163
−24.593
4.193
1.00
89.96
O


ATOM
5572
N
SER
H
178
−98.353
−26.292
3.237
1.00
90.01
N


ATOM
5573
CA
SER
H
178
−97.573
−27.400
3.799
1.00
90.10
C


ATOM
5574
CB
SER
H
178
−98.120
−28.740
3.311
1.00
90.17
C


ATOM
5575
OG
SER
H
178
−98.173
−28.854
1.897
1.00
90.19
O


ATOM
5576
C
SER
H
178
−96.093
−27.261
3.414
1.00
90.15
C


ATOM
5577
O
SER
H
178
−95.216
−27.536
4.228
1.00
90.30
O


ATOM
5578
N
GLY
H
179
−95.847
−26.795
2.190
1.00
89.38
N


ATOM
5579
CA
GLY
H
179
−94.520
−26.586
1.624
1.00
89.50
C


ATOM
5580
C
GLY
H
179
−94.222
−27.558
0.504
1.00
89.56
C


ATOM
5581
O
GLY
H
179
−93.095
−27.588
−0.006
1.00
89.51
O


ATOM
5582
N
LEU
H
180
−95.249
−28.353
0.120
1.00
86.59
N


ATOM
5583
CA
LEU
H
180
−95.204
−29.364
−0.934
1.00
86.55
C


ATOM
5584
CB
LEU
H
180
−95.808
−30.690
−0.432
1.00
86.49
C


ATOM
5585
CG
LEU
H
180
−95.213
−31.355
0.829
1.00
85.74
C


ATOM
5586
CD1
LEU
H
180
−95.895
−32.655
1.095
1.00
84.95
C


ATOM
5587
CD2
LEU
H
180
−93.741
−31.644
0.678
1.00
85.10
C


ATOM
5588
C
LEU
H
180
−95.961
−28.891
−2.171
1.00
86.73
C


ATOM
5589
O
LEU
H
180
−97.032
−28.322
−2.045
1.00
86.85
O


ATOM
5590
N
TYR
H
181
−95.415
−29.126
−3.358
1.00
87.14
N


ATOM
5591
CA
TYR
H
181
−96.052
−28.716
−4.603
1.00
87.59
C


ATOM
5592
CB
TYR
H
181
−95.016
−28.595
−5.735
1.00
87.56
C


ATOM
5593
CG
TYR
H
181
−93.948
−27.568
−5.454
1.00
87.55
C


ATOM
5594
CD1
TYR
H
181
−94.132
−26.235
−5.796
1.00
87.69
C


ATOM
5595
CE1
TYR
H
181
−93.161
−25.278
−5.515
1.00
87.87
C


ATOM
5596
CZ
TYR
H
181
−91.992
−25.651
−4.873
1.00
87.74
C


ATOM
5597
OH
TYR
H
181
−91.035
−24.707
−4.584
1.00
88.45
O


ATOM
5598
CE2
TYR
H
181
−91.790
−26.973
−4.522
1.00
87.55
C


ATOM
5599
CD2
TYR
H
181
−92.767
−27.920
−4.810
1.00
87.68
C


ATOM
5600
C
TYR
H
181
−97.149
−29.678
−5.018
1.00
88.10
C


ATOM
5601
O
TYR
H
181
−97.100
−30.866
−4.684
1.00
88.23
O


ATOM
5602
N
SER
H
182
−98.136
−29.166
−5.767
1.00
91.91
N


ATOM
5603
CA
SER
H
182
−99.248
−29.952
−6.308
1.00
92.59
C


ATOM
5604
CB
SER
H
182
−100.509
−29.785
−5.470
1.00
92.69
C


ATOM
5605
OG
SER
H
182
−100.330
−30.303
−4.164
1.00
93.52
O


ATOM
5606
C
SER
H
182
−99.541
−29.520
−7.717
1.00
92.83
C


ATOM
5607
O
SER
H
182
−99.540
−28.324
−8.016
1.00
92.92
O


ATOM
5608
N
LEU
H
183
−99.775
−30.479
−8.591
1.00
94.42
N


ATOM
5609
CA
LEU
H
183
−100.126
−30.156
−9.964
1.00
95.22
C


ATOM
5610
CB
LEU
H
183
−98.948
−29.977
−10.943
1.00
95.09
C


ATOM
5611
CG
LEU
H
183
−98.157
−31.170
−11.505
1.00
94.86
C


ATOM
5612
CD1
LEU
H
183
−98.956
−31.979
−12.521
1.00
95.07
C


ATOM
5613
CD2
LEU
H
183
−96.968
−30.650
−12.264
1.00
95.32
C


ATOM
5614
C
LEU
H
183
−101.162
−31.078
−10.497
1.00
95.90
C


ATOM
5615
O
LEU
H
183
−101.322
−32.196
−10.002
1.00
96.13
O


ATOM
5616
N
SER
H
184
−101.854
−30.623
−11.521
1.00
95.87
N


ATOM
5617
CA
SER
H
184
−102.879
−31.424
−12.135
1.00
96.50
C


ATOM
5618
CB
SER
H
184
−104.260
−30.840
−11.836
1.00
96.55
C


ATOM
5619
OG
SER
H
184
−104.294
−29.427
−11.978
1.00
96.78
O


ATOM
5620
C
SER
H
184
−102.628
−31.509
−13.615
1.00
96.87
C


ATOM
5621
O
SER
H
184
−102.418
−30.487
−14.271
1.00
96.82
O


ATOM
5622
N
SER
H
185
−102.604
−32.728
−14.140
1.00
96.92
N


ATOM
5623
CA
SER
H
185
−102.465
−32.910
−15.572
1.00
97.63
C


ATOM
5624
CB
SER
H
185
−101.491
−34.018
−15.925
1.00
97.50
C


ATOM
5625
OG
SER
H
185
−101.281
−34.000
−17.329
1.00
97.39
O


ATOM
5626
C
SER
H
185
−103.862
−33.263
−16.038
1.00
98.29
C


ATOM
5627
O
SER
H
185
−104.576
−34.020
−15.365
1.00
98.57
O


ATOM
5628
N
VAL
H
186
−104.272
−32.687
−17.159
1.00
98.00
N


ATOM
5629
CA
VAL
H
186
−105.602
−32.908
−17.690
1.00
98.39
C


ATOM
5630
CB
VAL
H
186
−106.449
−31.646
−17.393
1.00
98.15
C


ATOM
5631
CG1
VAL
H
186
−106.939
−30.947
−18.653
1.00
98.29
C


ATOM
5632
CG2
VAL
H
186
−107.579
−31.941
−16.419
1.00
97.38
C


ATOM
5633
C
VAL
H
186
−105.545
−33.335
−19.166
1.00
99.17
C


ATOM
5634
O
VAL
H
186
−104.532
−33.123
−19.843
1.00
99.02
O


ATOM
5635
N
VAL
H
187
−106.617
−33.988
−19.637
1.00
101.68
N


ATOM
5636
CA
VAL
H
187
−106.742
−34.433
−21.023
1.00
102.74
C


ATOM
5637
CB
VAL
H
187
−106.004
−35.767
−21.355
1.00
102.60
C


ATOM
5638
CG1
VAL
H
187
−106.720
−36.984
−20.774
1.00
102.47
C


ATOM
5639
CG2
VAL
H
187
−105.770
−35.918
−22.853
1.00
102.04
C


ATOM
5640
C
VAL
H
187
−108.192
−34.310
−21.543
1.00
103.69
C


ATOM
5641
O
VAL
H
187
−109.132
−34.245
−20.745
1.00
103.73
O


ATOM
5642
N
THR
H
188
−108.344
−34.211
−22.880
1.00
107.37
N


ATOM
5643
CA
THR
H
188
−109.603
−34.099
−23.613
1.00
108.41
C


ATOM
5644
CB
THR
H
188
−109.767
−32.673
−24.199
1.00
108.35
C


ATOM
5645
OG1
THR
H
188
−110.529
−31.892
−23.270
1.00
107.92
O


ATOM
5646
CG2
THR
H
188
−110.414
−32.645
−25.597
1.00
108.00
C


ATOM
5647
C
THR
H
188
−109.659
−35.281
−24.573
1.00
109.45
C


ATOM
5648
O
THR
H
188
−108.768
−35.458
−25.419
1.00
109.44
O


ATOM
5649
N
VAL
H
189
−110.685
−36.121
−24.383
1.00
114.13
N


ATOM
5650
CA
VAL
H
189
−110.934
−37.340
−25.162
1.00
115.59
C


ATOM
5651
CB
VAL
H
189
−110.343
−38.638
−24.522
1.00
115.62
C


ATOM
5652
CG1
VAL
H
189
−108.822
−38.708
−24.677
1.00
115.89
C


ATOM
5653
CG2
VAL
H
189
−110.773
−38.810
−23.066
1.00
115.45
C


ATOM
5654
C
VAL
H
189
−112.427
−37.499
−25.477
1.00
116.45
C


ATOM
5655
O
VAL
H
189
−113.262
−37.061
−24.681
1.00
116.41
O


ATOM
5656
N
PRO
H
190
−112.796
−38.137
−26.609
1.00
120.19
N


ATOM
5657
CA
PRO
H
190
−114.227
−38.305
−26.893
1.00
120.99
C


ATOM
5658
CB
PRO
H
190
−114.267
−38.550
−28.402
1.00
121.02
C


ATOM
5659
CG
PRO
H
190
−112.925
−39.111
−28.741
1.00
120.60
C


ATOM
5660
CD
PRO
H
190
−111.951
−38.732
−27.671
1.00
120.17
C


ATOM
5661
C
PRO
H
190
−114.908
−39.418
−26.090
1.00
121.84
C


ATOM
5662
O
PRO
H
190
−114.259
−40.397
−25.691
1.00
121.99
O


ATOM
5663
N
SER
H
191
−116.237
−39.263
−25.865
1.00
123.47
N


ATOM
5664
CA
SER
H
191
−117.101
−40.221
−25.153
1.00
124.15
C


ATOM
5665
CB
SER
H
191
−118.450
−39.576
−24.858
1.00
124.20
C


ATOM
5666
OG
SER
H
191
−118.261
−38.280
−24.310
1.00
124.30
O


ATOM
5667
C
SER
H
191
−117.282
−41.493
−26.014
1.00
124.53
C


ATOM
5668
O
SER
H
191
−117.612
−42.568
−25.506
1.00
124.41
O


ATOM
5669
N
SER
H
192
−117.017
−41.336
−27.329
1.00
126.09
N


ATOM
5670
CA
SER
H
192
−117.054
−42.319
−28.417
1.00
126.73
C


ATOM
5671
CB
SER
H
192
−117.251
−41.599
−29.757
1.00
126.76
C


ATOM
5672
OG
SER
H
192
−116.846
−40.236
−29.760
1.00
127.04
O


ATOM
5673
C
SER
H
192
−115.799
−43.260
−28.454
1.00
127.12
C


ATOM
5674
O
SER
H
192
−115.557
−43.952
−29.454
1.00
127.14
O


ATOM
5675
N
SER
H
193
−115.018
−43.279
−27.349
1.00
127.68
N


ATOM
5676
CA
SER
H
193
−113.805
−44.088
−27.149
1.00
127.78
C


ATOM
5677
CB
SER
H
193
−112.610
−43.461
−27.873
1.00
127.70
C


ATOM
5678
OG
SER
H
193
−112.345
−42.148
−27.408
1.00
127.41
O


ATOM
5679
C
SER
H
193
−113.513
−44.240
−25.639
1.00
127.76
C


ATOM
5680
O
SER
H
193
−112.439
−44.720
−25.261
1.00
127.76
O


ATOM
5681
N
LEU
H
194
−114.488
−43.838
−24.794
1.00
126.91
N


ATOM
5682
CA
LEU
H
194
−114.439
−43.864
−23.333
1.00
126.94
C


ATOM
5683
CB
LEU
H
194
−115.735
−43.260
−22.749
1.00
126.93
C


ATOM
5684
CG
LEU
H
194
−115.625
−42.156
−21.690
1.00
126.77
C


ATOM
5685
CD1
LEU
H
194
−114.795
−40.978
−22.167
1.00
126.96
C


ATOM
5686
CD2
LEU
H
194
−115.156
−42.691
−20.368
1.00
126.40
C


ATOM
5687
C
LEU
H
194
−114.115
−45.241
−22.725
1.00
127.07
C


ATOM
5688
O
LEU
H
194
−112.938
−45.531
−22.502
1.00
127.06
O


ATOM
5689
N
GLY
H
195
−115.138
−46.067
−22.483
1.00
129.35
N


ATOM
5690
CA
GLY
H
195
−114.991
−47.405
−21.910
1.00
129.33
C


ATOM
5691
C
GLY
H
195
−114.124
−48.369
−22.705
1.00
129.46
C


ATOM
5692
O
GLY
H
195
−113.689
−49.391
−22.166
1.00
129.50
O


ATOM
5693
N
THR
H
196
−113.858
−48.040
−23.993
1.00
132.04
N


ATOM
5694
CA
THR
H
196
−113.058
−48.820
−24.960
1.00
131.92
C


ATOM
5695
CB
THR
H
196
−113.477
−48.498
−26.438
1.00
132.08
C


ATOM
5696
OG1
THR
H
196
−112.751
−47.369
−26.949
1.00
132.25
O


ATOM
5697
CG2
THR
H
196
−114.999
−48.281
−26.613
1.00
132.06
C


ATOM
5698
C
THR
H
196
−111.518
−48.784
−24.700
1.00
131.67
C


ATOM
5699
O
THR
H
196
−110.919
−49.843
−24.463
1.00
131.82
O


ATOM
5700
N
GLN
H
197
−110.895
−47.565
−24.756
1.00
129.94
N


ATOM
5701
CA
GLN
H
197
−109.460
−47.311
−24.533
1.00
129.20
C


ATOM
5702
CB
GLN
H
197
−108.927
−46.224
−25.488
1.00
129.35
C


ATOM
5703
CG
GLN
H
197
−108.355
−46.753
−26.805
1.00
130.14
C


ATOM
5704
CD
GLN
H
197
−109.414
−47.071
−27.848
1.00
131.31
C


ATOM
5705
OE1
GLN
H
197
−109.587
−48.228
−28.262
1.00
131.48
O


ATOM
5706
NE2
GLN
H
197
−110.143
−46.051
−28.303
1.00
131.48
N


ATOM
5707
C
GLN
H
197
−109.207
−46.879
−23.097
1.00
128.43
C


ATOM
5708
O
GLN
H
197
−109.925
−46.022
−22.565
1.00
128.38
O


ATOM
5709
N
THR
H
198
−108.180
−47.470
−22.474
1.00
125.73
N


ATOM
5710
CA
THR
H
198
−107.796
−47.158
−21.094
1.00
124.61
C


ATOM
5711
CB
THR
H
198
−107.122
−48.363
−20.388
1.00
124.84
C


ATOM
5712
OG1
THR
H
198
−106.301
−49.105
−21.306
1.00
124.99
O


ATOM
5713
CG2
THR
H
198
−108.135
−49.283
−19.708
1.00
124.58
C


ATOM
5714
C
THR
H
198
−106.987
−45.857
−20.999
1.00
123.61
C


ATOM
5715
O
THR
H
198
−106.191
−45.551
−21.896
1.00
123.40
O


ATOM
5716
N
TYR
H
199
−107.204
−45.094
−19.909
1.00
120.57
N


ATOM
5717
CA
TYR
H
199
−106.506
−43.832
−19.665
1.00
119.19
C


ATOM
5718
CB
TYR
H
199
−107.477
−42.643
−19.713
1.00
119.46
C


ATOM
5719
CG
TYR
H
199
−108.092
−42.453
−21.085
1.00
120.39
C


ATOM
5720
CD1
TYR
H
199
−109.468
−42.546
−21.275
1.00
120.86
C


ATOM
5721
CE1
TYR
H
199
−110.036
−42.391
−22.539
1.00
120.91
C


ATOM
5722
CZ
TYR
H
199
−109.221
−42.155
−23.635
1.00
121.46
C


ATOM
5723
OH
TYR
H
199
−109.762
−41.999
−24.888
1.00
122.60
O


ATOM
5724
CE2
TYR
H
199
−107.849
−42.073
−23.473
1.00
121.10
C


ATOM
5725
CD2
TYR
H
199
−107.293
−42.222
−22.204
1.00
120.87
C


ATOM
5726
C
TYR
H
199
−105.636
−43.860
−18.403
1.00
117.92
C


ATOM
5727
O
TYR
H
199
−106.150
−43.787
−17.280
1.00
117.83
O


ATOM
5728
N
ILE
H
200
−104.307
−44.000
−18.607
1.00
112.18
N


ATOM
5729
CA
ILE
H
200
−103.305
−44.070
−17.537
1.00
110.28
C


ATOM
5730
CB
ILE
H
200
−102.635
−45.478
−17.422
1.00
110.33
C


ATOM
5731
CG1
ILE
H
200
−101.813
−45.869
−18.686
1.00
110.02
C


ATOM
5732
CD1
ILE
H
200
−100.273
−45.895
−18.502
1.00
109.68
C


ATOM
5733
CG2
ILE
H
200
−103.663
−46.562
−17.076
1.00
109.77
C


ATOM
5734
C
ILE
H
200
−102.294
−42.915
−17.595
1.00
108.97
C


ATOM
5735
O
ILE
H
200
−101.857
−42.550
−18.690
1.00
108.81
O


ATOM
5736
N
CYS
H
201
−101.938
−42.331
−16.422
1.00
104.63
N


ATOM
5737
CA
CYS
H
201
−100.972
−41.234
−16.360
1.00
102.83
C


ATOM
5738
CB
CYS
H
201
−101.548
−39.967
−15.742
1.00
103.00
C


ATOM
5739
SG
CYS
H
201
−102.047
−40.124
−14.011
1.00
103.57
S


ATOM
5740
C
CYS
H
201
−99.664
−41.619
−15.735
1.00
101.34
C


ATOM
5741
O
CYS
H
201
−99.620
−42.123
−14.623
1.00
101.22
O


ATOM
5742
N
ASN
H
202
−98.597
−41.387
−16.472
1.00
97.30
N


ATOM
5743
CA
ASN
H
202
−97.247
−41.704
−16.069
1.00
95.57
C


ATOM
5744
CB
ASN
H
202
−96.462
−42.241
−17.251
1.00
95.80
C


ATOM
5745
CG
ASN
H
202
−97.176
−43.346
−17.972
1.00
96.46
C


ATOM
5746
OD1
ASN
H
202
−98.343
−43.214
−18.378
1.00
96.34
O


ATOM
5747
ND2
ASN
H
202
−96.477
−44.464
−18.152
1.00
98.40
N


ATOM
5748
C
ASN
H
202
−96.563
−40.507
−15.428
1.00
94.12
C


ATOM
5749
O
ASN
H
202
−96.055
−39.600
−16.099
1.00
93.94
O


ATOM
5750
N
VAL
H
203
−96.574
−40.524
−14.105
1.00
87.41
N


ATOM
5751
CA
VAL
H
203
−95.967
−39.525
−13.258
1.00
85.59
C


ATOM
5752
CB
VAL
H
203
−96.882
−39.258
−12.061
1.00
85.50
C


ATOM
5753
CG1
VAL
H
203
−96.265
−38.251
−11.108
1.00
85.70
C


ATOM
5754
CG2
VAL
H
203
−98.249
−38.784
−12.539
1.00
84.95
C


ATOM
5755
C
VAL
H
203
−94.577
−40.030
−12.858
1.00
84.64
C


ATOM
5756
O
VAL
H
203
−94.391
−41.218
−12.574
1.00
84.45
O


ATOM
5757
N
ASN
H
204
−93.588
−39.138
−12.902
1.00
83.70
N


ATOM
5758
CA
ASN
H
204
−92.224
−39.481
−12.540
1.00
82.43
C


ATOM
5759
CB
ASN
H
204
−91.418
−40.035
−13.723
1.00
82.54
C


ATOM
5760
CG
ASN
H
204
−89.922
−40.165
−13.482
1.00
83.30
C


ATOM
5761
OD1
ASN
H
204
−89.441
−40.517
−12.383
1.00
85.27
O


ATOM
5762
ND2
ASN
H
204
−89.140
−39.879
−14.517
1.00
83.81
N


ATOM
5763
C
ASN
H
204
−91.565
−38.291
−11.889
1.00
81.30
C


ATOM
5764
O
ASN
H
204
−91.286
−37.288
−12.550
1.00
81.32
O


ATOM
5765
N
HIS
H
205
−91.337
−38.414
−10.574
1.00
77.58
N


ATOM
5766
CA
HIS
H
205
−90.685
−37.427
−9.744
1.00
76.14
C


ATOM
5767
CB
HIS
H
205
−91.454
−37.230
−8.442
1.00
76.06
C


ATOM
5768
CG
HIS
H
205
−90.857
−36.229
−7.503
1.00
75.64
C


ATOM
5769
ND1
HIS
H
205
−90.239
−36.625
−6.336
1.00
76.03
N


ATOM
5770
CE1
HIS
H
205
−89.849
−35.513
−5.734
1.00
76.64
C


ATOM
5771
NE2
HIS
H
205
−90.180
−34.432
−6.441
1.00
77.05
N


ATOM
5772
CD2
HIS
H
205
−90.829
−34.877
−7.573
1.00
76.21
C


ATOM
5773
C
HIS
H
205
−89.299
−37.980
−9.517
1.00
75.44
C


ATOM
5774
O
HIS
H
205
−89.065
−38.743
−8.589
1.00
75.18
O


ATOM
5775
N
LYS
H
206
−88.385
−37.600
−10.417
1.00
73.96
N


ATOM
5776
CA
LYS
H
206
−86.979
−37.986
−10.447
1.00
73.15
C


ATOM
5777
CB
LYS
H
206
−86.281
−37.363
−11.656
1.00
73.27
C


ATOM
5778
CG
LYS
H
206
−86.794
−37.835
−13.003
1.00
74.94
C


ATOM
5779
CD
LYS
H
206
−87.115
−36.632
−13.910
1.00
78.37
C


ATOM
5780
CE
LYS
H
206
−87.147
−36.984
−15.395
1.00
79.68
C


ATOM
5781
NZ
LYS
H
206
−85.794
−37.337
−15.949
1.00
80.06
N


ATOM
5782
C
LYS
H
206
−86.209
−37.648
−9.163
1.00
72.47
C


ATOM
5783
O
LYS
H
206
−85.353
−38.461
−8.802
1.00
72.50
O


ATOM
5784
N
PRO
H
207
−86.462
−36.491
−8.455
1.00
70.56
N


ATOM
5785
CA
PRO
H
207
−85.697
−36.185
−7.225
1.00
70.13
C


ATOM
5786
CB
PRO
H
207
−86.322
−34.879
−6.743
1.00
69.80
C


ATOM
5787
CG
PRO
H
207
−86.924
−34.278
−7.905
1.00
70.09
C


ATOM
5788
CD
PRO
H
207
−87.425
−35.399
−8.735
1.00
70.58
C


ATOM
5789
C
PRO
H
207
−85.773
−37.227
−6.108
1.00
70.07
C


ATOM
5790
O
PRO
H
207
−84.820
−37.356
−5.335
1.00
69.87
O


ATOM
5791
N
SER
H
208
−86.916
−37.935
−6.018
1.00
68.21
N


ATOM
5792
CA
SER
H
208
−87.194
−38.973
−5.046
1.00
67.94
C


ATOM
5793
CB
SER
H
208
−88.539
−38.716
−4.385
1.00
67.92
C


ATOM
5794
OG
SER
H
208
−89.602
−38.909
−5.302
1.00
67.48
O


ATOM
5795
C
SER
H
208
−87.246
−40.314
−5.716
1.00
68.07
C


ATOM
5796
O
SER
H
208
−87.561
−41.284
−5.045
1.00
68.37
O


ATOM
5797
N
ASN
H
209
−86.987
−40.383
−7.039
1.00
68.59
N


ATOM
5798
CA
ASN
H
209
−87.007
−41.608
−7.863
1.00
69.03
C


ATOM
5799
CB
ASN
H
209
−85.849
−42.531
−7.490
1.00
68.43
C


ATOM
5800
CG
ASN
H
209
−85.528
−43.582
−8.510
1.00
67.30
C


ATOM
5801
OD1
ASN
H
209
−84.818
−44.533
−8.219
1.00
66.47
O


ATOM
5802
ND2
ASN
H
209
−86.032
−43.453
−9.735
1.00
66.92
N


ATOM
5803
C
ASN
H
209
−88.377
−42.353
−7.902
1.00
69.99
C


ATOM
5804
O
ASN
H
209
−88.433
−43.554
−8.197
1.00
70.02
O


ATOM
5805
N
THR
H
210
−89.471
−41.613
−7.631
1.00
72.45
N


ATOM
5806
CA
THR
H
210
−90.855
−42.086
−7.590
1.00
73.73
C


ATOM
5807
CB
THR
H
210
−91.646
−41.269
−6.551
1.00
73.38
C


ATOM
5808
OG1
THR
H
210
−91.020
−41.436
−5.287
1.00
73.71
O


ATOM
5809
CG2
THR
H
210
−93.102
−41.676
−6.445
1.00
73.49
C


ATOM
5810
C
THR
H
210
−91.535
−42.071
−8.946
1.00
74.90
C


ATOM
5811
O
THR
H
210
−92.022
−41.024
−9.360
1.00
75.20
O


ATOM
5812
N
LYS
H
211
−91.585
−43.231
−9.620
1.00
77.05
N


ATOM
5813
CA
LYS
H
211
−92.263
−43.437
−10.906
1.00
78.60
C


ATOM
5814
CB
LYS
H
211
−91.466
−44.407
−11.799
1.00
78.20
C


ATOM
5815
CG
LYS
H
211
−90.121
−43.868
−12.276
1.00
78.47
C


ATOM
5816
CD
LYS
H
211
−89.225
−44.961
−12.861
1.00
79.14
C


ATOM
5817
CE
LYS
H
211
−87.899
−45.180
−12.118
1.00
79.84
C


ATOM
5818
NZ
LYS
H
211
−88.045
−45.808
−10.756
1.00
79.07
N


ATOM
5819
C
LYS
H
211
−93.626
−44.036
−10.514
1.00
79.91
C


ATOM
5820
O
LYS
H
211
−93.659
−45.045
−9.812
1.00
80.45
O


ATOM
5821
N
VAL
H
212
−94.737
−43.412
−10.906
1.00
82.17
N


ATOM
5822
CA
VAL
H
212
−96.090
−43.875
−10.541
1.00
83.80
C


ATOM
5823
CB
VAL
H
212
−96.641
−42.980
−9.387
1.00
83.43
C


ATOM
5824
CG1
VAL
H
212
−98.161
−42.945
−9.333
1.00
82.71
C


ATOM
5825
CG2
VAL
H
212
−96.056
−43.399
−8.048
1.00
83.07
C


ATOM
5826
C
VAL
H
212
−97.043
−43.973
−11.768
1.00
85.51
C


ATOM
5827
O
VAL
H
212
−96.916
−43.183
−12.705
1.00
85.62
O


ATOM
5828
N
ASP
H
213
−97.978
−44.954
−11.767
1.00
91.75
N


ATOM
5829
CA
ASP
H
213
−98.956
−45.139
−12.847
1.00
93.82
C


ATOM
5830
CB
ASP
H
213
−98.589
−46.341
−13.728
1.00
93.63
C


ATOM
5831
CG
ASP
H
213
−97.548
−46.026
−14.798
1.00
94.16
C


ATOM
5832
OD1
ASP
H
213
−96.407
−45.655
−14.433
1.00
93.97
O


ATOM
5833
OD2
ASP
H
213
−97.872
−46.152
−15.999
1.00
95.62
O


ATOM
5834
C
ASP
H
213
−100.383
−45.216
−12.285
1.00
95.40
C


ATOM
5835
O
ASP
H
213
−100.652
−46.061
−11.428
1.00
95.72
O


ATOM
5836
N
LYS
H
214
−101.282
−44.302
−12.722
1.00
100.62
N


ATOM
5837
CA
LYS
H
214
−102.669
−44.262
−12.237
1.00
102.69
C


ATOM
5838
CB
LYS
H
214
−102.927
−43.032
−11.344
1.00
102.71
C


ATOM
5839
CG
LYS
H
214
−103.874
−43.291
−10.173
1.00
103.55
C


ATOM
5840
CD
LYS
H
214
−103.192
−44.189
−9.125
1.00
105.57
C


ATOM
5841
CE
LYS
H
214
−104.059
−44.491
−7.930
1.00
106.85
C


ATOM
5842
NZ
LYS
H
214
−103.355
−45.388
−6.978
1.00
107.17
N


ATOM
5843
C
LYS
H
214
−103.738
−44.391
−13.331
1.00
104.02
C


ATOM
5844
O
LYS
H
214
−103.780
−43.579
−14.257
1.00
104.21
O


ATOM
5845
N
LYS
H
215
−104.602
−45.424
−13.210
1.00
107.40
N


ATOM
5846
CA
LYS
H
215
−105.688
−45.687
−14.146
1.00
108.78
C


ATOM
5847
CB
LYS
H
215
−106.100
−47.176
−14.114
1.00
108.88
C


ATOM
5848
CG
LYS
H
215
−107.148
−47.597
−15.157
1.00
109.42
C


ATOM
5849
CD
LYS
H
215
−107.634
−49.047
−14.925
1.00
109.90
C


ATOM
5850
CE
LYS
H
215
−108.585
−49.581
−15.984
1.00
109.81
C


ATOM
5851
NZ
LYS
H
215
−109.153
−50.911
−15.614
1.00
109.19
N


ATOM
5852
C
LYS
H
215
−106.856
−44.787
−13.794
1.00
109.66
C


ATOM
5853
O
LYS
H
215
−107.389
−44.852
−12.682
1.00
109.51
O


ATOM
5854
N
VAL
H
216
−107.230
−43.924
−14.746
1.00
113.78
N


ATOM
5855
CA
VAL
H
216
−108.363
−43.014
−14.588
1.00
115.02
C


ATOM
5856
CB
VAL
H
216
−108.107
−41.543
−15.014
1.00
114.92
C


ATOM
5857
CG1
VAL
H
216
−109.154
−40.613
−14.400
1.00
115.00
C


ATOM
5858
CG2
VAL
H
216
−106.699
−41.087
−14.631
1.00
115.30
C


ATOM
5859
C
VAL
H
216
−109.536
−43.669
−15.330
1.00
115.97
C


ATOM
5860
O
VAL
H
216
−109.489
−43.867
−16.557
1.00
116.09
O


ATOM
5861
N
GLU
H
217
−110.555
−44.058
−14.540
1.00
117.62
N


ATOM
5862
CA
GLU
H
217
−111.782
−44.729
−14.961
1.00
118.53
C


ATOM
5863
CB
GLU
H
217
−111.995
−45.986
−14.109
1.00
118.74
C


ATOM
5864
CG
GLU
H
217
−111.067
−47.138
−14.433
1.00
119.59
C


ATOM
5865
CD
GLU
H
217
−111.166
−48.270
−13.432
1.00
120.38
C


ATOM
5866
OE1
GLU
H
217
−111.208
−49.441
−13.875
1.00
121.05
O


ATOM
5867
OE2
GLU
H
217
−111.207
−47.989
−12.209
1.00
119.83
O


ATOM
5868
C
GLU
H
217
−112.953
−43.808
−14.703
1.00
118.88
C


ATOM
5869
O
GLU
H
217
−112.821
−42.934
−13.834
1.00
118.97
O


ATOM
5870
N
PRO
H
218
−114.122
−44.009
−15.386
1.00
116.71
N


ATOM
5871
CA
PRO
H
218
−115.287
−43.133
−15.123
1.00
116.74
C


ATOM
5872
CB
PRO
H
218
−116.291
−43.519
−16.221
1.00
116.73
C


ATOM
5873
CG
PRO
H
218
−115.502
−44.323
−17.225
1.00
116.66
C


ATOM
5874
CD
PRO
H
218
−114.436
−45.003
−16.436
1.00
116.64
C


ATOM
5875
C
PRO
H
218
−115.854
−43.290
−13.704
1.00
116.70
C


ATOM
5876
O
PRO
H
218
−115.904
−44.408
−13.181
1.00
116.58
O


ATOM
5877
N
LYS
H
219
−116.237
−42.143
−13.088
1.00
113.24
N


ATOM
5878
CA
LYS
H
219
−116.788
−41.948
−11.735
1.00
113.26
C


ATOM
5879
CB
LYS
H
219
−117.941
−40.927
−11.762
1.00
113.15
C


ATOM
5880
C
LYS
H
219
−117.177
−43.217
−10.958
1.00
113.17
C


ATOM
5881
O
LYS
H
219
−116.309
−43.911
−10.428
1.00
113.03
O


TER
5882

LYS
H
219


ATOM
5883
N
GLU
L
1
−83.598
9.104
−8.215
1.00
89.00
N


ATOM
5884
CA
GLU
L
1
−83.105
8.099
−9.150
1.00
88.92
C


ATOM
5885
CB
GLU
L
1
−82.880
6.751
−8.461
1.00
89.36
C


ATOM
5886
CG
GLU
L
1
−84.070
6.181
−7.715
1.00
91.53
C


ATOM
5887
CD
GLU
L
1
−83.726
4.828
−7.121
1.00
95.85
C


ATOM
5888
OE1
GLU
L
1
−84.033
3.797
−7.766
1.00
97.73
O


ATOM
5889
OE2
GLU
L
1
−83.125
4.799
−6.020
1.00
97.18
O


ATOM
5890
C
GLU
L
1
−84.004
7.949
−10.356
1.00
88.12
C


ATOM
5891
O
GLU
L
1
−85.216
8.101
−10.217
1.00
88.16
O


ATOM
5892
N
ILE
L
2
−83.411
7.657
−11.540
1.00
80.34
N


ATOM
5893
CA
ILE
L
2
−84.157
7.483
−12.793
1.00
79.70
C


ATOM
5894
CB
ILE
L
2
−83.280
7.451
−14.089
1.00
79.60
C


ATOM
5895
CG1
ILE
L
2
−82.210
8.557
−14.067
1.00
79.33
C


ATOM
5896
CD1
ILE
L
2
−81.071
8.384
−15.048
1.00
79.74
C


ATOM
5897
CG2
ILE
L
2
−84.147
7.542
−15.369
1.00
78.97
C


ATOM
5898
C
ILE
L
2
−85.116
6.292
−12.684
1.00
79.51
C


ATOM
5899
O
ILE
L
2
−84.774
5.260
−12.087
1.00
79.69
O


ATOM
5900
N
VAL
L
3
−86.336
6.475
−13.222
1.00
75.05
N


ATOM
5901
CA
VAL
L
3
−87.387
5.480
−13.213
1.00
74.49
C


ATOM
5902
CB
VAL
L
3
−88.466
5.847
−12.180
1.00
74.17
C


ATOM
5903
CG1
VAL
L
3
−89.738
5.038
−12.386
1.00
73.26
C


ATOM
5904
CG2
VAL
L
3
−87.938
5.678
−10.762
1.00
73.55
C


ATOM
5905
C
VAL
L
3
−87.930
5.343
−14.619
1.00
74.81
C


ATOM
5906
O
VAL
L
3
−88.324
6.345
−15.213
1.00
75.07
O


ATOM
5907
N
LEU
L
4
−87.943
4.102
−15.150
1.00
76.54
N


ATOM
5908
CA
LEU
L
4
−88.444
3.802
−16.494
1.00
76.82
C


ATOM
5909
CB
LEU
L
4
−87.469
2.927
−17.283
1.00
76.43
C


ATOM
5910
CG
LEU
L
4
−86.023
3.376
−17.305
1.00
75.61
C


ATOM
5911
CD1
LEU
L
4
−85.152
2.333
−17.948
1.00
75.85
C


ATOM
5912
CD2
LEU
L
4
−85.867
4.665
−18.035
1.00
75.72
C


ATOM
5913
C
LEU
L
4
−89.832
3.173
−16.430
1.00
77.41
C


ATOM
5914
O
LEU
L
4
−90.056
2.200
−15.694
1.00
77.43
O


ATOM
5915
N
THR
L
5
−90.771
3.759
−17.190
1.00
81.19
N


ATOM
5916
CA
THR
L
5
−92.164
3.318
−17.228
1.00
81.79
C


ATOM
5917
CB
THR
L
5
−93.081
4.395
−16.653
1.00
81.50
C


ATOM
5918
OG1
THR
L
5
−92.466
4.961
−15.492
1.00
81.23
O


ATOM
5919
CG2
THR
L
5
−94.456
3.864
−16.325
1.00
81.01
C


ATOM
5920
C
THR
L
5
−92.589
2.850
−18.609
1.00
82.60
C


ATOM
5921
O
THR
L
5
−92.693
3.655
−19.545
1.00
82.60
O


ATOM
5922
N
GLN
L
6
−92.844
1.542
−18.718
1.00
86.45
N


ATOM
5923
CA
GLN
L
6
−93.272
0.915
−19.961
1.00
87.55
C


ATOM
5924
CB
GLN
L
6
−92.783
−0.532
−20.062
1.00
87.69
C


ATOM
5925
CG
GLN
L
6
−91.335
−0.717
−19.614
1.00
88.23
C


ATOM
5926
CD
GLN
L
6
−90.571
−1.688
−20.464
1.00
88.69
C


ATOM
5927
OE1
GLN
L
6
−90.813
−1.842
−21.674
1.00
89.57
O


ATOM
5928
NE2
GLN
L
6
−89.610
−2.339
−19.849
1.00
88.76
N


ATOM
5929
C
GLN
L
6
−94.794
1.027
−20.150
1.00
88.17
C


ATOM
5930
O
GLN
L
6
−95.549
0.843
−19.186
1.00
88.08
O


ATOM
5931
N
SER
L
7
−95.210
1.356
−21.406
1.00
92.93
N


ATOM
5932
CA
SER
L
7
−96.564
1.589
−21.944
1.00
93.33
C


ATOM
5933
CB
SER
L
7
−96.506
1.734
−23.455
1.00
93.66
C


ATOM
5934
OG
SER
L
7
−95.744
0.662
−24.002
1.00
94.08
O


ATOM
5935
C
SER
L
7
−97.621
0.545
−21.540
1.00
93.56
C


ATOM
5936
O
SER
L
7
−98.173
0.714
−20.438
1.00
94.05
O


ATOM
5937
N
PRO
L
8
−98.002
−0.509
−22.328
1.00
89.31
N


ATOM
5938
CA
PRO
L
8
−98.988
−1.432
−21.786
1.00
89.18
C


ATOM
5939
CB
PRO
L
8
−99.665
−1.986
−23.045
1.00
88.74
C


ATOM
5940
CG
PRO
L
8
−98.757
−1.659
−24.189
1.00
88.87
C


ATOM
5941
CD
PRO
L
8
−97.560
−0.968
−23.664
1.00
89.25
C


ATOM
5942
C
PRO
L
8
−98.220
−2.509
−21.001
1.00
89.49
C


ATOM
5943
O
PRO
L
8
−97.120
−2.908
−21.409
1.00
90.02
O


ATOM
5944
N
ALA
L
9
−98.759
−2.985
−19.873
1.00
88.96
N


ATOM
5945
CA
ALA
L
9
−98.053
−4.053
−19.169
1.00
88.68
C


ATOM
5946
CB
ALA
L
9
−98.765
−4.391
−17.872
1.00
88.39
C


ATOM
5947
C
ALA
L
9
−98.084
−5.251
−20.134
1.00
88.68
C


ATOM
5948
O
ALA
L
9
−97.112
−6.002
−20.221
1.00
89.05
O


ATOM
5949
N
THR
L
10
−99.207
−5.369
−20.898
1.00
87.79
N


ATOM
5950
CA
THR
L
10
−99.482
−6.385
−21.913
1.00
87.63
C


ATOM
5951
CB
THR
L
10
−100.425
−7.495
−21.408
1.00
87.57
C


ATOM
5952
OG1
THR
L
10
−100.164
−7.809
−20.032
1.00
87.90
O


ATOM
5953
CG2
THR
L
10
−100.347
−8.760
−22.273
1.00
87.29
C


ATOM
5954
C
THR
L
10
−100.075
−5.713
−23.137
1.00
87.50
C


ATOM
5955
O
THR
L
10
−100.917
−4.820
−23.010
1.00
87.67
O


ATOM
5956
N
LEU
L
11
−99.629
−6.162
−24.311
1.00
85.14
N


ATOM
5957
CA
LEU
L
11
−100.052
−5.694
−25.610
1.00
85.16
C


ATOM
5958
CB
LEU
L
11
−98.939
−4.864
−26.272
1.00
84.97
C


ATOM
5959
CG
LEU
L
11
−99.099
−4.581
−27.782
1.00
85.13
C


ATOM
5960
CD1
LEU
L
11
−100.036
−3.397
−28.052
1.00
84.72
C


ATOM
5961
CD2
LEU
L
11
−97.749
−4.410
−28.473
1.00
84.38
C


ATOM
5962
C
LEU
L
11
−100.430
−6.921
−26.449
1.00
85.59
C


ATOM
5963
O
LEU
L
11
−99.553
−7.668
−26.915
1.00
85.35
O


ATOM
5964
N
SER
L
12
−101.755
−7.126
−26.629
1.00
87.35
N


ATOM
5965
CA
SER
L
12
−102.331
−8.240
−27.392
1.00
87.63
C


ATOM
5966
CB
SER
L
12
−103.635
−8.699
−26.760
1.00
87.50
C


ATOM
5967
OG
SER
L
12
−103.508
−8.769
−25.348
1.00
87.38
O


ATOM
5968
C
SER
L
12
−102.526
−7.861
−28.853
1.00
88.07
C


ATOM
5969
O
SER
L
12
−103.264
−6.922
−29.161
1.00
87.95
O


ATOM
5970
N
LEU
L
13
−101.813
−8.565
−29.745
1.00
90.88
N


ATOM
5971
CA
LEU
L
13
−101.831
−8.335
−31.192
1.00
91.71
C


ATOM
5972
CB
LEU
L
13
−100.701
−7.378
−31.623
1.00
91.67
C


ATOM
5973
CG
LEU
L
13
−100.791
−5.903
−31.217
1.00
91.61
C


ATOM
5974
CD1
LEU
L
13
−102.052
−5.231
−31.759
1.00
91.18
C


ATOM
5975
CD2
LEU
L
13
−99.596
−5.163
−31.719
1.00
91.99
C


ATOM
5976
C
LEU
L
13
−101.728
−9.624
−31.998
1.00
92.38
C


ATOM
5977
O
LEU
L
13
−101.018
−10.548
−31.621
1.00
92.53
O


ATOM
5978
N
SER
L
14
−102.430
−9.669
−33.122
1.00
94.83
N


ATOM
5979
CA
SER
L
14
−102.440
−10.820
−34.029
1.00
95.63
C


ATOM
5980
CB
SER
L
14
−103.631
−10.708
−34.985
1.00
95.73
C


ATOM
5981
OG
SER
L
14
−104.781
−10.186
−34.330
1.00
96.70
O


ATOM
5982
C
SER
L
14
−101.129
−10.844
−34.826
1.00
95.79
C


ATOM
5983
O
SER
L
14
−100.555
−9.778
−35.019
1.00
95.83
O


ATOM
5984
N
PRO
L
15
−100.625
−11.998
−35.321
1.00
95.86
N


ATOM
5985
CA
PRO
L
15
−99.367
−11.968
−36.100
1.00
96.06
C


ATOM
5986
CB
PRO
L
15
−99.108
−13.443
−36.424
1.00
95.91
C


ATOM
5987
CG
PRO
L
15
−99.911
−14.201
−35.411
1.00
95.88
C


ATOM
5988
CD
PRO
L
15
−101.133
−13.376
−35.187
1.00
95.86
C


ATOM
5989
C
PRO
L
15
−99.449
−11.099
−37.359
1.00
96.26
C


ATOM
5990
O
PRO
L
15
−100.544
−10.705
−37.754
1.00
96.51
O


ATOM
5991
N
GLY
L
16
−98.295
−10.773
−37.943
1.00
98.11
N


ATOM
5992
CA
GLY
L
16
−98.181
−9.941
−39.143
1.00
98.33
C


ATOM
5993
C
GLY
L
16
−98.383
−8.449
−38.937
1.00
98.54
C


ATOM
5994
O
GLY
L
16
−97.993
−7.651
−39.799
1.00
98.67
O


ATOM
5995
N
GLU
L
17
−98.983
−8.062
−37.787
1.00
99.90
N


ATOM
5996
CA
GLU
L
17
−99.288
−6.683
−37.389
1.00
100.20
C


ATOM
5997
CB
GLU
L
17
−100.384
−6.688
−36.311
1.00
100.28
C


ATOM
5998
CG
GLU
L
17
−101.685
−7.324
−36.768
1.00
101.97
C


ATOM
5999
CD
GLU
L
17
−102.932
−6.814
−36.069
1.00
104.11
C


ATOM
6000
OE1
GLU
L
17
−103.215
−7.262
−34.930
1.00
104.25
O


ATOM
6001
OE2
GLU
L
17
−103.634
−5.966
−36.673
1.00
105.22
O


ATOM
6002
C
GLU
L
17
−98.093
−5.813
−36.901
1.00
100.05
C


ATOM
6003
O
GLU
L
17
−97.050
−6.343
−36.489
1.00
100.22
O


ATOM
6004
N
ARG
L
18
−98.274
−4.462
−36.940
1.00
98.61
N


ATOM
6005
CA
ARG
L
18
−97.294
−3.490
−36.448
1.00
97.96
C


ATOM
6006
CB
ARG
L
18
−97.411
−2.125
−37.150
1.00
98.00
C


ATOM
6007
C
ARG
L
18
−97.512
−3.364
−34.938
1.00
97.49
C


ATOM
6008
O
ARG
L
18
−98.662
−3.277
−34.478
1.00
97.17
O


ATOM
6009
N
ALA
L
19
−96.403
−3.387
−34.168
1.00
96.77
N


ATOM
6010
CA
ALA
L
19
−96.424
−3.329
−32.702
1.00
96.23
C


ATOM
6011
CB
ALA
L
19
−95.987
−4.681
−32.146
1.00
96.39
C


ATOM
6012
C
ALA
L
19
−95.547
−2.230
−32.103
1.00
95.76
C


ATOM
6013
O
ALA
L
19
−94.357
−2.166
−32.434
1.00
95.97
O


ATOM
6014
N
THR
L
20
−96.110
−1.376
−31.214
1.00
91.20
N


ATOM
6015
CA
THR
L
20
−95.293
−0.340
−30.572
1.00
90.40
C


ATOM
6016
CB
THR
L
20
−95.325
1.056
−31.230
1.00
90.54
C


ATOM
6017
OG1
THR
L
20
−96.588
1.682
−31.029
1.00
90.68
O


ATOM
6018
CG2
THR
L
20
−94.868
1.074
−32.696
1.00
89.99
C


ATOM
6019
C
THR
L
20
−95.401
−0.299
−29.058
1.00
89.89
C


ATOM
6020
O
THR
L
20
−96.507
−0.211
−28.515
1.00
89.67
O


ATOM
6021
N
ILE
L
21
−94.216
−0.348
−28.391
1.00
89.06
N


ATOM
6022
CA
ILE
L
21
−93.995
−0.313
−26.942
1.00
88.32
C


ATOM
6023
CB
ILE
L
21
−93.116
−1.528
−26.499
1.00
88.77
C


ATOM
6024
CG1
ILE
L
21
−93.768
−2.851
−26.920
1.00
88.67
C


ATOM
6025
CD1
ILE
L
21
−92.833
−3.954
−27.076
1.00
89.74
C


ATOM
6026
CG2
ILE
L
21
−92.802
−1.523
−24.965
1.00
89.13
C


ATOM
6027
C
ILE
L
21
−93.336
1.017
−26.593
1.00
87.50
C


ATOM
6028
O
ILE
L
21
−92.492
1.502
−27.343
1.00
87.42
O


ATOM
6029
N
THR
L
22
−93.711
1.580
−25.442
1.00
86.61
N


ATOM
6030
CA
THR
L
22
−93.228
2.852
−24.892
1.00
85.95
C


ATOM
6031
CB
THR
L
22
−94.429
3.829
−24.756
1.00
85.95
C


ATOM
6032
OG1
THR
L
22
−94.598
4.524
−25.986
1.00
85.76
O


ATOM
6033
CG2
THR
L
22
−94.339
4.803
−23.539
1.00
85.55
C


ATOM
6034
C
THR
L
22
−92.460
2.679
−23.572
1.00
85.64
C


ATOM
6035
O
THR
L
22
−92.794
1.806
−22.769
1.00
85.64
O


ATOM
6036
N
CYS
L
23
−91.430
3.531
−23.376
1.00
84.41
N


ATOM
6037
CA
CYS
L
23
−90.581
3.635
−22.193
1.00
83.87
C


ATOM
6038
CB
CYS
L
23
−89.210
2.993
−22.411
1.00
83.55
C


ATOM
6039
SG
CYS
L
23
−88.246
2.756
−20.884
1.00
83.84
S


ATOM
6040
C
CYS
L
23
−90.476
5.130
−21.926
1.00
83.58
C


ATOM
6041
O
CYS
L
23
−90.122
5.901
−22.825
1.00
83.61
O


ATOM
6042
N
ARG
L
24
−90.854
5.547
−20.722
1.00
86.10
N


ATOM
6043
CA
ARG
L
24
−90.808
6.952
−20.364
1.00
85.89
C


ATOM
6044
CB
ARG
L
24
−92.213
7.501
−20.108
1.00
86.58
C


ATOM
6045
CG
ARG
L
24
−92.329
9.003
−20.355
1.00
89.45
C


ATOM
6046
CD
ARG
L
24
−93.738
9.387
−20.754
1.00
93.99
C


ATOM
6047
NE
ARG
L
24
−94.140
8.740
−22.011
1.00
97.92
N


ATOM
6048
CZ
ARG
L
24
−95.395
8.676
−22.464
1.00
99.98
C


ATOM
6049
NH1
ARG
L
24
−96.391
9.220
−21.767
1.00
100.74
N


ATOM
6050
NH2
ARG
L
24
−95.661
8.067
−23.617
1.00
100.60
N


ATOM
6051
C
ARG
L
24
−89.905
7.151
−19.167
1.00
84.88
C


ATOM
6052
O
ARG
L
24
−90.261
6.760
−18.045
1.00
84.96
O


ATOM
6053
N
ALA
L
25
−88.724
7.744
−19.412
1.00
81.15
N


ATOM
6054
CA
ALA
L
25
−87.731
8.027
−18.382
1.00
79.72
C


ATOM
6055
CB
ALA
L
25
−86.380
8.312
−19.017
1.00
79.78
C


ATOM
6056
C
ALA
L
25
−88.200
9.231
−17.572
1.00
78.88
C


ATOM
6057
O
ALA
L
25
−88.784
10.167
−18.138
1.00
78.99
O


ATOM
6058
N
SER
L
26
−87.966
9.206
−16.247
1.00
76.82
N


ATOM
6059
CA
SER
L
26
−88.358
10.287
−15.348
1.00
75.42
C


ATOM
6060
CB
SER
L
26
−88.450
9.772
−13.915
1.00
75.49
C


ATOM
6061
OG
SER
L
26
−87.222
9.221
−13.472
1.00
75.52
O


ATOM
6062
C
SER
L
26
−87.406
11.488
−15.437
1.00
74.61
C


ATOM
6063
O
SER
L
26
−87.717
12.544
−14.900
1.00
74.72
O


ATOM
6064
N
GLN
L
27
−86.253
11.323
−16.107
1.00
72.38
N


ATOM
6065
CA
GLN
L
27
−85.220
12.338
−16.288
1.00
70.85
C


ATOM
6066
CB
GLN
L
27
−84.048
12.033
−15.370
1.00
71.05
C


ATOM
6067
CG
GLN
L
27
−84.312
12.084
−13.891
1.00
72.55
C


ATOM
6068
CD
GLN
L
27
−83.007
11.927
−13.147
1.00
75.22
C


ATOM
6069
OE1
GLN
L
27
−82.991
11.733
−11.922
1.00
77.67
O


ATOM
6070
NE2
GLN
L
27
−81.878
12.001
−13.860
1.00
74.71
N


ATOM
6071
C
GLN
L
27
−84.659
12.234
−17.689
1.00
69.65
C


ATOM
6072
O
GLN
L
27
−84.826
11.201
−18.338
1.00
69.54
O


ATOM
6073
N
TYR
L
28
−83.938
13.270
−18.144
1.00
67.82
N


ATOM
6074
CA
TYR
L
28
−83.315
13.256
−19.469
1.00
66.27
C


ATOM
6075
CB
TYR
L
28
−82.720
14.647
−19.814
1.00
65.44
C


ATOM
6076
CG
TYR
L
28
−82.242
14.748
−21.246
1.00
62.81
C


ATOM
6077
CD1
TYR
L
28
−83.140
14.945
−22.287
1.00
60.19
C


ATOM
6078
CE1
TYR
L
28
−82.712
15.014
−23.616
1.00
60.09
C


ATOM
6079
CZ
TYR
L
28
−81.367
14.853
−23.920
1.00
59.59
C


ATOM
6080
OH
TYR
L
28
−80.976
14.901
−25.241
1.00
59.93
O


ATOM
6081
CE2
TYR
L
28
−80.448
14.675
−22.895
1.00
59.81
C


ATOM
6082
CD2
TYR
L
28
−80.891
14.616
−21.566
1.00
61.47
C


ATOM
6083
C
TYR
L
28
−82.227
12.130
−19.499
1.00
65.99
C


ATOM
6084
O
TYR
L
28
−81.359
12.080
−18.619
1.00
65.99
O


ATOM
6085
N
VAL
L
29
−82.307
11.221
−20.474
1.00
63.65
N


ATOM
6086
CA
VAL
L
29
−81.330
10.143
−20.565
1.00
63.33
C


ATOM
6087
CB
VAL
L
29
−81.883
8.722
−20.249
1.00
63.11
C


ATOM
6088
CG1
VAL
L
29
−82.900
8.275
−21.283
1.00
62.31
C


ATOM
6089
CG2
VAL
L
29
−82.446
8.626
−18.831
1.00
62.70
C


ATOM
6090
C
VAL
L
29
−80.584
10.181
−21.876
1.00
63.57
C


ATOM
6091
O
VAL
L
29
−79.775
9.281
−22.153
1.00
63.59
O


ATOM
6092
N
GLY
L
30
−80.845
11.218
−22.662
1.00
64.62
N


ATOM
6093
CA
GLY
L
30
−80.229
11.366
−23.972
1.00
64.86
C


ATOM
6094
C
GLY
L
30
−80.687
10.222
−24.847
1.00
64.90
C


ATOM
6095
O
GLY
L
30
−81.855
9.848
−24.790
1.00
64.96
O


ATOM
6096
N
SER
L
31
−79.789
9.641
−25.626
1.00
66.85
N


ATOM
6097
CA
SER
L
31
−80.160
8.525
−26.486
1.00
67.60
C


ATOM
6098
CB
SER
L
31
−79.676
8.789
−27.908
1.00
67.46
C


ATOM
6099
OG
SER
L
31
−78.259
8.838
−27.958
1.00
68.34
O


ATOM
6100
C
SER
L
31
−79.553
7.209
−25.949
1.00
68.05
C


ATOM
6101
O
SER
L
31
−79.537
6.187
−26.654
1.00
68.16
O


ATOM
6102
N
TYR
L
32
−79.038
7.245
−24.705
1.00
68.98
N


ATOM
6103
CA
TYR
L
32
−78.390
6.098
−24.101
1.00
68.93
C


ATOM
6104
CB
TYR
L
32
−77.203
6.540
−23.233
1.00
68.85
C


ATOM
6105
CG
TYR
L
32
−76.275
7.517
−23.913
1.00
68.85
C


ATOM
6106
CD1
TYR
L
32
−75.477
7.123
−24.981
1.00
68.62
C


ATOM
6107
CE1
TYR
L
32
−74.636
8.030
−25.628
1.00
69.48
C


ATOM
6108
CZ
TYR
L
32
−74.565
9.342
−25.188
1.00
68.65
C


ATOM
6109
OH
TYR
L
32
−73.723
10.220
−25.823
1.00
68.17
O


ATOM
6110
CE2
TYR
L
32
−75.337
9.752
−24.114
1.00
69.22
C


ATOM
6111
CD2
TYR
L
32
−76.191
8.842
−23.487
1.00
69.84
C


ATOM
6112
C
TYR
L
32
−79.343
5.149
−23.374
1.00
69.13
C


ATOM
6113
O
TYR
L
32
−79.173
4.893
−22.172
1.00
69.45
O


ATOM
6114
N
LEU
L
33
−80.338
4.620
−24.111
1.00
69.39
N


ATOM
6115
CA
LEU
L
33
−81.322
3.663
−23.592
1.00
69.21
C


ATOM
6116
CB
LEU
L
33
−82.734
4.277
−23.585
1.00
68.46
C


ATOM
6117
CG
LEU
L
33
−83.871
3.332
−23.289
1.00
67.58
C


ATOM
6118
CD1
LEU
L
33
−84.932
3.981
−22.450
1.00
66.45
C


ATOM
6119
CD2
LEU
L
33
−84.435
2.734
−24.551
1.00
66.54
C


ATOM
6120
C
LEU
L
33
−81.253
2.322
−24.409
1.00
69.54
C


ATOM
6121
O
LEU
L
33
−81.075
2.353
−25.634
1.00
69.48
O


ATOM
6122
N
ASN
L
34
−81.395
1.160
−23.726
1.00
69.21
N


ATOM
6123
CA
ASN
L
34
−81.354
−0.137
−24.394
1.00
69.16
C


ATOM
6124
CB
ASN
L
34
−80.198
−0.975
−23.892
1.00
69.25
C


ATOM
6125
CG
ASN
L
34
−78.849
−0.323
−24.010
1.00
68.89
C


ATOM
6126
OD1
ASN
L
34
−78.531
0.370
−24.980
1.00
69.33
O


ATOM
6127
ND2
ASN
L
34
−78.024
−0.530
−23.008
1.00
67.82
N


ATOM
6128
C
ASN
L
34
−82.650
−0.889
−24.231
1.00
69.14
C


ATOM
6129
O
ASN
L
34
−83.387
−0.656
−23.268
1.00
69.19
O


ATOM
6130
N
TRP
L
35
−82.925
−1.789
−25.199
1.00
67.73
N


ATOM
6131
CA
TRP
L
35
−84.099
−2.654
−25.283
1.00
67.27
C


ATOM
6132
CB
TRP
L
35
−84.932
−2.329
−26.539
1.00
67.21
C


ATOM
6133
CG
TRP
L
35
−85.741
−1.060
−26.474
1.00
66.74
C


ATOM
6134
CD1
TRP
L
35
−85.421
0.143
−27.035
1.00
66.52
C


ATOM
6135
NE1
TRP
L
35
−86.415
1.068
−26.782
1.00
65.54
N


ATOM
6136
CE2
TRP
L
35
−87.413
0.463
−26.069
1.00
64.58
C


ATOM
6137
CD2
TRP
L
35
−87.026
−0.884
−25.859
1.00
64.96
C


ATOM
6138
CE3
TRP
L
35
−87.877
−1.723
−25.131
1.00
64.93
C


ATOM
6139
CZ3
TRP
L
35
−89.082
−1.206
−24.654
1.00
66.19
C


ATOM
6140
CH2
TRP
L
35
−89.442
0.131
−24.882
1.00
65.61
C


ATOM
6141
CZ2
TRP
L
35
−88.623
0.983
−25.590
1.00
64.83
C


ATOM
6142
C
TRP
L
35
−83.669
−4.127
−25.304
1.00
67.29
C


ATOM
6143
O
TRP
L
35
−82.820
−4.533
−26.114
1.00
67.16
O


ATOM
6144
N
TYR
L
36
−84.255
−4.924
−24.404
1.00
67.91
N


ATOM
6145
CA
TYR
L
36
−83.976
−6.350
−24.282
1.00
68.00
C


ATOM
6146
CB
TYR
L
36
−83.469
−6.681
−22.860
1.00
67.89
C


ATOM
6147
CG
TYR
L
36
−82.120
−6.066
−22.548
1.00
68.25
C


ATOM
6148
CD1
TYR
L
36
−82.022
−4.778
−22.030
1.00
67.50
C


ATOM
6149
CE1
TYR
L
36
−80.786
−4.178
−21.813
1.00
67.54
C


ATOM
6150
CZ
TYR
L
36
−79.624
−4.878
−22.084
1.00
67.87
C


ATOM
6151
OH
TYR
L
36
−78.406
−4.290
−21.837
1.00
68.43
O


ATOM
6152
CE2
TYR
L
36
−79.693
−6.165
−22.593
1.00
68.13
C


ATOM
6153
CD2
TYR
L
36
−80.938
−6.750
−22.825
1.00
68.33
C


ATOM
6154
C
TYR
L
36
−85.218
−7.145
−24.578
1.00
68.21
C


ATOM
6155
O
TYR
L
36
−86.330
−6.679
−24.296
1.00
68.38
O


ATOM
6156
N
GLN
L
37
−85.047
−8.355
−25.124
1.00
70.41
N


ATOM
6157
CA
GLN
L
37
−86.171
−9.249
−25.404
1.00
70.69
C


ATOM
6158
CB
GLN
L
37
−86.217
−9.637
−26.884
1.00
70.79
C


ATOM
6159
CG
GLN
L
37
−87.418
−10.520
−27.247
1.00
71.62
C


ATOM
6160
CD
GLN
L
37
−87.155
−11.323
−28.493
1.00
72.47
C


ATOM
6161
OE1
GLN
L
37
−86.164
−12.081
−28.566
1.00
72.90
O


ATOM
6162
NE2
GLN
L
37
−88.040
−11.177
−29.500
1.00
71.79
N


ATOM
6163
C
GLN
L
37
−86.013
−10.494
−24.545
1.00
70.52
C


ATOM
6164
O
GLN
L
37
−84.967
−11.132
−24.592
1.00
70.54
O


ATOM
6165
N
GLN
L
38
−87.038
−10.860
−23.775
1.00
70.53
N


ATOM
6166
CA
GLN
L
38
−86.931
−12.057
−22.949
1.00
70.45
C


ATOM
6167
CB
GLN
L
38
−86.840
−11.705
−21.480
1.00
69.65
C


ATOM
6168
CG
GLN
L
38
−86.360
−12.875
−20.682
1.00
67.53
C


ATOM
6169
CD
GLN
L
38
−86.403
−12.621
−19.208
1.00
65.49
C


ATOM
6170
OE1
GLN
L
38
−87.137
−11.746
−18.711
1.00
64.80
O


ATOM
6171
NE2
GLN
L
38
−85.617
−13.401
−18.475
1.00
64.47
N


ATOM
6172
C
GLN
L
38
−87.991
−13.132
−23.217
1.00
71.40
C


ATOM
6173
O
GLN
L
38
−89.150
−13.018
−22.787
1.00
71.38
O


ATOM
6174
N
LYS
L
39
−87.566
−14.201
−23.925
1.00
74.27
N


ATOM
6175
CA
LYS
L
39
−88.414
−15.349
−24.242
1.00
75.11
C


ATOM
6176
CB
LYS
L
39
−87.917
−16.069
−25.506
1.00
75.03
C


ATOM
6177
CG
LYS
L
39
−88.706
−15.584
−26.739
1.00
76.39
C


ATOM
6178
CD
LYS
L
39
−88.360
−16.236
−28.081
1.00
77.40
C


ATOM
6179
CE
LYS
L
39
−87.221
−15.555
−28.788
1.00
78.26
C


ATOM
6180
NZ
LYS
L
39
−85.899
−16.095
−28.348
1.00
80.80
N


ATOM
6181
C
LYS
L
39
−88.491
−16.269
−23.017
1.00
75.58
C


ATOM
6182
O
LYS
L
39
−87.502
−16.370
−22.291
1.00
75.90
O


ATOM
6183
N
PRO
L
40
−89.644
−16.914
−22.719
1.00
76.29
N


ATOM
6184
CA
PRO
L
40
−89.708
−17.786
−21.518
1.00
76.35
C


ATOM
6185
CB
PRO
L
40
−91.147
−18.292
−21.501
1.00
76.20
C


ATOM
6186
CG
PRO
L
40
−91.894
−17.355
−22.405
1.00
76.93
C


ATOM
6187
CD
PRO
L
40
−90.925
−16.909
−23.450
1.00
76.38
C


ATOM
6188
C
PRO
L
40
−88.664
−18.916
−21.460
1.00
76.28
C


ATOM
6189
O
PRO
L
40
−88.345
−19.556
−22.485
1.00
75.89
O


ATOM
6190
N
GLY
L
41
−88.107
−19.098
−20.254
1.00
75.59
N


ATOM
6191
CA
GLY
L
41
−87.064
−20.078
−19.974
1.00
75.41
C


ATOM
6192
C
GLY
L
41
−85.731
−19.660
−20.566
1.00
75.49
C


ATOM
6193
O
GLY
L
41
−84.851
−20.497
−20.835
1.00
75.64
O


ATOM
6194
N
GLN
L
42
−85.586
−18.334
−20.781
1.00
74.30
N


ATOM
6195
CA
GLN
L
42
−84.397
−17.742
−21.368
1.00
73.61
C


ATOM
6196
CB
GLN
L
42
−84.606
−17.525
−22.862
1.00
73.45
C


ATOM
6197
CG
GLN
L
42
−84.387
−18.753
−23.706
1.00
74.36
C


ATOM
6198
CD
GLN
L
42
−84.748
−18.410
−25.116
1.00
77.03
C


ATOM
6199
OE1
GLN
L
42
−84.038
−17.674
−25.821
1.00
77.97
O


ATOM
6200
NE2
GLN
L
42
−85.886
−18.913
−25.555
1.00
79.35
N


ATOM
6201
C
GLN
L
42
−84.012
−16.443
−20.711
1.00
73.06
C


ATOM
6202
O
GLN
L
42
−84.839
−15.780
−20.086
1.00
73.00
O


ATOM
6203
N
ALA
L
43
−82.740
−16.086
−20.869
1.00
70.82
N


ATOM
6204
CA
ALA
L
43
−82.159
−14.862
−20.351
1.00
70.31
C


ATOM
6205
CB
ALA
L
43
−80.642
−15.010
−20.300
1.00
70.14
C


ATOM
6206
C
ALA
L
43
−82.520
−13.713
−21.290
1.00
70.06
C


ATOM
6207
O
ALA
L
43
−82.668
−13.970
−22.495
1.00
70.12
O


ATOM
6208
N
PRO
L
44
−82.621
−12.445
−20.795
1.00
68.44
N


ATOM
6209
CA
PRO
L
44
−82.891
−11.307
−21.703
1.00
68.13
C


ATOM
6210
CB
PRO
L
44
−82.750
−10.099
−20.791
1.00
68.16
C


ATOM
6211
CG
PRO
L
44
−83.034
−10.619
−19.432
1.00
68.17
C


ATOM
6212
CD
PRO
L
44
−82.459
−11.985
−19.402
1.00
68.24
C


ATOM
6213
C
PRO
L
44
−81.876
−11.226
−22.844
1.00
68.23
C


ATOM
6214
O
PRO
L
44
−80.758
−11.726
−22.700
1.00
68.47
O


ATOM
6215
N
ARG
L
45
−82.266
−10.642
−23.989
1.00
70.66
N


ATOM
6216
CA
ARG
L
45
−81.416
−10.533
−25.184
1.00
71.08
C


ATOM
6217
CB
ARG
L
45
−81.934
−11.471
−26.279
1.00
71.21
C


ATOM
6218
CG
ARG
L
45
−81.142
−11.415
−27.568
1.00
73.90
C


ATOM
6219
CD
ARG
L
45
−81.430
−12.596
−28.471
1.00
79.03
C


ATOM
6220
NE
ARG
L
45
−80.438
−12.683
−29.554
1.00
84.54
N


ATOM
6221
CZ
ARG
L
45
−80.690
−12.402
−30.835
1.00
87.00
C


ATOM
6222
NH1
ARG
L
45
−81.918
−12.030
−31.216
1.00
87.47
N


ATOM
6223
NH2
ARG
L
45
−79.723
−12.505
−31.749
1.00
86.89
N


ATOM
6224
C
ARG
L
45
−81.367
−9.117
−25.714
1.00
70.91
C


ATOM
6225
O
ARG
L
45
−82.420
−8.556
−26.019
1.00
71.15
O


ATOM
6226
N
LEU
L
46
−80.163
−8.546
−25.857
1.00
67.97
N


ATOM
6227
CA
LEU
L
46
−80.068
−7.188
−26.379
1.00
67.99
C


ATOM
6228
CB
LEU
L
46
−78.637
−6.625
−26.287
1.00
67.90
C


ATOM
6229
CG
LEU
L
46
−78.428
−5.211
−26.816
1.00
66.29
C


ATOM
6230
CD1
LEU
L
46
−78.915
−4.190
−25.840
1.00
65.28
C


ATOM
6231
CD2
LEU
L
46
−77.002
−4.987
−27.135
1.00
65.27
C


ATOM
6232
C
LEU
L
46
−80.601
−7.154
−27.807
1.00
68.29
C


ATOM
6233
O
LEU
L
46
−80.152
−7.933
−28.653
1.00
68.46
O


ATOM
6234
N
LEU
L
47
−81.579
−6.270
−28.044
1.00
68.06
N


ATOM
6235
CA
LEU
L
47
−82.283
−6.067
−29.308
1.00
68.32
C


ATOM
6236
CB
LEU
L
47
−83.743
−5.852
−28.923
1.00
68.34
C


ATOM
6237
CG
LEU
L
47
−84.817
−6.605
−29.597
1.00
68.82
C


ATOM
6238
CD1
LEU
L
47
−84.498
−8.086
−29.676
1.00
69.06
C


ATOM
6239
CD2
LEU
L
47
−86.095
−6.363
−28.862
1.00
69.14
C


ATOM
6240
C
LEU
L
47
−81.796
−4.780
−29.959
1.00
68.67
C


ATOM
6241
O
LEU
L
47
−81.148
−4.803
−31.017
1.00
68.41
O


ATOM
6242
N
ILE
L
48
−82.145
−3.649
−29.306
1.00
69.72
N


ATOM
6243
CA
ILE
L
48
−81.815
−2.284
−29.689
1.00
70.11
C


ATOM
6244
CB
ILE
L
48
−83.112
−1.431
−29.887
1.00
70.29
C


ATOM
6245
CG1
ILE
L
48
−84.065
−2.014
−30.955
1.00
70.86
C


ATOM
6246
CD1
ILE
L
48
−83.492
−2.138
−32.379
1.00
71.97
C


ATOM
6247
CG2
ILE
L
48
−82.829
0.066
−30.109
1.00
70.03
C


ATOM
6248
C
ILE
L
48
−80.942
−1.687
−28.602
1.00
70.39
C


ATOM
6249
O
ILE
L
48
−81.302
−1.745
−27.420
1.00
70.31
O


ATOM
6250
N
TYR
L
49
−79.810
−1.099
−28.989
1.00
70.70
N


ATOM
6251
CA
TYR
L
49
−78.968
−0.435
−28.010
1.00
71.20
C


ATOM
6252
CB
TYR
L
49
−77.590
−1.069
−27.911
1.00
70.96
C


ATOM
6253
CG
TYR
L
49
−76.714
−0.865
−29.117
1.00
71.03
C


ATOM
6254
CD1
TYR
L
49
−75.752
0.141
−29.142
1.00
70.52
C


ATOM
6255
CE1
TYR
L
49
−74.926
0.328
−30.249
1.00
70.02
C


ATOM
6256
CZ
TYR
L
49
−75.042
−0.514
−31.342
1.00
71.17
C


ATOM
6257
OH
TYR
L
49
−74.224
−0.342
−32.434
1.00
73.08
O


ATOM
6258
CE2
TYR
L
49
−75.972
−1.545
−31.326
1.00
71.85
C


ATOM
6259
CD2
TYR
L
49
−76.808
−1.707
−30.220
1.00
71.13
C


ATOM
6260
C
TYR
L
49
−78.919
1.044
−28.346
1.00
71.57
C


ATOM
6261
O
TYR
L
49
−79.238
1.408
−29.469
1.00
71.66
O


ATOM
6262
N
ASP
L
50
−78.564
1.905
−27.395
1.00
74.27
N


ATOM
6263
CA
ASP
L
50
−78.497
3.349
−27.653
1.00
75.00
C


ATOM
6264
CB
ASP
L
50
−77.139
3.735
−28.250
1.00
74.83
C


ATOM
6265
CG
ASP
L
50
−75.967
3.734
−27.284
1.00
75.63
C


ATOM
6266
OD1
ASP
L
50
−76.147
3.291
−26.100
1.00
75.34
O


ATOM
6267
OD2
ASP
L
50
−74.876
4.166
−27.694
1.00
77.19
O


ATOM
6268
C
ASP
L
50
−79.668
3.901
−28.491
1.00
75.23
C


ATOM
6269
O
ASP
L
50
−79.471
4.380
−29.597
1.00
75.08
O


ATOM
6270
N
ALA
L
51
−80.886
3.792
−27.941
1.00
77.17
N


ATOM
6271
CA
ALA
L
51
−82.191
4.225
−28.464
1.00
77.67
C


ATOM
6272
CB
ALA
L
51
−82.332
5.731
−28.423
1.00
77.83
C


ATOM
6273
C
ALA
L
51
−82.707
3.685
−29.785
1.00
78.01
C


ATOM
6274
O
ALA
L
51
−83.899
3.370
−29.859
1.00
78.23
O


ATOM
6275
N
SER
L
52
−81.851
3.588
−30.815
1.00
79.08
N


ATOM
6276
CA
SER
L
52
−82.236
3.167
−32.165
1.00
79.89
C


ATOM
6277
CB
SER
L
52
−82.583
4.422
−32.960
1.00
79.80
C


ATOM
6278
OG
SER
L
52
−81.464
5.303
−32.972
1.00
80.89
O


ATOM
6279
C
SER
L
52
−81.107
2.426
−32.902
1.00
80.36
C


ATOM
6280
O
SER
L
52
−80.630
2.898
−33.927
1.00
80.53
O


ATOM
6281
N
ASN
L
53
−80.655
1.307
−32.399
1.00
79.99
N


ATOM
6282
CA
ASN
L
53
−79.569
0.605
−33.068
1.00
81.01
C


ATOM
6283
CB
ASN
L
53
−78.217
0.976
−32.453
1.00
81.07
C


ATOM
6284
CG
ASN
L
53
−77.521
2.098
−33.126
1.00
81.94
C


ATOM
6285
OD1
ASN
L
53
−77.719
3.262
−32.801
1.00
83.25
O


ATOM
6286
ND2
ASN
L
53
−76.688
1.768
−34.084
1.00
83.66
N


ATOM
6287
C
ASN
L
53
−79.799
−0.856
−32.911
1.00
81.48
C


ATOM
6288
O
ASN
L
53
−79.855
−1.332
−31.775
1.00
81.69
O


ATOM
6289
N
ARG
L
54
−79.942
−1.578
−34.030
1.00
83.24
N


ATOM
6290
CA
ARG
L
54
−80.161
−3.016
−33.967
1.00
83.75
C


ATOM
6291
CB
ARG
L
54
−80.652
−3.569
−35.300
1.00
83.62
C


ATOM
6292
CG
ARG
L
54
−82.146
−3.516
−35.411
1.00
84.05
C


ATOM
6293
CD
ARG
L
54
−82.627
−4.184
−36.662
1.00
85.38
C


ATOM
6294
NE
ARG
L
54
−82.768
−3.201
−37.726
1.00
86.77
N


ATOM
6295
CZ
ARG
L
54
−82.077
−3.221
−38.862
1.00
87.66
C


ATOM
6296
NH1
ARG
L
54
−82.265
−2.273
−39.774
1.00
88.38
N


ATOM
6297
NH2
ARG
L
54
−81.202
−4.198
−39.103
1.00
86.69
N


ATOM
6298
C
ARG
L
54
−78.886
−3.698
−33.520
1.00
84.05
C


ATOM
6299
O
ARG
L
54
−77.815
−3.445
−34.090
1.00
83.98
O


ATOM
6300
N
ALA
L
55
−78.992
−4.530
−32.472
1.00
84.40
N


ATOM
6301
CA
ALA
L
55
−77.839
−5.247
−31.952
1.00
85.14
C


ATOM
6302
CB
ALA
L
55
−78.179
−5.893
−30.624
1.00
85.11
C


ATOM
6303
C
ALA
L
55
−77.477
−6.305
−32.968
1.00
85.71
C


ATOM
6304
O
ALA
L
55
−78.351
−6.712
−33.745
1.00
85.99
O


ATOM
6305
N
THR
L
56
−76.206
−6.751
−32.979
1.00
86.17
N


ATOM
6306
CA
THR
L
56
−75.759
−7.777
−33.927
1.00
86.69
C


ATOM
6307
CB
THR
L
56
−74.278
−8.136
−33.741
1.00
86.68
C


ATOM
6308
OG1
THR
L
56
−73.521
−6.939
−33.546
1.00
87.91
O


ATOM
6309
CG2
THR
L
56
−73.711
−8.891
−34.927
1.00
86.39
C


ATOM
6310
C
THR
L
56
−76.706
−8.988
−33.974
1.00
86.77
C


ATOM
6311
O
THR
L
56
−77.074
−9.564
−32.935
1.00
86.59
O


ATOM
6312
N
GLY
L
57
−77.126
−9.299
−35.192
1.00
87.23
N


ATOM
6313
CA
GLY
L
57
−77.993
−10.423
−35.490
1.00
87.57
C


ATOM
6314
C
GLY
L
57
−79.441
−10.290
−35.096
1.00
87.78
C


ATOM
6315
O
GLY
L
57
−80.049
−11.273
−34.658
1.00
88.10
O


ATOM
6316
N
ILE
L
58
−80.016
−9.101
−35.244
1.00
87.20
N


ATOM
6317
CA
ILE
L
58
−81.425
−8.978
−34.934
1.00
87.35
C


ATOM
6318
CB
ILE
L
58
−81.811
−8.327
−33.570
1.00
87.35
C


ATOM
6319
CG1
ILE
L
58
−81.827
−6.826
−33.620
1.00
88.03
C


ATOM
6320
CD1
ILE
L
58
−83.170
−6.347
−33.346
1.00
88.97
C


ATOM
6321
CG2
ILE
L
58
−81.034
−8.853
−32.365
1.00
86.77
C


ATOM
6322
C
ILE
L
58
−82.207
−8.508
−36.187
1.00
87.67
C


ATOM
6323
O
ILE
L
58
−81.730
−7.605
−36.890
1.00
87.84
O


ATOM
6324
N
PRO
L
59
−83.368
−9.149
−36.519
1.00
89.23
N


ATOM
6325
CA
PRO
L
59
−84.122
−8.763
−37.733
1.00
88.93
C


ATOM
6326
CB
PRO
L
59
−85.388
−9.623
−37.657
1.00
89.01
C


ATOM
6327
CG
PRO
L
59
−85.468
−10.082
−36.245
1.00
89.16
C


ATOM
6328
CD
PRO
L
59
−84.048
−10.261
−35.824
1.00
89.32
C


ATOM
6329
C
PRO
L
59
−84.504
−7.301
−37.868
1.00
88.54
C


ATOM
6330
O
PRO
L
59
−84.854
−6.653
−36.870
1.00
88.42
O


ATOM
6331
N
ALA
L
60
−84.477
−6.816
−39.137
1.00
83.84
N


ATOM
6332
CA
ALA
L
60
−84.799
−5.458
−39.570
1.00
82.93
C


ATOM
6333
CB
ALA
L
60
−84.606
−5.330
−41.062
1.00
82.66
C


ATOM
6334
C
ALA
L
60
−86.193
−5.018
−39.187
1.00
82.59
C


ATOM
6335
O
ALA
L
60
−86.461
−3.816
−39.182
1.00
82.81
O


ATOM
6336
N
ARG
L
61
−87.084
−5.969
−38.843
1.00
82.13
N


ATOM
6337
CA
ARG
L
61
−88.445
−5.623
−38.435
1.00
81.73
C


ATOM
6338
CB
ARG
L
61
−89.354
−6.847
−38.462
1.00
81.85
C


ATOM
6339
CG
ARG
L
61
−89.359
−7.659
−37.194
1.00
81.26
C


ATOM
6340
CD
ARG
L
61
−90.278
−8.822
−37.413
1.00
80.17
C


ATOM
6341
NE
ARG
L
61
−89.937
−9.963
−36.570
1.00
78.82
N


ATOM
6342
CZ
ARG
L
61
−89.029
−10.886
−36.873
1.00
76.91
C


ATOM
6343
NH1
ARG
L
61
−88.341
−10.807
−38.009
1.00
76.02
N


ATOM
6344
NH2
ARG
L
61
−88.809
−11.902
−36.046
1.00
75.12
N


ATOM
6345
C
ARG
L
61
−88.481
−4.876
−37.082
1.00
81.60
C


ATOM
6346
O
ARG
L
61
−89.505
−4.278
−36.719
1.00
81.34
O


ATOM
6347
N
PHE
L
62
−87.340
−4.909
−36.361
1.00
80.86
N


ATOM
6348
CA
PHE
L
62
−87.142
−4.233
−35.085
1.00
80.77
C


ATOM
6349
CB
PHE
L
62
−86.330
−5.095
−34.126
1.00
80.82
C


ATOM
6350
CG
PHE
L
62
−87.051
−6.304
−33.582
1.00
80.99
C


ATOM
6351
CD1
PHE
L
62
−87.891
−6.194
−32.474
1.00
80.48
C


ATOM
6352
CE1
PHE
L
62
−88.549
−7.317
−31.961
1.00
80.37
C


ATOM
6353
CZ
PHE
L
62
−88.358
−8.552
−32.544
1.00
80.39
C


ATOM
6354
CE2
PHE
L
62
−87.521
−8.680
−33.637
1.00
80.11
C


ATOM
6355
CD2
PHE
L
62
−86.869
−7.558
−34.156
1.00
80.48
C


ATOM
6356
C
PHE
L
62
−86.454
−2.885
−35.304
1.00
80.72
C


ATOM
6357
O
PHE
L
62
−85.473
−2.781
−36.065
1.00
80.48
O


ATOM
6358
N
SER
L
63
−86.988
−1.842
−34.650
1.00
80.01
N


ATOM
6359
CA
SER
L
63
−86.451
−0.496
−34.796
1.00
79.87
C


ATOM
6360
CB
SER
L
63
−87.097
0.188
−35.998
1.00
79.76
C


ATOM
6361
OG
SER
L
63
−88.492
0.346
−35.794
1.00
79.38
O


ATOM
6362
C
SER
L
63
−86.716
0.313
−33.545
1.00
79.80
C


ATOM
6363
O
SER
L
63
−87.756
0.134
−32.899
1.00
80.10
O


ATOM
6364
N
GLY
L
64
−85.796
1.216
−33.233
1.00
78.03
N


ATOM
6365
CA
GLY
L
64
−85.932
2.069
−32.064
1.00
77.81
C


ATOM
6366
C
GLY
L
64
−85.979
3.545
−32.369
1.00
77.75
C


ATOM
6367
O
GLY
L
64
−85.410
4.015
−33.362
1.00
77.54
O


ATOM
6368
N
SER
L
65
−86.648
4.286
−31.498
1.00
79.48
N


ATOM
6369
CA
SER
L
65
−86.786
5.725
−31.645
1.00
79.85
C


ATOM
6370
CB
SER
L
65
−88.071
6.061
−32.395
1.00
80.07
C


ATOM
6371
OG
SER
L
65
−88.936
6.916
−31.658
1.00
81.22
O


ATOM
6372
C
SER
L
65
−86.802
6.406
−30.303
1.00
79.90
C


ATOM
6373
O
SER
L
65
−87.218
5.810
−29.299
1.00
80.21
O


ATOM
6374
N
GLY
L
66
−86.396
7.669
−30.313
1.00
80.25
N


ATOM
6375
CA
GLY
L
66
−86.375
8.510
−29.129
1.00
80.40
C


ATOM
6376
C
GLY
L
66
−85.013
9.072
−28.796
1.00
80.53
C


ATOM
6377
O
GLY
L
66
−83.974
8.600
−29.272
1.00
80.70
O


ATOM
6378
N
SER
L
67
−85.042
10.114
−27.981
1.00
81.13
N


ATOM
6379
CA
SER
L
67
−83.919
10.852
−27.414
1.00
80.80
C


ATOM
6380
CB
SER
L
67
−83.189
11.697
−28.461
1.00
80.91
C


ATOM
6381
OG
SER
L
67
−81.853
12.039
−28.110
1.00
80.63
O


ATOM
6382
C
SER
L
67
−84.608
11.712
−26.369
1.00
80.78
C


ATOM
6383
O
SER
L
67
−85.638
12.359
−26.648
1.00
80.82
O


ATOM
6384
N
GLY
L
68
−84.106
11.629
−25.152
1.00
80.25
N


ATOM
6385
CA
GLY
L
68
−84.685
12.411
−24.086
1.00
80.31
C


ATOM
6386
C
GLY
L
68
−85.363
11.660
−22.985
1.00
80.31
C


ATOM
6387
O
GLY
L
68
−84.718
11.273
−22.015
1.00
80.51
O


ATOM
6388
N
THR
L
69
−86.675
11.515
−23.100
1.00
82.51
N


ATOM
6389
CA
THR
L
69
−87.485
10.843
−22.083
1.00
82.90
C


ATOM
6390
CB
THR
L
69
−88.233
11.868
−21.213
1.00
82.86
C


ATOM
6391
OG1
THR
L
69
−88.760
12.908
−22.052
1.00
83.26
O


ATOM
6392
CG2
THR
L
69
−87.358
12.459
−20.113
1.00
82.48
C


ATOM
6393
C
THR
L
69
−88.458
9.850
−22.679
1.00
83.07
C


ATOM
6394
O
THR
L
69
−88.748
8.848
−22.029
1.00
83.38
O


ATOM
6395
N
ASP
L
70
−88.978
10.129
−23.894
1.00
81.27
N


ATOM
6396
CA
ASP
L
70
−89.936
9.260
−24.569
1.00
81.42
C


ATOM
6397
CB
ASP
L
70
−91.097
10.072
−25.179
1.00
81.76
C


ATOM
6398
CG
ASP
L
70
−92.078
10.729
−24.185
1.00
83.01
C


ATOM
6399
OD1
ASP
L
70
−91.678
10.988
−23.004
1.00
84.07
O


ATOM
6400
OD2
ASP
L
70
−93.239
11.000
−24.587
1.00
84.40
O


ATOM
6401
C
ASP
L
70
−89.221
8.380
−25.574
1.00
81.29
C


ATOM
6402
O
ASP
L
70
−88.591
8.878
−26.524
1.00
81.22
O


ATOM
6403
N
PHE
L
71
−89.282
7.055
−25.315
1.00
79.43
N


ATOM
6404
CA
PHE
L
71
−88.621
6.023
−26.116
1.00
79.47
C


ATOM
6405
CB
PHE
L
71
−87.491
5.341
−25.318
1.00
79.30
C


ATOM
6406
CG
PHE
L
71
−86.342
6.288
−25.047
1.00
79.06
C


ATOM
6407
CD1
PHE
L
71
−85.296
6.423
−25.959
1.00
78.12
C


ATOM
6408
CE1
PHE
L
71
−84.259
7.324
−25.724
1.00
77.00
C


ATOM
6409
CZ
PHE
L
71
−84.270
8.099
−24.591
1.00
77.40
C


ATOM
6410
CE2
PHE
L
71
−85.299
7.997
−23.685
1.00
77.46
C


ATOM
6411
CD2
PHE
L
71
−86.331
7.089
−23.906
1.00
78.77
C


ATOM
6412
C
PHE
L
71
−89.580
5.022
−26.738
1.00
79.78
C


ATOM
6413
O
PHE
L
71
−90.625
4.711
−26.151
1.00
79.63
O


ATOM
6414
N
THR
L
72
−89.225
4.525
−27.942
1.00
81.31
N


ATOM
6415
CA
THR
L
72
−90.081
3.603
−28.663
1.00
81.88
C


ATOM
6416
CB
THR
L
72
−91.065
4.427
−29.511
1.00
81.84
C


ATOM
6417
OG1
THR
L
72
−92.207
4.693
−28.695
1.00
81.96
O


ATOM
6418
CG2
THR
L
72
−91.477
3.749
−30.838
1.00
81.93
C


ATOM
6419
C
THR
L
72
−89.439
2.388
−29.356
1.00
82.43
C


ATOM
6420
O
THR
L
72
−88.468
2.512
−30.116
1.00
82.66
O


ATOM
6421
N
LEU
L
73
−90.034
1.210
−29.100
1.00
83.21
N


ATOM
6422
CA
LEU
L
73
−89.652
−0.054
−29.719
1.00
83.49
C


ATOM
6423
CB
LEU
L
73
−89.457
−1.179
−28.699
1.00
83.62
C


ATOM
6424
CG
LEU
L
73
−89.058
−2.517
−29.301
1.00
82.79
C


ATOM
6425
CD1
LEU
L
73
−87.582
−2.573
−29.584
1.00
82.29
C


ATOM
6426
CD2
LEU
L
73
−89.460
−3.618
−28.413
1.00
82.50
C


ATOM
6427
C
LEU
L
73
−90.770
−0.407
−30.711
1.00
83.73
C


ATOM
6428
O
LEU
L
73
−91.959
−0.372
−30.355
1.00
83.42
O


ATOM
6429
N
THR
L
74
−90.369
−0.732
−31.956
1.00
86.82
N


ATOM
6430
CA
THR
L
74
−91.277
−1.021
−33.053
1.00
87.24
C


ATOM
6431
CB
THR
L
74
−91.296
0.199
−34.006
1.00
87.18
C


ATOM
6432
OG1
THR
L
74
−91.718
1.370
−33.299
1.00
87.71
O


ATOM
6433
CG2
THR
L
74
−92.148
−0.020
−35.242
1.00
87.14
C


ATOM
6434
C
THR
L
74
−90.953
−2.305
−33.805
1.00
87.64
C


ATOM
6435
O
THR
L
74
−89.853
−2.457
−34.353
1.00
87.70
O


ATOM
6436
N
ILE
L
75
−91.949
−3.209
−33.850
1.00
89.18
N


ATOM
6437
CA
ILE
L
75
−91.918
−4.473
−34.589
1.00
89.53
C


ATOM
6438
CB
ILE
L
75
−92.331
−5.734
−33.753
1.00
89.53
C


ATOM
6439
CG1
ILE
L
75
−91.573
−5.839
−32.405
1.00
89.06
C


ATOM
6440
CD1
ILE
L
75
−92.289
−5.229
−31.167
1.00
89.50
C


ATOM
6441
CG2
ILE
L
75
−92.117
−7.001
−34.571
1.00
89.83
C


ATOM
6442
C
ILE
L
75
−92.877
−4.185
−35.761
1.00
89.77
C


ATOM
6443
O
ILE
L
75
−94.087
−4.009
−35.537
1.00
89.63
O


ATOM
6444
N
SER
L
76
−92.317
−4.061
−36.993
1.00
91.77
N


ATOM
6445
CA
SER
L
76
−93.070
−3.740
−38.216
1.00
92.22
C


ATOM
6446
CB
SER
L
76
−92.136
−3.517
−39.405
1.00
92.21
C


ATOM
6447
OG
SER
L
76
−91.592
−4.712
−39.940
1.00
92.40
O


ATOM
6448
C
SER
L
76
−94.186
−4.736
−38.535
1.00
92.44
C


ATOM
6449
O
SER
L
76
−95.344
−4.330
−38.640
1.00
92.48
O


ATOM
6450
N
SER
L
77
−93.837
−6.033
−38.661
1.00
93.86
N


ATOM
6451
CA
SER
L
77
−94.764
−7.135
−38.930
1.00
94.04
C


ATOM
6452
CB
SER
L
77
−94.588
−7.661
−40.356
1.00
94.11
C


ATOM
6453
OG
SER
L
77
−93.307
−8.246
−40.564
1.00
94.95
O


ATOM
6454
C
SER
L
77
−94.478
−8.241
−37.914
1.00
93.95
C


ATOM
6455
O
SER
L
77
−93.479
−8.965
−38.057
1.00
94.05
O


ATOM
6456
N
LEU
L
78
−95.325
−8.358
−36.873
1.00
91.52
N


ATOM
6457
CA
LEU
L
78
−95.143
−9.379
−35.846
1.00
91.26
C


ATOM
6458
CB
LEU
L
78
−96.280
−9.355
−34.816
1.00
90.85
C


ATOM
6459
CG
LEU
L
78
−96.090
−8.432
−33.626
1.00
91.04
C


ATOM
6460
CD1
LEU
L
78
−97.403
−8.180
−32.922
1.00
90.49
C


ATOM
6461
CD2
LEU
L
78
−95.079
−8.997
−32.635
1.00
90.90
C


ATOM
6462
C
LEU
L
78
−94.984
−10.795
−36.418
1.00
91.43
C


ATOM
6463
O
LEU
L
78
−95.784
−11.244
−37.252
1.00
91.64
O


ATOM
6464
N
GLU
L
79
−93.919
−11.477
−35.993
1.00
91.30
N


ATOM
6465
CA
GLU
L
79
−93.657
−12.867
−36.364
1.00
91.18
C


ATOM
6466
CB
GLU
L
79
−92.191
−13.076
−36.792
1.00
91.43
C


ATOM
6467
CG
GLU
L
79
−91.819
−12.376
−38.093
1.00
92.72
C


ATOM
6468
CD
GLU
L
79
−92.563
−12.807
−39.343
1.00
95.02
C


ATOM
6469
OE1
GLU
L
79
−92.181
−13.849
−39.923
1.00
96.62
O


ATOM
6470
OE2
GLU
L
79
−93.520
−12.106
−39.747
1.00
95.71
O


ATOM
6471
C
GLU
L
79
−94.037
−13.648
−35.090
1.00
90.77
C


ATOM
6472
O
GLU
L
79
−94.210
−13.018
−34.051
1.00
90.66
O


ATOM
6473
N
PRO
L
80
−94.246
−14.970
−35.092
1.00
91.38
N


ATOM
6474
CA
PRO
L
80
−94.642
−15.622
−33.827
1.00
91.17
C


ATOM
6475
CB
PRO
L
80
−95.162
−16.983
−34.277
1.00
90.98
C


ATOM
6476
CG
PRO
L
80
−94.416
−17.259
−35.530
1.00
91.14
C


ATOM
6477
CD
PRO
L
80
−94.137
−15.944
−36.197
1.00
91.24
C


ATOM
6478
C
PRO
L
80
−93.529
−15.710
−32.776
1.00
90.98
C


ATOM
6479
O
PRO
L
80
−93.824
−15.728
−31.579
1.00
90.95
O


ATOM
6480
N
GLU
L
81
−92.252
−15.738
−33.220
1.00
92.87
N


ATOM
6481
CA
GLU
L
81
−91.086
−15.803
−32.334
1.00
92.64
C


ATOM
6482
CB
GLU
L
81
−89.820
−16.179
−33.114
1.00
92.93
C


ATOM
6483
CG
GLU
L
81
−89.377
−15.155
−34.143
1.00
94.89
C


ATOM
6484
CD
GLU
L
81
−89.752
−15.458
−35.582
1.00
98.75
C


ATOM
6485
OE1
GLU
L
81
−88.963
−15.078
−36.483
1.00
100.80
O


ATOM
6486
OE2
GLU
L
81
−90.828
−16.065
−35.812
1.00
99.87
O


ATOM
6487
C
GLU
L
81
−90.882
−14.511
−31.519
1.00
91.98
C


ATOM
6488
O
GLU
L
81
−90.150
−14.520
−30.521
1.00
92.22
O


ATOM
6489
N
ASP
L
82
−91.546
−13.415
−31.959
1.00
89.40
N


ATOM
6490
CA
ASP
L
82
−91.539
−12.075
−31.379
1.00
87.95
C


ATOM
6491
CB
ASP
L
82
−91.895
−11.046
−32.449
1.00
87.98
C


ATOM
6492
CG
ASP
L
82
−90.926
−10.958
−33.602
1.00
88.45
C


ATOM
6493
OD1
ASP
L
82
−89.798
−11.506
−33.485
1.00
88.93
O


ATOM
6494
OD2
ASP
L
82
−91.284
−10.338
−34.620
1.00
88.57
O


ATOM
6495
C
ASP
L
82
−92.511
−11.901
−30.230
1.00
87.09
C


ATOM
6496
O
ASP
L
82
−92.614
−10.788
−29.709
1.00
87.36
O


ATOM
6497
N
PHE
L
83
−93.237
−12.953
−29.829
1.00
83.84
N


ATOM
6498
CA
PHE
L
83
−94.176
−12.805
−28.726
1.00
82.86
C


ATOM
6499
CB
PHE
L
83
−95.420
−13.661
−28.959
1.00
83.10
C


ATOM
6500
CG
PHE
L
83
−96.319
−13.096
−30.029
1.00
83.64
C


ATOM
6501
CD1
PHE
L
83
−97.359
−12.230
−29.701
1.00
83.50
C


ATOM
6502
CE1
PHE
L
83
−98.177
−11.689
−30.693
1.00
83.49
C


ATOM
6503
CZ
PHE
L
83
−97.966
−12.014
−32.016
1.00
84.02
C


ATOM
6504
CE2
PHE
L
83
−96.938
−12.869
−32.365
1.00
83.78
C


ATOM
6505
CD2
PHE
L
83
−96.117
−13.413
−31.369
1.00
83.83
C


ATOM
6506
C
PHE
L
83
−93.453
−13.101
−27.412
1.00
82.13
C


ATOM
6507
O
PHE
L
83
−93.299
−14.268
−27.028
1.00
82.31
O


ATOM
6508
N
ALA
L
84
−92.949
−12.033
−26.751
1.00
76.94
N


ATOM
6509
CA
ALA
L
84
−92.164
−12.159
−25.522
1.00
75.79
C


ATOM
6510
CB
ALA
L
84
−90.682
−12.323
−25.879
1.00
75.58
C


ATOM
6511
C
ALA
L
84
−92.334
−10.966
−24.594
1.00
75.01
C


ATOM
6512
O
ALA
L
84
−93.255
−10.160
−24.765
1.00
75.03
O


ATOM
6513
N
VAL
L
85
−91.438
−10.861
−23.600
1.00
71.29
N


ATOM
6514
CA
VAL
L
85
−91.432
−9.745
−22.678
1.00
70.32
C


ATOM
6515
CB
VAL
L
85
−91.437
−10.138
−21.183
1.00
70.16
C


ATOM
6516
CG1
VAL
L
85
−91.439
−8.908
−20.288
1.00
69.53
C


ATOM
6517
CG2
VAL
L
85
−92.651
−10.994
−20.866
1.00
69.88
C


ATOM
6518
C
VAL
L
85
−90.304
−8.797
−23.120
1.00
70.01
C


ATOM
6519
O
VAL
L
85
−89.175
−9.222
−23.397
1.00
69.49
O


ATOM
6520
N
TYR
L
86
−90.654
−7.517
−23.255
1.00
71.60
N


ATOM
6521
CA
TYR
L
86
−89.729
−6.496
−23.705
1.00
71.23
C


ATOM
6522
CB
TYR
L
86
−90.308
−5.790
−24.934
1.00
71.07
C


ATOM
6523
CG
TYR
L
86
−90.265
−6.692
−26.152
1.00
71.27
C


ATOM
6524
CD1
TYR
L
86
−91.321
−7.560
−26.446
1.00
71.96
C


ATOM
6525
CE1
TYR
L
86
−91.269
−8.413
−27.552
1.00
72.18
C


ATOM
6526
CZ
TYR
L
86
−90.142
−8.412
−28.365
1.00
72.28
C


ATOM
6527
OH
TYR
L
86
−90.035
−9.235
−29.460
1.00
72.35
O


ATOM
6528
CE2
TYR
L
86
−89.084
−7.566
−28.083
1.00
71.38
C


ATOM
6529
CD2
TYR
L
86
−89.139
−6.736
−26.969
1.00
71.38
C


ATOM
6530
C
TYR
L
86
−89.346
−5.577
−22.575
1.00
71.10
C


ATOM
6531
O
TYR
L
86
−90.215
−5.087
−21.856
1.00
70.74
O


ATOM
6532
N
TYR
L
87
−88.031
−5.404
−22.384
1.00
72.64
N


ATOM
6533
CA
TYR
L
87
−87.469
−4.603
−21.302
1.00
72.75
C


ATOM
6534
CB
TYR
L
87
−86.618
−5.511
−20.388
1.00
72.34
C


ATOM
6535
CG
TYR
L
87
−87.400
−6.389
−19.435
1.00
71.58
C


ATOM
6536
CD1
TYR
L
87
−87.502
−7.761
−19.645
1.00
70.97
C


ATOM
6537
CE1
TYR
L
87
−88.202
−8.579
−18.759
1.00
70.24
C


ATOM
6538
CZ
TYR
L
87
−88.801
−8.023
−17.642
1.00
71.79
C


ATOM
6539
OH
TYR
L
87
−89.522
−8.801
−16.773
1.00
73.47
O


ATOM
6540
CE2
TYR
L
87
−88.691
−6.665
−17.400
1.00
72.08
C


ATOM
6541
CD2
TYR
L
87
−87.982
−5.860
−18.289
1.00
72.03
C


ATOM
6542
C
TYR
L
87
−86.616
−3.414
−21.770
1.00
73.36
C


ATOM
6543
O
TYR
L
87
−85.750
−3.591
−22.628
1.00
73.54
O


ATOM
6544
N
CYS
L
88
−86.835
−2.217
−21.188
1.00
77.68
N


ATOM
6545
CA
CYS
L
88
−86.028
−1.041
−21.514
1.00
78.32
C


ATOM
6546
CB
CYS
L
88
−86.872
0.181
−21.865
1.00
78.96
C


ATOM
6547
SG
CYS
L
88
−88.008
0.730
−20.559
1.00
82.86
S


ATOM
6548
C
CYS
L
88
−85.079
−0.775
−20.355
1.00
77.79
C


ATOM
6549
O
CYS
L
88
−85.490
−0.841
−19.189
1.00
78.19
O


ATOM
6550
N
GLN
L
89
−83.803
−0.530
−20.661
1.00
70.42
N


ATOM
6551
CA
GLN
L
89
−82.794
−0.329
−19.635
1.00
69.48
C


ATOM
6552
CB
GLN
L
89
−81.862
−1.567
−19.598
1.00
69.41
C


ATOM
6553
CG
GLN
L
89
−80.596
−1.517
−18.716
1.00
68.63
C


ATOM
6554
CD
GLN
L
89
−79.316
−1.228
−19.493
1.00
68.91
C


ATOM
6555
OE1
GLN
L
89
−78.460
−0.440
−19.069
1.00
70.17
O


ATOM
6556
NE2
GLN
L
89
−79.141
−1.849
−20.646
1.00
66.41
N


ATOM
6557
C
GLN
L
89
−82.029
0.950
−19.865
1.00
69.23
C


ATOM
6558
O
GLN
L
89
−81.925
1.426
−20.997
1.00
69.03
O


ATOM
6559
N
VAL
L
90
−81.461
1.492
−18.775
1.00
68.06
N


ATOM
6560
CA
VAL
L
90
−80.656
2.706
−18.760
1.00
67.45
C


ATOM
6561
CB
VAL
L
90
−81.630
3.921
−18.668
1.00
67.12
C


ATOM
6562
CG1
VAL
L
90
−81.574
4.653
−17.333
1.00
65.60
C


ATOM
6563
CG2
VAL
L
90
−81.443
4.859
−19.837
1.00
66.82
C


ATOM
6564
C
VAL
L
90
−79.600
2.620
−17.618
1.00
67.58
C


ATOM
6565
O
VAL
L
90
−79.731
1.769
−16.729
1.00
67.28
O


ATOM
6566
N
TRP
L
91
−78.554
3.479
−17.661
1.00
68.82
N


ATOM
6567
CA
TRP
L
91
−77.536
3.549
−16.616
1.00
68.81
C


ATOM
6568
CB
TRP
L
91
−76.122
3.592
−17.187
1.00
68.19
C


ATOM
6569
CG
TRP
L
91
−75.783
2.532
−18.187
1.00
66.71
C


ATOM
6570
CD1
TRP
L
91
−75.505
2.718
−19.507
1.00
66.34
C


ATOM
6571
NE1
TRP
L
91
−75.241
1.517
−20.112
1.00
64.66
N


ATOM
6572
CE2
TRP
L
91
−75.303
0.524
−19.173
1.00
65.19
C


ATOM
6573
CD2
TRP
L
91
−75.648
1.130
−17.944
1.00
65.02
C


ATOM
6574
CE3
TRP
L
91
−75.782
0.317
−16.803
1.00
63.85
C


ATOM
6575
CZ3
TRP
L
91
−75.544
−1.041
−16.918
1.00
63.53
C


ATOM
6576
CH2
TRP
L
91
−75.188
−1.613
−18.147
1.00
64.30
C


ATOM
6577
CZ2
TRP
L
91
−75.069
−0.853
−19.289
1.00
65.06
C


ATOM
6578
C
TRP
L
91
−77.833
4.838
−15.823
1.00
69.85
C


ATOM
6579
O
TRP
L
91
−78.470
5.746
−16.355
1.00
70.18
O


ATOM
6580
N
ASP
L
92
−77.387
4.921
−14.559
1.00
75.57
N


ATOM
6581
CA
ASP
L
92
−77.627
6.045
−13.651
1.00
76.89
C


ATOM
6582
CB
ASP
L
92
−79.015
5.835
−12.988
1.00
77.25
C


ATOM
6583
CG
ASP
L
92
−79.606
6.941
−12.110
1.00
79.26
C


ATOM
6584
OD1
ASP
L
92
−80.722
6.727
−11.559
1.00
80.34
O


ATOM
6585
OD2
ASP
L
92
−78.948
8.033
−11.967
1.00
81.56
O


ATOM
6586
C
ASP
L
92
−76.487
6.084
−12.615
1.00
77.32
C


ATOM
6587
O
ASP
L
92
−75.542
5.313
−12.746
1.00
77.83
O


ATOM
6588
N
SER
L
93
−76.544
6.982
−11.610
1.00
79.15
N


ATOM
6589
CA
SER
L
93
−75.499
7.077
−10.590
1.00
79.73
C


ATOM
6590
CB
SER
L
93
−75.288
8.516
−10.152
1.00
79.60
C


ATOM
6591
OG
SER
L
93
−76.511
9.086
−9.725
1.00
79.94
O


ATOM
6592
C
SER
L
93
−75.697
6.163
−9.379
1.00
80.03
C


ATOM
6593
O
SER
L
93
−74.897
5.233
−9.249
1.00
80.11
O


ATOM
6594
N
SER
L
94
−76.748
6.441
−8.493
1.00
84.21
N


ATOM
6595
CA
SER
L
94
−77.148
5.744
−7.232
1.00
84.27
C


ATOM
6596
CB
SER
L
94
−78.393
6.365
−6.597
1.00
84.59
C


ATOM
6597
OG
SER
L
94
−79.012
5.503
−5.650
1.00
85.72
O


ATOM
6598
C
SER
L
94
−77.349
4.300
−7.562
1.00
84.06
C


ATOM
6599
O
SER
L
94
−76.424
3.532
−7.245
1.00
85.11
O


ATOM
6600
N
PRO
L
95
−78.446
3.857
−8.247
1.00
79.86
N


ATOM
6601
CA
PRO
L
95
−78.457
2.457
−8.692
1.00
78.96
C


ATOM
6602
CB
PRO
L
95
−79.941
2.139
−8.851
1.00
79.07
C


ATOM
6603
CG
PRO
L
95
−80.647
3.510
−9.000
1.00
80.00
C


ATOM
6604
CD
PRO
L
95
−79.618
4.596
−8.780
1.00
79.83
C


ATOM
6605
C
PRO
L
95
−77.667
2.548
−10.032
1.00
77.85
C


ATOM
6606
O
PRO
L
95
−77.942
3.448
−10.846
1.00
78.00
O


ATOM
6607
N
PRO
L
96
−76.603
1.761
−10.262
1.00
70.15
N


ATOM
6608
CA
PRO
L
96
−75.851
1.923
−11.509
1.00
69.43
C


ATOM
6609
CB
PRO
L
96
−74.619
1.023
−11.313
1.00
69.39
C


ATOM
6610
CG
PRO
L
96
−74.644
0.592
−9.927
1.00
69.41
C


ATOM
6611
CD
PRO
L
96
−76.042
0.682
−9.445
1.00
70.05
C


ATOM
6612
C
PRO
L
96
−76.651
1.573
−12.768
1.00
68.90
C


ATOM
6613
O
PRO
L
96
−76.341
2.061
−13.862
1.00
68.98
O


ATOM
6614
N
VAL
L
97
−77.686
0.745
−12.598
1.00
66.11
N


ATOM
6615
CA
VAL
L
97
−78.557
0.277
−13.659
1.00
65.48
C


ATOM
6616
CB
VAL
L
97
−78.293
−1.226
−13.890
1.00
65.27
C


ATOM
6617
CG1
VAL
L
97
−78.875
−2.070
−12.764
1.00
64.59
C


ATOM
6618
CG2
VAL
L
97
−78.798
−1.693
−15.259
1.00
65.12
C


ATOM
6619
C
VAL
L
97
−80.005
0.547
−13.304
1.00
65.49
C


ATOM
6620
O
VAL
L
97
−80.340
0.630
−12.131
1.00
65.64
O


ATOM
6621
N
VAL
L
98
−80.859
0.719
−14.312
1.00
67.13
N


ATOM
6622
CA
VAL
L
98
−82.298
0.927
−14.142
1.00
67.28
C


ATOM
6623
CB
VAL
L
98
−82.792
2.409
−14.141
1.00
67.09
C


ATOM
6624
CG1
VAL
L
98
−84.293
2.487
−13.853
1.00
66.37
C


ATOM
6625
CG2
VAL
L
98
−82.029
3.259
−13.133
1.00
67.24
C


ATOM
6626
C
VAL
L
98
−82.954
0.110
−15.239
1.00
67.85
C


ATOM
6627
O
VAL
L
98
−82.553
0.205
−16.409
1.00
67.78
O


ATOM
6628
N
PHE
L
99
−83.944
−0.706
−14.863
1.00
70.44
N


ATOM
6629
CA
PHE
L
99
−84.703
−1.527
−15.806
1.00
70.85
C


ATOM
6630
CB
PHE
L
99
−84.611
−3.026
−15.427
1.00
70.67
C


ATOM
6631
CG
PHE
L
99
−83.397
−3.764
−15.931
1.00
69.18
C


ATOM
6632
CD1
PHE
L
99
−82.386
−4.146
−15.060
1.00
68.29
C


ATOM
6633
CE1
PHE
L
99
−81.243
−4.810
−15.532
1.00
68.03
C


ATOM
6634
CZ
PHE
L
99
−81.128
−5.108
−16.874
1.00
67.77
C


ATOM
6635
CE2
PHE
L
99
−82.132
−4.742
−17.750
1.00
67.63
C


ATOM
6636
CD2
PHE
L
99
−83.266
−4.080
−17.278
1.00
67.90
C


ATOM
6637
C
PHE
L
99
−86.164
−1.108
−15.758
1.00
71.49
C


ATOM
6638
O
PHE
L
99
−86.664
−0.705
−14.712
1.00
71.24
O


ATOM
6639
N
GLY
L
100
−86.847
−1.233
−16.875
1.00
73.30
N


ATOM
6640
CA
GLY
L
100
−88.275
−0.956
−16.922
1.00
74.74
C


ATOM
6641
C
GLY
L
100
−89.021
−2.176
−16.395
1.00
75.62
C


ATOM
6642
O
GLY
L
100
−88.418
−3.247
−16.191
1.00
75.82
O


ATOM
6643
N
GLY
L
101
−90.325
−2.017
−16.173
1.00
77.20
N


ATOM
6644
CA
GLY
L
101
−91.194
−3.082
−15.670
1.00
78.41
C


ATOM
6645
C
GLY
L
101
−91.351
−4.249
−16.630
1.00
79.36
C


ATOM
6646
O
GLY
L
101
−91.566
−5.391
−16.204
1.00
79.33
O


ATOM
6647
N
GLY
L
102
−91.211
−3.952
−17.923
1.00
79.85
N


ATOM
6648
CA
GLY
L
102
−91.351
−4.918
−18.998
1.00
80.96
C


ATOM
6649
C
GLY
L
102
−92.736
−4.862
−19.597
1.00
81.95
C


ATOM
6650
O
GLY
L
102
−93.700
−4.480
−18.921
1.00
82.12
O


ATOM
6651
N
THR
L
103
−92.842
−5.243
−20.873
1.00
82.02
N


ATOM
6652
CA
THR
L
103
−94.110
−5.263
−21.594
1.00
82.88
C


ATOM
6653
CB
THR
L
103
−94.169
−4.102
−22.607
1.00
82.67
C


ATOM
6654
OG1
THR
L
103
−94.459
−2.902
−21.906
1.00
82.87
O


ATOM
6655
CG2
THR
L
103
−95.193
−4.313
−23.719
1.00
82.37
C


ATOM
6656
C
THR
L
103
−94.255
−6.640
−22.208
1.00
83.86
C


ATOM
6657
O
THR
L
103
−93.358
−7.072
−22.945
1.00
83.91
O


ATOM
6658
N
LYS
L
104
−95.367
−7.334
−21.899
1.00
84.99
N


ATOM
6659
CA
LYS
L
104
−95.620
−8.650
−22.460
1.00
86.22
C


ATOM
6660
CB
LYS
L
104
−96.429
−9.521
−21.486
1.00
86.41
C


ATOM
6661
CG
LYS
L
104
−96.530
−10.982
−21.928
1.00
87.85
C


ATOM
6662
CD
LYS
L
104
−97.400
−11.773
−20.983
1.00
90.43
C


ATOM
6663
CE
LYS
L
104
−98.252
−12.784
−21.725
1.00
92.63
C


ATOM
6664
NZ
LYS
L
104
−99.625
−12.928
−21.124
1.00
94.80
N


ATOM
6665
C
LYS
L
104
−96.359
−8.467
−23.780
1.00
86.73
C


ATOM
6666
O
LYS
L
104
−97.348
−7.744
−23.820
1.00
87.11
O


ATOM
6667
N
VAL
L
105
−95.869
−9.096
−24.858
1.00
87.60
N


ATOM
6668
CA
VAL
L
105
−96.499
−9.049
−26.181
1.00
88.62
C


ATOM
6669
CB
VAL
L
105
−95.529
−8.643
−27.320
1.00
88.32
C


ATOM
6670
CG1
VAL
L
105
−96.210
−8.683
−28.680
1.00
87.75
C


ATOM
6671
CG2
VAL
L
105
−94.934
−7.267
−27.067
1.00
88.51
C


ATOM
6672
C
VAL
L
105
−97.097
−10.445
−26.370
1.00
89.97
C


ATOM
6673
O
VAL
L
105
−96.359
−11.421
−26.588
1.00
90.13
O


ATOM
6674
N
GLU
L
106
−98.437
−10.530
−26.218
1.00
92.87
N


ATOM
6675
CA
GLU
L
106
−99.263
−11.740
−26.323
1.00
94.05
C


ATOM
6676
CB
GLU
L
106
−100.269
−11.748
−25.136
1.00
93.91
C


ATOM
6677
CG
GLU
L
106
−101.676
−12.282
−25.390
1.00
95.35
C


ATOM
6678
CD
GLU
L
106
−102.706
−12.100
−24.284
1.00
97.66
C


ATOM
6679
OE1
GLU
L
106
−103.918
−12.230
−24.581
1.00
98.65
O


ATOM
6680
OE2
GLU
L
106
−102.309
−11.837
−23.123
1.00
98.64
O


ATOM
6681
C
GLU
L
106
−99.950
−11.798
−27.714
1.00
94.62
C


ATOM
6682
O
GLU
L
106
−100.023
−10.774
−28.395
1.00
94.58
O


ATOM
6683
N
ILE
L
107
−100.419
−12.986
−28.144
1.00
95.83
N


ATOM
6684
CA
ILE
L
107
−101.120
−13.133
−29.426
1.00
96.60
C


ATOM
6685
CB
ILE
L
107
−100.935
−14.524
−30.095
1.00
96.59
C


ATOM
6686
CG1
ILE
L
107
−99.502
−15.040
−29.959
1.00
97.14
C


ATOM
6687
CD1
ILE
L
107
−99.405
−16.507
−29.631
1.00
99.25
C


ATOM
6688
CG2
ILE
L
107
−101.348
−14.475
−31.577
1.00
96.87
C


ATOM
6689
C
ILE
L
107
−102.607
−12.810
−29.244
1.00
96.95
C


ATOM
6690
O
ILE
L
107
−103.225
−13.346
−28.328
1.00
96.97
O


ATOM
6691
N
LYS
L
108
−103.176
−11.938
−30.108
1.00
96.98
N


ATOM
6692
CA
LYS
L
108
−104.599
−11.607
−30.058
1.00
97.38
C


ATOM
6693
CB
LYS
L
108
−104.900
−10.160
−30.481
1.00
97.23
C


ATOM
6694
C
LYS
L
108
−105.325
−12.611
−30.945
1.00
97.70
C


ATOM
6695
O
LYS
L
108
−104.957
−12.802
−32.106
1.00
97.86
O


ATOM
6696
N
ARG
L
109
−106.320
−13.293
−30.379
1.00
97.85
N


ATOM
6697
CA
ARG
L
109
−107.120
−14.292
−31.082
1.00
98.21
C


ATOM
6698
CB
ARG
L
109
−106.779
−15.722
−30.606
1.00
98.23
C


ATOM
6699
C
ARG
L
109
−108.608
−14.008
−30.891
1.00
98.48
C


ATOM
6700
O
ARG
L
109
−109.004
−13.183
−30.048
1.00
98.46
O


ATOM
6701
N
THR
L
110
−109.425
−14.704
−31.702
1.00
97.91
N


ATOM
6702
CA
THR
L
110
−110.881
−14.658
−31.715
1.00
98.06
C


ATOM
6703
CB
THR
L
110
−111.405
−15.547
−32.862
1.00
98.16
C


ATOM
6704
OG1
THR
L
110
−112.496
−16.344
−32.388
1.00
99.22
O


ATOM
6705
CG2
THR
L
110
−110.303
−16.459
−33.489
1.00
98.04
C


ATOM
6706
C
THR
L
110
−111.359
−15.063
−30.318
1.00
98.03
C


ATOM
6707
O
THR
L
110
−110.979
−16.131
−29.828
1.00
98.07
O


ATOM
6708
N
VAL
L
111
−112.132
−14.190
−29.665
1.00
96.70
N


ATOM
6709
CA
VAL
L
111
−112.642
−14.402
−28.307
1.00
97.03
C


ATOM
6710
CB
VAL
L
111
−113.562
−13.244
−27.827
1.00
97.09
C


ATOM
6711
CG1
VAL
L
111
−113.975
−13.413
−26.361
1.00
96.68
C


ATOM
6712
CG2
VAL
L
111
−112.899
−11.889
−28.048
1.00
97.07
C


ATOM
6713
C
VAL
L
111
−113.266
−15.799
−28.123
1.00
97.35
C


ATOM
6714
O
VAL
L
111
−114.399
−16.045
−28.535
1.00
97.33
O


ATOM
6715
N
ALA
L
112
−112.487
−16.715
−27.528
1.00
98.73
N


ATOM
6716
CA
ALA
L
112
−112.891
−18.095
−27.255
1.00
98.93
C


ATOM
6717
CB
ALA
L
112
−111.740
−19.049
−27.531
1.00
98.76
C


ATOM
6718
C
ALA
L
112
−113.411
−18.247
−25.814
1.00
99.15
C


ATOM
6719
O
ALA
L
112
−113.018
−17.496
−24.916
1.00
99.01
O


ATOM
6720
N
ALA
L
113
−114.331
−19.202
−25.620
1.00
101.81
N


ATOM
6721
CA
ALA
L
113
−114.977
−19.468
−24.336
1.00
102.10
C


ATOM
6722
CB
ALA
L
113
−116.492
−19.449
−24.498
1.00
102.05
C


ATOM
6723
C
ALA
L
113
−114.502
−20.788
−23.690
1.00
102.28
C


ATOM
6724
O
ALA
L
113
−114.144
−21.749
−24.405
1.00
102.06
O


ATOM
6725
N
PRO
L
114
−114.478
−20.839
−22.331
1.00
103.19
N


ATOM
6726
CA
PRO
L
114
−113.984
−22.049
−21.663
1.00
103.27
C


ATOM
6727
CB
PRO
L
114
−113.447
−21.511
−20.332
1.00
103.29
C


ATOM
6728
CG
PRO
L
114
−114.314
−20.314
−20.022
1.00
103.13
C


ATOM
6729
CD
PRO
L
114
−114.848
−19.793
−21.346
1.00
103.11
C


ATOM
6730
C
PRO
L
114
−114.993
−23.176
−21.451
1.00
103.39
C


ATOM
6731
O
PRO
L
114
−116.121
−22.949
−20.990
1.00
103.53
O


ATOM
6732
N
SER
L
115
−114.560
−24.407
−21.775
1.00
102.39
N


ATOM
6733
CA
SER
L
115
−115.326
−25.629
−21.582
1.00
102.50
C


ATOM
6734
CB
SER
L
115
−114.770
−26.762
−22.451
1.00
102.27
C


ATOM
6735
OG
SER
L
115
−114.168
−26.312
−23.655
1.00
102.46
O


ATOM
6736
C
SER
L
115
−115.063
−25.913
−20.101
1.00
102.76
C


ATOM
6737
O
SER
L
115
−113.972
−26.357
−19.774
1.00
103.38
O


ATOM
6738
N
VAL
L
116
−116.005
−25.584
−19.202
1.00
103.10
N


ATOM
6739
CA
VAL
L
116
−115.844
−25.775
−17.746
1.00
103.42
C


ATOM
6740
CB
VAL
L
116
−116.618
−24.694
−16.929
1.00
103.37
C


ATOM
6741
CG1
VAL
L
116
−116.510
−24.909
−15.417
1.00
103.06
C


ATOM
6742
CG2
VAL
L
116
−116.146
−23.289
−17.306
1.00
102.93
C


ATOM
6743
C
VAL
L
116
−116.082
−27.243
−17.276
1.00
103.88
C


ATOM
6744
O
VAL
L
116
−116.879
−27.965
−17.875
1.00
103.91
O


ATOM
6745
N
PHE
L
117
−115.334
−27.686
−16.243
1.00
103.74
N


ATOM
6746
CA
PHE
L
117
−115.403
−29.026
−15.653
1.00
104.14
C


ATOM
6747
CB
PHE
L
117
−114.356
−29.950
−16.276
1.00
103.83
C


ATOM
6748
CG
PHE
L
117
−114.546
−30.170
−17.752
1.00
103.51
C


ATOM
6749
CD1
PHE
L
117
−115.308
−31.228
−18.220
1.00
103.82
C


ATOM
6750
CE1
PHE
L
117
−115.481
−31.431
−19.594
1.00
103.88
C


ATOM
6751
CZ
PHE
L
117
−114.894
−30.572
−20.500
1.00
102.95
C


ATOM
6752
CE2
PHE
L
117
−114.135
−29.520
−20.049
1.00
102.47
C


ATOM
6753
CD2
PHE
L
117
−113.957
−29.322
−18.679
1.00
102.84
C


ATOM
6754
C
PHE
L
117
−115.221
−28.963
−14.135
1.00
104.79
C


ATOM
6755
O
PHE
L
117
−114.699
−27.976
−13.608
1.00
104.81
O


ATOM
6756
N
ILE
L
118
−115.689
−29.999
−13.429
1.00
105.72
N


ATOM
6757
CA
ILE
L
118
−115.570
−30.083
−11.973
1.00
106.31
C


ATOM
6758
CB
ILE
L
118
−116.703
−29.392
−11.157
1.00
106.17
C


ATOM
6759
CG1
ILE
L
118
−116.318
−29.259
−9.671
1.00
106.10
C


ATOM
6760
CD1
ILE
L
118
−116.971
−28.104
−8.948
1.00
105.90
C


ATOM
6761
CG2
ILE
L
118
−118.068
−30.061
−11.350
1.00
106.16
C


ATOM
6762
C
ILE
L
118
−115.273
−31.515
−11.585
1.00
106.81
C


ATOM
6763
O
ILE
L
118
−115.994
−32.425
−12.004
1.00
106.98
O


ATOM
6764
N
PHE
L
119
−114.173
−31.715
−10.838
1.00
107.59
N


ATOM
6765
CA
PHE
L
119
−113.720
−33.030
−10.400
1.00
107.97
C


ATOM
6766
CB
PHE
L
119
−112.327
−33.337
−10.936
1.00
107.73
C


ATOM
6767
CG
PHE
L
119
−112.211
−33.252
−12.437
1.00
107.44
C


ATOM
6768
CD1
PHE
L
119
−111.963
−32.035
−13.065
1.00
107.12
C


ATOM
6769
CE1
PHE
L
119
−111.832
−31.959
−14.454
1.00
107.46
C


ATOM
6770
CZ
PHE
L
119
−111.941
−33.100
−15.220
1.00
107.76
C


ATOM
6771
CE2
PHE
L
119
−112.180
−34.317
−14.613
1.00
107.82
C


ATOM
6772
CD2
PHE
L
119
−112.321
−34.390
−13.223
1.00
107.63
C


ATOM
6773
C
PHE
L
119
−113.773
−33.107
−8.885
1.00
108.58
C


ATOM
6774
O
PHE
L
119
−113.236
−32.223
−8.204
1.00
108.62
O


ATOM
6775
N
PRO
L
120
−114.453
−34.144
−8.342
1.00
109.75
N


ATOM
6776
CA
PRO
L
120
−114.597
−34.244
−6.882
1.00
110.10
C


ATOM
6777
CB
PRO
L
120
−115.986
−34.865
−6.729
1.00
110.03
C


ATOM
6778
CG
PRO
L
120
−116.210
−35.651
−8.017
1.00
109.68
C


ATOM
6779
CD
PRO
L
120
−115.169
−35.245
−9.024
1.00
109.58
C


ATOM
6780
C
PRO
L
120
−113.509
−35.063
−6.169
1.00
110.63
C


ATOM
6781
O
PRO
L
120
−112.884
−35.921
−6.813
1.00
110.39
O


ATOM
6782
N
PRO
L
121
−113.284
−34.826
−4.839
1.00
112.38
N


ATOM
6783
CA
PRO
L
121
−112.258
−35.591
−4.101
1.00
112.95
C


ATOM
6784
CB
PRO
L
121
−112.477
−35.183
−2.645
1.00
112.85
C


ATOM
6785
CG
PRO
L
121
−113.056
−33.833
−2.741
1.00
112.82
C


ATOM
6786
CD
PRO
L
121
−113.936
−33.839
−3.955
1.00
112.45
C


ATOM
6787
C
PRO
L
121
−112.342
−37.096
−4.304
1.00
113.61
C


ATOM
6788
O
PRO
L
121
−113.373
−37.733
−4.076
1.00
113.95
O


ATOM
6789
N
SER
L
122
−111.224
−37.636
−4.780
1.00
115.25
N


ATOM
6790
CA
SER
L
122
−110.957
−39.021
−5.134
1.00
115.76
C


ATOM
6791
CB
SER
L
122
−109.538
−39.115
−5.709
1.00
115.91
C


ATOM
6792
OG
SER
L
122
−109.262
−40.311
−6.419
1.00
116.00
O


ATOM
6793
C
SER
L
122
−111.161
−40.037
−3.991
1.00
116.05
C


ATOM
6794
O
SER
L
122
−111.533
−39.700
−2.859
1.00
115.84
O


ATOM
6795
N
ASP
L
123
−110.912
−41.303
−4.349
1.00
116.73
N


ATOM
6796
CA
ASP
L
123
−110.946
−42.528
−3.559
1.00
117.16
C


ATOM
6797
CB
ASP
L
123
−110.564
−43.724
−4.488
1.00
117.21
C


ATOM
6798
CG
ASP
L
123
−109.458
−43.456
−5.531
1.00
117.36
C


ATOM
6799
OD1
ASP
L
123
−108.256
−43.470
−5.152
1.00
117.15
O


ATOM
6800
OD2
ASP
L
123
−109.799
−43.244
−6.721
1.00
117.04
O


ATOM
6801
C
ASP
L
123
−109.973
−42.424
−2.361
1.00
117.43
C


ATOM
6802
O
ASP
L
123
−110.401
−42.159
−1.226
1.00
117.38
O


ATOM
6803
N
GLU
L
124
−108.659
−42.605
−2.650
1.00
115.50
N


ATOM
6804
CA
GLU
L
124
−107.540
−42.560
−1.721
1.00
115.75
C


ATOM
6805
CB
GLU
L
124
−106.249
−43.030
−2.405
1.00
115.57
C


ATOM
6806
C
GLU
L
124
−107.375
−41.165
−1.165
1.00
116.01
C


ATOM
6807
O
GLU
L
124
−106.902
−41.025
−0.037
1.00
116.10
O


ATOM
6808
N
GLN
L
125
−107.782
−40.132
−1.944
1.00
114.68
N


ATOM
6809
CA
GLN
L
125
−107.713
−38.721
−1.544
1.00
114.99
C


ATOM
6810
CB
GLN
L
125
−108.446
−37.837
−2.570
1.00
114.92
C


ATOM
6811
CG
GLN
L
125
−107.624
−36.687
−3.144
1.00
114.27
C


ATOM
6812
CD
GLN
L
125
−107.616
−35.471
−2.268
1.00
113.67
C


ATOM
6813
OE1
GLN
L
125
−108.568
−34.712
−2.245
1.00
113.40
O


ATOM
6814
NE2
GLN
L
125
−106.543
−35.261
−1.535
1.00
113.42
N


ATOM
6815
C
GLN
L
125
−108.358
−38.560
−0.166
1.00
115.37
C


ATOM
6816
O
GLN
L
125
−107.775
−37.929
0.721
1.00
115.33
O


ATOM
6817
N
LEU
L
126
−109.542
−39.176
0.015
1.00
116.16
N


ATOM
6818
CA
LEU
L
126
−110.274
−39.125
1.268
1.00
116.50
C


ATOM
6819
CB
LEU
L
126
−111.768
−39.246
1.028
1.00
116.54
C


ATOM
6820
CG
LEU
L
126
−112.405
−37.947
0.560
1.00
117.03
C


ATOM
6821
CD1
LEU
L
126
−113.452
−38.207
−0.498
1.00
117.40
C


ATOM
6822
CD2
LEU
L
126
−112.930
−37.122
1.734
1.00
116.35
C


ATOM
6823
C
LEU
L
126
−109.768
−40.117
2.295
1.00
116.62
C


ATOM
6824
O
LEU
L
126
−109.705
−39.763
3.478
1.00
116.58
O


ATOM
6825
N
LYS
L
127
−109.360
−41.341
1.848
1.00
116.04
N


ATOM
6826
CA
LYS
L
127
−108.796
−42.389
2.722
1.00
116.17
C


ATOM
6827
CB
LYS
L
127
−108.491
−43.676
1.930
1.00
115.92
C


ATOM
6828
C
LYS
L
127
−107.530
−41.864
3.449
1.00
116.32
C


ATOM
6829
O
LYS
L
127
−107.066
−42.491
4.403
1.00
116.50
O


ATOM
6830
N
SER
L
128
−107.004
−40.693
2.994
1.00
115.89
N


ATOM
6831
CA
SER
L
128
−105.839
−39.983
3.526
1.00
115.99
C


ATOM
6832
CB
SER
L
128
−104.979
−39.431
2.391
1.00
115.95
C


ATOM
6833
OG
SER
L
128
−105.498
−38.222
1.860
1.00
116.15
O


ATOM
6834
C
SER
L
128
−106.254
−38.851
4.489
1.00
116.09
C


ATOM
6835
O
SER
L
128
−105.440
−38.405
5.302
1.00
116.17
O


ATOM
6836
N
GLY
L
129
−107.498
−38.394
4.378
1.00
115.76
N


ATOM
6837
CA
GLY
L
129
−108.029
−37.348
5.242
1.00
115.83
C


ATOM
6838
C
GLY
L
129
−107.873
−35.923
4.756
1.00
115.89
C


ATOM
6839
O
GLY
L
129
−107.638
−35.014
5.560
1.00
115.86
O


ATOM
6840
N
THR
L
130
−108.023
−35.717
3.440
1.00
116.18
N


ATOM
6841
CA
THR
L
130
−107.929
−34.404
2.804
1.00
116.14
C


ATOM
6842
CB
THR
L
130
−106.470
−33.935
2.694
1.00
116.00
C


ATOM
6843
OG1
THR
L
130
−106.445
−32.519
2.542
1.00
115.74
O


ATOM
6844
CG2
THR
L
130
−105.685
−34.641
1.590
1.00
115.70
C


ATOM
6845
C
THR
L
130
−108.774
−34.374
1.530
1.00
116.34
C


ATOM
6846
O
THR
L
130
−108.796
−35.354
0.790
1.00
116.29
O


ATOM
6847
N
ALA
L
131
−109.493
−33.274
1.289
1.00
117.60
N


ATOM
6848
CA
ALA
L
131
−110.354
−33.187
0.112
1.00
117.89
C


ATOM
6849
CB
ALA
L
131
−111.803
−33.060
0.539
1.00
117.93
C


ATOM
6850
C
ALA
L
131
−109.974
−32.076
−0.872
1.00
118.00
C


ATOM
6851
O
ALA
L
131
−110.061
−30.888
−0.541
1.00
117.96
O


ATOM
6852
N
SER
L
132
−109.554
−32.479
−2.088
1.00
118.64
N


ATOM
6853
CA
SER
L
132
−109.147
−31.585
−3.170
1.00
118.99
C


ATOM
6854
CB
SER
L
132
−107.705
−31.864
−3.607
1.00
119.09
C


ATOM
6855
OG
SER
L
132
−106.716
−31.360
−2.719
1.00
119.55
O


ATOM
6856
C
SER
L
132
−110.126
−31.669
−4.353
1.00
119.16
C


ATOM
6857
O
SER
L
132
−110.204
−32.688
−5.058
1.00
119.13
O


ATOM
6858
N
VAL
L
133
−110.883
−30.575
−4.546
1.00
121.01
N


ATOM
6859
CA
VAL
L
133
−111.888
−30.410
−5.601
1.00
121.04
C


ATOM
6860
CB
VAL
L
133
−113.241
−29.885
−5.055
1.00
121.01
C


ATOM
6861
CG1
VAL
L
133
−114.409
−30.512
−5.805
1.00
120.93
C


ATOM
6862
CG2
VAL
L
133
−113.379
−30.109
−3.550
1.00
120.63
C


ATOM
6863
C
VAL
L
133
−111.316
−29.472
−6.662
1.00
121.16
C


ATOM
6864
O
VAL
L
133
−110.865
−28.368
−6.330
1.00
121.07
O


ATOM
6865
N
VAL
L
134
−111.306
−29.913
−7.929
1.00
123.41
N


ATOM
6866
CA
VAL
L
134
−110.745
−29.089
−9.000
1.00
123.87
C


ATOM
6867
CB
VAL
L
134
−109.389
−29.596
−9.575
1.00
123.85
C


ATOM
6868
CG1
VAL
L
134
−108.399
−29.935
−8.468
1.00
124.11
C


ATOM
6869
CG2
VAL
L
134
−109.573
−30.782
−10.510
1.00
124.19
C


ATOM
6870
C
VAL
L
134
−111.715
−28.622
−10.084
1.00
124.09
C


ATOM
6871
O
VAL
L
134
−112.620
−29.356
−10.470
1.00
124.11
O


ATOM
6872
N
CYS
L
135
−111.492
−27.394
−10.580
1.00
126.57
N


ATOM
6873
CA
CYS
L
135
−112.270
−26.746
−11.628
1.00
126.85
C


ATOM
6874
CB
CYS
L
135
−112.871
−25.443
−11.105
1.00
127.54
C


ATOM
6875
SG
CYS
L
135
−114.387
−24.909
−11.952
1.00
131.74
S


ATOM
6876
C
CYS
L
135
−111.368
−26.496
−12.838
1.00
125.82
C


ATOM
6877
O
CYS
L
135
−110.424
−25.711
−12.749
1.00
125.75
O


ATOM
6878
N
LEU
L
136
−111.645
−27.170
−13.952
1.00
118.46
N


ATOM
6879
CA
LEU
L
136
−110.892
−27.007
−15.186
1.00
117.54
C


ATOM
6880
CB
LEU
L
136
−110.699
−28.362
−15.885
1.00
117.36
C


ATOM
6881
CG
LEU
L
136
−110.258
−28.353
−17.364
1.00
117.14
C


ATOM
6882
CD1
LEU
L
136
−108.845
−27.832
−17.534
1.00
117.06
C


ATOM
6883
CD2
LEU
L
136
−110.347
−29.727
−17.963
1.00
116.88
C


ATOM
6884
C
LEU
L
136
−111.616
−26.017
−16.100
1.00
117.22
C


ATOM
6885
O
LEU
L
136
−112.834
−26.070
−16.223
1.00
117.23
O


ATOM
6886
N
LEU
L
137
−110.862
−25.113
−16.732
1.00
113.80
N


ATOM
6887
CA
LEU
L
137
−111.347
−24.097
−17.663
1.00
113.18
C


ATOM
6888
CB
LEU
L
137
−111.033
−22.697
−17.099
1.00
113.02
C


ATOM
6889
CG
LEU
L
137
−112.020
−22.035
−16.120
1.00
112.83
C


ATOM
6890
CD1
LEU
L
137
−112.092
−22.756
−14.777
1.00
112.58
C


ATOM
6891
CD2
LEU
L
137
−111.601
−20.602
−15.845
1.00
112.49
C


ATOM
6892
C
LEU
L
137
−110.550
−24.361
−18.944
1.00
113.02
C


ATOM
6893
O
LEU
L
137
−109.562
−23.679
−19.214
1.00
113.12
O


ATOM
6894
N
ASN
L
138
−110.943
−25.399
−19.700
1.00
111.77
N


ATOM
6895
CA
ASN
L
138
−110.253
−25.808
−20.920
1.00
111.61
C


ATOM
6896
CB
ASN
L
138
−110.601
−27.233
−21.292
1.00
111.47
C


ATOM
6897
CG
ASN
L
138
−109.505
−27.894
−22.084
1.00
111.38
C


ATOM
6898
OD1
ASN
L
138
−109.548
−27.949
−23.314
1.00
111.97
O


ATOM
6899
ND2
ASN
L
138
−108.488
−28.400
−21.401
1.00
110.73
N


ATOM
6900
C
ASN
L
138
−110.408
−24.870
−22.109
1.00
111.70
C


ATOM
6901
O
ASN
L
138
−111.489
−24.343
−22.331
1.00
111.74
O


ATOM
6902
N
ASN
L
139
−109.310
−24.671
−22.862
1.00
112.71
N


ATOM
6903
CA
ASN
L
139
−109.150
−23.835
−24.063
1.00
113.10
C


ATOM
6904
CB
ASN
L
139
−109.074
−24.695
−25.321
1.00
112.89
C


ATOM
6905
CG
ASN
L
139
−107.809
−25.512
−25.418
1.00
112.69
C


ATOM
6906
OD1
ASN
L
139
−106.698
−24.985
−25.592
1.00
113.25
O


ATOM
6907
ND2
ASN
L
139
−107.952
−26.824
−25.323
1.00
112.42
N


ATOM
6908
C
ASN
L
139
−110.022
−22.557
−24.256
1.00
113.51
C


ATOM
6909
O
ASN
L
139
−111.145
−22.634
−24.764
1.00
113.56
O


ATOM
6910
N
PHE
L
140
−109.474
−21.388
−23.869
1.00
114.58
N


ATOM
6911
CA
PHE
L
140
−110.117
−20.073
−23.982
1.00
115.21
C


ATOM
6912
CB
PHE
L
140
−110.910
−19.733
−22.710
1.00
114.98
C


ATOM
6913
CG
PHE
L
140
−110.131
−19.560
−21.427
1.00
114.30
C


ATOM
6914
CD1
PHE
L
140
−109.951
−18.301
−20.871
1.00
113.56
C


ATOM
6915
CE1
PHE
L
140
−109.252
−18.145
−19.665
1.00
113.30
C


ATOM
6916
CZ
PHE
L
140
−108.742
−19.248
−19.012
1.00
112.97
C


ATOM
6917
CE2
PHE
L
140
−108.925
−20.503
−19.544
1.00
113.00
C


ATOM
6918
CD2
PHE
L
140
−109.630
−20.662
−20.742
1.00
113.60
C


ATOM
6919
C
PHE
L
140
−109.093
−18.977
−24.336
1.00
115.99
C


ATOM
6920
O
PHE
L
140
−107.912
−19.174
−24.052
1.00
116.10
O


ATOM
6921
N
TYR
L
141
−109.521
−17.845
−24.979
1.00
120.17
N


ATOM
6922
CA
TYR
L
141
−108.566
−16.788
−25.348
1.00
121.05
C


ATOM
6923
CB
TYR
L
141
−108.589
−16.291
−26.823
1.00
120.82
C


ATOM
6924
CG
TYR
L
141
−107.750
−15.032
−26.958
1.00
120.68
C


ATOM
6925
CD1
TYR
L
141
−106.363
−15.080
−26.839
1.00
120.23
C


ATOM
6926
CE1
TYR
L
141
−105.598
−13.920
−26.835
1.00
119.92
C


ATOM
6927
CZ
TYR
L
141
−106.211
−12.689
−26.980
1.00
119.83
C


ATOM
6928
OH
TYR
L
141
−105.449
−11.549
−27.013
1.00
119.70
O


ATOM
6929
CE2
TYR
L
141
−107.589
−12.612
−27.082
1.00
120.07
C


ATOM
6930
CD2
TYR
L
141
−108.350
−13.779
−27.060
1.00
120.62
C


ATOM
6931
C
TYR
L
141
−108.327
−15.636
−24.355
1.00
121.93
C


ATOM
6932
O
TYR
L
141
−107.188
−15.543
−23.901
1.00
122.12
O


ATOM
6933
N
PRO
L
142
−109.244
−14.684
−24.062
1.00
123.73
N


ATOM
6934
CA
PRO
L
142
−108.861
−13.603
−23.124
1.00
124.38
C


ATOM
6935
CB
PRO
L
142
−110.113
−12.728
−23.040
1.00
124.21
C


ATOM
6936
CG
PRO
L
142
−110.923
−13.107
−24.228
1.00
124.05
C


ATOM
6937
CD
PRO
L
142
−110.642
−14.545
−24.504
1.00
123.75
C


ATOM
6938
C
PRO
L
142
−108.418
−14.197
−21.774
1.00
125.09
C


ATOM
6939
O
PRO
L
142
−109.144
−15.019
−21.200
1.00
125.32
O


ATOM
6940
N
ARG
L
143
−107.192
−13.856
−21.311
1.00
124.90
N


ATOM
6941
CA
ARG
L
143
−106.641
−14.409
−20.070
1.00
125.50
C


ATOM
6942
CB
ARG
L
143
−105.176
−14.017
−19.884
1.00
125.50
C


ATOM
6943
CG
ARG
L
143
−104.366
−15.117
−19.235
1.00
125.34
C


ATOM
6944
CD
ARG
L
143
−103.690
−14.659
−17.962
1.00
125.22
C


ATOM
6945
NE
ARG
L
143
−102.648
−15.606
−17.567
1.00
125.08
N


ATOM
6946
CZ
ARG
L
143
−101.400
−15.591
−18.034
1.00
125.16
C


ATOM
6947
NH1
ARG
L
143
−101.021
−14.666
−18.911
1.00
124.93
N


ATOM
6948
NH2
ARG
L
143
−100.524
−16.506
−17.634
1.00
124.72
N


ATOM
6949
C
ARG
L
143
−107.452
−14.106
−18.824
1.00
125.98
C


ATOM
6950
O
ARG
L
143
−107.460
−14.920
−17.901
1.00
125.95
O


ATOM
6951
N
GLU
L
144
−108.136
−12.949
−18.798
1.00
128.30
N


ATOM
6952
CA
GLU
L
144
−108.959
−12.548
−17.665
1.00
129.21
C


ATOM
6953
CB
GLU
L
144
−109.478
−11.103
−17.821
1.00
129.25
C


ATOM
6954
CG
GLU
L
144
−109.909
−10.468
−16.501
1.00
130.44
C


ATOM
6955
CD
GLU
L
144
−111.255
−9.759
−16.456
1.00
132.01
C


ATOM
6956
OE1
GLU
L
144
−111.271
−8.538
−16.169
1.00
132.64
O


ATOM
6957
OE2
GLU
L
144
−112.294
−10.425
−16.687
1.00
132.51
O


ATOM
6958
C
GLU
L
144
−110.108
−13.544
−17.456
1.00
129.64
C


ATOM
6959
O
GLU
L
144
−110.948
−13.736
−18.341
1.00
129.70
O


ATOM
6960
N
ALA
L
145
−110.107
−14.200
−16.290
1.00
131.03
N


ATOM
6961
CA
ALA
L
145
−111.117
−15.180
−15.884
1.00
131.73
C


ATOM
6962
CB
ALA
L
145
−110.778
−16.562
−16.436
1.00
131.51
C


ATOM
6963
C
ALA
L
145
−111.214
−15.215
−14.350
1.00
132.29
C


ATOM
6964
O
ALA
L
145
−110.184
−15.248
−13.663
1.00
132.37
O


ATOM
6965
N
LYS
L
146
−112.449
−15.182
−13.817
1.00
132.82
N


ATOM
6966
CA
LYS
L
146
−112.696
−15.209
−12.374
1.00
133.49
C


ATOM
6967
CB
LYS
L
146
−113.637
−14.067
−11.965
1.00
133.42
C


ATOM
6968
C
LYS
L
146
−113.287
−16.547
−11.963
1.00
133.99
C


ATOM
6969
O
LYS
L
146
−114.152
−17.070
−12.668
1.00
134.05
O


ATOM
6970
N
VAL
L
147
−112.806
−17.113
−10.839
1.00
133.98
N


ATOM
6971
CA
VAL
L
147
−113.292
−18.390
−10.304
1.00
134.69
C


ATOM
6972
CB
VAL
L
147
−112.411
−19.629
−10.661
1.00
134.54
C


ATOM
6973
CG1
VAL
L
147
−112.819
−20.859
−9.854
1.00
134.55
C


ATOM
6974
CG2
VAL
L
147
−112.471
−19.944
−12.152
1.00
134.47
C


ATOM
6975
C
VAL
L
147
−113.592
−18.267
−8.801
1.00
135.34
C


ATOM
6976
O
VAL
L
147
−112.688
−17.986
−8.011
1.00
135.35
O


ATOM
6977
N
GLN
L
148
−114.876
−18.465
−8.429
1.00
137.17
N


ATOM
6978
CA
GLN
L
148
−115.370
−18.427
−7.052
1.00
137.96
C


ATOM
6979
CB
GLN
L
148
−116.388
−17.291
−6.837
1.00
137.70
C


ATOM
6980
C
GLN
L
148
−115.979
−19.790
−6.736
1.00
138.61
C


ATOM
6981
O
GLN
L
148
−116.844
−20.271
−7.470
1.00
138.56
O


ATOM
6982
N
TRP
L
149
−115.491
−20.421
−5.660
1.00
141.36
N


ATOM
6983
CA
TRP
L
149
−115.938
−21.733
−5.203
1.00
142.14
C


ATOM
6984
CB
TRP
L
149
−114.788
−22.495
−4.521
1.00
142.24
C


ATOM
6985
CG
TRP
L
149
−113.731
−23.024
−5.447
1.00
142.43
C


ATOM
6986
CD1
TRP
L
149
−112.536
−22.439
−5.742
1.00
142.44
C


ATOM
6987
NE1
TRP
L
149
−111.814
−23.239
−6.596
1.00
142.71
N


ATOM
6988
CE2
TRP
L
149
−112.534
−24.376
−6.862
1.00
142.61
C


ATOM
6989
CD2
TRP
L
149
−113.748
−24.278
−6.148
1.00
142.57
C


ATOM
6990
CE3
TRP
L
149
−114.676
−25.329
−6.246
1.00
142.51
C


ATOM
6991
CZ3
TRP
L
149
−114.365
−26.424
−7.041
1.00
142.73
C


ATOM
6992
CH2
TRP
L
149
−113.153
−26.494
−7.739
1.00
142.48
C


ATOM
6993
CZ2
TRP
L
149
−112.221
−25.486
−7.661
1.00
142.42
C


ATOM
6994
C
TRP
L
149
−117.120
−21.591
−4.247
1.00
142.57
C


ATOM
6995
O
TRP
L
149
−117.033
−20.863
−3.249
1.00
142.67
O


ATOM
6996
N
LYS
L
150
−118.226
−22.295
−4.569
1.00
144.16
N


ATOM
6997
CA
LYS
L
150
−119.468
−22.302
−3.801
1.00
144.48
C


ATOM
6998
CB
LYS
L
150
−120.683
−22.049
−4.710
1.00
144.30
C


ATOM
6999
C
LYS
L
150
−119.632
−23.585
−2.988
1.00
144.77
C


ATOM
7000
O
LYS
L
150
−120.027
−24.625
−3.528
1.00
144.70
O


ATOM
7001
N
VAL
L
151
−119.311
−23.497
−1.679
1.00
146.31
N


ATOM
7002
CA
VAL
L
151
−119.412
−24.586
−0.692
1.00
146.66
C


ATOM
7003
CB
VAL
L
151
−118.294
−24.522
0.403
1.00
146.70
C


ATOM
7004
CG1
VAL
L
151
−116.953
−24.974
−0.164
1.00
146.41
C


ATOM
7005
CG2
VAL
L
151
−118.160
−23.130
1.029
1.00
146.67
C


ATOM
7006
C
VAL
L
151
−120.871
−24.606
−0.156
1.00
146.88
C


ATOM
7007
O
VAL
L
151
−121.145
−24.253
1.003
1.00
147.08
O


ATOM
7008
N
ASP
L
152
−121.801
−25.021
−1.065
1.00
146.82
N


ATOM
7009
CA
ASP
L
152
−123.271
−25.064
−0.959
1.00
146.80
C


ATOM
7010
CB
ASP
L
152
−123.897
−26.226
−0.126
1.00
146.83
C


ATOM
7011
CG
ASP
L
152
−123.537
−26.390
1.350
1.00
147.22
C


ATOM
7012
OD1
ASP
L
152
−123.286
−27.540
1.772
1.00
147.06
O


ATOM
7013
OD2
ASP
L
152
−123.542
−25.373
2.091
1.00
147.71
O


ATOM
7014
C
ASP
L
152
−123.869
−23.668
−0.765
1.00
146.65
C


ATOM
7015
O
ASP
L
152
−124.196
−23.261
0.357
1.00
146.71
O


ATOM
7016
N
ASN
L
153
−123.943
−22.914
−1.897
1.00
144.71
N


ATOM
7017
CA
ASN
L
153
−124.425
−21.528
−2.001
1.00
144.46
C


ATOM
7018
CB
ASN
L
153
−125.953
−21.439
−1.869
1.00
144.46
C


ATOM
7019
C
ASN
L
153
−123.674
−20.586
−1.028
1.00
144.28
C


ATOM
7020
O
ASN
L
153
−124.248
−19.633
−0.488
1.00
144.25
O


ATOM
7021
N
ALA
L
154
−122.372
−20.880
−0.818
1.00
143.01
N


ATOM
7022
CA
ALA
L
154
−121.464
−20.135
0.053
1.00
142.71
C


ATOM
7023
CB
ALA
L
154
−121.086
−20.977
1.267
1.00
142.72
C


ATOM
7024
C
ALA
L
154
−120.210
−19.610
−0.706
1.00
142.37
C


ATOM
7025
O
ALA
L
154
−120.130
−19.742
−1.932
1.00
142.19
O


ATOM
7026
N
LEU
L
155
−119.257
−18.993
0.023
1.00
140.88
N


ATOM
7027
CA
LEU
L
155
−118.050
−18.380
−0.536
1.00
140.44
C


ATOM
7028
CB
LEU
L
155
−117.823
−16.932
0.015
1.00
140.45
C


ATOM
7029
CG
LEU
L
155
−117.618
−16.618
1.545
1.00
140.69
C


ATOM
7030
CD1
LEU
L
155
−116.331
−17.180
2.121
1.00
140.65
C


ATOM
7031
CD2
LEU
L
155
−118.850
−16.895
2.408
1.00
140.93
C


ATOM
7032
C
LEU
L
155
−116.732
−19.183
−0.610
1.00
140.07
C


ATOM
7033
O
LEU
L
155
−116.588
−20.271
−0.034
1.00
140.03
O


ATOM
7034
N
GLN
L
156
−115.773
−18.599
−1.355
1.00
139.27
N


ATOM
7035
CA
GLN
L
156
−114.412
−19.065
−1.560
1.00
138.38
C


ATOM
7036
CB
GLN
L
156
−114.000
−18.872
−3.028
1.00
138.41
C


ATOM
7037
C
GLN
L
156
−113.579
−18.175
−0.623
1.00
137.73
C


ATOM
7038
O
GLN
L
156
−113.130
−17.093
−1.018
1.00
137.58
O


ATOM
7039
N
SER
L
157
−113.446
−18.616
0.646
1.00
136.55
N


ATOM
7040
CA
SER
L
157
−112.721
−17.929
1.721
1.00
135.68
C


ATOM
7041
CB
SER
L
157
−112.829
−18.725
3.024
1.00
135.72
C


ATOM
7042
OG
SER
L
157
−112.063
−18.164
4.078
1.00
135.84
O


ATOM
7043
C
SER
L
157
−111.255
−17.640
1.348
1.00
134.91
C


ATOM
7044
O
SER
L
157
−110.917
−16.495
1.039
1.00
134.84
O


ATOM
7045
N
GLY
L
158
−110.430
−18.685
1.368
1.00
133.80
N


ATOM
7046
CA
GLY
L
158
−109.008
−18.642
1.050
1.00
132.49
C


ATOM
7047
C
GLY
L
158
−108.431
−20.040
0.993
1.00
131.57
C


ATOM
7048
O
GLY
L
158
−107.393
−20.317
1.605
1.00
131.46
O


ATOM
7049
N
ASN
L
159
−109.134
−20.930
0.262
1.00
131.76
N


ATOM
7050
CA
ASN
L
159
−108.811
−22.342
0.056
1.00
130.80
C


ATOM
7051
CB
ASN
L
159
−109.929
−23.221
0.638
1.00
131.25
C


ATOM
7052
CG
ASN
L
159
−109.880
−23.451
2.142
1.00
132.31
C


ATOM
7053
OD1
ASN
L
159
−109.971
−24.598
2.618
1.00
133.26
O


ATOM
7054
ND2
ASN
L
159
−109.757
−22.379
2.935
1.00
132.94
N


ATOM
7055
C
ASN
L
159
−108.624
−22.653
−1.431
1.00
129.73
C


ATOM
7056
O
ASN
L
159
−108.505
−23.822
−1.804
1.00
129.65
O


ATOM
7057
N
SER
L
160
−108.591
−21.603
−2.274
1.00
127.52
N


ATOM
7058
CA
SER
L
160
−108.425
−21.704
−3.725
1.00
126.23
C


ATOM
7059
CB
SER
L
160
−109.469
−20.846
−4.446
1.00
126.30
C


ATOM
7060
OG
SER
L
160
−109.200
−20.655
−5.828
1.00
126.45
O


ATOM
7061
C
SER
L
160
−106.999
−21.339
−4.185
1.00
125.19
C


ATOM
7062
O
SER
L
160
−106.455
−20.296
−3.786
1.00
125.17
O


ATOM
7063
N
GLN
L
161
−106.411
−22.217
−5.030
1.00
121.47
N


ATOM
7064
CA
GLN
L
161
−105.083
−22.072
−5.635
1.00
119.85
C


ATOM
7065
CB
GLN
L
161
−104.056
−23.039
−5.005
1.00
119.86
C


ATOM
7066
CG
GLN
L
161
−103.506
−22.571
−3.653
1.00
118.84
C


ATOM
7067
CD
GLN
L
161
−102.328
−23.378
−3.158
1.00
117.16
C


ATOM
7068
OE1
GLN
L
161
−102.397
−24.603
−2.963
1.00
116.92
O


ATOM
7069
NE2
GLN
L
161
−101.222
−22.698
−2.921
1.00
116.03
N


ATOM
7070
C
GLN
L
161
−105.242
−22.319
−7.133
1.00
118.95
C


ATOM
7071
O
GLN
L
161
−105.766
−23.363
−7.528
1.00
118.82
O


ATOM
7072
N
GLU
L
162
−104.825
−21.345
−7.963
1.00
118.33
N


ATOM
7073
CA
GLU
L
162
−104.962
−21.418
−9.426
1.00
117.09
C


ATOM
7074
CB
GLU
L
162
−105.833
−20.264
−9.963
1.00
117.33
C


ATOM
7075
CG
GLU
L
162
−107.230
−20.213
−9.365
1.00
118.23
C


ATOM
7076
CD
GLU
L
162
−108.093
−19.008
−9.697
1.00
119.60
C


ATOM
7077
OE1
GLU
L
162
−108.981
−18.686
−8.871
1.00
120.56
O


ATOM
7078
OE2
GLU
L
162
−107.893
−18.394
−10.774
1.00
119.76
O


ATOM
7079
C
GLU
L
162
−103.644
−21.459
−10.184
1.00
115.93
C


ATOM
7080
O
GLU
L
162
−102.662
−20.845
−9.766
1.00
115.86
O


ATOM
7081
N
SER
L
163
−103.647
−22.165
−11.322
1.00
111.07
N


ATOM
7082
CA
SER
L
163
−102.489
−22.316
−12.191
1.00
109.71
C


ATOM
7083
CB
SER
L
163
−101.877
−23.692
−11.995
1.00
109.62
C


ATOM
7084
OG
SER
L
163
−100.544
−23.673
−12.462
1.00
109.51
O


ATOM
7085
C
SER
L
163
−102.920
−22.133
−13.642
1.00
108.94
C


ATOM
7086
O
SER
L
163
−103.903
−22.743
−14.060
1.00
108.88
O


ATOM
7087
N
VAL
L
164
−102.201
−21.295
−14.405
1.00
105.03
N


ATOM
7088
CA
VAL
L
164
−102.542
−21.022
−15.802
1.00
103.99
C


ATOM
7089
CB
VAL
L
164
−102.773
−19.514
−16.036
1.00
103.97
C


ATOM
7090
CG1
VAL
L
164
−103.039
−19.200
−17.514
1.00
103.77
C


ATOM
7091
CG2
VAL
L
164
−103.910
−18.992
−15.150
1.00
103.63
C


ATOM
7092
C
VAL
L
164
−101.564
−21.644
−16.792
1.00
103.53
C


ATOM
7093
O
VAL
L
164
−100.362
−21.538
−16.601
1.00
103.39
O


ATOM
7094
N
THR
L
165
−102.091
−22.274
−17.853
1.00
101.85
N


ATOM
7095
CA
THR
L
165
−101.325
−22.954
−18.890
1.00
101.44
C


ATOM
7096
CB
THR
L
165
−102.216
−23.832
−19.797
1.00
101.33
C


ATOM
7097
OG1
THR
L
165
−101.518
−25.050
−20.047
1.00
101.63
O


ATOM
7098
CG2
THR
L
165
−102.564
−23.174
−21.154
1.00
101.27
C


ATOM
7099
C
THR
L
165
−100.281
−22.150
−19.652
1.00
101.38
C


ATOM
7100
O
THR
L
165
−99.298
−22.756
−20.095
1.00
101.70
O


ATOM
7101
N
GLU
L
166
−100.472
−20.818
−19.816
1.00
99.24
N


ATOM
7102
CA
GLU
L
166
−99.572
−19.945
−20.587
1.00
98.97
C


ATOM
7103
CB
GLU
L
166
−98.098
−19.974
−20.102
1.00
98.88
C


ATOM
7104
C
GLU
L
166
−99.697
−20.306
−22.078
1.00
98.77
C


ATOM
7105
O
GLU
L
166
−99.142
−21.307
−22.528
1.00
98.60
O


ATOM
7106
N
GLN
L
167
−100.477
−19.476
−22.806
1.00
98.98
N


ATOM
7107
CA
GLN
L
167
−100.866
−19.465
−24.226
1.00
98.76
C


ATOM
7108
CB
GLN
L
167
−100.619
−18.080
−24.829
1.00
98.72
C


ATOM
7109
CG
GLN
L
167
−101.771
−17.617
−25.680
1.00
99.11
C


ATOM
7110
CD
GLN
L
167
−101.652
−16.212
−26.210
1.00
98.86
C


ATOM
7111
OE1
GLN
L
167
−100.585
−15.749
−26.632
1.00
97.98
O


ATOM
7112
NE2
GLN
L
167
−102.774
−15.509
−26.232
1.00
98.96
N


ATOM
7113
C
GLN
L
167
−100.379
−20.583
−25.164
1.00
98.55
C


ATOM
7114
O
GLN
L
167
−99.184
−20.661
−25.437
1.00
98.71
O


ATOM
7115
N
ASP
L
168
−101.315
−21.413
−25.685
1.00
99.05
N


ATOM
7116
CA
ASP
L
168
−101.028
−22.523
−26.606
1.00
99.09
C


ATOM
7117
CB
ASP
L
168
−102.317
−23.274
−26.979
1.00
99.32
C


ATOM
7118
CG
ASP
L
168
−102.104
−24.674
−27.550
1.00
99.97
C


ATOM
7119
OD1
ASP
L
168
−102.562
−25.653
−26.910
1.00
100.99
O


ATOM
7120
OD2
ASP
L
168
−101.493
−24.792
−28.649
1.00
100.34
O


ATOM
7121
C
ASP
L
168
−100.314
−22.062
−27.873
1.00
98.85
C


ATOM
7122
O
ASP
L
168
−100.550
−20.955
−28.348
1.00
98.71
O


ATOM
7123
N
SER
L
169
−99.438
−22.909
−28.415
1.00
100.81
N


ATOM
7124
CA
SER
L
169
−98.685
−22.582
−29.627
1.00
101.16
C


ATOM
7125
CB
SER
L
169
−97.451
−23.472
−29.760
1.00
101.15
C


ATOM
7126
OG
SER
L
169
−97.761
−24.820
−29.446
1.00
101.65
O


ATOM
7127
C
SER
L
169
−99.575
−22.679
−30.869
1.00
101.31
C


ATOM
7128
O
SER
L
169
−99.754
−21.678
−31.580
1.00
101.38
O


ATOM
7129
N
LYS
L
170
−100.153
−23.883
−31.102
1.00
102.36
N


ATOM
7130
CA
LYS
L
170
−101.038
−24.200
−32.217
1.00
102.39
C


ATOM
7131
CB
LYS
L
170
−101.379
−25.698
−32.216
1.00
102.24
C


ATOM
7132
C
LYS
L
170
−102.314
−23.331
−32.252
1.00
102.58
C


ATOM
7133
O
LYS
L
170
−102.579
−22.700
−33.279
1.00
102.74
O


ATOM
7134
N
ASP
L
171
−103.082
−23.269
−31.147
1.00
102.64
N


ATOM
7135
CA
ASP
L
171
−104.324
−22.495
−31.140
1.00
102.90
C


ATOM
7136
CB
ASP
L
171
−105.526
−23.442
−31.106
1.00
103.27
C


ATOM
7137
CG
ASP
L
171
−105.506
−24.392
−29.928
1.00
104.57
C


ATOM
7138
OD1
ASP
L
171
−105.745
−23.923
−28.777
1.00
104.99
O


ATOM
7139
OD2
ASP
L
171
−105.253
−25.610
−30.149
1.00
106.77
O


ATOM
7140
C
ASP
L
171
−104.471
−21.335
−30.135
1.00
102.74
C


ATOM
7141
O
ASP
L
171
−105.576
−21.073
−29.646
1.00
102.59
O


ATOM
7142
N
SER
L
172
−103.359
−20.635
−29.852
1.00
100.89
N


ATOM
7143
CA
SER
L
172
−103.227
−19.472
−28.961
1.00
100.63
C


ATOM
7144
CB
SER
L
172
−103.082
−18.200
−29.785
1.00
100.55
C


ATOM
7145
OG
SER
L
172
−101.988
−18.375
−30.673
1.00
100.64
O


ATOM
7146
C
SER
L
172
−104.216
−19.316
−27.790
1.00
100.63
C


ATOM
7147
O
SER
L
172
−104.704
−18.214
−27.521
1.00
100.47
O


ATOM
7148
N
THR
L
173
−104.472
−20.427
−27.075
1.00
101.55
N


ATOM
7149
CA
THR
L
173
−105.404
−20.472
−25.947
1.00
101.94
C


ATOM
7150
CB
THR
L
173
−106.570
−21.451
−26.219
1.00
102.01
C


ATOM
7151
OG1
THR
L
173
−106.081
−22.676
−26.772
1.00
101.82
O


ATOM
7152
CG2
THR
L
173
−107.633
−20.855
−27.104
1.00
101.98
C


ATOM
7153
C
THR
L
173
−104.772
−20.776
−24.598
1.00
102.15
C


ATOM
7154
O
THR
L
173
−103.765
−21.484
−24.518
1.00
102.13
O


ATOM
7155
N
TYR
L
174
−105.412
−20.244
−23.535
1.00
103.33
N


ATOM
7156
CA
TYR
L
174
−105.056
−20.408
−22.127
1.00
103.64
C


ATOM
7157
CB
TYR
L
174
−105.206
−19.082
−21.362
1.00
103.64
C


ATOM
7158
CG
TYR
L
174
−104.277
−17.986
−21.829
1.00
104.23
C


ATOM
7159
CD1
TYR
L
174
−104.687
−17.055
−22.777
1.00
104.83
C


ATOM
7160
CE1
TYR
L
174
−103.842
−16.032
−23.202
1.00
104.70
C


ATOM
7161
CZ
TYR
L
174
−102.566
−15.937
−22.680
1.00
104.23
C


ATOM
7162
OH
TYR
L
174
−101.722
−14.944
−23.097
1.00
104.02
O


ATOM
7163
CE2
TYR
L
174
−102.141
−16.844
−21.726
1.00
104.62
C


ATOM
7164
CD2
TYR
L
174
−102.998
−17.860
−21.304
1.00
104.52
C


ATOM
7165
C
TYR
L
174
−105.997
−21.431
−21.504
1.00
103.87
C


ATOM
7166
O
TYR
L
174
−107.064
−21.700
−22.057
1.00
104.08
O


ATOM
7167
N
SER
L
175
−105.595
−21.995
−20.347
1.00
102.93
N


ATOM
7168
CA
SER
L
175
−106.332
−22.973
−19.539
1.00
103.00
C


ATOM
7169
CB
SER
L
175
−106.041
−24.403
−19.985
1.00
102.80
C


ATOM
7170
OG
SER
L
175
−106.359
−24.591
−21.356
1.00
102.75
O


ATOM
7171
C
SER
L
175
−105.962
−22.755
−18.072
1.00
103.21
C


ATOM
7172
O
SER
L
175
−104.783
−22.635
−17.747
1.00
103.20
O


ATOM
7173
N
LEU
L
176
−106.977
−22.654
−17.203
1.00
103.24
N


ATOM
7174
CA
LEU
L
176
−106.843
−22.420
−15.768
1.00
103.52
C


ATOM
7175
CB
LEU
L
176
−107.739
−21.236
−15.365
1.00
103.27
C


ATOM
7176
CG
LEU
L
176
−107.431
−20.545
−14.039
1.00
103.20
C


ATOM
7177
CD1
LEU
L
176
−107.592
−19.051
−14.163
1.00
103.38
C


ATOM
7178
CD2
LEU
L
176
−108.324
−21.057
−12.919
1.00
102.64
C


ATOM
7179
C
LEU
L
176
−107.242
−23.673
−14.992
1.00
104.05
C


ATOM
7180
O
LEU
L
176
−108.113
−24.416
−15.435
1.00
104.03
O


ATOM
7181
N
SER
L
177
−106.604
−23.901
−13.838
1.00
106.42
N


ATOM
7182
CA
SER
L
177
−106.865
−25.033
−12.954
1.00
107.19
C


ATOM
7183
CB
SER
L
177
−105.776
−26.103
−13.103
1.00
107.15
C


ATOM
7184
OG
SER
L
177
−105.396
−26.726
−11.883
1.00
107.51
O


ATOM
7185
C
SER
L
177
−106.960
−24.511
−11.525
1.00
107.81
C


ATOM
7186
O
SER
L
177
−105.938
−24.183
−10.913
1.00
107.98
O


ATOM
7187
N
SER
L
178
−108.187
−24.401
−11.006
1.00
109.82
N


ATOM
7188
CA
SER
L
178
−108.404
−23.923
−9.640
1.00
110.68
C


ATOM
7189
CB
SER
L
178
−109.637
−23.037
−9.550
1.00
110.59
C


ATOM
7190
OG
SER
L
178
−109.580
−22.260
−8.365
1.00
110.61
O


ATOM
7191
C
SER
L
178
−108.545
−25.119
−8.723
1.00
111.35
C


ATOM
7192
O
SER
L
178
−109.106
−26.138
−9.138
1.00
111.31
O


ATOM
7193
N
THR
L
179
−108.013
−25.016
−7.490
1.00
112.95
N


ATOM
7194
CA
THR
L
179
−108.073
−26.125
−6.548
1.00
113.88
C


ATOM
7195
CB
THR
L
179
−106.758
−26.909
−6.514
1.00
113.79
C


ATOM
7196
OG1
THR
L
179
−106.386
−27.280
−7.847
1.00
113.74
O


ATOM
7197
CG2
THR
L
179
−106.834
−28.145
−5.611
1.00
113.77
C


ATOM
7198
C
THR
L
179
−108.553
−25.724
−5.182
1.00
114.71
C


ATOM
7199
O
THR
L
179
−107.882
−24.962
−4.474
1.00
114.65
O


ATOM
7200
N
LEU
L
180
−109.722
−26.275
−4.812
1.00
118.09
N


ATOM
7201
CA
LEU
L
180
−110.357
−26.055
−3.520
1.00
119.20
C


ATOM
7202
CB
LEU
L
180
−111.889
−26.053
−3.651
1.00
119.25
C


ATOM
7203
CG
LEU
L
180
−112.697
−25.644
−2.407
1.00
119.28
C


ATOM
7204
CD1
LEU
L
180
−114.165
−25.928
−2.615
1.00
119.03
C


ATOM
7205
CD2
LEU
L
180
−112.461
−24.166
−2.009
1.00
119.13
C


ATOM
7206
C
LEU
L
180
−109.866
−27.159
−2.606
1.00
119.92
C


ATOM
7207
O
LEU
L
180
−110.065
−28.345
−2.899
1.00
119.94
O


ATOM
7208
N
THR
L
181
−109.184
−26.772
−1.521
1.00
122.06
N


ATOM
7209
CA
THR
L
181
−108.604
−27.754
−0.616
1.00
123.16
C


ATOM
7210
CB
THR
L
181
−107.127
−28.063
−1.014
1.00
123.08
C


ATOM
7211
OG1
THR
L
181
−106.567
−29.038
−0.136
1.00
123.12
O


ATOM
7212
CG2
THR
L
181
−106.238
−26.818
−1.078
1.00
123.36
C


ATOM
7213
C
THR
L
181
−108.908
−27.572
0.878
1.00
123.93
C


ATOM
7214
O
THR
L
181
−108.302
−26.732
1.551
1.00
123.89
O


ATOM
7215
N
LEU
L
182
−109.843
−28.402
1.387
1.00
125.26
N


ATOM
7216
CA
LEU
L
182
−110.268
−28.455
2.796
1.00
126.41
C


ATOM
7217
CB
LEU
L
182
−111.637
−27.786
3.030
1.00
126.34
C


ATOM
7218
CG
LEU
L
182
−112.719
−28.101
2.014
1.00
126.48
C


ATOM
7219
CD1
LEU
L
182
−113.984
−28.549
2.693
1.00
126.44
C


ATOM
7220
CD2
LEU
L
182
−112.970
−26.921
1.120
1.00
126.14
C


ATOM
7221
C
LEU
L
182
−110.209
−29.909
3.360
1.00
127.14
C


ATOM
7222
O
LEU
L
182
−110.020
−30.857
2.582
1.00
127.07
O


ATOM
7223
N
SER
L
183
−110.342
−30.071
4.710
1.00
128.51
N


ATOM
7224
CA
SER
L
183
−110.276
−31.365
5.420
1.00
129.50
C


ATOM
7225
CB
SER
L
183
−110.270
−31.151
6.933
1.00
129.46
C


ATOM
7226
OG
SER
L
183
−111.490
−30.598
7.401
1.00
129.48
O


ATOM
7227
C
SER
L
183
−111.373
−32.372
5.024
1.00
130.09
C


ATOM
7228
O
SER
L
183
−112.396
−31.961
4.470
1.00
130.38
O


ATOM
7229
N
LYS
L
184
−111.155
−33.690
5.317
1.00
129.50
N


ATOM
7230
CA
LYS
L
184
−112.095
−34.801
5.041
1.00
129.96
C


ATOM
7231
CB
LYS
L
184
−111.467
−36.149
5.457
1.00
129.94
C


ATOM
7232
CG
LYS
L
184
−112.371
−37.378
5.337
1.00
130.00
C


ATOM
7233
CD
LYS
L
184
−111.722
−38.645
5.899
1.00
130.26
C


ATOM
7234
CE
LYS
L
184
−111.877
−38.816
7.398
1.00
130.53
C


ATOM
7235
NZ
LYS
L
184
−111.238
−40.069
7.891
1.00
130.87
N


ATOM
7236
C
LYS
L
184
−113.443
−34.572
5.767
1.00
130.23
C


ATOM
7237
O
LYS
L
184
−114.502
−34.925
5.229
1.00
130.35
O


ATOM
7238
N
ALA
L
185
−113.383
−33.962
6.979
1.00
128.95
N


ATOM
7239
CA
ALA
L
185
−114.520
−33.631
7.835
1.00
129.05
C


ATOM
7240
CB
ALA
L
185
−114.017
−33.124
9.179
1.00
128.94
C


ATOM
7241
C
ALA
L
185
−115.462
−32.597
7.185
1.00
129.19
C


ATOM
7242
O
ALA
L
185
−116.605
−32.936
6.863
1.00
129.18
O


ATOM
7243
N
ASP
L
186
−114.966
−31.354
6.971
1.00
128.16
N


ATOM
7244
CA
ASP
L
186
−115.687
−30.221
6.376
1.00
128.35
C


ATOM
7245
CB
ASP
L
186
−114.806
−28.953
6.347
1.00
128.45
C


ATOM
7246
CG
ASP
L
186
−114.168
−28.529
7.673
1.00
129.00
C


ATOM
7247
OD1
ASP
L
186
−114.007
−29.394
8.569
1.00
129.87
O


ATOM
7248
OD2
ASP
L
186
−113.810
−27.337
7.806
1.00
129.15
O


ATOM
7249
C
ASP
L
186
−116.305
−30.524
4.993
1.00
128.32
C


ATOM
7250
O
ASP
L
186
−117.296
−29.897
4.615
1.00
128.32
O


ATOM
7251
N
TYR
L
187
−115.733
−31.497
4.259
1.00
127.00
N


ATOM
7252
CA
TYR
L
187
−116.209
−31.924
2.945
1.00
127.07
C


ATOM
7253
CB
TYR
L
187
−115.100
−32.670
2.180
1.00
126.77
C


ATOM
7254
CG
TYR
L
187
−115.569
−33.414
0.944
1.00
125.78
C


ATOM
7255
CD1
TYR
L
187
−115.946
−32.728
−0.206
1.00
124.72
C


ATOM
7256
CE1
TYR
L
187
−116.374
−33.406
−1.348
1.00
124.08
C


ATOM
7257
CZ
TYR
L
187
−116.404
−34.790
−1.356
1.00
123.97
C


ATOM
7258
OH
TYR
L
187
−116.821
−35.459
−2.483
1.00
123.19
O


ATOM
7259
CE2
TYR
L
187
−116.021
−35.494
−0.225
1.00
124.41
C


ATOM
7260
CD2
TYR
L
187
−115.610
−34.804
0.916
1.00
125.07
C


ATOM
7261
C
TYR
L
187
−117.468
−32.791
3.070
1.00
127.53
C


ATOM
7262
O
TYR
L
187
−118.479
−32.485
2.430
1.00
127.68
O


ATOM
7263
N
GLU
L
188
−117.399
−33.880
3.883
1.00
129.18
N


ATOM
7264
CA
GLU
L
188
−118.501
−34.818
4.128
1.00
129.38
C


ATOM
7265
CB
GLU
L
188
−118.018
−36.009
4.966
1.00
129.23
C


ATOM
7266
C
GLU
L
188
−119.720
−34.118
4.776
1.00
129.63
C


ATOM
7267
O
GLU
L
188
−120.858
−34.507
4.509
1.00
129.72
O


ATOM
7268
N
LYS
L
189
−119.473
−33.061
5.588
1.00
129.95
N


ATOM
7269
CA
LYS
L
189
−120.511
−32.273
6.264
1.00
130.00
C


ATOM
7270
CB
LYS
L
189
−120.039
−31.825
7.670
1.00
129.92
C


ATOM
7271
CG
LYS
L
189
−118.929
−30.782
7.664
1.00
129.43
C


ATOM
7272
CD
LYS
L
189
−118.905
−29.927
8.907
1.00
128.46
C


ATOM
7273
CE
LYS
L
189
−118.314
−28.582
8.591
1.00
127.90
C


ATOM
7274
NZ
LYS
L
189
−118.087
−27.786
9.815
1.00
127.98
N


ATOM
7275
C
LYS
L
189
−121.069
−31.088
5.414
1.00
130.15
C


ATOM
7276
O
LYS
L
189
−121.505
−30.081
5.980
1.00
130.07
O


ATOM
7277
N
HIS
L
190
−121.065
−31.213
4.066
1.00
131.73
N


ATOM
7278
CA
HIS
L
190
−121.571
−30.175
3.149
1.00
131.90
C


ATOM
7279
CB
HIS
L
190
−120.507
−29.099
2.854
1.00
131.89
C


ATOM
7280
CG
HIS
L
190
−120.453
−27.999
3.875
1.00
132.02
C


ATOM
7281
ND1
HIS
L
190
−119.727
−28.135
5.050
1.00
132.00
N


ATOM
7282
CE1
HIS
L
190
−119.891
−26.999
5.709
1.00
131.80
C


ATOM
7283
NE2
HIS
L
190
−120.668
−26.149
5.035
1.00
131.85
N


ATOM
7284
CD2
HIS
L
190
−121.033
−26.774
3.863
1.00
132.09
C


ATOM
7285
C
HIS
L
190
−122.174
−30.772
1.865
1.00
132.01
C


ATOM
7286
O
HIS
L
190
−121.590
−31.676
1.268
1.00
131.94
O


ATOM
7287
N
LYS
L
191
−123.346
−30.255
1.450
1.00
133.19
N


ATOM
7288
CA
LYS
L
191
−124.125
−30.712
0.292
1.00
133.24
C


ATOM
7289
CB
LYS
L
191
−125.583
−30.226
0.390
1.00
133.19
C


ATOM
7290
C
LYS
L
191
−123.561
−30.517
−1.125
1.00
133.24
C


ATOM
7291
O
LYS
L
191
−122.976
−31.456
−1.677
1.00
133.17
O


ATOM
7292
N
VAL
L
192
−123.773
−29.304
−1.709
1.00
134.37
N


ATOM
7293
CA
VAL
L
192
−123.399
−28.887
−3.077
1.00
134.31
C


ATOM
7294
CB
VAL
L
192
−124.535
−28.062
−3.783
1.00
134.37
C


ATOM
7295
CG1
VAL
L
192
−125.918
−28.395
−3.228
1.00
134.20
C


ATOM
7296
CG2
VAL
L
192
−124.511
−28.243
−5.303
1.00
134.07
C


ATOM
7297
C
VAL
L
192
−122.028
−28.179
−3.199
1.00
134.22
C


ATOM
7298
O
VAL
L
192
−121.539
−27.580
−2.235
1.00
134.12
O


ATOM
7299
N
TYR
L
193
−121.430
−28.253
−4.417
1.00
133.81
N


ATOM
7300
CA
TYR
L
193
−120.149
−27.659
−4.813
1.00
133.58
C


ATOM
7301
CB
TYR
L
193
−119.001
−28.671
−4.620
1.00
133.46
C


ATOM
7302
CG
TYR
L
193
−118.739
−29.051
−3.181
1.00
133.01
C


ATOM
7303
CD1
TYR
L
193
−118.875
−30.366
−2.752
1.00
132.19
C


ATOM
7304
CE1
TYR
L
193
−118.643
−30.720
−1.424
1.00
131.86
C


ATOM
7305
CZ
TYR
L
193
−118.251
−29.752
−0.512
1.00
131.88
C


ATOM
7306
OH
TYR
L
193
−118.014
−30.081
0.802
1.00
131.77
O


ATOM
7307
CE2
TYR
L
193
−118.107
−28.437
−0.920
1.00
132.04
C


ATOM
7308
CD2
TYR
L
193
−118.345
−28.096
−2.248
1.00
132.53
C


ATOM
7309
C
TYR
L
193
−120.174
−27.183
−6.281
1.00
133.60
C


ATOM
7310
O
TYR
L
193
−120.575
−27.945
−7.169
1.00
133.62
O


ATOM
7311
N
ALA
L
194
−119.740
−25.930
−6.530
1.00
133.66
N


ATOM
7312
CA
ALA
L
194
−119.665
−25.342
−7.876
1.00
133.63
C


ATOM
7313
CB
ALA
L
194
−121.049
−24.958
−8.382
1.00
133.53
C


ATOM
7314
C
ALA
L
194
−118.735
−24.126
−7.930
1.00
133.57
C


ATOM
7315
O
ALA
L
194
−118.548
−23.429
−6.929
1.00
133.52
O


ATOM
7316
N
CYS
L
195
−118.161
−23.874
−9.113
1.00
133.43
N


ATOM
7317
CA
CYS
L
195
−117.267
−22.740
−9.350
1.00
133.34
C


ATOM
7318
CB
CYS
L
195
−115.877
−23.185
−9.815
1.00
133.14
C


ATOM
7319
SG
CYS
L
195
−115.801
−24.879
−10.473
1.00
132.53
S


ATOM
7320
C
CYS
L
195
−117.914
−21.755
−10.331
1.00
133.40
C


ATOM
7321
O
CYS
L
195
−118.453
−22.174
−11.358
1.00
133.32
O


ATOM
7322
N
GLU
L
196
−117.874
−20.455
−10.011
1.00
134.32
N


ATOM
7323
CA
GLU
L
196
−118.465
−19.444
−10.880
1.00
134.46
C


ATOM
7324
CB
GLU
L
196
−119.065
−18.302
−10.040
1.00
134.58
C


ATOM
7325
CG
GLU
L
196
−120.267
−17.617
−10.681
1.00
135.04
C


ATOM
7326
CD
GLU
L
196
−121.579
−18.381
−10.662
1.00
135.55
C


ATOM
7327
OE1
GLU
L
196
−121.760
−19.254
−9.778
1.00
135.81
O


ATOM
7328
OE2
GLU
L
196
−122.434
−18.093
−11.532
1.00
135.51
O


ATOM
7329
C
GLU
L
196
−117.416
−18.934
−11.879
1.00
134.37
C


ATOM
7330
O
GLU
L
196
−116.423
−18.340
−11.458
1.00
134.31
O


ATOM
7331
N
VAL
L
197
−117.636
−19.176
−13.196
1.00
133.36
N


ATOM
7332
CA
VAL
L
197
−116.719
−18.778
−14.283
1.00
133.27
C


ATOM
7333
CB
VAL
L
197
−116.337
−19.982
−15.188
1.00
133.17
C


ATOM
7334
CG1
VAL
L
197
−115.194
−19.624
−16.131
1.00
132.97
C


ATOM
7335
CG2
VAL
L
197
−115.984
−21.209
−14.357
1.00
133.07
C


ATOM
7336
C
VAL
L
197
−117.217
−17.552
−15.101
1.00
133.31
C


ATOM
7337
O
VAL
L
197
−118.137
−17.677
−15.917
1.00
133.28
O


ATOM
7338
N
THR
L
198
−116.575
−16.382
−14.887
1.00
133.26
N


ATOM
7339
CA
THR
L
198
−116.887
−15.099
−15.541
1.00
133.21
C


ATOM
7340
CB
THR
L
198
−116.962
−13.990
−14.468
1.00
133.25
C


ATOM
7341
OG1
THR
L
198
−117.383
−14.550
−13.215
1.00
133.25
O


ATOM
7342
CG2
THR
L
198
−117.879
−12.849
−14.872
1.00
133.03
C


ATOM
7343
C
THR
L
198
−115.863
−14.812
−16.668
1.00
133.19
C


ATOM
7344
O
THR
L
198
−114.677
−14.630
−16.373
1.00
133.08
O


ATOM
7345
N
HIS
L
199
−116.314
−14.791
−17.952
1.00
132.62
N


ATOM
7346
CA
HIS
L
199
−115.419
−14.594
−19.104
1.00
132.74
C


ATOM
7347
CB
HIS
L
199
−114.732
−15.945
−19.441
1.00
132.53
C


ATOM
7348
CG
HIS
L
199
−113.816
−15.924
−20.625
1.00
132.36
C


ATOM
7349
ND1
HIS
L
199
−112.592
−15.293
−20.576
1.00
132.07
N


ATOM
7350
CE1
HIS
L
199
−112.048
−15.482
−21.764
1.00
131.86
C


ATOM
7351
NE2
HIS
L
199
−112.843
−16.186
−22.565
1.00
132.18
N


ATOM
7352
CD2
HIS
L
199
−113.974
−16.479
−21.850
1.00
132.26
C


ATOM
7353
C
HIS
L
199
−116.057
−13.921
−20.361
1.00
133.02
C


ATOM
7354
O
HIS
L
199
−116.002
−12.693
−20.484
1.00
133.04
O


ATOM
7355
N
GLN
L
200
−116.617
−14.739
−21.297
1.00
135.50
N


ATOM
7356
CA
GLN
L
200
−117.267
−14.333
−22.548
1.00
135.70
C


ATOM
7357
CB
GLN
L
200
−116.849
−15.247
−23.719
1.00
135.56
C


ATOM
7358
C
GLN
L
200
−118.801
−14.300
−22.335
1.00
135.94
C


ATOM
7359
O
GLN
L
200
−119.373
−13.205
−22.296
1.00
135.79
O


ATOM
7360
N
GLY
L
201
−119.440
−15.467
−22.161
1.00
136.37
N


ATOM
7361
CA
GLY
L
201
−120.882
−15.553
−21.905
1.00
136.75
C


ATOM
7362
C
GLY
L
201
−121.202
−15.288
−20.440
1.00
136.97
C


ATOM
7363
O
GLY
L
201
−120.302
−15.402
−19.596
1.00
137.00
O


ATOM
7364
N
LEU
L
202
−122.472
−14.930
−20.109
1.00
134.74
N


ATOM
7365
CA
LEU
L
202
−122.867
−14.645
−18.717
1.00
134.75
C


ATOM
7366
CB
LEU
L
202
−124.283
−14.035
−18.632
1.00
134.74
C


ATOM
7367
CG
LEU
L
202
−124.427
−12.560
−18.170
1.00
134.94
C


ATOM
7368
CD1
LEU
L
202
−123.963
−12.347
−16.720
1.00
134.59
C


ATOM
7369
CD2
LEU
L
202
−123.779
−11.579
−19.147
1.00
134.83
C


ATOM
7370
C
LEU
L
202
−122.724
−15.854
−17.774
1.00
134.70
C


ATOM
7371
O
LEU
L
202
−123.054
−16.975
−18.176
1.00
134.76
O


ATOM
7372
N
SER
L
203
−122.207
−15.602
−16.531
1.00
132.85
N


ATOM
7373
CA
SER
L
203
−121.939
−16.541
−15.416
1.00
132.69
C


ATOM
7374
CB
SER
L
203
−122.407
−15.956
−14.084
1.00
132.67
C


ATOM
7375
OG
SER
L
203
−121.456
−15.053
−13.544
1.00
132.56
O


ATOM
7376
C
SER
L
203
−122.401
−18.015
−15.589
1.00
132.56
C


ATOM
7377
O
SER
L
203
−123.604
−18.287
−15.636
1.00
132.54
O


ATOM
7378
N
SER
L
204
−121.425
−18.953
−15.678
1.00
131.25
N


ATOM
7379
CA
SER
L
204
−121.638
−20.395
−15.878
1.00
130.96
C


ATOM
7380
CB
SER
L
204
−121.054
−20.820
−17.229
1.00
130.82
C


ATOM
7381
OG
SER
L
204
−120.861
−22.219
−17.363
1.00
130.49
O


ATOM
7382
C
SER
L
204
−121.140
−21.326
−14.709
1.00
130.87
C


ATOM
7383
O
SER
L
204
−119.996
−21.801
−14.776
1.00
130.88
O


ATOM
7384
N
PRO
L
205
−121.976
−21.642
−13.662
1.00
129.59
N


ATOM
7385
CA
PRO
L
205
−121.498
−22.529
−12.582
1.00
129.34
C


ATOM
7386
CB
PRO
L
205
−122.188
−21.966
−11.329
1.00
129.18
C


ATOM
7387
CG
PRO
L
205
−123.445
−21.284
−11.852
1.00
129.34
C


ATOM
7388
CD
PRO
L
205
−123.354
−21.187
−13.377
1.00
129.61
C


ATOM
7389
C
PRO
L
205
−121.783
−24.031
−12.775
1.00
129.05
C


ATOM
7390
O
PRO
L
205
−122.934
−24.470
−12.651
1.00
129.03
O


ATOM
7391
N
VAL
L
206
−120.725
−24.823
−13.066
1.00
126.14
N


ATOM
7392
CA
VAL
L
206
−120.845
−26.276
−13.214
1.00
125.92
C


ATOM
7393
CB
VAL
L
206
−119.918
−26.893
−14.300
1.00
125.90
C


ATOM
7394
CG1
VAL
L
206
−119.966
−28.417
−14.279
1.00
125.78
C


ATOM
7395
CG2
VAL
L
206
−120.302
−26.382
−15.685
1.00
125.56
C


ATOM
7396
C
VAL
L
206
−120.724
−26.885
−11.794
1.00
125.88
C


ATOM
7397
O
VAL
L
206
−119.719
−26.691
−11.099
1.00
125.71
O


ATOM
7398
N
THR
L
207
−121.805
−27.568
−11.367
1.00
124.30
N


ATOM
7399
CA
THR
L
207
−121.986
−28.167
−10.047
1.00
124.17
C


ATOM
7400
CB
THR
L
207
−123.337
−27.725
−9.471
1.00
124.15
C


ATOM
7401
C
THR
L
207
−121.831
−29.677
−9.931
1.00
124.10
C


ATOM
7402
O
THR
L
207
−121.768
−30.406
−10.930
1.00
123.98
O


ATOM
7403
N
LYS
L
208
−121.783
−30.124
−8.660
1.00
122.52
N


ATOM
7404
CA
LYS
L
208
−121.667
−31.498
−8.184
1.00
122.52
C


ATOM
7405
CB
LYS
L
208
−120.276
−32.080
−8.506
1.00
122.45
C


ATOM
7406
C
LYS
L
208
−121.901
−31.530
−6.663
1.00
122.58
C


ATOM
7407
O
LYS
L
208
−121.475
−30.621
−5.947
1.00
122.64
O


ATOM
7408
N
SER
L
209
−122.584
−32.578
−6.183
1.00
120.30
N


ATOM
7409
CA
SER
L
209
−122.872
−32.856
−4.770
1.00
120.25
C


ATOM
7410
CB
SER
L
209
−124.216
−32.272
−4.345
1.00
120.16
C


ATOM
7411
OG
SER
L
209
−125.283
−32.698
−5.173
1.00
120.24
O


ATOM
7412
C
SER
L
209
−122.830
−34.387
−4.659
1.00
120.28
C


ATOM
7413
O
SER
L
209
−123.482
−35.073
−5.458
1.00
120.26
O


ATOM
7414
N
PHE
L
210
−122.005
−34.914
−3.725
1.00
117.17
N


ATOM
7415
CA
PHE
L
210
−121.750
−36.351
−3.506
1.00
117.28
C


ATOM
7416
CB
PHE
L
210
−120.883
−36.611
−2.253
1.00
117.33
C


ATOM
7417
CG
PHE
L
210
−121.132
−35.842
−0.967
1.00
117.55
C


ATOM
7418
CD1
PHE
L
210
−120.074
−35.499
−0.128
1.00
117.54
C


ATOM
7419
CE1
PHE
L
210
−120.300
−34.825
1.076
1.00
117.48
C


ATOM
7420
CZ
PHE
L
210
−121.585
−34.509
1.459
1.00
117.93
C


ATOM
7421
CE2
PHE
L
210
−122.650
−34.837
0.646
1.00
118.09
C


ATOM
7422
CD2
PHE
L
210
−122.427
−35.521
−0.560
1.00
117.92
C


ATOM
7423
C
PHE
L
210
−122.906
−37.373
−3.653
1.00
117.31
C


ATOM
7424
O
PHE
L
210
−122.822
−38.309
−4.460
1.00
117.16
O


TER
7425

PHE
L
210


END



















SEQUENCES







LIST OF VH SEQUENCES


SEQ ID NO: 360


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 361 (=360-AS)


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSS


 


SEQ ID NO: 550 AX132_VH DNA SEQUENCE


GAAGTGCAGCTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGTCTGTCTTGCAAGGCCTCTGGTTACACCTTCTCTTCTTACGGGA


TGTACTGGGTGCGTCAGGCACCAGGTAAGGGTCTGGAATGGATCGGTTGGATCGACCCAGGCAGCGGTGGCACCAAGTACAACGAAAAGTTCAAGGGTAA


GGCCACCATCTCTAGAGACAACTCTAAGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACTACTGCGCCCGTGAACGT


TACGGTTACTACTTCGACTACTGGGGTCAGGGTACGCTGGTGACTGTCTCGAGC


 


SEQ ID NO: 362


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAN


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 363 (=362-AS)


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAN


DGYSFDYWGQGTLVTVSS


 


SEQ ID NO: 561 >AX213-VH [SEQ ID NO: 12]


CAGGTGCAATTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGTCTGTCTTGCAAGGCTAGCGGTTACACCTTCTCTCGCTACGGTATCA


ACTGGGTGCGTCAGGCACCAGGTAAGGGTCTGAATGGATCGGTCGGATCGACCCAGGTAACGGTGGTACTAGGTACAACGAAAAGTTCAAGGGTAAGGCCACC


ATCTCTAGAGACAACTCTAAGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACTACTGCGCCCGTGCAAATGACGGTTACT


CCTTCGACTACTGGGGTCAGGGTACGCTGGTGACTGTCTCGAGC


 


SEQ ID NO: 364


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYSIYWVRQAPGKGLEWIGWIDPGNGGTRYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 365


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRQGFTWVRQAPGKGLEWIGWIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 366


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYSFSWVRQAPGKGLEWIGYIDPGSGGTKYNQKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARQR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 367


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAN


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 368


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGISWVRQAPGKGLEQIGWIDPGSGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 369


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTNYWVRQAPGKGLEWIGYIDPGSGGTRYNQKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 370


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSYYWVRQAPGKGLEWIGYIDPGSGGTKYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 371


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYANTWVRQAPGKGLEWIGWIDPGNGGTSYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 372


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGYYWVRQAPGKGLEWIGWIDPGSGGTRYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 373


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYAINWVRQAPGKGLEWIGWIDPGSGGTRYNEKFKGQATISRDNSKNTLYLQMNSLRAEDTAVYYCARHR


VGYSLDFWGQGTLVTVSSAS


 


SEQ ID NO: 374


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGIYWVRQAPGKGLEWIGYIDPGSGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYH


YGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 375


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGYYWVRQVPGKGLEWIGYIDPGNGGTSYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYH


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 376


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYAYNWVRQAPGKGLEWIGWIDPGSGGTRYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


FAYYLDYWGQGTLVTVSSAS


 


SEQ ID NO: 377


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGFSWVRQAPGKGLEWIGRIDPGSGGTRYNQQFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


DGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 378


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYAFNWVRQAPGKGLEWIGYIDPGSGGTRYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 379


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGIYWVRQAPGKGLEWIGWIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


AGYYLDYWGQGTLVTVSSAS


 


SEQ ID NO: 380


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTITWVRQAPGKGLEWIGYIDPGSGGTKYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARHR


VGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 381


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSFIWVRQAPGKGLEWIGYIDPGSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRTEDTAVYYCARYR


SGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 382


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTFYWVRQAPGKGLEWIGYIDPGSGGTRYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 383


QVQLLESGGGLVQPGGSLRLSCKASGQTFSSYGFNWVRQAPGKGLEWIGWIDPGSGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAN


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 384


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGYYWVRQAPGKGLEWIGRIDPGSGGTSYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VG?SFDYWGQGTLVTVSSAS


 


SEQ ID NO: 385


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGIYWVRQAPGKGLEWIGRIDPGNGGTRYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 386


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYANYWVRQAPGKGLEWIGYIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSH


VGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 387


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSNSWVRQAPGKGLEWIGWIDPGNGGTRYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 388


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYSITWVRQAPGKGLEWIGWIDPGSGGTRYNEKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARHR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 389


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGFSWVRQAPGKGLEWIGWIDPGNGGTRYNQQFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 390


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTYTWVRQAPGKGLEWIGWIDPGSGGTRYNEKFEGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 391


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYSYYWVRQAPGKGLEWIGRIDPGSGGTRYNQKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 392


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGYSWVRQAPGKGLEWIGRIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARDR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 393


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTFSWVRQAPGKGLEWIGYIDPGNGGTRYNEQFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARQR


VGYNLDYWGQGTLVTVSSAS


 


SEQ ID NO: 394


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGFSWVRQAPGKGLEWIGWIDPGNGGTRYNEQFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARQR


VGYSLDYWGEGTLVTVSSAS


 


SEQ ID NO: 395


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSNSWVRQAPGKGLEWIGWIDPGNGGTRYNEQFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARQR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 396


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGQSWVRQAPGKGLEWIGRIDPGSGGTRYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


DGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 397


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYAISWVRQAPGKGLEWIGRIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


DGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 398


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSYYWVRQAPGKGLEWIGYIDPGSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 399


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTYNWVRQAPGKGLEWIGYIDPGNGGTNYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 400


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTISWVRQAPGKGLEWIGYIDPGNGGTRYNQQFQGKATISRDNSKNTLYLQMNSLRVEDTAVYYCARSR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 401


QVQLLESGGGLLQPGGSLRLSCKASGYTFSRYTFNWVRQAPGKGLEWIGWIDPGSGGTRYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 402


QVQLLESGGGLVQPGGSLRLSCKGQRLPPRYGYYWVRQAPGKGLEWIGYIDPGNGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYRS


GYYLDYWGQGTLVTVSSAS


 


SEQ ID NO: 403


QVQLLESGGGLVQPGGSLRLSCKASGYTYSRYTFSWVRQAPGKGLEWIGYIDPGSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 404


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGYYWVRQAPGKGLEWIGYIDPGSGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 405


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGFSWVRQAPGKGLEWIGRIDPGSGGTRYNEKFQSKATISWDNSKNTLYLQMNSLRAEDTAVYYCARSR


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 406


QVQLLESGGGLVQPGGSLRLSCKASDYTFSSYGNNWVRQAPGKGLEWIGRIDPGNGGTRYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


DGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 407


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGISWVRQAPGKGLEWIGWIDPGNGGTKYNQKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 408


QVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTINWVRQAPGKGLEWIGWIDPGSGGTRYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARHR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 409


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGISWVRQAPGKGLEWIGRIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAQDTAVYYCARAN


DGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 410


QVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAD


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 411


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


VYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 412


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


IYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 413


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


LYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 414


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGR


IYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 415


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGR


FYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 416


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGR


LYYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 417


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


IYYDFDYWGQGTLVTVSSAS


 


SEQ ID NO: 418


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGK


IYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 419


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGY


LYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 420


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


IYYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 421


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGN


LYYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 422


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCSRGK


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 423


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGS


IGYNLDYWGQGTLVTVSSAS


 


SEQ ID NO: 424


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGR


DGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 425


EVQLLESGGGLVQPGGSLRLSCKASGFTFSAYGMYWVRQAPGKGLEWIGRIDPSNGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDAAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 426


EVQLLESGGGLVQPGGSLRLSCKASGFTFSDYGMYWVRQAPGKGLEWIGRINPNSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 427


EVQLLESGGGLVQPGGSLRLSCKASGFTFSSYQMSWVRQAPGKGLEWIGRIDPGSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 428


EVQLLESGGGLVQPGGSLRLSCKASGFTFSYYYMYWVRQAPGKGLEWVGRISPSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 429


EVQLLESGGGLVQPGGSLRLSCKASGFTFTAYGMYWVRQAPGKGLEWIGRIDPGSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 430


EVQLLESGGGLVQPGGSLRLSCKASGFTFTSYQMSWVRQAPGKGLEWIGRINPGSGGTKYDEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 431


EVQLLESGGGLVQPGGSLRLSCKASGFTFTSYWMSWVRQAPGKGLEWIGRINPGSGGTKYDEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 432


EVQLLESGGGLVQPGGSLRLSCKASGLTFTDYGMYWVRQAPGKGLEWIGWINPDSGSTKYAEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 433


EVQLLESGGGLVQPGGSLRLSCKASGYTFSYYGMYWVRQAPGKGLEWIGRIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 434


EVQLLESGGGLVQPGGSLRLSCKASGYTFTDYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 435


EVQLLESGGGLVQPGGSLRLSCKASGYTFTNYGMNWVRQAPGKGLEWIGRIDPSSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 436


EVQLLESGGGLVQPGGSLRLSCKASGYTFTSYGMYWVRQAPGKGLEWIGRIDPSSGGTKYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 437


EVQLLESGGGLVQPGGSLRLSCKASGYTFTSYWMSWVRQAPGKGLEWVGRISPGGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 438


EVQLLESGGGLVQPGGSLRLSCQASGYTFSSYGMYWVRQAPGKGLEWIGRINPGSGGTNYDEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 439


EVQLLESGGGLVQPGGSLRLSCEASGFTFSSYGMYWVRQAPGKGLEWIGRINPKQRWHKYNQKFKGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 440


EVQLLESGGGLVQPGGSLRLSCEASGFSFSNYGMYWVRQAPGKGLEWIGLDRPRQRWHQLNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 441


EVQLLESGGGLVQPGGSLRLSCAASGYSFSAYYIHWVRQAPGKGLESIGRIDPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 442


EVQLLESGGGLVQPGGSLRLSCKASGFSFSSYGIYWVRQAPGKGLEWIGLDRPKQRVGTKYNQKFQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARE


RYGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 443


EVQLLESGGGLVQPGDSLRLSCAASGYSFSTFGIYWVRQAPGKGLEWIGLDRPRQRWPKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 444


EVQLLESGGGLVQPGGSLRLSCEASGFTFSDYGIHWVRQAPGKGLEWIGLDRPKQRWHQYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 445


EVQLLESGGGLVQPGGSLRLSCAASGYTFSDFGIYWVRQAPGKGLEWIGSDRPRQRVAPKYNQKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARE


RYGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 446


EVQLLESGGGLVQPGGSLRLSCQASGYSFTTYGMYWVRQAPGKGLEWIGRIDPSSGGTKYNQKFQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 447


EVQLLESGGGLVQPGGSLRLSCAASGFTFTNYGMYWVRQAPGKGLEWIGLDRPKQRGTKYNQKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 448


EVQLLESGGGLVQPGGSLRLSCKASGYTFSYFGIYWVRQAPGKGLEWIGSDRPRQRWHQVQRKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 449


EVQLLESGGGLVQPGGSLRLSCTASGFTFSNYGMYWVRQAPGKGLEWIGRIDPNSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 450


EVQLLESGGGLVQPGGSLRLSCTASGYSFTAFGMYWVRQAPGKGLEWIGRINPSSGGTNYNEQFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 451


EVQLLESGGGLVQPGGSLRLSCKASGFTFSSYGMYWVRQAPGKGLEWIGSDRPRQRWHQVQPKVQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 452


EVQLLESGGGLVQPGGSLRLSCKASGYSFSAYGMYWVRQAPGKGLEWIGRIDPNSGGTKQNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 453


EVQLLESGGGLVQPGGSLRLSCEASGYTFTSFQMHWVRQAPGKGLESIGRIDPGSGGTKYNQKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 454


EVQLLESGGGLVQPGGSLRLSCAASGYTFSSFSMYWVRQAPGKGLEWIGLDRPRQRWHQVNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 455


EVQLLESGGGLVQPGGSLRLSCQASGYTFTNYGMYWVRQAPGKGLEWIGRIDPGNGGTKYNEKFKGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 456


EVQLLESGGGLVQPGGSLRLSCQASGYTFTAFGMYWVRQAPGKGLEWIGRIDPGSGGTKYNEKFQGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 457


EVQLLESGGGLVQPGGSLRLSCKASGFSFTSYGMYWVRQAPGKGLEWIGQDRPKYGGTKYNEKFKGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 458


EVQLLESGGGLVQPGGSLRLSCQASGFTFSTYGIYWVRQAPGKGLEWIGRINPSNGGTKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 459


EVQLLESGGGLVQPGGSLRLSCKASGFSFSSYGMYWVRQAPGKGLEWIGSDRPRQRWGTKYNEKFQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARE


RYGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 460


EVQLLESGGGLVQPGGSLRLSCEASGYSFSNFGMYWVRQAPGKGLEWIGWINPSNGGTKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


GYYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 461


EVQLLESGGGLVQPGGSLRLSCTASDFSFSTFSMYWVRQAPGKGLEWIGSDQPRQGGTKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 462


EVQLLESGGGLVQPGGSLRLSCAASGYTFSDFGIYWVRQAPGKGLEWIGSDRPRQGGTKYNEKFKDRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 463


EVQLLESGGGLVQPGGSLRLSCAASGYSFTSFGIYWVRQAPGKGLEWIGSDRPKQRGTKYNEKFKGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 464


EVQLLESGGGLVQPGGSLRLSCQASGFSFSDYYMSWVRQAPGKGLESIGRINPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 465


EVQLLESGGGLVQPGGSLRLSCAASGYSFSDYGIYWVRQAPGKGLEWIGSDRPKQRWHQVNEKFQGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 466


EVQLLESGGGLVQPGGSLRLSCKASGYSFSTYYMYWVRQAPGKGLEWIGRIDPDSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 467


EVQLLESGGGLVQPGGSLRLSCEASGYTFSAFQIYWVRQAPGKGLEWIGRIDPGNGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 468


EVQLLESGGGLVQPGGSLRLSCQASGFSFSNFYMYWVRQAPGKGLEWIGRIDPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 469


EVQLLESGGGLVQPGGSLRLSCKASGFTFSAFGIYWVRQAPGKGLEWIGRINPDNGGTKYNEKFQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 470


EVQLLESGGGLVQPGGSLRLSCKASGYTFSTYGMYWVRQAPGKGLEWIGRDQPRQGGTNYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 471


EVQLLESGGGLVQPGGSLRLSCAASGYSFSTYGIYWVRQAPGKGLEWIGRINPNNGGTKYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 472


EVQLLESGGGLVQPGGSLRLSCTASGFSFSAYGMYWVRQAPGKGLEWIGSDRPRQGGTKYNEKFKGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 473


EVQLLESGGGLVQPGGSLRLSCAASGFSFSNYYMYWVRQAPGKGLEWIGRIDPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 474


EVQLLESGGGLVQPGGSLRLSCEASGYTFTSYGMYWMRQAPGKGLEWIGRIDPGSGGTKYNEKFQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 475


EVQLLESGGGLVQPGGSLRLSCAASGFTFTNYGMYWVRQAPGKGLEWIGSDRPKQRWAPKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARE


RYGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 476


EVQLLESGGGLVQPGGSLRLSCKASGYTFSDFAMYWVRQAPGKGLEWIGSDQPRQRWHQVQPKVQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 477


EVQLLESGGGLVQPGGSLRLSCKASGYSFTNFGMYWVRQAPGKGLEWIGRINPGNGGTKQNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 478


EVQLLESGGGLVQPGGSLRLSCAASGYSFSYYGMYWVRQAPGKGLEWIGRINPSSGGTKYNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 479


EVQLLESGGGLVQPGGSLRLSCEASGYSFSAFGIYWVRQAPGKGLEWIGRINPNSGGTKYNEKFKGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 480


EVQLLESGGGLVQPGGSLRLSCKTSGYTFSAFQIYWVRQAPGKGLEWIGRIDPGSGGTKYNQKFKGRTTISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 481


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQDKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCAREK


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 482


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQEKFKGKVTISRDNSKNTLYLQMNSLRAEDTAVYYCAREK


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 483


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYK


SGWYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 484


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQEKFKGKATISRDNSKNTLYLQMNSLRAEDTALYYCAREK


YGYYFDYWGQGMLVTVSSAS


 


SEQ ID NO: 485


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTNYQEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 486


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 487


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTNYQQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYK


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 488


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYADKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 489


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYEEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 490


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQDKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCAREK


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 491


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYQEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCAREK


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 492


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNDKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 493


EVQLLESGGGLVQPGGSVRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYYEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYK


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 494


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYEEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYK


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 495


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWMRQAPGKGLEWIGWIDPGSGGTKYEDKFEGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 496


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTNYTQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARYR


SGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 497


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYSHKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 498


EVQLLESGGGLVQPGGSLRLSCAASGYSFSAYYIHWVRQAPGKGLEWIGRIDPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARER


YGYYFDYWGQGTLVTVSSAS


 


SEQ ID NO: 499


EVQLLESGGGLVQPGGSLRLSCAASGYSFSAYYIHWVRQAPGKGLEWIGRIDPGSGGTKYNEKFQGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


LYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 500


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTRYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARGF


LYYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 501


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTINWVRQAPGKGLEWIGYIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 502


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTISWVRQAPGKGLEWIGYIDPGNGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 503


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTINWVRQAPGKGLEWIGWIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 504


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTINWVRQAPGKGLEWIGWIDPGNGGSRYNQKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 505


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYTINWVRQAPGKGLEWIGYIDPGSGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARSR


VGYSFDNWGQGTLVTVSSAS


 


SEQ ID NO: 506


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSINWVRQAPGKGLEWIGYIDPGNGGTRYNEKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 507


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYTINWVRQAPGKGLEWIGWIDPGSGGTRYNEKFQSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSFDYWGQGTLVTVSSAS


 


SEQ ID NO: 508


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYSINWVRQAPGKGLEWIGYIDPGNGGTKYNQKFQGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 509


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYAINWVRQAPGKGLEWIGYIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARAR


VGYSLDYWGQGTLVTVSSAS


 


SEQ ID NO: 510


EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYSISWVRQAPGKGLEWIGYIDPGSGGTRYNQKFKSKATISRDNSKNTLYLQMNSLRAEDTAVYYCARQR


VGYSLDYWGQGTLVTVSSAS


 


LIST OF VK SEQUENCES


SEQ ID NO: 512


EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVAFG


GGTKVEIK


 


SEQ ID NO: 511


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 551 AX132_VK DNA SEQUENCE


GAAATCGTGCTGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCCGGGGAACGTGCCACCATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGA


ACTGGTATCAGCAGAAGCCAGGTCAGGCGCCACGTCTGCTGATCTACGACGCCTCTAACCGTGCCACCGGTATCCCAGCCCGTTTCTCTGGTTCTGGTTC


TGGCACCGACTTCACCCTGACCATCTCTTCTCTGGAACCAGAAGACTTCGCCGTGTACTACTGCCAGGTATGGGACAGCTCTCCTCCTGTGGTGTTCGGT


GGTGGTACCAAAGTGGAGATCAAA


 


SEQ ID NO: 513


EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 514


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVAFG


GGTKVEIK


 


SEQ ID NO: 515


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPLVFG


GGTKVEIK


 


SEQ ID NO: 516


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPLAFG


GGTKVEIK


 


SEQ ID NO: 517


EIVLTQSPATLSLSPGERATITCRASQYIGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQAWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 518


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVMFG


GGTKVEIK


 


SEQ ID NO: 519


DIQMTQSPSSLSASVGDRVTITCRASQAISNYLTWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQGWDSSPTFGGG


TKVEIK


 


SEQ ID NO: 520


EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPLVFG


GGTKVEIK


 


SEQ ID NO: 521


EIVLTQSPATLSLSPGERATITCRASQYVGSYLTWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 522


EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDNSPPVVFG


GGTKVEIK


 


SEQ ID NO: 523


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 524


EIVLTQSPATLSLSPGERATITCRASQYIGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQAWDSSPPVTFG


DGTKVEIK


 


SEQ ID NO: 525


DIQMTQSPSSLSASVGDRVTITCRASQDVSNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSGSYLTFGGG


TKVEIK


 


SEQ ID NO: 526


EIVLTQSPATLSLSPGERATITCQASQYVGSYLSWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSYHAVVFG


GGTKVEIK


 


SEQ ID NO: 527


EIVLTQSPATLSLSPGERATITCQASQYVGSYLSWYQQKPGQAPRLLIYDASNRAAGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWGSYHAVMFG


GGTKVEIK


 


SEQ ID NO: 528


EIVLTQSPATLSLSPGERATITCRASQYVGSYLSWYQQKPGQAPRLLIYDASNRAAGIPARFSGSGSGTDFTLNISSLEPEDFAVYYCQVWGSYHSVMFG


GGTKVEIK


 


SEQ ID NO: 529


EIVLTQSPATLSLSPGERATITCQASQYVGSYLSWYQQKPGQAPRLLIYDASNRAAGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDTDHSVVFG


GGTKVEIK


 


SEQ ID NO: 530


EIVLTQSPATLSLSPGERATITCQASQYVGSYLSWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDTDHAVAFG


GGTKVEIK


 


SEQ ID NO: 531


EIVLTQSPATLSLSPGERATITCRASQYVGSYLSWYQQKPGQAPRLLIYDASNRASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSHSVIFG


GGTKVEIK


 


SEQ ID NO: 532


EIVLTQSPATLSLSPGERATITCRASQYVGSYLSWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSYPPVVFG


GGTKVEIK


 


SEQ ID NO: 533


EIVLTQSPATLSLSPGERATITCRASQYVGSYLSWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSYHAVVFG


GGTKVEIK


 


SEQ ID NO: 534


EIVLTQSPATLSLSPGERATITCRASQYVGSYLSWYQQKPGQAPRLLIYDASNRASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSDHAVVFG


GGTKVEIK


 


SEQ ID NO: 535


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWGSNHASLFG


GGTKVEIK


 


SEQ ID NO: 536


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWGSTARVAFG


GGTKVEIK


 


SEQ ID NO: 537


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWNSTPPVVFG


GGTKVEIK


 


SEQ ID NO: 538


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWSSSPPVIFG


GGTKVEIK


 


SEQ ID NO: 539


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWSSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 540


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWSSNHAVVFG


GGTKVEIK


 


SEQ ID NO: 541


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWGSNPPVAFG


GGTKVEIK


 


SEQ ID NO: 542


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSTPPVVFG


GGTKVEIK


 


SEQ ID NO: 543


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSNPPVVFG


GGTKVEIK


 


SEQ ID NO: 544


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQGYSSNDGVIFG


GGTKVEIK


 


SEQ ID NO: 545


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWGSNHSVVFG


GGTKVEIK


 


SEQ ID NO: 546


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDAANRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSNHSVVFG


GGTKVEIK


 


SEQ ID NO: 547


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRAAGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


SEQ ID NO: 548


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSSAVVFG


GGTKVEIK


 


SEQ ID NO: 549


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDLTLTISSLEPEDFAVYYCQVWDSSPPVVFG


GGTKVEIK


 


LIST OF VH-CDR1 SEQUENCES


SEQ ID NO: 183


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XXSXXXXXXXXXXWXR


Wherein X at position 1 is K, A, E, Q or T; X at position 2 is A or T; X at position 4 is G or D; X


at position 5 is Y, F, L or Q; X at position 6 is T or S; X at position 7 is F or Y; X at position 8 is


S or T; X at position 9 is S, R, A, N, D, T or Y; X at position 10 is Y, F or Q; X at position 11 is


G, S, T, A, Y, Q or W; X at position 12 is M, I, F, Y, N or Q; X at position 13 is Y, S, N, T, H or


I; and X at position 15 is V or M.


 


SEQ ID NO: 184


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XXXXXXXXXX


Wherein X at position 1 is G or D; X at position 2 is Y, F, L or Q; X at position 3 is T or S; X at


position 4 is F or Y; X at position 5 is S or T; X at position 6 is S, R, A, N, D, T or Y; X at


position 7 is Y, F or Q; X at position 8 is G, S, T, A, Y, Q or W; X at position 9 is M, I, F, Y, N


or Q; and X at position 10 is Y, S, N, T, H or I.


 


SEQ ID NO: 185


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XASXXXFXXXXXXWXR


Wherein X at position 1 is K, A, E, Q or T; X at position 4 is G or D; X at position 5 is Y, F, L


or Q; X at position 6 is T or S; X at position 8 is S or T; X at position 9 is S, R, A, N, D, T or Y;


X at position 10 is Y, F or Q; X at position 11 is G, S, T, A, Y, Q or W; X at position 12 is M, I,


F, Y, N or Q; X at position 13 is Y, S, N, T, H or I; and X at position 15 is V or M


 


SEQ ID NO: 186


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XXXFXXXXXX


Wherein X at position 1 is G or D; X at position 2 is Y, F, L or Q; X at position 3 is T or S; X at


position 5 is S or T; X at position 6 is S, R, A, N, D, T or Y; X at position 7 is Y, F or Q; X at


position 8 is G, S, T, A, Y, Q or W; X at position 9 is M, I, F, Y, N or Q; and X at position 10 is


Y, S, N, T, H or I.


 


SEQ ID NO: 187


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XASXXXFXXXXXXWVR


Wherein X at position 1 is K, A, E, Q or T; X at position 4 is G or D; X at position 5 is Y, F, L


or Q; X at position 6 is T or S; X at position 8 is S or T; X at position 9 is S, R, A, N, D, T or Y;


X at position 10 is Y, F or Q; X at position 11 is G, S, T, A, Y, Q or W; X at position 12 is M, I,


F, Y, N or Q; and X at position 13 is Y, S, N, T, H or I.


 


SEQ ID NO: 188


Consensus sequence for Variant Heavy Chain CDR1 Sequence


XXXFXXXXXX


Wherein X at position 1 is G or D; X at position 2 is Y, F, L or Q; X at position 3 is T or S; X at


position 5 is S or T; X at position 6 is S, R, A, N, D, T or Y; X at position 7 is Y, F or Q; X at


position 8 is G, S, T, A, Y, Q or W; X at position 9 is M, I, F, Y, N or Q; and X at position 10 is


Y, S, N, T, H or I.


 


SEQ ID NO: 189


KASGYTFSSYGMYWVR


 


SEQ ID NO: 190 132 CDR1SEQUENCE


AAGGCCTCTGGTTACACCTTCTCTTCTTACGGGATGTACTGGGTGCGT


 


SEQ ID NO: 191 132 CDR1 SEQUENCE (SHORTENED)


GYTFSSYGMY


 


SEQ ID NO: 192 132 CDR1 SEQUENCE (SHORTENED)


GGTTACACCTTCTCTTCTTACGGGATGTAC


 


SEQ ID NO: 197


KASGYTFSSYSIYWVR


 


SEQ ID NO: 198


KASGYTFSRQGFTWVR


 


SEQ ID NO: 199


KASGYTFSSYSFSWVR


 


SEQ ID NO: 193


KASGYTFSRYGINWVR


 


SEQ ID NO: 194 213 CDR1 SEQUENCE


AAGGCTAGCGGTTACACCTTCTCTCGCTACGGTATCAACTGGGTGCGT


 


SEQ ID NO: 195 213 CDR1 SEQUENCE


GYTFSRYGIN


 


SEQ ID NO: 196 213 CDR1 SEQUENCE


GGTTACACCTTCTCTCGCTACGGTATCAAC


 


SEQ ID NO: 200


KASGYTFSRYGISWVR


 


SEQ ID NO: 201


KASGYTFSSYTNYWVR


 


SEQ ID NO: 202


KASGYTFSRYSYYWVR


 


SEQ ID NO: 203


KASGYTFSSYANTWVR


 


SEQ ID NO: 204


KASGYTFSSYGYYWVR


 


SEQ ID NO: 205


KASGYTFSRYAINWVR


 


SEQ ID NO: 206


KASGYTFSRYGIYWVR


 


SEQ ID NO: 207


KASGYTFSRYGYYWVR


 


SEQ ID NO: 208


KASGYTFSRYAYNWVR


 


SEQ ID NO: 209


KASGYTFSRYGFSWVR


 


SEQ ID NO: 210


KASGYTFSRYAFNWVR


 


SEQ ID NO: 211


KASGYTFSSYGIYWVR


 


SEQ ID NO: 212


KASGYTFSRYTITWVR


 


SEQ ID NO: 213


KASGYTFSRYSFIWVR


 


SEQ ID NO: 214


KASGYTFSRYTFYWVR


 


SEQ ID NO: 215


KASGQTFSSYGFNWVR


 


SEQ ID NO: 216


KASGYTFSRYANYWVR


 


SEQ ID NO: 217


KASGYTFSRYSNSWVR


 


SEQ ID NO: 218


KASGYTFSSYSITWVR


 


SEQ ID NO: 219


KASGYTFSSYTYTWVR


 


SEQ ID NO: 220


KASGYTFSSYSYYWVR


 


SEQ ID NO: 221


KASGYTFSSYGYSWVR


 


SEQ ID NO: 222


KASGYTFSRYTFSWVR


 


SEQ ID NO: 223


KASGYTFSSYGFSWVR


 


SEQ ID NO: 224


KASGYTFSSYGQSWVR


 


SEQ ID NO: 225


KASGYTFSSYAISWVR


 


SEQ ID NO: 226


KASGYTFSSYTYNWVR


 


SEQ ID NO: 227


KASGYTFSSYTISWVR


 


SEQ ID NO: 228


KASGYTFSRYTFNWVR


 


SEQ ID NO: 229


KGQRLPPRYGYYWVR


 


SEQ ID NO: 230


KASGYTYSRYTFSWVR


 


SEQ ID NO: 231


KASDYTFSSYGNNWVR


 


SEQ ID NO: 232


KASGYTFSSYGISWVR


 


SEQ ID NO: 233


KASGYTFSSYTINWVR


 


SEQ ID NO: 234


KASGFTFSAYGMYWVR


 


SEQ ID NO: 235


KASGFTFSDYGMYWVR


 


SEQ ID NO: 236


KASGFTFSSYQMSWVR


 


SEQ ID NO: 237


KASGFTFSYYYMYWVR


 


SEQ ID NO: 238


KASGFTFTAYGMYWVR


 


SEQ ID NO: 239


KASGFTFTSYQMSWVR


 


SEQ ID NO: 240


KASGFTFTSYWMSWVR


 


SEQ ID NO: 241


KASGLTFTDYGMYWVR


 


SEQ ID NO: 242


KASGYTFSYYGMYWVR


 


SEQ ID NO: 243


KASGYTFTDYGMYWVR


 


SEQ ID NO: 244


KASGYTFTNYGMNWVR


 


SEQ ID NO: 245


KASGYTFTSYGMYWVR


 


SEQ ID NO: 246


KASGYTFTSYWMSWVR


 


SEQ ID NO: 247


QASGYTFSSYGMYWVR


 


SEQ ID NO: 248


EASGFTFSSYGMYWVR


 


SEQ ID NO: 249


EASGFSFSNYGMYWVR


 


SEQ ID NO: 250


AASGYSFSAYYIHWVR


 


SEQ ID NO: 251


KASGFSFSSYGIYWVR


 


SEQ ID NO: 252


AASGYSFSTFGIYWVR


 


SEQ ID NO: 253


EASGFTFSDYGIHWVR


 


SEQ ID NO: 254


AASGYTFSDFGIYWVR


 


SEQ ID NO: 255


QASGYSFTTYGMYWVR


 


SEQ ID NO: 256


AASGFTFTNYGMYWVR


 


SEQ ID NO: 257


KASGYTFSYFGIYWVR


 


SEQ ID NO: 258


TASGFTFSNYGMYWVR


 


SEQ ID NO: 259


TASGYSFTAFGMYWVR


 


SEQ ID NO: 260


KASGFTFSSYGMYWVR


 


SEQ ID NO: 261


KASGYSFSAYGMYWVR


 


SEQ ID NO: 262


EASGYTFTSFQMHWVR


 


SEQ ID NO: 263


AASGYTFSSFSMYWVR


 


SEQ ID NO: 264


QASGYTFTNYGMYWVR


 


SEQ ID NO: 265


QASGYTFTAFGMYWVR


 


SEQ ID NO: 266


KASGFSFTSYGMYWVR


 


SEQ ID NO: 267


QASGFTFSTYGIYWVR


 


SEQ ID NO: 268


KASGFSFSSYGMYWVR


 


SEQ ID NO: 269


EASGYSFSNFGMYWVR


 


SEQ ID NO: 270


TASDFSFSTFSMYWVR


 


SEQ ID NO: 271


AASGYSFTSFGIYWVR


 


SEQ ID NO: 272


QASGFSFSDYYMSWVR


 


SEQ ID NO: 273


AASGYSFSDYGIYWVR


 


SEQ ID NO: 274


KASGYSFSTYYMYWVR


 


SEQ ID NO: 275


EASGYTFSAFQIYWVR


 


SEQ ID NO: 276


QASGFSFSNFYMYWVR


 


SEQ ID NO: 277


KASGFTFSAFGIYWVR


 


SEQ ID NO: 278


KASGYTFSTYGMYWVR


 


SEQ ID NO: 279


AASGYSFSTYGIYWVR


 


SEQ ID NO: 280


TASGFSFSAYGMYWVR


 


SEQ ID NO: 281


AASGFSFSNYYMYWVR


 


SEQ ID NO: 282


EASGYTFTSYGMYWMR


 


SEQ ID NO: 283


KASGYTFSDFAMYWVR


 


SEQ ID NO: 284


KASGYSFTNFGMYWVR


 


SEQ ID NO: 285


AASGYSFSYYGMYWVR


 


SEQ ID NO: 286


EASGYSFSAFGIYWVR


 


SEQ ID NO: 287


KTSGYTFSAFQIYWVR


 


SEQ ID NO: 288


KASGYTFSSYGMYWMR


 


SEQ ID NO: 289


KASGYTFSRYTISWVR


 


SEQ ID NO: 290


KASGYTFSRYTINWVR


 


SEQ ID NO: 291


KASGYTFSRYSINWVR


 


SEQ ID NO: 292


KASGYTFSSYSINWVR


 


SEQ ID NO: 293


KASGYTFSSYAINWVR


 


SEQ ID NO: 294


KASGYTFSRYSISWVR


 


LIST OF VH-CDR2 SEQUENCES


SEQ ID NO: 64


Consensus sequence for Variant Heavy Chain CDR2 Sequence


XXGXXXPXXXXXXXXXXXXXXXT


Wherein X at position 1 is W, S or Q; X at position 2 is I or V; X at position 4 is W, R, Y, S, L


or Q; X at position 5 is I or D; X at position 6 is D, N, R, Q or S; X at position 8 is G, R, S, K, N


or D; X at position 9 is S, N, Q, G or Y; X at position 10 is G or R; X at position 11 is G, W, S or


T; X at position 12 is T, H, P or S; X at position 13 is K, R, N, Q, S or Y; X at position 14 is Y,


V, Q or L; X at position 15 is N, Q, A, E, D, Y, S or T; X at position 16 is E, Q, D, P, R or H; X


at position 17 is K, Q or S; X at position 18 is F or V; X at position 19 is K, Q or E; X at position


20 is S, or D; Xat position 21 is K, R or Q; and X at position 22 is A, V, F or T.


 


SEQ ID NO: 65


Consensus sequence for Variant Heavy Chain CDR2 Sequence


XXXPXXXXXXXXXXXXX


Wherein X at position 1 is R, Y, S, L or Q; X at position 2 is I or D; X at position 3 is D, N, R, Q


or S; X at position 5 is G, R, S, K, N or D; X at position 6 is S, N, Q, G or Y; X at position 7 is G


or R; X at position 8 is G, W, S or T; X at position 9 is T, H, P or S; X at position 10 is K, R, N,


Q, S or Y; X at position 11 is Y, V, Q or L; X at position 12 is N, Q, A, E, D, Y, S or T; X at


position 13 is E, Q, D, P, R or H; X at position 14 is K, Q or S; X at position 15 is F or V; X at


position 16 is K, Q or E; and X at position 17 is G, S or D.


 


SEQ ID NO: 66


Consensus sequence for Variant Heavy Chain CDR2 Sequence


XXGXXXPXXXXXXYXXXXXXXXT


Wherein X at position 1 is W, S or Q; X at position 2 is I or V; X at position 4 is W, R, Y, S, L


or Q; X at position 5 is I or D; X at position 6 is D, N, R, Q or S; X at position 8 is G, R, S, K, N


or D; X at position 9 is S, N, Q, G or Y; X at position 10 is G or R; X at position 11 is G, W, S or


T; X at position 12 is T, H, P or S; X at position 13 is K, R, N, Q, S or Y; X at position 15 is N,


Q, A, E, D, Y, S or T; X at position 16 is E, Q, D, P, R or H; X at position 17 is K, Q or S; X at


position 18 is F or V; X at position 19 is K, Q or E; X at position 20 is G, S or D; X at position


21 is K, R or Q; and X at position 22 is A, V, F or T.


 


SEQ ID NO: 67


Consensus sequence for Variant Heavy Chain CDR2 Sequence


XXXPXXXXXXYXXXXXX


Wherein X at position 1 is W, R, Y, S, L or Q; X at position 2 is I or D; X at position 3 is D, N,


R, Q or S; X at position 5 is G, R, S, K, N or D; X at position 6 is S, N, Q, G or Y; X at position


7 is G or R; X at position 8 is G, W, S or T; X at position 9 is T, H, P or S; X at position 10 is K,


R, N, Q, S or Y; X at positino 12 is N, Q, A, E, D, Y, S or T; X at position 13 is E, Q, D, P, R or


H; X at position 14 is K, Q or S; X at position 15 is F or V; X at position 16 is K, Q or E; and X


at position 17 is G, S or D.


 


SEQ ID NO: 68


WIGWIDPGSGGTKYNEKFKGKAT


 


SEQ ID NO: 69 132 CDR2 SEQUENCE


TGGATCGGTTGGATCGACCCAGGCAGCGGTGGCACCAAGTACAACGAAAAGTTCAAGGGTAAGGCCACC


 


SEQ ID NO: 70 132 CDR2 SEQUENCE (SHORTENED)


WIDPGSGGTKYNEKFKG


 


SEQ ID NO: 71 132 CDR2 SEQUENCE (SHORTENED)


TGGATCGACCCAGGCAGCGGTGGCACCAAGTACAACGAAAAGTTCAAGGGT


 


SEQ ID NO: 76


WIGWIDPGNGGTRYNQKFQSKAT


 


SEQ ID NO: 77


WIGWIDPGNGGTRYNEKFKGKAT


 


SEQ ID NO: 78


WIGYIDPGSGGTKYNQKFQGKAT


 


SEQ ID NO: 72


WIGRIDPGNGGTRYNEKFKGKAT


 


SEQ ID NO: 73 213 CDR2 SEQUENCE


TGGATCGGTCGGATCGACCCAGGTAACGGTGGTACTAGGTACAACGAAAAGTTCAAGGGTAAGGCCACC


 


SEQ ID NO: 74 213 CDR2 SEQUENCE


RIDPGNGGTRYNEKFKG


 


SEQ ID NO: 75 213 CDR2 SEQUENCE


CGGATCGACCCAGGTAACGGTGGTACTAGGTACAACGAAAAGTTCAAGGGT


 


SEQ ID NO: 79


QIGWIDPGSGGTRYNQKFKSKAT


 


SEQ ID NO: 80


WIGYIDPGSGGTRYNQKFQGKAT


 


SEQ ID NO: 81


WIGYIDPGSGGTKYNQKFQSKAT


 


SEQ ID NO: 82


WIGWIDPGNGGTSYNQKFKSKAT


 


SEQ ID NO: 83


WIGWIDPGSGGTRYNQKFKGKAT


 


SEQ ID NO: 84


WIGWIDPGSGGTRYNEKFKGQAT


 


SEQ ID NO: 85


WIGYIDPGSGGTRYNEKFKGKAT


 


SEQ ID NO: 86


WIGYIDPGNGGTSYNEKFKGKAT


 


SEQ ID NO: 87


WIGRIDPGSGGTRYNQQFQGKAT


 


SEQ ID NO: 88


WIGYIDPGSGGTRYNEKFQGKAT


 


SEQ ID NO: 89


WIGWIDPGSGGTRYNEKFQSKAT


 


SEQ ID NO: 90


WIGYIDPGSGGTKYNEKFQGKAT


 


SEQ ID NO: 91


WIGYIDPGSGGTKYNQKFKGKAT


 


SEQ ID NO: 92


WIGYIDPGSGGTRYNQKFKGKAT


 


SEQ ID NO: 93


WIGWIDPGSGGTRYNQKFKSKAT


 


SEQ ID NO: 94


WIGRIDPGSGGTSYNEKFQSKAT


 


SEQ ID NO: 95


WIGRIDPGNGGTRYNQKFQSKAT


 


SEQ ID NO: 96


WIGYIDPGSGGTKYNEKFKGKAT


 


SEQ ID NO: 97


WIGWIDPGSGGTRYNEKFKSKAT


 


SEQ ID NO: 98


WIGWIDPGNGGTRYNQQFKGKAT


 


SEQ ID NO: 99


WIGWIDPGSGGTRYNEKFEGKAT


 


SEQ ID NO: 100


WIGRIDPGSGGTRYNQKFQGKAT


 


SEQ ID NO: 101


WIGRIDPGSGGTKYNEKFKGKAT


 


SEQ ID NO: 102


WIGYIDPGNGGTRYNEQFKGKAT


 


SEQ ID NO: 103


WIGWIDPGNGGTRYNEQFQGKAT


 


SEQ ID NO: 104


WIGRIDPGSGGTRYNEKFQGKAT


 


SEQ ID NO: 105


WIGRIDPGSGGTRYNEKFQSKAT


 


SEQ ID NO: 106


WIGYIDPGNGGTNYNQKFQSKAT


 


SEQ ID NO: 107


WIGYIDPGNGGTRYNQQFQGKAT


 


SEQ ID NO: 108


WIGWIDPGSGGTRYNQKFQSKAT


 


SEQ ID NO: 109


WIGYIDPGNGGTRYNEKFQSKAT


 


SEQ ID NO: 110


WIGYIDPGSGGTRYNQKFKSKAT


 


SEQ ID NO: 111


WIGRIDPGNGGTRYNEKFQGKAT


 


SEQ ID NO: 112


WIGWIDPGNGGTKYNQKFQSKAT


 


SEQ ID NO: 113


WIGWIDPGSGGTRYNEKFQGKAT


 


SEQ ID NO: 114


WIGRIDPSNGGTKYNQKFKGKAT


 


SEQ ID NO: 115


WIGRINPNSGGTKYNEKFKGKAT


 


SEQ ID NO: 116


WIGRIDPGSGGTKYNQKFKGKAT


 


SEQ ID NO: 117


WVGRISPSGGSTYYADSVKGRFT


 


SEQ ID NO: 118


WIGRINPGSGGTKYDEKFKGRAT


 


SEQ ID NO: 119


WIGWINPDSGSTKYAEKFKGRAT


 


SEQ ID NO: 120


WIGRIDPSSGGTKYNQKFKGKAT


 


SEQ ID NO: 121


WVGRISPGGGTTYYADSVKGRFT


 


SEQ ID NO: 122


WIGRINPGSGGTNYDEKFKGRAT


 


SEQ ID NO: 123


WIGRINPKQRWHKYNQKFKGKVT


 


SEQ ID NO: 124


WIGLDRPRQRWHQLNEKFQGRAT


 


SEQ ID NO: 125


SIGRIDPGSGGTKYNEKFQGRAT


 


SEQ ID NO: 126


WIGLDRPKQRVGTKYNQKFQGRVT


 


SEQ ID NO: 127


WIGLDRPRQRWPKYNEKFKGRAT


 


SEQ ID NO: 128


WIGLDRPKQRWHQYNEKFQGRAT


 


SEQ ID NO: 129


WIGSDRPRQRVAPKYNQKFKGRAT


 


SEQ ID NO: 130


WIGRIDPSSGGTKYNQKFQGRVT


 


SEQ ID NO: 131


WIGLDRPKQRGTKYNQKFQGRAT


 


SEQ ID NO: 132


WIGSDRPRQRWHQVQRKFKGRAT


 


SEQ ID NO: 133


WIGRIDPNSGGTKYNEKFQGRAT


 


SEQ ID NO: 134


WIGRINPSSGGTNYNEQFQGRAT


 


SEQ ID NO: 135


WIGSDRPRQRWHQVQPKVQGRAT


 


SEQ ID NO: 136


WIGRIDPNSGGTKQNEKFQGRAT


 


SEQ ID NO: 137


SIGRIDPGSGGTKYNQKFQGRAT


 


SEQ ID NO: 138


WIGLDRPRQRWHQVNEKFQGRAT


 


SEQ ID NO: 139


WIGRIDPGNGGTKYNEKFKGKVT


 


SEQ ID NO: 140


WIGRIDPGSGGTKYNEKFQGKVT


 


SEQ ID NO: 141


WIGQDRPKYGGTKYNEKFKGRVT


 


SEQ ID NO: 142


WIGRINPSNGGTKYNEKFKGRAT


 


SEQ ID NO: 143


WIGSDRPRQRWGTKYNEKFQGRVT


 


SEQ ID NO: 144


WIGWINPSNGGTKYNEKFKGRAT


 


SEQ ID NO: 145


WIGSDQPRQGGTKYNEKFKGRAT


 


SEQ ID NO: 146


WIGSDRPRQGGTKYNEKFKDRVT


 


SEQ ID NO: 147


WIGSDRPKQRGTKYNEKFKGKVT


 


SEQ ID NO: 148


SIGRINPGSGGTKYNEKFQGRAT


 


SEQ ID NO: 149


WIGSDRPKQRWHQVNEKFQGKVT


 


SEQ ID NO: 150


WIGRIDPDSGGTKYNEKFQGRAT


 


SEQ ID NO: 151


WIGRIDPGNGGTKYNEKFKGKAT


 


SEQ ID NO: 152


WIGRIDPGSGGTKYNEKFQGRAT


 


SEQ ID NO: 153


WIGRINPDNGGTKYNEKFQGRVT


 


SEQ ID NO: 154


WIGRDQPRQGGTNYNEKFQGRAT


 


SEQ ID NO: 155


WIGRINPNNGGTKYNEKFQGKAT


 


SEQ ID NO: 156


WIGSDRPRQGGTKYNEKFKGRVT


 


SEQ ID NO: 157


WIGRIDPGSGGTKYNEKFQGRVT


 


SEQ ID NO: 158


WIGSDRPKQRWAPKYNEKFKGRAT


 


SEQ ID NO: 159


WIGSDQPRQRWHQVQPKVQGRVT


 


SEQ ID NO: 160


WIGRINPGNGGTKQNEKFKGRAT


 


SEQ ID NO: 161


WIGRINPSSGGTKYNEKFKGRAT


 


SEQ ID NO: 162


WIGRINPNSGGTKYNEKFKGRVT


 


SEQ ID NO: 163


WIGRIDPGSGGTKYNQKFKGRTT


 


SEQ ID NO: 164


WIGWIDPGSGGTKYQDKFKGKAT


 


SEQ ID NO: 165


WIGWIDPGSGGTKYQEKFKGKVT


 


SEQ ID NO: 166


WIGWIDPGSGGTKYQEKFKGKAT


 


SEQ ID NO: 167


WIGWIDPGSGGTNYQEKFKGKAT


 


SEQ ID NO: 168


WIGWIDPGSGGTNYQQKFKGKAT


 


SEQ ID NO: 169


WIGWIDPGSGGTKYADKFKGKAT


 


SEQ ID NO: 170


WIGWIDPGSGGTKYEEKFKGKAT


 


SEQ ID NO: 171


WIGWIDPGSGGTKYNDKFKGKAT


 


SEQ ID NO: 172


WIGWIDPGSGGTKYYEKFKGKAT


 


SEQ ID NO: 173


WIGWIDPGSGGTKYEDKFEGKAT


 


SEQ ID NO: 174


WIGWIDPGSGGTNYTQKFKGKAT


 


SEQ ID NO: 175


WIGWIDPGSGGTKYSHKFKGKAT


 


SEQ ID NO: 176


WIGYIDPGSGGTRYNEKFQSKAT


 


SEQ ID NO: 177


WIGYIDPGNGGTRYNQKFKSKAT


 


SEQ ID NO: 178


WIGWIDPGSGGTRYNEKFQSKAT


 


SEQ ID NO: 179


WIGWIDPGNGGSRYNQKFKGKAT


 


SEQ ID NO: 180


WIGYIDPGNGGTRYNEKFQGKAT


 


SEQ ID NO: 181


WIGYIDPGNGGTKYNQKFQGKAT


 


SEQ ID NO: 182


WIGYIDPGSGGTKYNEKFKGKAT


 


LIST OF VH-CDR3 SEQUENCES


SEQ ID NO: 1


Consensus sequence for Variant Heavy Chain CDR3 Sequence


CXRXXXXXXXDXWGX


Wherein X at position 2 is A or S; X at position 4 is E, Y, A, G, S. H, Q or D; X at position 5 is


R, K, F, N, H, D, S or Y; X at position 6 is Y, V, S. D, I, L. F or A; X at position 7 is G, Y or A;


X at position 8 is Y or W; X at position 9 is Y, S, N or D; X at position 10 is F or L; X at


position 12 is Y, N or F; and X at position 15 is Q or E.


 


SEQ ID NO: 2


Consensus sequence for Variant Heavy Chain CDR3 Sequence


XXXXXXXDX


Wherein X at position 1 is E, Y, A, G, S, H, Q or D; X at position 2 is R, K, F, N, H, D, S or Y;


X at position 3 is Y, V, S, D, I, L, F or A; X at position 4 is G, Y or A; X at position 5 is Y or W;


X at position 6 is Y, S, N or D; X at position 7 is F or L; and X at position 9 is Y, N or F.


 


SEQ ID NO: 3


Consensus sequence for Variant Heavy Chain CDR3 Sequence


CARXXXXYXXDYWGX


Wherein X at position 4 is E, Y, A, G, S, H, Q or D; X at position 5 is R, K, F, N, H, D, S or Y;


X at position 6 is Y, V, S, D, I, L, F or A; X at position 7 is G, Y or A; X at position 9 is Y, S, N


or D; X at position 10 is F or L; and X at position 15 is Q or E.


 


SEQ ID NO: 4


Consensus sequence for Variant Heavy Chain CDR3 Sequence


XXXXYXXDY


Wherein X at position 1 is E, Y, A, G, S, H, Q or D; X at position 2 is R, K, F, N, H, D, S or Y;


X at position 3 is Y, V, S, D, I, L, F or A; X at position 4 is G, Y or A; X at position 6 is Y, S, N


or D; and X at position 7 is F or L.


 


SEQ ID NO: 5


CARERYGYYFDYWGQ


 


SEQ ID NO: 6 132 CDR3 SEQUENCE


TGCGCCCGTGAACGTTACGGTTACTACTTCGACTACTGGGGTCAG


 


SEQ ID NO: 7 132 CDR3 SEQUENCE (SHORTENED)


ERYGYYFDY


 


SEQ ID NO: 8 132 CDR3 SEQUENCE (SHORTENED)


GAACGTTACGGTTACTACTTCGACTAC


 


SEQ ID NO: 13


CARARVGYSLDYWGQ


 


SEQ ID NO: 14


CARYRVGYSLDYWGQ


 


SEQ ID NO: 15


CARQRVGYSLDYWGQ


 


SEQ ID NO: 9


CARANDGYSFDYWGQ


 


SEQ ID NO: 10 213 CDR3 SEQUENCE


TGCGCCCGTGCAAATGACGGTTACTCCTTCGACTACTGGGGTCAG


 


SEQ ID NO: 11 213 CDR3 SEQUENCE


ANDGYSFDY


 


SEQ ID NO: 12 213 CDR3 SEQUENCE


GCAAATGACGGTTACTCCTTCGACTAC


 


SEQ ID NO: 16


CARARVGYSFDYWGQ


 


SEQ ID NO: 17


CARSRVGYSFDYWGQ


 


SEQ ID NO: 18


CARYRSGYSLDYWGQ


 


SEQ ID NO: 19


CARERVGYSLDYWGQ


 


SEQ ID NO: 20


CARHRVGYSLDFWGQ


 


SEQ ID NO: 21


CARYHYGYSFDYWGQ


 


SEQ ID NO: 22


CARYHDGYSFDYWGQ


 


SEQ ID NO: 23


CARERFAYYLDYWGQ


 


SEQ ID NO: 24


CARSRDGYYFDYWGQ


 


SEQ ID NO: 25


CARARDGYSFDYWGQ


 


SEQ ID NO: 26


CARERAGYYLDYWGQ


 


SEQ ID NO: 27


CARHRVGYYFDYWGQ


 


SEQ ID NO: 28


CARANVGYSFDYWGQ


 


SEQ ID NO: 29


CARSHVGYYFDYWGQ


 


SEQ ID NO: 30


CARHRVGYSLDYWGQ


 


SEQ ID NO: 31


CARSRVGYSLDYWGQ


 


SEQ ID NO: 32


CARYRDGYSFDYWGQ


 


SEQ ID NO: 33


CARDRVGYSLDYWGQ


 


SEQ ID NO: 34


CARQRVGYNLDYWGQ


 


SEQ ID NO: 35


CARQRVGYSLDYWGE


 


SEQ ID NO: 36


CARSRDGYSLDYWGQ


 


SEQ ID NO: 37


CARYRSGYYLDYWGQ


 


SEQ ID NO: 38


CARYRVGYSFDYWGQ


 


SEQ ID NO: 39


CARSRDGYSFDYWGQ


 


SEQ ID NO: 40


CARARDGYSLDYWGQ


 


SEQ ID NO: 41


CARHRVGYSFDYWGQ


 


SEQ ID NO: 42


CARADVGYSFDYWGQ


 


SEQ ID NO: 43


CARGFV


 


NO: 44


CARGFIYYSFDYWGQ


 


SEQ ID NO: 45


CARGFLYYSFDYWGQ


 


SEQ ID NO: 46


CARGRIYYSFDYWGQ


 


SEQ ID NO: 47


CARGRFYYSFDYWGQ


 


SEQ ID NO: 48


CARGRLYYSLDYWGQ


 


SEQ ID NO: 49


CARGFIYYDFDYWGQ


 


SEQ ID NO: 50


CARGKIYYSFDYWGQ


 


SEQ ID NO: 51


CARGYLYYSFDYWGQ


 


SEQ ID NO: 52


CARGFIYYSLDYWGQ


 


SEQ ID NO: 53


CARGNLYYSLDYWGQ


 


SEQ ID NO: 54


CSRGKVGYSLDYWGQ


 


SEQ ID NO: 55


CARGSIGYNLDYWGQ


 


SEQ ID NO: 56


CARGRDGYSLDYWGQ


 


SEQ ID NO: 57


CAREKYGYYFDYWGQ


 


SEQ ID NO: 58


CARYKSGWYFDYWGQ


 


SEQ ID NO: 59


CARYRSGYYFDYWGQ


 


SEQ ID NO: 60


CARYKSGYYFDYWGQ


 


SEQ ID NO: 61


CAREKSGYYFDYWGQ


 


SEQ ID NO: 62


CARERSGYYFDYWGQ


 


SEQ ID NO: 63


CARSRVGYSFDNWGQ


 


LIST OF VK_CDR1


SEQ ID NO: 347


Consensus sequence for Variant Light Chain CDR1 sequence


ITCXASQYXGXYLXWYQ


Wherein X at position 4 is R or Q; X at position 9 is V or I; X at position 11 is T or S; and X at


position 14 is N, S or T.


 


SEQ ID NO: 348


Consensus sequence for Variant Light Chain CDR1 sequence


XASQYXGXYLX


Wherein X at position 1 is R or Q; X at position 6 is V or I; X at position 8 is T or S; and X at


position 11 is S or T.


 


SEQ ID NO: 353


ITCRASQYVGTYLNWYQ


 


SEQ ID NO: 349


ITCRASQYVGSYLNWYQ


 


SEQ ID NO: 350 132 & 189 CDR1 SEQUENCE


ATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGAACTGGTATCAG


 


SEQ ID NO: 351 132 & 189 CDR1 SEQUENCE (SHORTENED)


RASQYVGSYLN


 


SEQ ID NO: 352 132 & 189 CDR1 SEQUENCE (SHORTENED)


CGTGCCTCTCAGTATGTCGGCAGCTACCTGAAC


 


SEQ ID NO: 354


ITCRASQYIGSYLNWYQ


 


SEQ ID NO: 355


ITCRASQAISNYLTWYQ


 


SEQ ID NO: 356


ITCRASQYVGSYLTWYQ


 


SEQ ID NO: 357


ITCRASQDVSNYLNWYQ


 


SEQ ID NO: 358


ITCQASQYVGSYLSWYQ


 


SEQ ID NO: 359


ITCRASQYVGSYLSWYQ


 


LIST OF VK_CDR2


SEQ ID NO: 335


Consensus sequence for Variant Light Chain CDR2 sequence


LIYDXSNRAXGIP


Wherein X at position 5 is S or A; and X at position 10 is T, A or S.


 


SEQ ID NO: 336


Consensus sequence for Variant Light Chain CDR2 sequence


DXSNRAX


Wherein X at position 2 is S or A; and X at position 7 is T, A or S.


 


SEQ ID NO: 337


Consensus sequence for Variant Light Chain CDR2 sequence


LIYDAXNRAXGIP


Wherein X at position 6 is S or A; and X at position 10 is T, A or S.


 


SEQ ID NO: 338


Consensus sequence for Variant Light Chain CDR2 sequence


DAXNRAX


Wherein X at position 3 is S or A; and X at position 7 is T, A or S.


 


SEQ ID NO: 339


LIYDASNRATGIP


 


SEQ ID NO: 340 132 & 189 CDR2 SEQUENCE


CTGATCTACGACGCCTCTAACCGTGCCACCGGTATCCCA


 


SEQ ID NO: 341 132 & 189 CDR2 SEQUENCE (SHORTENED)


DASNRAT


 


SEQ ID NO: 342 132 & 189 CDR2 SEQUENCE (SHORTENED)


GACGCCTCTAACCGTGCCACC


 


SEQ ID NO: 343


LIYAASSLQSGVP


 


SEQ ID NO: 344


LIYDAANRATGIP


 


SEQ ID NO: 345


LIYDASNRAAGIP


 


SEQ ID NO: 346


LIYDASNRASGIP


 


LIST OF VK_CDR3


SEQ ID NO: 295


Consensus sequence for Variant Light Chain CDR3 Sequence


YYCQXXXXXXXXXFGX


Wherein X at position 5 is V, A or G; X at position 6 is W or Y; X at position 7 is D, G, S or N;


X at position 8 is S, T or N; X at position 9 is S, N, Y, D or T; X at position 10 is P, H, A, D or


S; X at position 11 is P, A, S, R or G; X at position 12 is V, L or S; X at position 13 is A, V, M,


I, L or T; and X at position 16 is G or D.


 


SEQ ID NO: 296


Consensus sequence for Variant Light Chain CDR3 Sequence


QXXXXXXXXX


Wherein X at position 2 is V, A or G; X at position 3 is W or Y; X at position 4 is D, G, S or N;


X at position 5 is S, T or N; X at position 6 is S, N, Y, D or T; X at position 7 is P, H, A, D or S;


X at position 8 is P, A, S, R or G; X at position 9 is V, L or S; and X at position 10 is A, V, M, I,


L or T.


 


SEQ ID NO: 297


Consensus sequence for Variant Light Chain CDR3 Sequence


YYCQXXXXXXXVXFGX


Wherein X at position 5 is V, A or G; X at position 6 is W or Y; X at position 7 is D, G, S or N;


X at position 8 is S, T or N; X at position 9 is S, N, Y, D or T; X at position 10 is P, H, A, D or


S; X at position 11 is P, A, S, R or G; and X at position 13 is A, C, M, I, L or T.


 


SEQ ID NO: 298


Consensus sequence for Variant Light Chain CDR3 Sequence


QXXXXXXXVX


Wherein X at position 2 is V, A or G; X at position 3 is W or Y; X at position 4 is D, G, S or N;


X at position 5 is S, T or N; X at position 6 is S, N, Y, D or T; X at position 7 is P, H, A, D or S;


X at position 8 is P, A, S, R or G; and X at position 10 is A, V, M, I, L or T.


 


SEQ ID NO: 299


Consensus sequence for Variant Light Chain CDR3 Sequence


YYCQXXXXXXXVXFGG


Wherein X at position 5 is V, A or G; X at position 7 is D, G, S or N; X at position 8 is S, T or


N; X at position 9 is S, N, Y, D or T; X at position 10 is P, H, A, D or S; X at position 11 is P, A,


S, R or G; and X at position 13 is A, V, M, I, L or T.


 


SEQ ID NO: 300


Consensus sequence for Variant Light Chain CDR3 Sequence


QXXXXXXXVX


Wherein X at position 2 is V, A or G; X at position 4 is D, G, S or N; X at position 5 is S, T or


N; X at position 6 is S, N, Y, D or T; X at position 7 is P, H, A, D or S; X at position 8 is P, A, S,


R or G; and X at position 10 is A, V, M, I, L or T.


 


SEQ ID NO: 305


YYCQVWDSSPPVAFGG


 


SEQ ID NO: 301


YYCQVWDSSPPVVFGG


 


SEQ ID NO: 302 132 & 189 CDR3 SEQUENCE


TACTACTGCCAGGTATGGGACAGCTCTCCTCCTGTGGTGTTCGGTGGT


 


SEQ ID NO: 303 132 & 189 CDR3 SEQUENCE (SHORTENED)


QVWDSSPPVV


 


SEQ ID NO: 304 132 & 189 CDR3SEQUENCE (SHORTENED)


CAGGTATGGGACAGCTCTCCTCCTGTGGTG


 


SEQ ID NO: 306


YYCQVWDSSPPLVFGG


 


SEQ ID NO: 307


YYCQVWDSSPPLAFGG


 


SEQ ID NO: 308


YYCQAWDSSPPVVFGG


 


SEQ ID NO: 309


YYCQVWDSSPPVMFGG


 


SEQ ID NO: 310


YYCQGWDSSPTFGG


 


SEQ ID NO: 311


YYCQVWDNSPPVVFGG


 


SEQ ID NO: 312


YYCQAWDSSPPVTFGD


 


SEQ ID NO: 313


YYCQQSGSYLTFGG


 


SEQ ID NO: 314


YYCQVWDSYHAVVFGG


 


SEQ ID NO: 315


YYCQVWGSYHAVMFGG


 


SEQ ID NO: 316


YYCQVWGSYHSVMFGG


 


SEQ ID NO: 317


YYCQVWDTDHSVVFGG


 


SEQ ID NO: 318


YYCQVWDTDHAVAFGG


 


SEQ ID NO: 319


YYCQVWDSSHSVIFGG


 


SEQ ID NO: 320


YYCQVWDSYPPVVFGG


 


SEQ ID NO: 321


YYCQVWDSDHAVVFGG


 


SEQ ID NO: 322


YYCQVWGSNHASLFGG


 


SEQ ID NO: 323


YYCQVWGSTARVAFGG


 


SEQ ID NO: 324


YYCQVWNSTPPVVFGG


 


SEQ ID NO: 325


YYCQVWSSSPPVIFGG


 


SEQ ID NO: 326


YYCQVWSSSPPVVFGG


 


SEQ ID NO: 327


YYCQVWSSNHAVVFGG


 


SEQ ID NO: 328


YYCQVWGSNPPVAFGG


 


SEQ ID NO: 329


YYCQVWDSTPPVVFGG


 


SEQ ID NO: 330


YYCQVWDSNPPVVFGG


 


SEQ ID NO: 331


YYCQGYSSNDGVIFGG


 


SEQ ID NO: 332


YYCQVWGSNHSVVFGG


 


SEQ ID NO: 333


YYCQVWDSNHSVVFGG


 


SEQ ID NO: 334


YYCQVWDSSSAVVFGG


 


SEQ ID NO: 552 AX132_VH-CH1 (FAB) AMINO ACID SEQUENCE


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARERYGY


YFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK


PSNTKVDKKVEPKSCDKTHT


 


SEQ ID NO: 553 AX132_VH-CH1 (FAB) DNA SEQUENCE


GAAGTGCAGCTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGTCTGTCTTGCAAGGCCTCTGGTTACACCTTCTCTTCTTACGGGATGT


ACTGGGTGCGTCAGGCACCAGGTAAGGGTCTGGAATGGATCGGTTGGATCGACCCAGGCAGCGGTGGCACCAAGTACAACGAAAAGTTCAAGGGTAAGGCCAC


CATCTCTAGAGACAACTCTAAGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACTACTGCGCCCGTGAACGTTACGGTTAC


TACTTCGACTACTGGGGTCAGGGTACGCTGGTGACTGTCTCGAGCGCAAGCACCAAAGGCCCATCGGTATTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTG


GGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCC


GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAG


CCCAGCAACACTAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACA


 


SEQ ID NO: 554 AX132_VK-CK (FAB) AMINO ACID SEQUENCE


EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFGGGT


KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV


TKSFNRGEC


 


SEQ ID NO: 555 AX132_VK-CK (FAB) DNA SEQUENCE


GAAATCGTGCTGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCCGGGGAACGTGCCACCATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGAACT


GGTATCAGCAGAAGCCAGGTCAGGCGCCACGTCTGCTGATCTACGACGCCTCTAACCGTGCCACCGGTATCCCAGCCCGTTTCTCTGGTTCTGGTTCTGGCAC


CGACTTCACCCTGACCATCTCTTCTCTGGAACCAGAAGACTTCGCCGTGTACTACTGCCAGGTATGGGACAGCTCTCCTCCTGTGGTGTTCGGTGGTGGTACC


AAAGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGA


ATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG


CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTC


ACAAAGAGCTTCAACAGGGGAGAGTGT


 


SEQ ID NO: 556 AX132 FULL HEAVY CHAIN (IGG2) AMINO ACID SEQUENCE


EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARERYGY


YFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHK


PSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD


WLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKS


RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK


 


SEQ ID NO: 557 AX132 FULL HEAVY CHAIN (IGG2) DNA SEQUENCE


GAAGTGCAGCTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGTCTGTCTTGCAAGGCCTCTGGTTACACCTTCTCTTCTTACGGGATGT


ACTGGGTGCGTCAGGCACCAGGTAAGGGTCTGGAATGGATCGGTTGGATCGACCCAGGCAGCGGTGGCACCAAGTACAACGAAAAGTTCAAGGGTAAGGCCAC


CATCTCTAGAGACAACTCTAAGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACTACTGCGCCCGTGAACGTTACGGTTAC


TACTTCGACTACTGGGGTCAGGGTACGCTGGTGACTGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCG


AGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCC


GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAG


CCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCC


CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTA


CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGAC


TGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCAC


AGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTG


GGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGC


AGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGTAAA


 


SEQ ID NO: 558 AX132 FULL LIGHT CHAIN AMINO ACID SEQUENCE


EIVLTQSPATLSLSPGERATITCRASQYVGTYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVAFGGGT


KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV


TKSFNRGEC


 


SEQ ID NO: 559 AX132 FULL LIGHT CHAIN DNA SEQUENCE


GAGATTGTGCTGACCCAGAGCCCTGCCACCCTGTCCCTGAGCCCTGGAGAGAGGGCTACCATCACTTGTAGGGCAAGCCAATATGTGGGCACCTACCTGAACT


GGTATCAACAGAAGCCTGGACAAGCCCCAAGACTGCTGATTTATGATGCCAGCAACAGGGCTACAGGCATCCCTGCCAGGTTCTCTGGCTCTGGCTCTGGCAC


AGACTTCACCCTGACCATCTCCTCCTTGGAACCTGAGGACTTTGCTGTCTACTACTGTCAGGTGTGGGACTCCAGCCCTCCTGTGGCATTTGGAGGAGGCACC


AAGGTGGAGATTAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGA


ATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG


CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTC


ACAAAGAGCTTCAACAGGGGAGAGTGT


 


SEQ ID NO: 560 AX132 DISPLAY VECTOR SEQUENCE


GCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAA


TTTACCGGTTCTTGTAAGGAGGAATTAAAAAATGAAAAAGTCTTTAGTCCTCAAAGCCTCCGTAGCCGTTGCTACCCTCGTTCCGATGCTAAGCTTCGCTGAA


ATCGTGCTGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCCGGGGAACGTGCCACCATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGAACTGGT


ATCAGCAGAAGCCAGGTCAGGCGCCACGTCTGCTGATCTACGACGCCTCTAACCGTGCCACCGGTATCCCAGCCCGTTTCTCTGGTTCTGGTTCTGGCACCGA


CTTCACCCTGACCATCTCTTCTCTGGAACCAGAAGACTTCGCCGTGTACTACTGCCAGGTATGGGACAGCTCTCCTCCTGTGGTGTTCGGTGGTGGTACCAAA


GTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATA


ACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC


CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA


AAGAGCTTCAACAGGGGAGAGTGTTGATAAGGCGCGCCACAATTTCACAGTAAGGAGGTTTAACTTATGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTC


CTTTCTATTCTCACTCCGCTGGATCCGAAGTGCAGCTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGTCTGTCTTGCAAGGCCTCTGG


TTACACCTTCTCTTCTTACGGGATGTACTGGGTGCGTCAGGCACCAGGTAAGGGTCTGGAATGGATCGGTTGGATCGACCCAGGCAGCGGTGGCACCAAGTAC


AACGAAAAGTTCAAGGGTAAGGCCACCATCTCTAGAGACAACTCTAAGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACT


ACTGCGCCCGTGAACGTTACGGTTACTACTTCGACTACTGGGGTCAGGGTACGCTGGTGACTGTCTCGAGCGCAAGCACCAAAGGCCCATCGGTATTCCCCCT


GGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAGCCGGTGACGGTGTCGTGGAACTCAGGCGCT


CTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACTGTGCCCTCCAGCAGCTTGGGCACCCAGA


CCTACATCTGCAACGTGAATCACAAGCCCAGCAACACTAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACAGCGGCCGCTTATCCATA


CGACGTACCAGACTACGCAGGAGGTCATCACCATCATCACCATTAGAGATCTGGAGGAGGTGAGGAGAAGTCCCGGCTGTTGGAGAAGGAGAACCGTGAACTG


GAAAAGATCATTGCTGAGAAAGAGGAGCGTGTCTCTGAACTGCGCCATCAACTCCAGTCTGTAGGAGGTTGTTAATAAGTCGACCTCGACCAATTCGCCCTAT


AGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTT


TCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG


CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCC


GGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCAC


GTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCC


TATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA


ATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAG


ACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTT


CCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA


 


ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGT


 


GCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATG


TAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACT


ATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCT


GGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCT


ACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTC


ATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTT


TCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC


TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTA


GCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGT


CTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACA


CCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGA


GCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGG


GGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATT


CTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCC


AATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGCTGGAAAGCGGGCAGTGAA


 


SEQ ID NO: 572 SEQUENCE CONTAINING FC DOMAIN OF IGG1


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSC


DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV


SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS


VMHEALHNHYTQKSLSLSPGK


 


SEQ ID NO: 573 SEQUENCE CONTAINING FC DOMAIN OF IGG2


ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVTSSNFGTQTYTCNVDHKPSNTKVDKTVERKCC


VECPIPCPAPPVAGPSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKG


LPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE


ALHNHYTQKSLSLSPGK


 


SEQ ID NO: 574 SEQUENCE CONTAINING FC DOMAIN OF IGG4


ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG


PPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK


GLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH


EALHNHYTQKSLSLSLGK


 


SEQ ID NO: 575 SEQUENCE CONTAINING FC DOMAIN OF IGG4


ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVTSSNFGTQTYTCNVDHKPSNTKVDKTVERKCC


VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKG


LPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE


ALHNHYTQKSLSLSPGK

## Claims

1. An isolated PCSK9-specific antagonist which comprises:
(a) heavy chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein
(i) the CDR1 sequence is selected from the group consisting of: SEQ ID NO: 189 and residues 4-13 of SEQ ID NO: 183;
(ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NO: 68 and residues 4-20 of SEQ ID NO: 68; and
(iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NO: 5 and residues 4-12 of SEQ ID NO: 5 and

(b) a light chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein
(i) the CDR1 sequence is selected from the group consisting of: SEQ ID NO: 349 and residues 4-14 of SEQ ID NO: 349;
(ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NO: 339 and residues 4-10 of SEQ ID NO: 335; and
(iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NO: 301 and residues 4-13 of SEQ ID NO: 301;

said antagonist which inhibits human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.

2. The PCSK9-specific antagonist of claim 1 which comprises heavy and light chain regions having, in contiguous order, sequences for framework (FR) 1, CDR1, FR2, CDR2, FR3, CDR3, FR4 comprising:
(a) heavy chain framework (FR) sequences 1, 2, 3 and 4 of SEQ ID NOs: 583, 584, 585 and 586, respectively; and
(b) light chain FR sequences 1, 2, 3 and 4 of SEQ ID NOs: 587, 588, 589 and 590, respectively.

3. The PCSK9-specific antagonist of claim 1 which comprises:
(a) a heavy chain variable region comprising sequence selected from the group consisting of: SEQ ID NOs: 360-361 and
(b) a light chain variable region comprising SEQ ID NO: 511.

4. The PCSK9-specific antagonist of claim 1 which comprises:
(a) a heavy chain comprising SEQ ID NO: 556; and
(b) a light chain comprising SEQ ID NO: 558.

5. The PCSK9-specific antagonist of claim 1 that binds to human PCSK9 with a KD of less than 5 nM.

6. The PCSK9-specific antagonist of claim 1 that antagonizes PCSK9's inhibition of cellular LDL uptake at an IC50 of less than 100 nM.

7. The PCSK9-specific antagonist of claim 1 that antagonizes PCSK9's inhibition of cellular uptake by at least 50%.

8. The PCSK9-specific antagonist of claim 1 which is an antibody molecule.

9. A composition comprising the PCSK9-specific antagonist of claim 1 and a pharmaceutically acceptable carrier.